PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Calkins, DJ; Sterling, P				Calkins, DJ; Sterling, P			Absence of spectrally specific lateral inputs to midget ganglion cells in primate retina	NATURE			English	Article							GENICULATE-NUCLEUS; CONE CONNECTIONS; HORIZONTAL CELLS; MONKEY RETINA; MACAQUE; MECHANISMS; OPPONENT	VISUAL information is conveyed to the brain by retinal ganglion cells. Midget ganglion cells serve fine spatial vision(1,2) by summing excitation from a receptive field 'centre', receiving input from a single cone in the central retina, with lateral inhibition from a receptive field 'surround', receiving input from many surrounding cones, Midget ganglion cells are also thought to serve colour opponent vision(1-6) because the centre excitation is from a cone of one spectral type, while the surround inhibition is from cones of the other type(4,6). The two major cone types, middle(M)- and long(L)wavelength sensitive, are equally numerous and randomly distributed in the primate central retina(7-9), so a spectrally homogeneous surround requires that the cells mediating lateral interactions (horizontal or amacrine cells) receive selective input from only one cone type. Horizontal cells cannot do this because they receive input indiscriminately from M and L cones(10-12). Here we report that the amacrine cells connected to midget ganglion cells are similarly indiscriminate, The absence of spectral specificity in the inhibitory wiring raises doubt about the involvement of midget ganglion cells in colour vision and suggests that colour opponency may instead be conveyed by a different type of ganglion cell.	UNIV PENN, DEPT NEUROSCI, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Calkins, David/0000-0002-8475-9959				BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; CALKINS DJ, 1994, NATURE, V371, P70, DOI 10.1038/371070a0; CRONER LJ, 1995, VISION RES, V35, P7, DOI 10.1016/0042-6989(94)E0066-T; Dacey DM, 1996, SCIENCE, V271, P656, DOI 10.1126/science.271.5249.656; DEMONASTERIO FM, 1978, J NEUROPHYSIOL, V41, P1418, DOI 10.1152/jn.1978.41.6.1418; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DOWLING JE, 1966, PROC R SOC SER B-BIO, V166, P80, DOI 10.1098/rspb.1966.0086; GRUNERT U, 1990, J COMP NEUROL, V297, P509, DOI 10.1002/cne.902970405; Kaplan E., 1990, Progress in Retinal Research, V9, P273, DOI 10.1016/0278-4327(90)90009-7; KLUG K, 1992, SOC NEUR ABSTR, V18; KLUG KY, 1993, INVEST OPHTH VIS SCI, V34, pA1398; KOLB H, 1991, J COMP NEUROL, V303, P617, DOI 10.1002/cne.903030408; Lee BB, 1996, VISION RES, V36, P631, DOI 10.1016/0042-6989(95)00167-0; Lennie P., 1991, COMPUTATIONAL MODELS, P71, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; MERIGAN WH, 1991, J NEUROSCI, V11, P994; MOLLON JD, 1992, NATURE, V360, P677, DOI 10.1038/360677a0; Packer OS, 1996, J NEUROSCI, V16, P2251; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; TSUKAMOTO Y, 1992, VISION RES, V32, P1809, DOI 10.1016/0042-6989(92)90042-H; VARDI N, 1994, VISION RES, V34, P1235, DOI 10.1016/0042-6989(94)90198-8; VARDI N, 1994, VISUAL NEUROSCI, V11, P135, DOI 10.1017/S0952523800011172; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; ZRENNER E, 1983, NEUROPHYSIOLOGICAL A	28	81	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					613	615		10.1038/381613a0	http://dx.doi.org/10.1038/381613a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637598				2022-12-01	WOS:A1996UQ65700053
J	Ehrhardt, DW; Wais, R; Long, SR				Ehrhardt, DW; Wais, R; Long, SR			Calcium spiking in plant root hairs responding to Rhizobium nodulation signals	CELL			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; CYTOSOLIC FREE CALCIUM; CYTOPLASMIC CALCIUM; HOST SPECIFICITY; MELILOTI; ALFALFA; CELLS; ACID; OSCILLATIONS; CHANNELS	Rhizobium lipochitooligosaccharide signal molecules stimulate multiple responses in legume host plants, including changes in host gene expression, cell growth, and mitoses leading to root nodule development. The basis for signal transduction in the plant is not known. We examined cytoplasmic free calcium in host root hairs using calcium-sensitive reporter dyes. Image analysis of injected dyes revealed localized periodic spikes in cytoplasmic calcium levels that ensued after a characteristic lag following signal application. Structural features of the signal molecules required to cause nodulation responses in alfalfa are also essential for stimulating calcium spiking. A nonnodulating alfalfa mutant is defective in calcium spiking, consistent with the possibility that this mutant is blocked in an early stage of nodulation signal perception.			Ehrhardt, DW (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT BIOL SCI, STANFORD, CA 94305 USA.							ALLEN NS, 1994, ADV MOL GENETICS PLA, V3, P107; ATKINSON EM, 1994, THESIS STANFORD U ST; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.pp.46.060195.001201; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARKSON DT, 1988, J CELL SCI, V91, P71; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; DUDLEY ME, 1987, PLANTA, V171, P289, DOI 10.1007/BF00398674; DUDLEY ME, 1989, PLANT CELL, V1, P65, DOI 10.1105/tpc.1.1.65; EHRHARDT DW, 1995, J BACTERIOL, V177, P6237, DOI 10.1128/jb.177.21.6237-6245.1995; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; FELLE H, 1988, PLANTA, V174, P495, DOI 10.1007/BF00634478; FELLE HH, 1995, PLANT J, V7, P939, DOI 10.1046/j.1365-313X.1995.07060939.x; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Kijne J.W., 1992, BIOL NITROGEN FIXATI, P349; KURKDJIAN AC, 1995, PLANT PHYSIOL, V107, P783, DOI 10.1104/pp.107.3.783; MCAINSH MR, 1995, PLANT CELL, V7, P1207, DOI 10.1105/tpc.7.8.1207; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MILLER DD, 1992, J CELL SCI, V101, P7; MUNNS DN, 1970, PLANT SOIL, V32, P90, DOI 10.1007/BF01372849; MYLONA P, 1995, PLANT CELL, V7, P869, DOI 10.1105/tpc.7.7.869; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PETERSON MA, 1981, CROP SCI, V21, P611, DOI 10.2135/cropsci1981.0011183X002100040033x; READ ND, 1992, J MICROSC-OXFORD, V166, P57, DOI 10.1111/j.1365-2818.1992.tb01507.x; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROCHE P, 1991, J BIOL CHEM, V266, P10933; SAUNDERS MJ, 1982, SCIENCE, V217, P943, DOI 10.1126/science.217.4563.943; SAUNDERS MJ, 1983, DEV BIOL, V99, P41, DOI 10.1016/0012-1606(83)90252-X; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; SMITH JT, 1993, ELECTROPHORESIS, V14, P396, DOI 10.1002/elps.1150140165; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	39	446	480	3	68	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 31	1996	85	5					673	681		10.1016/S0092-8674(00)81234-9	http://dx.doi.org/10.1016/S0092-8674(00)81234-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646776	Bronze			2022-12-01	WOS:A1996UP34400008
J	Funabiki, H; Yamano, H; Kumada, K; Nagao, K; Hunt, T; Yanagida, M				Funabiki, H; Yamano, H; Kumada, K; Nagao, K; Hunt, T; Yanagida, M			Cut2 proteolysis required for sister-chromatid separation in fission yeast	NATURE			English	Article							MATURATION-PROMOTING FACTOR; CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MUTANTS; MITOSIS; KINASE; GENE; DEGRADATION	ALTHOUGH mitotic cyclins are well-known substrates for ubiquitin-mediated proteolysis at the metaphase-anaphase transition(1-4), their degradation is not essential for separation of sister chromatids(5-8); several lines of evidence suggest that proteolysis of other protein(s) is required, however(4,6,9-11). Here we report the anaphase-specific proteolysis of the Schizosaccharomyces pombe Cut2 protein, which is essential for sister-chromatid separation(12,13). Cut2 is located in the nucleus, where it is concentrated along the short metaphase spindle. The rapid degradation of Cut2 at anaphase requires its amino-terminal region and the activity of Cut9 (ref. 14), a component of the 20S cyclosome/anaphase-promoting complex (APC), which is necessary for cyclin destruction(3,4,11). Expression of non-degradable Cut2 blocks sister-chromatid separation but not cell-cycle progression. This defect can be overcome by grafting the N terminus of cyclin B onto the truncated Cut2, demonstrating that the regulated proteolysis of Cut2 is essential for sister-chromatid separation.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	Kyoto University			Nagao, Koji/F-5281-2011	Funabiki, Hironori/0000-0003-4831-4087; Nagao, Koji/0000-0003-1418-6988				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CREANOR J, 1990, J CELL SCI, V96, P435; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RIMMINGTON G, 1994, J CELL SCI, V107, P2729; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H	27	406	413	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					438	441		10.1038/381438a0	http://dx.doi.org/10.1038/381438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632802				2022-12-01	WOS:A1996UN47900055
J	DeChiara, TM; Bowen, DC; Valenzuela, DM; Simmons, MV; Poueymirou, WT; Thomas, S; Kinetz, E; Compton, DL; Rojas, E; Park, JS; Smith, C; DiStefano, PS; Glass, DJ; Burden, SJ; Yancopoulos, GD				DeChiara, TM; Bowen, DC; Valenzuela, DM; Simmons, MV; Poueymirou, WT; Thomas, S; Kinetz, E; Compton, DL; Rojas, E; Park, JS; Smith, C; DiStefano, PS; Glass, DJ; Burden, SJ; Yancopoulos, GD			The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo	CELL			English	Article							ORIGINAL SYNAPTIC SITES; TORPEDO ELECTRIC ORGAN; ACETYLCHOLINE-RECEPTORS; BASAL LAMINA; REGENERATING MUSCLE; GROWTH-FACTOR; AGRIN; NERVE; EXPRESSION; PROTEIN	Formation of neuromuscular synapses requires a series of inductive interactions between growing motor axons and differentiating muscle cells, culminating in the precise juxtaposition of a highly specialized nerve terminal with a complex molecular structure on the postsynaptic muscle surface. The receptors and signaling pathways mediating these inductive interactions are not known. We have generated mice with a targeted disruption of the gene encoding MuSK, a receptor tyrosine kinase selectively localized to the postsynaptic muscle surface. Neuromuscular synapses do not form in these mice, suggesting a failure in the induction of synapse formation. Together with the results of an accompanying manuscript, our findings indicate that MuSK responds to a critical nerve-derived signal (agrin), and in turn activates signaling cascades responsible for all aspects of synapse formation, including organization of the postsynaptic membrane, synapse-specific transcription, and presynaptic differentiation.	NYU,MED CTR,MOL NEUROBIOL PROGRAM,NEW YORK,NY 10016	New York University	DeChiara, TM (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Smith, Cynthia/AAY-6219-2020; Glass, David/AAI-3910-2021	Smith, Cynthia/0000-0003-3691-0324; Burden, Steven/0000-0002-3550-6891	NINDS NIH HHS [NS27963, NS21579, R01 NS036193-01A1S1, R01 NS036193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021579, R01NS036193, R01NS027963] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BARBACID M, 1993, ONCOGENE, V8, P2033; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; Burden Steven J., 1995, Seminars in Developmental Biology, V6, P59, DOI 10.1016/S1044-5781(06)80085-X; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CARTAUD J, 1993, EUR J NEUROSCI, V5, P191, DOI 10.1111/j.1460-9568.1993.tb00485.x; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CONOVER JC, 1995, NATURE, V375, P35; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FALLS DL, 1990, COLD SH Q B, V55, P397; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GANJU P, 1995, ONCOGENE, V11, P281; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARRIS DA, 1989, NATURE, V337, P173, DOI 10.1038/337173a0; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; KUFFLER DP, 1986, J COMP NEUROL, V250, P228, DOI 10.1002/cne.902500209; LETINSKY MS, 1976, J NEUROCYTOL, V5, P691, DOI 10.1007/BF01181582; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCMAHAN UJ, 1984, J CELL BIOL, V98, P1453, DOI 10.1083/jcb.98.4.1453; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; QU Z, 1994, J NEUROSCI, V14, P6834; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SANES JR, 1995, DEV BIOL, V6, P163; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMON AM, 1992, DEVELOPMENT, V114, P545; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	65	714	731	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					501	512		10.1016/S0092-8674(00)81251-9	http://dx.doi.org/10.1016/S0092-8674(00)81251-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653786	hybrid			2022-12-01	WOS:A1996UM41500008
J	deLecea, L; Criado, JR; ProsperoGarcia, O; Gautvik, KM; Schweitzer, P; Danielson, PE; Dunlop, CLM; Siggins, GR; Henriksen, SJ; Sutcliffe, JG				deLecea, L; Criado, JR; ProsperoGarcia, O; Gautvik, KM; Schweitzer, P; Danielson, PE; Dunlop, CLM; Siggins, GR; Henriksen, SJ; Sutcliffe, JG			A cortical neuropeptide with neuronal depressant and sleep-modulating properties	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; SOMATOSTATIN; METABOLITES; INHIBITION; BRAIN; CA1	ACETYLCHOLINE (ACh) plays a key role in the transitions between the different phases of sleep(1): Slow-wave sleep requires low ACh concentrations in the brain, whereas rapid-eye-movement (REM) sleep is associated with high levels of ACh, Also, these phases of sleep are differentially sensitive to a number of endogenous neuropeptides and cytokines, including somatostatin, which has been shown to increase REM sleep without significantly affecting other phases(2). Here we report the cloning and initial characterization of cortistatin, a neuropeptide that exhibits strong structural similarity to somatostatin, although it is the product of a different gene. Administration of cortistatin depresses neuronal electrical activity but, unlike somatostatin, induces low-frequency waves in the cerebral cortex and antagonizes the effects of acetylcholine on hippocampal and cortical measures of excitability. This suggests a mechanism for cortical synchronization related to sleep.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			de Lecea, Luis/B-3171-2009; de Lecea, Luis/ABE-4005-2021	de Lecea, Luis/0000-0002-8921-5942; de Lecea, Luis/0000-0002-8921-5942	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058543] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH058543] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN P, 1971, EXP BRAIN RES, V13, P208; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P607; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DELECEA L, 1994, MOL BRAIN RES, V25, P286, DOI 10.1016/0169-328X(94)90164-3; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; MAURER R, 1982, P NATL ACAD SCI-BIOL, V79, P4815, DOI 10.1073/pnas.79.15.4815; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHARFMAN HE, 1989, BRAIN RES, V493, P205, DOI 10.1016/0006-8993(89)91155-4; SCHONBRUNN AH, 1978, J BIOL CHEM, V235, P6473; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIROMANI PJ, 1987, ANNU REV PHARMACOL, V27, P137; STEFFENSEN SC, 1991, BRAIN RES, V538, P46, DOI 10.1016/0006-8993(91)90374-5; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VEBER DF, 1979, NATURE, V280, P512, DOI 10.1038/280512a0	21	308	317	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					242	245		10.1038/381242a0	http://dx.doi.org/10.1038/381242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622767				2022-12-01	WOS:A1996UL24900056
J	Triolo, T; Sternglanz, R				Triolo, T; Sternglanz, R			Role of interactions between the origin recognition complex and SIR1 in transcriptional silencing	NATURE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; YEAST; PROTEIN; STATES; LOCI	TRANSCRIPTIONAL silencing of the HM mating-type loci in the yeast Saccharomyces cerevisiae is caused by the localized formation of an altered chromatin structure, analogous to heterochromatin in higher eukaryotes. Silencing depends on cis-acting sequences, termed silencers, as well as several trans-acting factors, including histones H4 and H3, proteins RAP1 and ABF1, and the four SIR proteins (SIR1-4)(1). Each of the four HM silencers contains an autonomously replicating sequence (ARS) to which the origin replication complex (ORC)(2) binds. This six-protein complex is required for initiation of DNA replication, as well as for silencing(3-7). Efficient establishment of the silenced state requires both passage through the S phase of the cell cycle(8) and SIR1 protein(9,10). Previous experiments suggested that SIR1 might be localized to the silencers by binding to ORC and/or RAP1 (ref. 11). Here we report that SIR1 can bind directly to ORC1, the largest of the ORC subunits, and that targeting of SIR1 to ORC1 at a silencer is sufficient to establish a silenced state.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook								BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STUDIER W, 1990, METHOD ENZYMOL, V185, P5	18	234	240	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					251	253		10.1038/381251a0	http://dx.doi.org/10.1038/381251a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622770				2022-12-01	WOS:A1996UL24900059
J	Gao, JH; Parsons, LM; Bower, JM; Xiong, JH; Li, JQ; Fox, PT				Gao, JH; Parsons, LM; Bower, JM; Xiong, JH; Li, JQ; Fox, PT			Cerebellum implicated in sensory acquisition and discrimination rather than motor control	SCIENCE			English	Article							CORTICOPONTINE PROJECTION; ORGANIZATION; MOVEMENT; MONKEY; CORTEX	Recent evidence that the cerebellum is involved in perception and cognition challenges the prevailing view that its primary function is fine motor control. A new alternative hypothesis is that the lateral cerebellum is not activated by the control of movement per se, but is strongly engaged during the acquisition and discrimination of sensory information. Magnetic resonance imaging of the lateral cerebellar output (dentate) nucleus during passive and active sensory tasks confirmed this hypothesis. These findings suggest that the lateral cerebellum may be active during motor, perceptual, and cognitive performances specifically because of the requirement to process sensory data.	UNIV TEXAS, HLTH SCI CTR, SCH MED, RES IMAGING CTR, SAN ANTONIO, TX 78284 USA; CALTECH, PASADENA, CA 91125 USA	University of Texas System; University of Texas Health San Antonio; California Institute of Technology			Li, Jinqi/F-7778-2010; Bower, James/F-8343-2010; Fox, Peter/B-4725-2010	Fox, Peter/0000-0002-0465-2028; Xiong, Jinhu/0000-0001-5262-5756; Parsons, Lawrence/0000-0001-7498-8742	NIDA NIH HHS [P20 DA52176-01] Funding Source: Medline; NIMH NIH HHS [MH/DA52145] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baddeley A.D., 1986, WORKING MEMORY; BOWEN J, 1995, HUMAN BRAIN MAPPING, V2, P255, DOI DOI 10.1002/HBM.460020407; BOWER JM, 1990, J COMP NEUROL, V302, P768, DOI 10.1002/cne.903020409; BOWER JM, 1992, BEHAV BRAIN SCI, V15, P714; BOWER JM, IN PRESS BEHAV BRAIN; BOWER JM, IN PRESS PROG BRAIN; Brodal A, 1981, NEUROLOGICAL ANATOMY; BRODAL P, 1978, BRAIN, V101, P251, DOI 10.1093/brain/101.2.251; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; ELLERMAN JM, 1994, NMR BIOMED, V7, P63, DOI 10.1002/nbm.1940070110; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FOX PT, 1985, P NATL ACAD SCI USA, V82, P7462, DOI 10.1073/pnas.82.21.7462; Gao J.-H., 1995, Society for Neuroscience Abstracts, V21, P270; GLICKSTEIN M, 1985, J COMP NEUROL, V235, P343, DOI 10.1002/cne.902350306; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; Ito M., 1984, CEREBELLUM NEURAL CO; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; LEINER HC, 1995, HUMAN BRAIN MAPPING, V2, P244; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Parsons L. M., 1995, Society for Neuroscience Abstracts, V21, P272; PARSONS LM, 1995, NATURE, V375, P54, DOI 10.1038/375054a0; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; SABATINI U, 1993, J CEREBR BLOOD F MET, V13, P639, DOI 10.1038/jcbfm.1993.82; SCHMAHMANN JD, 1990, J COMP NEUROL, V295, P299, DOI 10.1002/cne.902950212; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SCHMAHMANN JD, IN PRESS; SEITZ RJ, 1990, NEUROREPORT, V1, P17; STRICK PL, 1983, J NEUROSCI, V3, P2007; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; Welker W, 1987, NEW CONCEPTS CEREBEL, P239; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	37	531	545	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					545	547		10.1126/science.272.5261.545	http://dx.doi.org/10.1126/science.272.5261.545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614803				2022-12-01	WOS:A1996UG82600043
J	Hu, H; Aro, A; Payton, M; Korrick, S; Sparrow, D; Weiss, ST; Rotnitzky, A				Hu, H; Aro, A; Payton, M; Korrick, S; Sparrow, D; Weiss, ST; Rotnitzky, A			The relationship of bone and blood lead to hypertension - The normative aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY-FLUORESCENCE; PRESSURE RELATIONS; ALCOHOL INTAKE; CONFOUNDERS; HEMOGLOBIN; EXPOSURE; BURDEN	Objective.-To test the hypothesis that long-term lead accumulation, as reflected by levels of lead in bone (as opposed to blood, which reflects recent lead exposure), is associated with an increased odds of developing hypertension. Design.-Case-control study of participants in the Veterans Administration (now Department of Veterans Affairs) Normative Aging Study, a 30-year longitudinal study of men. Participants.-Of 1171 active subjects who were seen between August 1991 and December 1994, 590 (50%) participated in this investigation and had data on all variables of interest. Main Outcome Measures.-Hypertension was defined as taking daily medication for the treatment of hypertension or systolic blood pressure higher than 160 mm Hg or diastolic blood pressure of 96 mm Hg or higher during the time of examination. Levels of lead in the tibia (representing cortical bone) and the patella (representing trabecular bone) were measured in vivo with a K x-ray fluorescence (KXRF) instrument. Levels of lead in blood were measured by graphite furnace atomic absorption spectroscopy. Results.-Blood lead levels were low, ranging from less than 0.05 to 1.35 mu mol/L (<1 to 28 mu g/dL), with a mean (SD) of 0.30 (0.20) mu mol/L (6.3 [4.1] mu g/dL). Bone lead levels were similar to those described in other general populations. In comparison to nonhypertensives, mean levels of lead in blood and both tibia and patella bone lead levels were significantly higher in hypertensive subjects. In a logistic regression model of hypertensive status that began with age, race, body mass index, family history of hypertension, history of ethanol ingestion, pack-years of smoking, dietary sodium intake, dietary calcium intake, blood lead, tibia lead, and patella lead, the variables that remained after backward elimination were body mass index, family history of hypertension, and level of lead in the tibia. An increase from the midpoint of the lowest quintile to the midpoint of the highest quintile of tibia lead from 8 to 37 mu g per gram of bone mineral was associated with an increased odds ratio of hypertension of 1.5. Conclusion.-Our findings suggest that long-term lead accumulation, as reflected by levels of lead in bone, may be an independent risk factor for developing hypertension in men in the general population.	HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT HLTH PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; DEPT VET AFFAIRS,NORMAT AGING STUDY,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Hu, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIEHS NIH HHS [NIEHS ES 05257-01A1, NIEHS P42-ES05947, NIEHS 2 P30 ES 00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, P42ES005947, R01ES005257] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARRY PSI, 1970, BRIT J IND MED, V27, P339; BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; Bell B, 1972, AGING HUM DEVELOP, V3, P4; Burger D E, 1990, Basic Life Sci, V55, P287; *CDC, 1991, PREV LEAD POIS YOUNG; COCHRAN WG, 1968, TECHNOMETRICS, V10, P637, DOI 10.2307/1267450; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FINE BP, 1988, TOXICOL APPL PHARM, V93, P388, DOI 10.1016/0041-008X(88)90041-5; GORDON CL, 1993, BRIT J IND MED, V50, P637; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; HENSE HW, 1994, EPIDEMIOLOGY, V5, P120, DOI 10.1097/00001648-199401000-00018; HERTZPICCIOTTO I, 1993, EPIDEMIOL REV, V15, P352, DOI 10.1093/oxfordjournals.epirev.a036125; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; HU H, 1994, JAMA-J AM MED ASSOC, V272, P1512, DOI 10.1001/jama.272.19.1512; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; JONES KW, 1987, INVITRO BOD COMPOSIT, V363, P373; KIM R, 1995, PHYS MED BIOL, V40, P1475, DOI 10.1088/0031-9155/40/9/007; KOPP SJ, 1988, ENVIRON HEALTH PERSP, V78, P91, DOI 10.2307/3430507; LANDRIGAN PJ, 1994, JAMA-J AM MED ASSOC, V271, P239, DOI 10.1001/jama.271.3.239; LANDRIGAN PJ, 1991, ENVIRON HEALTH PERSP, V91, P81, DOI 10.2307/3430987; MANTON WI, 1985, BRIT J IND MED, V42, P168; PERRY HM, 1988, ENVIRON HEALTH PERSP, V78, P107, DOI 10.2307/3430509; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHROEDER HA, 1968, ARCH ENVIRON HEALTH, V17, P965, DOI 10.1080/00039896.1968.10665354; SCHWARTZ J, 1995, ARCH ENVIRON HEALTH, V50, P31, DOI 10.1080/00039896.1995.9955010; SHARP DS, 1990, AM J EPIDEMIOL, V131, P1098, DOI 10.1093/oxfordjournals.aje.a115603; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SHARP DS, 1990, AM J EPIDEMIOL, V131, P845, DOI 10.1093/oxfordjournals.aje.a115575; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; TYROLER HA, 1988, ENVIRON HEALTH PERSP, V78, P3, DOI 10.2307/3430491; WARD KD, 1994, INT J OBESITY, V18, P137; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780	37	242	252	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1171	1176		10.1001/jama.275.15.1171	http://dx.doi.org/10.1001/jama.275.15.1171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609684				2022-12-01	WOS:A1996UE62500028
J	Mayer, A; Wickner, W; Haas, A				Mayer, A; Wickner, W; Haas, A			Sec18p (NSF)-driven release of sec17p (alpha-SNAP) can precede docking and fusion of yeast vacuoles	CELL			English	Article							VESICULAR TRANSPORT; SACCHAROMYCES-CEREVISIAE; VESICLE FUSION; GOLGI STACK; MEMBRANE-PROTEINS; SEGREGATION; ATTACHMENT; PATHWAY; PURIFICATION; INHERITANCE	S. cerevisiae inherits its vacuole by projecting vacuole-derived membrane vesicles and tubules into the bud, where they fuse to establish the daughter vacuole. This homotypic fusion event can be assayed in vitro. It requires Sec17p and Sec18p, the homologs of the mammalian alpha-SNAP and NSF, which cooperate in multiple steps of membrane trafficking. We now report that Sec17p, Sec18p, and ATP are only needed for an early stage of the reaction that results in Sec17p release. Sec17p and Sec18p actions precede, and are needed for, the step employing the Ras-like GTPase Ypt7p. Sec18p-driven release of Sec17p can even precede vacuole docking, as it can occur prior to mixing of vacuoles and is insensitive to vacuole concentration. Sec17p and Sec18p thus may function in a predocking stage of the reaction, rather than in bilayer fusion per se.			Mayer, A (corresponding author), DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HAAS A, IN PRESS EMBO J; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NICOLSON TA, 1995, J CELL BIOL, V130, P835, DOI 10.1083/jcb.130.4.835; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XU Z, 1996, IN PRESS J CELL BIOL	63	496	501	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					83	94		10.1016/S0092-8674(00)81084-3	http://dx.doi.org/10.1016/S0092-8674(00)81084-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620540	hybrid			2022-12-01	WOS:A1996UE55900011
J	Nishiyama, KI; Suzuki, T; Tokuda, H				Nishiyama, KI; Suzuki, T; Tokuda, H			Inversion of the membrane topology of SecG coupled with SecA-dependent preprotein translocation	CELL			English	Article							PROTON MOTIVE FORCE; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; INNER MEMBRANE; INVITRO TRANSLOCATION; ALKALINE-PHOSPHATASE; SECRETORY PROTEINS; RECONSTITUTION	E. coli preprotein translocase comprises SecA and a SecY/E/G complex. SecA delivers the preprotein to the putative protein-conducting channel formed by SecY/E by undergoing ATP-driven cycles of membrane insertion and deinsertion. SecG renders the translocase highly efficient. An antibody raised against the C-terminal region of SecG inhibits preprotein translocation into everted membrane vesicles despite the exposure of this region to the inside of membrane vesicles in the absence of preprotein translocation. When preprotein translocation was started with ATP and then blocked by the inhibition of ATP hydrolysis, the C-terminal region was exposed to the outside of membrane vesicles. Another region of SecG showed a change in membrane sidedness upon preprotein translocation, indicating that SecG undergoes topology inversion. This topology inversion was tightly coupled to the SecG function and linked with the insertion-deinsertion cycle of SecA.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM YJ, 1994, CELL, V78, P845; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; NISHIYAMA K, 1992, J BIOL CHEM, V267, P7170; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1994, FEBS LETT, V346, P65, DOI 10.1016/0014-5793(94)00317-3; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	44	187	189	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					71	81		10.1016/S0092-8674(00)81083-1	http://dx.doi.org/10.1016/S0092-8674(00)81083-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620539	Bronze			2022-12-01	WOS:A1996UE55900010
J	Hareven, D; Gutfinger, T; Parnis, A; Eshed, Y; Lifschitz, E				Hareven, D; Gutfinger, T; Parnis, A; Eshed, Y; Lifschitz, E			The making of a compound leaf: Genetic manipulation of leaf architecture in tomato	CELL			English	Article							PLANT DEVELOPMENT; CLONAL ANALYSIS; HOMEOBOX GENE; MAIZE; EXPRESSION; LEAVES; KNOTTED-1; MERISTEM; FATES	The most distinctive morphogenetic feature of leaves is their being either simple or compound. To study the basis for this dichotomy, we have exploited the maize homeobox-containing Knotted-1 (Kn1) gene in conjunction with mutations that alter the tomato compound leaf. We show that misexpression of Kn1 confers different phenotypes on simple and compound leaves. Up to 2000 leaflets, organized in compound reiterated units, are formed in tomato leaves expressing Kn1. In contrast, Kn1 induces leaf malformations but fails to elicit leaf ramification in plants with inherent simple leaves such as Arabidopsis or in tomato mutant plants with simple leaves. Moreover, the tomato Kn1 ortholog, unlike that of Arabidopsis, is expressed in the leaf primordia. Presumably, the two alternative leaf forms are conditioned by different developmental programs in the primary appendage that is common to all types of leaves.	HEBREW UNIV JERUSALEM, FAC AGR, DEPT GENET & FIELD CROPS, IL-70700 REHOVOT, ISRAEL	Hebrew University of Jerusalem	Hareven, D (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.			Eshed, Yuval/0000-0001-8290-0018				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BECRAFT PW, 1994, GENETICS, V136, P295; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CARUSO JL, 1968, AM J BOT, V55, P1169, DOI 10.2307/2440737; CUTTER EG, 1971, PLANT ANATOMY EXPT I, P117; DENGLER NG, 1984, BOT GAZ, V145, P66, DOI 10.1086/337428; DOLAN L, 1991, DEVELOPMENT, P39; FREELING M, 1992, DEV BIOL, V153, P44, DOI 10.1016/0012-1606(92)90090-4; FREELING M, 1985, GENETICS, V111, P617; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; HAREVEN D, 1994, EUPHYTICA, V79, P235, DOI 10.1007/BF00022524; HELM J., 1951, Zuchter, V21, P89, DOI 10.1007/BF00710588; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D.P., 1991, MOL PLANT PATHOLOGY; KAPLAN D R, 1973, Cellule, V69, P251; KAPLAN DR, 1983, SCI AM, V249, P98, DOI 10.1038/scientificamerican0783-98; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MARKS GA, 1987, PLANT MOL BIOL REP, V5, P311; MATHAN DS, 1962, AM J BOT, V49, P504, DOI 10.2307/2439421; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MCCORMICK S, 1991, PLANT TISSUE CULTU B, V6, P1; PNUELI L, 1994, PLANT CELL, V6, P175, DOI 10.1105/tpc.6.2.175; POETHIG RS, 1985, PLANTA, V165, P170, DOI 10.1007/BF00395039; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; SIHA N, 1994, DEV GENET, V15, P401; SINHA N, 1993, CURR TOP DEV BIOL, V28, P47, DOI 10.1016/S0070-2153(08)60209-4; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; SMITH LG, 1992, DEVELOPMENT, V116, P21; Steeves TA, 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STETTLER RF, 1964, AM J BOT, V51, P253, DOI 10.2307/2440294; STEVENS AM, 1986, TOMATO CROP; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	41	325	353	2	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					735	744		10.1016/S0092-8674(00)81051-X	http://dx.doi.org/10.1016/S0092-8674(00)81051-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625411	Bronze			2022-12-01	WOS:A1996TZ99000011
J	Gurley, RJ; Lum, N; Sande, M; Lo, B; Katz, MH				Gurley, RJ; Lum, N; Sande, M; Lo, B; Katz, MH			Persons found in their homes helpless or dead	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPORT	Background. Healthcare providers and providers of emergency services are sometimes Galled to help with people who are found alone in their homes either helpless or dead. It is not known who is at risk for being found helpless or dead, what the mortality rates are among those found alive, or how frequently this situation occurs. Methods. We conducted a population-based study of patients who were found in their homes either helpless or dead. Over 12 weeks, paramedics employed by the city of San Francisco identified 387 such events involving 367 persons. We obtained information on these patients from the emergency-medical-services department or the hospitals to which they were taken and determined their outcomes. Results. The median age of the persons found helpless or dead was 73 years; 51 percent were women. The frequency of such incidents increased sharply with age, from a rate of 3 per 1000 per year among those 60 to 64 years of age to 27 per 1000 per year among those 85 years of age or older. The highest rate was among men 85 years and older who were living alone (123 per 1000 per year). In 23 percent of the cases, the person was found dead, an additional 5 percent died in the hospital. Thus, total mortality was 28 percent, Of the patients found alive, 62 percent were admitted to the hospital. The average hospital stay was eight days, and 52 percent of those admitted required intensive care. Of the survivors, 62 percent were unable to return to living independently. The total mortality was 67 percent for patients who were estimated to have been helpless for more than 72 hours, as compared with 12 percent for those who had been helpless for less than 1 hour. Conclusions. For elderly people who live alone, becoming incapacitated and unable to Set help is a common event, which usually marks the end of their ability to live independently. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; CITY & CTY SAN FRANCISCO,DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO & BERKELEY,JOINT MED SCH PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco Department of Public Health; University of California System; University of California San Francisco								Cantor M., 1985, HDB AGING SOCIAL SCI, P745; CRIMMINS EM, 1990, RES AGING, V12, P3, DOI 10.1177/0164027590121001; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Hennon C. B., 1983, FAM RELAT, P149; JACOBSEN SJ, 1990, AM J PUBLIC HEALTH, V80, P871, DOI 10.2105/AJPH.80.7.871; STEINBACH U, 1992, J GERONTOL, V47, pS183, DOI 10.1093/geronj/47.4.S183; TREAS J, 1977, GERONTOLOGIST, V17, P486, DOI 10.1093/geront/17.6.486; TREAS J, 1981, GERONTOLOGIST, V21, P98; 1993, STAT B METROP INSUR, V74, P2	10	141	142	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1710	1716		10.1056/NEJM199606273342606	http://dx.doi.org/10.1056/NEJM199606273342606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637517				2022-12-01	WOS:A1996UT40000006
J	Merson, MH				Merson, MH			Returning home: Reflections on the USA's response to the HIV AIDS epidemic	LANCET			English	Editorial Material											Merson, MH (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 20834,NEW HAVEN,CT 06520, USA.							BRANDT A, 1987, NO MAGIC BULLET; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; FRANCIS DP, 1992, JAMA-J AM MED ASSOC, V268, P1444, DOI 10.1001/jama.268.11.1444; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; NORMAND J, 1995, PREVENTING HIV TRANS; *OFF TECHN ASS, 1995, EFF AIDS PREV EFF; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; STRYKER J, 1995, JAMA-J AM MED ASSOC, V273, P1143, DOI 10.1001/jama.273.14.1143; 1993, MMWR MORBID MORTAL W, V42, P337; 1993, INVESTING HLTH, P99; 1993, MMWR MORBID MORTAL W, V42, P329; 1995, MMWR MORBID MORTAL W, V44, P849	16	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1673	1676		10.1016/S0140-6736(96)91494-4	http://dx.doi.org/10.1016/S0140-6736(96)91494-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642965	hybrid			2022-12-01	WOS:A1996UQ70100017
J	Wong, VS; Wreghitt, TG; Alexander, GJM				Wong, VS; Wreghitt, TG; Alexander, GJM			Prospective study of hepatitis B vaccination in patients with chronic hepatitis C	BRITISH MEDICAL JOURNAL			English	Article							STRATEGIES		UNIV CAMBRIDGE,SCH CLIN MED,ADDENBROOKES NHS TRUST,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES NHS TRUST,DEPT VIROL,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital								ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; CATTERALL AP, 1992, GUT, V33, P576, DOI 10.1136/gut.33.5.576; ESTEBAN R, 1993, J HEPATOL, V17, P567; ILAN Y, 1994, ISRAEL J MED SCI, V30, P259; 1987, UPDATE HEPATITIS B P, V107, P353	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1336	1337		10.1136/bmj.312.7042.1336	http://dx.doi.org/10.1136/bmj.312.7042.1336			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646046	Green Published			2022-12-01	WOS:A1996UN47600021
J	Mrzljak, L; Bergson, C; Pappy, M; Huff, R; Levenson, R; GoldmanRakic, PS				Mrzljak, L; Bergson, C; Pappy, M; Huff, R; Levenson, R; GoldmanRakic, PS			Localization of dopamine D4 receptors in GABAergic neurons of the primate brain	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; SOMATOSTATIN; SLEEP; METABOLITES; INHIBITION; CA1	DOPAMINE receptors are the principal targets of drugs used in the treatment of schizophrenia(1). Among the five mammalian dopamine-receptor subtypes, the D4 subtype is of particular interest because of its high affinity for the atypical neuroleptic clozapine(1-3). Interest in clozapine stems from its effectiveness in reducing positive and negative symptoms in acutely psychotic and treatment-resistant schizophrenic patients,without eliciting extrapyramidal side effects(4). We have produced a subtype-specific antibody against the D4 receptor and localized it within specific cellular elements and synaptic circuits of the central nervous system. The D4-receptor antibody labelled GABAergic neurons in the cerebral cortex, hippocampus, thalamic reticular nucleus, globus pallidus and the substantia nigra (pars reticulata). Labelling was also observed in a subset of cortical pyramidal cells. Our findings suggest that clozapine's beneficial effects in schizophrenia may be achieved, in part, through D4-mediated GABA modulation, possibly implicating disinhibition of excitatory transmission in intrinsic cortical, thalamocortical and extrapyramidal pathways.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510; PENN STATE UNIV,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; UPJOHN PHARMACIA CELL BIOL,KALAMAZOO,MI 49001	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Levenson, Robert/0000-0002-0936-8421				ANDERSEN P, 1971, EXP BRAIN RES, V13, P208; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P607; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DELECEA L, 1994, MOL BRAIN RES, V25, P286, DOI 10.1016/0169-328X(94)90164-3; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; MAURER R, 1982, P NATL ACAD SCI-BIOL, V79, P4815, DOI 10.1073/pnas.79.15.4815; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHARFMAN HE, 1989, BRAIN RES, V493, P205, DOI 10.1016/0006-8993(89)91155-4; SCHONBRUNN AH, 1978, J BIOL CHEM, V235, P6473; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIROMANI PJ, 1987, ANNU REV PHARMACOL, V27, P137; STEFFENSEN SC, 1991, BRAIN RES, V538, P46, DOI 10.1016/0006-8993(91)90374-5; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VEBER DF, 1979, NATURE, V280, P512, DOI 10.1038/280512a0	21	389	403	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					245	248		10.1038/381245a0	http://dx.doi.org/10.1038/381245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622768				2022-12-01	WOS:A1996UL24900057
J	Niemann, HB; Atreya, SK; Carignan, GR; Donahue, TM; Haberman, JA; Harpold, DN; Hartle, RE; Hunten, DM; Kasprzak, WT; Mahaffy, PR; Owen, TC; Spencer, NW; Way, SH				Niemann, HB; Atreya, SK; Carignan, GR; Donahue, TM; Haberman, JA; Harpold, DN; Hartle, RE; Hunten, DM; Kasprzak, WT; Mahaffy, PR; Owen, TC; Spencer, NW; Way, SH			The Galileo probe mass spectrometer: Composition of Jupiter's atmosphere	SCIENCE			English	Article							GIANT PLANETS; ABUNDANCES; SATURN; SOLAR; RATIO	The composition of the jovian atmosphere from 0.5 to 21 bars along the descent trajectory was determined by a quadrupole mass spectrometer on the Galileo probe. The mixing ratio of He (helium) to H-2 (hydrogen), 0.156, is close to the solar ratio. The abundances of methane, water, argon, neon, and hydrogen sulfide were measured; krypton and xenon were detected. As measured in the jovian atmosphere, the amount of carbon is 2.9 times the solar abundance relative to H-2, the amount of sulfur is greater than the solar abundance, and the amount of oxygen is much less than the solar abundance. The neon abundance compared with that of hydrogen is about an order of magnitude less than the solar abundance. Isotopic ratios of carbon and the noble gases are consistent with solar values. The measured ratio of deuterium to hydrogen (D/H) of (5 +/- 2) x 10(-5) indicates that this ratio is greater in solar-system hydrogen than in local interstellar hydrogen, and the He-3/He-4 ratio of (1.1 +/- 0.2) x 10(-4) provides a new value for protosolar (solar nebula) helium isotopes. Together, the D/H and He-3/He-4 ratios are consistent with conversion in the sun of protosolar deuterium to present-day He-3.	UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822	University of Michigan System; University of Michigan; University of Arizona; University of Hawaii System	Niemann, HB (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771, USA.		Mahaffy, Paul/E-4609-2012; Harpold, Dan/I-3345-2013	Mahaffy, Paul/0000-0003-1896-1726; 				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; DEPATER I, 1985, ICARUS, V62, P143, DOI 10.1016/0019-1035(85)90177-0; GAUTIER D, 1989, ORIGIN EVOLUTION PLA, P504; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; LINSKY JL, 1993, ASTROPHYS J, V402, P694, DOI 10.1086/172170; LINSKY JL, 1995, LIGHT ELEMENT ABUNDA, P215; LUNINE JI, 1985, ASTROPHYS J SUPPL S, V58, P493, DOI 10.1086/191050; MARTEN A, 1980, ICARUS, V41, P410, DOI 10.1016/0019-1035(80)90225-0; Mason B., 1962, METEORITES; NIEMANN HB, 1992, SPACE SCI REV, V60, P111, DOI 10.1007/BF00216852; NOLL KS, 1991, ICARUS, V89, P168, DOI 10.1016/0019-1035(91)90096-C; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; POLLACK JB, 1989, ORIGIN EVOLUTION PLA, P564; RAGENT B, 1996, SCIENCE, V272, P855; Roulston M. S, 1995, EOS ABSTR AGU FALL M, V76, P343; SMITH WH, 1989, ASTROPHYS J, V336, P967, DOI 10.1086/167067; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; SPRAGUE AL, IN PRESS ICARUS; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; WIIK HB, 1956, GEOCHIM COSMOCHIM AC, V9, P279, DOI 10.1016/0016-7037(56)90028-X; [No title captured]	29	207	211	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					846	849		10.1126/science.272.5263.846	http://dx.doi.org/10.1126/science.272.5263.846			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629016				2022-12-01	WOS:A1996UK75700049
J	Muller, JE; Mittleman, MA; Maclure, M; Sherwood, JB; Tofler, GH				Muller, JE; Mittleman, MA; Maclure, M; Sherwood, JB; Tofler, GH			Triggering myocardial infarction by sexual activity - Low absolute risk and prevention by regular physical exertion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the relative risks of nonfatal myocardial infarction (MI) triggered by sexual activity among the general population and in patients with prior coronary heart disease. Design.-Relative risks and effect modification were calculated by the case-crossover method, a new epidemiologic technique designed to quantify the transient change in risk following exposure to a potential disease trigger. Setting/Participants.-A total of 1774 patients with MI were interviewed in 45 hospitals throughout the United States. Data were gathered on potential triggers of MI occurring immediately prior to the event and during the previous year. Results are presented for the 858 patients who were sexually active in the year prior to the MI, with attention to the 273 patients who had coronary artery disease prior to their index MI, and the effect of regular exertion on risk. Main Outcome Measure.-The relative risk of nonfatal MI following sexual activity. Results.-Of the 858 patients, 79 (9%) reported sexual activity in the 24 hours preceding MI, and 27 (3%) reported sexual activity in the 2 hours preceding onset of symptoms of MI. The relative risk of MI occurring in the 2 hours after sexual activity was 2.5 (95% confidence interval [CI], 1.7-3.7). The relative risk of triggering onset of MI among patients with a history of prior angina (2.1 [95% CI, 0.8-5.8]) or prior MI (2.9 [95% CI, 1.3-6.5) was not greater than that observed in those without prior cardiac disease. Sexual activity was a likely contributor to the onset of MI in only 0.9% of cases and regular exertion was associated with decreasing risk. Conclusions.-Sexual activity can trigger the onset of MI, However, the relative risk is low, and since the absolute hourly risk of MI is extremely low, the absolute risk increase caused by sexual activity also is extremely low (1 chance in a million for a healthy individual). Moreover, the relative risk is not increased in patients with a prior history of cardiac disease and regular exercise appears to prevent triggering, These findings should be useful for counseling patients and decreasing the fear of sexual activity that often prevents complete rehabilitation from cardiovascular disease.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Muller, JE (corresponding author), DEACONESS HOSP,DIV CARDIOVASC,INST PREVENT CARDIOVASC DIS,DEPT MED,1 AUTUMN ST,5TH FLOOR,BOSTON,MA 02215, USA.			Mittleman, Murray/0000-0001-9788-7274	NHLBI NIH HHS [HL41016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 1995, 1995 STAT SUPPL HEAR; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANDERSON KM, 1993, AM HEART J, V121, P293; ESLER M, 1995, J CLIN ENDOCR METAB, V80, P435, DOI 10.1210/jc.80.2.435; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HELLERSTEIN HK, 1970, ARCH INTERN MED, V125, P987, DOI 10.1001/archinte.125.6.987; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; NALBANTGIL I, 1976, AM HEART J, V91, P405, DOI 10.1016/S0002-8703(76)80235-9; PAPADOPOULOS C, 1980, ARCH INTERN MED, V140, P38, DOI 10.1001/archinte.140.1.38; PAPADOPOULOS C, 1986, CHEST, V90, P681, DOI 10.1378/chest.90.5.681; ROTHMAN KJ, 1981, AM J EPIDEMIOL, V114, P253, DOI 10.1093/oxfordjournals.aje.a113189; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; STEIN RA, 1977, CIRCULATION, V55, P738, DOI 10.1161/01.CIR.55.5.738; TARDIF GS, 1989, ARCH PHYS MED REHAB, V70, P763; TRIMBLE GX, 1970, MED ASPECTS HUM SEX, V5, P64; UENO M, 1963, JPN J LEGAL MED, V17, P330; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396	23	281	293	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1405	1409		10.1001/jama.275.18.1405	http://dx.doi.org/10.1001/jama.275.18.1405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618365				2022-12-01	WOS:A1996UJ30300025
J	Foulkes, NS; Duval, G; SassoneCorsi, P				Foulkes, NS; Duval, G; SassoneCorsi, P			Adaptive inducibility of CREM as transcriptional memory of circadian rhythms	NATURE			English	Article							PINEAL N-ACETYLTRANSFERASE; BETA-ADRENERGIC-RECEPTOR; GLAND; SPERMATOGENESIS; EXPRESSION; REPRESSOR; DIRECTS; SWITCH	THE CREM gene(1-4) encodes the transcriptional repressor ICER(3,5), which has been implicated in the molecular mechanisms controlling circadian rhythms in mammals(4-6). ICER is rhythmically expressed in the pineal gland, with peak levels occurring at night(5). ICER levels are regulated by light by means of the suprachiasmatic nucleus (SCN); transcription is induced during darkness by adrenergic input to the pineal gland from the SCN, which activates the ICER promoter using cyclic AMP and the transcriptional activator CREB. This induction is transient because ICER represses its own transcription(3), Here we show that the response of the CREM gene to adrenergic stimulation is determined by night length, Depending on the photoperiod of the prior entraining cycles, the CREM gene is either subsensitive or supersensitive to induction. This differential responsiveness is controlled by the changing balance between positive (CREB) and negative (ICER) transcriptional regulators. Thus, the transcriptional response of the CREM gene is determined by the memory of past photoperiods.	INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Jansen, Heiko T./A-5770-2008; Foulkes, Nicholas S/K-7003-2013	Jansen, Heiko T./0000-0003-0178-396X; Foulkes, Nicholas S/0000-0002-1794-9891				ARMSTRONG A, 1995, MOL CELL BIOL, V15, P1826; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; DEGUCHI T, 1973, P NATL ACAD SCI USA, V70, P2411, DOI 10.1073/pnas.70.8.2411; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; ILLNEROVA H, 1985, J PINEAL RES, V2, P67, DOI 10.1111/j.1600-079X.1985.tb00628.x; ILLNEROVA H, 1988, PINEAL RES REV, V6, P173; ILNEROVA H, 1986, CIRCADIAN RHYTHMS MA, P1; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P2107, DOI 10.1073/pnas.72.6.2107; ROMERO JA, 1974, SCIENCE, V184, P1091, DOI 10.1126/science.184.4141.1091; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P1661, DOI 10.1073/pnas.72.5.1661; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SASSONECORSI PA, 1995, REV CELL DEV BIOL, V11, P355; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEHLE JH, 1995, MOL ENDOCRINOL, V9, P706, DOI 10.1210/me.9.6.706; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; SUMIOVA A, 1995, P NATL ACAD SCI USA, V92, P7754; TAKAHASHI JS, 1994, CURR BIOL, V4, P165, DOI 10.1016/S0960-9822(94)00040-0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	85	85	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					83	85		10.1038/381083a0	http://dx.doi.org/10.1038/381083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609995				2022-12-01	WOS:A1996UJ05300062
J	Mahon, BE; Mintz, ED; Greene, KD; Wells, JG; Tauxe, RV				Mahon, BE; Mintz, ED; Greene, KD; Wells, JG; Tauxe, RV			Reported cholera in the United States, 1992-1994 - A reflection of global changes in cholera epidemiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIBRIO-CHOLERAE; OUTBREAK; AMERICA; STRAIN; VCA-3	Objective.-To describe US cholera surveillance data from 1992 to 1994 and the domestic impact of the epidemics of Vibrio cholerae O1 in Latin America and V cholerae O139 in Asia. Design, Setting, and Participants.-Retrospective review of surveillance data from all cases of cholera reported to the Centers for Disease Control and Prevention (CDC) from January 1, 1992, through December 31, 1994, in the United States and its territories. Main Outcome Measures.-Clinical, epidemiologic, and laboratory surveillance data. Results.-From 1992 through 1994, 160 cases of cholera were reported to CDC by 20 states and 1 territory. This is a marked increase: only 136 cases were reported from 1965 through 1991. Outbreaks affecting 75 passengers on an airplane from Latin America and 5 passengers on a cruise ship in Southeast Asia accounted for 50% of cases. Vibrio cholerae O139 caused 6 cases (4%). The proportion of V cholerae O1 isolates resistant to at least 1 antimicrobial agent rose from 3% in 1992 to 93% in 1994. Of 158 patients whose location of exposure was known, 151 (96%) acquired infection abroad (125 in Latin America, 26 in Asia). Of 105 persons whose reason for travel was known, 31 (30%) were US residents who had returned to their country of origin to visit family or friends, and 65 (62%) were non-US residents visiting the United States from cholera-affected countries. The cholera rate among persons arriving in the United States from cholera-affected regions was 0.27 case per 100 000 air travelers, not substantially increased from earlier estimates. Conclusions.-Cholera has increased in the United States since 1991, reflecting global changes in cholera epidemiology, and is now primarily travel associated and antimicrobial resistant. Most travelers were not traditional tourists; reaching them with prevention measures may be difficult. The risk of cholera to the individual traveler remains extremely low.			Mahon, BE (corresponding author), CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							ALBERT MJ, 1993, LANCET, V341, P704; ALMEIDA RJ, 1992, J CLIN MICROBIOL, V30, P300, DOI 10.1128/JCM.30.2.300-304.1992; BART KJ, 1970, J INFECT DIS, V121, pS17, DOI 10.1093/infdis/121.Supplement.S17; BESSER RE, 1994, JAMA-J AM MED ASSOC, V272, P1203, DOI 10.1001/jama.272.15.1203; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; BOYCE TG, 1995, J INFECT DIS, V172, P1401, DOI 10.1093/infdis/172.5.1401; *CDCP, 1995, HLTH INF INT TRAV 19; CHONGSANGUAN M, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92841-G; EberhartPhillips J, 1996, EPIDEMIOL INFECT, V116, P9, DOI 10.1017/S0950268800058891; EVINS GM, 1995, J INFECT DIS, V172, P173, DOI 10.1093/infdis/172.1.173; FINELLI L, 1992, J INFECT DIS, V166, P1433, DOI 10.1093/infdis/166.6.1433; GOLDBERG S, 1983, INFECT IMMUN, V42, P224, DOI 10.1128/IAI.42.1.224-230.1983; JOHNSTON JM, 1983, NEW ENGL J MED, V309, P523, DOI 10.1056/NEJM198309013090903; KLONTZ KC, 1987, ANN INTERN MED, V107, P846, DOI 10.7326/0003-4819-107-6-846; Levine Myron M., 1994, P395; LOWRY PW, 1989, ARCH INTERN MED, V149, P2079, DOI 10.1001/archinte.149.9.2079; MACPHERSON DW, 1992, CAN MED ASSOC J, V146, P1947; MEKALANOS JJ, 1994, SCIENCE, V265, P1387, DOI 10.1126/science.8073279; *NAT COMM CLIN LAB, 1993, M2A5 NAT COMM CLIN L; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; SHIMADA T, 1993, LANCET, V341, P1347; SNYDER JD, 1982, JAMA-J AM MED ASSOC, V247, P2268, DOI 10.1001/jama.1982.03320410050031; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; TAYLOR JL, 1993, J INFECT DIS, V167, P1330, DOI 10.1093/infdis/167.6.1330; *US DEP TRANSP, 1995, INT AIR TRAV STAT 19; WEBER JT, 1994, ARCH INTERN MED, V154, P551, DOI 10.1001/archinte.154.5.551; WEISSMAN JB, 1975, AM J EPIDEMIOL, V100, P487; *WHO, 1991, WHO PROGR CONTR DIAR; WOODWARD WE, 1970, J INFECT DIS, V121, pS10, DOI 10.1093/infdis/121.Supplement.S10; 1991, MMWR-MORBID MORTAL W, V40, P516; 1991, MMWR-MORBID MORTAL W, V40, P108; 1995, WKLY EPIDEMIOL REC, V70, P201; 1977, MMWR-MORBID MORTAL W, V26, P307; 1995, EPIDEMIOL B PAN AM H, V16, P11; 1993, LANCET, V342, P387; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P501; 1995, MMWR-MORBID MORTAL W, V44, P385; 1992, MMWR-MORBID MORTAL W, V41, P664; 1977, MMWR-MORBID MORTAL W, V26, P302; 1988, MMWR-MORBID MORTAL W, V37, P617; 1995, MMWR-MORBID MORTAL W, V44, P215	44	34	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1996	276	4					307	312		10.1001/jama.276.4.307	http://dx.doi.org/10.1001/jama.276.4.307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX583	8656543				2022-12-01	WOS:A1996UX58300036
J	Petitti, DB; Sidney, S; Bernstein, A; Wolf, S; Quesenberry, C; Ziel, HK				Petitti, DB; Sidney, S; Bernstein, A; Wolf, S; Quesenberry, C; Ziel, HK			Stroke in users of low-dose oral contraceptives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOEMBOLIC DISEASE; RISK; PROGESTOGENS; SAFETY	Background Previous studies have linked the use of oral contraceptive agents to an increased risk of stroke, but those studies have been limited to oral contraceptives containing more estrogen than is now generally used. Methods In a population-based, case-control study, we identified fatal and nonfatal strokes in female members of the California Kaiser Permanente Medical Care Program who were 15 through 44 years of age. Matched controls were randomly selected from female members who had not had strokes. Information about the use of oral contraceptives (essentially limited to low-estrogen preparations) was obtained in interviews. Results-A total of 408 confirmed strokes occurred in a total of 1.1 million women during 3.6 million woman-years of observation. The incidence of stroke was thus 11.3 per 100,000 woman-years. On the basis of data from 295 women with stroke who were interviewed and their controls, the odds ratio for ischemic stroke among current users of oral contraceptives, as compared with former users and women who had never used such drugs, was 1.18 (95 percent confidence interval, 0.54 to 2.59) after adjustment for other risk factors for stroke. The adjusted odds ratio for hemorrhagic stroke was 1.14 (95 percent confidence interval, 0.60 to 2.16). With respect to the risk of hemorrhagic stroke, there was a positive interaction between the current use of oral contraceptives and smoking (odds ratio for women with both these factors, 3.64; 95 percent confidence interval, 0.95 to 13.87). Conclusions Stroke is rare among women of childbearing age. Low-estrogen oral-contraceptive preparations do not appear to increase the risk of stroke. (C)1996, Massachusetts Medical Society.	KAISER PERMANENTE MED CARE PROGRAM,PASADENA,CA; KAISER PERMANENTE MED CARE PROGRAM,OAKLAND,CA	Kaiser Permanente; Kaiser Permanente					NICHD NIH HHS [N01-HD-3108] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1995, LANCET, V346, P1575; DYKEN ML, 1984, STROKE, V15, P1105; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Lorentz IT, 1962, BRIT MED J, V2, P1191; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; ORY HW, 1983, MAKING CHOICES; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; 1975, JAMA-J AM MED ASSOC, V231, P718	19	268	274	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					8	15		10.1056/NEJM199607043350102	http://dx.doi.org/10.1056/NEJM199607043350102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637557				2022-12-01	WOS:A1996UU47900002
J	Wesson, DR; Ling, W				Wesson, DR; Ling, W			Addiction medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL DEPENDENCE; BUPRENORPHINE; NALTREXONE		SUMMIT MED CTR, OAKLAND, CA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	Wesson, DR (corresponding author), UNIV CALIF SAN FRANCISCO, OAKLAND, CA USA.			, Walter/0000-0003-0664-5099				ALTERMAN AI, 1994, J NERV MENT DIS, V182, P157, DOI 10.1097/00005053-199403000-00005; CALHOUN S, IN PRESS PSYCHOACTIV; DOLE VP, 1995, JAMA-J AM MED ASSOC, V274, P1307; FRATTOLA L, 1990, DRUG EXP CLIN RES, V16, P371; HOLLANDER JE, 1995, ANN EMERG MED, V26, P671, DOI 10.1016/S0196-0644(95)70035-8; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; LESHNER A, 1995, NIDA NOTES, V10, P3; Ling W, 1996, ARCH GEN PSYCHIAT, V53, P401; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; ROBINSON GM, 1993, DRUG ALCOHOL DEPEN, V33, P81, DOI 10.1016/0376-8716(93)90036-P; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876	11	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1792	1793		10.1001/jama.275.23.1792	http://dx.doi.org/10.1001/jama.275.23.1792			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642712				2022-12-01	WOS:A1996UQ15200011
J	Davenport, RJ; Dennis, MS; Warlow, CP				Davenport, RJ; Dennis, MS; Warlow, CP			Effect of correcting outcome data for case mix: An example from stroke medicine	BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE	Objective-To show the influence of variations in case mix on clinical outcome indicators for patients admitted to hospital with acute stroke. Design-''Before and after'' cohort study, with prospective, consecutive identification of patients and prospective follow up; multiple logistic regression analyses to correct for case mix variations. Setting-University teaching hospital. Subjects-216 patients with stroke identified before the introduction of an organised stroke service, and 252 patients with stroke identified after its introduction. Main outcome measures-Case fatality at 30 days and 12 months; for survivors at 12 months, proportions of patients who were independent (according to the Oxford handicap scale) and of those living at home. Results-Crude outcome data suggested that patients in the cohort identified after the introduction of the stroke service were significantly more likely to be alive, independent, and living at home than patients managed before the stroke service. After adjustment for age and sex these ''improvements'' were less impressive but still significant. After adjustment for many other possible prognostic indicators, however, the differences between the two groups for all four outcomes were non-significant, suggesting that the ''improvements'' may have been entirely due to differences in case mix between the two cohorts, rather than the new stroke service. Conclusions-Variations in case mix have a crucial influence on the interpretation of outcome data, and this is particularly important in non-randomised comparative studies. Such studies, comparing performance within and between different provider units, are likely to become increasingly common in the new reformed NHS. To allow meaningful interpretation, these studies must try to correct for case mix.			Davenport, RJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BION J, 1993, BRIT MED J, V307, P953, DOI 10.1136/bmj.307.6910.953; Carstairs V, 1991, DEPRIVATION HLTH; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; *SCOTT OFF, 1994, CLIN OUTC IND; *SCOTT OFF, 1995, CLIN OUTC IND; WARLOW C, 1995, STROKE MODULE COCHRA; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539	15	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1503	1505		10.1136/bmj.312.7045.1503	http://dx.doi.org/10.1136/bmj.312.7045.1503			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646140	Green Published			2022-12-01	WOS:A1996UR82300018
J	Kirkwood, A; Rioult, MG; Bear, MF				Kirkwood, A; Rioult, MG; Bear, MF			Experience-dependent modification of synaptic plasticity in visual cortex	NATURE			English	Article							LONG-TERM DEPRESSION; AREA CA1; HIPPOCAMPUS; NEURONS; RAT	IN many regions of the cerebral cortex, Ca2+ influx through NMDA (N-methyl-D-aspartate) sensitive glutamate receptors (NMDA receptors) can trigger two forms of synaptic plasticity: long-term depression (LTD) and long-term potentiation (LTP)(1). LTD is induced by low levels of postsynaptic NMDA-receptor activation, for instance in response to low-frequency stimulation, whereas LTP is induced by the stronger activation that occurs following high-frequency stimulation(2-4). Theoretical studies have shown that the properties of synaptic LTD and LTP can account for many aspects of experience-dependent plasticity in the developing visual cortex, provided that the LTD-LTP crossover point (the modification threshold, theta(m)) varies as a function of the history of cortical activity(5-7). Here we provide direct experimental evidence that the value of theta(m) depends on sensory experience. We find in visual cortex of light-deprived rats that LTP is enhanced and LTD diminished over a range of stimulation frequencies, and that these effects can be reversed by as little as two days of light exposure. Our findings support the idea that a variable synaptic-modification threshold allows synaptic weights in neural networks to achieve a stable equilibrium.	BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912; BROWN UNIV,HOWARD HUGHES MED INST,PROVIDENCE,RI 02912	Brown University; Brown University; Howard Hughes Medical Institute				Rioult, Marika G/0000-0002-7473-2664; Bear, Mark/0000-0002-9903-2541				Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BUISSERET P, 1976, J PHYSIOL-LONDON, V255, P511, DOI 10.1113/jphysiol.1976.sp011293; BUISSERET P, 1978, NATURE, V272, P816, DOI 10.1038/272816a0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CLOTHIAUX EE, 1991, J NEUROPHYSIOL, V66, P1785, DOI 10.1152/jn.1991.66.5.1785; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; GABBOTT PLA, 1986, EXP BRAIN RES, V64, P225; KERR DS, 1996, P NATL ACAD SCI USA, V62, P11637; Kimura F, 1990, Neuroreport, V1, P65, DOI 10.1097/00001756-199009000-00018; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; MAYFORD M, 1905, CELL, V81, P1; Mulkey R. M., 1992, Society for Neuroscience Abstracts, V18, P1498; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; SELIG DK, 1995, NEURON, V15, P417, DOI 10.1016/0896-6273(95)90045-4; SHOUVAL H, IN PRESS NEURAL COMP; Steele P. M., 1994, Society for Neuroscience Abstracts, V20, P1514; WAGNER JJ, 1995, J NEUROSCI, V15, P1577; WEXLER EM, 1993, NEUROREPORT, V4, P591, DOI 10.1097/00001756-199305000-00034	30	444	453	2	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					526	528		10.1038/381526a0	http://dx.doi.org/10.1038/381526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632826				2022-12-01	WOS:A1996UP43500061
J	Brooks, PC; Stromblad, S; Sanders, LC; vonSchalscha, TL; Aimes, RT; StetlerStevenson, WG; Quigley, JP; Cheresh, DA				Brooks, PC; Stromblad, S; Sanders, LC; vonSchalscha, TL; Aimes, RT; StetlerStevenson, WG; Quigley, JP; Cheresh, DA			Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3	CELL			English	Article							EXTRACELLULAR-MATRIX; IV COLLAGENASE; ADHESION MOLECULES; UROKINASE RECEPTOR; TUMOR PROGRESSION; METASTASIS; VITRONECTIN; BINDING; EXPRESSION; INHIBITOR	Cellular invasion depends on cooperation between adhesive and proteolytic mechanisms. Evidence is provided that the matrix metalloproteinase MMP-2 can be localized in a proteolytically active form on the surface of invasive cells, based on its ability to bind directly integrin alpha v beta 3. MMP-2 and alpha v beta 3 were specifically colocalized on angiogenic blood vessels and melanoma cells in vivo. Expression of alpha v beta 3 on cultured melanoma cells enabled their binding to MMP-2 in a proteolytically active form, facilitating cell-mediated collagen degradation. In vitro, these proteins formed an SDS-stable complex that depended on the noncatalytic C-terminus of MMP-2, since a truncation mutant lost the ability to bind alpha v beta 3. These findings define a single cell-surface receptor that regulates both matrix degradation and motility, thereby facilitating directed cellular invasion.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA	Scripps Research Institute; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brooks, PC (corresponding author), Scripps Res Inst, DEPT IMMUNOL, IMM24 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Stromblad, Staffan/0000-0002-1236-6339	NATIONAL CANCER INSTITUTE [R01CA050286, R37CA050286, R01CA045726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45726, CA-50286] Funding Source: Medline; NHLBI NIH HHS [HL-54444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1990, CANCER RES, V50, P6757; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN PD, 1990, CANCER RES, V50, P6184; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; EMONARD HP, 1992, CANCER RES, V52, P5845; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FILARDO EJ, 1996, IN PRESS J CELL SCI; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GREVIN D, 1993, INT J DEV BIOL, V37, P519; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024; KNUDSEN KA, 1982, J CELL BIOCHEM, V18, P157, DOI 10.1002/jcb.1982.240180204; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MUELLER SC, 1991, J CELL SCI, V99, P213; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NEWMAN PJ, 1985, BLOOD, V65, P227; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PEPPER MS, 1994, J CELL BIOCHEM, V55, P419, DOI 10.1002/jcb.240550403; PFAFF M, 1994, J BIOL CHEM, V269, P20233; REINARTZ J, 1994, EXP CELL RES, V214, P486, DOI 10.1006/excr.1994.1286; RUCKLIDGE GJ, 1994, BIOCHEM SOC T, V22, P63, DOI 10.1042/bst0220063; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; THOMAS L, 1993, J CELL SCI, V105, P191; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320	59	1368	1411	0	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					683	693		10.1016/S0092-8674(00)81235-0	http://dx.doi.org/10.1016/S0092-8674(00)81235-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646777	Bronze			2022-12-01	WOS:A1996UP34400009
J	Fero, ML; Rivkin, M; Tasch, M; Porter, P; Carow, CE; Firpo, E; Polyak, K; Tsai, LH; Broudy, V; Perlmutter, RM; Kaushansky, K; Roberts, JM				Fero, ML; Rivkin, M; Tasch, M; Porter, P; Carow, CE; Firpo, E; Polyak, K; Tsai, LH; Broudy, V; Perlmutter, RM; Kaushansky, K; Roberts, JM			A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice	CELL			English	Article							CYCLIN-DEPENDENT KINASES; GROWTH FACTOR-I; TRANSGENIC MICE; FUSION GENES; INHIBITION; PROTOONCOGENE; FIBROBLASTS; DISRUPTION; SUBUNIT; HORMONE	Targeted disruption of the murine p27(Kip1) gene caused a gene dose-dependent increase in animal size without other gross morphologic abnormalities. All tissues were enlarged and contained more cells, although endocrine abnormalities were not evident. Thymic hyperplasia was associated with increased T lymphocyte proliferation, and T cells showed enhanced IL-2 responsiveness in vitro. Thus, p27 deficiency may cause a Cell-autonomous defect resulting in enhanced proliferation in response to mitogens. In the spleen, the absence of p27 selectively enhanced proliferation of hematopoietic progenitor cells. p27 deletion, like deletion of the Rb gene, uniquely caused neoplastic growth of the pituitary pars intermedia, Suggesting that p27 and Rb function in the same regulatory pathway. The absence of p27 also caused an ovulatory defect and female sterility. Maturation of secondary ovarian follicles into corpora lutea, which express high levels of p27, was markedly impaired.	FRED HUTCHINSON CANC RES CTR, PROGRAM CANC BIOL, DIV PUBL HLTH, SEATTLE, WA 98104 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; UNIV WASHINGTON, DEPT MED, DIV HEMATOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; JOHNS HOPKINS ONCOL CTR, HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA	Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine	Fero, ML (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, DIV PUBL HLTH, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.			Fero, Matthew/0000-0002-9967-4659	NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053049] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 31615] Funding Source: Medline; NIDDK NIH HHS [R01 DK 49855] Funding Source: Medline; NIGMS NIH HHS [GM53049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; BROUDY VC, 1988, ARCH BIOCHEM BIOPHYS, V265, P329, DOI 10.1016/0003-9861(88)90135-X; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; COATS S, 1996, IN PRESS SCIENCE; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GARY KA, 1992, INT J DEV NEUROSCI, V10, P131, DOI 10.1016/0736-5748(92)90041-W; Gehlert D R, 1988, Peptides, V9 Suppl 1, P161, DOI 10.1016/0196-9781(88)90240-9; GERDES J, 1992, J PATHOL, V168, P85, DOI 10.1002/path.1711680114; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HU NP, 1994, ONCOGENE, V9, P1021; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAWAMATA N, 1995, CANCER RES, V55, P2266; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANBUULOFFERS SC, 1995, J ENDOCRINOL, V144, P491, DOI 10.1677/joe.0.1440491; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WOLF E, 1994, ENDOCRINOLOGY, V135, P1877, DOI 10.1210/en.135.5.1877; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	59	1303	1339	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					733	744		10.1016/S0092-8674(00)81239-8	http://dx.doi.org/10.1016/S0092-8674(00)81239-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646781	hybrid			2022-12-01	WOS:A1996UP34400013
J	Seol, W; Choi, HS; Moore, DD				Seol, W; Choi, HS; Moore, DD			An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors	SCIENCE			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; RESPONSE ELEMENT; X-RECEPTOR; BETA-GENE; PROTEIN; ALPHA	SHP is an orphan member of the nuclear hormone receptor superfamily that contains the dimerization and ligand-binding domain found in other;family members but lacks the conserved DNA binding domain. In the yeast two-hybrid system, SHP interacted with several conventional and orphan members of the receptor superfamily, including retinoid receptors, the thyroid hormone receptor, and the orphan receptor MB67. SHP also interacted directly with these receptors in vitro. In mammalian cells, SHP specifically inhibited transactivation by the superfamily members with which it interacted. These results suggest that SHP functions as a negative regulator of receptor-dependent signaling pathways.	MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46546] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; Choi H. W., UNPUB; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	33	430	447	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1336	1339		10.1126/science.272.5266.1336	http://dx.doi.org/10.1126/science.272.5266.1336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650544				2022-12-01	WOS:A1996UN47200046
J	Yang, HY; Bard, M; Bruner, DA; Gleeson, A; Deckelbaum, RJ; Aljinovic, G; Pohl, TM; Rothstein, R; Sturley, SL				Yang, HY; Bard, M; Bruner, DA; Gleeson, A; Deckelbaum, RJ; Aljinovic, G; Pohl, TM; Rothstein, R; Sturley, SL			Sterol esterification in yeast: A two-gene process	SCIENCE			English	Article							ACYL-COENZYME-A; CHOLESTEROL ACYLTRANSFERASE; RAT-LIVER; TRANSFORMATION; METABOLISM; CELLS; DNA	Unesterified sterol modulates the function of eukaryotic membranes. In human cells, sterol is esterified to a storage form by acyl-coenzyme A (CoA): cholesterol acyl transferase (ACAT). Here, two genes are identified, ARE1 and ARE2, that encode ACAT-related enzymes in yeast. The yeast enzymes are 49 percent identical to each other and exhibit 23 percent identity to human ACAT. Deletion of ARE2 reduced sterol ester levels to approximately 25 percent of normal levels, whereas disruption of ARE1 did not affect sterol ester biosynthesis. Deletion of both genes resulted in a viable cell with undetectable esterified sterol. Measurements of [C-14]acetate incorporation into saponified lipids indicated down-regulation of sterol biosynthesis in the are1 are2 mutant cells. With the use of a consensus sequence to the yeast and human genes, an additional member of the ACAT gene family was identified in humans.	COLUMBIA UNIV COLL PHYS & SURG, INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MOLEC BIOPHYS, NEW YORK, NY 10032 USA; INDIANA UNIV PURDUE UNIV, DEPT BIOL, INDIANAPOLIS, IN 46202 USA; GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Indiana University System; Indiana University-Purdue University Indianapolis; Columbia University			Yang, Hongyuan/AAR-1326-2020	Yang, Hongyuan/0000-0002-8482-6031	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050237, R37GM050237] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00861] Funding Source: Medline; NIAID NIH HHS [R01 AI38598] Funding Source: Medline; NIGMS NIH HHS [GM 50237] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F. M, 1987, CURRENT PROTOCOLS MO, V1; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BILLHEIMER JT, 1992, ADV CHOLESTEROL RES; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1983, ENZYMES, V16, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIMSTERDENK D, 1994, MOL BIOL CELL, V5, P655, DOI 10.1091/mbc.5.6.655; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; ERICKSON SK, 1994, J LIPID RES, V35, P763; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; OKPODU CM, 1994, BIOTECHNIQUES, V16, P154; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHIRATOR.T, 1965, BIOCHIM BIOPHYS ACTA, V106, P625, DOI 10.1016/0005-2760(65)90078-0; STURLEY SL, 1994, J BIOL CHEM, V269, P21670; STURLEY SL, UNPUB; TABAS I, 1986, J BIOL CHEM, V261, P3147; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yang H., UNPUB	36	214	227	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1353	1356		10.1126/science.272.5266.1353	http://dx.doi.org/10.1126/science.272.5266.1353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650549				2022-12-01	WOS:A1996UN47200051
J	Clouthier, DE; Avarbock, MR; Maika, SD; Hammer, RE; Brinster, RL				Clouthier, DE; Avarbock, MR; Maika, SD; Hammer, RE; Brinster, RL			Rat spermatogenesis in mouse testis	NATURE			English	Article								RECENTLY, transplantation of mouse donor spermatogonial stem cells from a fertile testis to an infertile recipient mouse testis was described(1,2). The donor tells established spermatogenesis in the seminiferous tubules of the host, and normal spermatozoa were produced. In the most successful transplants, the recipient mice were fertile and sired up to 80 per cent of progeny from donor cells(2). Here we examine the feasibility of transplanting spermatogonial stem cells from other species to the mouse seminiferous tubule to generate spermatogenesis. Marked testis cells from transgenic rats sere transplanted to the testes of immunodeficient mice, and in all of 10 recipient mice (in 19 of 20 testes), rat spermatogenesis occurred. Epididymides of eight mice were examined, and the three from mice with the longest transplants (greater than or equal to 110 days) contained rat spermatozoa with normal morphology. The generation of rat spermatogenesis in mouse testes suggests that spermatogonial stem cells of many species could be transplanted, and opens the possibility of xenogeneic spermatogenesis for other species.	UNIV PENN, SCH VET MED, REPROD PHYSIOL LAB, PHILADELPHIA, PA 19104 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Clouthier, David/A-7062-2009	Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD036504] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVARBOCK MR, IN PRESS NATURE MED; Baker TG., 1972, REPROD BIOL, P398; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; BUCCI LR, 1987, MUTAT RES, V176, P259, DOI 10.1016/0027-5107(87)90057-1; CAMPER SA, 1995, BIOL REPROD, V52, P246, DOI 10.1095/biolreprod52.2.246; CATZEFLIS FM, 1993, MAMMAL PHYLOGENY : PLACENTALS, P159; DEKRETSER DM, 1988, PHYSL REPROD, P932; ENDERS GC, 1993, SERTOLI CELL, P447; FISHEL S, 1995, LANCET, V345, P1641, DOI 10.1016/S0140-6736(95)90149-3; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Hogan B., 2014, MANIPULATING MOUSE E; Jiang FX, 1995, INT J ANDROL, V18, P326, DOI 10.1111/j.1365-2605.1995.tb00570.x; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; Russell LD, 1993, SERTOLI CELL, P365; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819	22	285	319	1	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					418	421		10.1038/381418a0	http://dx.doi.org/10.1038/381418a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632797	Green Accepted			2022-12-01	WOS:A1996UN47900050
J	Yunus, MB; Aldag, JC				Yunus, MB; Aldag, JC			Restless legs syndrome and leg cramps in fibromyalgia syndrome: A controlled study	BRITISH MEDICAL JOURNAL			English	Article											Yunus, MB (corresponding author), UNIV ILLINOIS,COLL MED,DEPT MED,BOX 1649,PEORIA,IL 61656, USA.							CLOUGH C, 1987, BRIT MED J, V294, P262, DOI 10.1136/bmj.294.6567.262; MONTPLAISIR J, 1986, CLIN NEUROPHARMACOL, V9, P456, DOI 10.1097/00002826-198610000-00006; REYNOLDS G, 1986, BRIT MED J, V292, P659, DOI 10.1136/bmj.292.6521.659; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; Yunus Muhammad B., 1993, P1383	5	108	114	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1339	1339		10.1136/bmj.312.7042.1339	http://dx.doi.org/10.1136/bmj.312.7042.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646049	Green Published			2022-12-01	WOS:A1996UN47600024
J	Lalvani, A; Shastri, JS				Lalvani, A; Shastri, JS			HIV epidemic in India: Opportunity to learn from the past	LANCET			English	Editorial Material									RN COOPER HOSP,AIDS SURVEILLANCE & ZONAL BLOOD TESTING CTR,BOMBAY,MAHARASHTRA,INDIA		Lalvani, A (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.			Lalvani, Ajit/0000-0002-2396-246X				BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; ESSEX M, 1996, 8 ANN M NAT COOP VAC; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; JACOB KS, 1989, BRIT MED J, V299, P721, DOI 10.1136/bmj.299.6701.721; JAIN MK, 1994, J ACQ IMMUN DEF SYND, V7, P1185; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; 1995, WKLY EPIDEMIOL REC, V70, P353	10	28	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1349	1350		10.1016/S0140-6736(96)91007-7	http://dx.doi.org/10.1016/S0140-6736(96)91007-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637338				2022-12-01	WOS:A1996UL90400006
J	Hoodless, PA; Haerry, T; Abdollah, S; Stapleton, M; OConnor, MB; Attisano, L; Wrana, JL				Hoodless, PA; Haerry, T; Abdollah, S; Stapleton, M; OConnor, MB; Attisano, L; Wrana, JL			MADR1, a MAD-related protein that functions in BMP2 signaling pathways	CELL			English	Article							BONE MORPHOGENETIC PROTEINS; FACTOR-BETA FAMILY; GENE; EXPRESSION; RECEPTOR; COMPLEX; INDUCE; CELLS	Components of the signaling pathways that lie downstream of Ser/Thr kinase receptors and are required for signaling by the TGF beta superfamily have been poorly defined. The Drosophila gene Mothers against dpp (Mad) and the C. elegans sma genes are implicated in these signaling pathways. We show that MAD functions downstream of DPP receptors and is required for receptor signaling. Phosphorylation of MADR1, a human homolog of MAD, is tightly regulated and rapidly induced by BMP2, but not TGF beta or activin. This phosphorylation is necessary for function, since a point mutant that yields a null phenotype in Drosophila is not phosphorylated. BMP2 treatment results in accumulation of MADR1 in the nucleus. MAD proteins may thus define a novel class of signaling molecules with nuclear function in Ser/Thr kinase receptor signaling pathways.	HOSP SICK CHILDREN,PROGRAM DEV BIOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DIV GASTROENTEROL,TORONTO,ON M5G 1X8,CANADA; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California Irvine; University of California System; University of California Irvine			Wrana, Jeffrey/F-8857-2013; O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506; Hoodless, Pamela/0000-0003-1371-0725	NIGMS NIH HHS [GM47462] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LENNON GG, 1996, IN PRESS GENOMICS; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; NOLL R, 1994, DEVELOPMENT, V120, P2329; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEKELSKY JJ, 1995, GENETICS, V139, P1347; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	57	627	664	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					489	500		10.1016/S0092-8674(00)81250-7	http://dx.doi.org/10.1016/S0092-8674(00)81250-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653785	Bronze			2022-12-01	WOS:A1996UM41500007
J	Minakami, H; Sato, I				Minakami, H; Sato, I			Reestimating date of delivery in multifetal pregnancies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIPLETS; STILLBIRTH; BIRTHS; RISK	Objective.-To clarify the optimal estimated date of delivery for multifetal pregnancies. Design, Subjects, and Setting.-A retrospective study of all 88 936 infants born of multifetal pregnancies and all 6 020 542 infants born of singleton pregnancies that occurred at 26 weeks or more of gestation between 1989 and 1993 in Japan. Main Outcome Measure.-Incidence of stillbirth and early neonatal death according to gestational age at delivery. Results.-The mean+/-SD duration of pregnancy was 37.0+/-2.7 weeks for multifetal pregnancies and 39.6+/-1.6 weeks for singleton pregnancies. In multifetal pregnancies, the incidence of stillbirth and of early neonatal death gradually declined until 37 to 38 weeks' gestation and then increased. These parameters in singleton pregnancies declined until 39 weeks' gestation before increasing. The lowest incidence of perinatal death (stillbirth plus early neonatal death) seen at 38 weeks' gestation in multifetal pregnancies corresponded to that seen at 43 weeks' gestation in singleton pregnancies (10.5 vs 9.7 per 1000 infants). The risk of perinatal death was more than 6 times as high for fetuses of multifetal pregnancies born at 37 weeks or later than for singleton fetuses born at 40 weeks or later (relative risk, 6.6; 95% confidence interval, 6.1-7.1). Conclusion.-Fetuses of multifetal pregnancies are at an increased risk of death after reaching the normative gestational age for singleton pregnancies. Limiting the estimated date of delivery to 37 to 38 weeks may be appropriate in multifetal pregnancies.			Minakami, H (corresponding author), JICHI MED SCH,DEPT OBSTET & GYNECOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		MINAKAMI, HISANORI/D-6477-2012					AHLENIUS I, 1995, ACTA OBSTET GYN SCAN, V74, P109, DOI 10.3109/00016349509008917; CHISWICK M, 1995, BRIT MED J, V310, P141, DOI 10.1136/bmj.310.6973.141; COLLINS MS, 1990, AM J OBSTET GYNECOL, V162, P1384, DOI 10.1016/0002-9378(90)90896-F; Crowley P., 1989, EFFECTIVE CARE PREGN, P776; ELSTER AD, 1991, OBSTET GYNECOL, V77, P387; FELDMAN GB, 1992, OBSTET GYNECOL, V79, P547; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; Imaizumi Y., 1994, J EPIDEMIOL, V4, P103; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; MCCLUREBROWNE JC, 1963, AM J OBSTET GYNECOL, V85, P573, DOI 10.1016/0002-9378(63)90304-1; MCLENNAN A, 1990, LANCET, V335, P267; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *MIN HLTH WELF CHI, 1994, TAB INF; MINAKAMI H, 1993, LANCET, V341, P1603, DOI 10.1016/0140-6736(93)90746-4; MORRISON I, 1985, AM J OBSTET GYNECOL, V152, P975, DOI 10.1016/0002-9378(85)90542-3; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239	17	105	111	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1432	1434		10.1001/jama.275.18.1432	http://dx.doi.org/10.1001/jama.275.18.1432			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618370				2022-12-01	WOS:A1996UJ30300030
J	Do, H; Falcone, D; Lin, JL; Andrews, DW; Johnson, AE				Do, H; Falcone, D; Lin, JL; Andrews, DW; Johnson, AE			The cotranslational integration of membrane proteins into the phospholipid bilayer is a multistep process	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE; POLYPEPTIDE TRANSLOCATION; PHOTOCROSS-LINKING; ER; SEC61P; INSERTION; ADJACENT; IDENTIFICATION; PREPROLACTIN	During the cotranslational integration of a nascent protein into the endoplasmic reticulum membrane, the transmembrane (TM) sequence moves out of an aqueous pore formed by Sec61 alpha, TRAM, and other proteins and into the nonpolar lipid bilayer. Photocross-linking reveals that this movement involves the sequential passage of the TM domain through three different proteinaceous environments: one adjacent to Sec61 alpha and TRAM and two adjacent to TRAM that place different restrictions on TM domain movement. In addition, the TM sequence is not allowed to diffuse into the bilayer from the final TRAM-proximal site until translation terminates. Cotranslational integration is therefore linked to translation and occurs via an ordered multistep pathway at an endoplasmic reticulum site that is multilayered both structurally and functionally.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University	Do, H (corresponding author), TEXAS A&M UNIV,HLTH SCI CTR,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843, USA.		Johnson, Arthur E/G-3457-2012	Andrews, David/0000-0002-9266-7157	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JANIAK F, 1994, J BIOL CHEM, V269, P9842; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; JOHNSON AE, 1996, IN PRESS COLD SPRING, V60; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	35	213	214	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					369	378		10.1016/S0092-8674(00)81115-0	http://dx.doi.org/10.1016/S0092-8674(00)81115-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616892	Bronze			2022-12-01	WOS:A1996UK14000010
J	Dybowski, R; Weller, P; Chang, R; Gant, V				Dybowski, R; Weller, P; Chang, R; Gant, V			Prediction of outcome in critically ill patients using artificial neural network synthesised by genetic algorithm	LANCET			English	Article							SEPSIS; SCORE	Background Decisions about which patients to admit to intensive care and how long to keep them there are difficult. A flexible computer-based mathematical model which is sensitive to the complexity of intensive care medicine, and which accurately models prognosis, seems highly desirable. Methods We have created, optimised by genetic algorithms, trained, and evaluated the performance of an artificial neural network (ANN) in the clinical setting of systemic inflammatory response syndrome and haemodynamic shock. 258 patients were selected from an intensive care database of 4484 patients al a London teaching hospital and randomised to a network training set (168) and a test set (90). The outcome evaluated was death during that hospital admission and the performance of the neural net was compared (by receiver operating characteristic [ROC] curves and by Brier scores) with that of a logistic regression model. Findings Artificial neural network performance increased with successive generations; the best-performing ANN was created after 7 generations and predicted outcome more accurately than the logistic regression model (ROC curve area 0.863 vs 0.753). Interpretation In this study, ANNs have lent themselves particularly well to modelling a complex clinical situation; we suggest that this relates to their inherently flexible nature which accommodates interactions between the clinical input fields. In addition, we have demonstrated the value of a second computational technique (genetic algorithms) in ''tuning'' ANN performance. These techniques can potentially be implemented in individual intensive care units; the outcome models which they will generate will be sensitive to local practice. Analysis of such accurate clinical outcome models may empower clinicians with a hitherto unappreciated degree of insight into those elements of their clinical practice which are most relevant to their patients' outcome.	CITY UNIV LONDON,DEPT SYST SCI,LONDON EC1V 0HB,ENGLAND; UNIV LONDON ST GEORGES HOSP,LONDON,ENGLAND	City University London; St Georges University London	Dybowski, R (corresponding author), UMDS,DIV INFECT,INFECT & IMMUN LAB,ST THOMAS HOSP CAMPUS,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.							ABRAHAM E, 1994, JAMA-J AM MED ASSOC, V271, P1876, DOI 10.1001/jama.271.23.1876; ATKINSON S, 1994, LANCET, V344, P1203, DOI 10.1016/S0140-6736(94)90514-2; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Breimann L, 1984, CLASSIFICATION REGRE; BUCHMAN TG, 1994, CRIT CARE MED, V22, P750, DOI 10.1097/00003246-199405000-00008; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Doig G S, 1993, Proc Annu Symp Comput Appl Med Care, P361; DYBOWSKI R, 1995, LANCET, V346, P1203, DOI 10.1016/S0140-6736(95)92904-5; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LONG WJ, 1993, COMPUT BIOMED RES, V26, P74, DOI 10.1006/cbmr.1993.1005; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MILLER GF, 1989, 3RD P INT C GEN ALG, P379; MONTANA DJ, 1989, P 11 INT JOINT C ART, P762; NARAYANAN MN, 1993, METHOD INFORM MED, V32, P55, DOI 10.1055/s-0038-1634888; RIPLEY BD, 1994, J R STAT SOC B, V56, P409; SAHASAKUL Y, 1990, BRIT HEART J, V64, P182; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WYATT J, 1995, LANCET, V346, P1175, DOI 10.1016/S0140-6736(95)92893-6; YATES JF, 1982, ORGAN BEHAV HUM PERF, V30, P132, DOI 10.1016/0030-5073(82)90237-9	27	161	167	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1146	1150		10.1016/S0140-6736(96)90609-1	http://dx.doi.org/10.1016/S0140-6736(96)90609-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609749				2022-12-01	WOS:A1996UG75500011
J	Morrison, PJ				Morrison, PJ			Anticipating more anticipation	LANCET			English	Editorial Material							REPEAT				Morrison, PJ (corresponding author), BELFAST CITY HOSP,NO IRELAND REG GENET CTR,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND.							Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; MORRISON PJ, 1993, LANCET, V342, P385; Morrison PJ, 1996, J MED GENET, V33, P504, DOI 10.1136/jmg.33.6.504; ODONOVAN MC, 1995, NAT GENET, V10, P379; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1132	1132		10.1016/S0140-6736(96)90605-4	http://dx.doi.org/10.1016/S0140-6736(96)90605-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609745				2022-12-01	WOS:A1996UG75500007
J	Rockall, TA; Logan, RFA; Devlin, HB; Northfield, TC				Rockall, TA; Logan, RFA; Devlin, HB; Northfield, TC			Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage	LANCET			English	Article								Background Acute upper gastrointestinal haemorrhage is a common medical emergency and hospital admission has usually been regarded as obligatory until the risk of further haemorrhage has receded. This policy means that some patients at low risk stay in hospital for longer than is necessary especially when delayed. We attempted to negligible risk of further bleeding or death and for whom early discharge or even outpatient management would be possible with no adverse effect on standards of care. Methods We used a validated risk scoring system based on age (score 0-2), presence of shock (0-2), comorbidity (0-3), diagnosis (0-2), and endoscopic stigmata of recent haemorrhage (0-2); the maximum possible score was 11. We studied patients identified through the UK National Audit of acute upper gastrointestinal haemorrhage; they had been admitted with upper gastrointestinal haemorrhage to hospitals in the UK during 4 months of 1993. This analysis was based on the 2531 patients from the national audit who underwent endoscopy after an acute admission. Findings 744 (29.4%) of the 2531 patients scored 2 or less on the risk score. Of these patients only 32 (4.3% [95% CI 3.0-6.0] rebled and only one (0.1% [0.006-0.75] died). Thus, the risk score identifies patients at low risk of rebleeding or death. The median hospital stay for these patients was 4 days; duration of hospital stay increased with risk score. Within risk score categories of 5 or less, there was a trend of increasing hospital stay as the time between admission and endoscopy increased. Interpretation Our risk score identifies a large proportion of patients with acute upper gastrointestinal haemorrhage who are at low risk of further bleeding or death. Early endoscopy and discharge of such patients could allow substantial resource savings.	QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; ST GEORGE HOSP,SCH MED,LONDON,ENGLAND	University of Nottingham; St Georges University London	Rockall, TA (corresponding author), ROYAL COLL SURGEONS ENGLAND,AUDIT UNIT,LONDON WC2A 3PN,ENGLAND.							LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X	4	248	261	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1138	1140		10.1016/S0140-6736(96)90607-8	http://dx.doi.org/10.1016/S0140-6736(96)90607-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609747				2022-12-01	WOS:A1996UG75500009
J	Nyberg, L; McIntosh, AR; Houle, S; Nilsson, LG; Tulving, E				Nyberg, L; McIntosh, AR; Houle, S; Nilsson, LG; Tulving, E			Activation of medial temporal structures during episodic memory retrieval	NATURE			English	Article							HIPPOCAMPUS; AMNESIA	MEDIAL temporal lobe structures have been implicated in human episodic memory. Patients with medial temporal lesions show memory deficits(1-3), and functional neuroimaging studies have revealed activation in this region during episodic encoding and retrieval when data are averaged over a sample of subjects(4-7). The relevance of such observations for memory performance has remained unclear, however. Here we have used positron emission tomography (PET) to examine cerebral blood how related to verbal episodic retrieval. We observed strong positive correlations between retrieval and blood flow in left medial temporal structures in individual normal human subjects. In addition, multivariate analysis showed that regions in the left medial temporal lobe were dominant components of a pattern of brain regions that distinguished a high-retrieval condition from conditions of lower retrieval. These results suggest that medial temporal activity is related to retrieval success rather than retrieval attempt, possibly by reflecting reactivation of stored patterns.	UMEA UNIV,DEPT PSYCHOL,S-90187 UMEA,SWEDEN; CLARKE INST PSYCHIAT,PET CTR,TORONTO,ON M5T 1R8,CANADA; UNIV STOCKHOLM,DEPT PSYCHOL,S-10691 STOCKHOLM,SWEDEN	Umea University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Stockholm University	Nyberg, L (corresponding author), BAYCREST CTR GERIATR CARE,ROTMAN RES INST,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.		Nyberg, Lars/C-2514-2009; Nyberg, Lars/M-5986-2019; McIntosh, Anthony R/G-4955-2011	Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Houle, Sylvain/0000-0002-4231-6316; McIntosh, Anthony/0000-0002-1784-5662				AMARAL DG, 1990, DISCUSSIONS NEUROSCI; BOOKSTEIN FL, 1990, COMMUN STAT THEORY, V19, P765, DOI 10.1080/03610929008830231; Edgington E. S., 1987, RANDOMIZATION TESTS; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P386, DOI 10.1037/0278-7393.11.2.386; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; HAIST F, 1992, J EXP PSYCHOL LEARN, V18, P691, DOI 10.1037/0278-7393.18.4.691; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; Kosslyn SM, 1996, J COGNITIVE NEUROSCI, V8, P78, DOI 10.1162/jocn.1996.8.1.78; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SMITH M, 1989, HDB NEUROPSYCHOLOGY, V3; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; TALAIRACH J, 1988, STEREOTAXIC ATLAS HU; Victor M, 1990, J Cogn Neurosci, V2, P246, DOI 10.1162/jocn.1990.2.3.246; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	25	306	311	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					715	717		10.1038/380715a0	http://dx.doi.org/10.1038/380715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614466				2022-12-01	WOS:A1996UG82700052
J	Souer, E; vanHouwelingen, A; Kloos, D; Mol, J; Koes, R				Souer, E; vanHouwelingen, A; Kloos, D; Mol, J; Koes, R			The no apical meristem gene of petunia is required for pattern formation in embryos and flowers and is expressed at meristem and primordia boundaries	CELL			English	Article							ARABIDOPSIS-THALIANA; ANTIRRHINUM-MAJUS; HOMEOTIC GENES; MORPHOGENESIS; MUTAGENESIS; MUTATIONS; PROTEINS; SEQUENCE	Petunia embryos carrying the no epical meristem (nam) mutation fail to develop a shoot apical meristem. Occasional shoots on nam(-) seedlings bear flowers that develop ten instead of five primordia in the second whorl. Double mutants with the homeotic gene green petals show that nam acts independently of organ identity in whorl 2 and now also affects primordium number in whorl 3. The nam gene was isolated by transposon tagging. The encoded protein shares a conserved N-terminal domain with several other proteins of unknown function and thus represents a novel class of proteins. Strikingly, nam mRNA accumulates in cells at the boundaries of meristems and primordia. These data indicate a role for nam in determining positions of meristems and primordia.			Souer, E (corresponding author), VRIJE UNIV AMSTERDAM,BIOCENTRUM,INST MOLEC BIOL SCI,DEPT GENET,DE BOELELAAN 1087,1081 HV AMSTERDAM,NETHERLANDS.			Souer, Erik/0000-0003-4459-2485; Koes, Ronald/0000-0003-3793-5072				ANGENENT GC, 1995, PLANT CELL, V7, P1569, DOI 10.1105/tpc.7.10.1569; ANGENENT GC, 1995, PLANT CELL, V7, P507, DOI 10.1105/tpc.7.5.507; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTON MK, 1993, DEVELOPMENT, V119, P823; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; CANAS LA, 1994, PLANT J, V6, P597, DOI 10.1046/j.1365-313X.1994.6040597.x; CLARK SE, 1993, DEVELOPMENT, V119, P397; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DOODEMAN M, 1984, THEOR APPL GENET, V67, P357, DOI 10.1007/BF00272875; ERRAMPALLI D, 1991, PLANT CELL, V3, P149, DOI 10.1105/tpc.3.2.149; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; GERATS AGM, 1990, PLANT CELL, V2, P1121, DOI 10.1105/tpc.2.11.1121; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; HAUGHN GW, 1995, CAN J BOT, V73, P959, DOI 10.1139/b95-105; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HERNANDEZ LF, 1993, PLANT CELL, V5, P1725, DOI 10.1105/tpc.5.12.1725; HERNANDEZ LF, 1991, PLANTA, V185, P139, DOI 10.1007/BF00194054; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JURGENS G, 1994, ANNU REV GENET, V28, P351, DOI 10.1146/annurev.ge.28.120194.002031; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; Jurgens G, 1991, DEVELOPMENT S, V1, P27; KOES R, 1995, P NATL ACAD SCI USA, V92, P8149, DOI 10.1073/pnas.92.18.8149; KUSH A, 1993, PLANT PHYSIOL, V102, P1051, DOI 10.1104/pp.102.3.1051; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; NAGATO Y, 1989, THEOR APPL GENET, V78, P11, DOI 10.1007/BF00299746; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHERIDAN WF, 1993, PLANT J, V3, P347, DOI 10.1111/j.1365-313X.1993.tb00186.x; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SOUER E, 1995, PLANT J, V7, P677, DOI 10.1046/j.1365-313X.1995.7040677.x; VANDERKROL AR, 1993, GENE DEV, V7, P1214, DOI 10.1101/gad.7.7a.1214; Vincent CA, 1995, CURR BIOL, V5, P1449, DOI 10.1016/S0960-9822(95)00282-X; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361	40	702	891	13	128	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					159	170		10.1016/S0092-8674(00)81093-4	http://dx.doi.org/10.1016/S0092-8674(00)81093-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612269	Bronze			2022-12-01	WOS:A1996UG25500005
J	Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM				Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM			Abnormal splicing of the leptin receptor in diabetic mice	NATURE			English	Article							YEAST; FRAGMENTS; MUTATION; CLONING; GENES; DNA	MUTATIONS in the mouse diabetes (db) gene result in obesity and diabetes in a syndrome resembling morbid human obesity(1), Previous data suggest that the db gene encodes the receptor for the obese (ob) gene product, leptin(2-7). A leptin receptor was recently cloned from choroid plexus and shown to map to the same 6-cM interval on mouse chromosome 4 as db(8). This receptor maps to the same 300-kilobase interval as db, and has at least six alternatively spliced forms. One of these splice variants is expressed at a high level in the hypothalamus, and is abnormally spliced in C57BL/Ks db/db mice, The mutant protein is missing the cytoplasmic region, and is likely to be defective in signal transduction. This suggests that the weight-reducing effects of leptin may be mediated by signal transduction through a leptin receptor in the hypothalamus.	ROCKEFELLER UNIV, DEPT MOLEC GENET, NEW YORK, NY 10021 USA	Rockefeller University	Lee, GH (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Friedman, Jeffrey M/E-5784-2011					BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BAHARY N, 1993, MAMM GENOME, V4, P511, DOI 10.1007/BF00364786; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; Lodish H, 1986, MOL CELL BIOL; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; MODI WS, 1995, CYTOGENET CELL GENET, V69, P232, DOI 10.1159/000133971; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NURMINSKY DI, 1993, BIOTECHNIQUES, V15, P201; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TARTON MD, 1996, NATURE, V379, P69; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	1985	2079	0	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					632	635		10.1038/379632a0	http://dx.doi.org/10.1038/379632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628397				2022-12-01	WOS:A1996TV68800050
J	Rubin, DM; Coux, O; Wefes, I; Hengartner, C; Young, RA; Goldberg, AL; Finley, D				Rubin, DM; Coux, O; Wefes, I; Hengartner, C; Young, RA; Goldberg, AL; Finley, D			Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome	NATURE			English	Article							TAT-MEDIATED TRANSACTIVATION; BINDING-PROTEIN; 26-S PROTEASE; MODULATOR; FAMILY; GENES	THE SUG1 gene of Saccharomyces cerevisiae encodes a putative ATPase. Mutations in SUG1 were isolated(1) as suppressors of a mutation in the transcriptional activation domain of GAL4. Sug1 was recently proposed to be a subunit of the RNA polymerase II holoenzyme and to mediate the association of transcriptional activators with holoenzyme(2). We show here that Sug1 is not a subunit of the holoenzyme, at least in its purified form, but of the 26S proteasome(3,4), a large complex of relative molecular-mass 2,000K that catalyses the ATP-dependent degradation of ubiquitin-protein conjugates. Sug1 co-purifies with the proteasome in both conventional and nickel-chelate affinity chromatography. Our observations account for the reduced ubiquitin-dependent proteolysis in sug1 mutants(5) and suggest that the effects of sug1 mutations on transcription are indirect results of defective proteolysis.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Coux, Olivier/P-6847-2019; Young, Richard A/F-6495-2012; Hengartner, Christoph/AAF-5132-2021; Coux, Olivier/B-3406-2010	Coux, Olivier/0000-0001-8455-3849; Young, Richard A/0000-0001-8855-8647; Coux, Olivier/0000-0001-8455-3849				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Crowe J, 1994, Methods Mol Biol, V31, P371; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; XU QL, 1995, MOL CELL BIOL, V15, P6025; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	28	146	147	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					655	657		10.1038/379655a0	http://dx.doi.org/10.1038/379655a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628401				2022-12-01	WOS:A1996TV68800057
J	Smith, SB; Cui, YJ; Bustamante, C				Smith, SB; Cui, YJ; Bustamante, C			Overstretching B-DNA: The elastic response of individual double-stranded and single-stranded DNA molecules	SCIENCE			English	Article								Single molecules of double-stranded DNA (dsDNA) were stretched with force-measuring laser tweezers. Under a longitudinal stress of similar to 65 piconewtons (pN), dsDNA molecules in aqueous buffer undergo a highly cooperative transition into a stable form with 5.8 angstroms rise per base pair, that is, 70% longer than B-form dsDNA. When the stress was relaxed below 65 pN, the molecules rapidly and reversibly contracted to their normal contour lengths. This transition was affected by changes in the ionic strength of the medium and the water activity or by cross-linking of the two strands of dsDNA. Individual molecules of single-stranded DNA were also stretched giving a persistence length of 7.5 angstroms and a stretch modulus of 800 pN. The overstretched form may play a significant role in the energetics of DNA recombination.	UNIV OREGON,INST MOLEC BIOL,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM-32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHTER EK, 1971, BIOPOLYMERS, V10, P1625, DOI 10.1002/bip.360100916; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BERMAN HM, 1994, CURR OPIN STRUC BIOL, V4, P345, DOI 10.1016/S0959-440X(94)90102-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CALLADINE CR, 1992, UNDERSTANDING DNA MO; Callen H.B., 1985, THERMODYNAMICS INTRO; DAVIDSON N, 1971, BACTERIOPHAGE LAMBDA, P56; GHISLAIN LP, 1994, REV SCI INSTRUM, V65, P2762, DOI 10.1063/1.1144613; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HEARST JE, 1984, Q REV BIOPHYS, V17, P1, DOI 10.1017/S0033583500005242; KLUG A, 1975, NATURE, V255, P530; LANDAU LD, 1986, THEORY ELASTICITY, P67; LANDAU LD, 1980, STATISTICAL PHYSIC 1; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Smith Steven B., 1995, Biophysical Journal, V68, pA250; SOBEL ES, 1991, BIOPOLYMERS, V31, P1559, DOI 10.1002/bip.360311311; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; THUNDAT T, 1994, NUCLEIC ACIDS RES, V22, P4224, DOI 10.1093/nar/22.20.4224; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; USSERY DW, 1992, METHOD ENZYMOL, V212, P242; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	2221	2322	13	382	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					795	799		10.1126/science.271.5250.795	http://dx.doi.org/10.1126/science.271.5250.795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628994				2022-12-01	WOS:A1996TU69400042
J	Lyons, SF				Lyons, SF			Shadow bands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					98	98						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656519				2022-12-01	WOS:A1996UV48500009
J	Legge, JS				Legge, JS			Peak-expiratory-flow meters and asthma self-management	LANCET			English	Editorial Material											Legge, JS (corresponding author), ABERDEEN ROYAL INFIRM,DEPT THORAC MED,ABERDEEN AB9 2ZB,SCOTLAND.							BOULET LP, 1994, THORAX, V49, P965, DOI 10.1136/thx.49.10.965; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P702, DOI 10.1016/0091-6749(93)90189-M; Miles JF, 1996, THORAX, V51, P403, DOI 10.1136/thx.51.4.403; VERSCHELDEN P, 1996, AM J RESP CRIT CARE, V153, pA777; 1994, BRIT MED J, V308, P564	8	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1709	1710		10.1016/S0140-6736(96)90802-8	http://dx.doi.org/10.1016/S0140-6736(96)90802-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656900				2022-12-01	WOS:A1996UT39600004
J	Nichols, CG; Shyng, SL; Nestorowicz, A; Glaser, B; Clement, JP; Gonzalez, G; AguilarBryan, L; Permutt, MA; Bryan, J				Nichols, CG; Shyng, SL; Nestorowicz, A; Glaser, B; Clement, JP; Gonzalez, G; AguilarBryan, L; Permutt, MA; Bryan, J			Adenosine diphosphate as an intracellular regulator of insulin secretion	SCIENCE			English	Article							ISOLATED MEMBRANE PATCHES; POTASSIUM CHANNELS; K+ CHANNELS; ATP; CELLS; ADP	Adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels couple the cellular metabolic state to electrical activity and are a critical link between blood glucose concentration and pancreatic insulin secretion. A mutation in the second nucleotide-binding fold (NBF2) of the sulfonylurea receptor (SUR) of an individual diagnosed with persistent hyperinsulinemic hypoglycemia of infancy generated K-ATP channels that could be opened by diazoxide but not in response to metabolic inhibition. The hamster SUR, containing the analogous mutation, had normal ATP sensitivity, but unlike wild-type channels, inhibition by ATP was not antagonized by adenosine diphosphate (ADP). Additional mutations in NBF2 resulted in the same phenotype, whereas an equivalent mutation in NBF1 showed normal sensitivity to MgADP. Thus, by binding to SUR NBF2 and antagonizing ATP inhibition of K-ATP channels, intracellular MgADP may regulate insulin secretion.	WASHINGTON UNIV,SCH MED,DIV ENDOCRINOL & METAB,ST LOUIS,MO 63110; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DIV ENDOCRINOL & METAB,IL-91010 JERUSALEM,ISRAEL; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Washington University (WUSTL); Hebrew University of Jerusalem; Baylor College of Medicine; Baylor College of Medicine	Nichols, CG (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110, USA.		Nichols, Colin/D-6336-2012; Glaser, Benjamin/F-8411-2017	Glaser, Benjamin/0000-0003-4711-5000				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; DUNNE MJ, 1986, FEBS LETT, V208, P59, DOI 10.1016/0014-5793(86)81532-0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; NICHOLS CG, 1991, BIOPHYS J, V60, P1164, DOI 10.1016/S0006-3495(91)82152-X; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zuppinger K, 1983, Prog Pediatr Surg, V16, P51	17	452	462	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1785	1787		10.1126/science.272.5269.1785	http://dx.doi.org/10.1126/science.272.5269.1785			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650576				2022-12-01	WOS:A1996UT11000042
J	Bortvin, A; Winston, F				Bortvin, A; Winston, F			Evidence that Spt6p controls chromatin structure by a direct interaction with histones	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PERIODIC TRANSCRIPTION; NUCLEAR-PROTEIN; ESSENTIAL GENE; YEAST; IDENTIFICATION; SNF2/SWI2; SUPPRESS; HOMOLOG; ENCODES	Genetic analysis has implicated SPT6, an essential gene of Saccharomyces cerevisiae, in the control of chromatin structure. Mutations in SPT6 and particular mutations in histone genes are able to overcome transcriptional defects in strains lacking the Snf/Swi protein complex. Here it is shown that an spt6 mutation causes changes in chromatin structure in vivo. In addition, both in vivo and in vitro experiments provide evidence that Spt6p interacts directly with histones and primarily with histone H3. Consistent with these findings, Spt6p is capable of nucleosome assembly in vitro.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School				Bortvin, Alex/0000-0003-0987-1905	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032967, R37GM032967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBET FM, 1988, CURRENT PROTOCOLS MO; BORTVIN A, UNPUB; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; EDMONDSON DG, IN PRESS GENES DEV; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARTZOG GA, IN PRESS MOL CELL BI; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HEREFORD L, 1982, CELL, V30, P305, DOI 10.1016/0092-8674(82)90036-8; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1987, MOL CELL BIOL, V7, P672, DOI 10.1128/MCB.7.2.672; NISHIWAKI K, 1993, MOL GEN GENET, V239, P313, DOI 10.1007/BF00276929; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PRELICH G, 1993, GENETICS, V135, P665; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; Sherman F., 1978, METHODS YEAST GENETI; SWANSON MS, 1990, MOL CELL BIOL, V10, P4935, DOI 10.1128/MCB.10.9.4935; SWANSON MS, 1992, GENETICS, V132, P325; van Holde K.E., 1989, CHROMATIN; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	40	280	280	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1473	1476		10.1126/science.272.5267.1473	http://dx.doi.org/10.1126/science.272.5267.1473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633238				2022-12-01	WOS:A1996UP89900045
J	Strelnitski, V; Haas, MR; Smith, HA; Erickson, EF; Colgan, SWJ; Hollenbach, DJ				Strelnitski, V; Haas, MR; Smith, HA; Erickson, EF; Colgan, SWJ; Hollenbach, DJ			Far-infrared hydrogen lasers in the peculiar star MWC 349A	SCIENCE			English	Article							RECOMBINATION LINE MASER; MWC-349	Far-infrared hydrogen recombination lines H15 alpha (169.4 micrometers), H12 alpha (88.8 micrometers), and H10 alpha (52.5 micrometers) were detected in the peculiar luminous star MWC 349A from the Kuiper Airborne Observatory. Here it is shown that at least H15 alpha is strongly amplified, with the probable amplification factor being greater than or about equal to 10(3) and a brightness temperature that is greater than or about equal to 10(7) kelvin. The other two lines also show signs of amplification, although to a lesser degree. Beyond H10 alpha the amplification apparently vanishes. The newly detected amplified lines fall into the laser wavelength domain. These lasers, as well as the previously detected hydrogen masers, may originate in the photoionized circumstellar disk of MWC 349A and constrain the disk's physics and structure.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; SEARCH EXTRATERR INTELLIGENCE INST,MT VIEW,CA 94043	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Strelnitski, V (corresponding author), SMITHSONIAN INST,NATL AIR & SPACE MUSEUM,ASTROPHYS LAB,WASHINGTON,DC 20560, USA.		Colgan, Sean W J/M-4742-2014					ALTENHOFF WJ, 1981, ASTRON ASTROPHYS, V93, P48; BEZARD B, 1986, ASTRON ASTROPHYS, V161, P387; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; COHEN M, 1985, ASTROPHYS J, V292, P249, DOI 10.1086/163154; DICKINSON RE, 1986, J GEOPHYS RES, V91, P70, DOI 10.1029/JA091iA01p00070; ERICKSON EF, 1995, P AIRB ASTR S GAL EC, P707; ERICKSON EF, 1984, P SOC PHOTOOPT INSTR, V509, P129; Gordiets B. F., 1983, Cosmic Research, V21, P725; GORDON MA, 1992, ASTROPHYS J, V387, P701, DOI 10.1086/171117; GWINN CR, 1992, ASTROPHYS J, V393, P149, DOI 10.1086/171493; HAAS MR, 1982, ICARUS, V51, P476, DOI 10.1016/0019-1035(82)90141-5; HAMANN F, 1986, ASTROPHYS J, V311, P909, DOI 10.1086/164828; HOLLENBACH D, 1994, ASTROPHYS J, V428, P654, DOI 10.1086/174276; KIM KJ, 1990, SCIENCE, V250, P88, DOI 10.1126/science.250.4977.88; KROLIK JH, 1978, ASTROPHYS J SUPPL S, V37, P459, DOI 10.1086/190538; MARTINPINTADO J, 1989, ASTRON ASTROPHYS, V215, pL13; MARTINPINTADO J, 1989, A A, V229, pL9; MASERS, 1984, ENCY AM; MATTHEWS S, 1977, 73204 X NASA, P1; MENTEN KM, 1995, ASTROPHYS J, V450, pL67, DOI 10.1086/316776; Merrill PW, 1933, ASTROPHYS J, V78, P87, DOI 10.1086/143490; Mumma M. J., 1993, ASTROPHYSICAL MASERS, P455; MUMMA MJ, 1981, SCIENCE, V212, P45, DOI 10.1126/science.212.4490.45; POPOULAR R, 1983, ASTRON ASTROPHYS, V117, P46; RODRIGUEZ LF, 1994, ASTROPHYS J, V428, P324, DOI 10.1086/174243; SCOVILLE N, 1983, ASTROPHYS J, V275, P201, DOI 10.1086/161526; SEATON MJ, 1959, MON NOT R ASTRON SOC, V119, P90, DOI 10.1093/mnras/119.2.90; SHU FH, 1993, ICARUS, V106, P92, DOI 10.1006/icar.1993.1160; SMITH H, UNPUB; SMITH HA, 1979, ASTROPHYS J, V233, P132, DOI 10.1086/157374; STEPANOVA GI, 1985, SOV ASTRON LETT, V11, P390; STOREY PJ, 1995, MON NOT R ASTRON SOC, V272, P41, DOI 10.1093/mnras/272.1.41; STRELENITSKI VS, 1994, P AIRB ASTR S GAL EC; STRELNITSKI VS, IN PRESS ASTROPHYS J; STRELNITSKI VS, 1996, AMAZING LIGHT, P603; THOMPSON RI, 1977, ASTROPHYS J, V218, P170, DOI 10.1086/155668; THUM C, 1995, ASTRON ASTROPHYS, V300, P843; THUM C, 1994, ASTRON ASTROPHYS, V283, P582; THUM C, 1992, ASTRON ASTROPHYS, V256, P507; THUM C, 1994, ASTRON ASTROPHYS, V288, pL25; WEAVER H, 1965, NATURE, V208, P29, DOI 10.1038/208029a0	41	42	42	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1459	1461		10.1126/science.272.5267.1459	http://dx.doi.org/10.1126/science.272.5267.1459			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633236	Green Published			2022-12-01	WOS:A1996UP89900040
J	Hiley, CMH; Morley, CJ				Hiley, CMH; Morley, CJ			Risk factors for sudden infant death syndrome: Further change in 1992-3	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PAEDIAT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge				Morley, Colin/0000-0001-5388-0214				HILEY CMH, 1994, BRIT MED J, V309, P703, DOI 10.1136/bmj.309.6956.703; 1994, OPCS MONITOR	2	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1996	312	7043					1397	1398						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP434	8646098	Green Published			2022-12-01	WOS:A1996UP43400025
J	Mamode, N; Scott, RN; McLaughlin, SC; McLelland, A; Pollock, JG				Mamode, N; Scott, RN; McLaughlin, SC; McLelland, A; Pollock, JG			Perioperative myocardial infarction in peripheral vascular surgery	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT BIOCHEM,GLASGOW G31 2ER,LANARK,SCOTLAND	University of Glasgow; University of Glasgow	Mamode, N (corresponding author), GLASGOW ROYAL INFIRM,PERIPHERAL VASC UNIT,GLASGOW G31 2ER,LANARK,SCOTLAND.							KALRA M, 1993, BRIT J SURG, V80, P28, DOI 10.1002/bjs.1800800110; MAMODE N, 1995, BMJ-BRIT MED J, V310, P1215, DOI 10.1136/bmj.310.6989.1215; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; TAYLOR LM, 1991, J VASC SURG, V15, P52; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1996	312	7043					1396	1397		10.1136/bmj.312.7043.1396	http://dx.doi.org/10.1136/bmj.312.7043.1396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP434	8646097	Green Published			2022-12-01	WOS:A1996UP43400024
J	Niemeyer, BA; Suzuki, E; Scott, K; Jalink, K; Zuker, CS				Niemeyer, BA; Suzuki, E; Scott, K; Jalink, K; Zuker, CS			The Drosophila light-activated conductance is composed of the two channels TRP and TRPL	CELL			English	Article							RETINAL-DEGENERATION; PHOTORECEPTOR DEACTIVATION; PROTEIN; GENE; MUTANT; PHOTOTRANSDUCTION; MELANOGASTER; RHODOPSIN; CA2+; MEMBRANE	Drosophila phototransduction is a G protein-coupled, calcium-regulated signaling cascade that serves as a model system for the dissection of phospholipase C (PLC) signaling in vivo. The Drosophila light-activated conductance is constituted in part by the transient receptor potential (trp) ion channel, yet trp mutants still display a robust response demonstrating the presence of additional channels. The transient receptor potential-like (trpl) gene encodes a protein displaying 40% amino acid identity with TRP. Mammalian homologs of TRP and TRPL recently have been isolated and postulated to encode components of the elusive I-crac conductance. We now show that TRP and TRPL localize to the membrane of the transducing organelle, together with rhodopsin and PLC, consistent with a role in PLC signaling during phototransduction. To determine the function of TRPL in vivo, we isolated trpl mutants and characterized them physiologically and genetically. We demonstrate that the light-activated conductance is composed of TRP and TRPL ion channels and that each can be activated on its own. We also use genetic and electrophysiological tools to study the contribution of each channel type to the light response and show that TRP and TRPL can serve partially overlapping functions.	UNIV TOKYO, INST MED SCI, TOKYO, JAPAN	University of Tokyo	Niemeyer, BA (corresponding author), UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT NEUROSCI, DEPT BIOL, LA JOLLA, CA 92093 USA.		Niemeyer, Barbara A./AAL-8972-2021	Jalink, Kees/0000-0001-7019-3440; Suzuki, Emiko/0000-0002-4005-0542; Niemeyer, Barbara A./0000-0002-6963-0575				BACIGALUPO J, 1990, SER CENT ES, P27; BACIGALUPO J, 1995, J NEUROSCI, V15, P7196; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARASH S, 1988, J GEN PHYSIOL, V92, P307, DOI 10.1085/jgp.92.3.307; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; HARDIE RC, 1993, P ROY SOC B-BIOL SCI, V252, P223, DOI 10.1098/rspb.1993.0069; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HOCHSTRATE P, 1989, J COMP PHYSIOL A, V166, P179, DOI 10.1007/BF00193462; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kumar JP, 1995, DEVELOPMENT, V121, P4359; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PERETZ A, 1994, J GEN PHYSIOL, V104, P1057, DOI 10.1085/jgp.104.6.1057; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; POLLOCK JA, 1995, J NEUROSCI, V15, P3747; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STIEVE H, 1986, MOL MECHANISM PHOTOR, P199; SUZUKI E, 1993, J ELECTRON MICROSC, V42, P178; SUZUKI E, 1994, J ELECTRON MICROSC, V43, P183; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VIHTELIC TS, 1991, GENETICS, V127, P761; Wolff Tanya, 1993, P1277; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; YEANDLE S, 1957, THESIS J HOPKINS U; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	59	290	295	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 31	1996	85	5					651	659		10.1016/S0092-8674(00)81232-5	http://dx.doi.org/10.1016/S0092-8674(00)81232-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646774	Bronze			2022-12-01	WOS:A1996UP34400006
J	Subramaniam, VN; Peter, F; Philp, R; Wong, SH; Hong, WJ				Subramaniam, VN; Peter, F; Philp, R; Wong, SH; Hong, WJ			GS28, a 28-kilodalton Golgi SNARE that participates in ER-Golgi transport	SCIENCE			English	Article							VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; FUSION; RECEPTORS; PROTEIN; FAMILY	Little is known about the integral membrane proteins that participate in the early secretory pathway of mammalian cells. The complementary DNA encoding a 28-kilodalton protein (p28) of the cis-Golgi was cloned and sequenced. The protein was predicted to contain a central coiled-coil domain with a carboxyl-terminal membrane anchor. An in vitro assay for endoplasmic reticulum-Golgi transport was used to show that p28 participates in the docking and fusion stage of this transport event. Biochemical studies established that p28 is a core component of the Golgi SNAP receptor (SNARE) complex.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Subramaniam, V. Nathan/A-1901-2010; HONG, Wanjin/E-9927-2010	Subramaniam, V. Nathan/0000-0002-4583-7790; 				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MCMAHON HT, 1994, J CELL BIOL, V125, P1015; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOGAARD M, 1994, CELL, V78, P936; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANG BL, 1994, EUR J CELL BIOL, V65, P298; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	22	122	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1161	1163		10.1126/science.272.5265.1161	http://dx.doi.org/10.1126/science.272.5265.1161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638159				2022-12-01	WOS:A1996UM88900047
J	Subramanya, HS; Doherty, AJ; Ashford, SR; Wigley, DB				Subramanya, HS; Doherty, AJ; Ashford, SR; Wigley, DB			Crystal structure of an ATP-dependent DNA ligase from bacteriophage T7	CELL			English	Article							RNA CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI; GENE; GUANYLYLTRANSFERASE; DOMAIN; CDNA	The crystal structure of the ATP-dependent DNA ligase from bacteriophage T7 has been solved at 2.6 Angstrom resolution. The protein comprises two domains with a deep cleft running between them. The structure of a complex with ATP reveals that the nucleotide binding pocket is situated on the larger N-terminal domain, at the base of the cleft between the two domains of the enzyme. Comparison of the overall domain structure with that of DNA methyltransferases, coupled with other evidence, suggests that DNA also binds in this cleft. Since this structure is the first of the nucleotidyl-transferase superfamily, which includes the eukaryotic mRNA capping enzymes, the relationship between the structure of DNA ligase and that of other nucleotidyl-transferases is also discussed.			Subramanya, HS (corresponding author), UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND.			Doherty, Aidan/0000-0002-6370-1109	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; CONG PJ, 1993, J BIOL CHEM, V268, P7256; DOHERTY AJ, 1996, IN PRESS J BIOL CHEM; DOHERTY AJ, 1996, IN PRESS NUCL ACIDS; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; GELLERT M, 1967, P NATL ACAD SCI USA, V57, P148, DOI 10.1073/pnas.57.1.148; HAMMOND JM, 1992, NUCLEIC ACIDS RES, V20, P2667, DOI 10.1093/nar/20.11.2667; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LI Y, 1995, VIROLOGY, V212, P134, DOI 10.1006/viro.1995.1462; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MODRICH P, 1973, J BIOL CHEM, V248, P7502; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Sheldrick G. M., 1991, CRYSTALLOGRAPHIC COM, V5, P145; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SODERHALL S, 1976, NATURE, V260, P640, DOI 10.1038/260640a0; Tan GT, 1996, BIOCHEM J, V314, P993, DOI 10.1042/bj3140993; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Wilson AJC, 1942, NATURE, V150, P151, DOI 10.1038/150152a0	44	206	209	1	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					607	615		10.1016/S0092-8674(00)81260-X	http://dx.doi.org/10.1016/S0092-8674(00)81260-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653795	Bronze			2022-12-01	WOS:A1996UM41500017
J	Petrie, KJ; Weinman, J; Sharpe, N; Buckley, J				Petrie, KJ; Weinman, J; Sharpe, N; Buckley, J			Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: Longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC REHABILITATION	Objective-To examine whether patients' initial perceptions of their myocardial infarction predict subsequent attendance at a cardiac rehabilitation course, return to work, disability, and sexual dysfunction. Design-Patients' perceptions of their illness were measured at admission with their first myocardial infarction and at follow up three and six months later. Setting-Two large teaching hospitals in Auckland, New Zealand. Subjects-143 consecutive patients aged under 65 with their first myocardial infarction. Main outcome measures-Attendance at rehabilitation course; time before returning to work; measures of disability with sickness impact profile questionnaire for sleep and rest, social interaction, recreational activity, and home management; and sexual dysfunction. Results-Attendance at the rehabilitation course was significantly related to a stronger belief during admission that the illness could be cured or controlled (t=2.08, P=0.04), Return to work within six weeks was significantly predicted by the perception that the illness would last a short time (t=-2.52, P=0.01) and have less grave consequences for the patient (t=-2.87, P=0.005), Patients' belief that their heart disease would have serious consequences was significantly related to later disability in work around the house, recreational activities, and social interaction, A strong illness identity was significantly related to greater sexual dysfunction at both three and six months. Conclusions-Patients' initial perceptions of illness are important determinants of different aspects of recovery after myocardial infarction, Specific illness perceptions need to be identified at an early stage as a basis for optimising outcomes from rehabilitation programmes.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,UNIT PSYCHOL,LONDON SE1 9RT,ENGLAND; UNIV AUCKLAND,SCH MED,DEPT MED,AUCKLAND,NEW ZEALAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Auckland	Petrie, KJ (corresponding author), UNIV AUCKLAND,SCH MED,DEPT PSYCHIAT & BEHAV SCI,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.			Buckley, Judith/0000-0003-0374-5369				ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BYRNE DG, 1982, J PSYCHOSOM RES, V26, P105, DOI 10.1016/0022-3999(82)90028-9; DIEDERIKS JPM, 1991, J PSYCHOSOM RES, V35, P687, DOI 10.1016/0022-3999(91)90119-9; FLAPAN AD, 1994, BMJ-BRIT MED J, V309, P1129, DOI 10.1136/bmj.309.6962.1129; GARRITY TF, 1973, SOC SCI MED, V7, P705, DOI 10.1016/0037-7856(73)90004-8; GARRITY TF, 1975, PSYCHOL ASPECTS MYOC; GOBLE AJ, 1991, BRIT HEART J, V65, P126; Leventhal H., 1980, MEDICALPSYCHOLOGY, V2, P7; Ley P., 1988, COMMUNICATING PATIEN; LIPKIN DP, 1991, BRIT HEART J, V65, P237; LOGAN RL, 1986, NEW ZEAL MED J, V99, P368; MAELAND JG, 1987, J PSYCHOSOM RES, V31, P471, DOI 10.1016/0022-3999(87)90005-5; SKELTON JA, 1991, MENTAL REPRESENTATIO; Stewart AL., 2017, MEASURING FUNCTIONIN; Weinman J, 1996, PSYCHOL HEALTH, V11, P114	16	463	471	0	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1191	1194						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL058	8634561				2022-12-01	WOS:A1996UL05800016
J	Strachan, DP; Butland, BK; Anderson, HR				Strachan, DP; Butland, BK; Anderson, HR			Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort	BRITISH MEDICAL JOURNAL			English	Article							RISK FACTOR; NATURAL-HISTORY; BIRTH; PREMATURITY; CHILDREN	Objective-To describe the incidence and prognosis of wheezing illness from birth to age 33 and the relation of incidence to, perinatal, medical, social, environmental, and lifestyle factors. Design-Prospective longitudinal study. Setting-England, Scotland, and Wales. Subjects-18 559 people born on 3-9 March 1958. 5801 (31%) contributed information at ages 7, 11, 16, 23, and 33 years. Attrition bias was evaluated using information on 14 571 (79%) subjects. Main outcome measure-History of asthma, wheezy bronchitis, or wheezing obtained from interview with subjects' parents at ages 7, 11, and 16 and reported at interview by subjects at ages 23 and 33. Results-The cumulative incidence of wheezing illness was 18% by age 7, 24% by age 16, and 43% by age 33. Incidence during childhood was strongly and independently associated with pneumonia, hay fever, and eczema. There were weaker independent associations with male sex, third trimester antepartum haemorrhage, whooping cough, recurrent abdominal pain, and migraine. Incidence from age 17 to 33 was associated strongly with active cigarette smoking and a history of hay fever. There were weaker independent associations with female sex, maternal albuminuria during pregnancy, and histories of eczema and migraine. Maternal smoking during pregnancy was weakly and inconsistently related to childhood wheezing but was a stronger and significant independent predictor of incidence after age 16. Among 880 subjects who developed asthma or wheezy bronchitis from birth to age 7, 50% had attacks in the previous year at age 7; 18% at 11, 10% at 16, 10% at 23, and 27% at 33. Relapse at 33 after prolonged remission of childhood wheezing was more common among current smokers and atopic subjects. Conclusion-Atopy and active cigarette smoking are major influences on the incidence and recurrence of wheezing during adulthood.			Strachan, DP (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Butland, Barbara/0000-0001-9952-3108				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON HR, 1987, CHEST, V91, pS127, DOI 10.1378/chest.91.6.127S; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BUTLER NR, 1969, PERINATAL PROBLEMS; Davie R., 1972, BIRTH 7 2 REPORT CHI; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Fogelman K., 1976, BRITAINS 16 YEAR OLD; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JONES A, 1994, BRIT J GEN PRACT, V44, P127; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; *SAS SYST, 1990, SAS STAT US GUID VER; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1985, J ROY COLL GEN PRACT, V35, P182; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0	21	475	477	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1195	1199						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634562				2022-12-01	WOS:A1996UL05800018
J	Py, B; Higgins, CF; Krisch, HM; Carpousis, AJ				Py, B; Higgins, CF; Krisch, HM; Carpousis, AJ			A DEAD-box RNA helicase in the Escherichia coli RNA degradosome	NATURE			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; PROTEIN; DEGRADATION; DECAY; GENE; INVITRO; MUTANT; INVIVO; ATPASE	THE Escherichia coli RNA degradosome is a multi-enzyme complex that contains the exoribonuclease polynucleotide phosphorylase (PNPase) and the endoribonuclease RNase E(1,2). Both enzymes are important in RNA processing and messenger RNA degradation(3-14). Here we report that enolase and RhlB are two other major components of the degradosome. Enolase is a glycolytic enzyme with an unknown role in RNA metabolism. RhlB is a member of the DEAD-box family of ATP-dependent RNA helicases, which are found in both prokaryotes and eukaryote(15-26). We show that the degradosome has an ATP-dependent activity that aids the degradation of structured RNA by PNPase. Incubation of the degradosome with affinity-purified antibody against RhlB inhibited the ATP-stimulated RNA degradation. These results suggest that RhlB acts by unwinding RNA structures that impede the processive activity of PNPase. RhlB is thus an important enzyme in mRNA turnover.	UNIV OXFORD, NUFFIELD DEPT CLIN BIOCHEM, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND; CNRS, LAB MICROBIOL & GENET MOLEC, UPR 9007, F-31062 TOULOUSE, FRANCE	University of Oxford; Cancer Research UK; University of Oxford; Centre National de la Recherche Scientifique (CNRS)			Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; KALMAN M, 1991, NEW BIOL, V3, P886; KLEIN M, 1994, EMBL DATA BANK; LIANG L, 1994, DEVELOPMENT, V120, P1201; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)80206-A; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SPRING TG, 1975, METHOD ENZYMOL, V62, P323; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0	30	454	457	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					169	172		10.1038/381169a0	http://dx.doi.org/10.1038/381169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610017				2022-12-01	WOS:A1996UK13900054
J	Duthie, DJR				Duthie, DJR			Aminoacid infusions to prevent postoperative hypothermia	LANCET			English	Editorial Material							ACID INFUSION				Duthie, DJR (corresponding author), PAPWORTH HOSP,DEPT ANAESTHESIA,CAMBRIDGE,ENGLAND.							CARLSON GL, 1994, AM J PHYSIOL, V266, pE848; GIOVANNINI I, 1988, CRIT CARE MED, V16, P667, DOI 10.1097/00003246-198807000-00004; HALL GM, 1978, ANAESTHESIA, V33, P924; HERSIO K, 1991, CRIT CARE MED, V19, P503, DOI 10.1097/00003246-199104000-00008; JEQUIER E, 1986, CLIN NUTR, V5, P181, DOI 10.1016/0261-5614(86)90022-1; SELIDEN E, 1994, CLIN SCI, V86, P611; SELLDEN E, 1996, BRIT J ANAESTH, V96, P227; SESSLER DI, 1993, FASEB J, V7, P638, DOI 10.1096/fasebj.7.8.8500688	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1199	1199		10.1016/S0140-6736(96)90728-X	http://dx.doi.org/10.1016/S0140-6736(96)90728-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622444				2022-12-01	WOS:A1996UJ59700003
J	Kamei, Y; Xu, L; Heinzel, T; Torchia, J; Kurokawa, R; Gloss, B; Lin, SC; Heyman, RA; Rose, DW; Glass, CK; Rosenfeld, MG				Kamei, Y; Xu, L; Heinzel, T; Torchia, J; Kurokawa, R; Gloss, B; Lin, SC; Heyman, RA; Rose, DW; Glass, CK; Rosenfeld, MG			A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors	CELL			English	Article							THYROID-HORMONE RECEPTORS; RETINOID X-RECEPTOR; GLUCOCORTICOID RECEPTOR; DNA-BINDING; FACTOR CREB; RXR-BETA; C-JUN; ACID; PROTEIN; FOS	Nuclear receptors regulate gene expression by direct activation of target genes and inhibition of AP-1. Here we report that, unexpectedly, activation by nuclear receptors requires the actions of CREB-binding protein (CBP) and that inhibition of AP-1 activity is the apparent result of competition for limiting amounts of CBP/p300 in cells. Utilizing distinct domains, CBP directly interacts with the ligand-binding domain of multiple nuclear receptors and with the p160 nuclear receptor coactivators, which upon cloning have proven to be variants of the SRC-1 protein. Because CBP represents a common factor, required in addition to distinct coactivators for function of nuclear receptors, CREB, and AP-1, we suggest that CBP/p300 serves as an integrator of multiple signal transduction pathways within the nucleus.	UNIV CALIF SAN DIEGO,SCH MED,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,WHITTIER DIABET ASSOC DEPT,LA JOLLA,CA 92093; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; Ligand Pharmaceuticals	Kamei, Y (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.		Lin, SC/G-4666-2010; Glass, Christopher/AAI-3933-2021; Heinzel, Thorsten/B-1013-2015	Glass, Christopher/0000-0003-4344-3592; 				Abate C, 1990, Semin Cancer Biol, V1, P19; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ONATE SA, 1995, SCIENCE, V270, P1354; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	62	1888	1947	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					403	414		10.1016/S0092-8674(00)81118-6	http://dx.doi.org/10.1016/S0092-8674(00)81118-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616895	Bronze, Green Published			2022-12-01	WOS:A1996UK14000013
J	Nakano, T; Kodama, H; Honjo, T				Nakano, T; Kodama, H; Honjo, T			In vitro development of primitive and definitive erythrocytes from different precursors	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; C-KIT; DEVELOPING MOUSE; STEM-CELLS; YOLK-SAC; EXPRESSION; INVITRO; BLOOD; CULTURE; EMBRYO	During mouse embryogenesis the production of ''primitive'' erythrocytes (EryP) precedes the production of ''definitive'' erythrocytes (EryD) in parallel with the transition of the hematopoietic site from the yolk sac to the fetal liver. On a macrophage colony-stimulating factor-deficient stromal cell line OP9, mouse embryonic stem cells were shown to give rise to EryP and EryD sequentially with a time course similar to that seen in murine ontogeny. Studies of the different growth factor requirements and limiting dilution analysis of precursor frequencies indicate that most EryP and EryD probably developed from different precursors by way of distinct differentiation pathways.	KYOTO UNIV,FAC ENGN,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN; OHU UNIV,SCH DENT,DEPT ANAT,KORIYAMA,FUKUSHIMA 963,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					BREIVIK H, 1971, J CELL PHYSIOL, V78, P73, DOI 10.1002/jcp.1040780111; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CRAIG ML, 1964, DEV BIOL, V10, P191, DOI 10.1016/0012-1606(64)90040-5; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; INGRAM VM, 1972, NATURE, V235, P338, DOI 10.1038/235338a0; JOYNER AL, 1993, GENE TARGETING; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KODAMA H, 1994, EXP HEMATOL, V22, P979; LEDER A, 1992, DEVELOPMENT, V116, P1041; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MIWA Y, 1991, DEVELOPMENT, V111, P543; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1995, Semin Immunol, V7, P197, DOI 10.1016/1044-5323(95)90047-0; NAKANO T, UNPUB; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; RUGH R, 1968, MOUSE; Sambrook J., 1989, MOL CLONING LAB MANU; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1983, BLOOD, V62, P1280; WONG PMC, 1986, BLOOD, V67, P716; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	30	185	194	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					722	724		10.1126/science.272.5262.722	http://dx.doi.org/10.1126/science.272.5262.722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614833				2022-12-01	WOS:A1996UJ05100051
J	Yang, JY; Jayaram, M; Harshey, RM				Yang, JY; Jayaram, M; Harshey, RM			Positional information within the Mu transposase tetramer: Catalytic contributions of individual monomers	CELL			English	Article							PHAGE-MU; STRAND TRANSFER; DNA ENDS; SITE; PROTEIN; RECOMBINATION; DOMAINS; MECHANISM; COMPLEXES; CLEAVAGE	The strand cleavage and strand transfer reactions of Mu DNA transposition require structural/catalytic contributions from separate polypeptide domains of individual transposase (MuA) monomers within the functional MuA tetramer. Based on catalytic complementation between two inactive MuA variants, we have derived certain rules by which the physical location of a MuA monomer within the transposition complex specifies its role in DNA breakage and transfer. During strand transfer, MuA monomers contributing domain II to the reaction occupy R1 (the subsite proximal to the strand-transferred nucleotide), while those contributing domain III alpha occupy R2. The positions of the monomers contributing these two domains appear to be reversed during DNA cleavage.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ALDAZ H, 1996, IN PRESS CELL, V85; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM K, 1995, NUCLEIC ACIDS RES, V23, P3937, DOI 10.1093/nar/23.19.3937; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE D, 1995, CURR TOP MICROBIOL, V204, P83; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1996, IN PRESS J MOL BIOL; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NAMGOONG S, 1994, J MOL BIOL, V238, P514, DOI 10.1006/jmbi.1994.1311; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SAVILAHTI H, 1996, IN PRESS CELL, V85; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANGJY, 1995, GENE DEV, V9, P2545; ZOU A, 1991, J BIOL CHEM, V266, P20476	40	34	35	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					447	455		10.1016/S0092-8674(00)81122-8	http://dx.doi.org/10.1016/S0092-8674(00)81122-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616899	Bronze			2022-12-01	WOS:A1996UK14000017
J	Durand, GM; Kovalchuk, Y; Konnerth, A				Durand, GM; Kovalchuk, Y; Konnerth, A			Long-term potentiation and functional synapse induction in developing hippocampus	NATURE			English	Article							EXCITATORY SYNAPSES; DENTATE GYRUS; RAT; SLICES; RECEPTORS; REGION	LONG-TERM potentiation (LTP) is a cellular mechanism that potentially underlies learning and memory(1). To test the hypothesis that LTP is involved in activity-dependent synapse formation, we combined whole-cell recordings and confocal microscopy to investigate hippocampal glutamatergic synapses at their earliest stages of development. Here we report that, during the first postnatal week, the hippocampal glutamatergic network becomes gradually functional owing to the transformation of precursor, pure NMDA (N-methyl-D-aspartate)-receptor-based synaptic contacts into conducting AMPA (alpha-amino-3-hydroxyd-methylisoxazole-4-proprionate)/NMDA-receptor-type synapses. This functional synapse induction is caused by an associative form of LTP, so it is input-specific and easily triggered experimentally by pairing presynaptic stimulation with postsynaptic depolarization. Our results challenge previous views that LTP occurs in the hippocampus only at later stages of development(2-6) and that its induction requires dendritic spines(7). They also provide direct evidence that LTP is important for the activity-dependent formation of conducting glutamatergic synapses in the developing mammalian brain.	UNIV SAARLAND, INST PHYSIOL, D-66421 HOMBURG, GERMANY	Saarland University								BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BEKENSTEIN JW, 1991, DEV BRAIN RES, V63, P245, DOI 10.1016/0165-3806(91)90084-V; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; EILERS J, 1995, P NATL ACAD SCI USA, V92, P10272, DOI 10.1073/pnas.92.22.10272; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HARNS KM, 1984, J PHYSIOL-LONDON, V346, P27; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KONNERTH A, 1990, PFLUG ARCH EUR J PHY, V417, P285, DOI 10.1007/BF00370994; KONNERTH A, 1990, TRENDS NEUROSCI, V13, P321, DOI 10.1016/0166-2236(90)90137-Y; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; WONG LA, 1993, MOL PHARMACOL, V44, P504; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	25	643	662	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1996	381	6577					71	75		10.1038/381071a0	http://dx.doi.org/10.1038/381071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609991				2022-12-01	WOS:A1996UJ05300058
J	Newburger, JW				Newburger, JW			Treatment of Kawasaki disease	LANCET			English	Editorial Material							INTRAVENOUS GAMMA-GLOBULIN				Newburger, JW (corresponding author), CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02115 USA.		Nakashima, Lynne/I-1708-2019	Nakashima, Lynne/0000-0002-0712-7958				Burns JC, 1995, INT CONGR SER, V1093, P296; DAJANI AS, 1994, CIRCULATION, V89, P916, DOI 10.1161/01.CIR.89.2.916; DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; FURUSHO K, 1984, LANCET, V2, P1055; HARADA K, 1993, P 4 INT S KAW DIS DA, P459; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KLASSEN TP, 1993, J PEDIATR-US, V122, P538, DOI 10.1016/S0022-3476(05)83532-2; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Rosenfeld EA, 1995, INT CONGR SER, V1093, P291; SCHNEIDER L, 1994, MMWR-MORBID MORTAL W, V43, P505; Silverman ED, 1995, INT CONGR SER, V1093, P301; TAUBERT KA, 1991, J PEDIATR-US, V119, P279, DOI 10.1016/S0022-3476(05)80742-5	12	25	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1128	1128		10.1016/S0140-6736(96)90600-5	http://dx.doi.org/10.1016/S0140-6736(96)90600-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609740				2022-12-01	WOS:A1996UG75500002
J	Muragaki, Y; Mundlos, S; Upton, J; Olsen, BR				Muragaki, Y; Mundlos, S; Upton, J; Olsen, BR			Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13	SCIENCE			English	Article							GENE; LIMB; EXPRESSION; REPRESSION; PROTEINS; HOXD-13; LOCUS	Hox genes regulate patterning during limb development. It is believed that they function in the determination of the timing and extent of local growth rates. Here, it is demonstrated that synpolydactyly, an inherited human abnormality of the hands and feet, is caused by expansions of a polyalanine stretch in the amino-terminal region of HOXD13. The homozygous phenotype includes the transformation of metacarpal and metatarsal bones to short carpal- and tarsal-like bones. The mutations identify the polyalanine stretch outside of the DNA binding domain of HOXD13 as a region necessary for proper protein function.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT SURG,DIV PLAST SURG,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Muragaki, Y (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Mundlos, Stefan/ABH-9585-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036819, R37AR036819, R01AR036820] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; DESPOSITO M, 1991, GENOMICS, V10, P43, DOI 10.1016/0888-7543(91)90482-T; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORGAN BA, 1994, DEVELOPMENT, P181; MURAGAKI Y, UNPUB; Polymeropoulos M. H., 1995, American Journal of Human Genetics, V57, pA200; ROBERTS DJ, 1994, AM J HUM GENET, V55, P1; ROGINA B, 1993, NUCLEIC ACIDS RES, V21, P1316, DOI 10.1093/nar/21.5.1316; ROSEN DR, 1993, HUM MOL GENET, V2, P617, DOI 10.1093/hmg/2.5.617; SARFARAZI M, 1995, HUM MOL GENET, V4, P1453, DOI 10.1093/hmg/4.8.1453; SAYLI BS, 1994, J MED GENET, V32, P421; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	26	457	479	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					548	551		10.1126/science.272.5261.548	http://dx.doi.org/10.1126/science.272.5261.548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614804				2022-12-01	WOS:A1996UG82600044
J	Minor, DL; Kim, PS				Minor, DL; Kim, PS			Context-dependent secondary structure formation of a designed protein sequence	NATURE			English	Article							DIFFERENT CONFORMATIONS; PENTAPEPTIDES	PROTEIN secondary structures have been viewed as fundamental building blocks for protein folding, structure and design. Previous studies indicate that the propensities of individual amino acids to form particular secondary structures are the result of a combination of local conformational preferences(1,2) and non-local factors(3-7). To examine the extent to which non-local factors influence the formation of secondary structural elements, we have designed an 11-amino-acid sequence (dubbed the 'chameleon' sequence) that folds as an alpha-helix when in one position but as a beta-sheet when in another position of the primary sequence of the IgG-binding domain of protein G (GB1). Both proteins, chameleon-alpha and chameleon-beta, are folded into structures similar to native GB1, as judged hy several biophysical criteria. Our results demonstrate that non-local interactions can determine the secondary structure of peptide sequences of substantial length. They also support views of protein folding that favour tertiary interactions as dominant determinants of structure (for example, see refs 8,9).	MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142; MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute								ACHARI A, 1992, BIOCHEMISTRY-US, V31, P10449, DOI 10.1021/bi00158a006; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COHEN BI, 1993, PROTEIN SCI, V2, P2134, DOI 10.1002/pro.5560021213; DILL KA, 1995, PROTEIN SCI, V4, P561; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; GARRATT RC, 1985, FEBS LETT, V188, P59, DOI 10.1016/0014-5793(85)80874-7; GOLDSMITH EJ, 1994, STRUCTURE, V2, P241, DOI 10.1016/S0969-2126(00)00025-3; GRONENBOM AM, 1993, J MOL BIOL, V223, P331; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; Laue T. M., 1994, MODERN ANAL ULTRACEN; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; ORBAN J, 1995, BIOCHEMISTRY-US, V34, P15291, DOI 10.1021/bi00046a038; PRIVALOV PL, 1989, ANNU REV BIOPHYS BIO, V18, P47, DOI 10.1146/annurev.biophys.18.1.47; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Woody R., 1985, PEPTIDES; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349	31	341	349	2	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					730	734		10.1038/380730a0	http://dx.doi.org/10.1038/380730a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614471				2022-12-01	WOS:A1996UG82700057
J	Jeevaratnam, DR; Menon, DK				Jeevaratnam, DR; Menon, DK			Survey of intensive care of severely head injured patients in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL PERFUSION-PRESSURE; RANDOMIZED CLINICAL-TRIAL; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; BRAIN INJURY; BLOOD-FLOW; MANAGEMENT; HYPERVENTILATION; STEROIDS	Objectives-To study practice in intensive care of patients with severe head injury in neurosurgical referral centres in United Kingdom. Design-Structured telephone interview of senior nursing staff in intensive care unit of adult neurosurgical referral centre. Setting-39 intensive care units in hospitals that accepted acute head injuries for specialist neurosurgical management, identified from Medical Directory and information from professional bodies. Main outcome measures-Details of organisation and administration of intensive care and patterns of monitoring and treatment for patients admitted with severe head injury. Results-Patients were managed in specialist neurosurgical intensive care units in 21 of the centres and in general intensive care units in 18. Their intensive care was coordinated by an anaesthetist in 25 units and by a neurosurgeon in 12. Annual caseload varied between units: 20 received >100 patients, 12 received 50-100, and seven received 25-49. Monitoring and treatment varied considerably between centres. Invasive arterial pressure monitoring was used routinely in 36 units, but central venous pressure monitoring was routinely used in 24 and intracranial pressure was routinely monitored in only 19. Corticosteroids were used to treat intracranial hypertension in 19 units. Seventeen units routinely aimed for arterial carbon dioxide pressure of 3.3-4.0 kPa, and one unit still used severe hyperventilation to a pressure of <3.3 kPa. Conclusion-The intensive care of patients with acute head injuries varied widely between the centres surveyed. Rationalisation of the intensive care of severe head injury with the production of widely accepted guidelines ought to improve the quality of care.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT ANAESTHESIA,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Jennett B., 1981, MANAGEMENT HEAD INJU; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Young B, 1991, Neurosurg Clin N Am, V2, P301	29	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					944	947						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616307				2022-12-01	WOS:A1996UF65900019
J	Grant, GF				Grant, GF			My brain stem stroke	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					917	917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611912				2022-12-01	WOS:A1996UE37100072
J	GomezSkarmeta, JL; Diez del Corral, R; delaCalleMustienes, E; FerresMarco, D; Modolell, J				GomezSkarmeta, JL; Diez del Corral, R; delaCalleMustienes, E; FerresMarco, D; Modolell, J			araucan and caupolican, two members of the novel iroquois complex, encode homeoproteins that control proneural and vein-forming genes	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; DROSOPHILA-MELANOGASTER; SUBSTRATE RECOGNITION; EXPRESSION; PROTEIN; SEGMENTATION; SEQUENCE; EXTRAMACROCHAETAE; SEARCH	In Drosophila imaginal wing discs, the achaete-scute (ac-sc) proneural genes and rhomboid (veinlet) are expressed in highly resolved patterns that prefigure the positions of sensory organs and wing veins, respectively. It is thought that these patterns are generated by a combination of factors (a prepattern) regulating these genes. We provide evidence for the existence of this prepattern by identifying two of its factors, Araucan and Caupolican. They are members of a novel family of homeoproteins, with homologs in vertebrates. Araucan and Caupolican, present in domains of the imaginal discs larger than those expressing as-sc and rhomboid, are necessary for expression of these genes in the overlapping domains. Araucan and Caupolican appear to be positive, direct regulators of ac-sc.			GomezSkarmeta, JL (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL SEVERO OCHOA, CANTOBLANCO, E-28049 MADRID, SPAIN.		Ferres-Marco, Maria/G-8364-2015; Gomez-Skarmeta, Jose Luis/B-5268-2014; DIEZ DEL CORRAL, RUTH/K-7974-2014	Ferres-Marco, Maria/0000-0002-0596-4891; Gomez-Skarmeta, Jose Luis/0000-0001-5125-4332; DIEZ DEL CORRAL, RUTH/0000-0003-2649-7214; de la Calle-Mustienes, Elisa/0000-0002-8975-6503				ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHEN SM, 1993, DEV DROSOPHILA MELAN, P747; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1992, INT J DEV BIOL, V36, P85; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; GOMEZSKARMETA JL, 1995, THESIS U AUTONOMA MA; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; LEYNS L, 1991, THESIS U LIBRE BRUXE; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN CURT, 1954, AMER SCI, V42, P213; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; XU T, 1993, DEVELOPMENT, V117, P1223	51	268	272	1	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					95	105		10.1016/S0092-8674(00)81085-5	http://dx.doi.org/10.1016/S0092-8674(00)81085-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620542	Bronze			2022-12-01	WOS:A1996UE55900012
J	Zhang, ZH; Vuori, K; Wang, HG; Reed, JC; Ruoslahti, E				Zhang, ZH; Vuori, K; Wang, HG; Reed, JC; Ruoslahti, E			Integrin activation by R-ras	CELL			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-5-BETA-1 INTEGRIN; EXTRACELLULAR-MATRIX; SURFACE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; CELL-ADHESION; AFFINITY; PROTEIN	Expression of a constitutively active R-ras converted two cell lines that grow in suspension into highly adherent cells. There was little change in cell surface expression of integrins, but attachment to surfaces coated with the integrin ligands was greatly enhanced. Cells transfected with activated R-ras bound integrin ligands from solution with higher affinities and assembled severalfold more fibronectin matrix than control transfectants. Introduction of a dominant negative R-ras into adherent cells reduced the adhesiveness of the cells, indicating that endogenous R-ras can control the ligand-binding activity of integrins. These results provide a mechanism for the modulation of integrin ligand-binding activity as well as a novel function for R-ras.	UNIV CALIF SAN DIEGO, SCH MED, MOL PATHOL PROGRAM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Zhang, ZH (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA067224, P01CA028896, R01CA062042] Funding Source: NIH RePORTER; NCI NIH HHS [CA28896, CA62042, CA67224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COX AD, 1994, ONCOGENE, V9, P3281; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1990, BLOOD, V76, P2017; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PIERSCHBACHER MD, 1981, CELL, V56, P281; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAEZ R, 1994, ONCOGENE, V9, P2977; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMYTH SS, 1993, BLOOD, V81, P2827; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SYMONS MH, 1992, J CELL BIOL, V118, P1235, DOI 10.1083/jcb.118.5.1235; VAHERI A, 1974, INT J CANCER, V13, P579, DOI 10.1002/ijc.2910130502; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YANG JT, 1993, DEVELOPMENT, V119, P1093; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	56	365	368	1	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					61	69		10.1016/S0092-8674(00)81082-X	http://dx.doi.org/10.1016/S0092-8674(00)81082-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620538	Bronze			2022-12-01	WOS:A1996UE55900009
J	Joossens, L; Raw, M				Joossens, L; Raw, M			Are tobacco subsidies a misuse of public funds?	BRITISH MEDICAL JOURNAL			English	Article								The European Union spends about 1000m ecu (pound 800m, $1240m) a year subsidising tobacco production but only about 1.55m ecu (pound 1.2m, $1.85m) on smoking prevention. The subsidies, part of the common agriculutral policy, were originally intended to encourage farmers to grow commercially valued varieties of tobacco and thus reduce imports. But they also aimed to guarantee farmers' income, a goal in direct conflict with the first. The policy has failed to adapt production to demand or reduce imports, Since most tobacco grown in the union has little commercial value. Reforms introduced in 1992 have had a limited impact on expenditure, and data produced as a result of the reforms show that it would be much cheaper to give farmers direct income support than to subsidise them growing tobacco. Tobacco subsidies should be abolished and more should be spent on smoking prevention.	UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON SE5,ENGLAND		Joossens, L (corresponding author), INT UNION AGAINST CANC,EUROPEAN UNION OFF,RUE PASCAL 33,B-1000 BRUSSELS,BELGIUM.							*COMM EUR COMM, 1993, 9371 COMM EUR COMM; JOOSSENS L, 1991, BRIT J ADDICT, V86, P1191, DOI 10.1111/j.1360-0443.1991.tb01699.x; SLAMA K, 1995, TOBACCO HLTH; 1994, OFFICIAL J EUROPEAN, V37; 1992, OFFICIAL J EUROPEA L, V215, P70; 1992, OFFICIAL J EUROPEA L, V351, P17	6	8	8	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					832	835						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608295	Green Published			2022-12-01	WOS:A1996UD37800031
J	Gash, DM; Zhang, ZM; Ovadia, A; Cass, WA; Yi, A; Simmerman, L; Russell, D; Martin, D; Lapchak, PA; Collins, F; Hoffer, BJ; Gerhardt, GA				Gash, DM; Zhang, ZM; Ovadia, A; Cass, WA; Yi, A; Simmerman, L; Russell, D; Martin, D; Lapchak, PA; Collins, F; Hoffer, BJ; Gerhardt, GA			Functional recovery in parkinsonian monkeys treated with GDNF	NATURE			English	Article							L-DOPA; NEURONS	PARKINSON's disease results from the progressive degeneration of dopamine neurons that innervate the striatum(1,2). In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons(3-9). Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally into rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)(10-14). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.	AMGEN INC,THOUSAND OAKS,CA 91320; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,NEUROSCI TRAINING PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,NEUROSCI TRAINING PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,ROCKY MT CTR SENSOR TECHNOL,DENVER,CO 80262	Amgen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gash, DM (corresponding author), UNIV KENTUCKY,COLL MED,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536, USA.		Lapchak, Paul/P-1845-2019	Lapchak, Paul/0000-0003-4413-7554; Gash, Don/0000-0002-2504-2528				BANKIEWICZ K, 1993, EXP NEUROL, V124, P140, DOI 10.1006/exnr.1993.1185; BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOUGLE KL, 1995, P NATL ACAD SCI USA, V92, P1669; GASH OM, 1995, J COMP NEUROL, V363, P345; GREENAMYRE JT, 1994, ANN NEUROL, V35, P655, DOI 10.1002/ana.410350605; HARDING AJ, 1994, J NEUROSCI METH, V51, P83, DOI 10.1016/0165-0270(94)90028-0; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; HOMYKIEWICZ O, 1986, ADV NEUROL, V45, P19; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Jellinger KA, 1986, ADV NEUROL, V45, P1; KEAMS CM, 1995, BRAIN RES, V672, P104; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OVADIA A, 1995, NEUROBIOL AGING, V16, P931, DOI 10.1016/0197-4580(95)02012-8; ROBERTSON GS, 1988, NEUROSCI LETT, V89, P204, DOI 10.1016/0304-3940(88)90382-5; ROBERTSON GS, 1989, J NEUROSCI, V9, P3326; SMITH RD, 1993, NEUROSCIENCE, V52, P7, DOI 10.1016/0306-4522(93)90176-G; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O	22	809	852	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					252	255		10.1038/380252a0	http://dx.doi.org/10.1038/380252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637574				2022-12-01	WOS:A1996UB11700053
J	Bifani, PJ; Plikaytis, BB; Kapur, V; Stockbauer, K; Pan, X; Lutfey, ML; Moghazeh, SL; Eisner, W; Daniel, TM; Kaplan, MH; Crawford, JT; Musser, JM; Kreiswirth, BN				Bifani, PJ; Plikaytis, BB; Kapur, V; Stockbauer, K; Pan, X; Lutfey, ML; Moghazeh, SL; Eisner, W; Daniel, TM; Kaplan, MH; Crawford, JT; Musser, JM; Kreiswirth, BN			Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIOLOGY; POLYMORPHISM; TOOL	Objective.-To determine whether isolates of Mycobacterium tuberculosis from New York and elsewhere that are resistant to four or more primary antimicrobial agents and responsible for widespread disease in the 1990s represent a newly emerged clone or a heterogeneous array of unrelated organisms. Setting.-New York City area and selected locations in the United States. Patients.-M tuberculosis isolates from 1953 patients in New York and multidrug-resistant isolates from six patients from other US communities. Design.-Convenience sample of all M tuberculosis strains (M tuberculosis isolates resistant to rifampin, streptomycin, isoniazid, and ethambutol, and sometimes ethionamide, kanamycin, capreomycin, or ciprofloxacin) submitted to the Public Health Research Institute Tuberculosis Center since 1991 and samples submitted to the Centers for Disease Control and Prevention from throughout the United States, The samples submitted were representative of the New York City strains of M tuberculosis. Main Outcome Measure.-Characterization of resistant M tuberculosis strains studied by IS6110 and polymorphic CC-rich repetitive sequence (PGRS) hybridization patterns, multiplex polymerase chain reaction (PCR) analysis, and automated DNA sequencing of genes containing mutations associated with resistance to rifampin (rpoB), isoniazid (katG and inhA locus), and streptomycin (strA and rrs). Results.-Multidrug-resistant M tuberculosis isolates were recovered from 253 New York City patients and had the same or closely allied IS6110 and PGRS patterns, multiplex PCR type, and gene mutations associated with resistance to rifampin, isoniazid, and streptomycin. Isolates with these same molecular characteristics were recovered from patients in Florida and Nevada, health care workers in Atlanta, Ga, and Miami, Fla, and an individual who recently moved from New York City to Denver, Cole, and caused disease or skin test conversion in at least 12 people in a nursing home environment. Conclusions.-The results document the molecular origin and spread of progeny of a closely related family of multidrug-resistant M tuberculosis strains that have recently shared a common ancestor and undergone clonal expansion. The multidrug-resistant phenotype in these organisms arose by sequential acquisition of resistance-conferring mutations in several genes, most likely as a consequence of antibiotic selection of randomly occurring mutants in concert with inadequately treated infections. Dissemination of these difficult-to-treat bacteria throughout New York City and to at least four additional US cities has adverse implications for tuberculos control in the 21st century.	PUBL HLTH RES INST,TB CTR,NEW YORK,NY 10016; BAYLOR COLL MED,DEPT PATHOL,SECT MOLEC PATHOBIOL,HOUSTON,TX; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30341; N SHORE UNIV HOSP,MANHASSET,NY 11030; CASE WESTERN RESERVE UNIV,CTR INT HLTH,CLEVELAND,OH	Baylor College of Medicine; Centers for Disease Control & Prevention - USA; Northwell Health; North Shore University Hospital; Case Western Reserve University			Kapur, Vivek/F-7610-2013	Kapur, Vivek/0000-0002-9648-0138; Bifani, Pablo/0000-0001-9651-6439	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI37004] Funding Source: Medline; NIDA NIH HHS [R01-DA09238] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; HEWLETT D, 1995, INFECT DIS CLIN PRAC, V4, P389, DOI 10.1097/00019048-199509000-00020; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; HORN DL, IN PRESS INFECT DIS; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; LONGUET P, 1995, 35TH INT C ANT AG CH; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755; SIDDIQI S, 1989, BACTEC TB SYSTEMS PR; SMALL PM, 1993, INFECT AGENT DIS, V2, P132; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1991, MMWR MORBID MORTAL W, V40, P585; 1992, MMWR MORBID MORTAL W, V41, P507; 1990, NCCLS M24P NAT COMM	26	319	336	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					452	457		10.1001/jama.275.6.452	http://dx.doi.org/10.1001/jama.275.6.452			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627966				2022-12-01	WOS:A1996TU63800033
J	Tofler, IR; Stryer, BK; Micheli, LJ; Herman, LR				Tofler, IR; Stryer, BK; Micheli, LJ; Herman, LR			Physical and emotional problems of elite female gymnasts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ATHLETE TRIAD; AMENORRHEA; INJURIES; OSTEOPOROSIS; SWIMMERS; GROWTH		UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; CHILDRENS HOSP,MED CTR,BOSTON,MA 02115; FLORIDA STATE UNIV,TALLAHASSEE,FL 32306	University of California System; University of California Los Angeles; Harvard University; Boston Children's Hospital; State University System of Florida; Florida State University	Tofler, IR (corresponding author), LOUISIANA STATE UNIV,CHILDRENS HOSP NEW ORLEANS,DEPT PSYCHIAT,200 HENRY CLAY AVE,NEW ORLEANS,LA 70118, USA.							BAKER R, 1996, NY TIMES        0420, pA17; CLAESSENS AL, 1992, MED SCI SPORT EXER, V24, P755; COAKLEY J, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P77; COOK PC, 1995, ORTHOP CLIN N AM, V26, P453; DONNELLY P, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P95; DRINKWATER BL, 1990, JAMA-J AM MED ASSOC, V263, P545, DOI 10.1001/jama.263.4.545; DUMMER GM, 1987, PHYSICIAN SPORTSMED, V15, P75, DOI 10.1080/00913847.1987.11709350; EMANS SJ, 1990, OBSTET GYNECOL, V76, P585; FRISCH RE, 1984, BIOL REV, V59, P161, DOI 10.1111/j.1469-185X.1984.tb00406.x; GARRICK JG, 1980, AM J SPORT MED, V8, P261, DOI 10.1177/036354658000800409; GOLDSTEIN JD, 1991, AM J SPORT MED, V19, P463, DOI 10.1177/036354659101900507; GOULD D, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P19; KAPLAN HI, 1988, SYNOPSIS PSYCHIAT BE, P598; KIBLER WB, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P203; LOUCKS AB, 1985, MED SCI SPORT EXER, V17, P56, DOI 10.1249/00005768-198502000-00010; MANDELBAUM BR, 1989, AM J SPORT MED, V17, P305, DOI 10.1177/036354658901700301; MANDELBAUM BR, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P217; MICHELI LJ, 1989, PEDIAT EXERC SCI, V1, P329; NASH H L, 1987, Physician and Sportsmedicine, V15, P129; NATTIV A, 1994, CLIN SPORT MED, V13, P405; NATTIV A, 1993, PHYSICIAN SPORTSMED, V21, P66, DOI 10.1080/00913847.1993.11710401; OPIC H, 1995, REPORT INDEPENDENT I; OTIS CL, 1992, CLIN SPORT MED, V11, P351; PILLEMER FG, 1988, CLIN SPORT MED, V7, P679; POWERS SK, 1994, EXERCISE PHYSL THEOR, P480; ROBERTS GAF, 1992, ADVANCES IN CHITIN AND CHITOSAN, P179; ROSEN LW, 1986, PHYSICIAN SPORTSMED, V14, P79, DOI 10.1080/00913847.1986.11708966; ROSEN LW, 1988, PHYSICIAN SPORTSMED, V16, P140, DOI 10.1080/00913847.1988.11709603; ROWLAND TW, 1993, INTENSIVE PARTICIPAT, P177; Ryan J., 1995, LITTLE GIRLS PRETTY; Seefeldt V, 1978, J PHYS ED RECREATION, V49, P38; SINGER D, 1995, REHABIL MANAGE   DEC, P121; Skolnick AA, 1996, JAMA-J AM MED ASSOC, V275, P22, DOI 10.1001/jama.275.1.22; SKOLNICK AA, 1993, JAMA-J AM MED ASSOC, V270, P921, DOI 10.1001/jama.270.8.921; THEINTZ GE, 1993, J PEDIATR-US, V122, P306, DOI 10.1016/S0022-3476(06)80139-3; TOFLER I, 1995, INT J SPORTS PSYCHIA; TOFLER I, 1996, INT SOC SPORT SCI RE; TOFLER I, 1996, INT SOC SPORTS  0506; WEISS M, 1995, SPORTS PSYCHOL INTER, P41; Weiss M R, 1990, Exerc Sport Sci Rev, V18, P331; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013; YEAGER KK, 1993, MED SCI SPORT EXER, V25, P775, DOI 10.1249/00005768-199307000-00003; 1996, NBS SPORTS      0302; 1994, TECHNIQUE, V15, P18; 1994, REUTERS NEWS SE 1128	45	94	94	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					281	283		10.1056/NEJM199607253350412	http://dx.doi.org/10.1056/NEJM199607253350412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657248				2022-12-01	WOS:A1996UZ53200012
J	Miller, FG; Fins, JJ				Miller, FG; Fins, JJ			A proposal to restructure hospital care for dying patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CORNELL UNIV,COLL MED,NEW YORK,NY 10021; UNIV VIRGINIA,CHARLOTTESVILLE,VA 22908; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; University of Virginia; Cornell University; NewYork-Presbyterian Hospital			Ram, Prem/K-4511-2012	Fins, Joseph/0000-0002-7221-0053				COLBURN D, 1995, WASHINGTON POST 1122, pA1; COLBURN D, 1995, WASHINGTON POST 1205, P7; COWLEY G, 1995, NEWSWEEK        1204, P74; Gilbert Susan, 1995, N Y Times Web, pC7; GOMEZ CF, 1996, CARING DYING IDENTIF, P27; GOODMAN E, 1995, JAMA-J AM MED ASSOC, V273, P1039; HORSBURGH CR, 1995, NEW ENGL J MED, V333, P735, DOI 10.1056/NEJM199509143331117; JAMES N, 1992, SOC SCI MED, V34, P1363, DOI 10.1016/0277-9536(92)90145-G; JECKER NS, 1991, J MED PHILOS, V16, P285, DOI 10.1093/jmp/16.3.285; Konner M., 1987, BECOMING DOCTOR JOUR; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MATHEWS JJ, 1991, WOMEN HEALTH, V17, P39, DOI 10.1300/J013v17n01_03; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; NULAND SB, 1994, HOW WE DIE RELFECTIO; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT JR, 1976, NEW ENGL J MED, V294, P1205, DOI 10.1056/NEJM197605272942203; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; STODDARD S, 1992, HOSPICE MOVEMENT; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WINSLOW R, 1995, WALL STREET J   0721, pB1; 1995, JAMA-J AM MED ASSOC, V274, P1591	24	57	57	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1740	1742		10.1056/NEJM199606273342612	http://dx.doi.org/10.1056/NEJM199606273342612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637523				2022-12-01	WOS:A1996UT40000012
J	Elena, SF; Cooper, VS; Lenski, RE				Elena, SF; Cooper, VS; Lenski, RE			Punctuated evolution caused by selection of rare beneficial mutations	SCIENCE			English	Article							EQUILIBRIA; RATES	For more than two decades there has been intense debate over the hypothesis that most morphological evolution occurs during relatively brief episodes of rapid change that punctuate much longer periods of stasis, A clear and unambiguous case of punctuated evolution is presented for cell size in a population of Escherichia coli evolving for 3000 generations in a constant environment, The punctuation is caused by natural selection as rare, beneficial mutations sweep successively through the population, This experiment shows that the most elementary processes in population genetics can give rise to punctuated evolutionary dynamics.			Elena, SF (corresponding author), MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824, USA.		Elena, Santiago F./A-4191-2011	Elena, Santiago F./0000-0001-8249-5593; Lenski, Richard/0000-0002-1064-8375; Cooper, Vaughn/0000-0001-7726-0765				ARNOLD SJ, 1983, AM ZOOL, V23, P347, DOI 10.1093/icb/23.2.347; BOOKSTEIN FL, 1978, PALEOBIOLOGY, V4, P120, DOI 10.1017/S0094837300005807; CHARLESWORTH B, 1982, EVOLUTION, V36, P474, DOI 10.1111/j.1558-5646.1982.tb05068.x; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; Eldredge N., 1972, P82; Falconer D. S, 1981, INTRO QUANTITATIVE G; GINGERICH PD, 1984, SYST ZOOL, V33, P335, DOI 10.2307/2413079; GINGERICH PD, 1983, SCIENCE, V222, P159, DOI 10.1126/science.222.4620.159; GINZBURG LR, 1981, PALEOBIOLOGY, V7, P426, DOI 10.1017/S0094837300025483; Gould S.J., 1982, P83; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Haldane JBS, 1927, P CAMB PHILOS SOC, V23, P838, DOI 10.1017/S0305004100015644; JOHNSON PA, 1995, P ROY SOC B-BIOL SCI, V259, P125, DOI 10.1098/rspb.1995.0019; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Levinton J. S., 1988, GENETICS PALEONTOLOG; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Neidhardt F.C., 1990, PHYSL BACTERIAL CELL; NEWMAN CM, 1985, NATURE, V315, P400, DOI 10.1038/315400a0; Travisano M, 1996, GENETICS, V143, P15; Turner J., 1986, PATTERNS PROCESSES H, P183; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; WILLIAMSON PG, 1981, NATURE, V293, P437, DOI 10.1038/293437a0	25	198	205	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1802	1804		10.1126/science.272.5269.1802	http://dx.doi.org/10.1126/science.272.5269.1802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650581				2022-12-01	WOS:A1996UT11000047
J	Rhodes, JM				Rhodes, JM			Cholesterol crystal embolism: An important ''new'' diagnosis for the general physician	LANCET			English	Editorial Material							EMBOLIZATION				Rhodes, JM (corresponding author), UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Rhodes, Jonathan M/C-2496-2009					BLANKENSHIP JC, 1995, CHEST, V107, P662, DOI 10.1378/chest.107.3.662; CABILI S, 1993, ANGIOLOGY, V44, P821, DOI 10.1177/000331979304401010; CROSS SS, 1991, J CLIN PATHOL, V44, P859, DOI 10.1136/jcp.44.10.859; DAHLBERG PJ, 1989, SURGERY, V105, P737; FINE MJ, 1987, ANGIOLOGY, V38, P769, DOI 10.1177/000331978703801007; GAINES PA, 1988, LANCET, V1, P168; Moolenaar W, 1996, GUT, V38, P196, DOI 10.1136/gut.38.2.196; RICHARDS AM, 1965, AM J CARDIOL, V15, P696, DOI 10.1016/0002-9149(65)90359-0; WONG FKM, 1995, AM J KIDNEY DIS, V26, P508	9	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1641	1641		10.1016/S0140-6736(96)91482-8	http://dx.doi.org/10.1016/S0140-6736(96)91482-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642953				2022-12-01	WOS:A1996UQ70100005
J	Sinauer, N; Annest, JL; Mercy, JA				Sinauer, N; Annest, JL; Mercy, JA			Unintentional, nonfatal firearm-related injuries - A preventable public health burden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUNSHOT WOUNDS; NORTH-CAROLINA; FATALITIES; CHILDREN; CALIFORNIA; DEATHS	Objective.-To describe the magnitude and characteristics of unintentional, nonfatal firearm-related injuries treated in US hospital emergency departments. Design.-Data were obtained from medical records for all firearm-related injury cases identified using the National Electronic Injury Surveillance System (NEISS) from June 1, 1992, through May 31, 1994. We report on cases classified as unintentional gunshot wounds. Setting.-NEISS comprises 91 hospitals that are a stratified probability sample of all hospitals in the United States and its territories that have at least 6 beds and provide 24-hour emergency service. Main Outcome Measures.-Number of and population rates for unintentional, nonfatal firearm-related injuries. Results.-An estimated 34 485 (95% confidence interval [CI], 25 225-43 745) persons (6.7 per 100 000 population; 95% CI, 4.9-8.5) were treated for unintentional, nonfatal firearm-related injuries in US emergency departments during the 2-year study period. The majority of patients were male (87%) and aged 15 to 34 years (61%); 38% required hospitalization. Injuries were most often to an extremity (73%), were self-inflicted (70%), involved a handgun (57%), and resulted during common gun-related activities. Conclusions.-Further development of effective interventions are needed to reduce the risk of injury from unintentional discharge of a firearm during routine gun-handling practices by those who own and use firearms. These injuries often occur during common gun-related activities such as gun cleaning, loading/unloading, hunting, target shooting, and showing, handling, or carrying. Studies are needed to evaluate the efficacy of existing gun safety training courses and assess the potential role of various gun safety devices (eg, trigger locks and loading indicators) in future prevention strategies.	NATL CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT & PROGRAMMING,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA								American Academy of Pediatrics, 1994, STOP FIR INJ; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BAKER SP, 1992, INJURY FACT BOOK, P149; CARTER GL, 1989, ANN EMERG MED, V18, P406, DOI 10.1016/S0196-0644(89)80581-5; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; COLE TB, 1988, AM J PUBLIC HEALTH, V78, P1585, DOI 10.2105/AJPH.78.12.1585; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; DOWD MD, 1994, PEDIATRICS, V94, P867; Go Bette K., 1995, P21; *HANDG CONTR INC, 1995, STAT WHICH REQ SAF T; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; HEMENWAY D, 1990, J POLICY ANAL MANAG, V9, P94, DOI 10.2307/3325116; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEE RK, 1993, AM J PREV MED, V9, P16, DOI 10.1016/S0749-3797(18)30673-1; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARTIN JR, 1991, ANN EMERG MED, V20, P58, DOI 10.1016/S0196-0644(05)81120-5; MORROW PL, 1986, AM J PUBLIC HEALTH, V76, P1120, DOI 10.2105/AJPH.76.9.1120; *NATL CTR INJ, 1995, INJ MORT NAT SUMM IN; *OUTD EMP PUBL, 1993, 1993 HUNT ED PROGR P; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; STUCKY W, 1991, J PEDIATR ORTHOPED, V11, P64, DOI 10.1097/01241398-199101000-00013; *US BUR CENS, 1993, CURR POP REP P25, V1104, P12; *US CONS PROD SAF, 1994, NAT EL INJ SURV SYST; *US DEP JUST, 1993, CRIM VICT US; WALLER J A, 1973, Accident Analysis and Prevention, V5, P351, DOI 10.1016/0001-4575(73)90033-X; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WINTEMUTE GJ, 1989, J TRAUMA, V29, P457, DOI 10.1097/00005373-198904000-00007; Zawitz MW, 1996, NCJ160093 US DEP JUS; Zimring F. E., 1987, CITIZENS GUIDE GUN C; 1992, MMWR-MORBID MORTAL W, V41, P442	31	53	54	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1740	1743						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP307	8637171				2022-12-01	WOS:A1996UP30700027
J	Connolly, AJ; Ishihara, H; Kahn, ML; Farese, RV; Coughlin, SR				Connolly, AJ; Ishihara, H; Kahn, ML; Farese, RV; Coughlin, SR			Role of the thrombin receptor In development and evidence for a second receptor	NATURE			English	Article							ACTIVATION; DOMAIN; MICE	THROMBIN, a coagulation protease generated at sites of vascular injury, activates platelets, endothelial cells, leukocytes and mesenchymal cells(1,2). A G-protein-coupled receptor that is proteolytically activated by thrombin(3) is a target for drug development aimed at blocking thrombosis, inflammation and proliferation. Here we show that although disruption of the thrombin-receptor (tr) gene in mice causes about half the tr(-/-) embryos to die at embryonic day 9-10, half survive to become grossly normal adult mice with no bleeding diathesis. Strikingly, tr(-/-) platelets respond strongly to thrombin, whereas tr(-/-) fibroblasts lose their ability to respond to thrombin. We conclude that the thrombin receptor plays an unexpected role in embryonic development, suggesting a possible new function for the 'coagulation' proteases themselves. Moreover, a second platelet thrombin receptor exists, and different thrombin receptors have tissue-specific roles. This may allow development of therapeutics that will selectively block thrombin's different cellular actions.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes								BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BEVIGLIA L, 1993, THROMB RES, V71, P3001; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JZ, 1983, HEMAT ONVOL CLIN N A, V7, P1107; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; HOGAN B, 1994, MANIPULATING MOUSE E, P1; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kahn M, 1996, MOL MED, V2, P349, DOI 10.1007/BF03401632; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KINLOUGHRATHBONE RL, 1993, THROMB HAEMOSTASIS, V70, P1019; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAGES B, 1994, BLOOD, V83, P2549, DOI 10.1182/blood.V83.9.2549.bloodjournal8392549; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; RYDEL TJ, 1994, J BIOL CHEM, V269, P22000; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	30	433	446	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					516	519		10.1038/381516a0	http://dx.doi.org/10.1038/381516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632823				2022-12-01	WOS:A1996UP43500058
J	Kanopka, A; Muhlemann, O; Akusjarvi, G				Kanopka, A; Muhlemann, O; Akusjarvi, G			Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA	NATURE			English	Article							RNA; BINDING; INVITRO; SITE; TERMINATION; EXPRESSION; SELECTION; ENHANCER; SF2	THE adenovirus L1 unit(1) represents an example of an alternatively spliced precursor messenger (pre-mRNA) where one 5' splice can be joined to one of two alternative 3' splice sites, producing the 52,55K or the IIIa mRNAs (Fig, 1a). Efficient usage of the distal IIIa 3' splice site requires late viral protein synthesis and is therefore confined to the late phase of virus infection(2-4). Here we show that, in extracts from uninfected cells, the classical SR proteins(5), which are essential splicing factors(5-7), inhibit IIIa pre-mRNA splicing by binding to an intronic repressor element and preventing recruitment of the U2 small nuclear ribonucleoprotein particle to the spliceosome. We further show that the viral repressor element has splicing-enhancer activity when appropriately placed in the pre-mRNA. Together, our results demonstrate that SR proteins function as activators or repressors of splicing depending on where on the pre-mRNA they bind.	UNIV UPPSALA,DEPT IMMUNOL & MED MICROBIOL,BMC,S-75123 UPPSALA,SWEDEN	Uppsala University				Muhlemann, Oliver/0000-0003-0657-1368				AKUSJARVI G, 1981, NATURE, V292, P420, DOI 10.1038/292420a0; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HIMMELSPACH M, 1995, RNA, V1, P794; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; IMPERIALE M, 1995, CURR TOP MICROBIOL, P139; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P2379, DOI 10.1093/nar/19.9.2379; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Moore M., 1993, RNA WORLD, P303; NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SVENSSON C, 1986, P NATL ACAD SCI USA, V83, P4690, DOI 10.1073/pnas.83.13.4690; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	30	207	210	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					535	538		10.1038/381535a0	http://dx.doi.org/10.1038/381535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632829				2022-12-01	WOS:A1996UP43500064
J	Nennig, ME; Shinefield, HR; Edwards, KM; Black, SB; Fireman, BH				Nennig, ME; Shinefield, HR; Edwards, KM; Black, SB; Fireman, BH			Prevalence and incidence of adult pertussis in an urban population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; OUTBREAK	Objectives.-To determine the prevalence of Bordetella pertussis infection among adults who have prolonged cough for 2 weeks or longer and to estimate the incidence of B pertussis infection in adults in a defined urban population. Design.-A prospective clinical study. Setting.-Kaiser Permanente, San Francisco (Calif) Medical Center. Participants.-One hundred fifty-three referred and participating health plan members 18 years old or older with the complaint of cough:persisting for 2 weeks or longer and 154 health plan members 18 years old or older with no cough for the past 3 months (controls) were enrolled. Medical records for an additional 100 patients randomly sampled from 676 patients 18 years old or older with an ambulatory diagnosis of cough (60 with prolonged cough) were also reviewed. Main Outcome Measures.-Prevalence of adult pertussis as determined by enzyme-linked immunosorbent assay IgG antibody levers to pertussis toxin in individuals with prolonged cough for 2 weeks or longer and the incidence of adult pertussis in San Francisco Kaiser health plan members. Results.-The prevalence of adult pertussis was 12.4% of the participating referrals. The incidence of adult pertussis was estimated to be 176 cases per 100 000 person-years (95% confidence interval, 97 to 255 cases). Conclusions.-Adult pertussis is a significantly greater public health threat than previously suspected, Booster doses of acellular pertussis vaccine after 7 years of age may bean effective approach to minimize transmission and infection.	KAISER PERMANENTE MED GRP,KAISER PERMANENTE PEDIAT VACCINE STUDY CTR,OAKLAND,CA; KAISER PERMANENTE MED GRP,DIV RES,OAKLAND,CA; VANDERBILT UNIV,MED CTR,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232	Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Vanderbilt University								ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; AOYAMA T, 1992, AM J DIS CHILD, V146, P163, DOI 10.1001/archpedi.1992.02160140029015; BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; Cherry J D, 1984, Curr Probl Pediatr, V14, P1; CHERRY JD, 1995, CLIN INFECT DIS, V20, P1271, DOI 10.1093/clinids/20.5.1271; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; HERWALDT LA, 1991, ARCH INTERN MED, V151, P1510, DOI 10.1001/archinte.151.8.1510; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; MORTIMER EA, 1994, VACCINES, P91; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; PATRIARCA PA, 1988, AM J PUBLIC HEALTH, V78, P833, DOI 10.2105/AJPH.78.7.833; ROBERTSON PW, 1987, MED J AUSTRALIA, V147, P522; SCHMITTGROHE S, 1995, CLIN INFECT DIS, V21, P860, DOI 10.1093/clinids/21.4.860; STEKETEE RW, 1988, J INFECT DIS, V157, P441, DOI 10.1093/infdis/157.3.441; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; 1993, MMWR-MORBID MORTAL W, V42, P959; 1993, MMWR-MORBID MORTAL W, V42, P952; 1982, MMWR-MORBID MORTAL W, V30, P1; 1995, MMWR-MORBID MORTAL W, V44, P525	25	183	188	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1672	1674		10.1001/jama.275.21.1672	http://dx.doi.org/10.1001/jama.275.21.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637142				2022-12-01	WOS:A1996UN25200031
J	Mochizuki, T; Wu, GQ; Hayashi, T; Xenophontos, SL; Veldhuisen, B; Saris, JJ; Reynolds, DM; Cai, YQ; Gabow, PA; Pierides, A; Kimberling, WJ; Breuning, MH; Deltas, CC; Peters, DJM; Somlo, S				Mochizuki, T; Wu, GQ; Hayashi, T; Xenophontos, SL; Veldhuisen, B; Saris, JJ; Reynolds, DM; Cai, YQ; Gabow, PA; Pierides, A; Kimberling, WJ; Breuning, MH; Deltas, CC; Peters, DJM; Somlo, S			PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein	SCIENCE			English	Article							INTRACRANIAL ANEURYSMS; FUNCTIONAL EXPRESSION; SPANNING PROTEINS; CALCIUM-CHANNEL; HETEROGENEITY; SEQUENCES	A second gene for autosomal dominant polycystic kidney disease was identified by positional cloning. Nonsense mutations in this gene (PKD2) segregated with the disease in three PKD2 families. The predicted 968-amino acid sequence of the PKD2 gene product has six transmembrane spans with intracellular amino- and carboxyl-termini. The PKD2 protein has amino acid similarity with PKD1, the Caenorhabditis elegans homolog of PKD1, and the family of voltage-activated calcium (and sodium) channels, and it contains a potential calcium-binding domain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED & MOLEC GENET, DIV RENAL, BRONX, NY 10461 USA; CYPRUS INST NEUROL & GENET, AGIOS DHOMENTIOS 2012, NICOSIA, CYPRUS; LEIDEN UNIV, DEPT HUMAN GENET, SYLVIUS LABS, 2333 AL LEIDEN, NETHERLANDS; UNIV COLORADO, HLTH SCI CTR, DEPT INTERNAL MED, DENVER, CO 80220 USA; NICOSIA GEN HOSP, DEPT NEPHROL, NICOSIA 1311, CYPRUS; BOYS TOWN NATL RES HOSP, DEPT PATHOL, OMAHA, NE 68131 USA; BOYS TOWN NATL RES HOSP, DEPT OTOLARYNGOL, OMAHA, NE 68131 USA	Yeshiva University; Albert Einstein College of Medicine; Leiden University; Leiden University - Excl LUMC; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Boys Town National Research Hospital; Boys Town National Research Hospital			Deltas, Constantinos/J-9345-2013; Breuning, Martijn H/E-3429-2010; Deltas, Constantinos/A-4936-2013; Peters, Dorien/AFH-8507-2022	Deltas, Constantinos/0000-0001-5549-9169; Deltas, Constantinos/0000-0001-5549-9169; Peters, Dorien/0000-0001-6974-7143	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002015, R01DK048383] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02015, DK48383] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; *BESTFIT, 1994, PROGR MAN WISC PACK; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; CONSTANTINOUDELTAS CD, 1995, HUM GENET, V95, P416; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEALMEIDA S, 1995, HUM GENET, V96, P83, DOI 10.1007/BF00214191; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GABOW PA, 1990, KIDNEY INT, V38, P1177, DOI 10.1038/ki.1990.330; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GULATI J, 1992, J BIOL CHEM, V267, P25073; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HILLE B, 1992, IONIC CHANNELS EXCIT, P250; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOCHIZUKI T, UNPUB; MOCHIZUKI T, 1994, J AM SOC NEPHROL, V5, pA631; NAKASHIMA H, 1992, FEBS LETT, V303, P141, DOI 10.1016/0014-5793(92)80506-C; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; PETERS DJM, 1995, AM J HUM GENET, V57, pA200; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RIESS O, 1994, CYTOGENET CELL GENET, V65, P238, DOI 10.1159/000133638; ROMEO G, 1988, LANCET, V2, P8; ROST B, 1995, PROTEIN SCI, V4, P521; SANMILLAN JL, 1995, AM J HUM GENET, V56, P248; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; SOMIO S, 1993, J AM SOC NEPHROL, V4, P1371; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TORRES VE, 1993, AM J KIDNEY DIS, V22, P513, DOI 10.1016/S0272-6386(12)80922-X; VELDHUISEN B, UNPUB; WARD CJ, 1994, CELL, V77, P881; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347	54	1082	1136	3	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1339	1342		10.1126/science.272.5266.1339	http://dx.doi.org/10.1126/science.272.5266.1339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650545				2022-12-01	WOS:A1996UN47200047
J	Iijima, T; Witter, MP; Ichikawa, M; Tominaga, T; Kajiwara, R; Matsumoto, G				Iijima, T; Witter, MP; Ichikawa, M; Tominaga, T; Kajiwara, R; Matsumoto, G			Entorhinal-hippocampal interactions revealed by real-time imaging	SCIENCE			English	Article							FREQUENCY-DEPENDENT DEPRESSION; SUBICULAR COMPLEX; MEMORY SYSTEM; RAT; CONNECTIONS; CORTEX; INVITRO; ORGANIZATION; INHIBITION; IPSPS	The entorhinal cortex provides the major cortical input to the hippocampus, and both structures have been implicated in memory processes. The dynamics of neuronal circuits in the entorhinal-hippocampal system were studied in slices by optical imaging with high spatial and temporal resolution. Reverberation of neural activity was detected in the entorhinal cortex and was more prominent when the inhibition due to gamma-aminobutyric acid was slightly suppressed. Neural activity was transferred in a frequency-dependent way from the entorhinal cortex to the hippocampus. The entorhinal neuronal circuit could contribute to memory processes by holding information and selectively gating the entry of information into the hippocampus.	VRIJE UNIV AMSTERDAM,GRAD SCH NEUROSCI,NEUROSCI RES INST,DEPT ANAT & EMBRYOL,1081 BT AMSTERDAM,NETHERLANDS; TOHOKU UNIV,SENDAI,MIYAGI 980,JAPAN	Vrije Universiteit Amsterdam; Tohoku University	Iijima, T (corresponding author), ELECTROTECH LAB,MOL & CELLULAR NEUROSCI SECT,1-1-4 UMEZONO,TSUKUBA,IBARAKI 305,JAPAN.		Tominaga, Takashi/C-5332-2012	Tominaga, Takashi/0000-0003-1078-7989				BENARDO LS, 1993, BRAIN RES, V607, P81, DOI 10.1016/0006-8993(93)91491-A; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1992, HIPPOCAMPUS, V2, P99, DOI 10.1002/hipo.450020203; CHROBAK JJ, 1994, J NEUROSCI, V14, P6160; DEADWYLER SA, 1975, EXP NEUROL, V49, P35, DOI 10.1016/0014-4886(75)90194-6; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; Edelman G.M., 1989, REMEMBERED PRESENT B; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; FINCH DM, 1988, J NEUROSCI, V8, P2213; FINCH DM, 1986, BRAIN RES, V397, P205, DOI 10.1016/0006-8993(86)90621-9; FRANESIC I, 1994, P NATL ACAD SCI USA, V91, P13014; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HEBB DO, 1949, ORG BEHAVIOR; HEINEMANN U, 1992, DENTATE GYRUS ITS S, V7, P273; HUGUENARD JR, 1986, J NEUROPHYSIOL, V56, P1; ICHIKAWA M, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P638; IIJIMA T, 1992, NEUROSCIENCE, V51, P211, DOI 10.1016/0306-4522(92)90486-L; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; JONES RSG, 1993, TRENDS NEUROSCI, V16, P58, DOI 10.1016/0166-2236(93)90018-H; JONES RSG, 1995, HIPPOCAMPUS, V5, P125, DOI 10.1002/hipo.450050207; LOTHMAN EW, 1991, PROG NEUROBIOL, V37, P1, DOI 10.1016/0301-0082(91)90011-O; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; TSUKAHARA N, 1972, BRAIN RES, V40, P67, DOI 10.1016/0006-8993(72)90108-4; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; WITTER MP, 1993, HIPPOCAMPUS, V3, P33; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	34	182	183	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1176	1179		10.1126/science.272.5265.1176	http://dx.doi.org/10.1126/science.272.5265.1176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638163				2022-12-01	WOS:A1996UM88900052
J	Lakowski, B; Hekimi, S				Lakowski, B; Hekimi, S			Determination of life-span in Caenorhabditis elegans by four clock genes	SCIENCE			English	Article							OXIDATIVE STRESS	The nematode worm Caenorhabditis elegans is a model system for the study of the genetic basis of aging. Maternal-effect mutations in four genes-clk-1, clk-2, clk-3, and gro-1-interact genetically to determine both the duration of development and life-span. Analysis of the phenotypes of these mutants suggests the existence of a general physiological clock in the worm. Mutations in certain genes involved in dauer formation (an alternative larval stage induced by adverse conditions in which development is arrested) can also extend life-span, but the life extension of Clock mutants appears to be independent of these genes. The daf-2(e1370) clk-1(e2519) worms, which carry life-span-extending mutations from two different pathways, live nearly five times as long as wild-type worms.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA	McGill University								BJORKSTEN J, 1968, J AM GERIATR SOC, V16, P408, DOI 10.1111/j.1532-5415.1968.tb02821.x; Comfort A., 1979, BIOL SENESCENCE; Curtis H.J., 1966, BIOL MECH AGING; DORMAN JB, 1995, GENETICS, V141, P1399; FINCH DL, 1990, LONGEVITY SENESCENCE; FLEMING JE, 1992, MUTAT RES, V275, P267, DOI 10.1016/0921-8734(92)90031-J; FRIEDMAN DB, 1988, GENETICS, V118, P75; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HEKIMI S, 1995, GENETICS, V141, P1351; ISHII N, 1994, J GERONTOL, V49, pB117, DOI 10.1093/geronj/49.3.B117; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; LARSEN PK, COMMUNICATION; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; MEDVEDEV ZA, 1961, SOWJETWISS NATURWISS, V12, P1273; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Pearl R., 1928, RATE LIVING; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SACHER GA, 1966, PERSPECTIVES EXPT GE, pCH26; SZILARD L, 1959, P NATL ACAD SCI USA, V45, P30, DOI 10.1073/pnas.45.1.30; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WONG A, 1995, GENETICS, V139, P1247	25	401	425	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1010	1013		10.1126/science.272.5264.1010	http://dx.doi.org/10.1126/science.272.5264.1010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638122				2022-12-01	WOS:A1996UL61900045
J	Paris, N; Stanley, CM; Jones, RL; Rogers, JC				Paris, N; Stanley, CM; Jones, RL; Rogers, JC			Plant cells contain two functionally distinct vacuolar compartments	CELL			English	Article							TONOPLAST INTRINSIC PROTEIN; GRAIN ASPARTIC PROTEINASE; DEVELOPING PEA COTYLEDONS; THIOL PROTEASE; ARABIDOPSIS-THALIANA; STRUCTURAL ASPECTS; BARLEY LECTIN; ALEURAIN; ACCUMULATION; PRECURSOR	The plant cell vacuole has multiple functions, including storage of proteins and maintenance of an acidic pH where proteases will have maximal activity. It has been assumed that these diverse functions occur in the same compartment. Here, we demonstrate that antibodies to two different tonoplast intrinsic proteins, alpha-TIP and TIP-Ma27, label vacuole membranes of two different compartments within the same cell. These compartments are functionally distinct, because barley lectin, a protein stored in root tips, is exclusively contained within the alpha-TIP compartment, while aleurain, a protease that serves as a marker for an acidified vacuolar environment, is exclusively contained within the TIP-Ma27 compartment. As cells develop large vacuoles, the two compartments merge; this may represent a process by which storage products in the alpha-TIP compartment are exposed to the acidic lytic TIP-Ma27 compartment for degradation.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,MOL CYTOL CORE FACIL,COLUMBIA,MO 65211; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of California System; University of California Berkeley				PARIS, Nadine/0000-0001-5818-9318	NIGMS NIH HHS [GM52427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052427] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bethke PC, 1996, PLANT PHYSIOL, V110, P521, DOI 10.1104/pp.110.2.521; BOLLER T, 1986, ANNU REV PLANT PHYS, V37, P137, DOI 10.1146/annurev.arplant.37.1.137; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; CHRISPEELS MJ, 1991, PLANT MOL BIOL, V42, P21; CRAIG S, 1979, AUST J PLANT PHYSIOL, V6, P81, DOI 10.1071/PP9790081; CRAIG S, 1980, AUST J PLANT PHYSIOL, V7, P329, DOI 10.1071/PP9800329; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HERMAN EM, 1994, PLANT PHYSIOL, V106, P1313, DOI 10.1104/pp.106.4.1313; HERMAN EM, 1994, ADV STRUCTURAL BIOL, P243; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; HOH B, 1995, J CELL SCI, V108, P299; HOLWERDA BC, 1993, J EXP BOT, V44, P321; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; HOLWERDA BC, 1992, PLANT CELL, V4, P307, DOI 10.1105/tpc.4.3.307; HOLWERDA BC, 1992, PLANT PHYSIOL, V99, P848, DOI 10.1104/pp.99.3.848; JOHNSON KD, 1989, PLANT PHYSIOL, V91, P1006, DOI 10.1104/pp.91.3.1006; KERVINEN J, 1993, PHYTOCHEMISTRY, V32, P799, DOI 10.1016/0031-9422(93)85208-9; KIRSCH T, 1994, P NATL ACAD SCI USA, V91, P3403, DOI 10.1073/pnas.91.8.3403; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; LUDEVID D, 1992, PLANT PHYSIOL, V100, P1633, DOI 10.1104/pp.100.4.1633; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MARTYMAZARS D, 1995, EUR J CELL BIOL, V66, P106; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; NAKAMURA K, 1993, J EXP BOT, V44, P331; NAKAMURA K, 1993, PLANT PHYSIOL, V101, P1, DOI 10.1104/pp.101.1.1; Okita TW, 1996, ANNU REV PLANT PHYS, V47, P327, DOI 10.1146/annurev.arplant.47.1.327; ROST TL, 1988, AM J BOT, V75, P1571, DOI 10.2307/2444707; RUNEBERGROOS P, 1994, PLANT PHYSIOL, V105, P321, DOI 10.1104/pp.105.1.321; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; SCHROEDER MR, 1993, PLANT PHYSIOL, V101, P451, DOI 10.1104/pp.101.2.451; STAAB JF, 1994, J BIOL CHEM, V269, P23736; TORMAKANGAS K, 1994, PLANTA, V195, P116, DOI 10.1007/BF00206299; WICK SM, 1985, PROTOPLASMA, V126, P198, DOI 10.1007/BF01281795; WINK M, 1993, J EXP BOT, V44, P231; ZHU Y, 1994, J BIOL CHEM, V269, P3846	38	335	346	0	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					563	572		10.1016/S0092-8674(00)81256-8	http://dx.doi.org/10.1016/S0092-8674(00)81256-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653791	Bronze			2022-12-01	WOS:A1996UM41500013
J	Tan, S; Hunziker, Y; Sargent, DF; Richmond, TJ				Tan, S; Hunziker, Y; Sargent, DF; Richmond, TJ			Crystal structure of a yeast TFIIA/TBP/DNA complex	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR-IIA; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TFIIA; INITIATION; SUBUNITS; IDENTIFICATION; GENES; EXPRESSION	The X-ray crystal structure of the transcription factor IIA (TFIIA) in complex with the TATA-box-binding protein (TBP) and TATA-element DNA is presented at 2.5 Angstrom resolution. TFIIA is composed of a beta-barrel and a four-helix bundle motif that together have a boot-like appearance. The beta-barrel extends the TBP beta-sheet and bridges over the DNA major groove immediately upstream of the TATE box. The four-helix bundle contributes substantially to the surface of the complex available for interaction with additional transcription factors.	ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zeidler MP, 1996, GENE DEV, V10, P50, DOI 10.1101/gad.10.1.50	50	256	261	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					127	134		10.1038/381127a0	http://dx.doi.org/10.1038/381127a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610010				2022-12-01	WOS:A1996UK13900040
J	Giffin, W; Torrance, H; Rodda, DJ; Prefontaine, GG; Pope, L; Hache, RJG				Giffin, W; Torrance, H; Rodda, DJ; Prefontaine, GG; Pope, L; Hache, RJG			Sequence-specific DNA binding by Ku autoantigen and its effects on transcription	NATURE			English	Article							MAMMARY-TUMOR VIRUS; ACTIVATED PROTEIN-KINASE; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENT; REGION; ANTIGEN; DOMAIN	DNA-DEPENDENT protein kinase (DNA-PK) has been implicated in several nuclear processes including transcription(1-3), DNA replication(4,5), double-stranded DNA break repair, and V(D)J recom bination(6-10). Linkage of kinase and substrate on DNA in cis is required for efficient phosphorylation(11). Recruitment of DNA-PK to DNA is by Ku autoantigen, a DNA-end-binding protein required for DNA-PK catalytic activity(11). Although Ku is known to translocate along naked DNA(12), how DNA-end binding by Ku might lead to DNA-PK-mediated phosphorylation of sequence-specific DNA-binding proteins in vivo has not been obvious. Here we report the identification of Ku as a transcription factor that recruits DNA-PK directly to specific DNA sequences. NRE1 (negative regulatory element 1) is a DNA sequence element (-394/ - 381) in the long terminal repeat of mouse mammary tumour virus (MMTV) that is important for repressing inappropriate viral expression(13-16). We show that direct binding of Ku/DNA-PK to NRE1 represses glucocorticoid-induced MMTV transcription.	UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute								Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAY G, 1991, J BIOL CHEM, V266, P3052; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANEVA M, 1989, J BIOL CHEM, V264, P13407	28	187	188	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					265	268		10.1038/380265a0	http://dx.doi.org/10.1038/380265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637578				2022-12-01	WOS:A1996UB11700057
J	HunterEnsor, M; Ousley, A; Sehgal, A				HunterEnsor, M; Ousley, A; Sehgal, A			Regulation of the Drosophila protein timeless suggests a mechanism for resetting the circadian clock by light	CELL			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; MELANOGASTER; EXPRESSION	Circadian behavioral rhythms in Drosophila depend on the appropriate regulation of at least two genes, period (per) and timeless (tim). Previous studies demonstrated that levels of PER and TIM RNA cycle with the same phase and that the PER and TIM proteins interact directly. Here we show the cyclic expression of TIM protein in adult heads and report that it lags behind peak levels of TIM RNA by several hours. We also show that nuclear expression of TIM depends upon the expression of PER protein. Finally, we report that the expression of TIM, but not PER, is rapidly reduced by light, suggesting that TIM mediates light-induced resetting of the circadian clock. Since both PER and TIM RNA are unaffected by light treatment, the effects of light on TIM appear to be posttranscriptional.	UNIV PENN,SCH MED,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine	HunterEnsor, M (corresponding author), UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.							ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; ESKIN A, 1979, FED PROC, V38, P2570; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	40	324	333	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					677	685		10.1016/S0092-8674(00)81046-6	http://dx.doi.org/10.1016/S0092-8674(00)81046-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625406	hybrid			2022-12-01	WOS:A1996TZ99000006
J	Kallberg, E; Jainandunsing, S; Gray, D; Leanderson, T				Kallberg, E; Jainandunsing, S; Gray, D; Leanderson, T			Somatic mutation of immunoglobulin V genes in vitro	SCIENCE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; B-CELLS; T-CELLS; MATURATION; GENERATION; ANTIGEN; MEMORY	The molecular mechanism behind affinity maturation is the introduction of point mutations in immunoglobulin (Ig) V genes, followed by the selective proliferation of B cells expressing mutants with increased affinity for antigen. An in vitro culture system was developed in which somatic hypermutation of Ig V genes was sustained in primed B cells. Cognate T cell help and cross-linking of the surface Ig were required, whereas the addition of lipopolysaccharide or a CD40 ligand to drive proliferation was insufficient. This system should facilitate understanding of the molecular and cellular mechanisms that regulate somatic mutation and B cell selection.	LUND UNIV,IMMUNOL UNIT,S-22362 LUND,SWEDEN; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0NN,ENGLAND	Lund University; Imperial College London			Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.immunol.12.1.881; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; DECKER DJ, 1995, IMMUNITY, V2, P195, DOI 10.1016/S1074-7613(95)80092-1; FULLER KA, 1993, J IMMUNOL, V151, P4505; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; Kabat EA, 1983, SEQUENCES PROTEINS I; KALLBERG E, 1995, EUR J IMMUNOL, V25, P2349, DOI 10.1002/eji.1830250834; KALLBERG E, UNPUB; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAWABE T, 1994, IMMUNITY, V1, P423; MANSER T, 1987, J IMMUNOL, V139, P234; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; RAJASEKAR R, 1988, SCAND J IMMUNOL, V27, P653, DOI 10.1111/j.1365-3083.1988.tb02398.x; RAZANAJAONA D, 1995, 9TH INT C IMM SAN FR; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; WOHLLEBEN G, IN PRESS INT IMMUNOL; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	25	56	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1285	1289		10.1126/science.271.5253.1285	http://dx.doi.org/10.1126/science.271.5253.1285			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638111				2022-12-01	WOS:A1996TX69500038
J	Martin, A; Wiggs, CL; Ungerleider, LG; Haxby, JV				Martin, A; Wiggs, CL; Ungerleider, LG; Haxby, JV			Neural correlates of category-specific knowledge	NATURE			English	Article							MENTAL-IMAGERY; VISUAL-CORTEX; RECOGNITION; IMPAIRMENT; PICTURES	AN intriguing and puzzling consequence of damage to the human brain is selective loss of knowledge about a specific category of objects, One patient may be unable to identify or name living things(1-3), whereas another may have selective difficulty identifying man-made objects(4-6). To investigate the neural correlates of this remarkable dissociation, we used positron emission tomography to map regions of the normal brain that are associated with naming animals and tools. We found that naming pictures of animals and tools was associated with bilateral activation of the ventral temporal lobes and Broca's area, In addition, naming animals selectively activated the left medial occipital lobe-a region involved in the earliest stages of visual processing. In contrast, naming tools selectively activated a left premotor area also activated by imagined hand movements(7), and an area in the left middle temporal gyrus also activated by the generation of action words(8-10). Thus the brain regions active during object identification are dependent, in part, on the intrinsic properties of the object presented.			Martin, A (corresponding author), NIMH, PSYCHOL & PSYCHOPATHOL LAB, BLDG 10, ROOM 3D-41, BETHESDA, MD 20892 USA.		martin, alex/B-6176-2009					CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; FARAH MJ, 1989, TRENDS NEUROSCI, V12, P395, DOI 10.1016/0166-2236(89)90079-9; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; HUMPHREYS GW, 1988, COGNITIVE NEUROPSYCH, V5, P67, DOI 10.1080/02643298808252927; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KROLL JF, 1984, J VERB LEARN VERB BE, V23, P39, DOI 10.1016/S0022-5371(84)90499-7; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SACCHETT C, 1992, COGNITIVE NEUROPSYCH, V9, P73, DOI 10.1080/02643299208252053; SAFFRAN EM, 1994, ATTENTION PERFORM, V15, P507; SHERIDAN J, 1993, COGNITIVE NEUROPSYCH, V10, P143, DOI 10.1080/02643299308253459; SILVERI MC, 1988, COGNITIVE NEUROPSYCH, V5, P677, DOI 10.1080/02643298808253278; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641	26	1191	1212	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					649	652		10.1038/379649a0	http://dx.doi.org/10.1038/379649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV688	8628399	Green Submitted			2022-12-01	WOS:A1996TV68800055
J	Durbin, JE; Hackenmiller, R; Simon, MC; Levy, DE				Durbin, JE; Hackenmiller, R; Simon, MC; Levy, DE			Targeted disruption of the mouse STAT1 results in compromised innate immunity to viral disease	CELL			English	Article							GAMMA SIGNAL-TRANSDUCTION; DNA-BINDING PROTEINS; MUTANT-CELL LINE; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; GENE; INDUCTION; IRF-1	The STAT1 transcription factor is activated in response to many cytokines and growth factors. To study the requirement for STAT1 in vivo, we disrupted the Stat1 gene in embryonic stem (ES) cells and in mice. Stat1(-/-) ES cells were unresponsive to interferon (IFN), but retained responsiveness to leukemia inhibitory factor (LIF) and remained LIF dependent for undifferentiated growth. Stat1(-/-) animals were born at normal frequencies and displayed no gross developmental defects. However, these animals failed to thrive and were extremely susceptible to viral disease. Cells and tissues from Stat1(-/-) mice were unresponsive to IFN, but remained responsive to all other cytokines tested. Thus, STAT1 appears to be specific for IFN pathways that are essential for viability in the face of otherwise innocuous pathogens.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	New York University; New York University; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Levy, David/GPS-4945-2022; Simon, Celeste/AAG-3941-2021; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COMPTON SR, 1993, LAB ANIM SCI, V43, P15; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HAVELL EA, 1972, ANTIMICROB AGENTS CH, V2, P476, DOI 10.1128/AAC.2.6.476; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUME DA, 1995, J INTERF CYTOK RES, V15, P279, DOI 10.1089/jir.1995.15.279; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; LORD KA, 1990, ONCOGENE, V5, P387; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIJNS VECJ, 1994, J IMMUNOL, V153, P2029; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WIKTORJEDRZEJCZ.W, 1990, P NATL ACAD SCI USA, V87, P7828; Wurst W., 1993, Gene targeting: a practical approach., P33; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	62	1278	1319	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					443	450		10.1016/S0092-8674(00)81289-1	http://dx.doi.org/10.1016/S0092-8674(00)81289-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608598	hybrid			2022-12-01	WOS:A1996TV70800013
J	Weissman, JS; Rye, HS; Fenton, WA; Beechem, JM; Horwich, AL				Weissman, JS; Rye, HS; Fenton, WA; Beechem, JM; Horwich, AL			Characterization of the active intermediate of a GroEL-GroES-mediated protein folding reaction	CELL			English	Article							RHODANESE; CYCLE	Recent studies of GroE-mediated protein folding indicate that substrate proteins are productively released from a cis ternary complex in which the nonnative substrate is sequestered within the GroEL channel underneath GroES. Here, we examine whether protein folding can occur in this space. Stopped-flow fluorescence anisotropy of a pyrene-rhodanese-GroEL complex indicates that addition of GroES and ATP (but not ADP) leads to a rapid change in substrate flexibility at GroEL. Strikingly, when GroES release is blocked by the use of either a nonhydrolyzable ATP analog or a single-ring GroEL mutant, substrates complete folding while remaining associated with chaperonin. We conclude that the cis ternary complex, in the presence of ATP, is the active state intermediate in the GroE-mediated folding reaction: folding is initiated in this state and for some substrates may be completed prior to the timed release of GroES triggered by ATP hydrolysis.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Yale University; Vanderbilt University	Weissman, JS (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.			Weissman, Jonathan/0000-0003-2445-670X; Rye, Hays/0000-0002-9420-3137				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; ELLIS RJ, 1994, CURR BIOL, V4, P633; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RAO BDN, 1980, BIOPHYS J, V32, P630, DOI 10.1016/S0006-3495(80)84999-X; ROUSSEAU DL, 1995, BIOCHEMISTRY-US, V34, P14508, DOI 10.1021/bi00044a029; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; TANDON S, 1989, J BIOL CHEM, V264, P9859; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YEE DP, 1994, J MOL BIOL, V241, P557, DOI 10.1006/jmbi.1994.1531; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	42	344	347	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					481	490		10.1016/S0092-8674(00)81293-3	http://dx.doi.org/10.1016/S0092-8674(00)81293-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608602	hybrid			2022-12-01	WOS:A1996TV70800017
J	Betts, CD; Astarloa, L; Bloch, C; Zacarias, F; Chelala, C				Betts, CD; Astarloa, L; Bloch, C; Zacarias, F; Chelala, C			The changing face of AIDS in Argentina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MINIST HLTH & SOCIAL ACT ARGENTINA,NATL PROGRAM AGAINST HUMAN RETROVIRUS & AIDS,BUENOS AIRES,DF,ARGENTINA; PAN AMER HLTH ORG,WHO,REG AIDS STD PROGRAM,BUENOS AIRES,DF,ARGENTINA	Pan American Health Organization; World Health Organization								ASTARLOA L, 1995, P 10 LAT AM STD C 4; AVOLIO J, 1993, 9 INT C AIDS JUN 6 1; CAHN P, 1989, 5 INT C AIDS JUN 4 9; CASIRO A, 1989, 5 INT C AIDS JUN 4 9; FAY O, 1989, 5 INT C AIDS JUN 4 9; MULTARE S, 1992, 8 INT C AIDS JUL 19; *PAN AM HLTH ORG, 1995, AIDS SURV AM Q REP; *PAN AM HLTH ORG, 1994, 1992 AIDS HIV STD AN; RIOMOLDI I, 1992, 8 INT C AIDS JUL 19; *US BUR CENS, 1995, HIV AIDS SURV DAT BA	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					94	96		10.1001/jama.276.2.94	http://dx.doi.org/10.1001/jama.276.2.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656518				2022-12-01	WOS:A1996UV48500007
J	Liu, F; Hata, A; Baker, JC; Doody, J; Carcamo, J; Harland, RM; Massague, J				Liu, F; Hata, A; Baker, JC; Doody, J; Carcamo, J; Harland, RM; Massague, J			A human Mad protein acting as a BMP-regulated transcriptional activator	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; MAMMALIAN-CELLS; INDUCTION; MESODERM	THE TGF-beta/activin/BMP cytokine family signals through serine/threonine kinase receptors, but how the receptors transduce the signal is unknown. The Mad (Mothers against decapentaplegic) gene from Drosophila(1) and the related Sma genes from Caenorhabditis elegans(2) have been genetically implicated in signalling by members of the bone-morphogenetic-protein (BMP) subfamily. We have cloned Smad1, a human homologue of Mad and Sma. Microinjection of Smad1 messenger RNA into Xenopus embryo animal caps mimics the mesoderm-ventralizing effects of BMP4. Smad1 moves into the nucleus in response to BMP4. Smad1 has transcriptional activity when fused to a heterologous DNA-binding domain, and this activity is increased by BMP4 acting through BMP-receptor types I and II. The transactivating activity resides in the conserved carboxy-terminal domain of Smad1 and is disrupted by a nonsense mutation that corresponds to null mutations found in Mad and in the related gene DPC4, a candidate tumour-suppressor gene in human pancreatic cancer(3), Additionally, we show that DPC4 contains a transcriptional activation domain. The results suggests that the Smad proteins are a new class of transcription factors that mediate responses to the TGF-beta family.	MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94709	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of California System; University of California Berkeley				Massague, Joan/0000-0001-9324-8408				CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DALE L, 1992, DEVELOPMENT, V115, P573; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; JONES CM, 1992, DEVELOPMENT, V115, P639; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LENNON GG, IN PRESS GENOMICS; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU F, 1995, MOL CELL BIOL, V15, P3479; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	23	570	601	1	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					620	623		10.1038/381620a0	http://dx.doi.org/10.1038/381620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637600				2022-12-01	WOS:A1996UQ65700055
J	Csink, AK; Henikoff, S				Csink, AK; Henikoff, S			Genetic modification of heterochromatic association and nuclear organization in Drosophila	NATURE			English	Article							POSITION-EFFECT VARIEGATION; MELANOGASTER; EXPRESSION	HETEROCHROMATIN is the highly compact, usually pericentromeric, region of eukaryotic chromosomes. Unlike the more gene-rich euchromatin, heterochromatin remains condensed during interphase, when it is sequestered to the periphery of the nucleus(1-3). Here we show, by using fluorescent in situ hybridization to interphase diploid nuclei of Drosophila, that the insertion of heterochromatin into a euchromatic gene, which results in position-effect variegation (PEV), also causes the aberrant association of the gene and its homologous copy with heterochromatin. In correlation with the gene's mutant variegating phenotype, the cytological association of the heterochromatic region is affected by chromosomal distance from heterochromatin and by genic modifiers of PEV. Proteins that are thought to be involved in the formation of heterochromatin can therefore influence the interphase nuclear position of a chromosomal region. This suggests that heterochromatin and proteins involved in its formation provide a structural framework for the interphase nucleus.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute				Henikoff, Steven/0000-0002-7621-8685				Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; EBERL DF, 1993, GENETICS, V134, P277; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Heitz E, 1928, JAHRB WISS BOT, V69, P762; HENIKOFF S, 1989, P NATL ACAD SCI USA, V86, P6704, DOI 10.1073/pnas.86.17.6704; HENIKOFF S, 1995, GENETICS, V140, P1007; KELLUM R, 1995, J CELL SCI, V108, P1407; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; MAYFIELD JE, 1975, CHROMOSOMA, V52, P37, DOI 10.1007/BF00285787; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Sokal R., 1981, BIOMETRY; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B; TALBERT PB, 1994, GENETICS, V136, P559; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068; WAKIMOTO BT, 1990, GENETICS, V125, P141; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3	23	269	279	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					529	531		10.1038/381529a0	http://dx.doi.org/10.1038/381529a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632827				2022-12-01	WOS:A1996UP43500062
J	Douglas, AS; Allan, TM; Helms, PJ				Douglas, AS; Allan, TM; Helms, PJ			Seasonality and the sudden infant death syndrome during 1987-9 and 1991-3 in Australia and Britain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION	Objective-To determine whether seasonality of the sudden infant death syndrome persists now that rates have fallen, mostly after widespread adoption of the ''face upwards' sleeping position. Design-Monthly data on the sudden infant death syndrome during 1987-9 were compared for seasonality with those of 1991-3; rates were studied as deaths per 1000 live births. Setting-Australia and Britain (England,Wales, and Scotland). Subjects-Infants under 1 year dying of the syndrome (2401 for Australia and 6630 for Britain). Main outcome measure-Extent of seasonal variation (amplitude) was established by cosinor analysis; amplitudes for the earlier and later years were compared. Results-The rate fell in every month, and, though it did so relatively more in winter than summer, seasonality remained a distinctive feature. In the comparison of amplitudes the ratio between the earlier and later years was 1.4 in both Australia and Britain. Some differences between the hemispheres were noted. Conclusions-Seasonality of the sudden infant death syndrome remains to be explained and continues to be an important aetiological lead. Studies from other countries are needed.	UNIV ABERDEEN, WELLCOME RES LIB, SCH MED, ABERDEEN AB9 2ZD, SCOTLAND; UNIV ABERDEEN, DEPT CHILD HLTH, SCH MED, ABERDEEN AB9 2ZD, SCOTLAND	University of Aberdeen; University of Aberdeen	Douglas, AS (corresponding author), UNIV ABERDEEN, DEPT MED & THERAPEUT, SCH MED, FORESTERHILL, ABERDEEN AB9 2ZD, SCOTLAND.							Abramson H, 1944, J PEDIATR-US, V25, P404, DOI 10.1016/S0022-3476(44)80005-1; ALLAN TM, 1994, SEASONAL VARIATION H; ARENDT J, 1995, MELATONIN MAMMALIAN, P207; Arrundale J., 1993, Health Bulletin (Edinburgh), V51, P106; BEAL S, 1994, MED J AUSTRALIA, V160, P660; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BOLTON DPG, 1993, ARCH DIS CHILD, V69, P187, DOI 10.1136/adc.69.2.187; CAMPBELL MJ, 1994, J ROY STAT SOC A STA, V157, P191, DOI 10.2307/2983358; DOUGLAS AS, 1991, LANCET, V337, P1393, DOI 10.1016/0140-6736(91)93069-L; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FLEMING PJ, 1993, ACTA PAEDIATR, V82, P57, DOI 10.1111/j.1651-2227.1993.tb12878.x; GILMAN EA, 1995, BRIT MED J, V310, P631, DOI 10.1136/bmj.310.6980.631; KAADA B, 1994, ACTA PAEDIATR, V83, P548, DOI 10.1111/j.1651-2227.1994.tb13079.x; MINORS DS, 1989, BIOL RHYTHMS CLIN PR, P172; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; NELSON EAS, 1989, LANCET, V1, P199; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; PEARCE EA, 1993, WORLD WEATHER GUIDE; Sothern R., 1972, PHYSIOL TEACH, V1, P1; WAKLEY T, 1855, LANCET, V1, P103; WEISSBLUTH L, 1994, J THEOR BIOL, V167, P13, DOI 10.1006/jtbi.1994.1046; WIGFIELD R, 1994, EARLY HUM DEV, V38, P161, DOI 10.1016/0378-3782(94)90208-9; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	25	34	35	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	1996	312	7043					1381	1383						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP434	8646093	Green Published			2022-12-01	WOS:A1996UP43400017
J	Zhu, X; Jiang, MS; Peyton, M; Boulay, G; Hurst, R; Stefani, E; Birnbaumer, L				Zhu, X; Jiang, MS; Peyton, M; Boulay, G; Hurst, R; Stefani, E; Birnbaumer, L			trp, a novel mammalian gene family essential for agonist-activated capacitative Ca2+ entry	CELL			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; MOLECULAR-CLONING; DROSOPHILA PHOTORECEPTORS; INTRACELLULAR CALCIUM; ACINAR-CELLS; MAST-CELLS; INFLUX; PHOTOTRANSDUCTION; MOBILIZATION; EXCITATION	Capacitative calcium entry (CCE) describes Ca2+ influx into cells that replenishes Ca2+ stores emptied through the action of IP3 and other agents. It is an essential component of cellular responses to many hormones and growth factors. The molecular basis of this form of Ca2+ entry is complex and may involve more than one type of channel. Studies on visual signal transduction in Drosophila led to the hypothesis that a protein encoded in frp may be a component of CCE channels. We report the existence of six trp-related genes in the mouse genome. Expression in L cells of small portions of these genes in antisense orientation suppressed CCE. Expression in COS cells of two full-length cDNAs encoding human trp homologs, Htrp1 and Htrp3, increased CCE. This identifies mammalian gene products that participate in CCE. We propose that trp homologs are subunits of CCE channels, not unlike those of classical voltage-gated ion channels.			Zhu, X (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT ANESTHESIOL,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.		Boulay, Guylain/D-9773-2010; Peyton, Michael/A-8728-2008		NHLBI NIH HHS [HL-45198] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; BERVEN LA, 1995, J BIOL CHEM, V270, P25893, DOI 10.1074/jbc.270.43.25893; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BYRON KL, 1995, J PHYSIOL-LONDON, V485, P455, DOI 10.1113/jphysiol.1995.sp020742; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOW TW, 1992, BLOOD, V80, P113; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FOSKETT JK, 1994, J BIOL CHEM, V269, P31525; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; Grudt TJ, 1996, MOL BRAIN RES, V36, P93, DOI 10.1016/0169-328X(95)00248-Q; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU Y, 1994, BIOCHEM BIOPH RES CO, V132, P346; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; JAMESKRACKE MR, 1994, J PHARMACOL EXP THER, V271, P824; KASS GEN, 1993, BIOCHIM BIOPHYS ACTA, V1223, P226; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LEVY FO, 1992, J BIOL CHEM, V267, P7553; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; MATHES C, 1994, J GEN PHYSIOL, V104, P107, DOI 10.1085/jgp.104.1.107; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MONTERO M, 1994, J BIOL CHEM, V269, P29451; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANDRIAMAMPITA C, 1994, J BIOL CHEM, V269, P29; RUDOLPH U, 1993, TRANSGENIC RES, V2, P345, DOI 10.1007/BF01976176; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUSS E, 1989, J GEN PHYSIOL, V94, P465, DOI 10.1085/jgp.94.3.465; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	64	580	610	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					661	671		10.1016/S0092-8674(00)81233-7	http://dx.doi.org/10.1016/S0092-8674(00)81233-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646775	Bronze			2022-12-01	WOS:A1996UP34400007
J	Derrick, BE; Martinez, JL				Derrick, BE; Martinez, JL			Associative, bidirectional modifications at the hippocampal mossy fibre-CA3 synapse	NATURE			English	Article							LONG-TERM POTENTIATION; FIBER SYNAPSES; AREA CA1; DEPRESSION; INDUCTION; NEURONS; PLASTICITY; FORMS; CELLS	LONG-TERM potentiation (LTP) and long-term depression (LTD) are activity-dependent changes in synaptic strength that may serve as the cellular mechanisms of information storage in the vertebrate brain(1-4). The messy fibre-CA3 synapse displays NMDA (N-methyl-D-aspartate) receptor-independent forms of LTP(5-8) and LTD(9-11) that were thought to be non-associative(9-11). Here we report that the messy fibre-CA3 synapse displays each of the known types of LTD in vivo, including associative, heterosynaptic acid homosynaptic LTD. These types of LTD are induced when only two of the three conditions necessary for messy fibre LTP induction are provided. Because some of these conditions can be provided by convergent CA3 afferents, each type of LTD can be induced in an associative manner, which suggests that LTD is involved in associative information storage. Similar to the induction of NMDA receptor-dependent LTD and LTP at other cortical synapses, messy fibre LTD occurs when synaptic conditions are insufficient to induce LTP, and both LTP and LTD induction are influenced by previous synaptic activity, consistent with the view that common principles govern activity-dependent plasticity at cortical synapses(2,12,22).			Derrick, BE (corresponding author), UNIV TEXAS,DIV LIFE SCI,SAN ANTONIO,TX 78249, USA.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CAUDLE RM, 1991, J PHARMACOL EXP THER, V258, P18; CHATTARJI S, 1989, BRAIN RES, V495, P145, DOI 10.1016/0006-8993(89)91228-6; DERRICK BE, 1994, P NATL ACAD SCI USA, V91, P10290, DOI 10.1073/pnas.91.22.10290; DERRICK BE, 1994, J NEUROSCI, V14, P4359; DERRICK BE, 1992, J PHARMACOL EXP THER, V263, P725; DRAKE CT, 1994, J NEUROSCI, V14, P3736; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; Intrator Nathan, 1993, P147; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; LAW CC, 1994, P NATL ACAD SCI USA, V91, P7797, DOI 10.1073/pnas.91.16.7797; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MARTINEZ JL, 1995, A REV PSYCHOL, V47, P173; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; WAGNER JJ, 1990, NEUROSCIENCE, V37, P45, DOI 10.1016/0306-4522(90)90190-F; WELSSKOPF M, 1993, NATURE, V362, P423; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WILSHAW D, 1990, NEURAL COMPUT, V2, P85; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	29	34	35	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					429	434		10.1038/381429a0	http://dx.doi.org/10.1038/381429a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632800				2022-12-01	WOS:A1996UN47900053
J	Larsen, CP; Elwood, ET; Alexander, DZ; Ritchie, SC; Hendrix, R; TuckerBurden, C; Cho, HR; Aruffo, A; Hollenbaugh, D; Linsley, PS; Winn, KJ; Pearson, TC				Larsen, CP; Elwood, ET; Alexander, DZ; Ritchie, SC; Hendrix, R; TuckerBurden, C; Cho, HR; Aruffo, A; Hollenbaugh, D; Linsley, PS; Winn, KJ; Pearson, TC			Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways	NATURE			English	Article							TRANSPLANTATION TOLERANCE; MONOCLONAL-ANTIBODIES; CELL ACTIVATION; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; INVIVO; COSTIMULATION; ALLOANTIGEN; EXPRESSION	THE receptor-ligand pairs CD28-B7 and CD40-gp39 are essential For the initiation and amplification of T-cell-dependent immune responses(1,2). CD28-B7 interactions provide 'second signals' necessary for optimal T-cell activation and IL-2 production(3-5), whereas CD40-gp39 signals co-stimulate B-cell, macrophage, endothelial cell and T-cell activation(6-12). Nonetheless, blockade of either of these pathways alone is not sufficient to permit engraftment of highly immunogenic allografts(13-15). Here we report that simultaneous but not independent blockade of the CD28 and CD40 pathways effectively aborts T-cell clonal expansion in vitro and in vivo, promotes long-term survival of fully allogeneic skin grafts, and inhibits the development of chronic vascular rejection of primarily vascularized cardiac allografts. The requirement for simultaneous blockade of these pathways for effective inhibition of alloimmunity indicates that, although they are interrelated, the CD28 and CD40 pathways are critical independent regulators of T-cell-dependent immune responses.	EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,CARLOS & MARGUERITE MASON TRANSPLANTAT RES CTR,ATLANTA,GA 30322; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Emory University; Emory University; Bristol-Myers Squibb	Larsen, CP (corresponding author), EMORY UNIV,SCH MED,DEPT SURG,1639 PIERCE DR,ATLANTA,GA 30322, USA.		Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.immunol.12.1.881; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; JENKINS MK, 1991, J IMMUNOL, V147, P2461; KAYE J, 1988, NATURE, V336, P580, DOI 10.1038/336580a0; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LIDSTAD ST, 1984, NATURE, V307, P168; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; PEARSON TC, 1993, TRANSPLANTATION, V55, P361, DOI 10.1097/00007890-199302000-00025; PEREIRA GMB, 1990, J IMMUNOL, V144, P2109; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0	29	1217	1283	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					434	438		10.1038/381434a0	http://dx.doi.org/10.1038/381434a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632801				2022-12-01	WOS:A1996UN47900054
J	Kannel, WB				Kannel, WB			Blood pressure as a cardiovascular risk factor - Prevention and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSION	Objective.-To examine the prevalence, incidence, predisposing factors for hypertension, its hazards as an ingredient of the cardiovascular risk profile, and the implications of this information for prevention and treatment. Methods.-Prospective longitudinal analysis of 36-year follow-up data from the Framingham Study of the relation of antecedent blood pressure to occurrence of subsequent cardiovascular morbidity and mortality depending on the metabolically linked burden of associated risk factors. Results.-Hypertension is one of the most prevalent and powerful contributors to cardiovascular diseases, the leading cause of death in the United States. There is, on average, a 20 mm Hg systolic and 10 mm Hg diastolic increment increase in blood pressure from age 30 to 65 years. Isolated systolic hypertension is the dominant variety. There is no evidence of a decline in the prevalence of hypertension over 4 decades despite improvements in its detection and treatment. Hypertension contributes to all of the major atherosclerotic cardiovascular disease outcomes increasing risk, on average, 2- to 3-fold. Coronary disease, the most lethal and common sequela, deserves highest priority. Hypertension clusters with dyslipidemia, insulin resistance, glucose intolerance, and obesity, occurring in isolation in less than 20%. The hazard depends on the number of these associated metabolically linked risk factors present. Coexistent overt cardiovascular disease also influences the hazard and choice of therapy. Conclusion.-The absence of a decline in the prevalence of hypertension indicates an urgent need for primary prevention by weight control, exercise, and reduced salt and alcohol intake. The urgency and choice of therapy of existing hypertension should be based on the multivariate cardiovascular risk profile that more appropriately targets hypertensive persons for treatment and prevention of cardiovascular sequelae.			Kannel, WB (corresponding author), BOSTON UNIV,SCH MED,FRAMINGHAM HEART STUDY,EVANS MEM RES FDN,DEPT MED,BOSTON,MA 02118, USA.				NHLBI NIH HHS [N01-HV-92922, N01-HV-52971] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; Anderson K. M., 1991, CIRCULATION, V83, P357; BELANGER A, 1988, 802970 US DEP HHS PH; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CUPPLES LA, 1987, SOME RISK FACTORS RE, P87; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V7, P676; GARRISON RJ, 1987, PREV MED, V16, P234; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; KANNEL WB, 1993, AM HEART J, V125, P1154, DOI 10.1016/0002-8703(93)90129-W; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KANNEL WB, 1991, P R COLL PHYS EDINB, V21, P273; Kannel William B., 1994, Am J Geriatr Cardiol, V3, P33; KRUMHOLZ HM, 1995, J AM COLL CARDIOL, V25, P879, DOI 10.1016/0735-1097(94)00473-4; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; *NIH, 1993, 932669 NIH NAT HEART; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; WILSON PWF, 1995, HYPERTENSION PATHOPH, V1, P99; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312; 1993, ARCH INTERN MED, V153, P154; 1992, JAMA-J AM MED ASSOC, V267, P1213; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	29	920	961	0	76	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1571	1576		10.1001/jama.275.20.1571	http://dx.doi.org/10.1001/jama.275.20.1571			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622248				2022-12-01	WOS:A1996UL02900029
J	Paunio, M; Virtamo, J; Gref, CG; Heinonen, OP				Paunio, M; Virtamo, J; Gref, CG; Heinonen, OP			Serum high density lipoprotein cholesterol, alcohol, and coronary mortality in male smokers	BRITISH MEDICAL JOURNAL			English	Article							RESEARCH CLINICS PREVALENCE; ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; CARDIOVASCULAR-DISEASE; ETHANOL INTOXICATION; BRAIN INFARCTION; MEN; RISK; CONSUMPTION; SUBFRACTIONS	Objective-To determine whether the increase in mortality from coronary heart disease with high concentrations (>1.75 mmol/1) of high density Lipoprotein cholesterol could be due to alcohol intake. Design-Cohort study. Setting-Placebo group of the alpha tocopherol, beta carotene cancer prevention (ATBC) study of south western population in Finland. Participants-7052 male smokers aged 50-69 years enrolled to the ATBC study in the 1980s. Main outcome measures-The relative and absolute rates for clinically or pathologically verified deaths from coronary heart disease for different concentrations of high density lipoprotein cholesterol with and without stratification for alcohol intake. Similar rates were also calculated for different alcohol consumption groups. Results-During the average follow up period of 6.7 years 258 men died from verified coronary heart disease. Coronary death rate steadily decreased with increasing concentration of high density Lipoprotein cholesterol until a high concentration. An increase in the rate was observed above 1.75 mol/1. This increase occurred among those who reported alcohol intake. Mortality was associated with alcohol intake in a J shaped dose response, and those who reported consuming more than five drinks a day (heavy drinkers) had the highest death rate. Mortality was higher in heavy drinkers than in non-drinkers or light or moderate drinkers in all high density lipoprotein categories from 0.91 mmol/1 upward. Conclusions-Mortality from coronary heart disease increases at concentrations of high density lipoprotein cholesterol over 1.75 mmol/1. The mortality was highest among heavy drinkers, but an increase was found among light drinkers also.	HELSINKI NATL PUBL HLTH INST,HELSINKI,FINLAND		Paunio, M (corresponding author), HELSINKI UNIV,DEPT PUBL HLTH,POB 21,SF-00014 HELSINKI,FINLAND.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN045165] Funding Source: NIH RePORTER; NCI NIH HHS [N0I-CN-45165] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1; Barrett-Connor E, 1992, Ann Epidemiol, V2, P77, DOI 10.1016/1047-2797(92)90040-W; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON DJ, 1986, CIRCULATION, V74, P1217, DOI 10.1161/01.CIR.74.6.1217; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HILLBOM M, 1983, NEUROLOGY, V33, P381, DOI 10.1212/WNL.33.3.381; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; HILLBOM M, 1990, ANN MED, V22, P347, DOI 10.3109/07853899009147918; HILLBOM ME, 1983, EUR J CLIN INVEST, V13, P45, DOI 10.1111/j.1365-2362.1983.tb00063.x; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KAPRIO J, 1982, INT J EPIDEMIOL, V11, P378, DOI 10.1093/ije/11.4.378; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; KUSTNER GM, 1976, CLIN CHEM, V22, P695; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LEE ET, 1980, STATISTICAL METHODS; MCGARRY GW, 1994, BRIT MED J, V309, P640, DOI 10.1136/bmj.309.6955.640; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOREYRA AE, 1982, CLIN CARDIOL, V5, P425, DOI 10.1002/clc.4960050707; PAUNIO M, 1994, CIRCULATION, V90, P2909, DOI 10.1161/01.CIR.90.6.2909; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PIETINEN P, 1988, AM J EPIDEMIOL, V128, P655, DOI 10.1093/oxfordjournals.aje.a115013; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Romanov K, 1987, Alcohol Alcohol Suppl, V1, P619; ROSSII KZ, 1994, GOSUDARSTVENNY NAUCH; *SAS STAT SOFTW, 1991, PHREG PROC PREL DOC; SHESTOV DB, 1993, CIRCULATION, V88, P846, DOI 10.1161/01.CIR.88.3.846; SHESTOV DB, 1982, NIH831966 US DEP HLT, P391; SIMPURA J, 1995, ADDICTION, V90, P673, DOI 10.1111/j.1360-0443.1995.tb02205.x; STENSVOLD I, 1992, EUR HEART J, V13, P1155, DOI 10.1093/oxfordjournals.eurheartj.a060331; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; WANNAMETHEE G, 1988, J ROY COLL GEN PRACT, V38, P440; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; 1986, PREV MED, V15, P254; 1994, NEW ENGL J MED, V330, P1029	43	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1200	1203						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634563				2022-12-01	WOS:A1996UL05800019
J	Olson, KE; Higgs, S; Gaines, PJ; Powers, AM; Davis, BS; Kamrud, KI; Carlson, JO; Blair, CD; Beaty, BJ				Olson, KE; Higgs, S; Gaines, PJ; Powers, AM; Davis, BS; Kamrud, KI; Carlson, JO; Blair, CD; Beaty, BJ			Genetically engineered resistance to dengue-2 virus transmission in mosquitoes	SCIENCE			English	Article							AMINO-ACID SEQUENCE; YELLOW-FEVER VIRUS; NUCLEOTIDE-SEQUENCE; MONOCLONAL-ANTIBODIES; JAMAICA GENOTYPE; TYPE-2 VIRUS; PROTEINS; EXPRESSION; GENOME; RNA	The control of arthropod-borne virus diseases such as dengue may ultimately require the genetic manipulation of mosquito vectors to disrupt virus transmission to human populations. To reduce the ability of mosquitoes to transmit dengue viruses, a recombinant Sindbis virus was used to transduce female Aedes aegypti with a 567-base antisense RNA targeted to the premembrane coding region of dengue type 2 (DEN-2) virus. The transduced mosquitoes were unable to support replication of DEN-P virus in their salivary glands and therefore were not able to transmit the virus.			Olson, KE (corresponding author), COLORADO STATE UNIV,DEPT MICROBIOL,ARTHROPAD BARNE & INFECT DIS LAB,FT COLLINS,CO 80523, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034014] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07352, AI34014] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHBURNER M, 1995, SCIENCE, V270, P1941, DOI 10.1126/science.270.5244.1941; BEATY BJ, 1979, MOSQ NEWS, V39, P232; BESANSKY NJ, 1995, PARASITOL TODAY, V270, P1941; CARLSON J, 1995, ANNU REV ENTOMOL, V40, P359, DOI 10.1146/annurev.en.40.010195.002043; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHANAS AC, 1982, J GEN VIROL, V58, P37, DOI 10.1099/0022-1317-58-1-37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMPTON J, 1990, PARASITOL TODAY, V6, P31, DOI 10.1016/0169-4758(90)90057-B; DEUBEL V, 1986, VIROLOGY, V155, P365, DOI 10.1016/0042-6822(86)90200-X; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; FALLON AM, 1991, NATURE, V352, P828, DOI 10.1038/352828a0; Gaines PJ, 1996, J VIROL, V70, P2132, DOI 10.1128/JVI.70.4.2132-2137.1996; GOULD EA, 1985, J GEN VIROL, V66, P1369, DOI 10.1099/0022-1317-66-7-1369; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HIGGS S, 1993, PARASITOL TODAY, V9, P444, DOI 10.1016/0169-4758(93)90098-Z; KARBER G, 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; MARCHUK D, 1990, NUCLEIC ACIDS RES, V19, P1154; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; MURRAY JM, 1993, J GEN VIROL, V74, P175, DOI 10.1099/0022-1317-74-2-175; OLSON KE, 1994, INSECT BIOCHEM MOLEC, V24, P39, DOI 10.1016/0965-1748(94)90121-X; POWERS AM, 1994, VIRUS RES, V32, P57, DOI 10.1016/0168-1702(94)90061-2; POWERS AM, UNPUB; POWERS AM, IN PRESS P NATL ACAD; RaymsKeller A, 1995, INSECT MOL BIOL, V4, P245, DOI 10.1111/j.1365-2583.1995.tb00030.x; RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987; ROSEN L, 1974, AM J TROP MED HYG, V23, P1153, DOI 10.4269/ajtmh.1974.23.1153; Sambrook J., 1989, MOL CLONING LAB MANU; SANFORD JC, 1985, J THEOR BIOL, V113, P395, DOI 10.1016/S0022-5193(85)80234-4; WHITEHEAD RH, 1971, T ROY SOC TROP MED H, V65, P661, DOI 10.1016/0035-9203(71)90051-4	32	156	161	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					884	886		10.1126/science.272.5263.884	http://dx.doi.org/10.1126/science.272.5263.884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629025				2022-12-01	WOS:A1996UK75700062
J	Xanthoudakis, S; Viola, JPB; Shaw, KTY; Luo, C; Wallace, JD; Bozza, PT; Curran, T; Rao, A				Xanthoudakis, S; Viola, JPB; Shaw, KTY; Luo, C; Wallace, JD; Bozza, PT; Curran, T; Rao, A			An enhanced immune response in mice lacking the transcription factor NFAT1	SCIENCE			English	Article							ACTIVATED T-CELLS; CYCLOSPORINE-A; NUCLEAR FACTOR; GENE; IDENTIFICATION; LYMPHOCYTE; COMPLEX; DISEASE	Transcription factors of the NFAT family are thought to play a major role in regulating the expression of cytokine genes and other inducible genes during the immune response. The role of NFAT1 was investigated by targeted disruption of the NFAT1 gene. Unexpectedly, cells from NFAT1(-/-) mice showed increased primary responses to Leishmania major and mounted increased secondary responses to ovalbumin in vitro. In an in vivo model of allergic inflammation, the accumulation of eosinophils and levels of serum immunoglobulin E were increased in NFAT1(-/-) mice. These results suggest that NFAT1 exerts a negative regulatory influence on the immune response.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; HOFFMANN LA ROCHE INC, DEPT CNS RES, NEUROGENET PROGRAM, NUTLEY, NJ 07110 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, HARVARD THORNDIKE LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST, SCH MED, BOSTON, MA 02115 USA	St Jude Children's Research Hospital; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Bozza, Patricia T./AAE-2933-2021; Curran, Tom/D-7515-2011; Viola, Joao P.B./AAP-4125-2020; Curran, Thomas/AAE-7631-2019; Bozza, Patricia T./AAM-4537-2021; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018	Viola, Joao P.B./0000-0002-0698-3146; Curran, Thomas/0000-0003-1444-7551; Bozza, Patricia T./0000-0001-8349-9529; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [R37CA042471, P30CA021765, R01CA042471] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, CA42471] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BACHMANN MF, 1995, J VIROL, V69, P4842, DOI 10.1128/JVI.69.8.4842-4846.1995; BOZZA PT, 1994, IMMUNOPHARMACOLOGY, V27, P131, DOI 10.1016/0162-3109(94)90047-7; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRADLEY LM, 1995, J IMMUNOL, V155, P1713; BROMBERG JS, 1995, CURR OPIN IMMUNOL, V7, P639, DOI 10.1016/0952-7915(95)80070-0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Daser A, 1995, CURR OPIN IMMUNOL, V7, P762, DOI 10.1016/0952-7915(95)80045-X; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LUO C, UNPUB; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SADLACK B, 1994, EUR J IMMUNOL, V24, P281, DOI 10.1002/eji.1830240144; SADLACK B, 1995, EUR J IMMUNOL, V25, P3053, DOI 10.1002/eji.1830251111; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHANKAR AH, 1993, J EXP MED, V178, P101, DOI 10.1084/jem.178.1.101; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang DZ, 1995, ANN NY ACAD SCI, V766, P182, DOI 10.1111/j.1749-6632.1995.tb26661.x; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; YASEEN NR, 1993, J BIOL CHEM, V268, P14285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	54	309	316	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					892	895		10.1126/science.272.5263.892	http://dx.doi.org/10.1126/science.272.5263.892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629027				2022-12-01	WOS:A1996UK75700065
J	Lowe, LA; Supp, DM; Sampath, K; Yokoyama, T; Wright, CVE; Potter, SS; Overbeek, P; Kuehn, MR				Lowe, LA; Supp, DM; Sampath, K; Yokoyama, T; Wright, CVE; Potter, SS; Overbeek, P; Kuehn, MR			Conserved left-right asymmetry of nodal expression and alterations in murine situs inversus	NATURE			English	Article							MOUSE; LATERALITY; SIDEDNESS; REVERSAL	VERTEBRATES have characteristic and conserved left-right (L-R) visceral asymmetries, for example the left-sided heart. In humans, alterations of L-R development can have serious clinical implications, including cardiac defects(1). Although little is known about how the embryonic L-R axis is established, a recent study in the chick embryo revealed L-R asymmetric expression of several previously cloned genes, including Cnr-1 (for chicken nodal-related-1), and indicated how this L-R molecular asymmetry might be important for subsequent visceral morphogenesis(2). Here we show that nodal(3) is asymmetrically expressed in mice at similar stages, as is Xnr-1 (for Xenopus nodal related-1)(4) in frogs. We also examine nodal expression in two mouse mutations that perturb L-R development, namely situs inversus viscerum (iv)(5), in which assignment of L-R asymmetry is apparently random and individuals develop either normally or are mirror-image-reverse (situs inversus), and inversion of embryonic turning (inv)(6), in which all individuals develop with situs inversus. In both, nodal expression is strikingly affected, being reversed or converted to symmetry. These results further support a key role for nodal and nodal-related genes in interpreting and relaying L-R patterning information in vertebrates. To our knowledge, our results provide the first direct evidence that iv and inv normally function well before the appearance of morphological L-R asymmetry.	NCI,EXPTL IMMUNOL BRANCH,NIH,BETHESDA,MD 20892; UNIV CINCINNATI,CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Vanderbilt University; Baylor College of Medicine			Supp, Dorothy/ABQ-7999-2022; Kuehn, Michael R/A-4573-2014	Supp, Dorothy/0000-0002-2429-6630; Kuehn, Michael R/0000-0002-7703-9160; Sampath, Karuna/0000-0002-0729-1977; Overbeek, Paul/0000-0001-9784-2084				BROWN NA, 1990, DEVELOPMENT, V109, P1; BROWN NA, 1989, DEVELOPMENT, V107, P637; BURN J, 1991, CIBA F SYMP, V162, P282; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DANOS MC, 1995, DEVELOPMENT, V121, P1467; FUJINAGA M, 1994, DEV BIOL, V162, P558, DOI 10.1006/dbio.1994.1109; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOGAN B, 1994, MANIPULATING MOUSE E, P357; JONES CM, 1995, DEVELOPMENT, V121, P3651; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; PANSERA F, 1994, MED HYPOTHESES, V42, P283, DOI 10.1016/0306-9877(94)90134-1; SEO JW, 1992, CIRCULATION, V86, P642, DOI 10.1161/01.CIR.86.2.642; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	24	402	418	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					158	161		10.1038/381158a0	http://dx.doi.org/10.1038/381158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610013	Green Submitted			2022-12-01	WOS:A1996UK13900050
J	Malaviya, R; Ikeda, T; Ross, E; Abraham, SN				Malaviya, R; Ikeda, T; Ross, E; Abraham, SN			Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; KLEBSIELLA-PNEUMONIAE; MICE; INFLAMMATION; RECRUITMENT; PERITONITIS; MOUSE	ALTHOUGH mast cells have been implicated in a variety of inflammatory conditions including immediate hypersensitivity and interstitial cystitis,(1,2) their physiological role in the body is unknown. We investigated the role of mast cells in host defence against bacterial infections using a well characterized mast-cell-deficiency mouse model(3,4). We report here that mast cells, which are selectively located at portals of bacterial entry, are important to host defence. Mast-cell-deficient WBB6F1-W/W-v mice (W/W-v) were up to 20-fold less efficient in clearing enterobacteria than WBB6F1+/+ (+/+)mice or mast-cell-reconstituted W/W-v (W/W-v + MC) mice. With higher bacterial inocula, only W/W-v mice died (80%). The limited bacterial clearance in W/W-v mice directly correlated with impaired neutrophil influx. The mast-cell chemoattractant TNF-alpha was implicated in the neutrophil response because TNF-alpha was locally released only in +/+ and W/W-v + MC mice, TNF-alpha-specific antibodies blocked over 70% of the neutrophil influx, and purified mast cells released TNF-alpha upon incubation with bacteria. Additionally, the type-1 fimbrial subunit, FimH, was the necessary enterobacterial component for mast-cell activation and neutrophil influx because an isogenic FimH(-) mutant evoked a limited neutrophil response in +/+ mice compared to wild-type bacteria.	WASHINGTON UNIV,BARNES JEWISH HOSP,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; AZABU UNIV,DEPT VET MICROBIOL,KANAGAWA,JAPAN	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Azabu University								ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; ARNOLD JW, 1993, MICROB PATHOGENESIS, V14, P217, DOI 10.1006/mpat.1993.1021; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; ESPOSITO AL, 1987, AM REV RESPIR DIS, V135, P676; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, J EXP MED, V150, P482, DOI 10.1084/jem.150.3.482; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Malaviya R, 1996, J IMMUNOL, V156, P1490; MALONE DG, 1988, ANN ALLERGY, V61, P27; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; OFEK I, 1993, INFECT IMMUN, V61, P4208, DOI 10.1128/IAI.61.10.4208-4216.1993; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SUZUKI N, 1993, AM J RESP CELL MOL, V9, P475, DOI 10.1165/ajrcmb/9.5.475; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	24	908	940	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					77	80		10.1038/381077a0	http://dx.doi.org/10.1038/381077a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609993				2022-12-01	WOS:A1996UJ05300060
J	Muller, T; Feichtinger, H; Berger, H; Muller, W				Muller, T; Feichtinger, H; Berger, H; Muller, W			Endemic Tyrolean infantile cirrhosis: An ecogenetic disorder	LANCET			English	Article							INDIAN CHILDHOOD CIRRHOSIS; COPPER STORAGE DISEASE; LIVER	Background 138 infants and young children died from an endemic infantile liver cirrhosis in a circumscribed rural area of western Austria between 1900 and 1974. Frequency of the disease peaked between 1930 and 1960. It has disappeared from this area since 1974. Methods Clinical and genetic data on the patients was gathered; pedigrees analysed and ethnographic studies and interviews were undertaken. Findings The disease, which was clinically and pathologically indistinguishable from Indian childhood cirrhosis and hepatic copper toxicosis, was transmitted by autosomal recessive inheritance. Cow's milk, contaminated with copper from untinned copper or brass vessels, may have contributed to the development of copper toxicosis. Replacement of untinned copper cooking utensils by modern industrial vessels has eradicated the disease. Interpretation Our findings strongly suggest that the endemic Tyrolean childhood cirrhosis-and by analogy non-Wilsonian hepatic copper toxicosis occurring elsewhere-is an ecogenetic disorder requiring the involvement of both genetic and environmental factors for the disease to become manifest.	COMMUNITY HOSP, DEPT PAEDIAT, A-6600 REUTTE, AUSTRIA; UNIV INNSBRUCK, DEPT PAEDIAT, REUTTE, AUSTRIA; UNIV INNSBRUCK, DEPT PATHOL, REUTTE, AUSTRIA	University of Innsbruck; University of Innsbruck								ADAMSON M, 1992, GASTROENTEROLOGY, V102, P1771, DOI 10.1016/0016-5085(92)91742-M; ALJAJEH IA, 1994, VIRCHOWS ARCH, V424, P225; BAKER A, 1995, J HEPATOL, V23, P538, DOI 10.1016/0168-8278(95)80059-X; BHAVE SA, 1992, ANN TROP PAEDIATR, V12, P23, DOI 10.1080/02724936.1992.11747542; BHAVE SA, 1982, ARCH DIS CHILD, V57, P922, DOI 10.1136/adc.57.12.922; Finney DJ., 1947, ANN EUGEN, V14, P319, DOI [10.1111/j.1469-1809.1947.tb02410.x, DOI 10.1111/J.1469-1809.1947.TB02410.X]; Fodisch H J, 1968, Verh Dtsch Ges Pathol, V52, P557; GOGL H, 1947, WIENER BEIRAGE KINDE, V1; HORSLEN SP, 1994, GUT, V35, P1497, DOI 10.1136/gut.35.10.1497; KAELIN A., 1955, ARCH JULIUS KLAUS STIFT, V30, P263; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; Lim C T, 1979, J Singapore Paediatr Soc, V21, P99; MULLERHOCKER J, 1987, VIRCHOWS ARCH A, V411, P379, DOI 10.1007/BF00713384; MULLERHOCKER J, 1988, PATHOL RES PRACT, V183, P39, DOI 10.1016/S0344-0338(88)80157-2; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; SCHULER F., 1942, Arch. Kinderheilk., V126, P5; TANNER MS, 1979, LANCET, V1, P1203; TANNER MS, 1983, LANCET, V2, P992; TANNER MS, 1986, RECENT ADV PAEDIATRI, V8, P103; VOGEL F, 1979, HUMAN GENETICS PROBL, P105; WALKERSMITH J, 1973, ARCH DIS CHILD, V48, P476, DOI 10.1136/adc.48.6.476; WEISS M, 1989, ACTA PAEDIATR SCAND, V79, P152	22	120	123	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					877	880		10.1016/S0140-6736(96)91351-3	http://dx.doi.org/10.1016/S0140-6736(96)91351-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622397				2022-12-01	WOS:A1996UC45000015
J	Qu, DQ; Ludwig, DS; Gammeltoft, S; Piper, M; Pelleymounter, MA; Cullen, MJ; Mathes, WF; Przypek, J; Kanarek, R; MaratosFlier, E				Qu, DQ; Ludwig, DS; Gammeltoft, S; Piper, M; Pelleymounter, MA; Cullen, MJ; Mathes, WF; Przypek, J; Kanarek, R; MaratosFlier, E			A role for melanin-concentrating hormone in the central regulation of feeding behaviour	NATURE			English	Article							MESSENGER-RIBONUCLEIC-ACID; RAT-BRAIN; PUTATIVE NEUROPEPTIDES; HYPOTHALAMUS; PEPTIDE; GENE; LOCALIZATION; STIMULATION; SYSTEM; RNA	THE hypothalamus plays a central role in the integrated regulation of energy homeostasis and body weight, and a number of hypothalamic neuropeptides, such as neuropeptide Y (ref. 1), galanin(2), CRH (ref. 3), and GLP-1 (ref. 4), have been implicated in the mediation of these effects. To discover new hypothalamic peptides involved in the regulation of body weight, we used differential display polymerase chain reaction(5) to identify messenger RNAs that are differentially expressed in the hypothalamus of ob/+ compared with ob/ob C57Bl/6J mice. We show here that one mRNA that is overexpressed in the hypothalamus of ob/ob mice encodes the neuropeptide melanin-concentrating hormone (MCH). Fasting further increased expression of MCH mRNA in both normal and obese animals. Neurons containing MCH are located in the zona incerta and in the lateral hypothalamus. These areas are involved in regulation of ingestive behaviour, but the role of MCH in mammalian physiology is unknown. To determine whether MCH is involved in the regulation of feeding, we injected MCH into the lateral ventricles of rats and found that their food consumption increased. These findings suggest that MCH participates in the hypothalamic regulation of body weight.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,ELLIOT P JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; AMGEN INC,DEPT NEUROBIOL,THOUSAND OAKS,CA 91320; TUFTS UNIV,DEPT PSYCHOL,MEDFORD,MA 02155	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Amgen; Tufts University				Ludwig, David/0000-0003-3307-8544				ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CECHETTO DF, 1988, J COMP NEUROL, V272, P579, DOI 10.1002/cne.902720410; CONE RD, 1993, ANN NY ACAD SCI, V680, P342, DOI 10.1111/j.1749-6632.1993.tb19694.x; JAKUBOWSKI M, 1991, J NEUROENDOCRIN; KAWAUCHI H, 1993, ANN NY ACAD SCI, V680, P64, DOI 10.1111/j.1749-6632.1993.tb19675.x; KAWAUCHI H, 1983, NATURE, V305, P423; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KYRKOULI SE, 1986, EUR J PHARMACOL, V122, P159, DOI 10.1016/0014-2999(86)90175-5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MATSUNAGA TO, 1989, PEPTIDES, V10, P773, DOI 10.1016/0196-9781(89)90112-5; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1993, ANN NY ACAD SCI, V680, P111, DOI 10.1111/j.1749-6632.1993.tb19678.x; NAITO N, 1988, CELL TISSUE RES, V253, P291; OOMURA Y, 1987, NEWS PHYSIOL SCI, V2, P199; PARKES D, 1992, ENDOCRINOLOGY, V131, P1826, DOI 10.1210/en.131.4.1826; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RANCE T, 1979, GEN COMP ENDOCR, V37, P64, DOI 10.1016/0016-6480(79)90047-9; RISOLD PY, 1992, NEUROSCI LETT, V136, P145, DOI 10.1016/0304-3940(92)90035-6; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SKOFITSCH G, 1985, BRAIN RES BULL, V15, P635, DOI 10.1016/0361-9230(85)90213-8; STANLEY BG, 1989, PHYSIOL BEHAV, V46, P173, DOI 10.1016/0031-9384(89)90251-5; TEMPEL DL, 1990, BRAIN RES BULL, V25, P821, DOI 10.1016/0361-9230(90)90177-2; THOMPSON RC, 1990, DNA CELL BIOL, V9, P637, DOI 10.1089/dna.1990.9.637; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; ZAMIR N, 1986, P NATL ACAD SCI USA, V83, P1528, DOI 10.1073/pnas.83.5.1528; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1098	1152	0	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					243	247		10.1038/380243a0	http://dx.doi.org/10.1038/380243a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637571				2022-12-01	WOS:A1996UB11700050
J	Dikstein, R; Ruppert, S; Tjian, R				Dikstein, R; Ruppert, S; Tjian, R			TAF(11)250 is a bipartite protein kinase that phosphorylates the basal transcription factor RAP74	CELL			English	Article							RNA POLYMERASE-II; MOLECULAR-CLONING; INITIATION-FACTOR; BINDING PROTEIN; TERMINAL DOMAIN; COACTIVATORS; GENE; ACTIVATION; PROMOTER; HELICASE	Some TAF subunits of transcription factor TFIID play a pivotal role in transcriptional activation by mediating protein-protein interactions, whereas other TAFs direct promoter selectivity via protein-DNA recognition. Here, we report that purified recombinant TAF(II)250 is a protein serine kinase that selectively phosphorylates RAP74 but not other basal transcription factors or common phosphoacceptor proteins. The phosphorylation of RAP74 also occurs in the context of the complete TFIID complex. Deletion analysis revealed that TAF(II)250 contains two distinct kinase domains each capable of autophosphorylation. However, both the N- and C-terminal kinase domains of TAF(II)250 are required for efficient transphosphorylation of RAP74 on serine residues. These findings suggest that the targeted phosphorylation of RAP74 by TAF(II)250 may provide a mechanism for signaling between components within the initiation complex to regulate transcription.			Dikstein, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,401 BARKER HALL,BERKELEY,CA 94720, USA.							BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NOGUCHI E, 1994, SOMAT CELL MOLEC GEN, V20, P505, DOI 10.1007/BF02255841; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OREILLEY DR, 1994, BACULOVIRUS EXPRESSI; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SOPTA M, 1985, J BIOL CHEM, V260, P353; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER P, 1995, CELL, V81, P1115; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351	40	179	185	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					781	790		10.1016/S0092-8674(00)81055-7	http://dx.doi.org/10.1016/S0092-8674(00)81055-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625415	Bronze			2022-12-01	WOS:A1996TZ99000015
J	Wang, G; Seidman, MM; Glazer, PM				Wang, G; Seidman, MM; Glazer, PM			Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair	SCIENCE			English	Article							C-MYC GENE; FORMING OLIGONUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; TARGETED MUTAGENESIS; TELOMERIC DNA; FREE-EXTRACTS; BINDING; INHIBITION; MUTATIONS; CLEAVAGE	When mammalian cells were treated with tripler-forming oligonucleotides of sufficient binding affinity, mutations were specifically induced in a simian virus 40 vector contained within the cells. Tripler-induced mutagenesis was not detected in xeroderma pigmentosum group A cells nor in Cockayne's syndrome group B cells, indicating a requirement for excision repair and for transcription-coupled repair, respectively, in the process. Tripler formation was also found to stimulate DNA repair synthesis in human cell extracts, in a pattern correlating with the inhibition of transcription in such extracts. These findings may have implications for therapeutic applications of tripler DNA and raise the possibility that naturally occurring triple helices are a source of genetic instability.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06520 USA; ONCORPHARM, GAITHERSBURG, MD 20877 USA	Yale University			Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560	NATIONAL CANCER INSTITUTE [R01CA064186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005775, R29ES005775] Funding Source: NIH RePORTER; NCI NIH HHS [CA64186] Funding Source: Medline; NIEHS NIH HHS [ES05775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; Helene Claude, 1993, Current Opinion in Biotechnology, V4, P29, DOI 10.1016/0958-1669(93)90028-U; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LEVY DD, 1995, CARCINOGENESIS, V16, P1557, DOI 10.1093/carcin/16.7.1557; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRAKASH L, 1976, GENETICS, V83, P285; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; QUAH SK, 1980, GENETICS, V96, P819; READ GS, 1982, P NATL ACAD SCI-BIOL, V79, P5215, DOI 10.1073/pnas.79.17.5215; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; WANG G, 1995, MOL CELL BIOL, V15, P1759; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	45	290	308	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					802	805		10.1126/science.271.5250.802	http://dx.doi.org/10.1126/science.271.5250.802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628995				2022-12-01	WOS:A1996TU69400044
J	Moons, MAW; Peters, L; Bartelds, AIM; Kerssens, JJ				Moons, MAW; Peters, L; Bartelds, AIM; Kerssens, JJ			Concerns about AIDS in general practice	BRITISH MEDICAL JOURNAL			English	Article							HIV		NETHERLANDS INST PRIMARY HLTH CARE,3500 BN UTRECHT,NETHERLANDS									Bartelds A I, 1993, Gesundheitswesen, V55, P3; BARTELDS AIM, 1994, CONTINUOUS MORBIDITY; MILNE RIG, 1988, BRIT MED J, V296, P533, DOI 10.1136/bmj.296.6621.533; SINGH S, 1993, BRIT J GEN PRACT, V43, P182; 1988, J R COLL GEN PRACT, V38, P219	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					285	286						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611785	Green Published			2022-12-01	WOS:A1996TU50700023
J	Levy, JA				Levy, JA			Surrogate markers in AIDS research - Is there truth in numbers?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIV; LYMPHOCYTES; INFECTION		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Levy, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143, USA.							BARKER E, 1995, P NATL ACAD SCI USA, V92, P11135, DOI 10.1073/pnas.92.24.11135; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAMERON B, 1996, 3 C RETR OPP INF WAS; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; DAQUILA RT, 1994, CLIN LAB MED, V14, P393, DOI 10.1016/S0272-2712(18)30385-8; DELOES SK, 1995, NEW ENGL J MED, V333, P408; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LEVY JA, 1995, LANCET, V345, P1619, DOI 10.1016/S0140-6736(95)90121-3; Levy JA, 1996, SCIENCE, V271, P670, DOI 10.1126/science.271.5249.670; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Pantaleo G, 1995, J ACQ IMMUN DEF SYND, V10, pS6; PHILLIPS AN, 1991, LANCET, V337, P389; Raboud JM, 1996, J ACQ IMMUN DEF SYND, V12, P46, DOI 10.1097/00042560-199605010-00007; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; VOLBERDING PA, 1988, MED MANAGEMENT AIDS, P353; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B	31	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					161	162		10.1001/jama.276.2.161	http://dx.doi.org/10.1001/jama.276.2.161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656510				2022-12-01	WOS:A1996UV48500034
J	Graham, B				Graham, B			Diagnosis of closed wrist injuries	LANCET			English	Editorial Material											Graham, B (corresponding author), UNIV TORONTO,TORONTO HOSP,TORONTO,ON,CANADA.							BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; Lichtman D., 1988, WRIST ITS DISORDERS; Thorpe AP, 1996, BRIT J RADIOL, V69, P109, DOI 10.1259/0007-1285-69-818-109; WILKENS EW, 1989, EMERGENCY MED SCI FD	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1709	1709		10.1016/S0140-6736(96)90801-6	http://dx.doi.org/10.1016/S0140-6736(96)90801-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656899				2022-12-01	WOS:A1996UT39600003
J	Hollenberg, SM; Parrillo, JE				Hollenberg, SM; Parrillo, JE			Critical care medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK SURGICAL PATIENTS; OXYGEN DELIVERY				Hollenberg, SM (corresponding author), RUSH MED COLL, CHICAGO, IL 60612 USA.		Hollenberg, Steven/AAR-4522-2020	Hollenberg, Steven/0000-0003-1293-8496				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; CIVETTA JM, 1990, ANN SURG, V212, P266, DOI 10.1097/00000658-199009000-00005; ESSERMAN L, 1995, JAMA-J AM MED ASSOC, V274, P1544, DOI 10.1001/jama.274.19.1544; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SUFFREDINI AF, 1994, CRIT CARE MED, V22, pS12; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; 1996, JAMA-J AM MED ASSOC, V275, P1232	16	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1799	1800		10.1001/jama.275.23.1799	http://dx.doi.org/10.1001/jama.275.23.1799			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642716				2022-12-01	WOS:A1996UQ15200015
J	Baba, TW; Trichel, AM; An, L; Liska, V; Martin, LN; MurpheyCorb, M; Ruprecht, RM				Baba, TW; Trichel, AM; An, L; Liska, V; Martin, LN; MurpheyCorb, M; Ruprecht, RM			Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL BISEXUAL MEN; RHESUS-MONKEYS; HIV SEROCONVERSION; HTLV-III; ACID-SECRETION; DISEASE STAGE; RISK-FACTORS; HUMAN SALIVA; TRANSMISSION	Unprotected receptive anal intercourse is a well-recognized risk factor for infection with human immunodeficiency virus-type 1 (HIV-1). Isolated human case reports have implicated HIV-1 transmission by oral-genital exposure. Adult macaques exposed nontraumatically to cell-free simian immunodeficiency virus (SIV) through the oral route became infected and developed acquired immunodeficiency syndrome (AIDS). The minimal virus dose needed to achieve systemic infection after oral exposure was 6000 times lower than the minimal dose required to achieve systemic infection after rectal exposure. Thus, unprotected receptive oral intercourse, even in the absence of mucosal lesions, should be added to the list of risk behaviors for HIV-1 transmission.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, LAB VIRAL PATHOGENESIS, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT PEDIAT, DIV NEWBORN MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; TULANE UNIV, TULANE REG PRIMATE RES CTR, COVINGTON, LA 70433 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Tulane University					NIAID NIH HHS [U01-AI24345, R01-AI34266, R01-AI32330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024345, R01AI034266, R01AI032330, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; AMEDEE AM, 1995, J VIROL, V69, P7982, DOI 10.1128/JVI.69.12.7982-7990.1995; AMORY J, 1992, CLIN RES, V40, pA51; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; ARCHIBALD DW, 1990, AIDS RES HUM RETROV, V6, P1425, DOI 10.1089/aid.1990.6.1425; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BABA TW, 1993, J WOMENS HEALTH, V2, P231; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BASKIN GB, 1986, J NATL CANCER I, V77, P127; BERGEY EJ, 1994, J ACQ IMMUN DEF SYND, V7, P995; BERTHIER A, 1986, LANCET, V2, P598; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; CONWAY MD, 1991, J MED PRIMATOL, V20, P152; COPPENHAVER DH, 1994, NEW ENGL J MED, V330, P1314, DOI 10.1056/NEJM199405053301815; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; FRANCHINI G, 1989, ANN NY ACAD SCI, V554, P81, DOI 10.1111/j.1749-6632.1989.tb22412.x; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FRIEDLAND G, 1990, AIDS, V4, P639, DOI 10.1097/00002030-199007000-00005; FULTZ PN, 1986, J INFECT DIS, V154, P896, DOI 10.1093/infdis/154.5.896; FULTZ PN, 1986, LANCET, V2, P1215; GIBB D, 1994, AIDS S1, V8, pS275; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1984, SCIENCE, V226, P451, DOI 10.1126/science.6208608; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KINGSLEY LA, 1987, LANCET, V1, P345; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LAIRMORE MD, 1993, AIDS RES HUM RETROV, V9, P565, DOI 10.1089/aid.1993.9.565; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LARSSON H, 1983, GASTROENTEROLOGY, V85, P900; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; Levy JA, 1994, HIV PATHOGENESIS AID; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; MALAMUD D, 1993, AIDS RES HUM RETROV, V9, P633, DOI 10.1089/aid.1993.9.633; MARTHAS ML, 1992, J MED PRIMATOL, V21, P99; MARTIN LN, 1994, ANTIMICROB AGENTS CH, V38, P1277, DOI 10.1128/AAC.38.6.1277; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; MCTAVISH D, 1991, DRUGS, V42, P138, DOI 10.2165/00003495-199142010-00008; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1990, J MED PRIMATOL, V19, P401; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MILLER CJ, 1994, AM J REPROD IMMUNOL, V31, P52, DOI 10.1111/j.1600-0897.1994.tb00847.x; MILLER CJ, 1994, AM J REPROD IMMUNOL, V188, P107; MURRAY AB, 1991, LANCET, V338, P830, DOI 10.1016/0140-6736(91)90726-6; ONKAWA S, 1990, FASEB J, V4, pA2264; PAUZA CD, 1994, AIDS RES HUM RETROV, V10, pS7; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; POURTOIS M, 1991, AIDS, V5, P598, DOI 10.1097/00002030-199105000-00022; ROGERS MF, 1990, PEDIATRICS, V85, P210; ROZENBAUM W, 1988, LANCET, V1, P1395; SPOUGE JL, 1992, P NATL ACAD SCI USA, V89, P7581, DOI 10.1073/pnas.89.16.7581; SU H, 1991, MOL IMMUNOL, V28, P811, DOI 10.1016/0161-5890(91)90044-K; VANGRIENSVEN GJP, 1987, AM J EPIDEMIOL, V125, P1048, DOI 10.1093/oxfordjournals.aje.a114620; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; WILLIAMSHERMANN D, 1993, INT C AIDS JUN; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277	66	130	133	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1486	1489		10.1126/science.272.5267.1486	http://dx.doi.org/10.1126/science.272.5267.1486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633242				2022-12-01	WOS:A1996UP89900049
J	Bayer, R				Bayer, R			AIDS prevention - Sexual ethics and responsibility	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIV; INFECTION; PARTNERS				Bayer, R (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10032, USA.				NIMH NIH HHS [K05 MH01376-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001376] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; BAYER R, 1993, AM J PUBLIC HEALTH, V83, P1471, DOI 10.2105/AJPH.83.10.1471; CHAMBERS DL, 1994, HARVARD CIVIL RIGHTS, V29, P353; COCHRAN SD, 1990, NEW ENGL J MED, V322, P774, DOI 10.1056/NEJM199003153221111; EKSTRAND M, 1993, AIDS, V7, P281, DOI 10.1097/00002030-199302000-00020; ILLINGWORTH P, 1990, AIDS GOOD SOC; KEGELES SM, 1988, JAMA-J AM MED ASSOC, V259, P216, DOI 10.1001/jama.259.2.216; MARKS G, 1992, PUBLIC HEALTH REP, V107, P100; MARKS G, 1991, AM J PUBLIC HEALTH, V81, P1321, DOI 10.2105/AJPH.81.10.1321; MASON HRC, 1995, HEALTH PSYCHOL, V14, P6, DOI 10.1037/0278-6133.14.1.6; MASS L, 1995, NATION          0417, P540; MOHR RD, 1986, RARITAN, V6, P38; PERRY SW, 1994, AIDS EDUC PREV, V6, P403; PILKINGTON CJ, 1994, J SEX RES, V31, P203, DOI 10.1080/00224499409551753; ROTELLO G, 1995, NATION          0417, P510; SIGNORILE M, 1995, NY TIMES        0226, V4, P15; SIMONI JM, 1995, J CONSULT CLIN PSYCH, V63, P474, DOI 10.1037/0022-006X.63.3.474; SOBO EJ, 1995, CHOOSING UNSAFE SEX; WILLIG C, 1995, J COMMUNITY APPL PSY, V4, P74; YEO M, 1991, PERSPECTIVES AIDS ET, P75	20	55	57	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1540	1542		10.1056/NEJM199606063342312	http://dx.doi.org/10.1056/NEJM199606063342312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN799	8618613	Green Published			2022-12-01	WOS:A1996UN79900012
J	Vega, KJ; Pina, I; Krevsky, B				Vega, KJ; Pina, I; Krevsky, B			Heart transplantation is associated with an increased risk for pancreaticobiliary disease	ANNALS OF INTERNAL MEDICINE			English	Article							GENERAL SURGICAL COMPLICATIONS; CARDIAC TRANSPLANTATION; CYCLOSPORINE THERAPY; CHOLELITHIASIS; RECIPIENTS; CHOLESTASIS; MANAGEMENT; BILE	Objective: To determine the risk factors for and the incidence, morbidity, mortality, and outcome of pancreaticobiliary disease in patients who have had orthotopic heart transplantation. Design: Retrospective case-control analysis. Setting: University hospital-based heart transplantation center. Patients: 20 case-patients with pancreaticobiliary disease and 40 controls; all patients received heart transplants between 1985 and 1994. Controls were matched to case-patients by time of transplantation and length of survival. Measurements: Charts were reviewed and data were extracted using a structured data abstraction protocol. Risk factors assessed before transplantation were cause of heart disease, history of diabetes, reproductive history, and sex. Risk factors assessed at presentation of pancreaticobiliary disease were weight change after transplantation, alcohol use, use of medications, recent total parenteral nutrition, age at symptom onset, recent rejection episode, cyclosporine level, complete blood count, time between transplantation and onset of symptoms, body mass index, calcium level, liver function test results before and at symptom onset, and lipid profile. Results: Pancreaticobiliary disease occurred in 20 of 255 transplant recipients (7.8%). The incidence of disease in these patients within 1 year after transplantation was 3.9% compared with an expected rate of 0.2% per year (P < 0.01). A decreased serum calcium level was the only risk factor found to differ significantly between the two groups (mean +/- SD, 2.19 +/- 0.17 mmol/L in case-patients and 2.31 +/- 0.14 mmol/L in controls; P = 0.005). The duration of hospitalization for the treatment of pancreaticobiliary disease was longer for patients who received transplants than for patients who did not receive transplants and were treated at Temple University Hospital during a similar period (17.1 days compared with 7.2 days; P < 0.001). However, the outcome was excellent in most patients. Conclusions: Pancreaticobiliary disease occurs 17.4 times (95% CI, 9.2 to 32.7 times) more frequently in patients receiving transplants than in the general population. It is a seldom recognized but apparently common complication of orthotopic heart transplantation that results in substantial morbidity and health care resource use. Further study is needed to ascertain why this condition occurs and how the risk for developing it can be reduced.	TEMPLE UNIV HOSP & MED SCH, GASTROENTEROL SECT, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV HOSP & MED SCH, CARDIOL SECT, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BORTNICHAK EA, 1985, AM J EPIDEMIOL, V121, P19, DOI 10.1093/oxfordjournals.aje.a113978; BURCKART GJ, 1988, TRANSPLANT P, V20, P190; COLON R, 1988, SURGERY, V103, P32; CSENDES A, 1978, ACTA CHIR SCAND, V144, P289; DISESA VJ, 1989, ARCH SURG-CHICAGO, V124, P539; EVERHART JE, 1994, DIGESTIVE DIS US EPI, P647; GIRARDET RE, 1989, J HEART TRANSPLANT, V8, P391; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; LORBER MI, 1987, TRANSPLANT P, V19, P1808; MERRELL SW, 1989, ARCH SURG-CHICAGO, V124, P889; PARASCANDOLA SA, 1989, J HEART TRANSPLANT, V8, P400; ROTOLO FS, 1986, AM J SURG, V151, P35, DOI 10.1016/0002-9610(86)90008-5; SAPALA MA, 1979, SURG GYNECOL OBSTET, V148, P36; SCHADE RR, 1983, TRANSPLANT P, V15, P2757; SPES CH, 1990, J HEART TRANSPLANT, V9, P404; STECK TB, 1991, J HEART LUNG TRANSPL, V10, P1029; STEED DL, 1985, SURGERY, V98, P739; STONE B, 1988, TRANSPLANT P, V20, P841; *UN NETW ORG SHAR, 1995, 1994 UN NETW ORG SHA; VOGELBERG KH, 1984, DEUT MED WOCHENSCHR, V109, P1712, DOI 10.1055/s-2008-1069440	20	16	16	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					980	983		10.7326/0003-4819-124-11-199606010-00005	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624065				2022-12-01	WOS:A1996UL90500005
J	Hanneman, RL				Hanneman, RL			Intersalt: Hypertension rise with age revisited	BRITISH MEDICAL JOURNAL			English	Article											Hanneman, RL (corresponding author), SALT INST,700 N FAIRFAX ST,ALEXANDRIA,VA 22314, USA.							SWALES JD, 1988, BRIT MED J, V297, P307, DOI 10.1136/bmj.297.6644.307; 1988, BRIT MED J, V297, P319	2	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1283	1284		10.1136/bmj.312.7041.1283	http://dx.doi.org/10.1136/bmj.312.7041.1283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634620	Green Published			2022-12-01	WOS:A1996UM40400026
J	Koh, JY; Suh, SW; Gwag, BJ; He, YY; Hsu, CY; Choi, DW				Koh, JY; Suh, SW; Gwag, BJ; He, YY; Hsu, CY; Choi, DW			The role of zinc in selective neuronal death after transient global cerebral ischemia	SCIENCE			English	Article							HISTOCHEMICALLY REACTIVE ZINC; FOREBRAIN ISCHEMIA; RAT HIPPOCAMPUS; ENDOGENOUS ZN-2+; CORTICAL-NEURONS; TEMPORAL PROFILE; CELL LOSS; BRAIN; NMDA; RELEASE	Zinc is present in presynaptic nerve terminals throughout the mammalian central nervous system and likely serves as an endogenous signaling substance. However, excessive exposure to extracellular zinc can damage central neurons. After transient forebrain ischemia in rats, chelatable zinc accumulated specifically in degenerating neurons in the hippocampal hilus and CA1, as well as in the cerebral cortex, thalamus, striatum, and amygdala. This accumulation preceded neurodegeneration, which could be prevented by the intraventricular injection of a zinc chelating agent. The toxic influx of zinc may be a key mechanism underlying selective neuronal death after transient global ischemic insults.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X; Hsu, Chung Y./0000-0002-5632-2733	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30337] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BLOMQVIST P, 1985, J CEREBR BLOOD F MET, V5, P420, DOI 10.1038/jcbfm.1985.57; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; CHARTON G, 1985, EXP BRAIN RES, V58, P202; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; CHOW HS, 1994, BRAIN RES, V639, P102, DOI 10.1016/0006-8993(94)91769-8; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CHUNG SH, 1984, PROC R SOC SER B-BIO, V221, P145, DOI 10.1098/rspb.1984.0028; CSERMELY P, 1988, J BIOL CHEM, V263, P6487; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DIEMER NH, 1992, ACTA NEUROL SCAND, V86, P45, DOI 10.1111/j.1600-0404.1992.tb08052.x; FREDENS K, 1973, HISTOCHEMISTRY, V37, P321, DOI 10.1007/BF00274968; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1982, BRAIN RES, V246, P338, DOI 10.1016/0006-8993(82)91188-X; FREDERICKSON CJ, 1992, J CHEM NEUROANAT, V5, P521, DOI 10.1016/0891-0618(92)90007-D; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1984, MERITS DEMERITS ZINC, VA, P289; GILL R, 1987, J NEUROSCI, V7, P3343; Gwag B. J., 1995, Society for Neuroscience Abstracts, V21, P1585; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; JOHANSEN FF, 1990, ACTA NEUROPATHOL, V81, P14, DOI 10.1007/BF00662632; JOHANSEN FF, 1987, ACTA NEUROPATHOL, V73, P110, DOI 10.1007/BF00693775; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KRESS Y, 1981, BRAIN RES, V220, P139, DOI 10.1016/0006-8993(81)90217-1; LEES GJ, 1989, ACTA NEUROPATHOL, V7, P519; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; NOHL H, 1991, FREE RADICAL BIO MED, V11, P581, DOI 10.1016/0891-5849(91)90139-T; Perrin D.D., 1979, STABILITY CONSTANTS; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rose K, 1993, IN VITRO BIOL METHOD, P46; ROSS T, 1995, BRAIN RES, V683, P117; SANDSTROM BE, 1994, FREE RADICAL BIO MED, V16, P177, DOI 10.1016/0891-5849(94)90141-4; SLOVITER RS, 1985, BRAIN RES, V330, P150, DOI 10.1016/0006-8993(85)90017-4; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WINEGAR BD, 1990, J PHYSIOL-LONDON, V425, P563, DOI 10.1113/jphysiol.1990.sp018118; YIM MB, 1994, J BIOL CHEM, V269, P1621	45	926	946	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1013	1016		10.1126/science.272.5264.1013	http://dx.doi.org/10.1126/science.272.5264.1013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638123				2022-12-01	WOS:A1996UL61900046
J	Zou, HY; Niswander, L				Zou, HY; Niswander, L			Requirement for BMP signaling in interdigital apoptosis and scale formation	SCIENCE			English	Article							INTERNUCLEOSOMAL DNA FRAGMENTATION; PROGRAMMED CELL-DEATH; MOUSE; MORPHOGENESIS; EXPRESSION	Interdigital cell death leads to regression of soft tissue between embryonic digits in many vertebrates. Although the signals that regulate interdigital apoptosis are not known, BMPs-signaling molecules of the transforming growth factor-beta superfamily-are expressed interdigitally. A dominant negative type I BMP receptor (dnBMPR-IB) was used here to block BMP signaling. Expression of dnBMPR in chicken embryonic hind limbs greatly reduced interdigital apoptosis and resulted in webbed feet. In addition, scales were transformed into feathers. The similarity of the webbing to webbed duck feet led to studies that indicate that BMPs are not expressed in the duck interdigit. These results indicate BMP signaling actively mediates cell death in the embryonic limb.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594; Zou, Hongyan/0000-0003-4216-5607				CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DHOUAILLY D, 1980, J EMBRYOL EXP MORPH, V58, P63; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FRANCISWEST PH, 1995, DEV DYNAM, V203, P187, DOI 10.1002/aja.1002030207; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; PAULOU MP, 1975, J EMBRYOL EXP MORPH, V34, P511; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROS MA, 1994, ANAT EMBRYOL, V190, P375; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Saunders J.W., 1967, MAJOR PROBLEMS DEV B, P289; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092-8674(93)90678-J; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WILKINSON DG, 1993, IN SITU HYBRIDIZATIO, P75; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZAKERI ZF, 1993, FASEB J, V7, P470, DOI 10.1096/fasebj.7.5.8462789; ZOU H, UNPUB	35	487	498	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					738	741		10.1126/science.272.5262.738	http://dx.doi.org/10.1126/science.272.5262.738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614838				2022-12-01	WOS:A1996UJ05100056
J	Florence, SL; Jain, N; Pospichal, MW; Beck, PD; Sly, DL; Kaas, JH				Florence, SL; Jain, N; Pospichal, MW; Beck, PD; Sly, DL; Kaas, JH			Central reorganization of sensory pathways following peripheral nerve regeneration in fetal monkeys	NATURE			English	Article							MACAQUE; CORTEX; MECHANISM	TRANSECTION Of a sensory nerve in adults results in profound abnormalities in sensory perception, even if the severed nerve is surgically repaired to facilitate accurate nerve regeneration, In marked contrast, fewer perceptual errors follow nerve transection and surgical repair in children(1-3), The basis for this superior recovery in children was unknown. Here rye show that there is little or no topographic order in the median nerve to the hand after median nerve section and surgical repair in immature macaque monkeys, Remarkably, however, in the same animals the representation of the reinnervated hand in primary somatosensory cortex (area 3b) is quite orderly, This indicates that there are mechanisms in the developing brain that can create cortical topography, despite disordered sensory inputs. Presumably the superior recovery of perceptual abilities after peripheral nerve transection in children depends on this restoration of somatotopy in the central sensory maps.	VANDERBILT UNIV,DEPT PATHOL,NASHVILLE,TN 37240	Vanderbilt University	Florence, SL (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240, USA.		Jain, Neeraj/B-2882-2010	Jain, Neeraj/0000-0002-3672-5850				BUCHTHAL F, 1979, J NEUROL NEUROSUR PS, V42, P436, DOI 10.1136/jnnp.42.5.436; BUNNELL S, 1956, SURG HAND; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CLINE HT, 1991, VISION VISUAL DYSFUN, V11; DARIANSMITH C, 1990, J COMP NEUROL, V299, P47, DOI 10.1002/cne.902990104; Dellon AL, 1981, EVALUATION SENSIBILI; FITZGERALD M, 1985, J COMP NEUROL, V240, P407, DOI 10.1002/cne.902400408; FLORENCE SL, 1994, CEREB CORTEX, V4, P391, DOI 10.1093/cercor/4.4.391; HALLIN RG, 1981, EXP NEUROL, V73, P90, DOI 10.1016/0014-4886(81)90047-9; HEBB DO, 1949, ORG BEHAVIOR; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; Jain N, 1995, DEV BRAIN RES, V90, P24, DOI 10.1016/0165-3806(96)83483-3; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KILLACKEY HP, 1995, TRENDS NEUROSCI, V18, P402, DOI 10.1016/0166-2236(95)93937-S; O'Leary D D, 1994, Curr Opin Neurobiol, V4, P535, DOI 10.1016/0959-4388(94)90054-X; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; SHATZ CJ, 1986, ANNU REV NEUROSCI, V9, P171, DOI 10.1146/annurev.ne.09.030186.001131; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Woolsey TA, 1990, DEV SENSORY SYSTEMS	19	75	77	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					69	71		10.1038/381069a0	http://dx.doi.org/10.1038/381069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609990				2022-12-01	WOS:A1996UJ05300057
J	Ewan, PW				Ewan, PW			Clinical study of peanut and nut allergy in 62 consecutive patients: New features and associations	BRITISH MEDICAL JOURNAL			English	Article							FOOD HYPERSENSITIVITY; NATURAL-HISTORY; ANAPHYLAXIS; PATTERNS; OIL	Objective-To investigate clinical features of acute allergic reactions to peanuts and other nuts. Design-Analysis of data from consecutive patients seen by one doctor over one year in an allergy clinic at a regional referral centre. Subjects-62 patients aged 11 months to 53 years seen between October 1993 and September 1994. Main outcome measures-Type and severity of allergic reactions, age at onset of symptoms, type of nut causing allergy, results of skin prick tests, and incidence of other allergic diseases and associated allergies. Results-Peanuts were the commonest cause of allergy (47) followed by Brazil nut (18), almond (14), and hazelnut (13). Onset of allergic symptoms occurred by the age of 2 years in 33/60 and by the age of 7 in 55/60. Peanuts accounted for all allergies in children sensitised in the first year of life and for 82% (27/33) of allergies in children sensitised by the third year of life. Multiple allergies appeared progressively with age. The commonest symptom was facial angioedema, and the major feature accounting for life threatening reactions was laryngeal oedema. Hypotension was uncommon. Of 55 patients, 53 were atopic-that is, had positive skin results of tests to common inhaled allergens-and all 53 had other allergic disorders (asthma, rhinitis, eczema) due to several inhaled allergens and other foods. Conclusions-Sensitisation, mainly to peanuts, is occurring in very young children, and multiple peanut/nut allergies appear progressively. Peanut and nut allergy is becoming common and can cause life threatening reactions. The main danger is laryngeal oedema. Young atopic children should avoid peanuts and nuts to prevent the development of this allergy.			Ewan, PW (corresponding author), UNIV CAMBRIDGE,SCH CLIN,ADDENBROOKES HOSP NHS TRUST,ALLERGY CLIN,CAMBRIDGE CB2 2QH,ENGLAND.							ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; ASSEM ESK, 1990, BRIT MED J, V300, P1377, DOI 10.1136/bmj.300.6736.1377; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BURKS AW, 1989, ALLERGY PROC, V10, P256; DONOVAN KL, 1990, BRIT MED J, V300, P1378, DOI 10.1136/bmj.300.6736.1378; FRIES JH, 1982, ANN ALLERGY, V48, P220; MONERETVAUTRIN DA, 1991, LANCET, V338, P1149, DOI 10.1016/0140-6736(91)92008-P; PLATTSMILLS TAE, 1982, CLIN ASPECTS IMMUNOL, P570; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SMITH T, 1990, BRIT MED J, V300, P1354, DOI 10.1136/bmj.300.6736.1354; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; WARREN JB, 1986, CLIN PHARMACOL THER, V40, P673, DOI 10.1038/clpt.1986.243; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	16	260	268	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1074	1078						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616415				2022-12-01	WOS:A1996UH81600026
J	Mellon, I; Rajpal, DK; Koi, M; Boland, CR; Champe, GN				Mellon, I; Rajpal, DK; Koi, M; Boland, CR; Champe, GN			Transcription-coupled repair deficiency and mutations in human mismatch repair genes	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI; COCKAYNE-SYNDROME; DNA DAMAGE; PREFERENTIAL REPAIR; SELECTIVE REPAIR; STRAND; YEAST; MECHANISM	Deficiencies in mismatch repair have been linked to a common cancer predisposition syndrome in humans, hereditary nonpolyposis colorectal cancer (HNPCC), and a subset of sporadic cancers. Here, several mismatch repair-deficient tumor cell lines and HNPCC-derived lymphoblastoid cell lines were found to be deficient in an additional DNA repair process termed transcription-coupled repair (TCR). The TCR defect was corrected in a mutant cell line whose mismatch repair deficiency had been corrected by chromosome transfer. Thus, the connection between excision repair and mismatch repair previously described in Escherichia coli extends to humans. These results imply that deficiencies in TCR and exposure to carcinogens present in the environment may contribute to the etiology of tumors associated with genetic defects in mismatch repair.	NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27706; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Diego	Mellon, I (corresponding author), UNIV KENTUCKY,MARKEY CANC CTR,TOXICOL PROGRAM,DEPT PATHOL,LEXINGTON,KY 40536, USA.		Koi, Minoru/C-3489-2012; Koi, Minoru/G-9197-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045535, R29GM045535] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45535-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BOYER JC, 1995, CANCER RES, V55, P6063; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAYNE LV, 1992, CANCER RES, V42, P1493; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MELLON I, UNPUB; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWEDER KS, IN PRESS GENETICS; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; UMAR A, 1994, J BIOL CHEM, V269, P14367; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; XIAO W, 1995, CARCINOGENESIS, V16, P1933, DOI 10.1093/carcin/16.8.1933	46	251	251	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					557	560		10.1126/science.272.5261.557	http://dx.doi.org/10.1126/science.272.5261.557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614807	Green Submitted			2022-12-01	WOS:A1996UG82600047
J	Szekeres, M; Nemeth, K; KonczKalman, Z; Mathur, J; Kauschmann, A; Altmann, T; Redei, GP; Nagy, F; Schell, J; Koncz, C				Szekeres, M; Nemeth, K; KonczKalman, Z; Mathur, J; Kauschmann, A; Altmann, T; Redei, GP; Nagy, F; Schell, J; Koncz, C			Brassinosteroids rescue the deficiency of CYP90, a cytochrome P450, controlling cell elongation and de-etiolation in arabidopsis	CELL			English	Article							GENES; SEQUENCES; THALIANA	The cpd mutation localized by T-DNA tagging on Arabidopsis chromosome 5-14.3 inhibits cell elongation controlled by the ecdysone-like brassinosteroid hormone brassinolide. The cpd mutant displays de-etiolation and derepression of light-induced genes in the dark, as well as dwarfism, male sterility, and activation of stress-regulated genes in the light. The CPD gene encodes a cytochrome P450 (CYP90) sharing homologous domains with steroid hydroxylases. The phenotype of the cpd mutant is restored to wild type both by feeding with C23-hydroxylated brassinolide precursors and by ectopic overexpression of the CPD cDNA. Brassinosteroids also compensate for different cell elongation defects of Arabidopsis dot, cop, fus, and axr2 mutants, indicating that these steroids play an essential role in the regulation of plant development.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST PLANT BIOL, H-6701 SZEGED, HUNGARY; MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY; MAX PLANCK INST MOLEK PFLANZENPHYSIOL, D-14476 GOLM, GERMANY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Max Planck Society; Max Planck Society			Nagy, Ferenc/D-3532-2015	Nagy, Ferenc/0000-0002-6157-9269; Koncz, Csaba/0000-0003-4422-9993; Szekeres, Miklos/0000-0002-6354-1790; Altmann, Thomas/0000-0002-3759-360X				ADAM G, 1986, PHYTOCHEMISTRY, V25, P1787, DOI 10.1016/S0031-9422(00)81151-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMER EE, 1994, PLANT MOL BIOL, V26, P1423; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; CHORY J, 1994, ARABIDOPSIS, P579; CRANE FL, 1993, OXIDOREDUCTION PLASM, V2; Davies P. J., 1987, PLANT HORMONES THEIR; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; ESTELLE M, 1994, ARABIDOPSIS, P555; FEDER N, 1968, AM J BOT, V55, P123, DOI 10.2307/2440500; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; FREY M, 1995, MOL GEN GENET, V246, P100, DOI 10.1007/BF00290138; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1543, DOI 10.1271/bbb.59.1543; GOTOH O, 1992, J BIOL CHEM, V267, P83; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KONCZ C, 1992, PLANT MOL BIOL, V20, P963, DOI 10.1007/BF00027166; KONCZ C, 1989, P NATL ACAD SCI USA, V86, P8467, DOI 10.1073/pnas.86.21.8467; Koncz C., 1992, METHODS ARABIDOPSIS; KONCZ C, 1994, PLANT MOL BIOL MAN B, V2, P1; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.pp.39.060188.000323; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sambrook J., 1989, MOL CLONING LAB MANU, V3; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WINKLER RG, 1995, PLANT CELL, V7, P1307, DOI 10.1105/tpc.7.8.1307	42	779	851	11	141	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					171	182		10.1016/S0092-8674(00)81094-6	http://dx.doi.org/10.1016/S0092-8674(00)81094-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612270	Bronze			2022-12-01	WOS:A1996UG25500006
J	Thea, DM; Porat, R; Nagimbi, K; Baangi, M; StLouis, ME; Kaplan, G; Dinarello, CA; Keusch, GT				Thea, DM; Porat, R; Nagimbi, K; Baangi, M; StLouis, ME; Kaplan, G; Dinarello, CA; Keusch, GT			Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN MONONUCLEAR-CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; FACTOR-ALPHA; SOLUBLE RECEPTORS; HIV-1-INFECTED PATIENTS; BLOOD MONOCYTES; TNF-ALPHA; IL-1	Objectives: To examine the relation of circulating cytokines and cytokine antagonists to the progression of human immunodeficiency virus type 1 (HIV-1) disease. Design: Cross-sectional analysis. Setting: An ambulatory acquired immunodeficiency syndrome (AIDS) research clinic in Kinshasa, Zaire. Patients: 48 women with AIDS, 51 women with HIV infection who were clinically asymptomatic, and 11 female controls who did not have HIV infection, all from Zaire. Measurements: Plasma levels of interleukin-1 beta, tumor necrosis factor-alpha (TNF-alpha), interleukin-6, interleukin-8, interferon-gamma, interleukin-1 beta receptor antagonist (interleukin-1Ra), and TNF soluble receptor p55 (TNFsRp55) were assayed by specific radioimmunoassays. Plasma levels of interferon-gamma were assayed by commercial enzyme-linked immunosorbent assay. The Wilcoxon rank-sum test was used to assess the significance of mean and median differences between groups. Results: Of the 48 patients with AIDS, circulating interleukin-1 beta was detected in 2, TNF-alpha in 4, interleukin-6 in 3, and interleukin-8 in 12. None of these factors were seen in any of the 11 controls. Median values of interleukin-lp (320 pg/ml), TNF-alpha (210 pg/mL), and interleukin-8 (750 pg/mL) were elevated in HIV-infected asymptomatic patients compared with patients with AIDS (2-, 2.6-, and 18.7-fold higher, respectively; P < 0.001). Interleukin-1Ra and TNFsRp55 levels were substantially higher than interleukin-1 beta and TNF-alpha levels in HIV-infected asymptomatic patients (73- and 14-fold, respectively) and were higher than those in patients with AIDS (17.8- and 1.74-fold, respectively). Conclusion: High circulating levels of the proinflammatory cytokines interleukin-1 beta and TNF-alpha, combined with an excess of their natural inhibitors interleukin-1Ra and TNFsRp55, were seen in clinically asymptomatic HIV-1-positive African women but not in African women with AIDS or in HIV-negative controls. Circulating cytokine antagonists may play a clinical role in modulating cytokine-associated symptoms in the early phases of HIV infection.	TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOGRAPH MED & INFECT DIS, BOSTON, MA 02111 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; MINIST HLTH, AIDS RES UNIT, KINSHASA, DEM REP CONGO	Tufts Medical Center; Centers for Disease Control & Prevention - USA; Rockefeller University				/0000-0001-5724-2965; Thea, Donald/0000-0002-6933-1030	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614, R01AI024755, P01AI026698, R37AI024755] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24755, AI-15614, P01-AI-26698] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; BARGETZI MJ, 1993, CANCER RES, V53, P4010; BREEN EC, 1990, J IMMUNOL, V144, P480; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; GIRARDIN E, 1992, IMMUNOLOGY, V76, P20; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GRANOWITZ EV, 1992, BLOOD, V79, P2356; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; KAUFFMAN CA, 1986, AM J CLIN NUTR, V44, P449, DOI 10.1093/ajcn/44.4.449; KIKUTA H, 1990, J INFECT DIS, V162, P35, DOI 10.1093/infdis/162.1.35; LISI PJ, 1987, LYMPHOKINE RES, V6, P229; LOWRY SF, 1993, ARCH SURG-CHICAGO, V128, P1235; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; MOLINA JM, 1990, J INFECT DIS, V161, P888, DOI 10.1093/infdis/161.5.888; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1994, P NATL ACAD SCI USA, V91, P108, DOI 10.1073/pnas.91.1.108; PORAT R, 1992, FASEB J, V6, P2482, DOI 10.1096/fasebj.6.7.1532945; POUTSIAKA DD, 1991, BLOOD, V78, P1275; RAMBALDI A, 1991, BLOOD, V78, P3248; RAUTONEN J, 1991, AIDS, V5, P1319, DOI 10.1097/00002030-199111000-00006; REKA S, 1994, LYMPHOKINE CYTOK RES, V13, P391; ROUXLOMBARD P, 1989, CLIN IMMUNOL IMMUNOP, V50, P374, DOI 10.1016/0090-1229(89)90144-X; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCHINDLER R, 1990, BLOOD, V75, P40; SCOTTALGARA D, 1991, AIDS RES HUM RETROV, V7, P381, DOI 10.1089/aid.1991.7.381; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAPIRO L, 1993, J INFECT DIS, V167, P1344, DOI 10.1093/infdis/167.6.1344; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; SUTTMANN U, 1994, CLIN SCI, V86, P461; VANDERMEER JWM, 1988, J LEUKOCYTE BIOL, V43, P216, DOI 10.1002/jlb.43.3.216; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VONSYDOW M, 1991, AIDS RES HUM RETROV, V7, P375, DOI 10.1089/aid.1991.7.375; 1989, MMWR MORB MORT WK S7, V38, P1	40	72	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					757	762		10.7326/0003-4819-124-8-199604150-00009	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633837				2022-12-01	WOS:A1996UD93600009
J	Weintraub, MS; Grosskopf, I; Rassin, T; Miller, H; Charach, G; Rotmensch, HH; Liron, M; Rubinstein, A; Iaina, A				Weintraub, MS; Grosskopf, I; Rassin, T; Miller, H; Charach, G; Rotmensch, HH; Liron, M; Rubinstein, A; Iaina, A			Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over three years	BRITISH MEDICAL JOURNAL			English	Article							POSTPRANDIAL LIPOPROTEIN METABOLISM; HIGH-DENSITY LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CHOLESTEROL-FED RABBITS; APOLIPOPROTEIN-E; PLASMA; RECEPTOR; CANINE; HYPERTRIGLYCERIDEMIA; ATHEROSCLEROSIS	Objective-To test the hypothesis that subjects who clear chylomicron remnants slowly from plasma may be at higher risk of coronary artery disease than indicated by their fasting plasma lipid concentrations. Design-Case control study over three years. Setting-An 800 bed general municipal hospital. Subjects-85 normolipidaemic patients with coronary artery disease selected prospectively and matched with 85 normolipidaemic subjects with normal coronary arteries on angiography. Interventions-All subjects were given a vitamin A fat loading test which specifically labels intestinal lipoproteins with retinyl palmitate. Main outcome measure-Postprandial lipoprotein metabolism. Results-The area below the chylomicron remnant retinyl palmitate curve was significantly increased in the coronary artery disease group as compared with the controls (mean 23.4 (SD 15.0) v 15.3 (8.9) mu mol/l.h; 95% confidence interval of difference 4.37 to 11.82). Conclusions-Normolipidaemic patients with coronary artery disease had significantly higher concentrations of chylomicron remnants in plasma than normolipidaemic subjects with normal coronary vessels. This may explain the mechanism underlying the susceptibility to atherosclerosis of coronary artery disease patients with normal fasting lipid values. As diet and drugs can ameliorate the accumulation of postprandial lipoproteins in plasma, the concentration of chylomicron remnants should be measured in patients at high risk of coronary artery disease.	TEL AVIV SOURASKY MED CTR,DEPT MED C,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,DEPT MED E,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,CORONARY CATHETERISAT UNIT,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,UNIT LIPID METAB,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,DEPT NEPHROL,TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Weintraub, MS (corresponding author), TEL AVIV SOURASKY MED CTR,DEPT INTERNAL MED C,TEL AVIV,ISRAEL.							BERR F, 1985, J LIPID RES, V26, P852; BERR F, 1984, J LIPID RES, V25, P805; BERR F, 1986, J LIPID RES, V27, P645; BLANCHET.EJ, 1971, J CELL BIOL, V51, P1, DOI 10.1083/jcb.51.1.1; CORTNER JA, 1987, J LIPID RES, V28, P195; DALE VP, 1962, PHYSIOL REV, V42, P674; DEMACKER PNM, 1991, EUR J CLIN INVEST, V21, P197, DOI 10.1111/j.1365-2362.1991.tb01809.x; EISENBERG S, 1984, J LIPID RES, V25, P1017; FLOREN CH, 1981, BIOCHIM BIOPHYS ACTA, V663, P336, DOI 10.1016/0005-2760(81)90219-8; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOODMAN DS, 1962, J CLIN INVEST, V41, P1886, DOI 10.1172/JCI104645; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; GRUNDY SM, 1976, METABOLISM, V25, P1225, DOI 10.1016/S0026-0495(76)80006-6; HAZARD WR, 1976, METABOLISM, V25, P777; HOLLANDER D, 1981, J LAB CLIN MED, V97, P449; HUI DY, 1986, J BIOL CHEM, V261, P4256; HUI DY, 1981, J BIOL CHEM, V256, P5646; KANE JP, 1983, ARTERIOSCLEROSIS, V3, P47, DOI 10.1161/01.ATV.3.1.47; KARPE F, 1995, ARTERIOSCL THROM VAS, V15, P199, DOI 10.1161/01.ATV.15.2.199; KORN ED, 1955, J BIOL CHEM, V215, P1; KRAINSKI SD, 1990, METABOLISM, V39, P357; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LIPPEL K, 1981, ARTERIOSCLEROSIS, V1, P406, DOI 10.1161/01.ATV.1.6.406; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; NESTEL PJ, 1982, NEW ENGL J MED, V307, P327; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; SCHOEFL GI, 1968, PROC R SOC SER B-BIO, V169, P153, DOI 10.1098/rspb.1968.0003; STENDER S, 1982, ARTERIOSCLEROSIS, V2, P493, DOI 10.1161/01.ATV.2.6.493; STENDER S, 1981, ATHEROSCLEROSIS, V39, P97; THOMPSON KH, 1983, J NUTR, V113, P2002, DOI 10.1093/jn/113.10.2002; WEINTRAUB M, 1992, J GERONTOL, V47, pB209, DOI 10.1093/geronj/47.6.B209; WEINTRAUB MS, 1989, CIRCULATION, V79, P1007, DOI 10.1161/01.CIR.79.5.1007; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; WILSON DE, 1985, METABOLISM, V34, P551, DOI 10.1016/0026-0495(85)90193-3; WILSON DE, 1983, METABOLISM, V32, P514, DOI 10.1016/0026-0495(83)90016-1; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1984, JAMA-J AM MED ASSOC, V251, P365	44	161	161	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					935	939						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616304	Green Published			2022-12-01	WOS:A1996UF65900016
J	Brenman, JE; Chao, DS; Gee, SH; McGee, AW; Craven, SE; Santillano, DR; Wu, ZQ; Huang, F; Xia, HH; Peters, MF; Froehner, SC; Bredt, DS				Brenman, JE; Chao, DS; Gee, SH; McGee, AW; Craven, SE; Santillano, DR; Wu, ZQ; Huang, F; Xia, HH; Peters, MF; Froehner, SC; Bredt, DS			Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha 1-syntrophin mediated by PDZ domains	CELL			English	Article							L-ARGININE; DYSTROPHIN; TISSUE; SYSTEM; BRAIN; CELLS	Neuronal nitric oxide synthase (nNOS) is concentrated at synaptic junctions in brain and motor endplates in skeletal muscle. Here, we show that the N-terminus of nNOS, which contains a PDZ protein motif, interacts with similar motifs in postsynaptic density-95 protein (PSD-95) and a related novel protein, PSD-93. nNOS and PSD-95 are coexpressed in numerous neuronal populations, and a PSD-95/nNOS complex occurs in cerebellum. PDZ domain interactions also mediate binding of nNOS to skeletal muscle syntrophin, a dystrophin-associated protein. nNOS isoforms lacking a PDZ domain, identified in nNOS(Delta/Delta) mutant mice, do not associate with PSD-95 in brain or with skeletal muscle sarcolemma. Interaction of PDZ-containing domains therefore mediates synaptic association of nNOS and may play a more general role in formation of macromolecular signaling complexes.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill	Brenman, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.							ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HALL AV, 1994, J BIOL CHEM, V269, P33082; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KIM E, 1995, IN PRESS NATURE; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; YANG B, 1994, J BIOL CHEM, V269, P6040	37	1391	1453	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					757	767		10.1016/S0092-8674(00)81053-3	http://dx.doi.org/10.1016/S0092-8674(00)81053-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625413	Bronze			2022-12-01	WOS:A1996TZ99000013
J	Ehlers, MD; Zhang, S; Bernhardt, JP; Huganir, RL				Ehlers, MD; Zhang, S; Bernhardt, JP; Huganir, RL			Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit	CELL			English	Article							RAT HIPPOCAMPAL-NEURONS; SPINAL-CORD NEURONS; PROTEIN-KINASE-C; GLUTAMATE RECEPTORS; CALCIUM; CHANNELS; RESPONSES; CLONING; ACID	NMDA (N-methyl-D-aspartate) receptors are excitatory neurotransmitter receptors in the brain critical for synaptic plasticity and neuronal development. These receptors are Ca2+-permeable glutamate-gated ion channels whose physiological properties are regulated by intracellular Ca2+. We report here the purification of a 20 kDa protein identified as calmodulin that interacts with the NR1 subunit of the NMDA receptor. Calmodulin binding to the NR1 subunit is Ca2+ dependent and occurs with homomeric NR1 complexes, heteromeric NR1/NR2 subunit complexes, and NMDA receptors from brain. Furthermore, calmodulin binding to NR1 causes a 4-fold reduction in NMDA channel open probability. These results demonstrate that NMDA receptor function can be regulated by direct binding of calmodulin to the NR1 subunit, and suggest a possible mechanism for activity-dependent feedback inhibition and Ca2+-dependent inactivation of NMDA receptors.			Ehlers, MD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BAER MF, 1995, NEURON, V15, P1; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KATSUWADA T, 1992, NATURE, V358, P36; KINCAID RL, 1982, J BIOL CHEM, V267, P10638; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEDINA I, 1995, J PHYSIOL-LONDON, V482, P567, DOI 10.1113/jphysiol.1995.sp020540; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; ZORUMSKI CF, 1989, CELL MOL NEUROBIOL, V9, P95, DOI 10.1007/BF00711446	41	462	479	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					745	755		10.1016/S0092-8674(00)81052-1	http://dx.doi.org/10.1016/S0092-8674(00)81052-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625412	hybrid			2022-12-01	WOS:A1996TZ99000012
J	Symons, M; Derry, JMJ; Karlak, B; Jiang, S; Lemahieu, V; McCormick, F; Francke, U; Abo, A				Symons, M; Derry, JMJ; Karlak, B; Jiang, S; Lemahieu, V; McCormick, F; Francke, U; Abo, A			Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; T-CELLS; GROWTH; LYMPHOCYTES; GENE; NCK; SH2	The Rho family of GTPases control diverse biological processes, including cell morphology and mitogenesis. We have identified WASP, the protein that is defective in Wiskott-Aldrich syndrome (WAS), as a novel effector for CDC42Hs, but not for the other Rho family members, Pac and Rho. This interaction is dependent on the presence of the G protein-binding domain. Cellular expression of epitope-tagged WASP produces clusters of WASP that are highly enriched in polymerized actin. This clustering is not observed with a C-terminally deleted WASP and is inhibited by coexpression with dominant negative CDC42Hs-N17, but not with dominant negative forms of Rac or Rho. Thus, WASP provides a novel link between CDC42Hs and the actin cytoskeleton, which suggests a molecular mechanism for many of the cellular abnormalities in WAS. The WASP sequence contains two novel domains that are homologous to other proteins involved in actin organization.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University	Symons, M (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.							Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KENNEY D, 1986, BLOOD, V68, P1329; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MULLEN CA, 1993, BLOOD, V82, P2961; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCHS HD, 1980, BLOOD, V55, P243; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STEPHEN F, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1006/JMBI.1990.9999; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WENGLER GS, 1995, BLOOD, V86, P3684; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	55	738	741	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					723	734		10.1016/S0092-8674(00)81050-8	http://dx.doi.org/10.1016/S0092-8674(00)81050-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625410	Bronze			2022-12-01	WOS:A1996TZ99000010
J	Wainberg, MA; Drosopoulos, WC; Salomon, H; Hsu, M; Borkow, G; Parniak, MA; Gu, ZX; Song, QB; Manne, J; Islam, S; Castriota, G; Prasad, VR				Wainberg, MA; Drosopoulos, WC; Salomon, H; Hsu, M; Borkow, G; Parniak, MA; Gu, ZX; Song, QB; Manne, J; Islam, S; Castriota, G; Prasad, VR			Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE INSERTION FIDELITY; HIGH-LEVEL RESISTANCE; INVITRO SELECTION; TYPE-1 RESISTANT; DNA-REPLICATION; INHIBITORS; EXTENSION; MUTATION; RNA	Monotherapy with (-)2',3'-dideoxy-3'-thiacytidine (3TC) leads to the appearance of a drug-resistant variant of human immunodeficiency virus-type 1 (HIV-1) with the methionine-184 --> valine (M184V) substitution in the reverse transcriptase (RT). Despite resulting drug resistance, treatment for more than 48 weeks is associated with a lower plasma viral burden than that at baseline. Studies to investigate this apparent contradiction revealed the following. (i) Titers of HIV-neutralizing antibodies remained stable in 3TC-treated individuals in contrast to rapid declines in those treated with azidothymidine (AZT). (ii) Unlike wild-type HIV, growth of M184V HIV in cell culture in the presence of d4T, AZT, Nevirapine, Delavirdine, or Saquinavir did not select for variants displaying drug resistance. (iii) There was an increase in fidelity of nucleotide insertion by the M184V mutant compared with wild-type enzyme.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; MCGILL UNIV,JEWISH GEN HOSP,MCGILL AIDS CTR,MONTREAL,PQ H3T 1E2,CANADA	Yeshiva University; Albert Einstein College of Medicine; McGill University			Borkow, Gadi/W-4294-2019; Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030861, P30AI027741, U01AI024845] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI-27741, R01 AI0-30861, UO1AI-24845] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOULERICE F, 1990, J VIROL, V64, P1745, DOI 10.1128/JVI.64.4.1745-1755.1990; Cleland W W, 1979, Methods Enzymol, V63, P103; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DROSOPOULOS W, UNPUB; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUBNER A, 1992, J MOL BIOL, V223, P595, DOI 10.1016/0022-2836(92)90975-P; INGRAND D, 1995, AIDS, V9, P1323, DOI 10.1097/00002030-199512000-00004; KAVLICK MF, 1995, ANTIVIR RES, V28, P133, DOI 10.1016/0166-3542(95)00044-M; KEY Y, 1994, J BIOL CHEM, V269, P15331; LARDER BA, 1991, J VIROL, V65, P5232, DOI 10.1128/JVI.65.10.5232-5236.1991; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PILLAY D, 1995, REV MED VIROL, V5, P23, DOI 10.1002/rmv.1980050104; PLUDA JM, 1995, J INFECT DIS, V171, P1438, DOI 10.1093/infdis/171.6.1438; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PRESTON BD, 1992, PHARM TECHNOL, V16, P34; PRINCE AM, 1987, J INFECT DIS, V156, P268, DOI 10.1093/infdis/156.2.268; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SALOMON H, 1995, ANTIVIR CHEM CHEMOTH, V6, P222, DOI 10.1177/095632029500600404; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TREMBLAY M, 1990, J INFECT DIS, V162, P735, DOI 10.1093/infdis/162.3.735; WAINBERG MA, 1995, AIDS, V9, P351, DOI 10.1097/00002030-199509040-00006; WAINBERG MA, 1995, AIDS RES HUM RETROV, V11, pS169; WAINBERG MA, 1994, AIDS, V8, P169; WAINBERG MA, 1991, AIDS, V5, P1061; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YU H, 1992, J BIOL CHEM, V267, P10888; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	54	281	286	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1282	1285		10.1126/science.271.5253.1282	http://dx.doi.org/10.1126/science.271.5253.1282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638110				2022-12-01	WOS:A1996TX69500037
J	Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP				Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP			Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice	CELL			English	Article							OBESE	OB-R is a high affinity receptor for leptin, an important circulating signal for the regulation of body weight. We identified an alternatively spliced transcript that encodes a form of mouse OB-R with a long intracellular domain, db/db mice also produce this alternatively spliced transcript, but with a 106 nt insertion that prematurely terminates the intracellular domain. We further identified a G-->T point mutation in the genomic OB-R sequence in db/db mice. This mutation generates a donor splice site that converts the 106 nt region to a novel exon retained in the OB-R transcript. We predict that the long intracellular domain form of OB-R is crucial for initiating intracellular signal transduction, and as a corollary, the inability to produce this form of OB-R leads to the severe obese phenotype found in db/db mice.			Chen, H (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEM DR,CAMBRIDGE,MA 02139, USA.							BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VALCARCEL J, 1995, PREMRNA PROCESSING, P97; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	18	1820	1921	1	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					491	495		10.1016/S0092-8674(00)81294-5	http://dx.doi.org/10.1016/S0092-8674(00)81294-5			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608603	Bronze			2022-12-01	WOS:A1996TV70800018
J	Sze, G				Sze, G			Contrast enhancement for cranial CT scanning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BRAIN METASTASES; MR				Sze, G (corresponding author), YALE UNIV,SCH MED,NEURORADIOL SECT,NEW HAVEN,CT 06520, USA.							JINKINS JR, 1986, NEUROSURGERY, V18, P664, DOI 10.1227/00006123-198605000-00027; LATCHAW RE, 1978, RADIOLOGY, V126, P681, DOI 10.1148/126.3.681; LEMAY M, 1986, AM J ROENTGENOL, V147, P963, DOI 10.2214/ajr.147.5.963; MITCHELL WG, 1988, PEDIATRICS, V82, P76; PRICE HI, 1982, RADIOGRAPHICS, V2, P7; SEARS ES, 1982, NEUROLOGY, V32, P815, DOI 10.1212/WNL.32.8.815; SZE G, 1989, AM J NEURORADIOL, V10, P965; SZE G, 1990, AM J NEURORADIOL, V11, P785; SZE G, 1988, RADIOLOGY, V168, P187, DOI 10.1148/radiology.168.1.3380956; SZE G, 1992, CRANIAL MRI CT, P539; SZE G, 1989, AJR AM J ROENTGENOL, V154, P1039	11	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1875	1876						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR975	8648856				2022-12-01	WOS:A1996UR97500014
J	Prakash, N; CohenCory, S; Frostig, RD				Prakash, N; CohenCory, S; Frostig, RD			Rapid and opposite effects of BDNF and NGF on the functional organization of the adult cortex in vivo	NATURE			English	Article							INTRINSIC SIGNALS; MESSENGER-RNA; VISUAL-CORTEX; ARCHITECTURE	THE adult cortex is thought to undergo plastic changes that are closely dependent on neuronal activity (reviewed in ref. 1), although it is not yet known what molecules are involved. Neurotrophins and their receptors have been implicated in several aspects of developmental plasticity(2-4), and their expression in the adult cortex suggests additional roles in adult plasticity(5-9). To examine these potential roles in viva, we used intrinsic-signal optical imaging to quantify the effects of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) on the functional representation of a stimulated whisker in the 'barrel' subdivision of the rat somatosensory cortex. Topical application of BDNF resulted in a rapid and long-lasting decrease in the size of a whisker representation, and a decrease in the amplitude of the activity-dependent intrinsic signal, In contrast, NGF application resulted in a rapid but transient increase in the size of a representation, and an increase in the amplitude of the activity-dependent intrinsic signal. These results demonstrate that neurotrophins can rapidly modulate stimulus-dependent activity in adult cortex, and suggest a role for neurotrophins in regulating adult cortical plasticity.	UNIV CALIF IRVINE, DEPT PSYCHOBIOL, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, CTR LEARNING & MEMORY, IRVINE, CA 92717 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; California Institute of Technology				Prakash, Neal/0000-0003-0288-6573				ALTAR CA, 1994, EXP NEUROL, V130, P31, DOI 10.1006/exnr.1994.1182; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; Cellerino A., 1995, Society for Neuroscience Abstracts, V21, P2010; CHEN C, IN PRESS J NEUROSCIM; CUELLO AC, 1992, MOL NEUROBIOL, V6, P451, DOI 10.1007/BF02757946; Frostig R. D., 1994, Society for Neuroscience Abstracts, V20, P1384; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; Kaas Jon H., 1995, P51; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MALONEK D, 1990, Society for Neuroscience Abstracts, V16, P292; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; Masino SA, 1996, P NATL ACAD SCI USA, V93, P4942, DOI 10.1073/pnas.93.10.4942; MASINO SA, 1993, P NATL ACAD SCI USA, V90, P9998, DOI 10.1073/pnas.90.21.9998; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; NAWA H, 1994, J NEUROSCI, V14, P3751; Pitts AF, 1995, SOMATOSENS MOT RES, V12, P329, DOI 10.3109/08990229509093666; RACAMORA N, 1993, SOC NEUR ABSTR, V19, P259; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; ZHOU XF, 1993, BRAIN RES, V622, P63, DOI 10.1016/0006-8993(93)90802-T	30	96	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1996	381	6584					702	706		10.1038/381702a0	http://dx.doi.org/10.1038/381702a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649516				2022-12-01	WOS:A1996UR97900054
J	Sadowski, LS; Munoz, SR				Sadowski, LS; Munoz, SR			Nonfatal and fatal firearm injuries in a rural county	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To measure the incidence of fatal and nonfatal firearm injuries in a rural setting. Design.-A prospective, population-based surveillance system using information from medical and legal records, newspapers, and members of the community. Setting.-A rural county in North Carolina. Main Outcome Measures.-Incidence rates and case-fatality ratios (fatal:nonfatal). Results.-Of the 114 firearm injuries detected by the surveillance system from January 1, 1990, through December 31, 1991, nearly two thirds were nonfatal, The overall age-adjusted annual incidence of firearm injuries was 66.4 per 100 000 population, and the incidence of nonfatal firearm injuries was 41.2 per 100 000 population, Subgroup annual incidence rates were greatest for African Americans. The overall case-fatality ratio was 1:1.8 (fatal:nonfatal). Conclusions.-Incidence rates and case-fatality ratios for firearm injury in this rural setting were greater than expected, based on national estimates, perhaps because of greater proportions of rifle injuries and self-inflicted injuries.	UNIV LA FRONTERA, SCH MED, CLIN EPIDEMIOL UNIT, TEMUCO, CHILE	Universidad de La Frontera	Sadowski, LS (corresponding author), UNIV N CAROLINA, DEPT MED, CB 7110, CHAPEL HILL, NC 27599 USA.				PHS HHS [R49/CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER GR, 1985, AM J PUBLIC HEALTH, V75, P165, DOI 10.2105/AJPH.75.2.165; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; *STAT GRAPH DAT MA, 1992, STATA REF MAN REL 3, V3, P66; *US BUR CENS, 1987, 1987 CURR POP SURV; *US BUR CENS, 1992, 1990 COUNT POP AG SE; *US CTR HLTH STAT, 1988, 1988 US DET MORT DAT; *US NAT CTR HLTH S, 1976, VIT HLTH STAT, V10; WINTEMUTE GJ, 1987, J TRAUMA, V27, P530; ZWERLING C, 1993, AM J PREV MED, V9, P21, DOI 10.1016/S0749-3797(18)30674-3	13	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1762	1764		10.1001/jama.275.22.1762	http://dx.doi.org/10.1001/jama.275.22.1762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637176				2022-12-01	WOS:A1996UP30700032
J	Shigemoto, R; Kulik, A; Roberts, JDB; Ohishi, H; Nusser, Z; Kaneko, T; Somogyi, P				Shigemoto, R; Kulik, A; Roberts, JDB; Ohishi, H; Nusser, Z; Kaneko, T; Somogyi, P			Target-cell-specific concentration of a metabotropic glutamate receptor In the presynaptic active zone	NATURE			English	Article							SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CALCIUM CURRENTS; MODULATION	THE probability of synaptic neurotransmitter release from nerve terminals is regulated by presynaptic receptors responding to transmitters released from the same nerve terminal or from terminals of other neurons. The release of glutamate, the major excitatory neurotransmitter, is suppressed by presynaptic autoreceptors(1-3). Here we show that a metabotropic glutamate receptor (mGluR7) in the rat hippocampus is restricted to the presynaptic grid, the site of synaptic vesicle fusion. Pyramidal cell terminals presynaptic to mGluR1 alpha-expressing interneurons have at least a ten-fold higher level of presynaptic mGluR7 than terminals making synapses with pyramidal cells and other types of interneuron. Distinct levels of mGluR7 are found at different synapses made by individual pyramidal axons or even single boutons. These results raise the possibility that presynaptic neurons could regulate the probability of transmitter release at individual synapses according to the postsynaptic target.	UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,DEPT PHARMACOL,OXFORD OX1 3TH,ENGLAND; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,SAKYO KU,KYOTO 606,JAPAN	University of Oxford; Kyoto University			Shigemoto, Ryuichi/E-3628-2013; Nusser, Zoltan/K-8587-2014	Shigemoto, Ryuichi/0000-0001-8761-9444; Nusser, Zoltan/0000-0001-7004-4111				BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; CHARPAK S, 1995, EUR J NEUROSCI, V7, P1548, DOI 10.1111/j.1460-9568.1995.tb01150.x; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GEREAU RW, 1995, J NEUROSCI, V15, P6879; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; KOERBER HR, 1991, J NEUROPHYSIOL, V65, P590, DOI 10.1152/jn.1991.65.3.590; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MACCAFERRI G, 1995, J NEURON, V15, P137; Manzoni O, 1995, EUR J NEUROSCI, V7, P2518, DOI 10.1111/j.1460-9568.1995.tb01051.x; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Ohishi H, 1995, NEUROSCI LETT, V202, P85, DOI 10.1016/0304-3940(95)12207-9; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SAHARA Y, 1993, J NEUROSCI, V13, P3041; Shigemoto R., 1995, Society for Neuroscience Abstracts, V21, P846; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; TAREILUS E, 1995, NEUROCHEM INT, V26, P539, DOI 10.1016/0197-0186(94)00149-O; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; VIGNES M, 1995, NEUROPHARMACOLOGY, V34, P973, DOI 10.1016/0028-3908(95)00093-L	31	337	359	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					523	525		10.1038/381523a0	http://dx.doi.org/10.1038/381523a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632825				2022-12-01	WOS:A1996UP43500060
J	Yang, YS; Kochoyan, M; Burgstaller, P; Westhof, E; Famulok, M				Yang, YS; Kochoyan, M; Burgstaller, P; Westhof, E; Famulok, M			Structural basis of ligand discrimination by two related RNA aptamers resolved by NMR spectroscopy	SCIENCE			English	Article							CONFORMATION; HAIRPIN; LOOP; INVITRO; COMPLEX; DNA	In a previous study, an RNA aptamer for the specific recognition of arginine was evolved from a parent sequence that bound citrulline specifically. The two RNAs differ al only 3 positions out of 44. The solution structures df the two aptamers complexed to their cognate amino acids have now been determined by two-dimensional nuclear magnetic resonance spectroscopy, Both aptamers contain two asymmetrical internal loops that are not well ordered in the free RNA but that fold into a compact structure upon ligand binding. Those nucleotides common to both RNAs include a conserved cluster of purine residues, three of which form an uneven plane containing a G:G pair, and two other residues nearly perpendicular to that surface, Two of the three variant nucleotides are stacked on the cluster of purines and form a triple contact to the amino acid side chain, whereas the edge of the third variant nucleotide is capping the binding pocket.	CBS FAC PHARM,F-34060 MONTPELLIER,FRANCE; ECOLE POLYTECH,CNRS,UNITE RECH ASSOCIEE D1254,GRP BIOPHYS,F-91128 PALAISEAU,FRANCE; UNIV MUNICH,GENZENTRUM,INST BIOCHEM,D-81675 MUNICH,GERMANY; INST BIOL MOLEC & CELLULAIRE,CNRS,UNITE PROPRE RECH 9002,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; University of Munich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; BLINGTON AD, 1994, CURR BIOL, V4, P427; BRUNGER AT, 1992, X PLOR USER MANUAL V; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burgstaller P, 1995, NUCLEIC ACIDS RES, V23, P4769, DOI 10.1093/nar/23.23.4769; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; ELINGTON AD, 1990, NATURE, V346, P818; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HIRAO I, 1995, CURR BIOL, V5, P1017, DOI 10.1016/S0960-9822(95)00205-3; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KELLOGG G, 1993, FEBS LETT, V327, P261; KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; NAGAL K, 1994, RNA PROTEIN INTERACT; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4508; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PRETTRE CG, 1976, BIOPOLYMERS, V15, P2277; PUGLISI EV, 1994, P NATL ACAD SCI USA, V91, P11467, DOI 10.1073/pnas.91.24.11467; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wuthrich K., 1986, NMR PROTEINS NUCL AC; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; Yang Y., UNPUB; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6	45	162	168	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1343	1347		10.1126/science.272.5266.1343	http://dx.doi.org/10.1126/science.272.5266.1343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650546				2022-12-01	WOS:A1996UN47200048
J	OKeefe, J; Burgess, N				OKeefe, J; Burgess, N			Geometric determinants of the place fields of hippocampal neurons	NATURE			English	Article							FREELY-MOVING RATS; UNIT-ACTIVITY; CELLS; DIRECTION; POSITION; LESIONS; MEMORY	THE human hippocampus has been implicated in memory(1), in particular episodic(2,3) or declarative(4) memory. In rats, hippocampal lesions cause selective spatial deficits(2,5-7), and hippocampal complex spike cells (place cells) exhibit spatially localized firing(8,9), suggesting a role in spatial memory(2), although broader functions have also been suggested(10,11). Here we report the identification of the environmental features controlling the location and shape of the receptive fields (place fields) of the place cells. This was done by recording from the same cell in four rectangular boxes that differed solely in the length of one or both sides. Most of our results are explained by a model in which the place field is formed by the summation of gaussian tuning curves, each oriented perpendicular to a box wall and peaked at a fixed distance from it.			OKeefe, J (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.		Burgess, Neil/B-2420-2009	Burgess, Neil/0000-0003-0646-6584				[Anonymous], 1983, CANADIAN PSYCHOL; BURGESS N, 1994, NEURAL NETWORKS, V7, P1065, DOI 10.1016/S0893-6080(05)80159-5; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; EICHENBAUM H, 1992, J COGNITIVE NEUROSCI, V4, P217, DOI 10.1162/jocn.1992.4.3.217; Gothard KM, 1996, J NEUROSCI, V16, P823; GOTHARD KM, 1995, SOC NEUR ABSTR, V21, P911; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MCNAUGHTON BL, 1994, COGNITIVE NEUROSCIEN, P585; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1989, J NEUROSCI, V9, P4101; MULLER RU, 1994, J NEUROSCI, V14, P7235; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1975, EXP NEUROL, V48, P152, DOI 10.1016/0014-4886(75)90230-7; OKEEFE J, 1979, PROG NEUROBIOL, V13, P419, DOI 10.1016/0301-0082(79)90005-4; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; REDISH AD, IN PRESS SYMBOLIC VI; Rudy JW, 1995, HIPPOCAMPUS, V5, P375, DOI 10.1002/hipo.450050502; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHARP PE, 1991, PSYCHOBIOLOGY, V19, P103; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TAUBE JS, 1990, J NEUROSCI, V10, P420; ZIPSER D, 1985, BEHAV NEUROSCI, V99, P1006, DOI 10.1037/0735-7044.99.5.1006	30	730	738	4	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					425	428		10.1038/381425a0	http://dx.doi.org/10.1038/381425a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632799				2022-12-01	WOS:A1996UN47900052
J	Ragent, B; Colburn, DS; Avrin, P; Rages, KA				Ragent, B; Colburn, DS; Avrin, P; Rages, KA			Results of the Galileo probe nephelometer experiment	SCIENCE			English	Article								The nephelometer experiment carried on the Galileo probe was designed to measure the jovian cloud structure and its microphysical characteristics from entry down to atmospheric pressure levels greater than 10 bars. Before this mission there was no direct evidence for the existence of the clouds below the uppermost cloud layer, and only theoretical models derived from remote sensing observations were available for describing such clouds. Only one significant cloud structure with a base at about 1.55 bars was found along the probe descent trajectory below an ambient pressure of about 0.4 bar, although many indications of small densities of particle concentrations were noted during much of the descent.	AEROSP CORP,COLORADO SPRINGS,CO 80912; SPACE PHYS RES INST,SUNNYVALE,CA 94087	Aerospace Corporation - USA	Ragent, B (corresponding author), SAN JOSE STATE UNIV FDN,SAN JOSE,CA 95172, USA.							ATREYA SK, 1985, PLANETARY METEOROLOG, P17; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; GIVENS JJ, 1983, P AIAA 21 AER SCI M, P1; JOHNSON TV, 1992, SPACE SCI REV, V60, P3, DOI 10.1007/BF00216848; MAROV MY, 1980, ICARUS, V44, P608, DOI 10.1016/0019-1035(80)90131-1; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; ONEILL WJ, 1983, P AIAA 21 AER SCI M, P1; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; RAGENT B, 1992, SPACE SCI REV, V60, P179, DOI 10.1007/BF00216854; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; WEIDENSCHILLING SJ, 1973, ICARUS, V61, P311	12	35	35	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					854	856		10.1126/science.272.5263.854	http://dx.doi.org/10.1126/science.272.5263.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629019				2022-12-01	WOS:A1996UK75700052
J	Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ				Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ			Manganese toxicity in children receiving long-term parenteral nutrition	LANCET			English	Article							CHOLESTASIS	Background In patients receiving long-term parenteral nutrition (PN), cholestatic disease acid nervous system disorders have been associated with high blood concentrations of manganese. In such patients, the normal homoeostatic mechanisms of the liver and gut ate bypassed and the requirement for this trace element is not known; nor has it been certain whether hypermanganesaemia causes the cholestasis or vice versa. We explored the direction of effect by serial tests of liver function after withdrawal of manganese supplements from children receiving long-term PN. We also examined the relation between blood manganese concentrations and brain lesions, as indicated by clinical examination and magnetic resonance imaging (MRI). Methods From a combined group of 57 children receiving PN we identified 11 with the combination of hypermanganesaemia and cholestasis; one also had a movement disorder. Manganese supplements were reduced in the first three and withdrawn in the remainder. MRI was done in two of these children. We also looked at manganese concentrations and MRI scans in six children who had received PN for more than 2 years without developing liver disease. Findings In the hypermanganesaemia/cholestasis group, four of the 11 patients died. In the seven survivors baseline whole-blood manganese was 615-1840 nmol/L, and after 4 months it had declined by a median of 643 nmol/L (p<0 . 01). Over the same interval total bilirubin declined by a median of 70 mu mol/L (p<0 . 05). Two of these children had movement disorders, one of whom survived to have an MRI scan; this showed, with T1 weighted images, bilateral symmetrically increased signal intensity in the globus pallidus and subthalamic nuclei. Such changes were also seen in five other children-one from the hypermanganesaemia/cholestasis group and four of six in the long-term PN group without liver disease (in all of whom blood manganese was above normal). Interpretation The cholestasis complicating PN is multifactorial, but these results add to the evidence that manganese contributes. In view of the additional hazard of basal ganglia damage from high manganese levels in children receiving long-term PN, we recommend a low dose regimen of not more than 0 . 018 mu mol/kg per 24 h together with regular examination of the nervous system.	GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT GASTROENTEROL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT CHEM PATHOL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT NEURORADIOL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Lalpour, Abdollah/0000-0002-7134-9395				AYOTTE P, 1985, BIOCHEM PHARMACOL, V34, P3857, DOI 10.1016/0006-2952(85)90435-6; BALL PA, 1994, PAEDIAT PARENTERAL N; DEVENYI AG, 1994, GASTROENTEROLOGY, V106, P1068, DOI 10.1016/0016-5085(94)90769-2; EJAMA A, 1992, LANCET, V339, P426; GRAEF JW, 1982, LEAD ABSORPTION CHIL, P153; HAMBIDGE KM, 1989, JPEN-PARENTER ENTER, V13, P168, DOI 10.1177/0148607189013002168; HUANG CC, 1989, ARCH NEUROL-CHICAGO, V46, P1104, DOI 10.1001/archneur.1989.00520460090018; KRIEGER D, 1995, LANCET, V346, P270, DOI 10.1016/S0140-6736(95)92164-8; LUSTIG S, 1982, ARCH INTERN MED, V142, P405, DOI 10.1001/archinte.142.2.405; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MIROWITZ SA, 1991, RADIOLOGY, V181, P117, DOI 10.1148/radiology.181.1.1909445; NELSON K, 1993, BRIT J IND MED, V50, P510; PLAA GL, 1982, BIOCHEM PHARMACOL, V31, P3698, DOI 10.1016/0006-2952(82)90602-5; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; REYNOLDS AP, 1994, ARCH DIS CHILD, V71, P527, DOI 10.1136/adc.71.6.527; SINGH J, 1974, ENVIRON PHYSIOL BIOC, V4, P16; UNDERWOOD EJ, 1977, TRACE ELEMENTS HUMAN, P170; 1988, AM J CLIN NUTR, V48, P1324; 1979, JAMA-J AM MED ASSOC, V241, P2051	19	227	230	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1218	1221		10.1016/S0140-6736(96)90735-7	http://dx.doi.org/10.1016/S0140-6736(96)90735-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622451				2022-12-01	WOS:A1996UJ59700010
J	Hall, DT; Feldman, PD; Holberg, JB; McGrath, MA				Hall, DT; Feldman, PD; Holberg, JB; McGrath, MA			Fluorescent hydroxyl emissions from Saturn's ring atmosphere	SCIENCE			English	Article							IRRADIANCE COMPARISON EXPERIMENT-1; MICROMETEORITE EROSION; PLASMA TRANSPORT; MAGNETOSPHERE; TORUS; MODEL; HYDROGEN; ORIGIN; CLOUD; WATER	Just before Earth passed through Saturn's ring plane on 10 August 1995, the Hubble Space Telescope Faint Object Spectrograph detected ultraviolet fluorescent emissions from a tenuous atmosphere of OH molecules enveloping the rings. Brightnesses decrease with increasing distance above the rings, implying a scale height of about 0.45 Saturn radii (R(S)). A spatial scan 0.28R(S) above the A and B rings indicates OH column densities of about 10(13) cm(-2) and number densities of up to 700 cm(-3). Saturn's rings must produce roughly 10(25) to 10(29) OH molecules per second to maintain the observed OH distribution.	UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85716; SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218	University of Arizona; Space Telescope Science Institute	Hall, DT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTROPHYS SCI,DEPT PHYS & ASTRON,BALTIMORE,MD 21218, USA.							BLAMONT J, 1974, NASA SP, P125; BROADFOOT AL, 1981, SCIENCE, V212, P206, DOI 10.1126/science.212.4491.206; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; CARLSON RW, 1980, NATURE, V283, P461, DOI 10.1038/283461a0; CHENG AF, 1982, J GEOPHYS RES-SPACE, V87, P4567, DOI 10.1029/JA087iA06p04567; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CONNERNEY JEP, 1986, GEOPHYS RES LETT, V13, P773, DOI 10.1029/GL013i008p00773; Cuzzi J.N., 1984, PLANETARY RINGS, V75, P73; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; DENNEFELD M, 1974, IAU S, V65, P471; DONES L, 1991, ICARUS, V92, P194, DOI 10.1016/0019-1035(91)90045-U; EVIATAR A, 1990, ANN GEOPHYS, V8, P725; GANBARUCH Z, 1994, J GEOPHYS RES-SPACE, V99, P11063, DOI 10.1029/93JA03143; HAFF PK, 1986, ICARUS, V66, P258, DOI 10.1016/0019-1035(86)90156-9; HAMILTON DP, 1993, NATURE, V365, P498, DOI 10.1038/365498c0; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HARRISON H, 1967, SCIENCE, V157, P1175, DOI 10.1126/science.157.3793.1175; HILTON DA, 1988, ICARUS, V73, P248, DOI 10.1016/0019-1035(88)90096-6; IP WH, 1995, ICARUS, V115, P295, DOI 10.1006/icar.1995.1098; IP WH, 1983, J GEOPHYS RES-SPACE, V88, P819, DOI 10.1029/JA088iA02p00819; IP WH, 1984, J GEOPHYS RES-SPACE, V89, P8843, DOI 10.1029/JA089iA10p08843; Ip WH, 1996, ASTROPHYS J, V457, P922, DOI 10.1086/176785; JOHNSON RE, 1989, ICARUS, V77, P311, DOI 10.1016/0019-1035(89)90092-4; JOHNSON RE, 1993, EOS, V74, P569; JUDGE DL, 1980, SCIENCE, V207, P431, DOI 10.1126/science.207.4429.431; LAZARUS AJ, 1983, J GEOPHYS RES-SPACE, V88, P8831, DOI 10.1029/JA088iA11p08831; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P11285, DOI 10.1029/93JA00308; NORTHROP TG, 1982, J GEOPHYS RES-SPACE, V87, P6045, DOI 10.1029/JA087iA08p06045; NORTHROP TG, 1987, ICARUS, V70, P124, DOI 10.1016/0019-1035(87)90079-0; PILCHER CB, 1970, SCIENCE, V167, P1372, DOI 10.1126/science.167.3923.1372; POSPIESZALSKA MK, 1991, ICARUS, V93, P45, DOI 10.1016/0019-1035(91)90162-M; RICHARDSON JD, 1986, J GEOPHYS RES, V91, P8749, DOI 10.1029/JA091iA08p08749; RICHARDSON JD, 1992, J GEOPHYS RES-SPACE, V97, P13705, DOI 10.1029/92JA00920; ROTTMAN GJ, 1993, J GEOPHYS RES-ATMOS, V98, P10667, DOI 10.1029/93JD00462; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; SCHLEICHER DG, 1983, THESIS U MARYLAND CO; SHEMANSKY DE, 1992, J GEOPHYS RES-SPACE, V97, P4143, DOI 10.1029/91JA02805; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SHEMANSKY DE, 1995, CALIBRATING HUBBLE S, P88; Shi M, 1995, J GEOPHYS RES-PLANET, V100, P26387, DOI 10.1029/95JE03099; SMYTH WH, 1993, ICARUS, V101, P18, DOI 10.1006/icar.1993.1002; WEISER H, 1977, SCIENCE, V197, P755, DOI 10.1126/science.197.4305.755-a; WOODS TN, 1993, J GEOPHYS RES-ATMOS, V98, P10679, DOI 10.1029/93JD00463	45	36	36	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					516	518		10.1126/science.272.5261.516	http://dx.doi.org/10.1126/science.272.5261.516			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614798				2022-12-01	WOS:A1996UG82600033
J	Hodel, AE; Gershon, PD; Shi, XN; Quiocho, FA				Hodel, AE; Gershon, PD; Shi, XN; Quiocho, FA			The 1.85 angstrom structure of vaccinia protein VP39: A bifunctional enzyme that participates in the modification of both mRNA ends	CELL			English	Article							TRANSFER RNA-SYNTHETASE; VIRUS POLY(A) POLYMERASE; HNRNP-C-PROTEINS; CRYSTAL-STRUCTURE; BINDING DOMAIN; CATALYTIC SUBUNIT; RESOLUTION; POLYADENYLATION; PURIFICATION; PROGRAM	VP39 is a bifunctional vaccinia virus protein that acts as both an mRNA cap-specific RNA 2'-O-methyltransferase and a poly(A) polymerase processivity factor. Here, we report the 1.85 Angstrom crystal structure of a VP39 variant complexed with its AdoMet cofactor. VP39 comprises a single core domain with structural similarity to the catalytic domains of other methyltransferases. Surface features and mutagenesis data suggest two possible RNA-binding sites with novel underlying architecture, one of which forms a cleft spanning the region adjacent to the methyltransferase active site. This report provides a prototypic structure for an RNA methyltransferase, a protein that interacts with the mRNA 5' cap, and an intact poxvirus protein.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System	Hodel, AE (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [1 RO1 GM51953-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, 1992, XPLOR VERSION 3 1; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; FUREY W, 1990, AM CRYST ASS M SUMM; GERSHON PD, 1993, EMBO J, V12, P4705, DOI 10.1002/j.1460-2075.1993.tb06159.x; GERSHON PD, 1993, J BIOL CHEM, V268, P2203; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; KANG CH, 1995, SCIENCE, V268, P1170, DOI 10.1126/science.7761833; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LEIJONMARCK M, 1980, NATURE, V286, P824, DOI 10.1038/286824a0; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHI X, 1996, RNA, V2, P80; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; WU JC, 1987, J BIOL CHEM, V262, P4778	54	144	146	3	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					247	256		10.1016/S0092-8674(00)81101-0	http://dx.doi.org/10.1016/S0092-8674(00)81101-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612277	Bronze			2022-12-01	WOS:A1996UG25500013
J	Sieweke, MH; Tekotte, H; Frampton, J; Graf, T				Sieweke, MH; Tekotte, H; Frampton, J; Graf, T			MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation	CELL			English	Article							TRANSCRIPTION FACTOR NF-E2; TRANSFERRIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; V-ETS; SACCHAROMYCES-CEREVISIAE; ERYTHROLEUKEMIC CELLS; ESCHERICHIA-COLI; TS MUTANTS; C-JUN; EXPRESSION	Using a yeast one-hybrid screen with a DNA-bound Ets-1 protein, we have identified MafB, an AP-1 like protein, as a direct interaction partner. MafB is specifically expressed in myelomonocytic cells and binds to the DNA-binding domain of Ets-1 via its basic region or leucine-zipper domain. Furthermore, it represses Ets-1 transactivation of synthetic promoters containing Ets binding sites and inhibits Ets-1-mediated transactivation of the transferrin receptor, which is known to be essential for erythroid differentiation, Accordingly, overexpression of MafB in an erythroblast cell line down-regulates the endogenous transferrin receptor gene and inhibits differentiation without affecting cell proliferation. These results highlight the importance of inhibitory interactions between transcription factors in regulating lineage-specific gene expression.			Sieweke, MH (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTRASSEL 69117, HEIDELBERG, GERMANY.		Sieweke, Michael/AAR-7515-2020; Graf, Thomas/B-4252-2015	Sieweke, Michael/0000-0002-3228-9537; Graf, Thomas/0000-0003-2774-4117; Tekotte, Hille/0000-0003-2164-7412				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAN LNL, 1989, NUCLEIC ACIDS RES, V17, P3763, DOI 10.1093/nar/17.10.3763; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORTON MA, 1983, EXP CELL RES, V144, P361, DOI 10.1016/0014-4827(83)90415-9; HU HYY, 1977, SCIENCE, V197, P559, DOI 10.1126/science.267327; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; IOTH K, 1995, MOL CELL BIOL, V15, P4184; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KILLISCH I, 1992, J CELL SCI, V103, P211; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NERLOV C, 1991, ONCOGENE, V6, P1583; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OMARY MB, 1980, NATURE, V286, P888, DOI 10.1038/286888a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; QUEVA C, 1993, ONCOGENE, V8, P2511; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1993, ONCOGENE, V8, P1783; SIEFF C, 1982, BLOOD, V60, P703; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	79	245	252	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					49	60		10.1016/S0092-8674(00)81081-8	http://dx.doi.org/10.1016/S0092-8674(00)81081-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620536	Bronze			2022-12-01	WOS:A1996UE55900008
J	Mason, JK; Mulligan, D				Mason, JK; Mulligan, D			Euthanasia by stages	LANCET			English	Article									VOLUNTARY EUTHANASIA SOC SCOTLAND,EDINBURGH,MIDLOTHIAN,SCOTLAND		Mason, JK (corresponding author), UNIV EDINBURGH,FAC LAW,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; CRANFORD RE, 1995, BRIT MED J, V311, P464, DOI 10.1136/bmj.311.7003.464; HARRIGAN P, 1995, LANCET, V346, P494, DOI 10.1016/S0140-6736(95)91332-7; *HM STAT OFF, 1994, GOV RESP REP SEL COM; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; WALL M, 1995, LANCET, V346, P368, DOI 10.1016/S0140-6736(95)92243-1; 1995, LANCET, V346, P259; [No title captured]	9	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					810	811		10.1016/S0140-6736(96)90875-2	http://dx.doi.org/10.1016/S0140-6736(96)90875-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622341				2022-12-01	WOS:A1996UB15300016
J	Lucas, SB; Peacock, CS; Hounnou, A; Brattegaard, K; Koffi, K; Honde, M; Andoh, J; Bell, J; DeCock, KM				Lucas, SB; Peacock, CS; Hounnou, A; Brattegaard, K; Koffi, K; Honde, M; Andoh, J; Bell, J; DeCock, KM			Disease in children infected with HIV in Abidjan, Cote d'Ivoire	BRITISH MEDICAL JOURNAL			English	Article							VIRUS; DIAGNOSIS; MORTALITY; UTILITY; INFANTS	Objective-To document the range of disease in African children infected with HIV. Design-Necropsy results in consecutive children aged 1 month or more who were HIV positive and in children who were HIV negative for comparison; IgA western blots on serum samples from children under 2 years of age who were positive for HIV-1 to test the validity of routine HIV serology. Setting-Largest hospital in Abidjan, Cote d'Ivoire. Subjects-78 children who were HIV positive and 77 children who were HIV negative on whom a necropsy was performed; their median ages at death were 18 and 21 months respectively. 36 HIV positive children and 29 HIV negative children mere 1-14 months old; 42 HIV positive and 48 HIV negative children were greater than or equal to 15 months old. Main outcome measures-Cause of death and prevalence of diseases confirmed pathologically. Results-Respiratory tract infections were more common in HIV positive than in HIV negative children (73 (94%) v 52 (68%); P<0.05), and were aetiologically heterogeneous. Pneumocystis carinii pneumonia was found in 11 out of 36 (31%) HIV positive children aged <15 months, but in no HIV negative children. Among older children measles was more common in HIV positive children (8/42 (19%) v 2/48 (4%); P < 0.06). Pyogenic meningitis was present in similar proportions of HIV positive and HIV negative children aged < 15 months (7/36 (19%) and 7/29 (24%)). In HIV positive children tuberculosis (1/78), lymphocytic interstitial pneumonitis (1/78), and HIV encephalitis (2/78) were rare. Conclusions-There is greater overlap between diseases associated with HIV infection and other common health problems in African children than there is in adults. Compared with adults, HIV positive children had a high prevalence of P carinii pneumonia and a low prevalence of tuberculosis. Measles, but not malaria, was associated with HIV infection.	UNIV LONDON UNIV COLL,LONDON MED SCH,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; UNIV HOSP,ABIDJAN,COTE IVOIRE; UNIV EDINBURGH,SCH MED,DEPT PATHOL,DEPT NEUROPATHOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of London; University College London; University of Edinburgh			Peacock, Christopher/A-4052-2012					BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Chin J, 1991, AIDS, V5 Suppl 2, pS57, DOI 10.1097/00002030-199101001-00009; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DOWELL SF, 1993, AIDS, V7, P1255, DOI 10.1097/00002030-199309000-00016; EMBREE JE, 1992, J INFECT DIS, V165, P262, DOI 10.1093/infdis/165.2.262; GIBB D, 1994, AIDS S1, V8, pS275; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; Kozlowski PB, 1995, PEDIAT NEUROPATHOLOG, P435; LANDESMAN S, 1991, JAMA-J AM MED ASSOC, V266, P3443, DOI 10.1001/jama.266.24.3443; LEPAGE P, 1991, AIDS, V5, pS117; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MGONE CS, 1991, J ACQ IMMUN DEF SYND, V4, P910; MIOTTI PG, 1992, INT J EPIDEMIOL, V21, P792; MULLER O, 1990, J TROP PEDIATRICS, V36, P283, DOI 10.1093/tropej/36.6.283; Nelson A M, 1992, Prog AIDS Pathol, V3, P1; NICOLL A, 1994, AIDS, V8, P995, DOI 10.1097/00002030-199407000-00019; PAN LX, 1993, J PATHOL, V170, P137, DOI 10.1002/path.1711700207; SASSANMOROKRO M, 1994, T ROY SOC TROP MED H, V88, P178, DOI 10.1016/0035-9203(94)90285-2; SCHULZ DM, 1962, ARCH PATHOL, V74, P244; SENSION MG, 1988, AM J DIS CHILD, V142, P1271, DOI 10.1001/archpedi.1988.02150120025021; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; WILLIAMS A. O., 1970, Ghana Medical Journal, V9, P23; 1987, MMWR-MORBID MORTAL W, V36, P1	25	140	140	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					335	338						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611829	Green Published			2022-12-01	WOS:A1996TV69800020
J	Joneson, T; White, MA; Wigler, MH; BarSagi, D				Joneson, T; White, MA; Wigler, MH; BarSagi, D			Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; PROTEIN	The RAS guanine nucleotide binding proteins activate multiple signaling events that regulate cell growth and differentiation. In quiescent fibroblasts, ectopic expression of activated H-RAS (H-RAS(V12), where V12 indicates valine-12) induces membrane ruffling, mitogen-activated protein (MAP) kinase activation, and stimulation of DNA synthesis. A mutant of activated H-RAS, H-RAS(V12C40) (where C40 indicates cysteine-40), was identified that was defective for MAP kinase activation and stimulation of DNA synthesis, but retained the ability to induce membrane ruffling. Another mutant of activated H-RAS, H-RAS(V12S35) (where S35 indicates serine-35), which activates MAP kinase, was defective for stimulation of membrane ruffling and induction of DNA synthesis. Expression of both mutants resulted in a stimulation of DNA synthesis that was comparable to that induced by H-RAS(V12). These results indicate that membrane ruffling and activation of MAP kinase represent distinct RAS effector pathways and that input from both pathways is required for the mitogenic activity of RAS.	SUNY STONY BROOK,DEPT MICROBIOL & MOLEC GENET,STONY BROOK,NY 11794; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory				Wigler, Michael/0000-0003-4396-1971; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA 55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; JONESON T, UNPUB; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THORBURN J, 1994, J BIOL CHEM, V269, P30580; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MG, UNPUB	18	361	362	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					810	812		10.1126/science.271.5250.810	http://dx.doi.org/10.1126/science.271.5250.810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628998				2022-12-01	WOS:A1996TU69400047
J	Trupp, M; Arenas, E; Fainzilber, M; Nilsson, AS; Sieber, BA; Grigoriou, M; Kilkenny, C; SalazarGrueso, E; Pachnis, V; Arumae, U; Sariola, H; Saarma, M; Ibanez, CF				Trupp, M; Arenas, E; Fainzilber, M; Nilsson, AS; Sieber, BA; Grigoriou, M; Kilkenny, C; SalazarGrueso, E; Pachnis, V; Arumae, U; Sariola, H; Saarma, M; Ibanez, CF			Functional receptor for GDNF encoded by the c-ret proto-oncogene	NATURE			English	Article							LINE	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF) promotes the survival and phenotype of central dopaminergic(1,2), noradrenergic(3) and motor neurons(4-6), as well as various subpopulations of peripheral sensory and sympathetic neurons(7,8). GDNF is structurally related to members of the transforming growth factor (TGF)-beta superfamily(9), several members of which have well-characterized receptor systems(10,11); however, GDNF receptors still remain undefined. Here we show that GDNF binds to, and induces tyrosine phosphorylation of, the product of the c-ret proto-oncogene, an orphan receptor tyrosine kinase, in a GDNF-responsive motor-neuron cell line. Ret protein could also bind GDNF and mediate survival and growth responses to GDNF upon transfection into naive fibroblasts. Moreover, high levels of c-ret mRNA expression were found in dopaminergic neurons of the adult substantia nigra, where exogenous GDNF protected Ret-positive neurons from 6-hydroxydopamine-induced cell death, Thus the product of the c-ret proto-oncogene encodes a functional receptor for GDNF that may mediate its neurotrophic effects on motor and dopaminergic neurons.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; UNIV CHICAGO,BRAIN RES INST,DEPT NEUROL,CHICAGO,IL 60637; UNIV HELSINKI,INST BIOTECHNOL,PROGRAM MOL NEUROBIOL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,PROGRAM DEV BIOL,FIN-00014 HELSINKI,FINLAND	Karolinska Institutet; MRC National Institute for Medical Research; University of Chicago; University of Helsinki; University of Helsinki			Arumäe, Urmas/E-8290-2016; Arenas, Ernest/AAO-5231-2020; Grigoriou, Maria/AAM-8332-2021	Arumäe, Urmas/0000-0003-3658-6464; Arenas, Ernest/0000-0003-0197-6577; Grigoriou, Maria/0000-0001-6336-5523; Fainzilber, Mike/0000-0001-8173-8557; Pachnis, Vassilis/0000-0001-9733-7686				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DOW E, 1994, AM J MED GENET, V53, P75, DOI 10.1002/ajmg.1320530116; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SUVANTO P, 1996, EUR J NEUROSCI, V8, P116; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	24	686	718	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					785	789		10.1038/381785a0	http://dx.doi.org/10.1038/381785a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657281				2022-12-01	WOS:A1996UU35600060
J	Bhattacharya, I; Sack, EM				Bhattacharya, I; Sack, EM			Screening colonoscopy: The cost of common sense	LANCET			English	Editorial Material							OCCULT BLOOD-TESTS; COLORECTAL-CANCER; MORTALITY				Bhattacharya, I (corresponding author), MICHAEL REESE HOSP & MED CTR,2929 S ELLIS,CHICAGO,IL 60616, USA.							ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; BHATTACHARYA I, 1996, IN PRESS GASTROENTER; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MULLER AD, 1995, ARCH INTERN MED, V108, P402; Parker S. L., 1996, CA CANC J CLIN, V65, P5; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; ROGGE JD, 1994, AM J GASTROENTEROL, V89, P1775; SACK EM, 1996, IN PRESS GASTROENTER; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	14	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1744	1745		10.1016/S0140-6736(96)90812-0	http://dx.doi.org/10.1016/S0140-6736(96)90812-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656910				2022-12-01	WOS:A1996UT39600014
J	Virmani, R; Farb, A; Burke, A				Virmani, R; Farb, A; Burke, A			Contraction-band necrosis: New use for an old friend	LANCET			English	Editorial Material											Virmani, R (corresponding author), ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306, USA.							ARBUSTINI E, 1993, CORONARY ARTERY DIS, V4, P751, DOI 10.1097/00019501-199309000-00001; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; FARB A, 1993, J MOL CELL CARDIOL, V25, P343, DOI 10.1006/jmcc.1993.1041; Hopster DJ, 1996, J CLIN PATHOL, V49, P403, DOI 10.1136/jcp.49.5.403; KARCH SB, 1986, HUM PATHOL, V17, P9, DOI 10.1016/S0046-8177(86)80150-2	5	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1710	1711		10.1016/S0140-6736(96)90803-X	http://dx.doi.org/10.1016/S0140-6736(96)90803-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656901				2022-12-01	WOS:A1996UT39600005
J	Torres, RM; Flaswinkel, H; Reth, M; Rajewsky, K				Torres, RM; Flaswinkel, H; Reth, M; Rajewsky, K			Aberrant B cell development and immune response in mice with a compromised BCR complex	SCIENCE			English	Review							X-LINKED AGAMMAGLOBULINEMIA; ANTIGEN RECEPTOR COMPLEX; PROTEIN-TYROSINE KINASES; IG-BETA COMPONENTS; MOUSE BONE-MARROW; SIGNAL-TRANSDUCTION; IMMUNOGLOBULIN HEAVY; SRC FAMILY; ALPHA; EXPRESSION	The immunoglobulin alpha (Ig-alpha)-Ig-beta heterodimer is the signaling component of the antigen receptor complex on B cells (BCR) and B cell progenitors (pre-BCR). A mouse mutant that lacks most of the Ig-alpha cytoplasmic tail exhibits only a small impairment in early B cell development but a severe block in the generation of the peripheral B cell pool, revealing a checkpoint in B cell maturation that ensures the expression of a functional BCR on mature B cells. B cells that do develop demonstrate a differential dependence on Ig-alpha signaling in antibody responses such that a signaling-competent Ig-alpha appears to be critical for the response to T-independent, but not T-dependent, antigens.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY; MAX PLANCK INST IMMUNOBIOL,D-79108 FREIBURG,GERMANY	University of Cologne; Max Planck Society				Rajewsky, Klaus/0000-0002-6633-6370				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BLUM JH, 1993, J BIOL CHEM, V268, P27236; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BROWN VK, 1994, J BIOL CHEM, V269, P17238; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CONLEY ME, 1992, J CLIN IMMUNOL, V12, P139, DOI 10.1007/BF00918144; CONLEY ME, 1994, IMMUNOL REV, V138, P5, DOI 10.1111/j.1600-065X.1994.tb00844.x; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; GILFILLAN S, 1994, INT IMMUNOL, V6, P1681, DOI 10.1093/intimm/6.11.1681; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HINSHELWOOD S, 1995, EUR J IMMUNOL, V25, P1113, DOI 10.1002/eji.1830250439; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; KAHN WN, 1995, IMMUNITY, V3, P283; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LIN JJ, 1992, J IMMUNOL, V149, P1548; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; LOFFERT D, 1994, IMMUNOL REV, V137, P135, DOI 10.1111/j.1600-065X.1994.tb00662.x; MATSUO T, 1993, J IMMUNOL, V150, P3766; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.immunol.13.1.655; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P111, DOI 10.1002/eji.1830040210; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TORRES RM, 1996, IN PRESS LAB PROTOCO; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; WIENANDS J, 1990, THESIS U FREIBURG GE; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; [No title captured]	60	243	249	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1804	1808		10.1126/science.272.5269.1804	http://dx.doi.org/10.1126/science.272.5269.1804			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650582				2022-12-01	WOS:A1996UT11000048
J	Stoeckle, MY; Douglas, RG				Stoeckle, MY; Douglas, RG			Infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC, WHITE HOUSE STN, NJ USA	Merck & Company	Stoeckle, MY (corresponding author), CORNELL UNIV MED COLL, NEW YORK, NY 10021 USA.							CAMERON B, 1996, 3 C RETR OPP INF WAS; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; CHANG YF, 1995, INFECT IMMUN, V63, P3543, DOI 10.1128/IAI.63.9.3543-3549.1995; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; GUIBERT M, 1995, ACTA PAEDIATR, V84, P831, DOI 10.1111/j.1651-2227.1995.tb13771.x; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; Lederberg J, 1996, JAMA-J AM MED ASSOC, V275, P243, DOI 10.1001/jama.275.3.243; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P12, DOI 10.1001/jama.274.1.12; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; RAMSAY ME, 1994, PEDIATR INFECT DIS J, V13, P1117, DOI 10.1097/00006454-199412000-00009; 1995, MMWR-MORBID MORTAL W, V44, P273; 1995, AM SOC MICROBIOL NEW, V61, P620; 1995, MMWR-MORBID MORTAL W, V44, P399; 1995, MMWR-MORBID MORTAL W, V44, P468; 1995, MMWR-MORBID M      S, V44, P1; 1995, MMWR-MORBID MORTAL W, V44, P625	19	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1816	1817		10.1001/jama.275.23.1816	http://dx.doi.org/10.1001/jama.275.23.1816			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642726				2022-12-01	WOS:A1996UQ15200025
J	Egan, KM; Newcomb, PA; Longnecker, MP; TrenthamDietz, A; Baron, JA; Trichopoulos, D; Stampfer, MJ; Willett, WC				Egan, KM; Newcomb, PA; Longnecker, MP; TrenthamDietz, A; Baron, JA; Trichopoulos, D; Stampfer, MJ; Willett, WC			Jewish religion and risk of breast cancer	LANCET			English	Article								Background The excess risk of breast cancer among Jewish women has been attributed to the effects of difference in lifestyle and reproductive patterns, but there is now evidence that Jewish women may be more likely than other women to inherit mutations in breast-cancer genes. We investigated whether any excessive risk among Jewish women is confined to those with a family history of breast cancer. Methods We assessed the effect of Jewish religion on breast cancer in a large population-based case-control study (6611 women with breast cancer and 9026 controls) in USA. Participants were given telephone interviews and asked about known and suspected risk factors for breast cancer. Findings Overall, Jewish women had only a slightly raised relative risk of breast cancer (1 . 10 [95% CI 0 . 84-1 . 44]; p=0 . 49). However, the relative risk was much higher for Jewish women with a first-degree relative who had breast cancer (3 . 78 [1 . 74-8 . 16]; p<0 . 001). The effect of family history was greater in Jewish women than in women of other religions (p interaction=0 . 05). Interpretation These results are consistent with data suggesting that certain groups of Jewish women have a higher than expected rate of mutation in the breast-cancer gene BRCA1.	UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI; NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC; DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH; DARTMOUTH COLL SCH MED,DEPT FAMILY & COMMUNITY MED,HANOVER,NH; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dartmouth College; Dartmouth College; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Egan, KM (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115, USA.			Longnecker, Matthew/0000-0001-6073-5322	NATIONAL CANCER INSTITUTE [R01CA047147, R01CA047305] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47147, CA 47305] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP DT, 1994, EUR J CANCER, V30A, P1738, DOI 10.1016/0959-8049(94)00455-E; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; NEWILL VA, 1961, J NATL CANCER I, V26, P405; SALBER EJ, 1969, JNCI-J NATL CANCER I, V43, P1013; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198	8	51	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1645	1646		10.1016/S0140-6736(96)91485-3	http://dx.doi.org/10.1016/S0140-6736(96)91485-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642956	hybrid			2022-12-01	WOS:A1996UQ70100008
J	Fried, M; Duffy, PE				Fried, M; Duffy, PE			Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta	SCIENCE			English	Article							INFECTED ERYTHROCYTES; MALARIA; PREGNANCY; AFRICA; ICAM-1	Women are particularly susceptible to malaria during first and second pregnancies, even though they may have developed immunity over years of residence in endemic areas. Plasmodium falciparum-infected red blood cells (IRBCs) were obtained from human placentas. These IRBCs bound to purified chondroitin sulfate A (CSA) but not to other extracellular matrix proteins or to other known IRBC receptors. IRBCs from nonpregnant donors did not bind to CSA. Placental IRBCs adhered to sections of fresh-frozen human placenta with an anatomic distribution similar to that of naturally infected placentas, and this adhesion was competitively inhibited by purified CSA. Thus, adhesion to CSA appears to select for a subpopulation of parasites that causes maternal malaria.	KENYA GOVT MED RES CTR,KISUMU,KENYA	Kenya Medical Research Institute	Fried, M (corresponding author), USA,MED RES UNIT KENYA,POB 54,KISUMU,KENYA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BRABIN BJ, 1985, REV INFECT DIS, V7, P579; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; FRIED M, UNPUB; GUPTA S, 1994, P NATL ACAD SCI USA, V91, P3715, DOI 10.1073/pnas.91.9.3715; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; McGregor I A, 1987, Parassitologia, V29, P153; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; RASHEED FN, 1993, AM J TROP MED HYG, V48, P154, DOI 10.4269/ajtmh.1993.48.154; REILLY K, 1993, PRIMARY CARE, V20, P665; RIGANTI M, 1990, IMMUNOL LETT, V25, P199, DOI 10.1016/0165-2478(90)90115-7; RINDWALD P, 1993, INFECT IMMUN, V61, P5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; WALTER PR, 1982, AM J PATHOL, V109, P330; WEINBERG ED, 1984, REV INFECT DIS, V6, P814; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	26	871	881	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1502	1504		10.1126/science.272.5267.1502	http://dx.doi.org/10.1126/science.272.5267.1502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633247				2022-12-01	WOS:A1996UP89900054
J	Nakayama, K; Ishida, N; Shirane, M; Inomata, A; Inoue, T; Shishido, N; Hori, I; Loh, DY; Nakayama, K				Nakayama, K; Ishida, N; Shirane, M; Inomata, A; Inoue, T; Shishido, N; Hori, I; Loh, DY; Nakayama, K			Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors	CELL			English	Article							GROWTH-FACTOR-BETA; CELL; MOUSE; DISRUPTION; INHIBITOR; ONCOGENE; MUTATIONS; KINASES; GENES; P21	Mice lacking p27(Kip1) have been created by gene targeting in embryonic stem cells. These mice are larger than the control animals, with thymus, pituitary, and adrenal glands and gonadal organs exhibiting striking enlargement. CDK2 activity is elevated about 10-fold in p27(-/-) thymocytes. Development of ovarian follicles seems to be impaired, resulting in female sterility. Similar to mice with the Rb mutation, the p27(-/-) mice often develop pituitary tumors spontaneously. The retinas of the mutant mice show a disturbed organization of the normal cellular layer pattern. These findings indicate that p27(Kip1) acts to regulate the growth of a variety of cells. Unexpectedly, the cell cycle arrest mediated by TGF beta, rapamycin, or contact inhibition remained intact in p27(-/-) cells, suggesting that p27(Kip1) is not required in these pathways.	NIPPON ROCHE RES CTR,DEPT TOXICOL & PATHOL,KAMAKURA,KANAGAWA 247,JAPAN; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED GENET & MOL MICROBIOL,ST LOUIS,MO 63110	Roche Holding; Howard Hughes Medical Institute; Washington University (WUSTL)	Nakayama, K (corresponding author), NIPPON ROCHE RES CTR,DEPT BIOL,KAMAKURA,KANAGAWA 247,JAPAN.			Shirane, Michiko/0000-0002-8297-9245				AHUJA SS, 1993, J IMMUNOL, V150, P3109; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BULLRICH F, 1995, CANCER RES, V55, P1199; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHAN LC, 1992, CANCER GENET CYTOGEN, V62, P47, DOI 10.1016/0165-4608(92)90037-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKER HJH, 1990, CANCER GENET CYTOGEN, V46, P135, DOI 10.1016/0165-4608(90)90021-2; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GILLETT C, 1994, CANCER RES, V54, P1812; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KAWAMATA N, 1995, CANCER RES, V55, P2266; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE KP, 1979, TOXICOL APPL PHARM, V51, P219, DOI 10.1016/0041-008X(79)90464-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MORI T, 1994, CANCER RES, V54, P3396; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHINOHARA M, 1994, BLOOD, V84, P3781; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAHL SM, 1989, IMMUNOL TODAY, V10, P258, DOI 10.1016/0167-5699(89)90136-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	65	1361	1399	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					707	720		10.1016/S0092-8674(00)81237-4	http://dx.doi.org/10.1016/S0092-8674(00)81237-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646779	Bronze			2022-12-01	WOS:A1996UP34400011
J	Feller, MB; Wellis, DP; Stellwagen, D; Werblin, FS; Shatz, CJ				Feller, MB; Wellis, DP; Stellwagen, D; Werblin, FS; Shatz, CJ			Requirement for cholinergic synaptic transmission in the propagation of spontaneous retinal waves	SCIENCE			English	Article							GABA-LIKE IMMUNOREACTIVITY; GANGLION-CELL DENDRITES; MAMMALIAN RETINA; CAT RETINA; ACETYLCHOLINE; RESPONSES; BUNGAROTOXIN; PATTERNS; SYSTEMS	Highly correlated neural activity in the form of spontaneous waves of action potentials is present in the developing retina weeks before vision. Optical imaging revealed that these waves consist of spatially restricted domains of activity that form a mosaic pattern over the entire retinal ganglion cell layer. Whole-cell recordings indicate that wave generation requires synaptic activation of neuronal nicotinic acetylcholine receptors on ganglion cells. The only cholinergic cells in these immature retinas are a uniformly distributed, bistratified population of amacrine cells, as assessed by antibodies to choline acetyltransferase. The results indicate that the major source of synaptic input to retinal ganglion cells is a system of cholinergic amacrine cells, whose activity is required for wave propagation in the developing retina.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Feller, MB (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,221 LIFE SCI ADDIT,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NEI NIH HHS [EY00561] Funding Source: Medline; NIGMS NIH HHS [GM07048] Funding Source: Medline; NIMH NIH HHS [NIMH 48108] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIZENMAN E, 1990, BRAIN RES, V517, P209, DOI 10.1016/0006-8993(90)91028-F; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DONG CJ, 1994, J NEUROSCI, V14, P2648; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAMASSAKIBRITTO DE, 1994, J COMP NEUROL, V347, P161, DOI 10.1002/cne.903470202; HEAULME M, 1986, BRAIN RES, V384, P224, DOI 10.1016/0006-8993(86)91158-3; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; KEYSER KT, 1993, J NEUROSCI, V13, P442; KITTILA CA, 1995, J NEUROPHYSIOL, V73, P703, DOI 10.1152/jn.1995.73.2.703; LEBEDA FJ, 1982, J NEUROPHYSIOL, V48, P622, DOI 10.1152/jn.1982.48.3.622; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8390, DOI 10.1073/pnas.83.21.8390; LIPPE WR, 1994, J NEUROSCI, V14, P1486, DOI 10.1523/JNEUROSCI.14-03-01486.1994; LUKASIEWICZ PD, 1990, J NEUROSCI, V10, P210; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Mooney R., UNPUB; MOSINGER JL, 1986, EXP EYE RES, V42, P631, DOI 10.1016/0014-4835(86)90052-7; ODONOVAN M, 1992, J EXP ZOOL, V261, P261, DOI 10.1002/jez.1402610306; PENN AA, 1994, J NEUROSCI, V14, P3805; Pourcho RG, 1980, BRAIN RES, V198, P33; RORIG B, 1994, NEUROREPORT, V5, P1197; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Sernagor E., 1994, Society for Neuroscience Abstracts, V20, P1470; SERNAGOR E, 1994, INVEST OPHTH VIS SCI, V35, P2125; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; TOOTLE JS, 1993, J NEUROPHYSIOL, V69, P1645, DOI 10.1152/jn.1993.69.5.1645; von der Malsburg C, 1973, Kybernetik, V14, P85; WASSLE H, 1989, J COMP NEUROL, V279, P43, DOI 10.1002/cne.902790105; WELLIS DP, UNPUB; Wong R O, 1993, Curr Opin Neurobiol, V3, P595, DOI 10.1016/0959-4388(93)90061-3; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WONG ROL, 1995, J NEUROSCI, V15, P2696; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; WOTRING VE, 1995, NEUROSCIENCE, V67, P293, DOI 10.1016/0306-4522(95)00011-7; Yazulla S, 1985, Neurosci Res Suppl, V2, pS147, DOI 10.1016/0921-8696(85)90014-3; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9; ZHANG ZW, 1991, BRIT J PHARMACOL, V102, P19, DOI 10.1111/j.1476-5381.1991.tb12125.x	47	419	425	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1182	1187		10.1126/science.272.5265.1182	http://dx.doi.org/10.1126/science.272.5265.1182			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638165				2022-12-01	WOS:A1996UM88900054
J	Elliott, P; Stamler, J; Nichols, R; Dyer, AR; Stamler, R; Kesteloot, H; Marmot, M				Elliott, P; Stamler, J; Nichols, R; Dyer, AR; Stamler, R; Kesteloot, H; Marmot, M			Intersalt revisited: Further analyses of 24 hour sodium excretion and blood pressure within and across populations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY SALT; OBSERVATIONAL DATA; REDUCTION; POTASSIUM; CORONARY	Objectives-To assess further the relation in Intersalt of 24 hour urinary sodium to blood pressure of individuals and populations, and the difference it blood pressure from young adulthood into middle age. Design-Standardised cross sectional study within and across populations. Setting-52 population samples in 32 countries. Subjects-10 074 men and women aged 20-59. Main outcome measures-Association of sodium and blood pressure from within population and cross population multiple linear regression analyses with multivariate correction for regression dilution bias. Relation of sample median daily urinary sodium excretion to difference in blood pressure with age. Results-In within population analyses (n=10 074), individual 24 hour urinary sodium excretion higher by 100 mmol (for example, 170 v 70 mmol) was associated with systolic/diastolic blood pressure higher on average by 3/0 to 6/3 mm Hg (with and without body mass in analyses). Associations were larger at ages 40-59. In cross population analyses (n=52), sample median 24 hour sodium excretion higher by 100 mmol was associated with median systolic/diastolic pressure higher on average by 5-7/2-4 mm Hg, and estimated mean difference in systolic/diastolic pressure at age 55 compared with age 25 greater by 10-11/6 mm Hg. Conclusions-The strong, positive association of urinary sodium with systolic pressure of individuals concurs with Intersalt cross population findings and results of other studies. Higher urinary sodium is also associated with substantially greater differences in blood pressure in middle age compared with young adulthood. These results support recommendations for reduction of high salt intake in populations for prevention and control of adverse blood pressure levels.	NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL 60611 USA; ST RAPHAEL UNIV HOSP, DEPT EPIDEMIOL, LOUVAIN, BELGIUM; UNIV LONDON UNIV COLL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND	Northwestern University; University of London; University College London; UCL Medical School	Elliott, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON W2 1PG, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; Department of Health, 1994, 46 DEP HLTH CARD REV; DYER AR, 1994, AM J EPIDEMIOL, V139, P927, DOI 10.1093/oxfordjournals.aje.a117099; DYER AR, 1989, J HUM HYPERTENS, V3, P299; DYER AR, 1995, NAT MED, V1, P994, DOI 10.1038/nm1095-994; DYER AR, 1994, HYPERTENSION, V23, P729, DOI 10.1161/01.HYP.23.6.729; DYER AR, 1994, AM J EPIDEMIOL, V139, P940, DOI 10.1093/oxfordjournals.aje.a117100; ELLIOTT P, 1988, BRIT MED J, V297, P319; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P289; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P323; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; JOOSSENS JV, 1994, J AM COLL NUTR, V13, P179; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KLEINBAUM DG, 1987, APPLIED REGRESSION A; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1988, AM J EPIDEMIOL, V127, P864, DOI 10.1093/oxfordjournals.aje.a114870; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *NAT RES COUNC COM, 1989, DIET HLTH IMPL RED C, V15, P413; PAFFENBARGER RS, 1968, AM J EPIDEMIOL, V88, P25, DOI 10.1093/oxfordjournals.aje.a120864; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; PRIOR IAM, 1980, EPIDEMIOLOGY ARTERIA, P243; ROSE G, 1986, J HYPERTENS, V4, P781; SANCHEZCASTILLO CP, 1987, CLIN SCI, V72, P95, DOI 10.1042/cs0720095; Snedecor GW, 1980, STAT METHODS; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; STAMLER J, 1960, PATHOGENESIS ESSENTI, P67; STAMLER J, 1967, LECTURES PREVENTIVE, P242; STAMLER J, 1979, HYPERTENSION UPDATE, P23; *US DHHS, 1991, DHHS PUBL; [No title captured]; [No title captured]	39	631	648	1	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	1996	312	7041					1249	1253		10.1136/bmj.312.7041.1249	http://dx.doi.org/10.1136/bmj.312.7041.1249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634612	Green Published			2022-12-01	WOS:A1996UM40400016
J	Hublin, JJ; Spoor, F; Braun, M; Zonneveld, F; Condemi, S				Hublin, JJ; Spoor, F; Braun, M; Zonneveld, F; Condemi, S			A Late Neanderthal associated with Upper Palaeolithic artefacts	NATURE			English	Article								THE French site of Arcy-sur-Cure is a key locality in documenting the Middle-Upper Palaeolithic transition in Europe. Reliable attribution of the fragmentary hominid fossils associated with its early Upper Palaeolithic Chatelperronian industry has not been possible. Here we report the first conclusive identification of one of these fossils as Neanderthal on the basis of newly discovered derived features of the bony labyrinth. Dated at about thirty-four thousand years (34 kyr) ago, the fossil is representative of the youngest known Neanderthal populations, and its archaeological context indicates that these hominids used a rich bone industry as well as personal ornaments. The evidence supports the hypothesis of a long term coexistence with technocultural interactions between the first modern humans and the last Neanderthals in Europe. However, the complete absence of the derived Neanderthal traits in labyrinths of modern Upper Palaeolithic specimens from western Europe argues against phylogenetic continuity between the two populations in this region.	UNIV NANCY 1, DEPT ANAT, F-54505 VANDOEUVRE LES NANCY, FRANCE; UNIV UTRECHT HOSP, DEPT DIAGNOST RADIOL, 3584 CX UTRECHT, NETHERLANDS; INST PALEONTOL HUMAINE, F-75013 PARIS, FRANCE; MUSEE HOMME PARIS, LAB ANTHROPOL, F-75116 PARIS, FRANCE; UCL, DEPT ANAT & DEV BIOL, EVOLUT ANAT UNIT, LONDON WC1E 6JJ, ENGLAND	Universite de Lorraine; Utrecht University; Utrecht University Medical Center; Museum National d'Histoire Naturelle (MNHN); University of London; University College London			Spoor, Fred/C-1718-2008; Condemi, Silvana/ABE-2701-2021	Condemi, Silvana/0000-0002-6516-0879				BISCHOFF JL, 1994, J ARCHAEOL SCI, V21, P541, DOI 10.1006/jasc.1994.1053; BISCHOFF JL, 1989, J ARCHAEOL SCI, V16, P553; Cabrera-Valdes V., 1989, J ARCHAEOL SCI, V16, P577, DOI [10.1016/0305-4403(89)90023-X, DOI 10.1016/0305-4403(89)90023-X]; CLARK GA, 1989, HUMAN REVOLUTION, P621; DEMARS PY, 1989, ERAUL LIEGE, V34, P29; Girard M., 1990, PALEOLITHIQUE MOYEN, V3, P295; HARROLD FB, 1989, HUMAN REVOLUTION, P677; HOWELL FC, 1994, INTERD CONT, P253; HUBLIN JJ, 1995, CR ACAD SCI II A, V321, P931; Klinken, 1994, ARCHAEOMETRY, V36, P337, DOI DOI 10.1111/J.1475-4754.1994.TB00975.X; Leroi-Gourhan A., 1958, ANN PALEONTOL, V44, P87; Leroyer C, 1983, B SOC PREHIST FRANC, V80, P41; LEROYER C, 1988, ERAUL LIEGE, V35, P103; LEUJEUNE M, 1987, ART MOBILIER PALEOLI, V4; LEVEQUE F, 1980, CR ACAD SCI D NAT, V291, P187; MAFFIER D, 1990, PALEOLITHIQUE MOYEN, P329; MELLARS PA, 1992, PHILOS T ROY SOC B, V337, P225, DOI 10.1098/rstb.1992.0100; MERCIER N, 1991, NATURE, V351, P735; Pelegrin J., 1995, CAHIERS QUATERNAIRE, V20, P297; RAK Y, 1994, SPECIES SPECIES CONC, P523; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; Spoor C.E, 1993, COMP MORPHOLOGY PHYL; SPOOR CF, 1994, COUR FORSCH SENCKENB, V171, P251; SPOOR CF, 1995, J ANAT, V186, P271; SPOOR F, 1994, NATURE, V369, P645, DOI 10.1038/369645a0; Straus L.G., 1993, EVOLUTIONARY ANTHR, V2, P195; STRINGER CB, 1991, NATURE, V351, P701, DOI 10.1038/351701a0; TABORIN Y, 1990, PALEOLITHIQUE MOYEN, P335; van Vark G. N., 1984, MULTIVARIATE STATIST, P323; WOLPOFF MH, 1992, NATURE, V356, P200, DOI 10.1038/356200b0	30	259	270	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					224	226		10.1038/381224a0	http://dx.doi.org/10.1038/381224a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UL249	8622762				2022-12-01	WOS:A1996UL24900050
J	Feng, Y; Broder, CC; Kennedy, PE; Berger, EA				Feng, Y; Broder, CC; Kennedy, PE; Berger, EA			HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BACTERIOPHAGE-T7 RNA-POLYMERASE; MOLECULAR-CLONING; HUMAN CD4; REGULATED EXPRESSION; CD4-MEDIATED FUSION; MEMBRANE-FUSION; VACCINIA VIRUS; HUMAN HOMOLOG; MURINE CELLS	A cofactor for HIV-1 (human immunodeficiency virus-type 1) fusion and entry was identified with the use of a novel functional complementary DNA (cDNA) cloning strategy. This protein, designated ''fusin,'' is a putative G protein-coupled receptor with seven transmembrane segments. Recombinant fusin enabled CD4-expressing nonhuman cell types to support HIV-1 Env-mediated cell fusion and HIV-1 infection. Antibodies to fusin blocked cell fusion and infection with normal CD4-positive human target cells. Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophage-tropic HIV-1 isolates.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Broder, Christopher/E-1169-2013					ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; ALKHATIB G, IN PRESS J VIROL; [Anonymous], COMMUNICATION; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BERGER EA, 1996, KEYST S CELL BIOL VI, P8; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAKRABARTI SK, COMMUNICATION; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Cho SG, 1995, AIDS RES HUM RETROV, V11, P1487, DOI 10.1089/aid.1995.11.1487; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DRAGIC T, 1993, J VIROL, V67, P2355, DOI 10.1128/JVI.67.4.2355-2359.1993; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; DUNN CS, 1995, J GEN VIROL, V76, P1327, DOI 10.1099/0022-1317-76-6-1327; EARL PL, 1991, CURRENT PROTOCOL S15, V2; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; FENG Y, 1996, KEYST S IMM HIV INF, P21; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILLESPIE FP, 1993, MOL CELL BIOL, V13, P2952, DOI 10.1128/MCB.13.5.2952; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HOXIE JA, 1988, J VIROL, V62, P2557, DOI 10.1128/JVI.62.8.2557-2568.1988; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOENIG S, 1989, P NATL ACAD SCI USA, V86, P2443, DOI 10.1073/pnas.86.7.2443; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Planelles Vincente, 1993, P17; RAMARLI D, 1993, AIDS RES HUM RETROV, V9, P1269, DOI 10.1089/aid.1993.9.1269; Richardson TM, 1996, J VIROL, V70, P753, DOI 10.1128/JVI.70.2.753-762.1996; SNYDER BW, 1995, MOL REPROD DEV, V40, P419, DOI 10.1002/mrd.1080400405; TRONO D, 1994, CLIN LAB MED, V14, P203, DOI 10.1016/S0272-2712(18)30375-5; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679	44	3534	3778	1	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					872	877		10.1126/science.272.5263.872	http://dx.doi.org/10.1126/science.272.5263.872			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629022				2022-12-01	WOS:A1996UK75700059
J	Schalk, I; Zeng, K; Wu, SK; Stura, EA; Matteson, J; Huang, MD; Tandon, A; Wilson, IA; Balch, WE				Schalk, I; Zeng, K; Wu, SK; Stura, EA; Matteson, J; Huang, MD; Tandon, A; Wilson, IA; Balch, WE			Structure and mutational analysis of Rab GDP-dissociation inhibitor	NATURE			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; GTP-BINDING PROTEIN; CHOROIDEREMIA GENE; CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; GERANYLGERANYL TRANSFERASE; PURIFICATION; RESOLUTION; SUBSTRATE; HOMOLOG	The crystal structure of the bovine alpha-isoform of Rab GDP-dissociation inhibitor (GDI), which functions in vesicle-membrane transport to recycle and regulate Rab GTPases, has been determined to a resolution of 1.81 Angstrom. GDI is constructed of two main structural units, a large complex multisheet domain I and a smaller alpha-helical domain II. The structural organization of domain I is surprisingly closely related to FAD-containing monooxygenases and oxidases. Sequence-conserved regions common to GDI and the choroideraemia gene product, which delivers Rab to catalytic subunits of Rab geranylgeranyltransferase II, are clustered on one face of the molecule. The two most sequence-conserved regions, which form a compact structure at the apex of GDI, are shown by site-directed mutagenesis to play a critical role in the binding of Rab proteins.	SCRIPPS RES INST, DEPT MOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, THESIS YALE U; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEKKER LV, 1991, J NEUROCHEM, V54, P205; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; FUREY W, 1990, AM CRYSTALLOGR ASS 4; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee D.E., 1993, PRACTICAL PROTEIN CR, P1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHALK IJ, 1994, J MOL BIOL, V244, P469, DOI 10.1006/jmbi.1994.1744; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STOTT K, 1993, J BIOL CHEM, V268, P6097; STURA EA, 1994, ACTA CRYSTALLOGR D, V50, P448, DOI 10.1107/S0907444994001794; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANBOKHOVEN H, 1994, HUM MOL GENET, V3, P1041, DOI 10.1093/hmg/3.7.1041; VANDENHURK JAJM, 1992, AM J HUM GENET, V50, P1195; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON AL, 1993, J BIOL CHEM, V268, P14561	52	141	144	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1996	381	6577					42	48		10.1038/381042a0	http://dx.doi.org/10.1038/381042a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609986				2022-12-01	WOS:A1996UJ05300048
J	Bochkarev, A; Barwell, JA; Pfuetzner, RA; Bochkareva, E; Frappier, L; Edwards, AM				Bochkarev, A; Barwell, JA; Pfuetzner, RA; Bochkareva, E; Frappier, L; Edwards, AM			Crystal structure of the DNA-Binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA	CELL			English	Article							NUCLEAR ANTIGEN EBNA-1; REPLICATION ORIGIN; HUMAN-CELLS; SITES; ORIP; PLASMIDS; ENHANCER; REFINEMENT; TARGET	The Epstein-Barr virus nuclear antigen 1 (EBNA1) protein binds to and activates DNA replication from oriP, the latent origin of DNA replication in Epstein-Barr virus. The crystal structure of the DNA-binding domain of EBNA1 bound to an 18 bp binding site was solved at 2.4 Angstrom resolution. EBNA1 comprises two domains, a flanking and a core domain. The flanking domain, which includes a helix that projects into the major groove and an extended chain that travels along the minor groove, makes all of the sequence-determining contacts with the DNA. The core domain, which is structurally homologous to the complete DNA-binding domain of the bovine papilloma virus E2 protein, makes no direct contacts with the DNA bases. A model for origin unwinding is proposed that incorporates the known biochemical and structural features of the EBNA1-origin interaction.	MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FUREY W, 1995, MACROMOLECULAR CRYST; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEIMAN Z, 1994, CURR OPIN GENE DEV, V4, P185; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	30	182	191	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					791	800		10.1016/S0092-8674(00)81056-9	http://dx.doi.org/10.1016/S0092-8674(00)81056-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625416	Bronze			2022-12-01	WOS:A1996TZ99000016
J	Lewis, M; Chang, G; Horton, NC; Kercher, MA; Pace, HC; Schumacher, MA; Brennan, RG; Lu, PZ				Lewis, M; Chang, G; Horton, NC; Kercher, MA; Pace, HC; Schumacher, MA; Brennan, RG; Lu, PZ			Crystal structure of the lactose operon repressor and its complexes with DNA and inducer	SCIENCE			English	Article							LAC REPRESSOR; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; RNA-POLYMERASE; OPERATOR; PROTEIN; MUTATIONS; SEQUENCE; REGION; GENE	The lac operon of Escherichia coli is the paradigm for gene regulation. Its key component is the lac repressor, a product of the lad gene. The three-dimensional structures of the intact lac repressor, the lac repressor bound to the gratuitous inducer isopropyl-beta-D-1-thiogalactoside (IPTG) and the lac repressor complexed with a 21-base pair symmetric operator DNA have been determined. These three structures show the conformation of the molecule in both the induced and repressed states and provide a framework for understanding a wealth of biochemical and genetic information. The DNA sequence of the lac operon has three lac repressor recognition sites in a stretch of 500 base pairs. The crystallographic structure of the complex with DNA suggests that the tetrameric repressor functions synergistically with catabolite gene activator protein (CAP) and participates in the quaternary formation of repression loops in which one tetrameric repressor interacts simultaneously with two sites on the genomic DNA.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	University of Pennsylvania; University of Pennsylvania; Oregon Health & Science University	Lewis, M (corresponding author), UNIV PENN,JOHNSON RES FDN,PHILADELPHIA,PA 19104, USA.		Horton, Nancy C/E-7881-2011	Horton, Nancy C/0000-0003-2710-8284; Brennan, Richard/0000-0001-7647-485X	NCRR NIH HHS [P41-RR06017] Funding Source: Medline; NIGMS NIH HHS [2-T32-GM082745, GM44617] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044617] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P207; ALBERTI S, 1991, NEW BIOL, V3, P57; BELLOMY GR, 1988, BIOCHEMISTRY-US, V27, P3900, DOI 10.1021/bi00411a002; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; Bourgeois S, 1976, Adv Protein Chem, V30, P1, DOI 10.1016/S0065-3233(08)60478-7; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; BRENOWITZ M, 1991, J BIOL CHEM, V286, P1281; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURSTEIN C, 1965, BIOCHIM BIOPHYS ACTA, V95, P634, DOI 10.1016/0005-2787(65)90517-4; CARUTHERS MH, 1980, ACCOUNTS CHEM RES, V13, P155, DOI 10.1021/ar50149a005; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG G, 1994, ACTA CRYSTALLOGR D, V50, P667, DOI 10.1107/S0907444994000727; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1994, BIOCHEMISTRY-US, V33, P8728, DOI 10.1021/bi00195a014; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; FAIRMAN R, 1995, PROTEIN SCI, V4, P1457, DOI 10.1002/pro.5560040803; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FLASHNER Y, 1988, P NATL ACAD SCI USA, V85, P8968, DOI 10.1073/pnas.85.23.8968; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GEISLER N, 1978, FEBS LETT, V87, P215, DOI 10.1016/0014-5793(78)80335-4; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GILBERT W, 1975, PROTEIN LIGAND INTER, P193; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAUROWITZ F, 1938, HOPPESEYLERS Z PHYSL, V254, P268; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOB F, 1961, COLD SPRING HARB SYM, V26, P193, DOI 10.1101/SQB.1961.026.01.024; JAREMA MAC, 1981, P NATL ACAD SCI-BIOL, V78, P2707, DOI 10.1073/pnas.78.5.2707; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM R, 1982, COLD SPRING HARB SYM, V47, P451, DOI 10.1101/SQB.1983.047.01.053; KORNBERG RD, 1981, SCI AM, V244, P48, DOI 10.1038/scientificamerican0281-52; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS MA, UNPUB; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Miller J. H., 1980, OPERON; MILLER JH, 1984, J MOL BIOL, V180, P205, DOI 10.1016/0022-2836(84)90438-8; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MILLER JH, 1970, LACTOSE OPERON; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MONOD J, 1942, THESIS U PARIS; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MULLERHILL B, 1964, J MOL BIOL, V10, P303, DOI 10.1016/S0022-2836(64)80049-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OTWINOWSKI Z, UNPUB HKL PROGRAM SU; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PLATT T, 1973, J BIOL CHEM, V248, P110; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHIGETA R, 1994, ACTA CRYSTALLOGR D, V50, P71, DOI 10.1107/S0907444993009382; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; Voet D, 1990, BIOCHEMISTRY; WADEJARDETZKY N, 1978, J MOL BIOL, V128, P259; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; ZUBAY G, 1970, P NATL ACAD SCI USA, V66, P104, DOI 10.1073/pnas.66.1.104	75	651	665	1	184	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1247	1254		10.1126/science.271.5253.1247	http://dx.doi.org/10.1126/science.271.5253.1247			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638105				2022-12-01	WOS:A1996TX69500027
J	White, K; Tahaoglu, E; Steller, H				White, K; Tahaoglu, E; Steller, H			Cell killing by the Drosophila gene reaper	SCIENCE			English	Article							DEATH	The reaper gene (rpr) is important for the activation of apoptosis in Drosophila. To investigate whether rpr expression is sufficient to induce apoptosis, transgenic flies were generated that express rpr complementary DNA or the rpr open reading frame in cells that normally live. Transcription of rpr from a heat-inducible promoter rapidly caused widespread ectopic apoptosis and organismal death. Ectopic overexpression of rpr in the developing retina resulted in eye ablation. The occurrence of cell death was highly sensitive to the dosage of the transgene. Because cell death induced by the protein encoded by rpr(RPR)could be blocked by the baculovirus p35 protein, RPR appears to activate a death program mediated by a ced-3/ICE (interleukin-1 converting enzyme)-like protease.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	White, K (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129, USA.		White, Kristin/D-7936-2013					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1994, APOPTOSIS, V2, P89; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; NEWCOMBCARBOY C, UNPUB; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; SONG HY, 1994, J BIOL CHEM, V269, P22492; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WHITE K, 1995, TRENDS CELL BIOL, V5, P74, DOI 10.1016/S0962-8924(00)88950-3; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	20	326	340	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					805	807		10.1126/science.271.5250.805	http://dx.doi.org/10.1126/science.271.5250.805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628996				2022-12-01	WOS:A1996TU69400045
J	Sheldon, TA; Raffle, A; Watt, I				Sheldon, TA; Raffle, A; Watt, I			Controversies in management - Department of health shoots itself in the hip - Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing	BRITISH MEDICAL JOURNAL			English	Article									AVON HLTH,BRISTOL BS2 8EE,AVON,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,DIRECTORATE CLIN RADIOL,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary	Sheldon, TA (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Sheldon, Trevor Andrew/0000-0002-7479-5913				BARLOW DM, 1994, ADVISORY GROUP OSTEO; Calman K, 1994, J Med Screen, V1, P101; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Chalmers I., 1995, SYSTEMATIC REV; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EVANS NJB, 1995, REV DEPT HLTH ARRANG; PECKHAM M, 1993, RES HLTH; Sox H. C., 1989, ASSESSMENT DIAGNOSTI; TORGERSON DJ, 1995, EUR J OBSTET GYN R B, V59, P57, DOI 10.1016/0028-2243(94)02002-V; 1995, MEASUREMENT BONE DEN	10	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					296	297						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611790				2022-12-01	WOS:A1996TU50700030
J	Durbec, P; MarcosGutierrez, CV; Kilkenny, C; Grigoriou, M; Wartiovaara, K; Suvanto, P; Smith, D; Ponder, B; Costantini, F; Saarma, M; Sariola, H; Pachnis, V				Durbec, P; MarcosGutierrez, CV; Kilkenny, C; Grigoriou, M; Wartiovaara, K; Suvanto, P; Smith, D; Ponder, B; Costantini, F; Saarma, M; Sariola, H; Pachnis, V			GDNF signalling through the Ret receptor tyrosine kinase	NATURE			English	Article							EXPRESSION	MUTATIONAL analysis in humans and mice has demonstrated that Ret, the product of the c-ret proto-oncogene, a member of the receptor tyrosine kinase (RTK) superfamily(1), is essential for development of the enteric nervous system and kidney(2-6). Despite the established role of Ret in mammalian embryogenesis, its cognate ligand(s) is currently unknown. Here we demonstrate, by using a Xenopus embryo bioassay, that glial-cell-line-derived neurotrophic factor (GDNF)(7), a distant member of the transforming growth factor(TGF)-beta superfamily, signals through the Ret RTK. Furthermore, using explant cultures from wild-type and Ret-deficient mouse embryos(4), we show that normal c-ret function is necessary for GDNF signalling in the peripheral nervous system, Our data strongly suggest that Ret is a functional receptor for GDNF, and that GDNF, in addition to its potential role in the differentiation and survival of central nervous system neurons(8-12), has profound effects on kidney organogenesis and the development of the peripheral nervous system.	NATL INST MED RES, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; UNIV HELSINKI, BIOCTR 1, INST BIOTECHNOL, FIN-00014 HELSINKI, FINLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 2QQ, ENGLAND; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; HELSINKI UNIV, CHILDRENS HOSP, FIN-000290 HELSINKI, FINLAND	MRC National Institute for Medical Research; University of Helsinki; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Columbia University; University of Helsinki			Grigoriou, Maria/AAM-8332-2021	Grigoriou, Maria/0000-0001-6336-5523				BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Borrello MG, 1995, ONCOGENE, V11, P2419; BRIVANLOU AH, 1994, CELL, V77, P283; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HEBENSTREIT PG, 1992, ONCOGENE, V7, P2499; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; RATHJEN FG, 1984, EMBO J, V3, P1; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SAIRIO K, 1994, INT J DEV BIOL, V38, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Suvanto P, 1996, EUR J NEUROSCI, V8, P816, DOI 10.1111/j.1460-9568.1996.tb01267.x; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	30	682	725	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					789	793		10.1038/381789a0	http://dx.doi.org/10.1038/381789a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657282				2022-12-01	WOS:A1996UU35600061
J	Morahan, G; Huang, DX; Tait, BD; Colman, PG; Harrison, LC				Morahan, G; Huang, DX; Tait, BD; Colman, PG; Harrison, LC			Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus	SCIENCE			English	Article							GENETIC-ANALYSIS; LOCALIZATION; MICE; IDENTIFICATION; LINKAGE; RECEPTOR; PROTEIN; GENOME; LOCUS	Insulin-dependent diabetes mellitus (IDDM) is a multigenic autoimmune disease. An IDDM susceptibility gene was mapped to chromosome 2q34. This gene may act early in diabetogenesis, because ''preclinical'' individuals also showed linkage, Human leukocyte antigen (HLA)-disparate, but not HLA-identical, sibs showed linkage, which was even stronger in families with affected females. The genes encoding insulin-like growth factor-binding proteins 2 and 5 were mapped to a 4-megabase pair interval near this locus, These results indicate the existence of a gene that acts at an early stage in IDDM development, screening for which may identify a specific subset of at-risk individuals.			Morahan, G (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Morahan, Grant/T-7501-2019	Colman, Peter/0000-0001-8718-6175				ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BLUM WF, 1993, GROWTH REGULAT, V3, P100; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BUONAVISTA N, 1992, GENOMICS, V13, P856, DOI 10.1016/0888-7543(92)90169-S; CARTER RE, 1995, GENOMICS, V27, P196, DOI 10.1006/geno.1995.1025; COPEMAN JB, 1995, NAT GENET, V9, P80, DOI 10.1038/ng0195-80; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEGOUYON B, 1993, P NATL ACAD SCI USA, V90, P1877, DOI 10.1073/pnas.90.5.1877; DUNCAN AMV, 1992, CYTOGENET CELL GENET, V60, P212, DOI 10.1159/000133340; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; FIELD LL, 1994, NAT GENET, V8, P189, DOI 10.1038/ng1094-189; GARCHON HJ, 1991, NATURE, V353, P260, DOI 10.1038/353260a0; GIANNINI S, 1994, J CLIN ENDOCR METAB, V79, P1824, DOI 10.1210/jc.79.6.1824; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HOLMANS P, 1993, AM J HUM GENET, V52, P362; HONEYMAN MC, 1993, SPRINGER SEMIN IMMUN, V14, P253; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; KRUGLYAK L, 1995, NAT GENET, V11, P241; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; LUO DF, 1995, AM J HUM GENET, V57, P911; LUO DF, IN PRESS HUM MOL GEN; MORAHAN G, 1994, P NATL ACAD SCI USA, V91, P5898, DOI 10.1073/pnas.91.13.5898; MORAHAN G, UNPUB; OWERBACH D, 1995, DIABETES, V44, P132, DOI 10.2337/diabetes.44.1.132; POCIOT F, 1994, AUTOIMMUNITY, V19, P169, DOI 10.3109/08916939408995692; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; SERREZE DV, 1994, J EXP MED, V180, P1553, DOI 10.1084/jem.180.4.1553; STOFFEL M, 1993, DIABETOLOGIA, V36, P335, DOI 10.1007/BF00400237; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; THOMSON G, 1994, NAT GENET, V8, P108, DOI 10.1038/ng1094-108; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1990, IMMUNOL TODAY, V11, P122, DOI 10.1016/0167-5699(90)90049-F; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; WU BL, 1993, CYTOGENET CELL GENET, V63, P29, DOI 10.1159/000133495; YOUNG A, 1995, GAS MANUAL USER GUID; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	42	103	107	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1811	1813		10.1126/science.272.5269.1811	http://dx.doi.org/10.1126/science.272.5269.1811			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650584				2022-12-01	WOS:A1996UT11000050
J	Yuvaniyama, J; Denu, JM; Dixon, JE; Saper, MA				Yuvaniyama, J; Denu, JM; Dixon, JE; Saper, MA			Crystal structure of the dual specificity protein phosphatase VHR	SCIENCE			English	Article							CDC25 PROTEIN; TYROSINE PHOSPHATASE; DETECTOR; P34CDC2	Dual specificity protein phosphatases (DSPs) regulate mitogenic signal transduction and control the cell cycle. Here, the crystal structure of a human DSP, vaccinia H1-related phosphatase (or VHR), was determined at 2.1 angstrom resolution. A shallow active site pocket in VHR allows for the hydrolysis of phosphorylated serine, threonine, or tyrosine protein residues, whereas the deeper active site of protein tyrosine phosphatases (PTPs) restricts substrate specificity to only phosphotyrosine. Positively charged crevices near the active site may explain the enzyme's preference for substrates with two phosphorylated residues. The VHR structure defines a conserved structural scaffold for both DSPs and PTPs. A ''recognition region,'' connecting helix alpha 1 to strand beta 1 may determine differences in substrate specificity between VHR, the PTPs, and other DSPs.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Yuvaniyama, Jirundon/0000-0002-6800-8944	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018849, R01DK018024] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34095] Funding Source: Medline; NIDDK NIH HHS [DK18849, DK18024] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROCA P, 1995, J BIOL CHEM, V270, P14229, DOI 10.1074/jbc.270.23.14229; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KWAK SP, 1994, J BIOL CHEM, V269, P3596; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P140; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STONE RL, 1994, J BIOL CHEM, V269, P31323; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; STUCKEY JH, UNPUB; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	35	299	306	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1328	1331		10.1126/science.272.5266.1328	http://dx.doi.org/10.1126/science.272.5266.1328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650541				2022-12-01	WOS:A1996UN47200043
J	Levy, D; Larson, MG; Vasan, RS; Kannel, WB; Ho, KKL				Levy, D; Larson, MG; Vasan, RS; Kannel, WB; Ho, KKL			The progression from hypertension to congestive heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR DYSFUNCTION; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; UNITED-STATES; FRAMINGHAM; MORTALITY; DISEASE; POPULATION; PREVALENCE	Objectives.-To study the relative and population-attributable risks of hypertension for the development of congestive heart failure (CHF), to assess the time course of progression from hypertension to CHF, and to identify risk factors that contribute to the development of overt heart failure in hypertensive subjects. Design.-Inception cohort study. Setting.-General community. Participants.-Original Framingham Heart Study and Framingham Offspring Study participants aged 40 to 89 years and free of CHF. To reflect more contemporary experience, the starting point of this study was January 1, 1970. Exposure Measures.-Hypertension (blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or current use of medications for treatment of high blood pressure) and other potential CHF risk factors were assessed at periodic clinic examinations. Outcome Measure.-The development of CHF. Results.-A total of 5143 eligible subjects contributed 72 422 person-years of observation. During up to 20.1 years of follow-up (mean, 14.1 years), there were 392 new cases of heart failure; in 91% (357/392), hypertension antedated the development of heart failure. Adjusting for age and heart failure risk factors in proportional hazards regression models, the hazard for developing heart failure in hypertensive compared with normotensive subjects was about 2-fold in men and 3-fold in women. Multivariable analyses revealed that hypertension had a high population-attributable risk for CHF, accounting for 39% of cases in men and 59% in women. Among hypertensive subjects, myocardial infarction, diabetes, left ventricular hypertrophy, and valvular heart disease were predictive of increased risk for CHF in both sexes. Survival following the onset of hypertensive CHF was bleak; only 24% of men and 31% of women survived 5 years. Conclusions.-Hypertension was the most common risk factor for CHF, and it contributed a large proportion of heart failure cases in this population-based sample. Preventive strategies directed toward earlier and more aggressive blood pressure control are likely to offer the greatest promise for reducing the incidence of CHF and its associated mortality.	NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Levy, D (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABF-6873-2021	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELMANN WH, 1989, J AM COLL CARDIOL, V13, P1219, DOI 10.1016/0735-1097(89)90293-3; AGUIRRE FV, 1989, AM J CARDIOL, V63, P1098, DOI 10.1016/0002-9149(89)90085-4; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1007; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cox DR, 1984, ANAL SURVIVAL DATA, P48; Cutler Jeffrey A., 1995, P253; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; ECHEVERRIA HH, 1983, AM J MED, V75, P750, DOI 10.1016/0002-9343(83)90403-5; ERIKSSON H, 1988, ACTA MED SCAND, V223, P197; ERIKSSON H, 1989, EUR HEART J, V10, P647, DOI 10.1093/oxfordjournals.eurheartj.a059542; Furberg C D, 1986, Adv Cardiol, V34, P124; GALDERISI M, 1991, AM J CARDIOL, V68, P85, DOI 10.1016/0002-9149(91)90716-X; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GLYNN JR, 1993, LANCET, V342, P530, DOI 10.1016/0140-6736(93)91651-2; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; IRIARTE M, 1993, AM J CARDIOL, V71, P308, DOI 10.1016/0002-9149(93)90796-F; KANNEL W, 1988, FRAMINGHAM STUDY, P5; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1987, AM J CARDIOL, V60, pI85; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; *SAS I INC, 1992, P229 SAS I INC, P433; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1027; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; Vasan RS, 1996, ARCH INTERN MED, V156, P146, DOI 10.1001/archinte.156.2.146; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; VASAN RS, 1995, CIRCULATION S1, V92, P665; WACKERS FJ, 1976, BRIT HEART J, V38, P906; WONG WF, 1989, AM J CARDIOL, V63, P1526, DOI 10.1016/0002-9149(89)90022-2; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1989, HYPERTENSION, V0013; 1994, MMWR-MORBID MORTAL W, V43, P77	55	1424	1487	3	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1557	1562		10.1001/jama.275.20.1557	http://dx.doi.org/10.1001/jama.275.20.1557			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622246				2022-12-01	WOS:A1996UL02900027
J	Staessen, JA; Roels, H; Fagard, R				Staessen, JA; Roels, H; Fagard, R			Lead exposure and conventional and ambulatory blood pressure - A prospective population study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK; RENAL-FUNCTION; UNITED-STATES; HYPERTENSION; ASSOCIATION; FRAMINGHAM; ALCOHOL; HEALTH; TRIALS	Objective.-To evaluate in a prospective fashion the association between low-level lead exposure and blood pressure. Design.-Prospective cohort study. Setting.-General population. Participants.-A random population sample (N=728; 49% men; age range, 20-82 years) was studied in Belgium for 1985 through 1989 and reexamined for 1991 through 1995. Mean Outcome Measures.-At baseline and follow-up, blood pressure was measured by conventional sphygmomanometry (15 total readings) and at followup also by 24-hour ambulatory monitoring. Lead exposure was estimated from blood lead and zinc protoporphyrin concentrations. Multivariate analyses controlled for sex, age, body mass index, smoking and drinking habits, physical activity, exposure at work, social class, menopausal status, use of medications (antihypertensive medication, oral contraceptives, hormonal replacement therapy), hematocrit or hemoglobin, serum total calcium concentration, 24-hour urinary sodium and potassium excretion, and gamma-glutamyltransferase activity. Results.-At baseline, mean (SD) systolic/diastolic conventional blood pressure was 130 (17)/77 (9) mm Hg. The mean blood lead concentration was 0.42 mu mol/L (8.7 mu g/dL), and the mean zinc protoporphyrin concentration was 1.0 mu g per gram of hemoglobin. Over the 5.2-year median follow-up, the mean blood lead concentration dropped by 32% (0.14 mu mol/L [2.9 mu g/dL]) (P<.001). Small but significant (P<.01) changes occurred in systolic (-1.5 mm Hg) and diastolic (+1.7 mm Hg) conventional blood pressure and in zinc protoporphyrin concentration (+0.5 mu g per gram of hemoglobin). Over the follow-up period, no consistent associations emerged between the changes in conventional blood pressure and in blood lead or zinc protoporphyrin concentrations. In addition, after adjustment for sex, age, and body mass index, blood lead and zinc protoporphyrin concentrations at baseline did not predict the development of hypertension in 47 patients (risk ratio for doubling of the initial lead concentration, 1.2; 95% confidence interval, 0.7-2.0). In a time-integrated analysis in which each person was characterized by all available measurements, conventional blood pressure did not correlate with blood lead or zinc protoporphyrin concentrations in a consistent manner. Similarly, the mean (SD) 24-hour blood pressure at follow-up (119 [11]/71 [8] mm Hg; N=684) did not show a consistent relationship with blood lead or zinc protoporphyrin concentrations at baseline or at follow-up. Conclusions.-Lead exposure at the intensity studied (<1.45 mu mol/L [<30 mu g/dL]) was not consistently associated with increased conventional or 24-hour blood pressure in the general population or with increased risk of hypertension. These findings argue against the hypothesis that current lead exposure levels are associated with excess cardiovascular morbidity and mortality caused by hypertension.	UNIV LOUVAIN, DEPT MOL & CARDIOVASC RES, HYPERTENS & CARDIOVASC REHABIL UNIT, LOUVAIN, BELGIUM; UNIV LOUVAIN, IND TOXICOL & OCCUPAT MED UNIT, BRUSSELS, BELGIUM	Universite Catholique Louvain			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; Astrand PO., 1986, TXB WORK PHYSL PHYSL, P486; CHABANEL A, 1995, HYPERTENSION PATHOPH, V1, P365; CLAEYS F, 1992, CADMIUM HUMAN ENV TO, P83; COATE D, 1989, J HEALTH ECON, V8, P173, DOI 10.1016/0167-6296(89)90002-7; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONWAY J, 1988, J HYPERTENS, V6, P111; COOPER WC, 1985, SCAND J WORK ENV HEA, V11, P331, DOI 10.5271/sjweh.2215; ELLIOTT P, 1988, BRIT MED J, V297, P319; GARTSIDE PS, 1988, ENVIRON HEALTH PERSP, V78, P31, DOI 10.2307/3430495; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HARLAN WR, 1984, AM J EPIDEMIOL, V120, P17, DOI 10.1093/oxfordjournals.aje.a113870; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; LOCKETT CJ, 1987, B ENVIRON CONTAM TOX, V38, P975, DOI 10.1007/BF01609083; Machin D, 1987, STAT TABLES DESIGN C, P89; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MANCIA G, 1983, LANCET, V2, P695; MCARDLE WD, 1991, EXERCISE PHYSL ENERG, P804; MOLLER L, 1992, AM J EPIDEMIOL, V136, P1091, DOI 10.1093/oxfordjournals.aje.a116574; NERI LC, 1988, ENVIRON HEALTH PERSP, V78, P123, DOI 10.2307/3430512; OBRIEN E, 1991, J HUM HYPERTENS, V5, P223; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; OLSEN NB, 1981, DAN MED BULL, V28, P168; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; Pickering TG., 1991, AMBULATORY MONITORIN; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; POCOCK SJ, 1984, BRIT MED J, V289, P872, DOI 10.1136/bmj.289.6449.872; RABINOWITZ M, 1987, HYPERTENSION, V10, P447, DOI 10.1161/01.HYP.10.4.447; SCHMID RW, 1957, ANAL CHEM, V29, P264, DOI 10.1021/ac60122a026; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SIEGEL S, 1988, NONPARAMETRIC STAT B, P73; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1991, J HUM HYPERTENS, V5, P355; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN J, 1984, ACTA CARDIOL, V39, P55; Staessen J A, 1994, J Cardiovasc Risk, V1, P87; Staessen J.A., 1993, J HYPERTENS S2, V11, pS35; STAESSEN JA, 1995, J HUM HYPERTENS, V9, P303; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; Thijs L, 1992, HIGH BLOOD PRESSURE, V1, P17; *US EPA, 1986, US EPA PUBL, P1; WEISS ST, 1986, AM J EPIDEMIOL, V123, P800, DOI 10.1093/oxfordjournals.aje.a114309; YAMADA Y, 1991, HYPERTENSION, V18, P819, DOI 10.1161/01.HYP.18.6.819; 1990, J HYPERTENS       S6, V8, pS135	53	59	62	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1563	1570		10.1001/jama.275.20.1563	http://dx.doi.org/10.1001/jama.275.20.1563			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622247				2022-12-01	WOS:A1996UL02900028
J	Nehls, M; Kyewski, B; Messerle, M; Waldschutz, R; Schuddekopf, K; Smith, AJH; Boehm, T				Nehls, M; Kyewski, B; Messerle, M; Waldschutz, R; Schuddekopf, K; Smith, AJH; Boehm, T			Two genetically separable steps in the differentiation of thymic epithelium	SCIENCE			English	Article							STROMAL CELL-TYPES; MICE; MICROENVIRONMENT; MATURATION; ALPHA	The development oi the thymus depends initially on epithelial-mesenchymal and subsequently on reciprocal lympho-stromal interactions. The genetic steps governing development and differentiation of the thymic microenvironment are unknown. With the use of a targeted disruption of the whn gene, which recapitulates the phenotype of the athymic nude mouse, the WHN transcription factor was shown to be the product of the nude locus. Formation of the thymic epithelial primordium before the entry of lymphocyte progenitors did not require the activity of WHN. However, subsequent differentiation of primitive precursor cells into subcapsular, cortical, and medullary epithelial cells of the postnatal thymus did depend on activity of the whn gene. These results define the first geneticallyd separable steps during thymic epithelial differentiation.	DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); MRC Laboratory Molecular Biology				Messerle, Martin/0000-0002-1227-3933				ALTEVOGT P, 1989, EUR J IMMUNOL, V19, P1509, DOI 10.1002/eji.1830190826; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; AUERBACH R, 1960, DEV BIOL, V2, P271, DOI 10.1016/0012-1606(60)90009-9; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; HOLLANDER GA, 1995, NATURE, V373, P350, DOI 10.1038/373350a0; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; KISHIHARA K, 1987, EUR J IMMUNOL, V17, P477, DOI 10.1002/eji.1830170407; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KUBO RT, 1989, J IMMUNOL, V142, P2736; LASTER AJ, 1986, DIFFERENTIATION, V31, P67, DOI 10.1111/j.1432-0436.1986.tb00385.x; LEDOUARIN NM, 1984, AM J ANAT, V170, P261, DOI 10.1002/aja.1001700305; MACDONALD HR, 1981, J IMMUNOL, V126, P885; MESSERLE M, UNPUB; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NEHLS M, 1995, MAMM GENOME, V6, P321, DOI 10.1007/BF00364794; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NEHLS M, 1994, BIOTECHNIQUES, V17, P770; RICH BE, 1995, J EXP MED, V181, P1223, DOI 10.1084/jem.181.3.1223; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WARREN A, 1994, CELL, V15, P45; [No title captured]	28	368	437	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					886	889		10.1126/science.272.5263.886	http://dx.doi.org/10.1126/science.272.5263.886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629026				2022-12-01	WOS:A1996UK75700063
J	Thompson, D; Oster, G				Thompson, D; Oster, G			Use of terfenadine and contraindicated drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSEQUENCES	Objective.-To assess changes in concurrent use of products containing terfenadine and contraindicated macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) and imidazole antifungals (ketoconazole, itraconazole) following reports of serious drug-drug interactions and changes in product labeling. Design.-Retrospective review of computerized pharmacy claims. Setting.-A large health insurer in New England. Patients.-Health plan members with 1 or more paid pharmacy claims for products containing terfenadine between January 1990 and June 1994. Main Outcome Measures.-Among persons with paid claims for terfenadine in any given month, percentage with a prescription for any contraindicated drug that alternatively was dispensed on the same day as (''same-day dispensing'') or had therapy days that overlapped those of (''overlapping use'') a prescription for terfenadine. Results.-Concurrent use of terfenadine and contraindicated drugs declined over the study period. The rate of same-day dispensing declined by 84%, from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first 6 months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin. Conclusions.-Despite substantial declines following reports of serious drug-drug interactions and changes in product labeling, concurrent use of terfenadine and contraindicated macrolide antibiotics and imidazole antifungals continues to occur.	POLICY ANAL INC,BROOKLINE,MA 02146	Policy Analysis Inc			Thompson, David/E-2431-2018	Thompson, David/0000-0001-8518-6307				[Anonymous], 1992, Med Lett Drugs Ther, V34, P9; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; CRANE JK, 1993, AM J MED, V95, P445, DOI 10.1016/0002-9343(93)90317-I; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HONIG PK, 1993, J CLIN PHARMACOL, V33, P1201, DOI 10.1002/j.1552-4604.1993.tb03920.x; *IMS AM LTD, 1995, 1995 NAT PRESCR AUD; MASHETER HC, 1993, CLIN REV ALLERG, V11, P5; *MM DOW INC, 1990, IMP DRUG WARN; *MM DOW INC, 1992, IMP DRUG WARN; *MM DOW INC, 1993, SELD PROD LAB; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; NIGHTINGALE SL, 1992, JAMA-J AM MED ASSOC, V268, P705, DOI 10.1001/jama.268.6.705; PECK CC, 1993, JAMA-J AM MED ASSOC, V269, P1550, DOI 10.1001/jama.269.12.1550; Pulmonary-Allergy Drugs Advisory Committee, 1990, P PULM ALL DRUGS ADV; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1535	16	88	88	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1339	1341		10.1001/jama.275.17.1339	http://dx.doi.org/10.1001/jama.275.17.1339			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614120				2022-12-01	WOS:A1996UG61200031
J	Enari, M; Talanian, RV; Wong, WW; Nagata, S				Enari, M; Talanian, RV; Wong, WW; Nagata, S			Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis	NATURE			English	Article								BINDING of Fas ligand or an agonistic anti-Fas antibody induces apoptosis in Fas-bearing cells(1). The interleukin-1 beta-converting enzyme (ICE) is a cysteine protease(2) that is involved in apoptosis induced by various stimuli, including Fas-mediated apoptosis(3-8). Several ICE homologues have been identified, and these are subdivided into three groups (ICE-, CPP32- and Ich-1-like proteases)(9-18). We show here that specific inhibitors of ICE- or CPP32-like proteases can inhibit Fas-mediated apoptosis. Transient ICE-like activity was found in the cytosolic fraction of Fas-activated cells, whereas ICE-dependent, CPP32-like activity gradually accumulated in the cytosol. Cell lysates from mouse lymphoma supplemented with either recombinant ICE or CPP32 induced apoptosis of nuclei. The CPP32 inhibitor inhibited ICE- or CPP32-induced apoptosis in the cell-free system, whereas the ICE-inhibitor only inhibited ICE-induced apoptosis. Cell extracts from thymocytes from ICE-null mice induced apoptosis in the cell-free system when it was supplemented with CPP32. These results indicate that Fas sequentially activates ICE- and CPP32-like proteases, and that downstream CPP32, together with a component(s) in the cytoplasm, causes apoptosis of nuclei.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; BASF BIORES CORP,WORCESTER,MA 01605; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	BASF; Osaka University			Enari, Masato/E-5507-2014; Nagata, Shigekazu/AAG-3203-2019	Enari, Masato/0000-0003-4293-3848; Nagata, Shigekazu/0000-0001-9758-8426				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMBERY N, 1995, PERSP DRUG DISC DES, V2, P389; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TWARI M, 1995, CELL, V81, P801; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7	30	952	978	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					723	726		10.1038/380723a0	http://dx.doi.org/10.1038/380723a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614469				2022-12-01	WOS:A1996UG82700055
J	Walcheck, B; Kahn, J; Fisher, JM; Wang, BB; Fisk, RS; Payan, DG; Feehan, C; Betageri, R; Darlak, K; Spatola, AF; Kishimoto, TK				Walcheck, B; Kahn, J; Fisher, JM; Wang, BB; Fisk, RS; Payan, DG; Feehan, C; Betageri, R; Darlak, K; Spatola, AF; Kishimoto, TK			Neutrophil rolling altered by inhibition of L-selectin shedding in vitro	NATURE			English	Article							ADHESION MOLECULE-1; CHEMOTACTIC FACTORS; ENDOTHELIAL-CELLS; PRECURSOR; INFLAMMATION; CLEAVAGE; PROTEIN; INVIVO; ALPHA	THE L-selectin adhesion molecule is involved in guiding leukocytes to sites of inflammation(1). L-selectin is cleaved by an unusual proteolytic activity at a membrane-proximal site resulting in rapid shedding from the cell surface(2-7). Although it has been demonstrated that L-selectin mediates, in part, the early event of leukocyte rolling under hydrodynamic flows(8-10), the contribution of shedding to L-selectin function has remained unknown. Here we show that hydroxamic acid-based metalloprotease inhibitors block L-selectin downregulation from the cell surface of stimulated neutrophils, without affecting Mac-1 mobilization or general neutrophil activation, and inhibit cleavage of L-selectin in a cell-free system. Unexpectedly, the hydroxamic acid-based inhibitors reduced neutrophil rolling velocity under hydrodynamic flow, resulting in increased neutrophil accumulation. These results suggest that L-selectin is cleaved in seconds-much faster than previously suspected-during the process of rolling under hydrodynamic flow, and that shedding of L-selectin may contribute significantly to the velocity of leukocyte rolling, L-selectin shedding during rolling interactions may be physiologically important for limiting leukocyte aggregation and accumulation at sites of inflammation.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,RIDGEFIELD,CT 06877; KHEPRI PHARMACEUT INC,S SAN FRANCISCO,CA 94080; UNIV LOUISVILLE,DEPT CHEM,LOUISVILLE,KY 40292; UNIV LOUISVILLE,DEPT BIOCHEM,LOUISVILLE,KY 40292	Boehringer Ingelheim; Boehringer Ingelheim; University of Louisville; University of Louisville								ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; HAMANN A, 1988, J IMMUNOL, V140, P737; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LEY K, 1991, BLOOD, V77, P2553; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SIMON SI, 1992, J IMMUNOL, V149, P2765; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPATOLA AF, 1992, PEPTIDES CHEM BIOL, P820; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	32	260	269	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					720	723		10.1038/380720a0	http://dx.doi.org/10.1038/380720a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614468				2022-12-01	WOS:A1996UG82700054
J	Dickason, RR; Huston, DP				Dickason, RR; Huston, DP			Creation of a biologically active interleukin-5 monomer	NATURE			English	Article							COLONY-STIMULATING FACTOR; BINDING	INTERLEUKIN-5 (IL-5) specifically induces the differentiation of eosinophils, which are important in host defence and the patho genesis of allergies and asthma(1,2). Structurally, IL-5 is a unique member of the short-chain helical-bundle subfamily of cytokines whose canonical motif contains four helices (A-D) arranged in an up-up-down-down topology(3,4). In contrast to other subfamily members, which fold unimolecularly into a single helical bundle(5-8), IL-5 forms a pair of helical bundles by the interdigitation of two identical monomers that contribute a D helix to the other's A-C helices(3). We predicted that the lack of bioactivity by an IL-5 monomer(9) was due to a short loop between helices C and D which physically prevents unimolecular folding of helix D into a functionally obligate structural motif. Here we report that, by lengthening this loop, we have engineered an insertional mutant of IL-5 that was expressed as a monomer with biological activity similar to that of native IL-5. These studies demonstrate that all of the structural features necessary for IL-5 to function are contained within a single helical bundle.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	Dickason, RR (corresponding author), BAYLOR COLL MED, DEPT MED, 1 BAYLOR PLAZA, FBRN B567, HOUSTON, TX 77030 USA.			Huston, David/0000-0002-2332-0010				BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KORKE M, 1994, INT ARCH ALLER A IMM, V104, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKENZIE ANJ, 1991, MOL IMMUNOL, V28, P155, DOI 10.1016/0161-5890(91)90099-6; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; Summers MD, 1987, MANUAL METHODS BACUL; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194	19	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					652	655		10.1038/379652a0	http://dx.doi.org/10.1038/379652a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628400				2022-12-01	WOS:A1996TV68800056
J	Eidelman, LA; Putterman, D; Putterman, C; Sprung, CL				Eidelman, LA; Putterman, D; Putterman, C; Sprung, CL			The spectrum of septic encephalopathy - Definitions, etiologies, and mortalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPSIS; SYSTEM; COMA	Objective.-To determine whether the severity of septic encephalopathy is correlated with gram-negative bacteremia and mortality and whether there exists a single or combination of metabolic derangement(s) that cause septic encephalopathy. Design and Setting.-Prospective case series in an academic medical center. Patients.-Fifty patients selected according to clinical and laboratory criteria for severe sepsis. The criteria included temperature, heart rate, respiratory rate, and hypotension and/or signs of systemic hypoperfusion. Main Outcome Measures.-A single or combination of metabolic and laboratory derangements and organ failures, three different methods to grade the severity of septic encephalopathy, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, gram-negative bacteremia and infection, and mortality. Results.-Encephalopathy was associated with an increase in mortality when graded by the Glasgow Coma Score; a score of 15 had 16% mortality, 13 to 14 had 20%, 9 to 12 had 50%, and 3 to 8 had 63% mortality (P<.05). Bacteremia was associated with encephalopathy; 13% of septic patients without encephalopathy vs 59% of patients with encephalopathy had bacteremia (P<.001) when graded by altered mental status. Septic encephalopathic patients had elevated serum urea nitrogen and bilirubin levels, increased APACHE II scores, and a higher incidence of renal failure. Conclusions.-The severity of septic encephalopathy correlated with mortality, bacteremia, and renal and hepatic dysfunction. The Glasgow Coma Score is a useful tool for characterizing septic encephalopathy. Considerable variations can be found according to different criteria used to classify septic encephalopathy.	HEBREW UNIV JERUSALEM,HADASSAH UNIV HOSP,DEPT ANESTHESIOL & CRIT CARE MED,IL-91120 JERUSALEM,ISRAEL; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY	Hebrew University of Jerusalem; Yeshiva University; Albert Einstein College of Medicine								[Anonymous], 1992, CRIT CARE MED, V20, P864; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; Bleck Thomas P., 1993, P193; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; BOLTON CF, 1986, NEW HORIZONS PERSPEC, P157; BOLTON CF, 1993, ANN NEUROL, V33, P4; BOWTON DL, 1989, CRIT CARE CLIN, V5, P785; Freedman D. A., 1980, STATISTICS; JACKSON AC, 1985, CAN J NEUROL SCI, V12, P303, DOI 10.1017/S0317167100035381; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOPPEL JD, 1989, TXB NEPHROLOGY, P1238; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LUCE JM, 1987, CHEST, V91, P883, DOI 10.1378/chest.91.6.883; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; MERRILL JP, 1953, AM J MED, V14, P519; MULLIE A, 1988, LANCET, V1, P137; PENDLEBURY WW, 1989, J NEUROPATH EXP NEUR, V48, P290, DOI 10.1097/00005072-198905000-00006; PINE RW, 1983, ARCH SURG-CHICAGO, V118, P242; Plum F., 1980, DIAGNOSIS STUPOR COM; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; TEASDALE G, 1974, LANCET, V2, P81; WIJDICKS EFM, 1992, ARCH NEUROL-CHICAGO, V49, P653, DOI 10.1001/archneur.1992.00530300093015; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429	25	267	285	3	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					470	473		10.1001/jama.275.6.470	http://dx.doi.org/10.1001/jama.275.6.470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627969				2022-12-01	WOS:A1996TU63800036
J	Rodewald, HR; Dessing, M; Dvorak, AM; Galli, SJ				Rodewald, HR; Dessing, M; Dvorak, AM; Galli, SJ			Identification of a committed precursor for the mast cell lineage	SCIENCE			English	Article							BONE-MARROW; PERIPHERAL-BLOOD; MICE; HYPERSENSITIVITY; INTERLEUKIN-4; ESTABLISHMENT; MATURATION; EXPRESSION; RECEPTORS; BASOPHILS	Mast cells originate from hematopoietic stem cells, but the mast cell-committed precursor has not been identified. In the study presented here, a cell population in murine fetal blood that fulfills the criteria of progenitor mastocytes was identified. It is defined by the phenotype Thy-1(lo)c-Kit(hi), contains cytoplasmic granules, and expresses RNAs encoding mast cell-associated proteases but lacks expression of the high-affinity immunoglobulin E receptor. Thy-1(lo)c-Kit(hi) cells generated functionally competent mast cells at high frequencies in vitro but lacked developmental potential for other hematopoietic lineages. When transferred intraperitoneally, this population reconstituted the peritoneal mast cell compartment of genetically mast cell-deficient W/W-v mice to wild-type levels.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rodewald, HR (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.				NCI NIH HHS [CA/AI-72074] Funding Source: Medline; NIAID NIH HHS [AI-33372, AI/CA-23990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI023990, R01AI033372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN JW, 1991, EUR J IMMUNOL, V21, P2559, DOI 10.1002/eji.1830211037; DVORAK AM, 1993, LAB INVEST, V68, P708; DVORAK AM, 1982, BLOOD, V59, P1279; DVORAK AM, 1994, AM J PATHOL, V144, P160; ENERBACK L, 1974, HISTOCHEMISTRY, V42, P301, DOI 10.1007/BF00492678; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; HUFF TF, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P105; ISCOVE NN, 1979, IMMUNOLOGICAL METHOD, P379; ISHIZAKA K, 1989, CURR OPIN IMMUNOL, V1, P625, DOI 10.1016/0952-7915(89)90031-9; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KINZER CA, 1995, J EXP MED, V182, P575, DOI 10.1084/jem.182.2.575; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P1085; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.immunol.7.1.59; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; KSUGAI T, 1995, BLOOD, V85, P1334; LANTZ CS, 1995, J IMMUNOL, V155, P4024; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Miller H. R. P., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P228; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; OGAWA M, 1991, J EXP MED, V174, P631; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; RA C, 1989, J BIOL CHEM, V264, P15323; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; RODEWALD HR, 1995, CURR OPIN IMMUNOL, V7, P176, DOI 10.1016/0952-7915(95)80002-6; ROLINK A, 1993, BLOOD, V81, P2290; ROTTEM M, 1992, BLOOD, V79, P972; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SONODA T, 1982, J CELL PHYSIOL, V112, P136, DOI 10.1002/jcp.1041120120; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TSAI M, 1995, AM J PATHOL, V146, P335; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; ZUCKERFRANKLIN D, 1981, BLOOD, V58, P544	45	283	287	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					818	822		10.1126/science.271.5250.818	http://dx.doi.org/10.1126/science.271.5250.818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629001				2022-12-01	WOS:A1996TU69400050
J	Winkelmann, BR; Nauck, M; Klein, B; Russ, AP; Bohm, BO; Siekmeier, R; Ihnken, K; Verho, M; Gross, W; Marz, W				Winkelmann, BR; Nauck, M; Klein, B; Russ, AP; Bohm, BO; Siekmeier, R; Ihnken, K; Verho, M; Gross, W; Marz, W			Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; myocardial infarction; peptidyl-dipeptidase A; polymorphism (genetics)		Background: Previous research has shown that the insertion/deletion (I/D) polymorphism of the angiotensin I-converting enzyme (ACE) gene is a major determinant of plasma ACE activity. It has been suggested that persons with the DD genotype (those who express, on average, the highest levels of circulating ACE) have an increased risk for myocardial infarction and coronary artery disease, particularly if they are otherwise at low risk. Subsequent studies, however, have not confirmed that ACE I/D gene polymorphism is a risk factor for coronary artery disease and myocardial infarction. Objective: To investigate the association between the I/D polymorphism of the ACE gene and the risk for coronary artery disease and myocardial infarction in patients in whom coronary artery disease status was documented by angiography. Design: Cross-sectional study. Setting: University medical center. Patients: 209 male case-patients with coronary artery disease and 92 male controls without coronary artery disease, as documented by coronary angiography. Measurements: Assessment of the cardiac risk profile by questionnaire; classification of patients by the degree of coronary artery stenosis; levels of lipoproteins, apolipoproteins, and fibrinogen; and ACE I/D gene polymorphism assessed by polymerase chain reaction amplification. Results: Plasma ACE activity was significantly associated with ACE I/D gene polymorphism. The ACE genotype was not associated with the presence of coronary artery disease or myocardial infarction. If a recessive effect of the D allele was assumed (DD compared with DI and II), the relative risk was 1.00 (95% CI, 0.76 to 1.30) for coronary artery disease and 1.03 (CI, 0.77 to 1.38) for myocardial infarction. Results of analyses were also negative when a dominant effect of the D allele was assumed and when low-risk subgroups were examined. The established risk factors age and apolipoprotein B level emerged as the most important risk predictors in multivariate analyses, followed by diastolic blood pressure and fasting glucose levels. Conclusions: In an angiographically defined study sample, ACE I/D gene polymorphism was not associated with an increased risk for coronary artery disease or myocardial infarction, despite its effects on plasma ACE activity.	UNIV FRANKFURT, GUSTAV EMBDEN CTR BIOL CHEM, D-60590 FRANKFURT, GERMANY	Goethe University Frankfurt			Nauck, Michael Albrecht/ABA-9752-2021; Boehm, Bernhard Otto/F-8750-2015	Nauck, Michael Albrecht/0000-0002-5749-6954; 				AGERHOLMLARSEN B, 1996, CIRCULATION S1, V92, P800; AHNVE S, 1995, J AM COLL CARDIOL, V26, P277; Andersson B., 1995, European Heart Journal, V16, P113; ARBUSTINI E, 1995, BRIT HEART J, V74, P584; ASSMANN G, 1994, ATHEROSCLEROSIS, V110, pS11, DOI 10.1016/0021-9150(94)05386-W; Austen W G, 1975, Circulation, V51, P5; BEOHAR N, 1995, J INVEST MED, V43, P275; BOHN M, 1993, CLIN GENET, V44, P292; BOLIBAR I, 1995, ARTERIOSCL THROM VAS, V15, P1035, DOI 10.1161/01.ATV.15.8.1035; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; FRIEDL W, 1995, ATHEROSCLEROSIS, V112, P137, DOI 10.1016/0021-9150(94)05406-9; GARDEMANN A, 1995, CIRCULATION, V92, P2796, DOI 10.1161/01.CIR.92.10.2796; GLASER C, 1994, CIRCULATION, V90, P364; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; HUANG HM, 1994, CIRC RES, V75, P454, DOI 10.1161/01.RES.75.3.454; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JAMIESON A, 1994, UNPUB COUNC ART 67 S, P120; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; LACHURIE ML, 1995, CIRCULATION, V91, P2933, DOI 10.1161/01.CIR.91.12.2933; LEATHAM E, 1994, J HUM HYPERTENS, V8, P635; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; LUDWIG E, 1995, CIRCULATION, V91, P2120, DOI 10.1161/01.CIR.91.8.2120; MARSHALL HW, 1994, CIRCULATION, V89, P567, DOI 10.1161/01.CIR.89.2.567; MARZ W, 1986, CLIN CHIM ACTA, V160, P1, DOI 10.1016/0009-8981(86)90330-X; MATTU RK, 1995, CIRCULATION, V91, P270, DOI 10.1161/01.CIR.91.2.270; MIETTINEN HE, 1994, HUM GENET, V94, P189; MORRIS BJ, 1994, J CLIN INVEST, V94, P1085, DOI 10.1172/JCI117423; Moussard C., 1995, European Heart Journal, V16, P370; OKAMURA T, 1990, J CARDIOVASC PHARM, V15, P353, DOI 10.1097/00005344-199003000-00002; PAYNE MN, 1994, CIRCULATION, V90, P2566, DOI 10.1161/circ.90.5.7955223; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; ROBITAILLE NM, 1994, CIRCULATION, V90, P110; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHUNKERT H, 1993, CIRC RES, V72, P312, DOI 10.1161/01.RES.72.2.312; SHANMUGAM V, 1993, PCR METH APPL, V3, P120; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; TIRET L, 1992, AM J HUM GENET, V51, P197; URATA H, 1990, J BIOL CHEM, V265, P22348; WESOLOWSKA EB, 1994, UNPUB COUNC ART 67 S, P78; *WHO STUD GROUP DI, 1985, DIAB MELL	44	94	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1996	125	1					19	+		10.7326/0003-4819-125-1-199607010-00004	http://dx.doi.org/10.7326/0003-4819-125-1-199607010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT399	8644984				2022-12-01	WOS:A1996UT39900003
J	Bone, LI				Bone, LI			As I was dying - An examination of classic literature and dying	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Bone, LI (corresponding author), MED COLL OHIO, 3000 ARLINGTON AVE, TOLEDO, OH 43699 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1091	1093		10.7326/0003-4819-124-12-199606150-00013	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633826				2022-12-01	WOS:A1996UQ65800012
J	Kimball, AM; Tant, M				Kimball, AM; Tant, M			A role for businesses in HIV prevention in Asia	LANCET			English	Editorial Material									ASIAN DEV BANK,MANILA,PHILIPPINES	Asian Development Bank	Kimball, AM (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195, USA.							ALBERS C, 1991, 10 INT C AIDS; BEHRAVESH N, 1993, DRI MCGRAW HILL INSI, P1; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; CHEN D, 1991, NAT SEM AIDS SOC IMP; Goss D., 1993, EMPL RELAT, V15, P25, DOI [10.1108/01425459310031804, DOI 10.1108/01425459310031804]; HANKINS C, 1995, CAN MED ASSOC J, V153, P1613; JANJAREEON WS, 1995, REG AIDS C AS PAC CH; SINGH YN, 1994, INT J STD AIDS, V5, P137, DOI 10.1177/095646249400500212; TANG S, 1992, REPORT SURVEY AIDS W; *UN, 1993, DEM YB, P200; WEIL J, 1992, WALL STREET J   0702, pB1; *WHO, 1993, WORLD DEV REP EST HI; 1994, FAR E EC REV, V158, P5	13	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1670	1672		10.1016/S0140-6736(96)91493-2	http://dx.doi.org/10.1016/S0140-6736(96)91493-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642964				2022-12-01	WOS:A1996UQ70100016
J	Risold, PY; Swanson, LW				Risold, PY; Swanson, LW			Structural evidence for functional domains in the rat hippocampus	SCIENCE			English	Article							INSITU HYBRIDIZATION; MESSENGER-RNA; AMMONS HORN; NEURONS; NUCLEUS; BRAIN; LOCALIZATION; ORGANIZATION; CONNECTIONS; PROJECTIONS	The hippocampus has two major outputs: multisynaptic pathways to the cerebral cortex and a massive descending projection directly to the lateral septal part of the basal ganglia. Here it is shown that the descending output is organized in such a way that different hippocampal regions map in an orderly way onto hypothalamic systems mediating the expression of different classes of goal-oriented behavior. This mapping is characterized by a unidirectional hippocampo-lateral septal projection and then by bidirectional lateral septo-hypothalamic projections, all topographically organized. The connectional evidence predicts that information processing in different regions of the hippocampus selectively influences the expression of different classes of behavior.	UNIV SO CALIF,PROGRAM NEURAL INFORMAT & BEHAV SCI,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California; University of Southern California			Risold, Pierre-Yves/M-7730-2018; Risold, Pierre-Yves/AAJ-9535-2021	Risold, Pierre-Yves/0000-0001-6801-591X; 				CANTERAS NS, 1994, J COMP NEUROL, V348, P41, DOI 10.1002/cne.903480103; CANTERAS NS, UNPUB; COHEN RS, 1992, PROG NEUROBIOL, V38, P423, DOI 10.1016/0301-0082(92)90045-G; ESCLAPEZ M, 1993, J COMP NEUROL, V331, P339, DOI 10.1002/cne.903310305; HAGLUND L, 1984, J COMP NEUROL, V229, P171, DOI 10.1002/cne.902290204; HANSEN S, 1982, BRAIN RES, V239, P213, DOI 10.1016/0006-8993(82)90843-5; HARLAN RE, 1987, J COMP NEUROL, V258, P159, DOI 10.1002/cne.902580202; KOHLER C, 1984, ANAT EMBRYOL, V170, P1, DOI 10.1007/BF00319452; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; RISOLD PY, 1995, P NATL ACAD SCI USA, V92, P3898, DOI 10.1073/pnas.92.9.3898; RISOLD PY, 1994, J COMP NEUROL, V348, P1, DOI 10.1002/cne.903480102; RISOLD PY, UNPUB; SIEGEL A, 1988, PROG NEUROBIOL, V31, P261, DOI 10.1016/0301-0082(88)90015-9; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SIMERLY RB, 1988, J COMP NEUROL, V270, P209, DOI 10.1002/cne.902700205; Squire L.R., 1987, MEMORY BRAIN; Swanson L. W, 1992, BRAIN MAPS STRUCTURE; SWANSON LW, 1989, J COMP NEUROL, V285, P413, DOI 10.1002/cne.902850402; SWANSON LW, 1981, J NEUROSCI, V1, P548; SWANSON LW, 1975, SCIENCE, V189, P303, DOI 10.1126/science.49928; SWANSON LW, 1978, J COMP NEUROL, V181, P681, DOI 10.1002/cne.901810402; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; Swanson LW, 1987, HDB CHEM NEUROANATOM, P125; TAUBE JS, 1995, J NEUROSCI, V15, P70; [No title captured]	26	282	283	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1484	1486		10.1126/science.272.5267.1484	http://dx.doi.org/10.1126/science.272.5267.1484			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633241				2022-12-01	WOS:A1996UP89900048
J	Wang, XZ; Ron, D				Wang, XZ; Ron, D			Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase	SCIENCE			English	Article							PROTEIN-KINASE; GROWTH ARREST; DNA DAMAGE; AGENTS; ONCOGENE; C/EBP; CELLS	CHOP, a member of the C/EBP family of transcription factors, mediates effects of cellular stress on growth and differentiation, It accumulates under conditions of stress and undergoes inducible phosphorylation on two adjacent serine residues (78 and 81). In vitro, CHOP is phosphorylated on these residues by p38 mitogen-activated protein kinase (MAP kinase). A specific inhibitor of p38 MAP kinase, SB203580, abolished the stress-inducible in vivo phosphorylation of CHOP. Phosphorylation of CHOP on these residues enhanced its ability to function as a transcriptional activator and was also required for the full inhibitory effect of CHOP on adipose cell differentiation. CHOP thus serves as a link between a specific stress-activated protein kinase, p38, and cellular growth and differentiation.	NYU, MED CTR, SKIRBALL INST BIOMOL MED, DEPT MED, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Ron, David/0000-0002-3014-5636				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERLJARD B, 1994, CELL, V76, P1025; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUETHY JD, 1992, CANCER RES, V52, P5; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PRICE BD, 1992, CANCER RES, V52, P3814; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; WANG X, UNPUB; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	29	719	743	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1347	1349		10.1126/science.272.5266.1347	http://dx.doi.org/10.1126/science.272.5266.1347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650547				2022-12-01	WOS:A1996UN47200049
J	Seymour, CA				Seymour, CA			Controversies in management - Screening asymptomatic people at high risk for hepatitis C - The case for	BRITISH MEDICAL JOURNAL			English	Article							VIRUS				Seymour, CA (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,LONDON SW17 0RE,ENGLAND.							ALTER HJ, 1995, SEMIN LIVER DIS, V15, P5; ASCHER NL, 1994, HEPATOLOGY, V20, P245; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; BRUNO S, 1994, BRIT MED J, V308, P697, DOI 10.1136/bmj.308.6930.697; CUCKLE HS, 1995, BRIT MED J, V311, P1460, DOI 10.1136/bmj.311.7018.1460; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; GOODRICK MJ, 1994, TRANSFUSION MED, V4, P113, DOI 10.1111/j.1365-3148.1994.tb00251.x; MACLENNAN S, 1994, TRANSFUSION MED, V4, P130; MORADPOUR D, 1995, NEW ENGL J MED, V332, P1092, DOI 10.1056/NEJM199504203321610; POLYNARD T, 1995, NEW ENGL J MED, V332, P1457; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1016/0270-9139(93)90215-9; SEYMOUR CA, 1994, BRIT MED J, V308, P670, DOI 10.1136/bmj.308.6930.670; SHIELL A, 1994, MED J AUSTRALIA, V160, P268, DOI 10.5694/j.1326-5377.1994.tb125830.x; TERRAULT N, 1995, NEW ENGL J MED, V332, P1509, DOI 10.1056/NEJM199506013322211; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; VANDERPOEL CL, 1994, LANCET, V344, P1475, DOI 10.1016/S0140-6736(94)90293-3; Watson JP, 1996, GUT, V38, P269, DOI 10.1136/gut.38.2.269; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	20	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1347	1348		10.1136/bmj.312.7042.1347	http://dx.doi.org/10.1136/bmj.312.7042.1347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646052	Green Published			2022-12-01	WOS:A1996UN47600027
J	Marengere, LEM; Waterhouse, P; Duncan, GS; Mittrucker, HW; Feng, GS; Mak, TW				Marengere, LEM; Waterhouse, P; Duncan, GS; Mittrucker, HW; Feng, GS; Mak, TW			Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4	SCIENCE			English	Article							ANTIGEN RECEPTOR; ZETA-CHAIN; LYMPHOCYTES-T; TCR ZETA; KINASE; CD28; PHOSPHORYLATION; CLONING; ZAP-70	The absence of CTLA-4 results in uncontrolled T cell proliferation. The T cell receptor-specific kinases FYN, LCK, and ZAP-70 as well as the RAS pathway were found to be activated in T cells of Ctla-4(-/-) mutant mice. In addition, CTLA-4 specifically associated with the tyrosine phosphatase SYP, an interaction mediated by the SRC homology 2 (SH2) domains SYP and phosphotyrosine sequence Tyr-Val-Lys-Met within the CTLA-4 cytoplasmic tail. The CTLA-4-associated SYP had phosphatase activity toward the RAS regulator p52(SHC). Thus, the RAS pathway and T cell activation through the T cell receptor are regulated by CTLA-4-associated SYP.	UNIV TORONTO, AMGEN INST, ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, AMGEN INST, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M5G 2C1, CANADA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Duncan, Gordon/AIE-7011-2022	Waterhouse, Paul/0000-0001-8745-5224				ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GROSS JA, 1992, J IMMUNOL, V149, P380; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; OKUMURA M, 1995, CURR OPIN IMMUNOL, V7, P312, DOI 10.1016/0952-7915(95)80104-9; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	53	437	448	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1996	272	5265					1170	1173		10.1126/science.272.5265.1170	http://dx.doi.org/10.1126/science.272.5265.1170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638161				2022-12-01	WOS:A1996UM88900050
J	Attenburrow, MEJ; Dowling, BA; Sharpley, AL; Cowen, PJ				Attenburrow, MEJ; Dowling, BA; Sharpley, AL; Cowen, PJ			Case-control study of evening melatonin concentration in primary insomnia	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford				Sharpley, Ann L/0000-0002-0623-1067; Cowen, Philip/0000-0001-5518-6138				DEMENT WC, 1982, J AM GERIATR SOC, V30, P25, DOI 10.1111/j.1532-5415.1982.tb03700.x; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	5	18	18	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1263	1264		10.1136/bmj.312.7041.1263	http://dx.doi.org/10.1136/bmj.312.7041.1263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM404	8634615	Green Published			2022-12-01	WOS:A1996UM40400020
J	Hennessy, TW; Hedberg, CW; Slutsker, L; White, KE; BesserWiek, JM; Moen, ME; Feldman, J; Coleman, WW; Edmonson, LM; MacDonald, KL; Osterholm, MT; Belongia, E; Boxrud, D; Boyer, W; Danila, R; Korlath, J; Leano, F; Mills, W; Soler, J; Sullivan, M; Deling, M; Geisen, P; Kontz, C; Elfering, K; Krueger, W; Masso, T; Mitchell, MF; Vought, K; Duran, A; Harrell, F; Jirele, K; Krivitsky, A; Manresa, H; Mars, R; Nierman, M; Schwab, A; Sedzielarz, F; Tillman, F; Wagner, D; Wieneke, D; Price, C				Hennessy, TW; Hedberg, CW; Slutsker, L; White, KE; BesserWiek, JM; Moen, ME; Feldman, J; Coleman, WW; Edmonson, LM; MacDonald, KL; Osterholm, MT; Belongia, E; Boxrud, D; Boyer, W; Danila, R; Korlath, J; Leano, F; Mills, W; Soler, J; Sullivan, M; Deling, M; Geisen, P; Kontz, C; Elfering, K; Krueger, W; Masso, T; Mitchell, MF; Vought, K; Duran, A; Harrell, F; Jirele, K; Krivitsky, A; Manresa, H; Mars, R; Nierman, M; Schwab, A; Sedzielarz, F; Tillman, F; Wagner, D; Wieneke, D; Price, C			A national outbreak of Salmonella enteritidis infections from ice cream	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOODBORNE OUTBREAK; UNITED-STATES; RAW-MILK; CONSUMPTION; GASTROENTERITIS; TRANSMISSION	Background. In September 1994, the Minnesota Department of Health detected an increase in the number of reports of Salmonella enteritidis infections. After a case-control study implicated a nationally distributed brand of ice cream (Schwan's) in the outbreak, the product was recalled and further epidemiologic and microbiologic investigations were conducted. Methods. We defined an outbreak-associated case of S. enteritidis infection as one in which S. enteritidis was cultured from a person who became ill in September or October 1994. We established national surveillance and surveyed customers of the implicated manufacturer, The steps involved in the manufacture of ice cream associated with cases of S. enteritidis infection were compared with those of products not known to be associated with infection matched for the date of manufacture. Cultures for bacteria were obtained from ice cream samples, the ice cream plant, and tanker trailers that had transported the ice cream base (premix) to the plant. Results. estimate that S. enteritidis gastroenteritis developed in 224,000 persons in the United States after they ate Schwan's ice cream. The attack rate for consumers was 6.6 percent. Ice cream associated with infection contained a higher percentage of premix that had been transported by tanker trailers that had carried nonpasteurized eggs immediately before (P = 0.02). S. enteritidis was isolated from 8 of 266 ice cream products (3 percent), but not from environmental samples obtained from the ice cream plant (n = 157) or tanker trailers (n = 204). Conclusions. This nationwide outbreak of salmonellosis was most likely the result of contamination of pasteurized ice cream premix during transport in tanker trailers that had previously carried nonpasteurized liquid eggs containing S. enteritidis. To prevent further outbreaks, food products not destined for repasteurization should be transported in dedicated containers.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55440; MINNESOTA DEPT HLTH,PUBL HLTH LAB,MINNEAPOLIS,MN 55440; MINNESOTA DEPT HLTH,EXECUT OFF,MINNEAPOLIS,MN 55440; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30341; MINNESOTA DEPT AGR,DIV DAIRY & FOOD INSPECT,ST PAUL,MN; US FDA,MINNEAPOLIS,MN; OLMSTED CTY HLTH DEPT,ROCHESTER,MN; US FDA,CHICAGO,IL	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)				Belongia, Edward/0000-0001-7478-0415				BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BLASER MJ, 1982, REV INFECT DIS, V4, P1096; *CDCP, 1995, SALM SURV ANN TAB SU; CHALKER RB, 1988, REV INFECT DIS, V10, P111; Ewing WH, 1986, IDENTIFICATION ENTER; GRASMICK A, 1992, CLIN MICROBIOLOGY PR, V1; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3203, DOI 10.1001/jama.268.22.3203; HEDBERG CW, 1993, J INFECT DIS, V167, P107, DOI 10.1093/infdis/167.1.107; HEDBERG CW, 1991, J INFECT DIS, V164, P1135, DOI 10.1093/infdis/164.6.1135; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; HEDBERG CW, 1987, NEW ENGL J MED, V316, P993, DOI 10.1056/NEJM198704163161605; HICKMANBRENNER FW, 1991, J CLIN MICROBIOL, V29, P2817, DOI 10.1128/JCM.29.12.2817-2823.1991; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; KORLATH JA, 1985, J INFECT DIS, V152, P592, DOI 10.1093/infdis/152.3.592; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; OSTERHOLM MT, 1981, NEW ENGL J MED, V304, P24, DOI 10.1056/NEJM198101013040106; OSTERHOLM MT, 1980, AM J EPIDEMIOL, V112, P8, DOI 10.1093/oxfordjournals.aje.a112978; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; TAYLOR A, 1974, AM J EPIDEMIOL, V100, P150, DOI 10.1093/oxfordjournals.aje.a112017; *US FDA, 1992, BACT AN MAN; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; 1994, MMWR-MORBID MORTAL W, V43, P740; 1988, JAMA-J AM MED ASSOC, V259, P2103; 1994, MMWR-MORBID MORTAL W, V43, P669	26	233	240	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1281	1286		10.1056/NEJM199605163342001	http://dx.doi.org/10.1056/NEJM199605163342001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609944				2022-12-01	WOS:A1996UK88000001
J	Zhang, JA; HagopianDonaldson, S; Serbedzija, G; Elsemore, J; PlehnDujowich, D; McMahon, AP; Flavell, RA; Williams, T				Zhang, JA; HagopianDonaldson, S; Serbedzija, G; Elsemore, J; PlehnDujowich, D; McMahon, AP; Flavell, RA; Williams, T			Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2	NATURE			English	Article							RETINOIC ACID; DNA-BINDING	THE retinoic acid-inducible transcription factor AP-2 is expressed in epithelial and neural crest cell lineages during murine development(1-5). AP-2 can regulate neural and epithelial gene transcription, and is associated with overexpression of c-erbB-2 in human breast-cancer cell lines(4-6). To ascertain the importance of AP-2 for normal development, we have derived mice containing a homozygous disruption of the AP-2 gene. These AP-2-null mice have multiple congenital defects and die at birth, In particular, the AP-2 knockout mice exhibit anencephaly, craniofacial defects and thoraco-abdominoschisis. Skeletal defects occur in the head and trunk region, where many bones are deformed or absent. Analysis of these mice earlier in embryogenesis indicates a failure of cranial neural-tube closure and defects in cranial ganglia development. We have shown that AP-2 is a fundamental regulator of mammalian craniofacial development.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA; HARVARD UNIV, BIOL LABS, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Yale University; Harvard University; Howard Hughes Medical Institute; Yale University; Yale University			McMahon, Andrew P/ABE-7520-2020					BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHEN JM, 1952, J ANAT, V86, P373; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COPP AJ, 1994, CIBA F SYMP, V181, P118; DAVIES AF, 1995, HUM MOL GENET, V4, P121; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; GUNTHER T, 1994, DEVELOPMENT, V120, P3119; Hall B. K., 1988, NEURAL CREST; HALL BK, 1986, J EMBRYOL EXP MORPH, V93, P133; KOTCH LE, 1992, AM J MED GENET, V44, P168, DOI 10.1002/ajmg.1320440210; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARK M, 1993, DEVELOPMENT, V119, P319; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY G, 1994, NEURAL TUBE DEFECTS, P55; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Warren G, 1996, GENOMICS, V31, P234, DOI 10.1006/geno.1996.0037; WEI X, 1993, AM J MED GENET, V47, P862, DOI 10.1002/ajmg.1320470613; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	30	497	515	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1996	381	6579					238	241		10.1038/381238a0	http://dx.doi.org/10.1038/381238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622766				2022-12-01	WOS:A1996UL24900055
J	Driver, J				Driver, J			Enhancement of selective listening by illusory mislocation of speech sounds due to lip-reading	NATURE			English	Article								MECHANISMS of human attention allow selective processing of just the relevant events among the many stimuli bombarding our senses(1). Most laboratory studies examine attention within just a single sense, but in the real world many important events are specified multimodally, as in verbal communication. Speech comprises visual lip movements as well as sounds, and lip-reading contributes to speech perception. even for listeners with good hearing, by a process of audiovisual integration(2). Such examples raise the problem of how we coordinate our spatial attention across the sensory modalities, to select sights and sounds from a common source for further processing. Here we show that this problem is alleviated by allowing some cross-modal matching before attentional selection is completed. Cross modal matching can lead to an illusion, whereby sounds are mislocated at their apparent visual source(3); this crossmodal illusion can enhance selective spatial attention to speech sounds.			Driver, J (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT PSYCHOL,MALET ST,LONDON WC1E 7HX,ENGLAND.		Driver, Jon/A-4779-2010					BERTELSON P, 1976, PERCEPT PSYCHOPHYS, V19, P531, DOI 10.3758/BF03211222; Blauert J., 1983, SPATIAL HEARING; CHERRY EC, 1953, J ACOUST SOC AM, V25, P975, DOI 10.1121/1.1907229; DRIVER J, 1994, ATTENTION PERFORM, V15, P311; MASSARO DW, 1995, CURR DIR PSYCHOL SCI, V4, P104, DOI 10.1111/1467-8721.ep10772401; MASSARO DW, 1987, PERSPECTIVES PERCEPT, P273; Massaro DW, 1987, SPEECH PERCEPTION EA; MCGURK H, 1976, NATURE, V263, P747; Naatanen R., 1992, ATTENTION BRAIN FUNC; RADEAU M, 1994, CAH PSYCHOL COGN, V13, P3; REISBERG D, 1978, ACTA PSYCHOL, V42, P331, DOI 10.1016/0001-6918(78)90007-0; WITKIN HA, 1952, J EXP PSYCHOL, V43, P58, DOI 10.1037/h0055889	12	197	200	1	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					66	68		10.1038/381066a0	http://dx.doi.org/10.1038/381066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UJ053	8609989				2022-12-01	WOS:A1996UJ05300056
J	Rossi, F; Labourier, E; Forne, T; Divita, G; Derancourt, J; Riou, JF; Antoine, E; Cathala, G; Brunel, C; Tazi, J				Rossi, F; Labourier, E; Forne, T; Divita, G; Derancourt, J; Riou, JF; Antoine, E; Cathala, G; Brunel, C; Tazi, J			Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I	NATURE			English	Article							SPLICING FACTOR; CONSERVED FAMILY; RNA; DOMAINS; REGULATORS; EXPRESSION; PARTICLES; CLONING; U1-70K	SEVERAL metazoan splicing factors are characterized by ribonucleoprotein (RNP) consensus sequences and arginine-serine repeats (RS domain)(1-8) which are essential for their function in splicing(5,9,10). These include members of the SR-protein family (SC35, SF2/ASF), the U1 small nuclear (sn)RNP protein (U1-70K) and the U2 snRNP auxiliary factor (U2AF). SR proteins are phosphorylated in vivo(11) and the phosphorylation state of U1-70K's RS domain influences its splicing activity(12). Here we report the purification of a protein kinase that is specific for SR proteins and show that it is DNA topoisomerase I. This enzyme lacks a canonical ATP-binding motif hut hinds ATP with a dissociation constant of 50 nM. Camptothecin and derivatives, known to be specific inhibitors of DNA topoisomerase I, strongly inhibit the kinase activity in the presence of DNA and affect the phosphorylation state of SR proteins. Thus, DNA topoisomerase I may well be one of the SR protein kinases operating in vivo.	CNRS,CTR RECH BIOCHIM MACROMOLEC,LP 9008,INSERM,U249,F-34033 MONTPELLIER 1,FRANCE; RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,UNITE CANCEROL,DEPT BIOL,F-94403 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Sanofi-Aventis			Forne, Thierry/D-3718-2013; DIVITA, GILLES/AAV-9214-2021	Forne, Thierry/0000-0002-9179-1551; Labourier, Emmanuel/0000-0001-8010-0674; Tazi, Jamal/0000-0002-1949-8748; riou, jean-francois/0000-0002-0055-6506				BACH M, 1990, METHOD ENZYMOL, V181, P232; BJORNSTI MA, 1989, CANCER RES, V49, P6318; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; COTWILL K, 1996, EMBO J, V15, P265; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DIVITA G, 1993, J BIOL CHEM, V268, P13178; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FU XD, 1995, RNA, V1, P663; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; MENNO A, 1993, NATURE, V365, P227; Moore M., 1993, RNA WORLD, P303; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P133; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053; ZIEVE G, 1981, J MOL BIOL, V145, P501, DOI 10.1016/0022-2836(81)90542-8; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	30	278	280	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					80	82		10.1038/381080a0	http://dx.doi.org/10.1038/381080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609994				2022-12-01	WOS:A1996UJ05300061
J	Khunti, K				Khunti, K			A method of creating a death register for general practice	BRITISH MEDICAL JOURNAL			English	Article							AUDIT				Khunti, K (corresponding author), UNIV LEICESTER,ELI LILLY NATL CLIN AUDIT CTR,DEPT GEN PRACTICE & PRIMARY HLTH CARE,LEICESTER LE5 4PW,LEICS,ENGLAND.		/ABC-9527-2021	Khunti, Kamlesh/0000-0003-2343-7099				BERLIN A, 1993, BRIT J GEN PRACT, V43, P70; BLACK DA, 1984, BMJ-BRIT MED J, V288, P1127, DOI 10.1136/bmj.288.6424.1127; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; NEVILLE RG, 1987, J ROY COLL GEN PRACT, V37, P496	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					952	952						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616311				2022-12-01	WOS:A1996UF65900023
J	AbouElela, S; Igel, H; Ares, M				AbouElela, S; Igel, H; Ares, M			RNase III cleaves eukaryotic preribosomal RNA at a U3 snoRNP-dependent site	CELL			English	Article							EXTERNAL TRANSCRIBED SPACER; PRECURSOR RIBOSOMAL-RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RIBONUCLEASE-III; PROCESSING EVENT; POLYMERASE-I; S-POMBE; YEAST	A yeast gene homologous to bacterial RNase III (RNT1) encodes a double-strand-specific endoribonuclease essential for ribosome synthesis. Two rRNA processing events are blocked in cells temperature sensitive for RNT1: cleavage at the snoRNA-dependent A0 site in the 5' ETS and cleavage in the 3' ETS. Recombinant RNT1 protein accurately cleaves a synthetic 5' ETS RNA at the AO site in vitro, in the absence of snoRNA or other factors. A synthetic 3' ETS substrate is specifically cleaved at a site 21 nt downstream of the 3' end of 28S rRNA. These observations show that a protein endonuclease collaborates with snoRNAs in eukaryotic rRNA processing and exclude a catalytic role for snoRNAs at certain pre-rRNA cleavage sites.			AbouElela, S (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, DEPT BIOL, CTR MOL BIOL RNA, SANTA CRUZ, CA 95064 USA.			Ares, Manny/0000-0002-2552-9168	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; Assur V., 1988, PRACTICAL GUIDE SURV, P201; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BAYEV AA, 1980, NUCLEIC ACIDS RES, V8, P4919, DOI 10.1093/nar/8.21.4919; BELTRAME M, 1994, NUCLEIC ACIDS RES, V22, P4057, DOI 10.1093/nar/22.20.4057; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BRAM RJ, 1980, CELL, V19, P393, DOI 10.1016/0092-8674(80)90513-9; COURT D, 1993, CONTROL MRNA STABILI, P70; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; GOOD L, 1994, J BIOL CHEM, V269, P22169; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KLEMENZ R, 1980, NUCLEIC ACIDS RES, V8, P2679, DOI 10.1093/nar/8.12.2679; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; NICHOLSON AW, 1988, NUCLEIC ACIDS RES, V16, P1577, DOI 10.1093/nar/16.4.1577; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; POTTER S, 1995, SCIENCE, V268, P1056, DOI 10.1126/science.7538698; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; ROSE MD, 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTONDO G, 1995, MOL GEN GENET, V247, P698, DOI 10.1007/BF00290401; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SHUMARD CM, 1988, J BIOL CHEM, V263, P19346; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VELDMAN GM, 1980, NUCLEIC ACIDS RES, V8, P5179, DOI 10.1093/nar/8.22.5179; VENEMA J, 1995, EMBO J, V14, P4883, DOI 10.1002/j.1460-2075.1995.tb00169.x; Wells SE, 1996, GENE DEV, V10, P220, DOI 10.1101/gad.10.2.220; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; YEH LCC, 1992, J MOL BIOL, V228, P827, DOI 10.1016/0022-2836(92)90867-J; YIP MT, 1989, J BIOL CHEM, V264, P4045	61	202	214	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					115	124		10.1016/S0092-8674(00)81087-9	http://dx.doi.org/10.1016/S0092-8674(00)81087-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620530	Bronze, Green Published			2022-12-01	WOS:A1996UE55900014
J	Li, W; Whaley, CD; Mondino, A; Mueller, DL				Li, W; Whaley, CD; Mondino, A; Mueller, DL			Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4(+) T cells	SCIENCE			English	Article							COSTIMULATORY SIGNAL; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; REGULATED KINASES; ACTIVATION DOMAIN; CLONAL ANERGY; GROWTH-FACTOR; C ACTIVATION; PROLIFERATION; STIMULATION	T cells activated by antigen receptor stimulation in the absence of accessory cell-derived costimulatory signals lose the capacity to synthesize the growth factor interleukin-2 (IL-2), a state called clonal anergy. An analysis of CD3- and CD28-induced signal transduction revealed reduced ERK and JNK enzyme activities in murine anergic T cells. The amounts of ERK and JNK proteins were unchanged, and the kinases could be fully activated in the presence of phorbol 12-myristrate 13-acetate. Dephosphorylation of the calcineurin substrate NFATp (preexisting nuclear factor of activated T cells) also remained inducible. These results suggest that a specific block in the activation of ERK and JNK contributes to defective IL-2 production in clonal anergy.	UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, CTR IMMUNOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Mondino, Anna/K-9434-2016	Mondino, Anna/0000-0003-0833-6927; Mueller, Daniel/0000-0003-1621-0419	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031669] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI 31669] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHO EA, 1993, J IMMUNOL, V151, P20; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HECHT TT, 1983, J IMMUNOL, V131, P1049; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI W, UNPUB; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONDINO A, UNPUB; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUELLER DL, 1991, J IMMUNOL, V147, P4118; MUELLER DL, 1990, J IMMUNOL, V144, P3701; MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1989, J IMMUNOL, V142, P2617; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; QUILL H, 1992, J IMMUNOL, V149, P2887; Sambrook J, 1989, MOL CLONING; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHALEY CD, UNPUB; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798	49	403	415	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 1	1996	271	5253					1272	1276		10.1126/science.271.5253.1272	http://dx.doi.org/10.1126/science.271.5253.1272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638107				2022-12-01	WOS:A1996TX69500034
J	Eliasson, L; Renstrom, E; Ammala, C; Berggren, PO; Bertorello, AM; Bokvist, K; Chibalin, A; Deeney, JT; Flatt, PR; Gabel, J; Gromada, J; Larsson, O; Lindstrom, P; Rhodes, CJ; Rorsman, P				Eliasson, L; Renstrom, E; Ammala, C; Berggren, PO; Bertorello, AM; Bokvist, K; Chibalin, A; Deeney, JT; Flatt, PR; Gabel, J; Gromada, J; Larsson, O; Lindstrom, P; Rhodes, CJ; Rorsman, P			PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells	SCIENCE			English	Article							DIAZOXIDE; GLIBENCLAMIDE; TOLBUTAMIDE; ACTIVATION; CHANNELS; CURRENTS; RELEASE	Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic beta cells. The molecular mechanisms involved are not fully understood but are believed to involve inhibition of potassium channels sensitive to adenosine triphosphate (K-ATP channels) in the beta cell membrane, causing membrane depolarization, calcium influx, and activation of the secretory machinery. In addition to these effects, sulfonylureas also promoted exocytosis by direct interaction with the secretory machinery not involving closure of the plasma membrane K-ATP channels. This effect was dependent on protein kinase C (PKC) and was observed at therapeutic concentrations of sulfonylureas, which suggests that it contributes to their hypoglycemic action in diabetics.	NOVO NORDISK AS,DEPT ISLET CELL PHYSIOL,DK-2100 COPENHAGEN,DENMARK; GOTHENBURG UNIV,DEPT PHYSIOL & PHARMACOL,DIV BIOPHYS,S-41390 GOTHENBURG,SWEDEN; KAROLINSKA INST,ROLF LUFT CTR DIABET RES,DEPT MOLEC MED,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ULSTER,DEPT BIOL & BIOMED SCI,COLERAINE BT52 1SA,LONDONDERRY,NORTH IRELAND; UMEA UNIV,DEPT HISTOL & CELL BIOL,S-90187 UMEA,SWEDEN; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215	Novo Nordisk; University of Gothenburg; Karolinska Institutet; Boston University; Boston University; Ulster University; Umea University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Rorsman, Patrik/A-4331-2016; Eliasson, Lena/E-9294-2012; Tuluc, Petronel/C-2527-2011	Rorsman, Patrik/0000-0001-7578-0767; Eliasson, Lena/0000-0002-6467-5029; Deeney, Jude/0000-0003-0988-9419; Berggren, Per-Olof/0000-0001-8991-413X; Flatt, Peter/0000-0001-8548-7943; Chibalin, Alexander/0000-0002-6339-6271				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8214; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BERNARDI H, 1993, P NATL ACAD SCI USA, V90, P1340, DOI 10.1073/pnas.90.4.1340; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; CARPENTIER JL, 1986, DIABETOLOGIA, V29, P259, DOI 10.1007/BF00454887; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; MEISSNER HP, 1976, FEBS LETT, V67, P37; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; PHILIPSON LH, 1995, SCIENCE, V270, P1159, DOI 10.1126/science.270.5239.1159; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RENSTROM E, UNPUB; THEVENOD F, 1992, J MEMBRANE BIOL, V129, P253; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	28	172	174	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					813	815		10.1126/science.271.5250.813	http://dx.doi.org/10.1126/science.271.5250.813			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628999				2022-12-01	WOS:A1996TU69400048
J	Pronk, GJ; Ramer, K; Amiri, P; Williams, LT				Pronk, GJ; Ramer, K; Amiri, P; Williams, LT			Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER	SCIENCE			English	Article							DEATH GENE CED-3; INHIBITION; ENZYME; ENCODES	Genetic studies indicated that the Drosophila melanogaster protein REAPER (RPR) controls apoptosis during embryo development. Induction of RPR expression in Drosophila Schneider cells rapidly stimulated apoptosis. RPR-mediated apoptosis was blocked by N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk) which suggests that an interleukin-1 beta converting enzyme (ICE)-like protease is required for RPR function. RPR-induced apoptosis was associated with increased ceramide production that was also blocked by Z-VAD-fmk, which suggests that ceramide generation requires an ICE-like protease as well. Thus, the intracellular RPR protein uses cell death signaling pathways similar to those used by the vertebrate transmembrane receptors Fas (CD95) and tumor necrosis factor receptor type 1.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Pronk, GJ (corresponding author), CHIRON CORP,ROOM M348,4560 HORTON ST,EMERYVILLE,CA 94608, USA.							ASHBURNER M, 1989, DROSOPHILA LABORATOR, P142; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; INOUE S, 1991, J BIOL CHEM, V266, P13311; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V376, P37; MARTIN JM, 1995, CELL, V82, P349; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICHOLSON DW, 1995, NATURE, V376, P379; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PRONK GJ, UNPUB; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHLEGEL J, 1995, FEBS LETT, V364, P139, DOI 10.1016/0014-5793(95)00374-I; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WNAG L, 1994, CELL, V78, P739; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	253	259	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					808	810		10.1126/science.271.5250.808	http://dx.doi.org/10.1126/science.271.5250.808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628997				2022-12-01	WOS:A1996TU69400046
J	Lavoie, BD; Shaw, GS; Millner, A; Chaconas, G				Lavoie, BD; Shaw, GS; Millner, A; Chaconas, G			Anatomy of a flexer-DNA complex inside a higher-order transposition intermediate	CELL			English	Article							HISTONE-LIKE PROTEIN; SITE-SPECIFIC RECOMBINATION; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; NUCLEOPROTEIN STRUCTURES; EDTA-IRON; HU-ALPHA; BINDING; IHF; REPLICATION	Escherichia coli HU, a nonsequence-specific histone- and HMG-like DNA-binding protein, was chemically converted into a series of HU-nucleases with an iron-EDTA-based cleavage moiety positioned at 16 rationally selected sites. Specific DNA cleavage patterns from each of these HU-nucleases allowed us to determine the precise localization, stoichiometry, and orientation of HU binding in the Mu transpososome, a multiprotein structure that mediates the chemical reactions in DNA transposition. Correlation of the DNA cleavage data with the position of the cleavage moiety in the HU three-dimensional structure indicates the presence of a dramatic DNA bend, for which the bend center, direction, and magnitude were assessed. The data, which directly localize selected HU amino acids with respect to DNA in the transpososome, were used as constraints for computer-based molecular modeling to derive the first snapshot of an HU-DNA interaction.			Lavoie, BD (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5C1,CANADA.		Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				AKI T, 1996, IN PRESS GENES CELLS, V2; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; Calladine CR., 1992, UNDERSTANDING DNA; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; EBRIGHT YW, 1992, BIOCHEMISTRY-US, V31, P10664, DOI 10.1021/bi00159a004; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GOSHIMA N, 1990, GENE, V96, P141, DOI 10.1016/0378-1119(90)90355-U; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAO LR, 1993, P NATL ACAD SCI USA, V90, P5598, DOI 10.1073/pnas.90.12.5598; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1995, CURR TOP MICROBIOL I, V204, P83; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; MAZZARELLI JM, 1993, BIOCHEMISTRY-US, V32, P2979, DOI 10.1021/bi00063a008; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; Nash Howard A., 1996, P149; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; NUNESDUBY SE, 1995, J MOL BIOL, V253, P228, DOI 10.1006/jmbi.1995.0548; OBERTO J, 1994, BIOCHIMIE, V76, P901, DOI 10.1016/0300-9084(94)90014-0; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SHINDO H, 1993, BIOL PHARM BULL, V16, P437; SHINDO H, 1992, NUCLEIC ACIDS RES, V20, P1553, DOI 10.1093/nar/20.7.1553; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; TANAKA H, 1993, J BIOCHEM-TOKYO, V113, P568, DOI 10.1093/oxfordjournals.jbchem.a124084; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; Wang ZG, 1996, J BIOL CHEM, V271, P9619, DOI 10.1074/jbc.271.16.9619; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WERNER MH, 1994, CURR BIOL, V4, P477, DOI 10.1016/S0960-9822(00)00108-1; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	55	90	91	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					761	771		10.1016/S0092-8674(00)81241-6	http://dx.doi.org/10.1016/S0092-8674(00)81241-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646783	Bronze			2022-12-01	WOS:A1996UP34400015
J	Deshpande, AM; Newlon, CS				Deshpande, AM; Newlon, CS			DNA replication fork pause sites dependent on transcription	SCIENCE			English	Article							RNA POLYMERASE-III; SACCHAROMYCES-CEREVISIAE; CONSENSUS SEQUENCE; YEAST CHROMOSOME; GENE; INVIVO; INITIATION; ORIGIN	Replication fork pause (RFP) sites transiently arresting replication fork movement were mapped to transfer RNA (tRNA) genes of Saccharomyces cerevisiae in vivo, RFP sites are polar, stalling replication forks only when they oppose the direction of tRNA transcription, Mutant tRNA genes defective in assembly of transcription initiation complexes and a temperature-sensitive RNA polymerase III mutant (rpc160-41) defective in initiation of transcription do not stall replication forks, suggesting that transcription is required for RFP activity.	UNIV MED & DENT NEW JERSEY, SCH MED, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA; UNIV MED & DENT NEW JERSEY, GRAD SCH BIOMED SCI, NEWARK, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DESHPANDE AS, UNPUB; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; FRIEDMAN KL, COMMUNICATION; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GREENFEDER SA, 1992, MOL BIOL CELL, V3, P999, DOI 10.1091/mbc.3.9.999; GUDENUS R, 1988, GENETICS, V119, P517; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1994, P NATL ACAD SCI USA, V91, P10660, DOI 10.1073/pnas.91.22.10660; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; ROTHSTEIN R, 1987, MOL CELL BIOL, V7, P1198, DOI 10.1128/MCB.7.3.1198; SHAW KJ, 1984, MOL CELL BIOL, V4, P657, DOI 10.1128/MCB.4.4.657; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STROBEL MC, 1986, MOL CELL BIOL, V6, P2663, DOI 10.1128/MCB.6.7.2663; THEIS JF, 1992, YEAST, V8, P223, DOI 10.1002/yea.320080308; THURIAUX P, 1992, MOL CELLULAR BIOL YE, P1; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917	34	276	279	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1996	272	5264					1030	1033		10.1126/science.272.5264.1030	http://dx.doi.org/10.1126/science.272.5264.1030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638128				2022-12-01	WOS:A1996UL61900051
J	Downing, AK; Knott, V; Werner, JM; Cardy, CM; Campbell, ID; Handford, PA				Downing, AK; Knott, V; Werner, JM; Cardy, CM; Campbell, ID; Handford, PA			Solution structure of a pair of calcium-binding epidermal growth factor-like domains: Implications for the Marfan syndrome and other genetic disorders	CELL			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; HUMAN FACTOR-IX; CONNECTIVE-TISSUE MICROFIBRILS; EGF-LIKE DOMAINS; COUPLING-CONSTANTS; FACTOR-X; PROTEINS; FIBRILLIN; ALPHA; RESIDUES	The nuclear magnetic resonance structure of a covalently linked pair of calcium-binding (cb) epidermal growth factor-like (EGF) domains from human fibrillin-1, the protein defective in the Marfan syndrome, is described. The two domains are in a rigid, rod-like arrangement, stabilized by interdomain calcium binding and hydrophobic interactions. We propose a model for the arrangement of fibrillin monomers in microfibrils that reconciles structural and antibody binding data, and we describe a set of disease-causing mutations that provide the first clues to the specificity of cbEGF interactions. The residues involved in stabilizing the domain linkage are highly conserved in fibrillin, fibulin, thrombomodulin, and the low density lipoprotein receptor. We propose that the relative orientation of tandem cbEGF domains in these proteins is similar, but that in others, including Notch, pairs adopt a completely different conformation.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford	Downing, AK (corresponding author), UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND.		Werner, Joern/E-1148-2013	Werner, Jorn/0000-0002-4712-1833	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARON M, 1992, PROTEIN SCI, V1, P81; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BORK P, 1996, IN PRESS Q REV BIOPH; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; *GEN COMP GROUP, 1994, PROGR MAN GCG PACK; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WY US, 1995, CHEM BIOL, V2, P91; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; [No title captured]	53	369	385	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1996	85	4					597	605		10.1016/S0092-8674(00)81259-3	http://dx.doi.org/10.1016/S0092-8674(00)81259-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653794	Bronze			2022-12-01	WOS:A1996UM41500016
J	Fremont, DH; Hendrickson, WA; Marrack, P; Kappler, J				Fremont, DH; Hendrickson, WA; Marrack, P; Kappler, J			Structures of an MHC class II molecule with covalently bound single peptides	SCIENCE			English	Article							PH; PROLIFERATION; T-HELPER-1; SEPARATION; BINDING	The high-resolution x-ray crystal structures of the murine major histocompatibility complex (MHC) class II molecule, I-E(k), occupied by either of two antigenic peptides were determined. They reveal the structural basis for the I-E(k) peptide binding motif and suggest general principles for additional alleles. A buried cluster of acidic amino acids in the binding groove predicted to be conserved among all murine I-E and human DR MHC class II molecules suggests how pH may influence MHC binding or exchange of peptides. These structures also complement mutational studies on the importance of individual peptide residues to T cell receptor recognition.	NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DIV BASIC IMMUNOL,DENVER,CO 80206	Howard Hughes Medical Institute; National Jewish Health	Fremont, DH (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687; Fremont, Daved/0000-0002-8544-2689				BENTAL N, UNPUB; BONIFACE JJ, 1993, BIOCHEMISTRY-US, V32, P11761, DOI 10.1021/bi00095a003; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUSIC V, 1994, NUCLEIC ACIDS RES, V22, P3663, DOI 10.1093/nar/22.17.3663; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; IGNATOWICZ L, 1995, J IMMUNOL, V154, P3852; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; REAY PA, 1994, J IMMUNOL, V152, P3946; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; Schild H, 1995, INT IMMUNOL, V7, P1957, DOI 10.1093/intimm/7.12.1957; SETTE A, 1992, J IMMUNOL, V148, P844; SPAIN LM, 1994, J IMMUNOL, V152, P1709; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0	30	319	326	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1001	1004		10.1126/science.272.5264.1001	http://dx.doi.org/10.1126/science.272.5264.1001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638119				2022-12-01	WOS:A1996UL61900042
J	Dockerty, JD; Cox, B; Borman, B; Sharples, K				Dockerty, JD; Cox, B; Borman, B; Sharples, K			Population mixing and the incidence of childhood leukaemias: Retrospective comparison in rural areas of New Zealand	BRITISH MEDICAL JOURNAL			English	Article									CENT REG HLTH AUTHOR,WELLINGTON,NEW ZEALAND		Dockerty, JD (corresponding author), UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,POB 913,DUNEDIN,NEW ZEALAND.			Dockerty, John/0000-0002-5644-9398				ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BRESLOW NE, 1984, INT J EPIDEMIOL, V13, P112, DOI 10.1093/ije/13.1.112; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; MUIR KR, 1990, BRIT MED J, V300, P676, DOI 10.1136/bmj.300.6725.676-b	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1203	1204						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634564				2022-12-01	WOS:A1996UL05800020
J	Coats, S; Flanagan, WM; Nourse, J; Roberts, JM				Coats, S; Flanagan, WM; Nourse, J; Roberts, JM			Requirement of p27(Kip1) for restriction point control of the fibroblast cell cycle	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; MAMMALIAN FIBROBLASTS; ACTIVATING KINASE; DEPENDENT KINASE; GROWTH-FACTOR; 3T3 CELLS; PHOSPHORYLATION; G1; OLIGONUCLEOTIDES; INHIBITION	Cells deprived of serum mitogens will either undergo immediate cell cycle arrest or complete mitosis and arrest in the next cell cycle. The transition from mitogen dependence to mitogen independence occurs in the mid- to late G(1) phase of the cell cycle and is called the restriction point. Murine Balb/c-3T3 fibroblasts deprived of serum mitogens accumulated the cyclin-dependent kinase (CDK) inhibitor p27(Kip1). This was correlated with inactivation of essential G(1) cyclin-CDK complexes and with cell cycle arrest in G(1). The ability of specific mitogens to allow transit through the restriction point paralleled their ability to down-regulate p27, and antisense inhibition of p27 expression prevented cell cycle arrest in response to mitogen depletion. Therefore, p27 is an essential component of the pathway that connects mitogenic signals to the cell cycle at the restriction point.	GILEAD SCI,FOSTER CITY,CA 94404; STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305	Gilead Sciences; Stanford University	Coats, S (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; ELDEIRY W, 1993, CELL, V75, P89; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARVEY JC, 1992, SCIENCE, V258, P1481; HERRERA R, UNPUB; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LARSSON O, 1989, J CELL PHYSIOL, V139, P477, DOI 10.1002/jcp.1041390305; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOF EB, 1983, EXP CELL RES, V147, P202, DOI 10.1016/0014-4827(83)90285-9; LEWIS J, 1996, P NATL ACAD SCI USA, V93, P2400; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, NATURE, V78, P67; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAVIPRAKASH K, 1995, J VIROL, V69, P69, DOI 10.1128/JVI.69.1.69-74.1995; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TOYASHIMA H, 1994, CELL, V78, P67; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	48	635	669	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					877	880		10.1126/science.272.5263.877	http://dx.doi.org/10.1126/science.272.5263.877			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629023				2022-12-01	WOS:A1996UK75700060
J	vonZahn, U; Hunten, DM				vonZahn, U; Hunten, DM			The helium mass fraction in Jupiter's atmosphere	SCIENCE			English	Article							VOYAGER MEASUREMENTS; ABUNDANCE; SOLAR; SATURN	On 7 December 1995, the NASA Galileo probe provided in situ measurements of the helium abundance in the atmosphere of Jupiter. A Jamin interferometer measured the refractive index of the jovian atmosphere in the pressure region from 2 to 14 bars. These measurements indicate that the atmospheric helium mole fraction is 0.136 +/- 0.004. The corresponding helium mass fraction is slightly below the presolar value, which suggests that separation of helium from hydrogen in Jupiter's interior is only in its early stages.	UNIV ARIZONA, DEPT PLANETARY SCI, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA	University of Arizona	vonZahn, U (corresponding author), UNIV ROSTOCK, INST ATMOSPHARENPHYS, SCHLOSS STR 4-6, KUHLUNGSBORN, GERMANY.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAHCALL JN, 1992, REV MOD PHYS, V64, P885, DOI 10.1103/RevModPhys.64.885; BASU S, 1995, ESA SPECIAL PUBLICAT, V376, P35; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; CONRATH B, 1987, J GEOPHYS RES, V92, P15003, DOI 10.1029/JA092iA13p15003; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; Jenkins F. A., 2001, FUNDAMENTALS OPTICS; KOSOVICHEV AG, 1992, MON NOT R ASTRON SOC, V259, P536, DOI 10.1093/mnras/259.3.536; LEWIS JS, 1974, SCI AM, V230, P51, DOI 10.1038/scientificamerican0374-50; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; OLIVE KA, 1995, ASTROPHYS J SUPPL S, V97, P49, DOI 10.1086/192134; Perez Hernandez F., 1994, Monthly Notices of the Royal Astronomical Society, V269, P475; PODOLAK M, 1975, ICARUS, V25, P627, DOI 10.1016/0019-1035(75)90044-5; PROFFITT CR, 1994, ASTROPHYS J, V425, P849, DOI 10.1086/174030; Roulston M. S, 1995, EOS ABSTR AGU FALL M, V76, P343; SALPETER EE, 1973, ASTROPHYS J LETT, V181, pL183; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; Stix M., 1989, SUN; VONZAHN U, 1992, SPACE SCI REV, V60, P263, DOI 10.1007/BF00216857	23	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					849	851		10.1126/science.272.5263.849	http://dx.doi.org/10.1126/science.272.5263.849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629017				2022-12-01	WOS:A1996UK75700050
J	Politano, L; Nigro, V; Nigro, G; Petretta, VR; Passamano, L; Papparella, S; DiSomma, S; Comi, LI				Politano, L; Nigro, V; Nigro, G; Petretta, VR; Passamano, L; Papparella, S; DiSomma, S; Comi, LI			Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPRESSION; LOCUS; GENE	Objective.-To characterize the presence and behavior of the dystrophinopathic myocardial damage in female carriers of a gene defect at the Xp21 locus of the X chromosome that causes Duchenne and Becker muscular dystrophies (DMD and BMD). Design.-Cohort study from April 1, 1985, to April 30, 1995, with cardiologic follow-up performed yearly for a minimum of 3 to a maximum of 10 years. Setting.-Counseling center for genetic muscular disorders, Patients.-A total of 197 women and girls aged 5 to 60 years ascertained to be carriers of the DMD (n=152) or BMD (n=45) gene. Main Outcome Measures.-Cardiac status at yearly examinations as determined by 12-lead electrocardiogram (ECG), 24-hour ambulatory ECG, M-mode and 2-dimensional echocardiography, and carotid pulse tracing. Myocardial scintigram was performed on each individual at least twice during the study, Immunohistochemical analysis of dystrophin from myocardium and/or skeletal muscle biopsy was performed in 12 carriers. Results.-Preclinical or clinically evident myocardial involvement was found in 166 cases (84.3%), without significant differences in percentage and behavior between DMD and BMD carriers. Its occurrence increased significantly with age, from 54.5% (18 cases) in carriers aged between 5 and 16 years to 90.2% (148 cases) in carriers older than 16 years. Dystrophin anomalies were detected at the membrane level of the myocardial fibers in all endomyocardial biopsy specimens. Conclusions.-Genetic anomalies can be considered the primary cause of myocardial damage in carriers of dystrophinopathic myopathies; myocardial damage shows the same behavior already described in DMD and BMD patients and progresses from preclinical to dilated cardiomyopathy, passing through stages of myocardial hypertrophy or dysrhythmias.	UNIV NAPLES 2,DEPT INTERNAL & EXPT MED,CARDIOMYOL & GENET SECT,NAPLES,ITALY; UNIV NAPLES 2,INST GEN PATHOL & ONCOL,NAPLES,ITALY; UNIV NAPLES,ENVIRONM PATHOL INTERUNIV CTR,NAPLES,ITALY; UNIV NAPLES,INTERDEPT CTR GENET IMMUNOL & CARDIOVASC DIS,NAPLES,ITALY	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; University of Naples Federico II; University of Naples Federico II			POLITANO, LUISA/AAK-6885-2020; Nigro, Vincenzo/AAB-2274-2022	Nigro, Vincenzo/0000-0002-3378-5006	Telethon [287] Funding Source: Medline	Telethon(Fondazione Telethon)		BEGGS AH, 1990, HUM GENET, V86, P45; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; BRAUNWALD E, 1994, HEART DISEASE TXB CA; COMI LI, 1992, INT J CARDIOL, V34, P297, DOI 10.1016/0167-5273(92)90028-2; COMI LI, 1993, ACTA CARDIOMIOL, V1, P117; COMI LI, 1991, ACTA CARDIOMIOL, V3, P35; DEVISSER M, 1992, MUSCLE NERVE, V15, P591, DOI 10.1002/mus.880150510; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; EMERY AEH, 1969, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5654.418; EMERY AH, 1990, PRINCIPLES PRACTICE; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; ISHIKAWA Y, 1995, SEMIN NEUROL, V15, P93, DOI 10.1055/s-2008-1041013; KAMAKURA K, 1990, J NEUROL, V237, P483, DOI 10.1007/BF00314767; LANE RJM, 1980, NEUROLOGY, V30, P497, DOI 10.1212/WNL.30.5.497; LIMONGELLI FM, 1982, CARDIOMYOLOGY, V1, P105; NICHOLSON LVB, 1990, ACTA NEUROPATHOL, V80, P239, DOI 10.1007/BF00294640; NIGRO G, 1983, MUSCLE NERVE, V6, P253, DOI 10.1002/mus.880060403; NIGRO G, 1995, MUSCLE NERVE, V18, P283, DOI 10.1002/mus.880180304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; NIGRO G, 1994, NEUROMUSCULAR DISORD, V4, P371, DOI 10.1016/0960-8966(94)90073-6; NIGRO G, 1995, ANN NY ACAD SCI, V752, P108, DOI 10.1111/j.1749-6632.1995.tb17412.x; NIGRO G, 1976, P 7 EUR C CARD AMST, P421; Nigro G., 1984, CARDIOMYOLOGY, V3, P45; NIGRO V, 1994, HUM MOL GENET, V3, P1907, DOI 10.1093/hmg/3.10.1907; NIGRO V, 1992, HUM MOL GENET, V1, P517, DOI 10.1093/hmg/1.7.517; PERLOFF JK, 1992, J CARDIOVASC ELECTR, V3, P394, DOI 10.1111/j.1540-8167.1992.tb00982.x; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; Politano L, 1986, CARDIOMYOLOGY, V5, P139; POLITANO L, 1993, 5EME C NAT MAL NEUR; SALZER HR, 1984, CARDIOMYOLOGY, V3, P23; STEARE SE, 1992, BRIT HEART J, V68, P304; TOWBIN JA, 1990, PEDIATR RES, V27, pA25; White T.J., 1990, PCR PROTOCOLS GUIDE, P272, DOI 10.1016/B978-0-12-372180-8.50037-8; WIEGAND V, 1984, Z KARDIOL, V73, P188	34	147	150	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1335	1338		10.1001/jama.275.17.1335	http://dx.doi.org/10.1001/jama.275.17.1335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614119				2022-12-01	WOS:A1996UG61200030
J	Dubrova, YE; Nesterov, VN; Krouchinsky, NG; Ostapenko, VA; Neumann, R; Neil, DL; Jeffreys, AJ				Dubrova, YE; Nesterov, VN; Krouchinsky, NG; Ostapenko, VA; Neumann, R; Neil, DL; Jeffreys, AJ			Human minisatellite mutation rate after the Chernobyl accident	NATURE			English	Article							IONIZING-RADIATION; HUMAN DNA; CHILDREN; LENGTH; LOCI	Germline mutation at human minisatellite loci has been studied among children horn in heavily polluted areas of the Mogilev district of Belarus after the Chernobyl accident and in a control population. The frequency of mutation was found to be twice as high in the exposed families as in the control group. Mutation rate in the Mogilev families was correlated with the level of caesium-137 surface contamination, consistent with radiation induction of germline mutation.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, LEICS, ENGLAND; RES INST RADIAT MED, MOGILYOV 212004, BELARUS	University of Leicester			Dubrova, Yuri/ABA-7148-2020	Neil, David/0000-0002-9994-9536; Dubrova, Yuri/0000-0001-5281-7539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BOCHKOV NP, 1993, VESTN ROS AKAD MED+, P51; CROMPTON NEA, 1990, RADIAT RES, V124, P300, DOI 10.2307/3577843; DROSDOVITCH VV, 1989, PROGNOSIS DOSES EXPO; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FAN YF, 1995, NT J RAD BIOL, V68, P177; GIVER CR, 1995, CARCINOGENESIS, V16, P267, DOI 10.1093/carcin/16.2.267; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1991, AM J HUM GENET, V48, P824; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KENIGSBERG YE, 1994, CHERNOBYL DISASTER M, P18; KIEFER J, 1988, RADIAT RES, V113, P71, DOI 10.2307/3577181; KODAIRA M, 1995, AM J HUM GENET, V57, P1275; LAZJUK GI, 1993, CHERNOBYL PAPERS, V1, P385; LAZYUK GI, 1994, GENETIKA+, V30, P1268; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; LUNING KG, 1971, MUTAT RES, V12, P291, DOI 10.1016/0027-5107(71)90017-0; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NEEL JV, 1988, AM J HUM GENET, V42, P663; NEEL JV, 1990, AM J HUM GENET, V46, P1053; NEEL JV, 1980, P 14 INT C GEN MIR, V1, P235; NELSON SL, 1994, CARCINOGENESIS, V15, P495, DOI 10.1093/carcin/15.3.495; ORLOV MY, 1992, ATOM ENERGY+, V72, P334, DOI 10.1007/BF00760881; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	31	315	337	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					683	686		10.1038/380683a0	http://dx.doi.org/10.1038/380683a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614461				2022-12-01	WOS:A1996UG82700040
J	Kobayashi, S; Yamada, M; Asaoka, M; Kitamura, T				Kobayashi, S; Yamada, M; Asaoka, M; Kitamura, T			Essential role of the posterior morphogen nanos for germline development in Drosophila	NATURE			English	Article							POLE CELL-FORMATION; MATERNAL GENE; BODY PATTERN; EMBRYO; PLASM; SEGMENTATION; ANTERIOR; OSKAR; ANTEROPOSTERIOR; MELANOGASTER	IN many animal groups, factors required for germline formation are localized in germ plasm(1), a region of the egg cytoplasm, In Drosophila embryos, germ plasm is located in the posterior pole region and is inherited in pole cells, the germline progenitors. Transplantation experiments have demonstrated that germ plasm contains factors that can form germline(2-4), and germ plasm also directs abdomen formation(5). Genetic analysis has shown that a common mechanism directs the localization of the abdomen and germline-forming factors to the posterior pole(6-12). The critical factor for abdomen formation is the nanos (nos) protein (nanos)(13-15). Here we show that nos is also essential for germline formation in Drosophila; pole cells lacking nanos activity fail to migrate into the gonads, and so do not become functional germ cells. In such pole cells, gene expression, which normally initiates within the gonad, begins prematurely during pole cell migration. Premature activation of genes in germline precursors may mean that these cells fail to develop normally. A function for nos protein in Drosophila germline formation is compatible with observations of its association with germ plasm in other animals(16-18).	UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	Kobayashi, S (corresponding author), UNIV TSUKUBA, INST BIOL SCI, GENE EXPT CTR, TSUKUBA, IBARAKI 305, JAPAN.		Yamada, Masashi/AAI-1059-2020; Yamada, Masashi/AAQ-1314-2021	Yamada, Masashi/0000-0002-8660-1653; Asaoka, Miho/0000-0001-5591-8626				BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CURTIS D, 1995, DEVELOPMENT, V121, P1899; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KOBAYASHI S, 1993, BIOTECH HISTOCHEM, V68, P237, DOI 10.3109/10520299309104704; KOBAYASHI S, 1993, DEVELOPMENT, V117, P885; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; OKADA M, 1974, DEV BIOL, V37, P43, DOI 10.1016/0012-1606(74)90168-7; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	29	239	251	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					708	711		10.1038/380708a0	http://dx.doi.org/10.1038/380708a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614464				2022-12-01	WOS:A1996UG82700050
J	Ballard, CG; Eastwood, C; Gahir, M; Wilcock, G				Ballard, CG; Eastwood, C; Gahir, M; Wilcock, G			A follow up study of depression in the carers of dementia sufferers	BRITISH MEDICAL JOURNAL			English	Article									YARDLEY GREEN HOSP,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; REASIDE CLIN,BIRMINGHAM B45 9BE,W MIDLANDS,ENGLAND; FRENCHAY HOSP,BRISTOL BS16 1LE,AVON,ENGLAND		Ballard, CG (corresponding author), NEWCASTLE GEN HOSP,MRC,NEUROCHEM PATHOL UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.			Ballard, Clive/0000-0003-0022-5632				BALLARD CG, 1995, INT J GERIATR PSYCH, V10, P477, DOI 10.1002/gps.930100607; COOPE B, 1995, INT J GERIATR PSYCH, V10, P237, DOI 10.1002/gps.930100310; COSTELLO CG, 1990, BR J PSYCH, V157, P612; MORRIS RG, 1988, BRIT J PSYCHIAT, V153, P147, DOI 10.1192/bjp.153.2.147; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583	5	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					947	947						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF659	8616308				2022-12-01	WOS:A1996UF65900020
J	Cook, DJ; Schlemmer, S; Balucani, N; Wagner, DR; Steiner, B; Saykally, RJ				Cook, DJ; Schlemmer, S; Balucani, N; Wagner, DR; Steiner, B; Saykally, RJ			Infrared emission spectra of candidate interstellar aromatic molecules	NATURE			English	Article							MICRON EMISSION; IRAS SOURCES; FEATURES; SPECTROSCOPY; HYDROCARBONS; CATIONS; BANDS; STATE	INTERSTELLAR dust is responsible, through surface reactions, for the creation of molecular hydrogen, the main component of the interstellar clouds in which new stars form, Intermediate between small, gas-phase molecules and dust are the polycyclic aromatic hydrocarbons (PAHs). Such molecules could account for 2-30% of the carbon in the Galaxy(1), and may provide nucleation sites for the formation of carbonaceous dust(2,3). Although PAHs have been proposed(4,5) as the sources of the unidentified infrared emission bands that are observed in the spectra of a variety of interstellar sources(6-11), the emission characteristics of such molecules are sources still poorly understood. Here we report laboratory emission spectra of several representative PAHs, obtained in conditions approximating those of the interstellar medium, and measured over the entire spectral region spanned by the unidentified infrared bands. We find that neutral PAHs of small and moderate size can at best make only a minor contribution to these emission bands, Cations of these molecules, as well as much larger PAHs and their cations, remain viable candidates for the sources of these bands.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Balucani, Nadia/GPX-7659-2022; Balucani, Nadia/B-8211-2011; Schlemmer, Stephan/E-2903-2015	Balucani, Nadia/0000-0001-5121-5683; Balucani, Nadia/0000-0001-5121-5683; Schlemmer, Stephan/0000-0002-1421-7281; SAYKALLY, RICHARD/0000-0001-8942-3656				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; Allamandola LJ, 1995, ASTR SOC P, V73, P23; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; ALLAMANDOLA LJ, 1989, ASTROPHYS J, V345, pL59, DOI 10.1086/185552; BRENNER JD, 1992, ASTROPHYS J, V388, pL39, DOI 10.1086/186325; CADWELL BJ, 1994, ASTROPHYS J, V429, P285, DOI 10.1086/174318; CHERCHNEFF I, 1989, ASTROPHYS J, V341, pL21, DOI 10.1086/185448; COHEN M, 1989, ASTROPHYS J, V341, P246, DOI 10.1086/167489; DEMUIZON MJ, 1990, ASTRON ASTROPHYS, V235, P367; FLICKINGER GC, 1991, ASTROPHYS J, V380, pL43, DOI 10.1086/186169; GEBALLE TR, 1985, ASTROPHYS J, V292, P500, DOI 10.1086/163182; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P3033, DOI 10.1021/j100010a011; JOBLIN C, 1994, ASTRON ASTROPHYS, V281, P923; JOBLIN C, 1995, ASTRON ASTROPHYS, V299, P835; LANGHOFF SR, IN PRESS J PHYS CHEM; LEGER A, 1989, ANN PHYS-PARIS, V14, P181, DOI 10.1051/anphys:01989001402018100; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; OMONT A, 1986, ASTRON ASTROPHYS, V164, P159; PETROFF MD, 1987, APPL PHYS LETT, V51, P406, DOI 10.1063/1.98404; SCHLEMMER S, 1994, SCIENCE, V265, P1686, DOI 10.1126/science.11539830; SCHUTTE WA, 1990, ASTROPHYS J, V360, P577, DOI 10.1086/169146; SHAN J, 1991, ASTROPHYS J, V383, P459, DOI 10.1086/170803; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SZCZEPANSKI J, 1993, ASTROPHYS J, V414, P646, DOI 10.1086/173110; SZCZEPANSKI J, 1993, CHEM PHYS LETT, V205, P434, DOI 10.1016/0009-2614(93)87147-U; TIELENS AGGM, 1990, NASA CONF P, V3061, P59; VALA M, 1994, J PHYS CHEM-US, V98, P9187, DOI 10.1021/j100088a017; WILLIAMS RM, 1995, ASTROPHYS J, V443, P675, DOI 10.1086/175559; WITTEBORN FC, 1989, ASTROPHYS J, V341, P270, DOI 10.1086/167490	29	100	101	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					227	229		10.1038/380227a0	http://dx.doi.org/10.1038/380227a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637570				2022-12-01	WOS:A1996UB11700044
J	Lidbrink, E; Elfving, J; Frisell, J; Jonsson, E				Lidbrink, E; Elfving, J; Frisell, J; Jonsson, E			Neglected aspects of false positive findings of mammography in breast cancer screening: Analysis of false positive cases from the Stockholm trial	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; MORTALITY; WOMEN	Objectives-To examine the implications of false positive results of mammography in terms of the time lag from screening and complete mammography to the point when women with false positive results are declared free of cancer; the extra examinations, biopsies, and check ups required; and the cost of these extra procedures. Design-Review of women with false positive results from the Stockholm mammography screening trial. Setting-Department of Oncology, South Hospital, Stockholm. Subjects-352 and 150 women with false positive results of mammography from the first and second screening rounds of the Stockholm trial. Main outcome measures-Extra examinations and investigations required and the cost of these procedures. Results-The 352 women from the first screening round made 1112 visits to the physician and had 397 fine needle aspiration biopsies, 187 mammograms, and 90 surgical biopsies before being declared free of cancer. After six months 64% of the women (219/342) were declared cancer free. The 150 women in the second round made 427 visits to the physician and had 145 fine needle aspiration biopsies, 70 mammograms, and 28 surgical biopsies, and after six months 73% (107/147) were declared cancer free. The follow up costs of the false positive screening results were Kr2.54m (pound 250 000) in the first round and Kr0.85m (pound 84 000) in the second round. Women under 50 accounted for about 41% of these costs. Conclusions-The examinations and investigations carried out after false positive mammography-especially in women under 50-and the cost of these procedures are a neglected but substantial problem.	SODER SJUKHUSET,STOCKHOLM,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED,STOCKHOLM,SWEDEN	Sodersjukhuset Hospital; Karolinska Institutet								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDERSSON I, 1981, RADIOLOGY, V138, P59, DOI 10.1148/radiology.138.1.7455098; BROWN ML, 1992, J GERONTOL, V47, P51; BROWN ML, 1992, CANCER-AM CANCER SOC, V69, P1963, DOI 10.1002/1097-0142(19920401)69:7+<1963::AID-CNCR2820691717>3.0.CO;2-0; COCKBURN J, 1992, SOC SCI MED, V34, P1129, DOI 10.1016/0277-9536(92)90286-Y; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEVITT JE, 1989, LANCET, V2, P1257; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; Erichsen G G, 1990, Nord Med, V105, P64; FENTIMAN IS, 1988, LANCET, V1, P1041; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; FRISELL J, 1989, BREAST CANCER RES TR, V13, P79, DOI 10.1007/BF01806553; FRISELL J, 1986, BREAST CANCER RES TR, V8, P45, DOI 10.1007/BF01805924; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; KOPANS DB, 1987, AJR AM J ROENTGENOL, V150, P785; Lerman C E, 1993, Oncology (Williston Park), V7, P67; LIDBRINK EK, 1994, ACTA ONCOL, V33, P353, DOI 10.3109/02841869409098428; MCLELLAND R, 1992, RADIOL CLIN N AM, V30, P235; MILLER AB, 1993, AM J PREV MED, V9, P175, DOI 10.1016/S0749-3797(18)30734-7; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; NIELSEN M, 1984, CANCER, V43, P107; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OKUBO I, 1991, CANCER, V67, P2021, DOI 10.1002/1097-0142(19910415)67:8<2021::AID-CNCR2820670802>3.0.CO;2-L; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; Skrabanek P, 1991, Int J Technol Assess Health Care, V7, P633; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Van Der Maas PJ, 1989, INT J CANCER, V43, P1055, DOI 10.1002/ijc.2910430617; WRIGHT CJ, 1986, SURGERY, V100, P594; 1986, MAMMOGRAFISCREENING, V3, P1	33	87	88	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					273	276						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611781				2022-12-01	WOS:A1996TU50700019
J	Jones, DC; Hayslett, JP				Jones, DC; Hayslett, JP			Outcome of pregnancy in women with moderate or severe renal insufficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-DISEASE; FAILURE	Background Pregnant women with mild preexisting renal disease have relatively few complications of pregnancy, but the risks of maternal and obstetrical complications in women with moderate or severe renal insufficiency remain uncertain. Methods We determined the frequency and types of maternal and obstetrical complications and the outcomes of pregnancy in 67 women with primary renal disease (82 pregnancies). All the women had initial serum creatinine concentrations of at least 1.4 mg per deciliter (124 mu mol per liter) and gestations that continued beyond the first trimester. Results The mean (+/-SD) serum creatinine con concentration increased from 1.9+/-0.8 mg per deciliter (168+/-71 mu mol per liter) in early pregnancy to 2.5+/-1.3 mg per deciliter (221+/-115 mu mol per liter) in the third trimester. The frequency of hypertension rose from 28 percent at base line to 48 percent in the third trimester, and that of high-grade proteinuria (urinary protein excretion, >3000 mg per liter) from 23 percent to 41 percent. For the 70 pregnancies (57 women) for which data were available during pregnancy and immediately post partum, pregnancy-related loss of maternal renal function occurred in 43 percent. Eight of these pregnancies (10 percent of the total) were associated with rapid acceleration of maternal renal insufficiency. Obstetrical complications included a high rate of preterm delivery (59 percent) and growth retardation (37 percent). The infant survival rate was 93 percent. Conclusions Among pregnant women with moderate or severe renal insufficiency, the rates of complications due to worsening renal function, hypertension, and obstetrical complications are increased, but fetal survival is high. (C) 1996, Massachusetts Medical Society.	YALE UNIV,DEPT INTERNAL MED,NEW HAVEN,CT 06520	Yale University	Jones, DC (corresponding author), YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,POB 208063,NEW HAVEN,CT 06520, USA.							ABE S, 1985, AM J OBSTET GYNECOL, V153, P508, DOI 10.1016/0002-9378(85)90463-6; AMINI SB, 1994, OBSTET GYNECOL, V83, P342; [Anonymous], 1975, LANCET, V2, P801; BARCELO P, 1986, KIDNEY INT, V30, P914, DOI 10.1038/ki.1986.272; BEAR RA, 1978, CAN MED ASSOC J, V118, P663; CUNNINGHAM FG, 1990, AM J OBSTET GYNECOL, V163, P453, DOI 10.1016/0002-9378(90)91175-C; HAYCOCK KA, 1994, STATVIEW; HOU S, 1985, NEW ENGL J MED, V312, P836, DOI 10.1056/NEJM198503283121306; Hughes EC, 1972, OBSTETRIC GYNECOLOGI, P423; IMBASCIATI E, 1986, AM J NEPHROL, V6, P193, DOI 10.1159/000167114; JUNGERS P, 1991, AM J KIDNEY DIS, V17, P116, DOI 10.1016/S0272-6386(12)81114-0; Jungers P, 1986, Adv Nephrol Necker Hosp, V15, P103; KATZ AI, 1980, KIDNEY INT, V18, P192, DOI 10.1038/ki.1980.128; Mackay EV, 1963, AUST NZ J OBSTET GYN, V3, P21; MITCH WE, 1976, LANCET, V2, P1326; PACKHAM DK, 1989, Q J MED, V71, P537; SURIAN M, 1984, NEPHRON, V36, P101, DOI 10.1159/000183126; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4	18	236	258	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					226	232		10.1056/NEJM199607253350402	http://dx.doi.org/10.1056/NEJM199607253350402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657238				2022-12-01	WOS:A1996UZ53200002
J	Waldman, T; Lengauer, C; Kinzler, KW; Vogelstein, B				Waldman, T; Lengauer, C; Kinzler, KW; Vogelstein, B			Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21	NATURE			English	Article							CYCLE; INSITU	PRECISE coordination of the S and M phases of the eukaryotic cell cycle is critical not only for normal cell division, but also for effective growth arrest under conditions of stress. When damaged, a cell must communicate signals to both the mitotic and DNA synthesis machineries so that a mitotic block is not followed by an extra S phase, or vice versa. The biochemical mechanisms regulating this coordination, termed checkpoints, have been identified in lower eukaryotes, but are largely unknown in mammalian cells(1-3). Here we show that p21(WAF1/CIP1), the prototype inhibitor of cyclin-dependent kinases (CDKs)(4), is required for this coordination in human cells. In the absence of p21, DNA-damaged cells arrest in a G2-like state, but then undergo additional S phases without intervening normal mitoses. They thereby acquire grossly deformed, polyploid nuclei and subsequently die through apoptosis. Perhaps not by coincidence, the DNA-damaging agents that can cause S/M uncoupling are used in the clinic to kill cancer cells preferentially.	JOHNS HOPKINS ONCOL CTR,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; PROGRAM HUMAN GENET,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine								CARDER P, 1993, ONCOGENE, V8, P1397; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GAO X, 1995, ONCOGENE, V11, P1395; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIBERSON RT, 1995, MICROSC RES TECHNIQ, V32, P246, DOI 10.1002/jemt.1070320307; GORCZYCA W, 1993, CANCER RES, V53, P1945; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; KUNG AL, 1990, CANCER RES, V50, P7307; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LICHTER P, 1992, HUMAN CYTOGENETICS P, P157; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MORROW CS, 1993, CANCER MED, P618; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NURSE P, 1994, CELL, V79, P5474; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; WALDMAN T, 1995, CANCER RES, V55, P5187	28	708	732	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					713	716		10.1038/381713a0	http://dx.doi.org/10.1038/381713a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649519				2022-12-01	WOS:A1996UR97900057
J	Dernburg, AF; Broman, KW; Fung, JC; Marshall, WF; Philips, J; Agard, DA; Sedat, JW				Dernburg, AF; Broman, KW; Fung, JC; Marshall, WF; Philips, J; Agard, DA; Sedat, JW			Perturbation of nuclear architecture by long-distance chromosome interactions	CELL			English	Article							SALIVARY-GLAND NUCLEI; DROSOPHILA-MELANOGASTER; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; EMBRYOGENESIS; DNA; HETEROCHROMATIN; RECOMBINATION; ORGANIZATION; MICROSCOPY	Position-effect variegation (PEV) describes the stochastic transcriptional silencing of a gene positioned adjacent to heterochromatin. Using FISH, we have tested whether variegated expression of the eye-color gene brown in Drosophila is influenced by its nuclear localization. In embryonic nuclei, a heterochromatic insertion at the brown locus is always spatially isolated from other heterochromatin. However, during larval development this insertion physically associates with other heterochromatic regions on the same chromosome in a stochastic manner. These observations indicate that the brown gene is silenced by specific contact with centromeric heterochromatin. Moreover, they provide direct evidence for long-range chromosome interactions and their impact on three-dimensional nuclear architecture, while providing a cohesive explanation for the phenomenon of PEV.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT STAT, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California San Francisco				Dernburg, Abby/0000-0001-8037-1079; Broman, Karl/0000-0002-4914-6671				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ASHBRUNER M, 1989, DROSOPHILA LAB MANUA; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CARMENA M, 1993, J CELL SCI, V105, P41; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; DERNBURG AF, 1996, IN PRESS GENETICS, V143; Doi M., 1986, THEORY POLYM DYNAMIC; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; DREESEN TD, 1991, GENE DEV, V5, P331, DOI 10.1101/gad.5.3.331; DREIBIN RA, 1986, COMPUT GRAPH, V22, P65; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; ENGELS WR, 1994, SCIENCE, V263, P1623, DOI 10.1126/science.8128250; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1983, J CELL SCI, V61, P31; FREIFELDER D, 1976, PHYSICAL BIOCH; FUCHS JP, 1983, J CELL SCI, V64, P331; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HABER JE, 1981, MOL CELL BIOL, V1, P1106, DOI 10.1128/MCB.1.12.1106; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; HAWLEY RS, 1992, DEV GENET, V13, P440, DOI 10.1002/dvg.1020130608; HELLGREN D, 1992, MUTAT RES, V284, P37, DOI 10.1016/0027-5107(92)90023-U; HENIKOFF S, 1995, GENETICS, V140, P1007; HENIKOFF S, 1994, GENETICS, V138, P1; HENIKOFF S, 1996, IN PRESS GENOMES; HILLIKER AJ, 1986, GENET RES, V47, P13, DOI 10.1017/S0016672300024459; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; KARPEN GH, 1990, CELL, V63, P97; KAUFFMAN BP, 1963, ACTA BIOL PORT, V7, P225; LICHTEN M, 1989, GENETICS, V123, P261; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOHE AR, 1993, GENETICS, V134, P1149; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; MARSHALL WF, 1996, IN PRESS MOL CELL BI, V7; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; Merriam J., 1968, DROS INFORM SERV, V43, P64; PALLADINO F, 1994, CURR OPIN CELL BIOL, V6, P373, DOI 10.1016/0955-0674(94)90029-9; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; RILES L, 1993, GENETICS, V134, P81; RINE J, 1980, MOL GEN GENET, V180, P99, DOI 10.1007/BF00267357; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; SLATIS HM, 1955, GENETICS, V40, P246; SMITH AV, 1991, DEVELOPMENT, V112, P997; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; TALBERT PB, 1994, GENETICS, V136, P559; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; Titterington DM., 1985, STAT ANAL FINITE MIX; VANSCHAIK NW, 1959, GENETICS, V44, P725; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEILER KS, 1992, GENETICS, V132, P929; Wolff Tanya, 1993, P1277; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	62	326	332	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					745	759		10.1016/S0092-8674(00)81240-4	http://dx.doi.org/10.1016/S0092-8674(00)81240-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646782	Bronze			2022-12-01	WOS:A1996UP34400014
J	Briggs, AH; Sculpher, MJ; Logan, RPH; Aldous, J; Ramsay, ME; Baron, JH				Briggs, AH; Sculpher, MJ; Logan, RPH; Aldous, J; Ramsay, ME; Baron, JH			Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; DISEASE	Objective-To assess the cost effectiveness of screening for and eradicating Helicobacter pylori in patients under 45 years of age presenting with dyspepsia. Design-A decision analytic model composed of a decision tree to represent the epidemiology of dyspepsia and a Markov process to model the outcomes of treatment. Patients-Patients under the age of 45 years presenting to their general practitioner with (peptic type) dyspepsia. Interventions-Conventional empirical treatment with healing and maintenance doses of cimetidine v eradication treatment solely in patients with confirmed peptic ulcer; and conventional empirical treatment for all dyspeptic patients compared with the use of a serology test to identify patients with H pylori, who then receive endoscopy to investigate the presence of peptic ulcer disease and, when disease is found, are given eradication treatment with a breath test to confirm successful eradication. Main outcome measures-Expected cumulative costs over a period of 10 years. The proportion of time patients spend without a recurrent ulcer. Results-After receiving eradication treatment, patients with confirmed ulcer spend an average of 99% of their time free fi om recurrent ulcer disease compared with 95% after treatment with cimetidine. Eradication treatment costs less than that with cimetidine. When the initial cost of identifying appropriate patients to receive eradication treatment is added to the analysis, however, these cost savings take almost eight years to accrue. Conclusions-Enthusiasm for introducing testing for and eradication of H pylori for dyspeptic patients in general practice should be tempered by an awareness that cost savings may take many years to realise.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND; ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT GASTROENTEROL,LONDON W2 1NY,ENGLAND	University of Nottingham; Imperial College London; Imperial College London	Briggs, AH (corresponding author), BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.		Briggs, Andrew/ABA-9009-2020	Briggs, Andrew/0000-0002-0777-1997; Sculpher, Mark/0000-0003-3746-9913				ALDOUS J, 1994, PILOT STUDY EFFECTS; ATHERTON JC, 1994, GUT, V35, P723, DOI 10.1136/gut.35.6.723; AXON ATR, 1995, BMJ-BRIT MED J, V310, P853, DOI 10.1136/bmj.310.6983.853; BARDHAN KD, 1984, GUT, V25, P711, DOI 10.1136/gut.25.7.711; BECK JR, 1983, MED DECIS MAKING, V3, P411; BELL GD, 1993, Q J MED, V86, P375; BELL GD, 1993, BR J MED EC, V6, P45; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; CAMPBELL LM, 1994, BR J MED EC, V7, P147; *CHART I PUBL FIN, 1990, HLTH DAT HLTH SERV T, V2; CLAUSEN MR, 1992, SCAND J GASTROENTERO, V27, P421, DOI 10.3109/00365529209000099; Duggan A. E., 1995, Gut, V37, pA58; EDENHOLM M, 1985, SCAND J GASTROENTERO, V20, P163, DOI 10.3109/00365528509103953; FORRESTER E, 1994, GASTROENTEROL PR FEB, P6; GRIBBLE EJ, 1994, GASTROENTEROLOGY INT, V7, P90; HASTINGS L, 1995, GUT, V37, pA6; *HM TREAS, 1991, EC APPR CENTR GOV TE; KATZ KD, 1992, AM J SURG, V163, P349, DOI 10.1016/0002-9610(92)90021-I; KEMMER TP, 1994, EUR J GASTROEN HEPAT, V6, P571, DOI 10.1097/00042737-199407000-00002; LABENZ J, 1994, AM J GASTROENTEROL, V89, P1785; LOGAN RPH, 1992, HELICOBACTER PYLORI, P88; MOORE RA, 1995, HELICOBACTER PYLORI; NETTEN A, 1994, UNIT COSTS COMMUNITY; NOVELL, 1995, QUATTRO PRO V6 0; PATEL P, 1994, LANCET, V344, P511, DOI 10.1016/S0140-6736(94)91899-6; PYM B, 1990, GASTROENTEROLOGY, V99, P27, DOI 10.1016/0016-5085(90)91225-U; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; SONNENBERG A, 1995, EUR J GASTROEN HEPAT, V7, P655; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; *TREEW SOFTW, 1995, DATA V2 6; TYTGAT GNJ, 1994, ALIMENT PHARM THERAP, V8, P359; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P189; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; 1994, JAMA-J AM MED ASSOC, V272, P65; 1991, GUT, V32, P95	36	127	127	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1321	1325		10.1136/bmj.312.7042.1321	http://dx.doi.org/10.1136/bmj.312.7042.1321			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646042	Green Published			2022-12-01	WOS:A1996UN47600016
J	Skinner, R; Cole, M; Pearson, ADJ; Coulthard, MG; Craft, AW				Skinner, R; Cole, M; Pearson, ADJ; Coulthard, MG; Craft, AW			Specificity of pH and osmolality of early morning urine sample in assessing distal renal tubular function in children: Results in healthy children	BRITISH MEDICAL JOURNAL			English	Article											Skinner, R (corresponding author), UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,SIR JAMES SPENCE INST CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							EDELMANN CM, 1967, AM J DIS CHILD, V114, P639, DOI 10.1001/archpedi.1967.02090270095009; RODRIGUEZSORIANO J, 1990, PEDIATR NEPHROL, V4, P268, DOI 10.1007/BF00857675; Silverman BW., 2018, DENSITY ESTIMATION S, DOI 10.1201/9781315140919; SWIFT PGF, 1991, CURRENT PAEDIAT, V1, P177	4	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1337	1338		10.1136/bmj.312.7042.1337	http://dx.doi.org/10.1136/bmj.312.7042.1337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646047	Green Published			2022-12-01	WOS:A1996UN47600022
J	Cleland, JGF; Swedberg, K				Cleland, JGF; Swedberg, K			Carvedilol for heart failure, with care	LANCET			English	Editorial Material							SURVIVAL		GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,S-41685 GOTHENBURG,SWEDEN; UNIV GLASGOW,CLIN RES INITIAT HEART FAILURE,GLASGOW G61 1BD,LANARK,SCOTLAND	Sahlgrenska University Hospital; University of Gothenburg; University of Glasgow			Swedberg, Karl/B-2475-2008; Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				Bristow MR, 1995, CIRCULATION S1, V92, P142; Cohn Jay N., 1996, Journal of the American College of Cardiology, V27, p169A; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLUCCI WS, 1995, CIRCULATION, V92, P394; CUBEDDU LX, 1987, CLIN PHARMACOL THER, V41, P31, DOI 10.1038/clpt.1987.6; Fowler Michael B., 1996, Journal of the American College of Cardiology, V27, p169A; HELD P, 1993, AM J CARDIOL, V71, pC39, DOI 10.1016/0002-9149(93)90085-Q; PACKER M, 1995, CIRCULATION S1, V92, P143; PACKER M, 1995, CIRCULATION S1, V92, P142; SACKNERBERNSTEI.J, 1995, CIRCULATION S1, V92, P395; SUNG CP, 1993, J CARDIOVASC PHARM, V21, P221, DOI 10.1097/00005344-199302000-00006; SWEDBERG K, 1979, LANCET, V1, P1374; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92; 1995, CIRCULATION, V92, P394; 1995, CIRCULATION, V92, P212	15	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1199	1201		10.1016/S0140-6736(96)90729-1	http://dx.doi.org/10.1016/S0140-6736(96)90729-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622445				2022-12-01	WOS:A1996UJ59700004
J	Giles, GG; Armstrong, BK; Burton, RC; Staples, MP; Thursfield, VJ				Giles, GG; Armstrong, BK; Burton, RC; Staples, MP; Thursfield, VJ			Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SKIN; QUEENSLAND; EDUCATION; CAMPAIGN	Objective-To describe recent trends in mortality from melanoma in Australia. Design-An analysis of trends in age standardised and age and sex specific mortalities by year of death and median year of birth (cohort). Setting-Australia. Subjects-All deaths from melanoma registered in Australia between 1931 and 1994. Results-Melanoma mortality rose steadily from 1931 to 1985. From 1959 the annual rate of increase was 6.3% in men and 2.9% in women, resulting in mortalities of 4.82 and 2.51 per 100 000 person years in 1985 and 1989, respectively. Mortalities for both sexes seem to have plateaued from June 1985 onwards. In 1990-4 the rate rose by 3.7% in men to 5.00 per 100 000 and in women it fell by 5.2% to 2.38 per 100 000. The non-significant increase after 1985 in mortality in men was restricted to those aged over 70 years of age, whereas the fall in rates in women was mostly in those aged under 55 years. This pattern was generally reflected in the state trends, though with some variation: rates for women in Queensland had peaked in the late 1970s; while rates for men in New South Wales continued to rise in 1990-4, placing them above those for Queensland. Examination of mortalities specific for age, period, and cohort for Australia as a whole showed several salient features. Rates in men rose steeply in cohorts born before about 1930; were stable in cohorts born between 1930 and 1950; and fell in more recent cohorts. Rates in women showed similar changes but about five years earlier. Conclusion-Melanoma mortality in Australia peaked in about 1985 and has now plateaued. On the basis of trends in cohorts it can be expected to fall in coming years.	AUSTRALIAN INST HLTH & WELF, ACTON, ACT 2061, AUSTRALIA; UNIV NEWCASTLE, FAC MED & HLTH SCI, CALLAGHAN, NSW 2308, AUSTRALIA	University of Newcastle	Giles, GG (corresponding author), ANTICANC COUNCIL VICTORIA, CANC EPIDEMIOL CTR, CARLTON, VIC 3053, AUSTRALIA.			Giles, Graham/0000-0003-4946-9099				ARMSTRONG BK, 1994, CANCER SURV, V20, P219; ARMSTRONG BK, 1987, MED J AUSTRALIA, V147, P150; Beardmore G. L., 1972, MELANOMA SKIN CANCER, P39; BONETT A, 1989, MED J AUSTRALIA, V151, P502, DOI 10.5694/j.1326-5377.1989.tb128496.x; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; COATES M, 1994, CANC NEW S WALES INC; COOKE K, 1992, NEW ZEAL MED J, V105, P303; CRISTOFOLINI M, 1993, J DERMATOL SURG ONC, V19, P117, DOI 10.1111/j.1524-4725.1993.tb03439.x; Davis N C, 1966, Med J Aust, V1, P643; ELWOOD JM, 1989, T MENZIES F, V15, P131; GILES GG, 1994, CANC FORUM, V18, P12; GILES GG, 1994, CANSTAT SKIN CANC; Green A, 1982, Australas J Dermatol, V23, P105, DOI 10.1111/j.1440-0960.1982.tb00739.x; Hill D, 1993, Eur J Cancer Prev, V2, P447; HOLMAN CDJ, 1980, INT J CANCER, V26, P703, DOI 10.1002/ijc.2910260602; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; JELFS PL, 1994, MED J AUSTRALIA, V161, P182, DOI 10.5694/j.1326-5377.1994.tb127379.x; JONES ME, 1992, MED J AUSTRALIA, V157, P373, DOI 10.5694/j.1326-5377.1992.tb137243.x; KHLAT M, 1992, AM J EPIDEMIOL, V135, P1103, DOI 10.1093/oxfordjournals.aje.a116210; KRICKER A, 1993, 13 IARC INT AG RES C; LANCASTER H. O., 1956, MED JOUR AUSTRALIA I, V43, P1082; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MCCARTHY WH, 1980, MED J AUSTRALIA, V2, P137, DOI 10.5694/j.1326-5377.1980.tb76944.x; ROUSH GC, 1992, CANCER-AM CANCER SOC, V69, P1714, DOI 10.1002/1097-0142(19920401)69:7&lt;1714::AID-CNCR2820690712&gt;3.0.CO;2-Z; SCOTTO J, 1991, INT J CANCER, V49, P490, DOI 10.1002/ijc.2910490403; SMITH T, 1979, BRIT MED J, V1, P253, DOI 10.1136/bmj.1.6158.253; STREETLY A, 1995, INT J EPIDEMIOL, V24, P897, DOI 10.1093/ije/24.5.897; SWERDLOW AJ, 1990, ANN NY ACAD SCI, V609, P235, DOI 10.1111/j.1749-6632.1990.tb32071.x; THORN M, 1992, BRIT J CANCER, V66, P563, DOI 10.1038/bjc.1992.315; VENZON DJ, 1984, AM J EPIDEMIOL, V119, P62, DOI 10.1093/oxfordjournals.aje.a113726; [No title captured]	33	157	160	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	1996	312	7039					1121	1125						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620126				2022-12-01	WOS:A1996UK06900019
J	Torcia, M; BracciLaudiero, L; Lucibello, M; Nencioni, L; Labardi, D; Rubartelli, A; Cozzolino, F; Aloe, L; Garaci, E				Torcia, M; BracciLaudiero, L; Lucibello, M; Nencioni, L; Labardi, D; Rubartelli, A; Cozzolino, F; Aloe, L; Garaci, E			Nerve growth factor is an autocrine survival factor for memory B lymphocytes	CELL			English	Article							MESSENGER-RNA; REGIONAL DISTRIBUTION; TRK PROTOONCOGENE; FACTOR RECEPTORS; FACTOR FAMILY; CELL MEMORY; FACTOR NGF; BCL-2; EXPRESSION; AFFINITY	Production of nerve growth factor (NGF) was assessed in cultures of human T and B lymphocytes and macrophages. NGF was constitutively produced by B cells only, which also expressed surface p140(trk-A) and p75(NGFR) molecules and hence efficiently bound and internalized the cytokine. Neutralization of endogenous NGF caused disappearance of Bcl-2 protein and apoptotic death of resting lymphocytes bearing surface IgG or IgA, a population comprising memory cells, while surface IgM/IgD ''virgin'' B lymphocytes were not affected. In vivo administration of neutralizing anti-NGF antibodies caused strong reduction in the titer of specific lgG in mice immunized with tetanus toroid, nitrophenol, or arsonate and reduced numbers of surface IgG or IgA B lymphocytes. Thus, NGF is an autocrine survival factor for memory B lymphocytes.	UNIV ROMA TOR VERGATA,DEPT EXPTL MED,I-00133 ROME,ITALY; UNIV FLORENCE,DEPT CLIN PHYSIOPATHOL,I-50139 FLORENCE,ITALY; CNR,INST NEUROBIOL,I-00185 ROME,ITALY; NATL INST CANC RES,SERV CLIN PATHOL,I-16132 GENOA,ITALY	University of Rome Tor Vergata; University of Florence; Consiglio Nazionale delle Ricerche (CNR); University of Genoa; IRCCS AOU San Martino IST			lucibello, maria/AAI-1417-2020; Nencioni, Lucia/K-5988-2016; Bracci Laudiero, Luisa/AAC-3521-2022; Bracci-Laudiero, Luisa/H-1541-2013; Rubartelli, Anna/AAA-1259-2021; Torcia, Maria Gabriella G/K-1840-2018	Nencioni, Lucia/0000-0003-4427-4823; Bracci-Laudiero, Luisa/0000-0002-1682-6371; Torcia, Maria Gabriella G/0000-0003-4740-4646; Cozzolino, Federico/0000-0002-2800-640X				ALOE L, 1994, AUTOIMMUNITY, V19, P141, DOI 10.3109/08916939409009542; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BARBACID M, 1994, J NEUROBIOL, V25, P386; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BRACCILAUDIERO L, 1993, NEUROREPORT, V4, P563, DOI 10.1097/00001756-199305000-00025; BRODIE C, 1992, J IMMUNOL, V148, P3492; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DICOU E, 1993, NEUROREPORT, V5, P321, DOI 10.1097/00001756-199312000-00036; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; EAGER KB, 1991, ONCOGENE, V6, P819; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10981; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HAWKINS CJ, 1994, IMMUNOL REV, V142, P127, DOI 10.1111/j.1600-065X.1994.tb00886.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KATAYAMA N, 1993, BLOOD, V81, P610; KIMATA H, 1991, EUR J IMMUNOL, V21, P137, DOI 10.1002/eji.1830210121; KISHIMOTO T, 1989, FUNDAMENTAL IMMUNOLO, P385; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MCCONKEY DJ, 1989, FASEB J, V3, P1844; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NISONOFF A, 1967, METHODS IMMUNOLOGY I, P1; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROMAGNANI S, 1982, J IMMUNOL, V129, P596; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; SODERSTROM S, 1990, J NEUROSCI RES, V27, P665, DOI 10.1002/jnr.490270427; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; UEYAMA T, 1993, J HYPERTENS, V11, P1061, DOI 10.1097/00004872-199310000-00009; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2840; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	62	357	374	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					345	356		10.1016/S0092-8674(00)81113-7	http://dx.doi.org/10.1016/S0092-8674(00)81113-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616890	Green Published, Bronze			2022-12-01	WOS:A1996UK14000008
J	Wellinger, RJ; Ethier, K; Labrecque, P; Zakian, VA				Wellinger, RJ; Ethier, K; Labrecque, P; Zakian, VA			Evidence for a new step in telomere maintenance	CELL			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; QUADRUPLEX STRUCTURE; MACRONUCLEAR DNA; BINDING PROTEIN; YEAST TELOMERE; 3' TERMINUS; S-PHASE; REPLICATION; RECOMBINATION	The strand of telomeric DNA that runs 5'3' toward a chromosome end is typically G rich. Telomerase-generated G tails are expected at one end of individual DNA molecules. Saccharomyces telomeres acquire TG(1-3) tails late in S phase. Moreover, the telomeres of linear plasmids can interact when the TG(1-3) tails are present. Molecules that mimic the structures predicted for telomere replication intermediates were generated in vitro. These in vitro generated molecules formed telomere-telomere interactions similar to those on molecules isolated from yeast, but only if both ends that interacted had a TG(1-3) tail. Moreover, TG(1-3), tails were generated in vivo in cells lacking telomerase. These data suggest a new step in telomere maintenance, cell cycle-regulated degradation of the C(1-3)A strand, which can generate a potential substrate for telomerase and telomere-binding proteins at every telomere.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	Wellinger, RJ (corresponding author), UNIV SHERBROOKE, FAC MED, DEPT MICROBIOL, SHERBROOKE, PQ J1H 5N4, CANADA.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026938, R37GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BEELER T, 1994, J BIOL CHEM, V269, P7279; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GILSON E, 1994, NUCLEIC ACIDS RES, V22, P5310, DOI 10.1093/nar/22.24.5310; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER XCW, 1995, TELOMERES, V29, P35; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HENIKOFF S, 1987, GENETICS, V117, P711; HOBZA P, 1987, J AM CHEM SOC, V109, P1302, DOI 10.1021/ja00239a003; HUANG KN, 1993, MOL CELL BIOL, V13, P3125, DOI 10.1128/MCB.13.6.3125; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KERR C, 1972, J BIOL CHEM, V247, P311; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SADOWSKI PD, 1985, NUCLEASES, P23; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SOMMERVILLE FW, 1987, ELECT MICROSCOPY MOL; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNDQUIST WI, 1993, CURR BIOL, V3, P893, DOI 10.1016/0960-9822(93)90229-H; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUNDQUIST WI, 1990, NUCL ACIDS MOL BIOL, V5, P1; SUTCLIFFE JG, 1978, NUCLEIC ACIDS RES, V5, P2721, DOI 10.1093/nar/5.8.2721; VOLOSHIN ON, 1992, J BIOMOL STRUCT DYN, V9, P643, DOI 10.1080/07391102.1992.10507945; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1992, CHROMOSOMA, V102, pS150, DOI 10.1007/BF02451800; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WELLINGER RJ, 1993, CHROMOSOME SEGRATI H, V72, P133; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILEY EA, 1995, GENETICS, V139, P67; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	73	258	264	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					423	433		10.1016/S0092-8674(00)81120-4	http://dx.doi.org/10.1016/S0092-8674(00)81120-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616897	Bronze			2022-12-01	WOS:A1996UK14000015
J	Buckley, NA; Smith, AJ				Buckley, NA; Smith, AJ			Evidence-based medicine in toxicology: Where is the evidence?	LANCET			English	Editorial Material											Buckley, NA (corresponding author), UNIV NEWCASTLE,DISCIPLINE CLIN PHARMACOL,FAC MED,UNIV DR,CALLAGHAN,NSW 2308,AUSTRALIA.		Smith, Ashley/GZB-0298-2022; Buckley, Nicholas A/D-4030-2012	Buckley, Nicholas A/0000-0002-6326-4711				Baselt R.C., 1989, DISPOSITION TOXIC DR; BUCKLEY NA, 1995, J TOXICOL-CLIN TOXIC, V33, P199, DOI 10.3109/15563659509017984; BUCKLEY NA, 1994, LANCET, V343, P159, DOI 10.1016/S0140-6736(94)90940-7; BUCKLEY NA, 1995, BMJ-BRIT MED J, V310, P219, DOI 10.1136/bmj.310.6974.219; BUCKLEY NA, 1994, MED J AUSTRALIA, V160, P188, DOI 10.5694/j.1326-5377.1994.tb126600.x; BUCKLEY NA, 1995, MED J AUSTRALIA, V162, P190, DOI 10.5694/j.1326-5377.1995.tb126020.x; CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; DEBARD ML, 1981, CLIN TOXICOL, V18, P1117, DOI 10.3109/15563658108990341; Ellenhorn MJ., 1997, MED TOXICOLOGY DIAGN, P610; FISHER WL, 1993, HDB MED TOXICOLOGY; HOOPER RG, 1979, JACEP-J AM COLL EMER, V8, P98, DOI 10.1016/S0361-1124(79)80150-1; JACOBSEN D, 1984, HUM TOXICOL, V3, P93, DOI 10.1177/096032718400300203; KOPPEL C, 1987, J TOXICOL-CLIN TOXIC, V25, P53; KOPPEL C, 1987, HUM TOXICOL, V6, P355, DOI 10.1177/096032718700600503; MATTHEW H, 1968, BMJ-BRIT MED J, V2, P101, DOI 10.1136/bmj.2.5597.101; NORMANN S, 1992, POISINDEX R SYSTEM, V86; POND SM, 1995, MED J AUSTRALIA, V162, P174, DOI 10.5694/j.1326-5377.1995.tb126015.x; RESCH F, 1982, KLIN PADIATR, V194, P42, DOI 10.1055/s-2008-1033768; SACKETT DL, 1989, CLIN EPIDEMIOLOGY BA; von Muhlendahl K E, 1978, Monatsschr Kinderheilkd, V126, P123; WEISSMAN RS, 1994, GOLDFRANKS TOXICOLOG; WINEK CL, 1977, CLIN TOXICOL, V11, P287, DOI 10.3109/15563657708989842; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001	23	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1167	1169		10.1016/S0140-6736(96)90615-7	http://dx.doi.org/10.1016/S0140-6736(96)90615-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609755				2022-12-01	WOS:A1996UG75500017
J	Habib, FM; Springall, DR; Davies, GJ; Oakley, CM; Yacoub, MH; Polak, JM				Habib, FM; Springall, DR; Davies, GJ; Oakley, CM; Yacoub, MH; Polak, JM			Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; IMMUNE-RESPONSE; FACTOR-ALPHA; MYOCARDITIS; RNA	Background Two important features of dilated cardiomyopathy (DCM) are low myocardial contractility and risk of thromboembolism. Nitric oxide (NO) exerts a negative inotropic effect on the myocardium and is produced by NO-synthase, an inducible form of which (iNOS) is stimulated by tumour necrosis factor (TNF-alpha). Accordingly, we hypothesised that locally produced TNF-alpha might contribute to the pathogenesis and complications of DCM by inducing iNOS in the heart. Methods iNOS and TNF-alpha were quantified by histochemistry and computerised image analysis in explanted heart tissues or myocardial biopsy material from patients with DCM (n=21) or ischaemic heart disease (IHD; n=10) and from normal donor hearts (n=9). Findings Immunoreactivity for iNOS was strong in myocytes of DCM hearts, particularly in areas adjacent to the endocardium, and moderately intense in blood vessels of DCM and IHD hearts, The median optical density of the immunostaining for iNOS was greater in cardiac myocytes of patients with DCM (0.86, range 0.21 to 1.29) than in those from patients with IHD (0.20, range 0.095 to 0.26) (p<0.01) or controls (0.01, range 0.001 to 0.02) (p<0.001). Staining for TNF-alpha was observed in the vascular endothelium and smooth muscle cells of patients with DCM but not in IHD or control tissues. Interpretation The localisation of iNOS and TNF-alpha within cardiac tissues in DCM suggests that TNF-alpha contributes to both the low contractility and the tendency to thromboembolism in these patients.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CARDIOL,LONDON,ENGLAND; HAREFIELD HOSP,HEART SCI CTR,HAREFIELD UB9 6JH,MIDDX,ENGLAND	Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital								ARBUSTINI E, 1989, AM J CARDIOL, V64, P991, DOI 10.1016/0002-9149(89)90796-0; BOWLES NE, 1989, CIRCULATION, V80, P1128, DOI 10.1161/01.CIR.80.5.1128; BOWLES NE, 1986, LANCET, V1, P1120; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1993, AM HEART J, V126, P761, DOI 10.1016/0002-8703(93)90926-Z; DUNKMAN WB, 1993, CIRCULATION, V87, P94; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; HABIB F, 1994, LANCET, V344, P371, DOI 10.1016/S0140-6736(94)91402-8; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; KATZ SD, 1993, CIRCULATION, V88, P55, DOI 10.1161/01.CIR.88.1.55; KIRCHHOFER D, 1994, J CLIN INVEST, V93, P2073, DOI 10.1172/JCI117202; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; LATIF N, 1993, J AM COLL CARDIOL, V22, P1378, DOI 10.1016/0735-1097(93)90546-D; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MATSUMORI A, 1994, CIRCULATION, V89, P955, DOI 10.1161/01.CIR.89.3.955; MCBRIDE JT, 1995, IMAGE ANAL HISTOLOGY; MCMURRAY J, 1991, BRIT HEART J, V66, P356; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNKVAD S, 1991, LYMPHOKINE CYTOK RES, V10, P325; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SEKO Y, 1993, J CLIN INVEST, V91, P1327, DOI 10.1172/JCI116333; TORREAMIONE G, 1995, CIRCULATION, V92, P1487, DOI 10.1161/01.CIR.92.6.1487; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WALLEY KR, 1994, J APPL PHYSIOL, V76, P1060, DOI 10.1152/jappl.1994.76.3.1060; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	30	293	303	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1151	1155		10.1016/S0140-6736(96)90610-8	http://dx.doi.org/10.1016/S0140-6736(96)90610-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609750				2022-12-01	WOS:A1996UG75500012
J	Normandeau, M; Taylor, AP; Dewdney, PE				Normandeau, M; Taylor, AP; Dewdney, PE			A galactic chimney in the Perseus arm of the Milky Way	NATURE			English	Article							H-I SHELLS; O-STARS; TERMINAL VELOCITIES; INTERSTELLAR-MEDIUM; MOLECULAR CLOUD; STELLAR WINDS; MASS-LOSS; EVOLUTION; SUPERSHELLS; COMPLEX	GALAXIES are surrounded by large haloes of hot gas(1) which must be replenished as the gas cools, This has led to the concept(2) of galactic 'chimneys'-cavities in the interstellar medium, created by multiple supernova explosions, that can act as conduits for the efficient transport of hot gas from a galaxy's disk to its halo. Here we present a high-resolution map of atomic hydrogen in the Perseus arm of our Galaxy, which shows clear evidence for the existence of such a chimney, This chimney appears to have been formed by the energetic winds from a cluster of young massive stars, and may currently have reached the stage of blowing out into the halo.	NATL RES COUNCIL CANADA,DOMINION RADIO ASTROPHYS OBSERV,OTTAWA,ON,CANADA	National Research Council Canada	Normandeau, M (corresponding author), UNIV CALGARY,DEPT PHYS & ASTRON,2500 UNIV DR NW,CALGARY,AB T2N 3E7,CANADA.							Alter G., 1970, CATALOGUE STAR CLUST; BURKI G, 1979, ASTRON ASTROPHYS, V79, P613; CHIOSI C, 1978, ASTRON ASTROPHYS, V63, P103; DEANDRES FL, 1982, ASTRON ASTROPHYS, V107, P43; DICKEL HR, 1980, ASTROPHYS J, V238, P829, DOI 10.1086/158044; DIGEL SW, IN PRESS ASTROPHYS; GOUDIS C, 1979, ASTROPHYS SPACE SCI, V61, P417, DOI 10.1007/BF00640542; GROENEWEGEN MAT, 1989, ASTRON ASTROPHYS, V221, P78; HARRIS GLH, 1976, ASTROPHYS J SUPPL S, V30, P451, DOI 10.1086/190368; HEILES C, 1987, ASTROPHYS J, V315, P555, DOI 10.1086/165158; Heiles C., 1974, Astronomy and Astrophysics Supplement Series, V14, P1; HEILES C, 1979, ASTROPHYS J, V229, P533, DOI 10.1086/156986; HEILES C, 1984, ASTROPHYS J SUPPL S, V55, P585, DOI 10.1086/190970; HOWARTH ID, 1989, ASTROPHYS J SUPPL S, V69, P527, DOI 10.1086/191321; JOSHI UC, 1983, J ROY ASTRON SOC CAN, V77, P40; LADA CJ, 1978, ASTROPHYS J, V226, pL39, DOI 10.1086/182826; LAMERS HJGLM, 1993, ASTROPHYS J, V412, P771, DOI 10.1086/172960; MACLOW M, 1988, ASTROPHYS J, V337, P776; MATHYS G, 1987, ASTRON ASTROPHYS SUP, V71, P201; NORMAN CA, 1989, ASTROPHYS J, V345, P372, DOI 10.1086/167912; PRINJA RK, 1990, ASTROPHYS J, V361, P607, DOI 10.1086/169224; TENORIOTAGLE G, 1988, ANNU REV ASTRON ASTR, V26, P145; THRONSON HA, 1985, ASTROPHYS J, V297, P662, DOI 10.1086/163565; TOMISAKA K, 1986, PUBL ASTRON SOC JPN, V38, P697; Vogler A, 1996, ASTRON ASTROPHYS, V305, P74; Weaver H., 1973, Astronomy and Astrophysics Supplement Series, V8, P1; WEAVER R, 1977, ASTROPHYS J, V218, P377, DOI 10.1086/155692	27	117	119	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					687	689		10.1038/380687a0	http://dx.doi.org/10.1038/380687a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614462				2022-12-01	WOS:A1996UG82700041
J	Landi, G				Landi, G			No to DNR orders in acute stroke	LANCET			English	Editorial Material											Landi, G (corresponding author), OSPED MAGGIORE POLICLIN,MILAN,ITALY.							Alexandrov AV, 1996, STROKE, V27, P232, DOI 10.1161/01.STR.27.2.232; BURTIN P, 1994, INTENS CARE MED, V20, P32, DOI 10.1007/BF02425052; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					848	848		10.1016/S0140-6736(96)91342-2	http://dx.doi.org/10.1016/S0140-6736(96)91342-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622388				2022-12-01	WOS:A1996UC45000006
J	Levy, A				Levy, A			Perioperative steroid cover	LANCET			English	Editorial Material											Levy, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							BROMBERG JS, 1991, TRANSPLANTATION, V51, P385, DOI 10.1097/00007890-199102000-00023; FRASER CG, 1952, JAMA-J AM MED ASSOC, V149, P1542, DOI 10.1001/jama.1952.72930340001009; Friedman RJ, 1995, J BONE JOINT SURG AM, V77A, P1801, DOI 10.2106/00004623-199512000-00002; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; LEWIS L, 1953, ANN INTERN MED, V39, P116, DOI 10.7326/0003-4819-39-1-116	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					846	847		10.1016/S0140-6736(96)91340-9	http://dx.doi.org/10.1016/S0140-6736(96)91340-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622386				2022-12-01	WOS:A1996UC45000004
J	MunozJordan, JL; Davies, KP; Cross, GAM				MunozJordan, JL; Davies, KP; Cross, GAM			Stable expression of mosaic coats of variant surface glycoproteins in Trypanosoma brucei	SCIENCE			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SITE-ASSOCIATED GENE; BLOOD-STREAM-FORM; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; PHOSPHOLIPASE-C; MEMBRANE-FORM; VSG 117; PURIFICATION; SEQUENCE	The paradigm of antigenic variation in parasites is the variant surface glycoprotein (VSG) of Af rican trypanosomes. Only one VSG is expressed at any time, except for short periods during switching, The reasons for this pattern of expression and the consequences of expressing more than one VSG are unknown. Trypanosoma brucei was genetically manipulated to generate cell lines that expressed two VSGs simultaneously. These VSGs were produced in equal amounts and were homogeneously distributed on the trypanosome surface. The double-expressor cells had similar population doubling times and were as infective as wild-type cells. Thus, the simultaneous expression of two VSGs is not intrinsically harmful.	ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021	Rockefeller University			Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Davies, Kelvin/0000-0002-0201-9210	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUR Z, 1989, P NATL ACAD SCI USA, V86, P9626, DOI 10.1073/pnas.86.23.9626; AGUR Z, 1992, PARASITOL TODAY, V8, P128, DOI 10.1016/0169-4758(92)90280-F; AGUR Z, 1995, PARASITOL TODAY, V11, P24, DOI 10.1016/0169-4758(95)80103-0; ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALINE RF, 1989, MOL BIOCHEM PARASIT, V32, P169, DOI 10.1016/0166-6851(89)90068-6; ALLEN G, 1982, J MOL BIOL, V157, P527, DOI 10.1016/0022-2836(82)90474-0; ALLEN G, 1983, BIOCHEM J, V209, P481, DOI 10.1042/bj2090481; BALTZ T, 1986, NATURE, V319, P602, DOI 10.1038/319602a0; BARRY D, 1992, PARASITOL TODAY, V8, P128; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BOOTHROYD JC, 1982, J MOL BIOL, V157, P547, DOI 10.1016/0022-2836(82)90475-2; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; BULOW R, 1986, J BIOL CHEM, V261, P1918; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; CARRINGTON M, 1989, MOL BIOCHEM PARASIT, V33, P289, DOI 10.1016/0166-6851(89)90091-1; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CORNELISSEN AWCA, 1985, CELL, V41, P825, DOI 10.1016/S0092-8674(85)80063-5; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CROZATIER M, 1990, MOL BIOCHEM PARASIT, V42, P1, DOI 10.1016/0166-6851(90)90107-W; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DEALMEIDA MLC, 1984, J PROTOZOOL, V31, P53, DOI 10.1111/j.1550-7408.1984.tb04289.x; DUSZENKO M, 1993, ADV CELL MOL BIOL M, V2, P227; EHLERS B, 1987, MOL CELL BIOL, V7, P1242, DOI 10.1128/MCB.7.3.1242; ESSER KM, 1985, SCIENCE, V229, P190, DOI 10.1126/science.3892689; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOX JA, 1986, J BIOL CHEM, V261, P5767; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; GRAHAM SV, 1991, MOL BIOCHEM PARASIT, V47, P31, DOI 10.1016/0166-6851(91)90145-V; GRAHAM SV, 1990, PARASITOLOGY, V101, P361, DOI 10.1017/S0031182000060558; GRAY AR, 1976, BIOLOGY KINETOPLASTI, V1, P493; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; JOHNSON JG, 1977, J PROTOZOOL, V24, P587, DOI 10.1111/j.1550-7408.1977.tb01020.x; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOSINSKI RJ, 1980, PARASITOLOGY, V80, P343, DOI 10.1017/S0031182000000809; LAMONT GS, 1986, PARASITOLOGY, V92, P355, DOI 10.1017/S003118200006412X; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LIU AYC, 1983, J MOL BIOL, V167, P57, DOI 10.1016/S0022-2836(83)80034-5; MILLER EN, 1981, PARASITOLOGY, V82, P63, DOI 10.1017/S0031182000041871; MYLER PJ, 1985, INFECT IMMUN, V47, P684, DOI 10.1128/IAI.47.3.684-690.1985; NAVARRO M, IN PRESS MOL CELL BI, V16; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SCHOLLER JK, 1988, MOL BIOCHEM PARASIT, V29, P89, DOI 10.1016/0166-6851(88)90123-5; SEYFANG A, 1990, J PROTOZOOL, V37, P546, DOI 10.1111/j.1550-7408.1990.tb01263.x; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; STRANG AM, 1993, BIOCHEM BIOPH RES CO, V196, P1430, DOI 10.1006/bbrc.1993.2412; TIMMERS HTM, 1987, J MOL BIOL, V184, P81; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; WILLIAMS BG, 1995, TRYP LEISHM SEM GLAS; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZAMZE SE, 1990, EUR J BIOCHEM, V187, P657, DOI 10.1111/j.1432-1033.1990.tb15350.x	62	48	48	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1795	1797		10.1126/science.272.5269.1795	http://dx.doi.org/10.1126/science.272.5269.1795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650579				2022-12-01	WOS:A1996UT11000045
J	Nudo, RJ; Wise, BM; SiFuentes, F; Milliken, GW				Nudo, RJ; Wise, BM; SiFuentes, F; Milliken, GW			Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct	SCIENCE			English	Article							OWL MONKEYS; CORTEX; ORGANIZATION; AREA; REORGANIZATION; REPRESENTATION; STIMULATION; STROKE; HAND; MAPS	Substantial functional reorganization lakes place in the motor cortex of adult primates after a focal ischemic infarct, as might occur in stroke. A subtotal lesion confined to a small portion of the representation of one hand was previously shown to result in a further loss of hand territory in the adjacent, undamaged cortex of adult squirrel monkeys. In the present study, retraining of skilled hand use after similar infarcts resulted in prevention of the loss of hand territory adjacent to the infarct. In some instances, the hand representations expanded into regions formerly occupied by representations of the elbow and shoulder. Functional reorganization in the undamaged motor cortex was accompanied by behavioral recovery of skilled hand function. These results suggest that, after local damage to the motor cortex, rehabilitative training can shape subsequent reorganization in the adjacent intact cortex, and that the undamaged motor cortex may play an important role in motor recovery.			Nudo, RJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77030, USA.		Nudo, Randolph/B-1623-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027974, R01NS030853] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27974, NS30853] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bach-y-Rita P., 1980, RECOVERY FUNCTION TH, P225; BENECKE R, 1991, EXP BRAIN RES, V83, P419; Black P, 1970, Trans Am Neurol Assoc, V95, P207; BLACK P, 1975, OUTCOME SEVERE DAMAG, P65; BUCY PC, 1944, PRECENTRAL MOTOR COR, P353; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; GLEES P, 1950, J NEUROPHYSIOL, V13, P137, DOI 10.1152/jn.1950.13.2.137; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; Gowland C, 1987, STROKE REHABILITATIO, P217; HOFFMAN DS, 1995, J NEUROPHYSIOL, V73, P891, DOI 10.1152/jn.1995.73.2.891; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KARNI A, 1995, NATURE, V377, P155; Lashley KS, 1924, ARCH NEURO PSYCHIATR, V12, P249, DOI 10.1001/archneurpsyc.1924.02200030002001; Nudo R. J., 1995, Society for Neuroscience Abstracts, V21, P517; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASSINGHAM RE, 1983, BRAIN, V106, P675, DOI 10.1093/brain/106.3.675; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; RIDDING MC, 1995, CAN J PHYSIOL PHARM, V73, P218, DOI 10.1139/y95-032; SANES JN, 1995, SCIENCE, V268, P1775, DOI 10.1126/science.7792606; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; SEITZ RJ, 1995, NEUROREPORT, V6, P742, DOI 10.1097/00001756-199503270-00009; STRICK PL, 1982, J NEUROPHYSIOL, V48, P139, DOI 10.1152/jn.1982.48.1.139; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TRAVIS A M, 1956, Am J Phys Med, V35, P273; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0	34	1309	1394	5	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1791	1794		10.1126/science.272.5269.1791	http://dx.doi.org/10.1126/science.272.5269.1791			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650578				2022-12-01	WOS:A1996UT11000044
J	Glickman, S; Kamm, MA				Glickman, S; Kamm, MA			Bowel dysfunction in spinal-card-injury patients	LANCET			English	Article							CORD INJURY; STIMULATION	Background This study aimed to determine the prevalence, nature, and effects-both physical and psychological-of spinal-cord-injury (SCI) on bower function. Methods 115 consecutive hospital outpatients (89 male, median age 38 years) with chronic SCI (median duration 62 months, range 9-491 months, 48% cervical, 47% thoracic, 5% lumbar) completed a questionnaire about pre and post injury bowel function, the Hospital Anxiety and Depression Scale (HADS), and self assessment of the impact of their disabilities and symptoms. Findings Nausea, diarrhoea, constipation, and faecal incontinence were all much more common (p<0 . 0001) after SCI. 95% of patients required at least one therapeutic method to initiate defaecation. Half the patients became dependent on others for toileting. 49% took more than 30 min to complete their toilet procedure. Bowel function was a source of distress in 54% of patients and this was significantly (p=0 . 005) associated with the time required for bowel management and frequency of incontinence (p=0 . 001). There was a highly significant correlation between the HADS scores and the time taken for bower management. On a scale of 0 (for no perceived problem) to 10 (maximum perceived problem), patients rated their loss of mobility as a mean of 6 . 8 (SD 3 . 3) and their bowel management as 5 . 1(SD 3 . 6). Interpretation Dowel function is a major physical and psychological problem in SCI patients.	CHARING CROSS HOSP,DEPT REHABIL MED,LONDON,ENGLAND; ST MARKS HOSP,MED PHYSIOL UNIT,LONDON EC1V 2PS,ENGLAND	Imperial College London; Imperial College London				Glickman, Scott/0000-0002-8084-9949				DEVROEDE G, 1979, GASTROENTEROLOGY, V77, P1258; FROST F, 1993, ARCH PHYS MED REHAB, V74, P696, DOI 10.1016/0003-9993(93)90027-8; GLICK ME, 1986, PARAPLEGIA, V24, P129, DOI 10.1038/sc.1986.17; HILL J, 1994, BRIT J SURG, V81, P1490, DOI 10.1002/bjs.1800811030; MACDONAGH RP, 1990, BRIT MED J, V300, P1494, DOI 10.1136/bmj.300.6738.1494; MACINTYRE AS, 1992, GUT, V33, P1062; MENARDO G, 1987, DIS COLON RECTUM, V30, P924, DOI 10.1007/BF02554277; STONE JM, 1990, ARCH PHYS MED REHAB, V71, P514; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	9	254	257	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1651	1653		10.1016/S0140-6736(96)91487-7	http://dx.doi.org/10.1016/S0140-6736(96)91487-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642958				2022-12-01	WOS:A1996UQ70100010
J	Krause, PJ; Telford, SR; Spielman, A; Sikand, V; Ryan, R; Christianson, D; Burke, G; Brassard, P; Pollack, R; Peck, J; Persing, DH				Krause, PJ; Telford, SR; Spielman, A; Sikand, V; Ryan, R; Christianson, D; Burke, G; Brassard, P; Pollack, R; Peck, J; Persing, DH			Concurrent lyme disease and babesiosis - Evidence for increased severity and duration of illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; MICROTI	Objective.-To determine whether patients coinfected with Lyme disease and babesiosis in sites where both diseases are zoonotic experience a greater number of symptoms for a longer period of time than those with either infection alone. Design.-Community-based, yearly serosurvey and clinic-based cohort study. Setting.-Island community in Rhode Island and 2 Connecticut medical clinics from 1990 to 1994. Study Participants.-Long-term residents of the island community and patients seeking treatment at the clinics. Main Outcome Measures.-Seroreactivity to the agents of Lyme disease and babesiosis and number and duration of symptoms. Results.-Of 1156 serosurvey subjects, 97 (8.4%) were seroreactive against Lyme disease spirochete antigen, of whom 14 (14%) also were seroreactive against babesial antigen. Of 240 patients diagnosed with Lyme disease, 26 (11%) were coinfected with babesiosis. Coinfected patients experienced fatigue (P=.002), headache (P<.001), sweats (P<.001), chills (P=.03), anorexia (P=.04), emotional lability (P=.02), nausea (P=.004), conjunctivitis (P=.04), and splenomegaly (P=.01) more frequently than those with Lyme disease alone. Thirteen (50%) of 26 coinfected patients were symptomatic for 3 months or longer compared with 7 (4%) of the 184 patients with Lyme disease alone from whom follow-up data were available (P<.001), Patients coinfected with Lyme disease experienced more symptoms and a more persistent episode of illness than did those (n=10) experiencing babesial infection alone. Circulating spirochetal DNA was detected more than 3 times as often in coinfected patients as in those with Lyme disease alone (P=.06). Conclusions.-Approximately 10% of patients with Lyme disease in southern New England are coinfected with babesiosis in sites where both diseases are zoonotic. The number of symptoms and duration of illness in patients with concurrent Lyme disease and babesiosis are greater than in patients with either infection alone. In areas where both Lyme disease and babesiosis have been reported, the possibility of concomitant babesial infection should be considered when moderate to severe Lyme disease has been diagnosed.	UNIV CONNECTICUT,SCH MED,DEPT LAB MED,FARMINGTON,CT 06030; HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115; MAYO CLIN,DEPT MED,ROCHESTER,MN; MAYO CLIN,DEPT PATHOL,ROCHESTER,MN	University of Connecticut; Harvard University; Harvard T.H. Chan School of Public Health; Mayo Clinic; Mayo Clinic	Krause, PJ (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT PEDIAT,FARMINGTON,CT 06030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019693, R37AI019693, R01AI032403, P01AI030548] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30548, AI 19693, AI 32403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG AL, 1992, AM J TROP MED HYG, V47, P249, DOI 10.4269/ajtmh.1992.47.249; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BENACH JL, 1981, J INFECT DIS, V144, P473; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; GOLIGHTLY LM, 1989, REV INFECT DIS, V11, P629; GRUNWALDT E, 1983, NEW ENGL J MED, V308, P1166; KIMSEY PB, 1990, CLIN RES, V38, P596; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; KRAUSE PJ, 1992, PEDIATRICS, V89, P1045; MALAWISTA SE, 1994, J INFECT DIS, V170, P1312, DOI 10.1093/infdis/170.5.1312; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PERSING DH, 1994, J INFECT DIS, V169, P668, DOI 10.1093/infdis/169.3.668; PURVIS AC, 1977, PARASITOLOGY, V75, P197, DOI 10.1017/S003118200006234X; RUEBUSH TK, 1977, ANN INTERN MED, V86, P6, DOI 10.7326/0003-4819-86-1-6; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; TELFORD SR, IN PRESS TOPLEY WILS; Vos A. J. de, 1987, Immune responses in parasitic infections: immunology, immunopathology, and immunoprophylaxis. Volume III: Protozoa, P183; 1991, LYME DIS SURVEILL SU, V2, P1	24	325	339	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1657	1660		10.1001/jama.275.21.1657	http://dx.doi.org/10.1001/jama.275.21.1657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637139				2022-12-01	WOS:A1996UN25200028
J	Kaplan, NM; Gifford, RW				Kaplan, NM; Gifford, RW			Choice of initial therapy for hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACOLOGICAL TREATMENT; ANTIHYPERTENSIVE AGENTS; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; GUIDELINES; MANAGEMENT; SOCIETY; TRIAL	Hypertension is one of the most common conditions treated by the clinician, yet accurate diagnosis and selection of the appropriate treatment can be challenging and recommendations regarding antihypertensive medications continue to evolve. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends diet and exercise for the initial treatment of mild hypertension, followed by a diuretic or P-blocker if necessary, unless contraindicated. This recommendation is based on outcome studies using these drugs that demonstrate reductions in major diseases that treatment of hypertension is intended to prevent: stroke and cardiovascular morbidity and mortality. Other antihypertensive drugs, while not tested in large trials evaluating outcomes, have unique advantages for certain patients. Consideration of the patient's medical conditions and needs, including the cost of medication, is essential to ensuring optimal treatment of hypertension.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; CLEVELAND CLIN FDN,DEPT NEPHROL INTERNAL MED & HYPERTENS,CLEVELAND,OH 44195	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation	Kaplan, NM (corresponding author), UNIV TEXAS,SW MED CTR,DIV HYPERTENS,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ACKER CG, 1995, NEW ENGL J MED, V333, P1572, DOI 10.1056/NEJM199512073332316; [Anonymous], 1993, BMJ, V307, P1541; APPLEGATE WB, 1991, ARCH INTERN MED, V151, P1817, DOI 10.1001/archinte.151.9.1817; BURNIER M, 1992, J INTERN MED, V232, P381, DOI 10.1111/j.1365-2796.1992.tb00603.x; CARTER BL, 1989, J FAM PRACTICE, V29, P257; FRISHMAN WH, 1994, ARCH INTERN MED, V154, P1461, DOI 10.1001/archinte.154.13.1461; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1989, HYPERTENSION S, V2, P65; GILLENWATER JY, 1995, J UROLOGY, V154, P110, DOI 10.1016/S0022-5347(01)67243-4; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Kaplan NM, 1994, CLIN HYPERTENSION, P191; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MAHEUX P, 1994, AM J HYPERTENS, V7, P416, DOI 10.1093/ajh/7.5.416; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PIERDOMENICO SD, 1995, EUR HEART J, V16, P692, DOI 10.1093/oxfordjournals.eurheartj.a060975; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; RIBACKE M, 1995, J INTERN MED, V237, P473, DOI 10.1111/j.1365-2796.1995.tb00872.x; *ROYAL AUSTR COLL, 1991, HYP DIAGN TREATM MAI; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SILAGY CA, 1992, AM J CARDIOL, V70, P1299, DOI 10.1016/0002-9149(92)90765-Q; SWALES JD, 1993, J HYPERTENS, V11, P899, DOI 10.1097/00004872-199309000-00003; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WRIGHT JT, 1995, AM J HYPERTENS, V8, pA27; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, ARCH INTERN MED, V153, P154	30	59	59	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1577	1580		10.1001/jama.275.20.1577	http://dx.doi.org/10.1001/jama.275.20.1577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622249				2022-12-01	WOS:A1996UL02900030
J	Gautam, M; Noakes, PG; Moscoso, L; Rupp, F; Scheller, RH; Merlie, JP; Sanes, JR				Gautam, M; Noakes, PG; Moscoso, L; Rupp, F; Scheller, RH; Merlie, JP; Sanes, JR			Defective neuromuscular synaptogenesis in agrin-deficient mutant mice	CELL			English	Article							CULTURED MUSCLE-CELLS; ACETYLCHOLINE-RECEPTOR CLUSTERS; TORPEDO ELECTRIC ORGAN; EXTRACELLULAR-MATRIX; PROTEIN; MOLECULES; INDUCTION; JUNCTION; REDISTRIBUTION; LOCALIZATION	During neuromuscular synapse formation, motor axons induce clustering of acetylcholine receptors (AChRs) in the muscle fiber membrane. The protein agrin, originally isolated from the basal lamina of the synaptic cleft, is synthesized and secreted by motoneurons and triggers formation of AChR clusters on cultured myotubes. We show here that postsynaptic AChR aggregates are markedly reduced in number, size, and density in muscles of agrin-deficient mutant mice. These results support the hypothesis that agrin is a critical organizer of postsynaptic differentiation. However, some postsynaptic differentiation does occur in the mutant, suggesting the existence of a second nerve-derived synaptic organizing signal. In addition, we show that intramuscular nerve branching and presynaptic differentiation are abnormal in the mutant, phenotypes which may reflect either a distinct effect of agrin or impaired retrograde signaling from a defective postsynaptic apparatus.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Stanford University	Gautam, M (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA.		Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; BENNETT MR, 1975, COLD SPRING HARB SYM, V40, P409, DOI 10.1101/SQB.1976.040.01.039; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; BURG MA, 1995, J NEUROSCI RES, V41, P49, DOI 10.1002/jnr.490410107; Campagna JA, 1995, NEURON, V15, P1365, DOI 10.1016/0896-6273(95)90014-4; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; COHEN MW, 1992, J NEUROSCI, V12, P2982, DOI 10.1523/JNEUROSCI.12-08-02982.1992; DAVEY DF, 1986, J NEUROSCI, V6, P673; DECHIARA TM, 1996, IN PRESS CELL; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FALLON JR, 1989, J CELL BIOL, V108, P1527, DOI 10.1083/jcb.108.4.1527; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARRIS A J, 1981, Philosophical Transactions of the Royal Society of London B Biological Sciences, V293, P287, DOI 10.1098/rstb.1981.0078; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; HOUENOU LJ, 1990, J NEUROBIOL, V21, P1249, DOI 10.1002/neu.480210809; KUROMI H, 1984, DEV BIOL, V103, P53, DOI 10.1016/0012-1606(84)90006-X; LUPA MT, 1989, J NEUROSCI, V9, P3937; MA E, 1994, J NEUROSCI, V14, P2943; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; PENG HB, 1995, J NEUROSCI, V15, P3027; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1982, J NEUROSCI, V2, P1760; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1992, J NEUROSCI, V12, P3535; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1991, DEVELOPMENT, V113, P1181; SMITH MA, 1992, MOL CELL NEUROSCI, V3, P406, DOI 10.1016/1044-7431(92)90052-4; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALLACE BG, 1989, J NEUROSCI, V9, P1294; ZISKINDCONHAIM L, 1984, J NEUROSCI, V4, P2346	53	755	770	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1996	85	4					525	535		10.1016/S0092-8674(00)81253-2	http://dx.doi.org/10.1016/S0092-8674(00)81253-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653788	hybrid			2022-12-01	WOS:A1996UM41500010
J	Bacher, G; Lutcke, H; Jungnickel, B; Rapoport, TA; Dobberstein, B				Bacher, G; Lutcke, H; Jungnickel, B; Rapoport, TA; Dobberstein, B			Regulation by the ribosome of the GTPase of the signal-recognition particle during protein targeting	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSLOCATION; RECEPTOR; HYDROLYSIS; SEQUENCE; BINDING; POLYPEPTIDE; REQUIRES; SRP	THE signal-recognition particle (SRP) is important for the targeting of many secretory and membrane proteins to the endoplasmic reticulum (ER). Targeting is regulated by three GTPases, the 54K subunit of SRP (SRP54), and the alpha- and beta-subunits of the SRP receptor(1). When a signal sequence emerges from the ribosome, SRP interacts with it and targets the resulting complex to the ER membrane by binding to the SRP receptor. Subsequently, SRP releases the signal sequence into the translocation channel(2,3). Here we use a complex of a ribosome with a nascent peptide chain, the SRP and its receptor, to investigate GTP binding to SRP54, and GTP hydrolysis. Our findings indicate that a ribosomal component promotes GTP binding to the SRP54 subunit of SRP, GTP-bound SRP54 is essential for high-affinity interaction between SRP and its receptor in the ER membrane. This interaction induces the release of the signal sequence from SRP, the insertion of the nascent polypeptide chain into the translocation channel, and GTP hydrolysis. The contribution of the ribosome had previously escaped detection because only synthetic signal peptides were used in the analysis(4).	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	Bacher, G (corresponding author), UNIV HEIDELBERG,ZMBH,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; HIGH S, 1991, J CELL BIOL, V113, P54; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	26	121	122	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					248	251		10.1038/381248a0	http://dx.doi.org/10.1038/381248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622769				2022-12-01	WOS:A1996UL24900058
J	Reijo, R; Alagappan, RK; Patrizio, P; Page, DC				Reijo, R; Alagappan, RK; Patrizio, P; Page, DC			Severe oligozoospermia resulting from deletions of azoospermia factor gene on Y chromosome	LANCET			English	Article							INFERTILITY; REGION	Background About 13% of cases of non-obstructive azoospermia are caused by deletion of the azoospermia factor (AZF), a gene or gene complex normally located on the long arm of the Y chromosome. Oligozoospermia is far more common than azoospermia, but little is known about genetic causes. We investigated whether severe oligozoospermia is caused by AZF deletions and, if so, whether those deletions are present in mature spermatozoa, Methods By PCR, we tested leucocyte DNA, from 35 men who presented at infertility clinics and who had severe oligozoospermia, for the presence of 118 DNA landmarks scattered across the Y chromosome. In the two men in whom Y-chromosome deletions in leucocyte DNA were detected, we also tested leucocyte DNA from the individuals' fathers, and in one man we tested sperm DNA. Findings In two men with ejaculate sperm counts of 40 000-100 000 per mL, we detected Y-chromosome leucocyte DNA similar in location to those reported in azoospermic individuals. No Y-chromosome deletions were detected in the fathers of the two men, For one of the two men, sperm DNA was tested, and it showed the same Y-chromosome deletion seen in leucocytes. Interpretation The Y-chromosome deletions in these two men are de-novo mutations, and are therefore the cause of their severe oligozoospermia. Not only is the absence of AZF compatible with spermatogenesis, albeit at reduced rate, but also the resultant sperm bear the mutant Y chromosome. Because intracytoplasmic sperm injection is increasingly used as a means of circumventing oligozoospermia, AZF deletions could be transmitted by this practice, and would probably result in infertile sons. In cases of severe oligozoospermia, it may be appropriate to offer Y-DNA testing and genetic counselling before starting assisted reproductive procedures.	WHITEHEAD INST,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA; FERTIL CTR SAN ANTONIO,MALE INFERTIL SERV,SAN ANTONIO,TX	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Patrizio, Pasquale/AGO-0674-2022	Reijo Pera, Renee/0000-0002-6487-1329				ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BHASIN S, 1994, J CLIN ENDOCR METAB, V79, P1525, DOI 10.1210/jc.79.6.1525; BORGAONKAR DS, 1971, NATURE, V230, P52, DOI 10.1038/230052a0; CHANDLEY AC, 1994, HUM MOL GENET, V3, P1449, DOI 10.1093/hmg/3.suppl_1.1449; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GYLLENSTEN U, 1990, PCR PROTOCOLS, V1, P300; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; NAKAHORI Y, 1994, HUM MOL GENET, V3, P1709, DOI 10.1093/hmg/3.9.1709; ORD T, 1990, HUM REPROD, V5, P987, DOI 10.1093/oxfordjournals.humrep.a137233; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; SILBER SJ, 1995, HUM REPROD, V10, P148, DOI 10.1093/humrep/10.1.148; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VANZYL JA, 1975, INT J FERTIL, V20, P129; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769	18	436	458	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1290	1293		10.1016/S0140-6736(96)90938-1	http://dx.doi.org/10.1016/S0140-6736(96)90938-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622504				2022-12-01	WOS:A1996UK75800009
J	Watson, MA; Chaconas, G				Watson, MA; Chaconas, G			Three-site synapsis during Mu DNA transposition: A critical intermediate preceding engagement of the active site	CELL			English	Article							INTEGRATION HOST FACTOR; STRAND-TRANSFER-REACTION; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; PHAGE-MU; B-PROTEIN; HIN INVERTASOME; A-PROTEIN; ENHANCER; ENDS	The chemical steps of bacteriophage Mu DNA transposition take place within a higher order nucleoprotein structure. We describe a novel intermediate that precedes the previously characterized transpososomes and directly demonstrates the interaction of a distant enhancer element with recombination regions. The transpositional enhancer interacts with the Mu left and right ends to form a three-site synaptic (LER) complex. Under normal reaction conditions, the LER complex is rapidly converted into the more stable Mu transpososomes. However, mutation of the Mu terminal nucleotides results in accumulation of the LER and a failure to form the type 0 transpososome. During the transition from LER to type 0, the Mu DNA termini and the active site of the transposase engage in a catalytically competent conformation.			Watson, MA (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON N6A 5C1, CANADA.			Watson, Mark/0000-0002-3557-101X				ALLISON RG, 1992, J BIOL CHEM, V267, P19963; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1995, CURR TOP MICROBIOL I, V204, P83; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANPUTTE P, 1992, TRENDS GENET, V8, P457; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; WESTMORELAND BC, 1969, SCIENCE, V163, P1343, DOI 10.1126/science.163.3873.1343; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, GENE DEV, V9, P2545, DOI 10.1101/gad.9.20.2545; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; ZOU A, 1991, J BIOL CHEM, V266, P20476	51	66	66	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					435	445		10.1016/S0092-8674(00)81121-6	http://dx.doi.org/10.1016/S0092-8674(00)81121-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616898	Bronze			2022-12-01	WOS:A1996UK14000016
J	Ferris, JP; Hill, AR; Liu, RH; Orgel, LE				Ferris, JP; Hill, AR; Liu, RH; Orgel, LE			Synthesis of long prebiotic oligomers on mineral surfaces	NATURE			English	Article								MOST theories of the origin of biological organization assume that polymers with lengths in the range of 30-60 monomers are needed to make a genetic system viable(1). But it has not proved possible to synthesize plausibly prebiotic polymers this long by condensation in aqueous solution, because hydrolysis competes with polymerization. The potential of mineral surfaces to facilitate prebiotic polymerization was pointed out long ago(2). Here we describe a system that models prebiotic polymerization by the oligomerization of activated monomers-both nucleotides and amino acids. We find that whereas the reactions in solution produce only short oligomers (the longest typically being a 10-mer), the presence of mineral surfaces (montmorillonite for nucleotides, illite and hydroxylapatite for amino acids) induces the formation of oligomers up to 55 monomers long. These are formed by successive 'feedings' with the monomers; polymerization takes place on the mineral surfaces in a manner akin to solid-phase synthesis of biopolymers(3,4).	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute	Ferris, JP (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ACEVEDO OL, 1986, NATURE, V321, P790, DOI 10.1038/321790a0; BERNAL JD, 1951, PHYSICAL BASIS LIFE; EHLER KW, 1976, BIOCHIM BIOPHYS ACTA, V434, P233, DOI 10.1016/0005-2795(76)90055-6; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; GIBBS D, 1980, J MOL EVOL, V15, P347, DOI 10.1007/BF01733141; HOLM NG, 1993, ORIGINS LIFE EVOL B, V23, P195, DOI 10.1007/BF01581839; KAWAMURA K, 1994, J AM CHEM SOC, V116, P7564, DOI 10.1021/ja00096a013; SCHWARTZ AW, 1985, J MOL EVOL, V21, P299, DOI 10.1007/BF02102362; Szostak J.W., 1993, RNA WORLD, P511	9	611	625	6	215	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					59	61		10.1038/381059a0	http://dx.doi.org/10.1038/381059a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609988	Green Submitted			2022-12-01	WOS:A1996UJ05300053
J	Gao, JM; Mammen, M; Whitesides, GM				Gao, JM; Mammen, M; Whitesides, GM			Evaluating electrostatic contributions to binding with the use of protein charge ladders	SCIENCE			English	Article								Electrostatic interactions between charges on ligands and charges on proteins that are remote from the binding interface can influence the free energy of binding (Delta G(b)). The binding affinities between charged ligands and the members of a charge ladder of bovine carbonic anhydrase (CAII) constructed by random acetylation of the amino groups on its surface were measured by affinity capillary electrophoresis (ACE). The values of Delta G(b) derived from this analysis correlated approximately linearly with the charge. Opposite charges on the ligand and the members of the charge ladder of CAII were stabilizing; like charges were destabilizing. The combination of ACE and protein charge ladders provides a tool for quantitatively examining the contributions of electrostatics to free energies of molecular recognition in biology.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM51559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051559] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON HA, 1942, ELECTROPHORESIS PROT, pCH5; BASAK SK, 1995, ANAL BIOCHEM, V226, P51, DOI 10.1006/abio.1995.1190; CHU YH, 1995, ACCOUNTS CHEM RES, V28, P461, DOI 10.1021/ar00059a004; DODGSON SJ, 1991, CARBONIC ANHYDRASES; GAO JM, 1994, P NATL ACAD SCI USA, V91, P12027, DOI 10.1073/pnas.91.25.12027; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Ise N, 1996, ACCOUNTS CHEM RES, V29, P3, DOI 10.1021/ar950019k; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; Schmitz KS, 1996, ACCOUNTS CHEM RES, V29, P7, DOI 10.1021/ar950129r; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0	12	82	84	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					535	537		10.1126/science.272.5261.535	http://dx.doi.org/10.1126/science.272.5261.535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614800				2022-12-01	WOS:A1996UG82600040
J	Lehman, A; Black, R; Ecker, JR				Lehman, A; Black, R; Ecker, JR			HOOKLESS1, an ethylene response gene, is required for differential cell elongation in the Arabidopsis hypocotyl	CELL			English	Article							NUCLEOTIDE-SEQUENCE; T-DNA; PLANTS; AUXIN; ACETYLTRANSFERASE; EXPRESSION; MUTANTS; GROWTH; MUTAGENESIS; THALIANA	Bending in plant tissues results from differential cell elongation. We have characterized Arabidopsis ''hookless'' mutants that are defective in differential growth in the hypocotyl. HOOKLESS1 was cloned and its predicted protein shows similarity to a diverse group of N-acetyltransferases. HOOKLESS1 mRNA is increased by treatment with ethylene and decreased in the ethylene-insensitive mutant ein2. High level expression of HOOKLESS1 mRNA results in constitutive hook curvature. The morphology of the hookless hypocotyl is phenocopied by inhibitors of auxin transport or by high levels of endogenous or exogenous auxin. Spatial patterns of expression of two immediate early auxin-responsive genes are altered in hookless1 mutants, suggesting that the ethylene response gene HOOKLESS1 controls differential cell growth by regulating auxin activity.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104; PENN STATE UNIV,DEPT BIOL,MEDIA,PA 19603	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University			Ecker, Joseph R/B-9144-2008	Ecker, Joseph R/0000-0001-5799-5895				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABELES FB, 1992, IN PRESS ETHYLENE PL; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANZAI H, 1990, NUCLEIC ACIDS RES, V18, P1890, DOI 10.1093/nar/18.7.1890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLACK RC, 1986, PLANT PHYSIOL, V80, P145, DOI 10.1104/pp.80.1.145; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; CASERO RA, 1991, J BIOL CHEM, V266, P810; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; Cleland R. E., 1987, Plant hormones and their role in plant growth and development., P132; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DARWIN C, 1896, POWER MOVEMENT PLANT, P87; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FIRN RD, 1980, ANNU REV PLANT PHYS, V31, P131, DOI 10.1146/annurev.pp.31.060180.001023; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; GIL P, 1996, IN PRESS EMBO J; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HEIM U, 1989, NUCLEIC ACIDS RES, V17, P7103, DOI 10.1093/nar/17.17.7103; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; HOU YM, 1993, PLANT CELL, V5, P329, DOI 10.1105/tpc.5.3.329; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; KANG BG, 1967, SCIENCE, V156, P958, DOI 10.1126/science.156.3777.958; KERK NM, 1995, DEVELOPMENT, V121, P2825; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; King JJ, 1995, PLANT CELL, V7, P2023, DOI 10.1105/tpc.7.12.2023; KRUGEL H, 1993, GENE, V127, P127, DOI 10.1016/0378-1119(93)90627-F; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LI Y, 1994, PLANT MOL BIOL, V24, P715, DOI 10.1007/BF00029853; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; Lomax Terri L., 1995, P509; MORGAN DG, 1964, NATURE, V201, P476, DOI 10.1038/201476a0; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; OELLER PW, 1993, J MOL BIOL, V233, P789, DOI 10.1006/jmbi.1993.1555; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; Reinecke D. M., 1987, Plant hormones and their role in plant growth and development., P24; ROMAN G, 1995, GENETICS, V139, P1393; RUBERY PH, 1990, SYM SOC EXP BIOL, V44, P119; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SCHWARK A, 1993, J PLANT PHYSIOL, V142, P585, DOI 10.1016/S0176-1617(11)80403-7; SCHWARK A, 1992, J PLANT PHYSIOL, V140, P562, DOI 10.1016/S0176-1617(11)80790-X; SILK WK, 1978, AM J BOT, V65, P310, DOI 10.2307/2442271; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; Tamas I. A., 1987, Plant hormones and their role in plant growth and development., P393; TENOVER FC, 1988, J BACTERIOL, V170, P471, DOI 10.1128/jb.170.1.471-473.1988; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; WYATT RE, 1993, PLANT MOL BIOL, V22, P731, DOI 10.1007/BF00027361; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153; ZIMMER W, 1991, MOL GEN GENET, V229, P41, DOI 10.1007/BF00264211	60	330	349	5	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					183	194		10.1016/S0092-8674(00)81095-8	http://dx.doi.org/10.1016/S0092-8674(00)81095-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612271	hybrid			2022-12-01	WOS:A1996UG25500007
J	Yoto, Y; Kudoh, T; Haseyama, K; Suzuki, N; Chiba, S				Yoto, Y; Kudoh, T; Haseyama, K; Suzuki, N; Chiba, S			Human parvovirus B19 infection associated with acute hepatitis	LANCET			English	Article							DISEASE	Background Human parvovirus (HPV) B19 infection produces a range manifestations including erythema infectiosum in children. Here we describe seven children who had acute hepatitis with HPV B19 infection. Methods Hepatic dysfunction was noted in three children referred to our hospital during the course of erythema infectiosum caused by HPV B19 infection diagnosed by ELISA and PCR. The role of HPV B19 in the pathogenesis of hepatic involvement was investigated retrospectively by PCR assay of stored serum samples from 773 patients admitted to our hospital. Findings 15 patients admitted to our hospital from January, 1991, to June, 1992, were HPV B19 DNA positive, of whom four had acute hepatitis of unknown origin. These four patients were aged between 7 months and 5 years. Of the seven patients, infection with hepatitis A, B, or C viruses or Epstein-Barr virus was ruled out in six by virological examinations. Interpretation Epidemiological evidence suggests that HPV B19 can be the cause of acute hepatitis.			Yoto, Y (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT PEDIAT,CHUO KU,S-1,W-16,SAPPORO,HOKKAIDO 060,JAPAN.							BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; HAAS L, 1990, J VET MED B, V37, P106, DOI 10.1111/j.1439-0450.1990.tb01033.x; JELINEK F, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P69; METZMAN R, 1989, J PEDIATR GASTR NUTR, V9, P112; MUIR K, 1992, LANCET, V339, P1139, DOI 10.1016/0140-6736(92)90735-L; OHGA S, 1993, AM J PEDIAT HEMATOL, V15, P291; SALIMANS MMM, 1989, J CLIN PATHOL, V42, P525, DOI 10.1136/jcp.42.5.525; TSUDA H, 1993, AM J GASTROENTEROL, V88, P1463; YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1; YOTO Y, 1993, ACTA HAEMATOL-BASEL, V90, P8	10	115	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					868	869		10.1016/S0140-6736(96)91348-3	http://dx.doi.org/10.1016/S0140-6736(96)91348-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622394				2022-12-01	WOS:A1996UC45000012
J	Jia, L; Bonaventura, C; Bonaventura, J; Stamler, JS				Jia, L; Bonaventura, C; Bonaventura, J; Stamler, JS			S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control	NATURE			English	Article							HUMAN-HEMOGLOBIN; NITRIC-OXIDE; BINDING	A dynamic cycle exists in which haemoglobin is S-nitrosylated in the lung when red blood cells are oxygenated, and the NO group is released during arterial-venous transit. The vasoactivity of S-nitrosohaemoglobin is promoted by the erythrocytic export of S-nitrosothiols. These findings highlight newly discovered allosteric and electronic properties of haemoglobin that appear to be involved in the control of blood pressure and which may facilitate efficient delivery of oxygen to tissues. The role of S-nitrosohaemoglobin in the transduction of NO-related activities may have therapeutic applications.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE MARINE BIOMED CTR,NICHOLAS SCH ENVIRONM,PIVERS ISL,NC 28516	Duke University; Duke University	Jia, L (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV RESP & CARDIOVASC MED,MSRB BLDG,ROOM 321,BOX 2612,DURHAM,NC 27710, USA.			Stamler, Jonathan/0000-0002-6866-1572; JIA, LEE/0000-0001-6839-5545				AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P29; BECKMAN JS, 1996, METHODS NITRIC OXIDE; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; JOCELYN PC, 1972, BIOCH SH GROUP, P243; KILBOURN RG, 1994, BIOCHEM BIOPH RES CO, V199, P155, DOI 10.1006/bbrc.1994.1208; KONDO T, 1995, METHOD ENZYMOL, V252, P72; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MANSOURI A, 1979, BIOCHEM BIOPH RES CO, V89, P441, DOI 10.1016/0006-291X(79)90649-1; OLSEN SB, 1996, CIRCULATION, V93, P329; Olson J S, 1981, Methods Enzymol, V76, P631; SALHANY JM, 1981, TRENDS BIOCH SCI JAN, P1; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TOOTHILL C, 1967, BRIT J ANAESTH, V39, P405, DOI 10.1093/bja/39.5.405; VOGEL WM, 1986, AM J PHYSIOL, V251, pH413, DOI 10.1152/ajpheart.1986.251.2.H413; WENNMALM A, 1992, BRIT J PHARMACOL, V106, P6507; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1	26	1382	1440	0	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					221	226		10.1038/380221a0	http://dx.doi.org/10.1038/380221a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637569				2022-12-01	WOS:A1996UB11700043
J	Grosskurth, H; Mayaud, P; Mosha, F; Todd, J; Senkoro, K; Newell, J; Gabone, R; Changalucha, J; West, B; Hayes, R; Mabey, D				Grosskurth, H; Mayaud, P; Mosha, F; Todd, J; Senkoro, K; Newell, J; Gabone, R; Changalucha, J; West, B; Hayes, R; Mabey, D			Asymptomatic gonorrhoea and chlamydial infection in rural Tanzanian men	BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED DISEASES; GONOCOCCAL INFECTIONS; RISK-FACTORS; EPIDEMIOLOGY; URETHRITIS; TRANSMISSION; TRACHOMATIS	Objective-To measure the prevalence of urethritis due to Neisseria gonorrhoeae and Chlamydia trachomatis in rural Tanzanian men. Design-About 500 men aged 15-54 years were selected from each of 12 rural communities by random cluster sampling; interviewed concerning past or present symptoms of sexually transmitted diseases; and asked to provide a first catch urine specimen, which was tested for pyuria with a leucocyte esterase dipstick test. Subjects with symptoms or with a positive result on testing were examined, and urethral swabs were taken for detection of N gonorrhoeae by gram stain and of C trachomatis by antigen detection immunoassay. Setting-Mwanza region, north western Tanzania. Subjects-5876 men aged 15-54 years. Main outcome measures-Prevalence of urethral symptoms, observed urethral discharge, pyuria, urethritis (>4 pus cells per high power field on urethral smear), N gonorrhoeae infection (intracellular gram negative diplococci), and C trachomatis infection (IDEIA antigen detection assay). Results-1618 (28%) subjects reported ever having had a urethral discharge. Current discharge was reported by 149 (2.5%) and observed on examination in 207 (3.5%). Gonorrhoea was found in 128 subjects (2.2%) and chlamydial infection in 39 (0.7%). Only 24 of 158 infected subjects complained of urethral discharge at the time of interview (15%). Conclusion-Infection with N gonorrhoeae and C trachomatis is commonly asymptomatic among men in this rural African population. This has important implications for the design of control programmes for sexually transmitted disease.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NATL INST MED RES,MWANZA,TANZANIA	University of London; London School of Hygiene & Tropical Medicine; National Institute of Medical Research				Todd, Jim/0000-0001-5918-4914; MAYAUD, Philippe/0000-0001-5730-947X; Hayes, Richard/0000-0002-1729-9892; Grosskurth, Heiner/0000-0001-9960-7280				Arya O P, 1977, Trop Doct, V7, P51; ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BARONGO LR, 1992, AIDS, V6, P1521, DOI 10.1097/00002030-199212000-00016; DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639; HANDSFIELD HH, 1974, NEW ENGL J MED, V290, P117, DOI 10.1056/NEJM197401172900301; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MAHEY DCW, 1994, GENITOURIN MED, V70, P1; MAYAUD P, 1992, GENITOURIN MED, V68, P361; MAYAUD P, 1993, 10TH P INT M ISSTDR; MCNAGNY SE, 1992, J INFECT DIS, V165, P573, DOI 10.1093/infdis/165.3.573; MEHEUS A, 1980, INT J EPIDEMIOL, V9, P239, DOI 10.1093/ije/9.3.239; NDOYE I, 1993, 10TH P INT M ISSTDR; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RIETMEIJER CAM, 1991, SEX TRANSM DIS, V18, P28, DOI 10.1097/00007435-199101000-00007; SCHACHTER J, 1994, CHLAMYDIAL INFECTION, P293; SCHULZ K, 1987, GENITOURIN MED, V62, P320; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; VANDYCK E, 1989, WHOVDT443; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WEST B, 1995, GENITOURIN MED, V71, P9; 1993, INVESTING HLTH; 1993, WHOGPASTD931	23	64	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					277	280						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611782	Green Published			2022-12-01	WOS:A1996TU50700020
J	Danese, MD; Powe, NR; Sawin, CT; Ladenson, PW				Danese, MD; Powe, NR; Sawin, CT; Ladenson, PW			Screening for mild thyroid failure at the periodic health examination - A decision and cost-effectiveness analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE TREATMENT; QUALITY-OF-LIFE; SUBCLINICAL HYPOTHYROIDISM; AUTOIMMUNE-THYROIDITIS; MICROSOMAL ANTIBODIES; MYOCARDIAL-INFARCTION; REPLACEMENT THERAPY; DOUBLE-BLIND; FOLLOW-UP; DISEASE	Objective.-To estimate the cost-effectiveness of periodic screening for mild thyroid failure by measurement of serum thyroid stimulating hormone (TSH) concentration. Design.-Cost-utility analysis using a state-transition computer decision model that accounted for case finding, medical consequences of mild thyroid failure, and costs of care during 40 years of simulated follow-up. Setting.-Periodic health examinations in offices of primary care physicians. Patients.-Hypothetical cohorts of women and men screened every 5 years during the recommended periodic examination, beginning at age 35 years. Interventions.-Adding the serum TSH assay to total serum cholesterol screening was compared to cholesterol screening alone. Main Outcome Measures.-Discounted quality-adjusted life years (QALYs) and direct medical costs from a societal perspective. Results.-The cost-effectiveness of screening 35-year-old patients with a serum TSH assay every 5 years was $9223 per QALY for women and $22 595 per QALY for men. The cost-effectiveness became more favorable when age at first screening was increased for both sexes and was always more favorable for women than men. Reduced progression to overt hypothyroidism and relief of symptoms increased QALYs, but did not substantially reduce direct medical costs. Finding hypercholesterolemia induced by mild thyroid failure reduced direct medical costs, but did not substantially increase QALYs. The cost of a TSH assay and the importance to patients of symptoms associated with thyroid failure were the most influential factors in sensitivity analyses. Conclusions.-The cost-effectiveness of screening for mild thyroid failure compares favorably with other generally accepted preventive medical practices. Physicians should consider measuring serum TSH concentration in patients aged 35 years and older undergoing routine periodic health examinations. The cost-effectiveness of screening is most favorable in elderly women.	JOHNS HOPKINS MED INST,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DIV GEN INTERNAL MED,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21218; DEPT VET AFFAIRS MED CTR,MED SERV,BOSTON,MA; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Boston University					NEI NIH HHS [T32 EY07127] Funding Source: Medline; NIA NIH HHS [K01 AG000561] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000561] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM MED ASS, 1994, PHYS CURR PROC TECHN; [Anonymous], 1994, Circulation, V89, P1333; Arem R, 1995, METABOLISM, V44, P1559, DOI 10.1016/0026-0495(95)90075-6; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BELL GM, 1985, CLIN ENDOCRINOL, V22, P83, DOI 10.1111/j.1365-2265.1985.tb01068.x; BOGNER U, 1993, ACTA ENDOCRINOL-COP, V128, P202, DOI 10.1530/acta.0.1280202; CHEUNG AP, 1992, MED J AUSTRALIA, V156, P312, DOI 10.5694/j.1326-5377.1992.tb139784.x; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DENKE MA, 1994, ARCH INTERN MED, V154, P317, DOI 10.1001/archinte.154.3.317; DIEKMAN T, 1995, ARCH INTERN MED, V155, P1490, DOI 10.1001/archinte.155.14.1490; DOSREMEDIOS LV, 1980, ARCH INTERN MED, V140, P1045, DOI 10.1001/archinte.140.8.1045; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; EPSTEIN KA, 1981, J CHRON DIS, V34, P175, DOI 10.1016/0021-9681(81)90063-1; FALKENBERG M, 1983, ACTA MED SCAND, V214, P361; FRANKLYN J, 1995, CLIN ENDOCRINOL, V43, P443, DOI 10.1111/j.1365-2265.1995.tb02615.x; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; GORDIN A, 1981, CLIN ENDOCRINOL, V15, P537, DOI 10.1111/j.1365-2265.1981.tb00699.x; HATZIANDREU EI, 1988, AM J PUBLIC HEALTH, V78, P1417, DOI 10.2105/AJPH.78.11.1417; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; HUNINK MGM, 1994, J VASC SURG, V19, P632, DOI 10.1016/S0741-5214(94)70036-2; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; LADENSON PW, 1994, THYROID, V4, P5; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107; MIURA S, 1994, INTERNAL MED, V33, P413, DOI 10.2169/internalmedicine.33.413; MONZANI F, 1993, CLIN INVESTIGATOR, V71, P367; *NAT CTR HLTH STAT, 1993, VIT HLTH STAT, V11, P242; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; NYSTROM E, 1981, ACTA MED SCAND, V210, P89; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; RIDGWAY EC, 1981, J CLIN ENDOCR METAB, V53, P1238, DOI 10.1210/jcem-53-6-1238; RINIKER M, 1981, CLIN ENDOCRINOL, V14, P69, DOI 10.1111/j.1365-2265.1981.tb00366.x; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; SMURAWSKA LT, 1994, STROKE, V25, P1628, DOI 10.1161/01.STR.25.8.1628; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P170; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; TOFT AD, 1994, NEW ENGL J MED, V331, P174; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; *US DEP HHS, 1988, FRAM STUD EP INV CAR; US Department of Health and Human Services National Institutes of Health, 1987, FRAM STUD EP INV CAR; *US DHEW, 1973, FRAM STUD EP INV CAR; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; WARTOFSKY L, 1991, THYROID FUNDAMENTAL, P1084; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; 1996, ANN INTERN MED, V124, P515; 1979, CAN MED ASSOC J, V121, P1; 1994, REDBOOK 1994; 1994, IMS AM; 1981, LANCET, V2, P128	61	161	168	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1996	276	4					285	292		10.1001/jama.276.4.285	http://dx.doi.org/10.1001/jama.276.4.285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX583	8656540				2022-12-01	WOS:A1996UX58300033
J	Karon, JM; Rosenberg, PS; McQuillan, G; Khare, M; Gwinn, M; Petersen, LR				Karon, JM; Rosenberg, PS; McQuillan, G; Khare, M; Gwinn, M; Petersen, LR			Prevalence of HIV infection in the United States, 1984 to 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; AIDS; BACKCALCULATION	Objective.-To estimate the number of persons infected with the human immunodeficiency virus (HIV) living in the United States and the change in HIV infection prevalence since 1984. Design.-We estimated HIV prevalence from 3 data sources. We estimated past HIV infection rates from a statistical procedure based on national acquired immunodeficiency syndrome (AIDS) case surveillance data and estimates of the time from HIV infection to AIDS diagnosis. We also analyzed HIV prevalence data from 2 national surveys, a survey of childbearing women and a household survey of current health status. We used other data sources to adjust these survey estimates to include groups not covered in the surveys. Results.-Approximately 0.3% of US residents (650 000-900 000 persons) were infected with HIV in 1992, Approximately 0.6% of men (including adolescent boys greater than or equal to 13 years of age) were infected, including approximately 2% of non-Hispanic black men and 1% of Hispanic men, Approximately 0.1% of women (including adolescent girls greater than or equal to 13 years of age) were infected, including approximately 0.6% of non-Hispanic black women. Approximately half of all infected persons were men who had sex with men, and one fourth were injecting drug users. The prevalence of HIV infection increased from 1984 to 1992, with a greater relative increase among women than men. Conclusions.-The 3 different data sources and methods are consistent in estimating that 650 000 to 900 000 persons were infected with HIV in the United States in 1992. Among adolescents and adults of both sexes, the proportion infected was substantially higher among non-Hispanic blacks and Hispanics than among non-Hispanic whites, HIV-related illness will be a major clinical and public health problem in the United States for years to come.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,ATLANTA,GA 30333; NCI,NIH,ROCKVILLE,MD	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Karon, JM (corresponding author), CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-48,ATLANTA,GA 30333, USA.							BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; Brookmeyer R., 1994, AIDS EPIDEMIOLOGY QU; *CDCP, 1993, HIVNCID1193036 PUBL, V3; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; EDLIN BR, 1995, 2 NAT C HUM RETR REL; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAY JW, 1994, APPL STAT-J ROY ST C, V43, P599, DOI 10.2307/2986260; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HOOVER DR, 1995, DRUGS, V49, P20, DOI 10.2165/00003495-199549010-00003; KARON JM, IN PRESS US DEP HL D, V821; MCQUILLAN GM, 1994, J ACQ IMMUN DEF SYND, V7, P1195; NELSON KE, 1994, AIDS RES HUM RETROV, V10, pS201; NWANYANWU OC, 1993, AM J PUBLIC HEALTH, V83, P571, DOI 10.2105/AJPH.83.4.571; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; Rosenberg Philip S., 1990, Annals of Epidemiology, V1, P105; ROSENBERG PS, 1994, STAT MED, V13, P1975, DOI 10.1002/sim.4780131909; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; ROSENBERG PS, 1991, STAT MED, V10, P1167, DOI 10.1002/sim.4780100802; ROSENBERG PS, 1991, APPL STAT-J ROY ST C, V40, P269; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; VANHAASTRECHT HJA, 1994, AIDS, V8, P363, DOI 10.1097/00002030-199403000-00011; WEINSTOCK HS, 1995, J ACQ IMMUN DEF SYND, V9, P514; ZACCARELLI M, 1994, AIDS, V8, P345, DOI 10.1097/00002030-199403000-00008; 1990, MMWR-MORBID MORTAL W, V39, P1; 1987, MMWR MORB MORTAL S1S, V36, pS1; 1990, MMWR-MORBID MORTAL W, V39, P117; 1986, PUBLIC HLTH REP, V101, P342; 1991, MMWR-MORBID MORTAL W, V40, P1; 1990, MMWR-MORBID MORTAL W, V39, P110; 1992, MMWR-MORBID MORTAL W, V41, P1; 1994, MMWR-MORBID MORTAL W, V43, P826	35	183	184	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					126	131		10.1001/jama.276.2.126	http://dx.doi.org/10.1001/jama.276.2.126			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV485	8656504				2022-12-01	WOS:A1996UV48500027
J	Gu, JG; Albuquerque, C; Lee, CJ; MacDermott, AB				Gu, JG; Albuquerque, C; Lee, CJ; MacDermott, AB			Synaptic strengthening through activation of Ca2+-permeable AMPA receptors	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; CHANNELS; CALCIUM; CURRENTS; ENTRY	POSTSYNAPTIC Ca2+ elevation during synaptic transmission is an important trigger for short- and long-term changes in synaptic strength in the vertebrate central nervous system(1). The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate) receptors, a subfamily of glutamate receptors, mediate much of the excitatory synaptic transmission in the brain and spinal cord(2). It has been shown that a subtype of the AMPA receptor is Ca2+ -permeable(3-6) and is present in subpopulations of neurons(7-12). When synaptically localized(13), these receptors should mediate postsynaptic Ca2+ influx, providing a trigger for changes in synaptic strength. Here we show that Ca2+-permeable AMPA receptors are synaptically localized on a subpopulation of dorsal horn neurons, that they provide a synaptically gated route of Ca2+ entry, and that activation of these receptors strengthens synaptic transmission mediated by AMPA receptors. This pathway for postsynaptic Ca2+ influx may provide a new form of activity-dependent modulation of synaptic strength.	COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Columbia University				Lee, C Justin/0000-0002-3555-0980				ABE T, 1983, J PHYSIOL-LONDON, V339, P243, DOI 10.1113/jphysiol.1983.sp014714; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GOLDSTEIN PA, 1995, J NEUROPHYSIOL, V73, P2522, DOI 10.1152/jn.1995.73.6.2522; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Jonas Peter, 1994, Current Opinion in Neurobiology, V4, P366, DOI 10.1016/0959-4388(94)90098-1; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KYROZIS A, 1995, J PHYSIOL-LONDON, V485, P373, DOI 10.1113/jphysiol.1995.sp020736; LERMA J, 1994, EUR J NEUROSCI, V6, P1080, DOI 10.1111/j.1460-9568.1994.tb00605.x; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MAYER ML, 1987, J NEUROSCI, V7, P3230; MURPHY TH, 1995, NEURON, V15, P159, DOI 10.1016/0896-6273(95)90073-X; OTIS TS, 1995, J PHYSIOL-LONDON, V482, P309, DOI 10.1113/jphysiol.1995.sp020519; REICHLING DB, 1993, J PHYSIOL-LONDON, V469, P67, DOI 10.1113/jphysiol.1993.sp019805; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Yin H z, 1994, Neurobiol Dis, V1, P43, DOI 10.1006/nbdi.1994.0006	28	206	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	1996	381	6585					793	796		10.1038/381793a0	http://dx.doi.org/10.1038/381793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657283				2022-12-01	WOS:A1996UU35600062
J	Shim, J; Lee, H; Park, J; Kim, H; Choi, EJ				Shim, J; Lee, H; Park, J; Kim, H; Choi, EJ			A non-enzymatic p21 protein inhibitor of stress-activated protein kinases	NATURE			English	Article							TRANSFORMATION; CELLS; JUN	THE stress-activated protein kinases (SAPKs), which are identical to the c-Jun amino-terminal kinases (JNKs), are activated in response to a variety of cellular stresses, including DNA damage, heat shock or tumour-necrosis factor-alpha(1,2). SAPK, a subfamily of the mitogen-activated protein (MAP) kinases, is a major protein kinase that phosphorylates c-Jun and other transcription factors(2-5). SAPK phosphorylation of transcription factors is important in stress-activated signalling cascades(1-6). Here we report that the protein p21(WAF1/CIP1/Sdi1), a DNA-damage-inducible cell-cycle inhibitor(7-10), acts as an inhibitor of the SAPK group of mammalian MAP kinases. This highlights a new biochemical activity of p21, which may provide the first evidence for a non-enzymatic inhibitory protein for SAPK. We suggest that p21, by inhibiting SAPK, may participate in regulating signalling cascades that are activated by cellular stresses such as DNA damage.	HANHYO INST TECHNOL,CELL BIOL LAB,SIHUNG SHI 429010,KYONGKI DO,SOUTH KOREA									AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARPER JW, 1993, CELL, V75, P805; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HILBERG F, 1992, ONCOGENE, V7, P2371; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OSAWA Y, 1995, BIOCHEM BIOPH RES CO, V216, P429, DOI 10.1006/bbrc.1995.2641; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	239	244	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					804	807		10.1038/381804a0	http://dx.doi.org/10.1038/381804a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657286				2022-12-01	WOS:A1996UU35600065
J	Nickel, JC; Siemens, DR; Lundie, MJ				Nickel, JC; Siemens, DR; Lundie, MJ			Allopurinol for prostatitis: Where is the evidence?	LANCET			English	Editorial Material											Nickel, JC (corresponding author), QUEENS UNIV,DEPT UROL,KINGSTON,ON,CANADA.							DOBLE A, 1991, BR J UROL, V65, P598; NEAL DE, 1994, UROLOGY, V43, P460, DOI 10.1016/0090-4295(94)90231-3; Nickel JC, 1996, J UROLOGY, V155, P1950, DOI 10.1016/S0022-5347(01)66056-7; NICKEL JC, 1996, CURR OPIN UROL, V6, P53; Persson BE, 1996, J UROLOGY, V155, P961, DOI 10.1016/S0022-5347(01)66358-4; Persson BE, 1996, J UROLOGY, V155, P958, DOI 10.1016/S0022-5347(01)66357-2	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1711	1712						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656902				2022-12-01	WOS:A1996UT39600006
J	Baylies, MK; Bate, M				Baylies, MK; Bate, M			twist: A myogenic switch in Drosophila	SCIENCE			English	Article							GENE FAMILY; DORSOVENTRAL PATTERN; ZYGOTIC GENE; MYOD FAMILY; EXPRESSION; MEMBER; SPECIFICATION; MESODERM; CELLS; INACTIVATION	Somatic muscle is derived from a subset of embryonic mesoderm. In Drosophila, Twist (Twi), a basic helix-loop-helix transcription factor, is a candidate regulator of mesodermal differentiation and myogenesis. Altering amounts of Twist after gastrulation revealed that high levels of Twist are required for somatic myogenesis and block the formation of other mesodermal derivatives. Expression of twist in the ectoderm drives these cells into myogenesis. Thus, after an initial role in gastrulation, twist regulates mesodermal differentiation and propels a specific subset of mesodermal cells into somatic myogenesis. Vertebrate homologs of twist may also participate in the subdivision of mesoderm.			Baylies, MK (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.							AZPLAZU N, 1993, GENE DEV, V7, P1325; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BATE M, IN PRESS SEM DEV BIO; BATE M, UNPUB; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; BAYLIES MK, 1992, NEURON, V9, P575, DOI 10.1016/0896-6273(92)90194-I; BAYLIES MK, UNPUB; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BODMER R, 1993, DEVELOPMENT, V118, P719; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; BRAND A, 1994, PRACTICAL USES CELL, P643; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; IP YT, 1994, EMBO J, V13, P5826, DOI 10.1002/j.1460-2075.1994.tb06926.x; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; KLERMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SIMPSON P, 1983, GENETICS, V105, P615; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	52	272	279	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1481	1484		10.1126/science.272.5267.1481	http://dx.doi.org/10.1126/science.272.5267.1481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633240				2022-12-01	WOS:A1996UP89900047
J	Engholm, G; Palmgren, F; Lynge, E				Engholm, G; Palmgren, F; Lynge, E			Lung cancer, smoking, and environment: A cohort study of the Danish population	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION	Objective-The almost twofold difference in lung cancer incidence between people living in Copenhagen and in the rural areas of Denmark in the 1980s led to public concern; this study was undertaken to assess the effects of air pollution and occupation on lung cancer in Denmark, with control for smoking habits. Design-Cohort study of national population. Subjects-People aged 30-64 and economically active in 1970 (927 470 men and 486 130 women). Main outcome measures-Relative risks for lung cancer estimated with multiplicative Poisson modelling of incidence rates. Results-Differences in smoking habit explained about 60% of the excess lung cancer risk in Copenhagen for men and 90% for women. After control for smoking, workers had double the lung cancer risk of teachers and academics. There was only a small independent effect of region. Conclusion-Smoking is the main factor behind the regional differences in lung cancer incidence in Denmark, and occupational risk factors also seem to have an important role. The outdoor air in Copenhagen around 1970 contained on average 50-80 mu g/m(3) of sulphur dioxide, 80-100 mu g/m(3) total suspended particulate matter, and up to 10 ng/m(3) benzo(a)pyrene and had peak values of daily smoke of 120 mu g/m(3). Region had only a small effect on incidence of lung cancer in the present study, which suggests that an influence of outdoor air pollution on lung cancer is identifiable only above this pollution level.	NATL ENVIRONM RES INST,DK-4000 ROSKILDE,DENMARK	Aarhus University	Engholm, G (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,BOX 839,DK-2100 COPENHAGEN O,DENMARK.			Lynge, Elsebeth/0000-0003-4785-5236				CARSTENSEN JM, 1988, INT J EPIDEMIOL, V17, P753, DOI 10.1093/ije/17.4.753; *DANM STAT, 1975, 1970 POP HOUS CENS, P72; FRIIS S, 1993, EUR J CANCER, V29A, P538, DOI 10.1016/S0959-8049(05)80147-9; HEMMINKI K, 1994, ENVIRON HEALTH PERSP, V102, P187, DOI 10.2307/3431951; *INT AG RES CANC, 1985, MON EV CARC RISK CHE, V38, P203; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; JENSEN FP, 1994, ENVIRON HEALTH PERSP, V102, P55, DOI 10.2307/3431931; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; LYNGE E, 1990, Scandinavian Journal of Work Environment and Health, V16, P1; LYNGE E, 1979, 37 DENM STAT, P27; LYNGE E, IN PRESS SOCIOECONOM; NIELSEN P E, 1988, Ugeskrift for Laeger, V150, P2229; Nielsen T., 1995, TRAFFIC PAH OTHER MU; NOY D, 1990, ATMOS ENVIRON A-GEN, V24, P2903, DOI 10.1016/0960-1686(90)90470-8; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; Speizer FE, 1994, EPIDEMIOLOGY LUNG CA, P131; *STAT I STRAL, 1987, NAT RAD DAN DWELL, P94; VANLOON AJM, 1995, J EPIDEMIOL COMMUN H, V49, P65, DOI 10.1136/jech.49.1.65; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800	19	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1259	1263		10.1136/bmj.312.7041.1259	http://dx.doi.org/10.1136/bmj.312.7041.1259			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634614	Green Published			2022-12-01	WOS:A1996UM40400019
J	Ast, G; Weiner, AM				Ast, G; Weiner, AM			A U1/U4/U5 snRNP complex induced by a 2'-O-methyl-oligoribonucleotide complementary to U5 snRNA	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; 3' SPLICE SITE; PREMESSENGER RNA; U6 SNRNA; U2; PROTEIN; ASSOCIATION; RECOGNIZES; DEPLETION	Nuclear messenger RNA splicing involves multiple interactions between the five spliceosomal small nuclear ribonucleoprotein particles (snRNPs) U1, U2, U4, U5, and U6 and numerous spliceosomal proteins. Here it is shown that binding of a 2'-O-methyl-oligoribonucleotide complementary to U5 small nuclear RNA (snRNA) nucleotides 68 to 88 (BU5Ae) disrupts the initial U4/U5/U6 tri-snRNP complex, enhances the U2/U6 interaction, and induces a U1/U4/U5 snRNP complex. The U1/U4/U5 snRNP complex interacts specifically with an RNA oligonucleotide containing the 5' splice site sequence and may therefore represent a transitional stage in the displacement of U1 from the 5' splice site by U5 snRNP.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AST G, UNPUB; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	34	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					881	884		10.1126/science.272.5263.881	http://dx.doi.org/10.1126/science.272.5263.881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629024				2022-12-01	WOS:A1996UK75700061
J	Aoufouchi, S; Yelamos, J; Milstein, C				Aoufouchi, S; Yelamos, J; Milstein, C			Nonsense mutations inhibit RNA splicing in a cell-free system: Recognition of mutant codon is independent of protein synthesis	CELL			English	Article							MESSENGER-RNA; SITE SELECTION; GENE; MATURATION; EXON; TRANSLATION; STABILITY; SEQUENCES; PRODUCT; OCCURS	Mutations resulting in premature termination codons reduce the corresponding mRNA levels. We describe a cell-free system in which depletion of the mutant immunoglobulin kappa mRNA pool correlates with inefficient splicing and not with RNA decay. Splicing deficiency does not depend on the sequence surrounding the in-frame nonsense codon and can be partially corrected by mutating the methionine initiation codon. Despite the apparent link between translation and low mutant mRNA levels, inefficient splicing is not dependent on protein synthesis. Abnormal splicing of mutant immunoglobulin RNA is observed with B-cell but not with HeLa or T-cell extracts. A nonsense mutant beta-globin RNA is normally spliced by B-cell extract. We propose that the phenomenon exhibits tissue and gene specificity.			Aoufouchi, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Aoufouchi, Said/I-2985-2016; Yelamos, Jose/N-2842-2016; AOUFOUCHI, Said/P-9926-2019	AOUFOUCHI, Said/0000-0001-6547-2664; Yelamos, Jose/0000-0003-1195-1496				BARKER GF, 1991, MOL CELL BIOL, V11, P2760, DOI 10.1128/MCB.11.5.2760; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; COOK GP, 1995, INT IMMUNOL, V7, P89, DOI 10.1093/intimm/7.1.89; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MAQUAT LE, 1995, RNA, V1, P453; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MURALIDHAR S, 1994, J VIROL, V68, P170, DOI 10.1128/JVI.68.1.170-176.1994; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; QIAN L, 1993, J IMMUNOL, V151, P6801; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	128	130	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					415	422		10.1016/S0092-8674(00)81119-8	http://dx.doi.org/10.1016/S0092-8674(00)81119-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616896	Bronze			2022-12-01	WOS:A1996UK14000014
J	Chiu, BCH; Cerhan, JR; Folsom, AR; Sellers, TA; Kushi, LH; Wallace, RB; Zheng, W; Potter, JD				Chiu, BCH; Cerhan, JR; Folsom, AR; Sellers, TA; Kushi, LH; Wallace, RB; Zheng, W; Potter, JD			Diet and risk of non-Hodgkin lymphoma in older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PEYER PATCHES; CANCER; MICE; FAT; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; REPRODUCIBILITY; CARCINOGENESIS	Objective.-To test whether high dietary intakes of fat, protein, and milk are associated with the development of non-Hodgkin lymphoma in older women. Design.-Prospective cohort study with a 7-year follow-up period. Setting.-General community. Participants.-Sample of 35 156 Iowa women aged 55 to 69 years with no prior history of cancer who returned the 1986 baseline questionnaire. Main Outcome Measure.-Non-Hodgkin lymphoma (104 incident cases). Main Results.-After controlling for age, marital status, residence, total energy intake, and transfusion history, the relative risks (RRs) for the highest tertile of intake compared with the lowest were 2.00 (95% confidence interval [CI], 1.21-3.30; P for trend=.01) for animal fat, 1.69 (95% CI, 1.07-2.67; P for trend=.02) for saturated fat, and 1.90 (95% CI, 1.18-3.04; P for trend=.01) for monounsaturated fat, and there was no association with vegetable fat or polyunsaturated fat. Greater intake of animal protein (RR=1.52; 95% CI, 0.94-2.44; P for trend=.08), but not vegetable protein, was associated with elevated risk, and this was mainly explained by greater consumption of red meat (RR=1.98; 95% CI, 1.13-3.47; P for trend=.02) and hamburger in particular (RR=2.35; 95% CI, 1.23-4.48; P for trend=.02). Milk and dairy product consumption were not associated with elevated risk. There was also a decreased risk of non-Hodgkin lymphoma with greater consumption of fruits (RR=0.64; 95% CI, 0.40-1.05; P for trend=.07). Conclusions.-A high-meat diet and a high intake of fat from animal sources is associated with an increased risk of non-Hodgkin lymphoma in older women.	UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center			Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Kushi, Lawrence/0000-0001-9136-1175; Potter, John/0000-0001-5439-1500; Cerhan, James/0000-0002-7482-178X	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER OF, 1993, J AM GERIATR SOC, V41, P1245, DOI 10.1111/j.1532-5415.1993.tb07310.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BOST KL, 1986, CARCINOGENESIS, V7, P1257, DOI 10.1093/carcin/7.8.1257; BOST KL, 1986, CARCINOGENESIS, V7, P1251, DOI 10.1093/carcin/7.8.1251; CANTOR KP, 1988, AM J PUBLIC HEALTH, V78, P570, DOI 10.2105/AJPH.78.5.570; CARROLL KK, 1986, CANCER, V58, P1818, DOI 10.1002/1097-0142(19861015)58:8+<1818::AID-CNCR2820581406>3.0.CO;2-4; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; CINADER B, 1983, IMMUNOL LETT, V6, P331, DOI 10.1016/0165-2478(83)90077-9; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM AS, 1976, LANCET, V2, P1184; DAVIS DAP, 1994, FUND APPL TOXICOL, V23, P81, DOI 10.1006/faat.1994.1082; DAVIS S, 1992, CANCER RES, V52, pS5492; ERICKSON KL, 1986, INT J IMMUNOPHARMACO, V8, P529, DOI 10.1016/0192-0561(86)90023-8; ESUMI H, 1989, JPN J CANCER RES, V80, P1176, DOI 10.1111/j.1349-7006.1989.tb01651.x; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, IN PRESS J OCCUP ENV; FRANCESCHI S, 1989, NUTR CANCER, V12, P333, DOI 10.1080/01635588909514034; FRIEDMAN A, 1994, CHEM IMMUNOL, V58, P259; LYNCH CF, 1994, AM J PUBLIC HEALTH, V84, P469, DOI 10.2105/AJPH.84.3.469; MALVY DJM, 1993, INT J EPIDEMIOL, V22, P761, DOI 10.1093/ije/22.5.761; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NIGG HN, 1990, EFFECTS PESTICIDES H, P35; OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665; PEARCE N, 1992, CANCER RES, V52, pS5496; RABKIN CS, 1993, SEMIN HEMATOL, V30, P286; Ries L, 1994, NIH PUBLICATION, V94-2789; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; TURTELTAUB KW, 1992, CANCER RES, V52, P4682; URSIN G, 1990, BRIT J CANCER, V61, P454, DOI 10.1038/bjc.1990.100; VITALE JJ, 1981, CANCER RES, V41, P3706; WARD MH, 1994, CANCER CAUSE CONTROL, V5, P422, DOI 10.1007/BF01694756; WEISENBURGER DD, 1994, ANN ONCOL, V5, pS19, DOI 10.1093/annonc/5.suppl_1.S19; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1976, INT CLASS DIS; YESS NJ, 1991, J ASSOC OFF ANA CHEM, V74, P273; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725	38	115	115	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1315	1321		10.1001/jama.275.17.1315	http://dx.doi.org/10.1001/jama.275.17.1315			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614116				2022-12-01	WOS:A1996UG61200027
J	Goodman, R; Graham, P				Goodman, R; Graham, P			Psychiatric problems in children with hemiplegia: Cross sectional epidemiological survey	BRITISH MEDICAL JOURNAL			English	Article							DISORDER; PREVALENCE	Objective-To examine the prevalence and predictors of psychiatric problems in children with hemiplegia. Design-Cross sectional questionnaire survey of an epidemiological sample with individual assessments of a representative subgroup, The questionnaire survey was repeated on school age subjects four years later. Subjects-428 hemiplegic children aged 2 1/2-16 years, of whom 149 (aged 6-10 years) were individually assessed. Main outcome measures-Psychiatric symptom scores and the occurrence of psychiatric disorder. Results-Psychiatric disorders affected 61% (95% confidence interval 53% to 69%) of subjects as judged by individual assessments and 54% (49% to 59%) and 42% (37% to 47%) as judged from parent and teacher questionnaires, respectively, Few affected children had been in contact with child mental health services, The strongest consistent predictor of psychiatric problems was intelligence quotient (IQ), which was highly correlated with an index of neurological severity; age, sex, and laterality of lesion had little or no predictive power. Conclusion-Though most hemiplegic children have considerable emotional or behavioural difficulties, these psychological complications commonly go unrecognised or untreated, Comprehensive health provision for children with chronic neurodevelopmental disorders such as hemiplegia should be psychologically as well as physically oriented.	INST CHILD HLTH,BEHAV SCI UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Goodman, R (corresponding author), INST PSYCHIAT,DEPT CHILD & ADOLESCENT PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; BRANDENBURG NA, 1990, J AM ACAD CHILD PSY, V29, P76, DOI 10.1097/00004583-199001000-00013; BRESLAU N, 1985, J AM ACAD CHILD PSY, V24, P87, DOI 10.1016/S0002-7138(09)60415-5; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; GOODMAN R, 1994, J CHILD PSYCHOL PSYC, V35, P1483, DOI 10.1111/j.1469-7610.1994.tb01289.x; GOODMAN R, 1995, J CHILD PSYCHOL PSYC, V36, P409, DOI 10.1111/j.1469-7610.1995.tb01299.x; Goodman R, 1996, J CHILD PSYCHOL PSYC, V37, P369, DOI 10.1111/j.1469-7610.1996.tb01418.x; Goodman R, 1996, DEV MED CHILD NEUROL, V38, P156; GOODMAN R, 1995, EUR CHILD ADOLES PSY, V4, P187, DOI 10.1007/BF01980457; GOODMAN R, 1994, CHILD ADOLESCENT PSY, P49; GOODMAN R, IN PRESS DEV MED CHI; KORNHUBER HH, 1985, EUR ARCH PSY CLIN N, V235, P129, DOI 10.1007/BF00380981; MCGUIRE J, 1986, J CHILD PSYCHOL PSYC, V27, P7, DOI 10.1111/j.1469-7610.1986.tb00618.x; Richman N., 1977, EPIDEMIOLOGICAL APPR, P125; RUTTER M, 1975, BRIT J PSYCHIAT, V126, P493, DOI 10.1192/bjp.126.6.493; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1968, BRIT J PSYCHIAT, V114, P563, DOI 10.1192/bjp.114.510.563; RUTTER M, 1970, ED HLTH BEHAVIOR; Rutter M., 1970, CLIN DEV MED, V35; SEIDEL UP, 1975, DEV MED CHILD NEUROL, V17, P563; TAYLOR E, 1986, BRIT J PSYCHIAT, V149, P760, DOI 10.1192/bjp.149.6.760; Wechsler D., 1997, WECHSLER INTELLIGENC; World Health Organization, 2012, WHO APPL ICD 10 DEAT	23	100	100	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1065	1069						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616413				2022-12-01	WOS:A1996UH81600024
J	Schneider, BL; Yang, QH; Futcher, AB				Schneider, BL; Yang, QH; Futcher, AB			Linkage of replication to start by the Cdk inhibitor Sic1	SCIENCE			English	Article							PROTEIN-KINASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; YEAST; CYCLINS; CLB5; DNA	In Saccharomyces cerevisiae, three G(1) cyclins (Clns) are important for Start, the event committing cells to division. Sic1, an inhibitor of Clb-Cdc28 kinases, became phosphorylated at Start, and this phosphorylation depended on the activity of Clns. Sic1 was subsequently lost, which depended on the activity of Clns and the ubiquitin-conjugating enzyme Cdc34. Inactivation of Sic1 was the only nonredundant essential function of Clns, because a sic1 deletion rescued the inviability of the cln1 cln2 cln3 triple mutant. In sic1 mutants, DNA replication became uncoupled from budding. Thus, Sic1 may be a substrate of Cln-Cdc28 complexes, and phosphorylation and proteolysis of Sic1 may regulate commitment to replication at Start.	SUNY STONY BROOK, GRAD PROGRAM GENET, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Schneider, BL (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.				NIGMS NIH HHS [GM39978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROSS F, UNPUB COMMUNICATION; CROSS FR, COMMUNICATION; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; EPSTEIN CB, 1994, MOL CELL BIOL, V14, P2041, DOI 10.1128/MCB.14.3.2041; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GARRELS J, UNPUB; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; SCHNEIDER BL, UNPUB; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	21	195	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					560	562		10.1126/science.272.5261.560	http://dx.doi.org/10.1126/science.272.5261.560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614808				2022-12-01	WOS:A1996UG82600048
J	Miles, MM; Shaw, RJ				Miles, MM; Shaw, RJ			Effect of inadvertent intradermal administration of high dose percutaneous BCG vaccine	BRITISH MEDICAL JOURNAL			English	Article									PARKSIDE HLTH COMMUNITY TRUST,LONDON W9 3XZ,ENGLAND; ST MARYS HOSP,CHEST & ALLERGY CLIN,LONDON W2 1NY,ENGLAND	Imperial College London								*DEP HLTH, 1992, IMM INF DIS, P76; HALL C, 1994, INDEPENDENT     1125, P4; 1990, BRIT MED J, V30, P995	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1014	1014						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616349				2022-12-01	WOS:A1996UG61000027
J	Bobola, N; Jansen, RP; Shin, TH; Nasmyth, K				Bobola, N; Jansen, RP; Shin, TH; Nasmyth, K			Asymmetric accumulation of ASH1p in postanaphase nuclei depends on a myosin and restricts yeast mating-type switching to mother cells	CELL			English	Article							HO GENE; SACCHAROMYCES-CEREVISIAE; CYCLE REGULATION; PROTEIN-KINASE; TRANSCRIPTION; EXPRESSION; FINGER; SW15; REPRESSION; ACTIVATION	Cell division in haploid yeast gives rise to a ''mother'' cell capable of mating-type switching and a ''daughter'' cell that is not. Switching is initiated by the HO endonuclease, whose gene is only transcribed in cells that have previously given birth to a bud (mother cells). HO expression depends on a minimyosin, She1p/Myo4p, which accumulates preferentially in growing buds. We describe a gene, ASH1, that is necessary to repress HO in daughters. ASH1 encodes a zinc finger protein whose preferential accumulation in daughter cell nuclei at the end of anaphase depends on She1p/Myo4p. The greater abundance of Ash1p in daughter cells is responsible for restricting HO expression to mother cells.			Bobola, N (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; HAARER BK, 1994, J CELL SCI, V107, P1055; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOCH C, 1993, SCIENCE, V261, P1550; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517	38	285	287	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					699	709		10.1016/S0092-8674(00)81048-X	http://dx.doi.org/10.1016/S0092-8674(00)81048-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625408	Bronze			2022-12-01	WOS:A1996TZ99000008
J	Vassar, MJ; Kizer, KW				Vassar, MJ; Kizer, KW			Hospitalizations for firearm-related injuries - A population-based study of 9562 patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URBAN TRAUMA CENTER; HOMICIDE	Objective.-To determine the incidence, nature, demographics, severity, and hospital charges associated with inpatient treatment of firearm-related injuries. Design.-A retrospective, 1-year, population-based study of firearm-related hospitalizations based on the 1991 California Hospital Discharge Abstract Data Tapes. Setting.-California acute care hospitals that reported firearm-related discharges. Patients.-A total of 9562 patients discharged with firearm-related injuries. Main Outcome Measures.-Per capita hospital discharge rates, according to age, race, and sex. Results.-A total of 9562 firearm-injured persons were discharged from California hospitals in 1991, representing a rate of 32 discharges per 100 000 population, Males aged 15 to 24 years accounted for 72% of the hospitalizations. For all causes of firearm-related injury, the highest age- and race-specific discharge rate was 439 per 100 000 for black persons aged 15 to 24 years, The highest county discharge rate was 55 per 100 000 for Los Angeles County. Statewide, there were 1.8 hospital discharges per firearm-related fatality (both in the hospital and in the community). Assaults accounted for 74% of cases, Among black males aged 15 to 24 years, assaults accounted for 598 discharges per 100 000 population. Hospital charges for 9193 patients exceeded $164 million; mean and median charges per patient discharged were $17 888 and $8535, respectively, Publicly financed health insurance programs sponsored 56% of patients; 25% had private insurance, and 19% were uninsured, Fifty-three percent of the discharges occurred at 13 of the 371 hospitals that discharged patients with firearm-related injuries. Conclusions.-Firearm-related violence is a major cause of hospitalization of young urban black males and represents a significant cost to publicly financed health care, The impact on individual hospitals is highly disproportionate, While hospital discharge data can be used for population-based surveillance of firearm-related trauma, there is need for improvement in local, state, and national surveillance of these injuries.	UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; *CA DEP HLTH SERV, 1994, 4 EPIC CAL DEP HLTH; CLANCY TV, 1994, J TRAUMA, V37, P1, DOI 10.1097/00005373-199407000-00001; EASTMAN AB, 1994, J TRAUMA, V36, P835, DOI 10.1097/00005373-199406000-00014; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HUTSON HR, 1994, NEW ENGL J MED, V330, P324, DOI 10.1056/NEJM199402033300506; *J HOPK HLTH SERV, 1989, DET INJ SEV HOSP DIS; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; KLEIN SR, 1991, AM SURGEON, V57, P793; LANGLOIS JA, 1995, AM J PUBLIC HEALTH, V85, P1261, DOI 10.2105/AJPH.85.9.1261; MARGANITT B, 1990, AM J PUBLIC HEALTH, V10, P1463; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; ORDOG GJ, 1995, J TRAUMA, V38, P291, DOI 10.1097/00005373-199502000-00029; OZONOFF V, 1995, MMWR-MORBID MORTAL W, V44, P160; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; RIDDICK L, 1993, AM J FOREN MED PATH, V14, P216; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; RYAN M, 1993, AM SURGEON, V59, P831; SHELEY JF, 1995, PUBLIC HEALTH REP, V110, P18; SMITH RS, 1992, ARCH SURG-CHICAGO, V127, P668; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; TARDIFF K, 1995, PUBLIC HEALTH REP, V110, P13; *US BUR CENS, 1990, 1990 CENS POP; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US GEN ACC OFF, 1991, TRAUM CAR LIF SYST; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1994, MONTHLY VITAL STAT R, V43, P1; 1994, MMWR-MORBID MORTAL W, V43, P37	37	35	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1734	1739		10.1001/jama.275.22.1734	http://dx.doi.org/10.1001/jama.275.22.1734			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637170				2022-12-01	WOS:A1996UP30700026
J	Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M				Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M			Infection with hepatitis GB virus C in patients on maintenance hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FULMINANT-HEPATITIS; NON-A; PREVALENCE; REGION; RNA	Background. A recently discovered non-AE hepatitis virus has been designated hepatitis GB virus C (HGBV-C), but little is known about its mode of transmission and its clinical manifestations. We studied 519 patients on maintenance hemodialysis to determine whether they were infected with HGBV-C. Methods. HGBV-C RNA was identified in serum by a reverse-transcription-polymerase-chain-reaction assay with nested primers deduced from a nonstructural region. A nucleotide sequence of 100 bp in the nonstructural region was determined on HGBV-C clones. Results. HGBV-C RNA was detected in 3.1 percent of the patients on hemodialysis (16 of 519), as compared with 0.9 percent of healthy blood donors (4 of 448, P<0.03). None of the 16 patients had evidence of active liver disease, although 7 were also infected with hepatitis C virus. Eight patients with HGBV-C infection were followed for 7 to 16 years. In two patients the virus was present at the start of hemodialysis. One had a history of transfusion, and HGBV-C RNA persisted over a period of 16 years; the other became free of HGBV-C after 10 years. In five patients, HGBV-C RNA was first detected 3 to 20 weeks after blood transfusion and persisted for up to 13 years. One patient with no history of transfusion was infected with an HGBV-C variant with the same sequence as in two of the patients with post-transfusion HGBV-C infections. Conclusions. Patients on maintenance hemodialysis are at increased risk for HGBV-C infection. This virus produces persistent infections, which may be transmitted by transfusions but may also be transmitted by other means. (C) 1996, Massachusetts Medical Society.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; MASUKO HOSP, NAGOYA, AICHI, JAPAN; MASUKO INST MED RES, NAGOYA, AICHI, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO, JAPAN; MIYAKAWA MED RES FDN, TOKYO, JAPAN	Jichi Medical University; University of Yamanashi; Toshiba Corporation			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; CHAN TM, 1993, HEPATOLOGY, V17, P5, DOI 10.1002/hep.1840170103; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LONDON WT, 1969, NEW ENGL J MED, V281, P571, DOI 10.1056/NEJM196909112811101; Masuko K, 1994, J Viral Hepat, V1, P65, DOI 10.1111/j.1365-2893.1994.tb00063.x; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1002/hep.1840200505; SATO S, 1995, ANN INTERN MED, V122, P241, DOI 10.7326/0003-4819-122-4-199502150-00001; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SZMUNESS W, 1974, JAMA-J AM MED ASSOC, V227, P901, DOI 10.1001/jama.227.8.901; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	27	449	454	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1485	1490		10.1056/NEJM199606063342301	http://dx.doi.org/10.1056/NEJM199606063342301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618602				2022-12-01	WOS:A1996UN79900001
J	Chen, RT; Hausinger, S; Dajani, AS; Hanfling, M; Baughman, AL; Pallansch, MA; Patriarca, PA				Chen, RT; Hausinger, S; Dajani, AS; Hanfling, M; Baughman, AL; Pallansch, MA; Patriarca, PA			Seroprevalence of antibody against poliovirus in inner-city preschool children - Implications for vaccination policy in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARALYTIC POLIOMYELITIS; VACCINES; IMMUNOGENICITY; CHILDHOOD; RESPONSES; OUTBREAK; DISEASE; OMAN; LIVE	Objectives.-To assess susceptibility to poliomyelitis in selected inner-city preschool children in the United States and to estimate the contribution of secondary spread of live attenuated oral poliovirus vaccine virus to type-specific immunity, Design.-Cross-sectional seroprevalence study, Methods.-Serum neutralizing antibody levels against poliovirus types 1, 2, and 3 were analyzed according to vaccination status, agp, and other sociodemographic variables, Setting.-Hospital and satellite clinics serving inner-city populations in Houston, Tex, and Detroit, Mich, 1990 to 1991, Participants.-A total of 526 children aged 12 to 47 months seeking medical care were enrolled in the seroprevalence study; 144 children aged 12 to 35 months without a history of previous oral poliovirus vaccination were enrolled in the secondary spread study. Results.-Seropositive rates were similar in children in both cities, ranging from about 80% for types 1 and 3 in 12- to 23-month-old children to more than 90% in those aged 36 to 47 months. The most important predictor of seropositivity was the number of doses of oral poliovirus vaccine received (P<.01), with levels approximately 90% for all 3 serotypes among children who had received 3 or more doses. In children likely to have been unvaccinated, seropositive rates ranged from 9% to 18% for poliovirus types 1 and 3 and from 29% to 42% for type 2; secondary spread of vaccine virus appeared to have occurred among children who had previously received 1 dose or less but not those with 2 or more doses. Conclusions.-Levels of immunity to poliovirus among inner-city preschoolers are high and may be predicted by the number of doses of oral poliovirus vaccine received, Secondary spread of the vaccine virus plays a modest role in increasing polio immunity in inner-city populations, especially against types 1 and 3, This role will decrease in importance if the recently attained high levels of immunization coverage in the United States are sustained and if the risk of importation of wild poliovirus continues to diminish.	CTR DIS CONTROL & PREVENT, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; BAYLOR COLL MED, SECT ACAD AMBULATORY PEDIAT, HOUSTON, TX 77030 USA; WAYNE STATE UNIV, SCH MED, DEPT PEDIAT, DETROIT, MI 48201 USA; CHILDRENS HOSP MICHIGAN, DIV INFECT DIS, DETROIT, MI 48201 USA	Centers for Disease Control & Prevention - USA; Wayne State University; Children's Hospital of Michigan	Chen, RT (corresponding author), CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM E61, ATLANTA, GA 30333 USA.				PHS HHS [200-89-0735] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BENYESHMELNICK M, 1976, AM J EPIDEMIOL, V86, P112; BOTTIGER M, 1984, REV INFECT DIS, V6, pS548; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CIRNE MD, 1995, J INFECT DIS, V171, P1097, DOI 10.1093/infdis/171.5.1097; COHENABBO A, 1995, PEDIATR INFECT DIS J, V14, P100, DOI 10.1097/00006454-199502000-00004; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; FADEN H, 1990, J INFECT DIS, V162, P1291, DOI 10.1093/infdis/162.6.1291; Finney D., 1964, STAT METHOD BIOL ASS, P524; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FOX JP, 1960, PAN AM SANITARY BURE, V50, P144; Francis Thomas, 1957, EVALUATION 1954 FIEL; GARD S, 1959, 1 INT C LIV POL VACC, P350; GELFAND HM, 1959, PAN AM SANITARY BURE, V44, P203; HARDEGREE M C, 1970, Bulletin of the World Health Organization, V43, P461; HINMAN AR, 1988, AM J PUBLIC HEALTH, V78, P291, DOI 10.2105/AJPH.78.3.291; HINMAN AR, 1993, AM J DIS CHILD, V147, P536, DOI 10.1001/archpedi.1993.02160290042020; HORSTMANN DM, 1959, JAMA-J AM MED ASSOC, V170, P1; HOVI T, 1986, LANCET, V1, P1427; *I MED, 1988, PUBL IOM, V8804; KIMBALL AC, 1960, PAN AM SANITARY BURE, V50, P161; KOPROWSKI H, 1960, PAN AM SANITARY BURE, V44, P159; KUCHARSKA Z, 1982, J HYG EPID MICROB IM, V26, P74; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P203, DOI 10.1001/jama.1995.03530030025009; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MODLIN JF, 1993, 33 INT C ANT AG CHEM; MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B; *NAT IMM PROGR, 1994, BIOL SURV SUMM; NIGHTINGALE EO, 1977, NEW ENGL J MED, V297, P249, DOI 10.1056/NEJM197708042970505; OGRA PL, 1984, REV INFECT DIS, V6, pS361; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PAUL JR, 1960, 5TH INT POL C COP, P359; PETER G, 1995, AAP NEWS, V11, P13; PLOTKIN SA, 1995, PEDIATR INFECT DIS J, V14, P835, DOI 10.1097/00006454-199510000-00003; SABIN AB, 1961, AM J DIS CHILD, V101, P546, DOI 10.1001/archpedi.1961.04020060004002; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P1844, DOI 10.1001/jama.269.14.1844; SPRENT P, 1993, APPL NONPARAMETRIC S, P28; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; SUTTER RW, 1993, INT J EPIDEMIOL, V22, P936, DOI 10.1093/ije/22.5.936; Sutter RW, 1993, MEASLES POLIOMYELITI, P279; *US BUR CENS, 1994, COUNT CIT DAT BOOK 1; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1995, MMWR-MORBID MORTAL W, V44, P613; 1995, MMWR-MORBID MORTAL W, V44, P273; 1994, MMWR-MORBID MORTAL W, V43, P720	50	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1639	1645		10.1001/jama.275.21.1639	http://dx.doi.org/10.1001/jama.275.21.1639			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637136				2022-12-01	WOS:A1996UN25200025
J	Kiyokawa, H; Kineman, RD; ManovaTodorova, KO; Soares, VC; Hoffman, ES; Ono, M; Khanam, D; Hayday, AC; Frohman, LA; Koff, A				Kiyokawa, H; Kineman, RD; ManovaTodorova, KO; Soares, VC; Hoffman, ES; Ono, M; Khanam, D; Hayday, AC; Frohman, LA; Koff, A			Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1)	CELL			English	Article							MOUSE; FIBROBLASTS; THYMOCYTES; APOPTOSIS; MUTATION; G(1); P21	Disruption of the cyclin-dependent kinase-inhibitory domain of p27 enhances growth of mice. Growth is attributed to an increase in cell number, due to increased cell proliferation, most obviously in tissues that ordinarily express p27 at the highest levels. Disruption of p27 function leads to nodular hyperplasia in the intermediate lobe of the pituitary. However, increased growth occurs without an increase in the amounts of either growth hormone or IGF-I. In addition, female mice were infertile. Luteal cell differentiation is impaired, and a disordered estrus cycle is detected. These results reflect a disturbance of the hypothalamic-pituitary-ovarian axis. The phenotypes of these mice suggest that loss of p27 causes an alteration in cell proliferation that can lead to specific endocrine dysfunction.	UNIV ILLINOIS,DEPT MED,CHICAGO,IL 60612; YALE UNIV,DEPT BIOL,IMMUNOBIOL SECT,NEW HAVEN,CT 06511	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yale University	Kiyokawa, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Kineman, Rhonda D/H-2221-2011	Kineman, Rhonda D/0000-0001-7322-1152; Kiyokawa, Hiroaki/0000-0002-7942-6455	NIDDK NIH HHS [NIDDK30667] Funding Source: Medline; NIGMS NIH HHS [GM52597, GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030667, R37DK030667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052597, R55GM052597, R01GM037759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen IT, 1996, ONCOGENE, V12, P595; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COATS S, 1996, IN PRESS SCIENCE; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Koff A, 1995, Prog Cell Cycle Res, V1, P141; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORSTYN G, 1983, J CLIN INVEST, V72, P1877; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOSS TJ, 1996, CELL GROWTH DIFFER, V7, P135; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WILSON A, 1988, J IMMUNOL, V140, P1461; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; [No title captured]	43	1128	1152	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					721	732		10.1016/S0092-8674(00)81238-6	http://dx.doi.org/10.1016/S0092-8674(00)81238-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646780	hybrid			2022-12-01	WOS:A1996UP34400012
J	Wilkinson, P; Sayer, J; Laji, K; Grundy, C; Marchant, B; Kopelman, P; Timmis, AD				Wilkinson, P; Sayer, J; Laji, K; Grundy, C; Marchant, B; Kopelman, P; Timmis, AD			Comparison of case fatality in south Asian and white patients after acute myocardial infarction: Observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; MORTALITY; LONDON; MEN; HYPERINSULINEMIA; BANGLADESHIS; PROGNOSIS; ENGLAND; WALES	Objective-To compare mortality in south Asian (Indian, Pakistani, and Bangladeshi) and white patients in the six months after hospital admission for acute myocardial infarction. Design-Observational study. Setting-District general hospital in east London. Patients-149 south Asian and 313 white patients aged <65 years admitted to the coronary care unit with acute myocardial infarction from. 1 December 1988 to 31 December 1992. Main outcome measure-All cause mortality in the first six months after myocardial infarction. Results-The admission rate in the south Asians was estimated to be 2.04 times that in the white patients. Most aspects of treatment were similar in the two groups, except that a higher proportion of the south Asians received thrombolytic drugs (81.2% v 73.8%). After adjustment for age, sex, previous myocardial infarction, and treatment with thrombolysis or aspirin, or both, the south Asians had a poorer survival over the six months from myocardial infarction (hazard ratio 2.02 (95% cofidence interval 1.14 to 3.56), P=0.018), but a substantially higher proportion were diabetic (38% v 11%, P<0.001), and additional adjustment for diabetes removed much of their excess risk (adjusted hazard ratio 1.26 (0.68 to 2.33), P=0.47). Conclusion-South Asian patients had a higher risk of admission with myocardial infarction and a higher risk of death over the ensuing six months than the white patients. The higher case fatality among the south Asians, largely attributable to diabetes, may contribute to the increased risk of death from coronary heart disease in south Asians living in Britain.	LONDON CHEST HOSP, DEPT CARDIOL, LONDON, ENGLAND; NEWHAM DIST GEN HOSP, DEPT CARDIOL, LONDON, ENGLAND; NEWHAM DIST GEN HOSP, DEPT DIABET, LONDON, ENGLAND	University of London; Queen Mary University London	Wilkinson, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, ENVIRONM EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND.			Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BECKLES GLA, 1986, LANCET, V1, P1298; BHATNAGAR D, 1995, LANCET, V345, P405; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P109; COX DR, 1972, J R STAT SOC B, V34, P187; HUGHES LO, 1989, BRIT MED J, V298, P1345, DOI 10.1136/bmj.298.6684.1345; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; LOWTY PJ, 1984, BRIT HEART J, V52, P610; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1992, BRIT HEART J, V67, P341, DOI 10.1136/hrt.67.5.341; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, BRIT MED J, V299, P179, DOI 10.1136/bmj.299.6692.179-a; MUKHTAR HT, 1995, BRIT HEART J, V73, P122; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; TUNSTALLPEDOE H, 1975, LANCET, V2, P833; 1986, LANCET, V1, P1307	24	94	95	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1996	312	7042					1330	1333		10.1136/bmj.312.7042.1330	http://dx.doi.org/10.1136/bmj.312.7042.1330			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646044	Green Published			2022-12-01	WOS:A1996UN47600019
J	Yamasaki, L; Jacks, T; Bronson, R; Goillot, E; Harlow, E; Dyson, NJ				Yamasaki, L; Jacks, T; Bronson, R; Goillot, E; Harlow, E; Dyson, NJ			Tumor induction and tissue atrophy in mice lacking E2F-1	CELL			English	Article							TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA PROTEIN; BINDING PROTEIN; GENE; EXPRESSION; CLONING; MOUSE; CELLS; SITE; TRANSACTIVATION	The retinoblastoma tumor suppressor protein (pRB) is a transcriptional repressor that regulates gene expression by physically associating with transcription factors such as E2F family members. Although pRB and its upstream regulators are commonly mutated in human cancer, the physiological role of the pRB-E2F pathway is unknown. To address the function of E2F-1 and pRB/E2F-1 complexes in vivo, we have produced mice homozygous for a nonfunctional E2F-1 allele. Mice lacking E2F-1 are viable and fertile, yet experience testicular atrophy and exocrine gland dysplasia. Surprisingly, mice lacking E2F-1 develop a broad and unusual spectrum of tumors. Although overexpression of E2F-1 in tissue culture cells can stimulate cell proliferation and be oncogenic, loss of E2F-1 in mice results in tumorigenesis, demonstrating that E2F-1 also functions as a tumor suppressor.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH VET MED,USDA,HUMAN NUTR RES CTR AGING,DEPT PATHOL,BOSTON,MA 02111	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Tufts University; United States Department of Agriculture (USDA)	Yamasaki, L (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 49,13TH ST,CHARLESTOWN,MA 02129, USA.			Goillot, Evelyne/0000-0003-0026-4690	NATIONAL CANCER INSTITUTE [P01CA042063, R01CA064402, R01CA060636] Funding Source: NIH RePORTER; NCI NIH HHS [CA64402, CA60636, CA42063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DUHL DMJ, 1994, DEVELOPMENT, V120, P1695; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOROWITZ JM, 1996, IN PRESS MOL CELL DI; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HU NP, 1994, ONCOGENE, V9, P1021; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Russell L, 1990, HISTOLOGICAL HISTOPA; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLACK RS, 1993, ONCOGENE, V8, P1585; SLANSKY JE, 1995, TRANSCRIPTIONAL CONT; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; Turusov V., 1994, PATHOLOGY TUMORS LAB; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	75	636	648	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					537	548		10.1016/S0092-8674(00)81254-4	http://dx.doi.org/10.1016/S0092-8674(00)81254-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653789	Bronze			2022-12-01	WOS:A1996UM41500011
J	Li, LM; Cohen, SN				Li, LM; Cohen, SN			tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells	CELL			English	Article							ANTI-SENSE RNA; ANCHORAGE-INDEPENDENT GROWTH; MULTIPLE SIGNAL-TRANSDUCTION; DNA-BINDING PROTEINS; SEQUENCES COMPLEMENTARY; RETROVIRAL VECTORS; SUPPRESSOR GENES; LEUCINE ZIPPER; LAC REPRESSOR; STEM-CELLS	Using a novel strategy that enables the isolation of previously unknown genes encoding selectable recessive phenotypes, we identified a gene (tsg101) whose homozygous functional disruption produces cell transformation. Antisense RNA from a transactivated promoter introduced randomly into transcribed genes throughout the genome of mouse 3T3 fibroblasts was used to knock out alleles of chromosomal genes adjacent to promoter inserts, generating clones that grew in 0.5% agar and formed metastatic tumors in nude mice. Removal of the transactivator restored normal growth. The protein encoded by tsg101 cDNA encodes a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated previously in tumorigenesis. Overexpression of tsg101 antisense transcripts in naive 3T3 cells resulted in cell transformation and increased stathmin-specific mRNA.	STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University; Stanford University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BOOTH PM, 1994, GENE, V146, P303, DOI 10.1016/0378-1119(94)90310-7; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DETLOFF PJ, 1994, MOL CELL BIOL, V14, P6936, DOI 10.1128/MCB.14.10.6936; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1990, J BIOL CHEM, V265, P11650; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HAWLEY RG, 1987, P NATL ACAD SCI USA, V84, P2406, DOI 10.1073/pnas.84.8.2406; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIGUCHI S, 1994, J BIOCHEM-TOKYO, V116, P128, DOI 10.1093/oxfordjournals.jbchem.a124485; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; ROOS G, 1993, LEUKEMIA, V7, P1538; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TEMSAMANI J, 1991, J BIOL CHEM, V266, P468; VOLLOCH V, 1991, BIOCHEM BIOPH RES CO, V179, P1593, DOI 10.1016/0006-291X(91)91756-3; VOLLOCH V, 1991, BIOCHEM BIOPH RES CO, V179, P1600, DOI 10.1016/0006-291X(91)91757-4; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819	63	296	344	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					319	329		10.1016/S0092-8674(00)81111-3	http://dx.doi.org/10.1016/S0092-8674(00)81111-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616888	Bronze			2022-12-01	WOS:A1996UK14000006
J	Surprenant, A; Rassendren, F; Kawashima, E; North, RA; Buell, G				Surprenant, A; Rassendren, F; Kawashima, E; North, RA; Buell, G			The cytolytic P-2Z receptor for extracellular ATP identified as a P-2X receptor (P2X(7))	SCIENCE			English	Article								The P-2Z receptor is responsible for adenosine triphosphate (ATP)-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. Other ATP-gated channels, the P-2X receptors, are permeable only to small cations. Here, an ATP receptor, the P2X(7) receptor, was cloned from rat brain and exhibited both these properties. This protein is homologous to other P-2X receptors but has a unique carboxyl-terminal domain that was required for the lytic actions of ATP. Thus, the P2X(7) (or P-2Z) receptor is a bifunctional molecule that could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells.			Surprenant, A (corresponding author), GLAXO INST MOLEC BIOL SA,PLAN LES OUATES,CH-1228 GENEVA,SWITZERLAND.		Rassendren, Francois/AAA-6190-2021; North, Richard/GQA-6156-2022	Rassendren, Francois/0000-0003-3320-2461				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/blood.V85.11.3173.bloodjournal85113173; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Collo G, 1996, J NEUROSCI, V16, P2495; DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; EVANS RJ, 1995, J PHYSIOL-LONDON, V487P, pP193; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; HICKMAN SE, 1994, BLOOD, V84, P2452; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; SURPRENANT A, UNPUB; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WILEY JS, 1994, BRIT J PHARMACOL, V112, P946, DOI 10.1111/j.1476-5381.1994.tb13172.x; ZAMBON A, 1994, CELL IMMUNOL, V156, P458, DOI 10.1006/cimm.1994.1190	24	1384	1448	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					735	738		10.1126/science.272.5262.735	http://dx.doi.org/10.1126/science.272.5262.735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614837				2022-12-01	WOS:A1996UJ05100055
J	Skoog, I; Lernfelt, B; Landahl, S; Palmertz, B; Andreasson, LA; Nilsson, L; Persson, G; Oden, A; Svanborg, A				Skoog, I; Lernfelt, B; Landahl, S; Palmertz, B; Andreasson, LA; Nilsson, L; Persson, G; Oden, A; Svanborg, A			15-year longitudinal study of blood pressure and dementia	LANCET			English	Article							WHITE-MATTER LESIONS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; CLINICAL-DIAGNOSIS; POPULATION; CT; ENCEPHALOPATHY; DISORDER; AGE	Background Vascular causes of dementia may be more common than supposed. Vascular factors may also have a role in late-onset Alzheimer's disease, but the role of hypertension in the development of dementia is unclear. Methods As part of the Longitudinal Population Study of 70-year-olds in Goteborg, Sweden, we analysed the relation between blood pressure and the development of dementia in the age intervals 70-75, 75-79, and 79-85 years in those non-demented at age 70 (n=382). The sample was followed up for 15 years and examined repeatedly with a comprehensive investigation, including a psychiatric and physical examination. Findings Participants who developed dementia at age 79-85 had higher systolic blood pressure at age 70 (mean 178 vs 164 mm Hg, p=0.034) and higher diastolic blood pressure at ages 70 (101 vs 92, p=0.004) and 75 (97 vs 90, p=0.022) than those who did not develop dementia, For subtypes of dementia, higher diastolic blood pressure was recorded at age 70 (101, p=0.019) for those developing Alzheimer's disease and at age 75 (101, p=0.015) for those developing vascular dementia than for those who did not develop dementia. Participants with white-matter lesions on computed tomography at age 85 had higher blood pressure at age 70 than those without such lesions. Blood pressure declined in the years before dementia onset and was then similar to or lower than that in non-demented individuals. Interpretation Previously increased blood pressure may increase the risk for dementia by inducing small-vessel disease and white-matter lesions. To what extent the decline in blood pressure before dementia onset is a consequence or a cause of the brain disease remains to be elucidated.	SAHLGRENS UNIV HOSP,SECT PSYCHIAT,DEPT CLIN NEUROSCI,GOTHENBURG,SWEDEN; OSTRA HOSP,DEPT RADIOL,GOTHENBURG,SWEDEN; VASA HOSP,DEPT GERIATR MED,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT MATH,S-41124 GOTHENBURG,SWEDEN; UNIV ILLINOIS,DEPT MED,GERIATR MED SECT,CHICAGO,IL	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BLENNOW K, 1991, ACTA NEUROL SCAND, V83, P187, DOI 10.1111/j.1600-0404.1991.tb04675.x; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; BRUN A, 1986, ANN NEUROL, V19, P253, DOI 10.1002/ana.410190306; DELAMONTE SM, 1989, ANN NEUROL, V25, P450, DOI 10.1002/ana.410250506; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V75, P262, DOI 10.1111/j.1600-0404.1987.tb07931.x; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; FARMER ME, 1990, J CLIN EPIDEMIOL, V43, P475, DOI 10.1016/0895-4356(90)90136-D; FERRER I, 1990, J NEUROL SCI, V98, P37, DOI 10.1016/0022-510X(90)90180-U; Guo ZC, 1996, BRIT MED J, V312, P805, DOI 10.1136/bmj.312.7034.805; HACHINSKI V, 1992, LANCET, V340, P645; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; LARSON EB, 1993, NEW ENGL J MED, V328, P203, DOI 10.1056/NEJM199301213280308; LOTZ PR, 1986, AM J NEURORADIOL, V7, P817; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; PERSSON G, 1980, ACTA PSYCHIAT SCAND, V62, P119, DOI 10.1111/j.1600-0447.1980.tb00600.x; REIS DJ, 1988, ARCH NEUROL-CHICAGO, V45, P180, DOI 10.1001/archneur.1988.00520260066022; RINDER L, 1975, ACTA MED SCAND, V198, P397, DOI 10.1111/j.0954-6820.1975.tb19563.x; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; SCHEINBERG P, 1988, STROKE, V19, P1291, DOI 10.1161/01.STR.19.10.1291; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; SKOOG I, 1994, DEMENTIA, V5, P137, DOI 10.1159/000106711; SKOOG I, 1994, J GERIATR PSYCH NEUR, V7, P169, DOI 10.1177/089198879400700308; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; STARR JM, 1992, J HYPERTENS, V10, pS31; STRANDGAARD S, 1994, LANCET, V344, P519, DOI 10.1016/S0140-6736(94)91903-8; TALMAN WT, 1985, ANN NEUROL, V18, P1, DOI 10.1002/ana.410180102	30	1321	1354	1	70	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1141	1145		10.1016/S0140-6736(96)90608-X	http://dx.doi.org/10.1016/S0140-6736(96)90608-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609748				2022-12-01	WOS:A1996UG75500010
J	Grammer, LC				Grammer, LC			Cefaclor serum sickness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Grammer, LC (corresponding author), NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014				ACKLEY AM, 1981, SOUTHERN MED J, V74, P1550; HEBERT AA, 1991, J AM ACAD DERMATOL, V25, P805, DOI 10.1016/S0190-9622(08)80973-5; KEARNS GL, 1994, J PEDIATR-US, V125, P805, DOI 10.1016/S0022-3476(94)70112-1; LAWLEY TJ, 1993, ALLERGY PRINCIPLES P, P990; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3	5	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1152	1153						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609672				2022-12-01	WOS:A1996UE62500009
J	Brahams, D				Brahams, D			Unnatural death, AIDS, and coroners	LANCET			English	Editorial Material											Brahams, D (corresponding author), OLD SQ CHAMBERS,LONDON WC1,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					777	777		10.1016/S0140-6736(96)90862-4	http://dx.doi.org/10.1016/S0140-6736(96)90862-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622328				2022-12-01	WOS:A1996UB15300003
J	Harries, AD; Mbewe, LN; Salaniponi, FML; Nyangulu, DS; Veen, J; Ringdal, T; Nunn, P				Harries, AD; Mbewe, LN; Salaniponi, FML; Nyangulu, DS; Veen, J; Ringdal, T; Nunn, P			Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi	LANCET			English	Article							INFECTION; CHEMOTHERAPY; MORTALITY; NAIROBI; KENYA	Malawi is one of the poorest countries in the world. Despite the lack of resources, the country has a good tuberculosis (TB) recording and reporting system, developed in 1984 by the International Union against Tuberculosis and Lung Disease. Since 1985, Malawi has experienced an upsurge in TB notifications, mainly because of the HIV epidemic. The number of notified TB cases rose from 5334 in 1985 to 19 496 in 1994, according to the Malawi national TB programme. The national cure rate decreased from 80% in 1988 to 63% in 1992, as the TB programme struggled to cope with increasing numbers of patients while the economic situation worsened. The deterioration in treatment outcomes was more pronounced in the large cities of Blantyre and Lilongwe than elsewhere. This feature causes concern because Queen Elizabeth Central Hospital, Blantyre, and Kamuzu Central Hospital, Lilongwe, diagnose and treat 30-40% of all registered TB cases in Malawi. We have assessed the rates of TB notifications and treatment outcomes in Queen Elizabeth Central Hospital and the measures introduced to improve treatment outcomes.	MINIST HLTH,NATL TB PROGRAMME,LILONGWE,MALAWI; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE; WHO,GLOBAL TB PROGRAMME,CH-1211 GENEVA,SWITZERLAND	World Health Organization	Harries, AD (corresponding author), QUEEN ELIZABETH CENT HOSP,DEPT MED,COLL MED,POB 95,BLANTYRE,MALAWI.							ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; KOOL HEJ, 1990, TROP GEOGR MED, V42, P128; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; REEVE PA, 1989, BRIT MED J, V298, P1567, DOI 10.1136/bmj.298.6687.1567; World Health Organization, 1993, TREATM TUB GUID NAT	9	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					807	809		10.1016/S0140-6736(96)90874-0	http://dx.doi.org/10.1016/S0140-6736(96)90874-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622340				2022-12-01	WOS:A1996UB15300015
J	Teunisse, RJ; Cruysberg, JR; Hoefnagels, WH; Verbeek, AL; Zitman, FG				Teunisse, RJ; Cruysberg, JR; Hoefnagels, WH; Verbeek, AL; Zitman, FG			Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome	LANCET			English	Article							BONNET,CHARLES SYNDROME; RELIABILITY; INTERVIEW	Background Bonnet's Syndrome (CBS) characterised by the presence of complex visual hallucinations in psychologically normal people, was considered for a long time to be rare. Systematic research on CBS has been limited. However, it has been realised that CBS occurs frequently in elderly, visually handicapped patients, and we have been able to study the syndrome in a large number of patients. Methods After screening 505 visually handicapped patients, 60 were found to meet proposed diagnostic criteria for CBS (generally, the existence of hallucinations without delusions or loss of insightful cognition.) Psychopathological characteristics, personal meaning, and the emotional impact of hallucinations, as well as factors influencing the hallucinations, were analysed. Findings Although diagnostic criteria demand merely ''partial insight'', all patients had full insight into the unreal nature of their hallucinations. Other characteristics varied. In 46 (77%) patients, hallucinations lacked a personal meaning. Sensory deprivation and a low level of arousal seemed to favour the occurrence of hallucinations. CBS caused considerable distress in only 17 (28%) patients. However, all patients were glad to be told that their hallucinations were not due to mental disease. The proper diagnosis had been made in only one of the 16 patients who had consulted a doctor. Interpretation Although largely unrecognised in clinical practice, CBS should be considered as a diagnosis in patients who complain of hallucinations and who meet defined diagnostic criteria. There is no proven treatment, but many patients will benefit from reassurance that their hallucinations do not imply mental illness.	UNIV NIJMEGEN HOSP, DEPT OPHTHALMOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT GERIATR MED, 6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT EPIDEMIOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Teunisse, RJ (corresponding author), UNIV NIJMEGEN HOSP, DEPT PSYCHIAT, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Zitman, Frans G./E-7705-2010; Verbeek, A.L.M./H-8103-2014; Cruysberg, Johannes R. M./D-4313-2009	Verbeek, A.L.M./0000-0002-2319-5002; Cruysberg, Johannes R. M./0000-0002-5330-0774				*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P398; BONNER C, 1760, ESSAI ANAL FACULTES; COLE MG, 1992, CAN J PSYCHIAT, V37, P267, DOI 10.1177/070674379203700411; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584; de Morsier G, 1967, ANN MED PSYCHOL, V125, P677; FUCHS T, 1992, DELUSIONS HALLUCINAT, P187; GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3; HOOIJER C, 1991, INT J GERIATR PSYCH, V6, P71, DOI 10.1002/gps.930060205; OLBRICH HM, 1987, GRAEF ARCH CLIN EXP, V225, P217, DOI 10.1007/BF02175452; PODOLL K, 1989, FORTSCHR NEUROL PSYC, V57, P43, DOI 10.1055/s-2007-1000744; SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809; SIATKOWSKI RM, 1990, J CLIN NEURO-OPHTHAL, V10, P215; TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254; TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4; WHITE NJ, 1980, BRIT J PSYCHIAT, V136, P284, DOI 10.1192/bjp.136.3.284	16	283	286	0	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					794	797		10.1016/S0140-6736(96)90869-7	http://dx.doi.org/10.1016/S0140-6736(96)90869-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UB153	8622335	Green Submitted			2022-12-01	WOS:A1996UB15300010
J	Wu, JR; Gilbert, DM				Wu, JR; Gilbert, DM			A distinct G(1) step required to specify the Chinese hamster DHFR replication origin	SCIENCE			English	Article							DNA-REPLICATION	Nuclei isolated from Chinese hamster ovary (CHO) cells at various times during the G(1) phase of the cell cycle were stimulated to enter S phase by incubation in Xenopus egg cytosol. Replication of DNA initiated within the dihydrofolate reductase (DHFR) origin locus in nuclei isolated late in G(1), but at random sites in nuclei isolated early in G(1). A discrete transition point occurred 3 to 4 hours after metaphase. Neither replication licensing nor nuclear assembly was sufficient for origin recognition. Thus, a distinct cell cycle-regulated event in the nucleus restricts the initiation of replication to specific sites downstream of the DHFR gene.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								BURHANS WC, 1994, SCIENCE, V263, P639, DOI 10.1126/science.8303270; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MADINE MA, 1995, NATURE, V375, P4221; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075	14	110	111	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1270	1272		10.1126/science.271.5253.1270	http://dx.doi.org/10.1126/science.271.5253.1270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638106				2022-12-01	WOS:A1996TX69500033
J	Reith, J; Jorgensen, HS; Pedersen, PM; Nakayama, H; Raaschou, HO; Jeppesen, LL; Olsen, TS				Reith, J; Jorgensen, HS; Pedersen, PM; Nakayama, H; Raaschou, HO; Jeppesen, LL; Olsen, TS			Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome	LANCET			English	Article							FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; HYPOTHERMIA; BRAIN; DAMAGE	Background In laboratory animals, cerebral ischaemia is worsened by hyperthermia and improved by hypothermia. Whether these observations apply to human beings with stroke is unknown. We therefore examined the relation between body temperature on admission with acute stroke and various indices of stroke severity and outcome. Methods In a prospective and consecutive study 390 stroke patients were admitted to hospital within 6 h after stroke (median 2.4 h). We determined body temperature on admission, initial stroke severity, infarct size, mortality, and outcome in survivors. Stroke severity was measured on admission, weekly, and at discharge on the Scandinavian Stroke Scale (SSS). Infarct size was determined by computed tomography. Multiple logistic and linear regression outcome analyses included relevant confounders and potential predictors such as age, gender, stroke severity on admission, body temperature, infections, leucocytosis, diabetes, hypertension, atrial fibrillation, ischaemic heart disease, smoking, previous stroke, and comorbidity. Findings Mortality was lower and outcome better in patients with mild hypothermia on admission; both were worse in patients with hyperthermia. Body temperature was independently related to initial stroke severity (p<0.009), infarct size (p<0.0001), mortality (p<0.02), and outcome in survivors (SSS at discharge) (p<0.003). For each 1 degrees C increase in body temperature the relative risk of poor outcome (death or SSS score on discharge <30 points) rose by 2.2 (95% CI 1.4-3.5) (p<0.002). Interpretation We have shown that, in acute human stroke, an association exists between body temperature and initial stroke severity, infarct size, mortality, and outcome. Only intervention trials of hypothermic treatment can prove whether this relation is causal.	BISPEBJERG HOSP, DEPT RADIOL, DK-2400 COPENHAGEN NV, DENMARK	University of Copenhagen; Bispebjerg Hospital	Reith, J (corresponding author), BISPEBJERG HOSP, DEPT NEUROL, DK-2400 COPENHAGEN NV, DENMARK.							[Anonymous], 1989, Stroke, V20, P1407; ASPLUND K, 1985, STROKE, V16, P885; BOISVERT DP, 1991, J CEREB BLOOD FLOW M, V11, pS637; BUCHAN A, 1992, NEUROL CLIN, V10, P49, DOI 10.1016/S0733-8619(18)30233-0; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CASTILLO J, 1994, CEREBROVASC DIS, V4, P66, DOI 10.1159/000108454; CHAMBERLAIN JM, 1991, CLIN PEDIATR, V30, P24, DOI 10.1177/0009922891030004S08; CHOPP M, 1992, STROKE, V23, P104, DOI 10.1161/01.STR.23.1.104; CHYATTE D, 1989, J NEUROSURG, V70, P489, DOI 10.3171/jns.1989.70.3.0489; Crowell RM, 1970, STROKE, V1, P439, DOI 10.1161/01.STR.1.6.439; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; HEISS WD, 1990, STROKE S1, V21, P2; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; JORGENSEN HS, 1994, LANCET, V344, P156; JORGENSEN HS, 1994, STROKE, V25, P97, DOI 10.1161/01.STR.25.1.97; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MELLERGARD P, 1992, NEUROSURGERY, V31, P671; MELLERGARD P, 1994, ACTA NEUROCHIR, P485; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; NORUSIS MJ, 1992, LOGISTIC REGRESSION; NURSE S, 1994, J NEUROSCI, V14, P7726; OLSEN TS, 1983, STROKE, V14, P332, DOI 10.1161/01.STR.14.3.332; SACCANI S, 1992, J CARDIOVASC SURG, V33, P311; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; 1992, STATISTCAL PACKAGE S; 1985, WHO TECH REP SER, V727	32	633	654	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 17	1996	347	8999					422	425		10.1016/S0140-6736(96)90008-2	http://dx.doi.org/10.1016/S0140-6736(96)90008-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618482				2022-12-01	WOS:A1996TV72200008
J	Meraz, MA; White, JM; Sheehan, KCF; Bach, EA; Rodig, SJ; Dighe, AS; Kaplan, DH; Riley, JK; Greenlund, AC; Campbell, D; CarverMoore, K; DuBois, RN; Clark, R; Aguet, M; Schreiber, RD				Meraz, MA; White, JM; Sheehan, KCF; Bach, EA; Rodig, SJ; Dighe, AS; Kaplan, DH; Riley, JK; Greenlund, AC; Campbell, D; CarverMoore, K; DuBois, RN; Clark, R; Aguet, M; Schreiber, RD			Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway	CELL			English	Article							INTERFERON-GAMMA RECEPTOR; PROTEIN-TYROSINE KINASE; TRANSCRIPTION; TRANSDUCTION; BINDING; ALPHA; IRF-1; IFN; PHOSPHORYLATION; COMPLEMENTATION	The JAK-STAT signaling pathway has been implicated in mediating biologic responses induced by many cytokines. However, cytokines that promote distinct cellular responses often activate identical STAT proteins, thereby raising the question of how specificity is manifest within this signaling pathway. Here we report the generation and characterization of mice deficient in STAT1. STAT1-deficient mice show no overt developmental abnormalities, but display a complete lack of responsiveness to either IFN alpha or IFN gamma and are highly sensitive to infection by microbial pathogens and viruses. In contrast, these mice respond normally to several other cytokines that activate STAT1 in vitro. These observations document that STAT1 plays an obligate and dedicated role in mediating IFN-dependent biologic responses and reveal an unexpected level of physiologic specificity for STAT1 action.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110; UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 92080	Washington University (WUSTL); University of Zurich; Vanderbilt University; Vanderbilt University; Roche Holding; Genentech			Rodig, Scott/Y-3889-2019; DuBois, Raymond N./AAX-8869-2020; Dighe, Anand/AAP-9640-2020; MERAZ RIOS, MARCO ANTONIO/F-4194-2016; Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013; Kaplan, Daniel H/N-2779-2013	MERAZ RIOS, MARCO ANTONIO/0000-0001-6748-8117; Schreiber, Robert D/0000-0001-6311-0432; Kaplan, Daniel H/0000-0002-7851-7320; White, James Michael/0000-0001-5110-6567; Bach, Erika/0000-0002-5997-4489; Dighe, Anand/0000-0003-4130-0758; Schreiber, Robert/0000-0003-1590-2341				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, J IMMUNOL, V2, P689; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	52	1355	1399	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					431	442		10.1016/S0092-8674(00)81288-X	http://dx.doi.org/10.1016/S0092-8674(00)81288-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608597	Bronze			2022-12-01	WOS:A1996TV70800012
J	Mauskopf, JA; Paul, JE; Wichman, DS; White, AD; Tilson, HH				Mauskopf, JA; Paul, JE; Wichman, DS; White, AD; Tilson, HH			Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine - Implications for HIV screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COST-BENEFIT-ANALYSIS; INFECTION; ANTIBODY; PERFORMANCE; KNOWLEDGE; CONTINUE; HEALTH; CARE	Objectives.-To estimate the economic impact of (1) treating pregnant women who are human immunodeficiency virus (HIV)-positive with zidovudine and (2) voluntary screening programs for pregnant women for HIV infection and offering treatment with zidovudine to those found to be HIV-positive. Main Outcome Measures.-Number of cases of pediatric HIV infection and costs of screening, zidovudine treatment, and pediatric HIV infection treatment. Design.-Health care costs associated with treatment of HIV-positive pregnant women and their newborns are estimated as the costs of zidovudine and its administration and the reduction in costs of treating pediatric HIV infection. The lifetime costs of pediatric HIV infection are derived from the published literature. Estimates of the reduction in maternal-to-fetal transmission rates are taken from the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group (ACTG) Protocol 076, Costs of a voluntary screening program include costs of screening tests and counseling. Sensitivity and threshold analyses are performed to determine the impact of changes in input parameter values including zidovudine treatment costs, efficacy of treatment, costs of pediatric HIV infection, prevalence of HIV infection in pregnant women, screening test sensitivity and specificity, and pregnancy termination rates on the results. Results.-Assuming transmission rates are reduced from 25.5% to 8.3% as found in the ACTG 076 trial, treatment costs of $104 502 for 100 HIV-positive pregnant women and their newborns are offset by the reduction of $1 701 333 associated with fewer cases of pediatric HIV infection for a net savings of $1 596 831. The sensitivity and threshold analyses show that overall cost savings from treatment of HIV-positive pregnant women and their newborns are achieved for a wide range of possible maternal treatment costs, efficacy rates, and lifetime pediatric HIV treatment costs. In the base-case analysis for the voluntary screening program, overall cost savings are seen when the HIV prevalence rate among pregnant women is greater than 4.6 per 1000. However, this threshold prevalence rate is sensitive to changes in parameter values-especially pediatric HIV treatment costs, counseling costs, efficacy of treatment, and years of additional HIV treatment for the pregnant women. Conclusions.-Offering zidovudine treatment to pregnant women known to be HIV-positive will decrease the number of cases of pediatric HIV infection and reduce health care costs. Voluntary screening programs for pregnant women will further decrease the number of cases of pediatric HIV infection. The effect of a screening program on health care costs varies according to HIV prevalence and the costs associated with the screening program.			Mauskopf, JA (corresponding author), GLAXO WELLCOME INC,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.			Mauskopf, Josephine/0000-0002-6098-5548				ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BARBACCI MB, 1990, SEX TRANSM DIS, V17, P122, DOI 10.1097/00007435-199007000-00002; BARNHART H, 1995, 2 C RETR OPP INF WAS; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; BRANDEAU ML, 1992, ARCH INTERN MED, V152, P2229, DOI 10.1001/archinte.152.11.2229; BROWN AE, 1995, NEW ENGL J MED, V332, P963, DOI 10.1056/NEJM199504063321419; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; *CDCP, 1994, NAT HIV SER SUMM RES, V3; CHAVEY WE, 1994, J FAM PRACTICE, V38, P249; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; Faden R R, 1993, Womens Health Issues, V3, P216, DOI 10.1016/S1049-3867(05)80067-2; FEHRS LJ, 1991, AM J PUBLIC HEALTH, V81, P619, DOI 10.2105/AJPH.81.5.619; FREDERICK T, 1994, PEDIATR INFECT DIS J, V13, P1091, DOI 10.1097/00006454-199412000-00004; GARRETT HM, 1994, RED BOOK, P48; GWINN M, 1992, J ACQ IMMUN DEF SYND, V5, P505; GWINN M, 1993, 9TH INT C AIDS BERL; HARDY LM, 1991, HIV SCREENING PREGNA; HAVENS PL, 1996, 3 C ANT OPP INF WASH; HEDLUND K, 1990, 6 INT C AIDS SAN FRA; HEGARTY JD, 1988, JAMA-J AM MED ASSOC, V260, P1901; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HSIA DC, 1995, ARCH PEDIAT ADOL MED, V149, P489, DOI 10.1001/archpedi.1995.02170180019003; JOHNSTONE FD, 1990, BRIT MED J, V300, P23, DOI 10.1136/bmj.300.6716.23; LINDSAY MK, 1991, OBSTET GYNECOL, V77, P599; LINDSAY MK, 1989, OBSTET GYNECOL, V78, P678; LURIE P, 1994, JAMA-J AM MED ASSOC, V272, P1832, DOI 10.1001/jama.272.23.1832; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; MCCARTHY BD, 1993, ARCH INTERN MED, V153, P1107, DOI 10.1001/archinte.153.9.1107; PARROTT RH, 1991, J ACQ IMMUN DEF SYND, V4, P122; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; STEIN Z, 1993, AM J PUBLIC HEALTH, V83, P1379, DOI 10.2105/AJPH.83.10.1379; The European Collaborative Study, 1994, PEDIATRICS, V94, P815; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; *US BUR CENS, 1995, 1995 STAT ABSTR US, P494; VENTURA SJ, 1995, VITAL HLTH STAT S, V3; WEBER B, 1993, J VIROL METHODS, V44, P251, DOI 10.1016/0166-0934(93)90060-5; YOGEV R, 1992, MANAGEMENT HIV INFEC, P8; 1994, MMWR-MORBID MORTAL W, V43, P1	42	63	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					132	138		10.1001/jama.276.2.132	http://dx.doi.org/10.1001/jama.276.2.132			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656505				2022-12-01	WOS:A1996UV48500028
J	Chen, CR; Cheng, TO; Huang, T; Zhou, UL; Chen, JY; Huang, YG; Li, HJ				Chen, CR; Cheng, TO; Huang, T; Zhou, UL; Chen, JY; Huang, YG; Li, HJ			Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVE STENOSIS	Background Percutaneous balloon valvuloplasty has been the accepted first-line treatment for congenital pulmonic stenosis in children. Its efficacy in adolescents and adults is less well defined. Methods Between December 1985 and July 1995 we performed percutaneous pulmonic valvuloplasty with a single Inoue balloon catheter in 53 adolescent or adult patients 13 to 55 years of age (mean [+/-SD], 26+/-11). Follow-up studies were performed 0.2 to 9.8 years after the procedure (mean, 6.9+/-3.1) by Doppler echocardiography (in all the patients) and by cardiac catheterization and angiography (in nine patients). Results After balloon valvuloplasty, the systolic pressure gradient across the pulmonic valve decreased from 91+/-46 mm Hg to 38+/-32 mm Hg (P<0.001), and the diameter of the pulmonic-valve orifice increased from 8.9+/-3.6 mm to 17.4+/-4.6 mm (P<0.001). In the nine patients catheterized at followup, the systolic gradient decreased from 107+/-48 mm Hg before valvuloplasty to 50+/-29 mm Hg after valvuloplasty and to 30+/-16 mm Hg at follow-up (P<0.001 for the comparison of the gradient before and after valvuloplasty; P<0.001 for the comparison before valvuloplasty and at follow-up; and P<0.05 for the comparison after valvuloplasty and at followup). In the same nine patients, the diameter of the pulmonic valve, as measured by right ventricular angiography, increased from 8.3+/-1.4 mm before valvuloplasty to 17.2+/-2.0 mm after valvuloplasty (P<0.001) and to 18.4+/-1.4 mm at follow-up (P=0.08). Incompetence of the pulmonic valve was noted in 7 of the 53 patients (13 percent) after balloon valvuloplasty, but it had disappeared at followup in all of them. Conclusions Patients with congenital pulmonic stenosis who present in late adolescence or adult life can be treated with percutaneous balloon valvuloplasty with excellent short-term and long-term results that are similar to those in young children. (C)1996, Massachusetts Medical Society.	GUANGDONG CARDIOVASC INST,DEPT CARDIOL,GUANGZHOU,PEOPLES R CHINA; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT MED,DIV CARDIOL,WASHINGTON,DC 20052	George Washington University								ALKASAB S, 1988, AM J CARDIOL, V62, P822, DOI 10.1016/0002-9149(88)91234-9; BARRAUD P, 1992, ARCH MAL COEUR VAISS, V85, P435; BENSHACHAR G, 1985, J AM COLL CARDIOL, V5, P754, DOI 10.1016/S0735-1097(85)80407-1; BOUTAUD P, 1990, ARCH MAL COEUR VAISS, V83, P969; Carminati M, 1993, Cardiologia, V38, P361; CHEN CR, 1988, CATHETER CARDIO DIAG, V15, P55, DOI 10.1002/ccd.1810150113; CHEN CR, 1995, AM HEART J, V129, P1197, DOI 10.1016/0002-8703(95)90404-2; CHEN CR, 1987, CHIN J CARDIOL, V15, P234; CHENG TO, 1994, CIRCULATION, V89, P896, DOI 10.1161/01.CIR.89.2.896; Eckert S., 1994, European Heart Journal, V15, P265; FAIT F, 1995, J INFASIVE CARDIO SC, V7, pC16; FAWZY ME, 1990, CATHETER CARDIO DIAG, V21, P77, DOI 10.1002/ccd.1810210204; GUTGESELL HP, 1992, J AM COLL CARDIOL, V20, P174, DOI 10.1016/0735-1097(92)90155-G; HERRMANN HC, 1991, AM J CARDIOL, V68, P1111, DOI 10.1016/0002-9149(91)90510-R; KAN JS, 1984, CIRCULATION, V69, P554, DOI 10.1161/01.CIR.69.3.554; KAN JS, 1982, NEW ENGL J MED, V307, P540, DOI 10.1056/NEJM198208263070907; KAUL UA, 1993, AM HEART J, V126, P1152, DOI 10.1016/0002-8703(93)90668-Y; LANDZBERG MJ, 1993, CIRCULATION, V88, P341; Lau K W, 1993, J Heart Valve Dis, V2, P321; LAU KW, 1993, CATHETER CARDIO DIAG, V29, P99, DOI 10.1002/ccd.1810290203; MAATOUK F, 1995, ARCH MAL COEUR VAISS, V88, P63; MCCRINDLE BW, 1991, CIRCULATION, V83, P1915, DOI 10.1161/01.CIR.83.6.1915; NUGENT EW, 1977, CIRCULATION, V56, P38; OCONNOR BK, 1992, J AM COLL CARDIOL, V20, P169, DOI 10.1016/0735-1097(92)90154-F; PRESBITERO P, 1988, Giornale Italiano di Cardiologia, V18, P155; RAO PS, 1988, AM J CARDIOL, V62, P979, DOI 10.1016/0002-9149(88)90909-5; RAO PS, 1992, PERCUTANEOUS BALLOON, P365; SADRAMELI MA, 1995, J AM COLL CARDIOL, P25; SHERMAN W, 1990, AM HEART J, V119, P186, DOI 10.1016/S0002-8703(05)80100-0; SIEVERT H, 1989, EUR HEART J, V10, P712, DOI 10.1093/oxfordjournals.eurheartj.a059555; STANGER P, 1990, AM J CARDIOL, V65, P775, DOI 10.1016/0002-9149(90)91387-L; TEUPE CHJ, 1995, CIRCULATION S1, V92, P357	32	100	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					21	25		10.1056/NEJM199607043350104	http://dx.doi.org/10.1056/NEJM199607043350104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637537				2022-12-01	WOS:A1996UU47900004
J	Prandoni, P; Lensing, AWA; Cogo, A; Cuppini, S; Villalta, S; Carta, M; Cattelan, AM; Polistena, P; Bernardi, E; Prins, MH				Prandoni, P; Lensing, AWA; Cogo, A; Cuppini, S; Villalta, S; Carta, M; Cattelan, AM; Polistena, P; Bernardi, E; Prins, MH			The long-term clinical course of acute deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; thromboembolism; blood coagulation disorders; recurrence; neoplasms	VEIN THROMBOSIS; PULMONARY-EMBOLISM; LOWER-EXTREMITY; STANDARD; SEQUELAE	Background: In patients who have symptomatic deep venous thrombosis, the long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae have not been well documented. Objective: To determine the clinical course of patients during the 8 years after their first episode of symptomatic deep venous thrombosis. Design: Prospective cohort study. Setting: University outpatient thrombosis clinic. Patients: 355 consecutive patients with a first episode of symptomatic deep venous thrombosis. Measurements: Recurrent venous thromboembolism, the post-thrombotic syndrome, and death. Potential risk factors for these outcomes were also evaluated. Results: The cumulative incidence of recurrent venous thromboembolism was 17.5% after 2 years of follow-up (95% CI, 13.6% to 22.2%), 24.6% after 5 years (CI, 19.6% to 29.7%), and 30.3% after 8 years (CI, 23.6% to 37.0%). The presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively). The cumulative incidence of the post-thrombotic syndrome was 22.8% after 2 years (CI, 18.0% to 27.5%), 28.0% after 5 years (CI, 22.7% to 33.3%), and 29.1% after 8 years (CI, 23.4% to 34.7%). The development of ipsilateral recurrent deep venous thrombosis was strongly associated with the risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). Survival after 8 years was 70.2% (CI, 64.7% to 75.6%). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1). Conclusion: Patients with symptomatic deep venous thrombosis, especially those without transient risk factors for deep venous thrombosis, have a high risk for recurrent venous thromboembolism that persists for many years. The post-thrombotic syndrome occurs in almost one third of these patients and is strongly related to ipsilateral recurrent deep venous thrombosis. These findings challenge the widely adopted use of short-course anticoagulation therapy in patients with symptomatic deep venous thrombosis.	UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV HOSP PADUA, PADUA, ITALY	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova	Prandoni, P (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & I, F-4, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.		Carta, Mariarosa/ABF-9677-2021	Cattelan, Anna Maria/0000-0003-2869-2945; Carta, Mariarosa/0000-0002-7143-4928				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1994, HAEMOSTASIS S1; BEYTH RJ, 1995, ARCH INTERN MED, V155, P1031, DOI 10.1001/archinte.155.10.1031; BRANDJES DPM, 1991, THROMB HAEMOSTASIS, V65, pA1568; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; GJORES J E, 1956, Acta Chir Scand Suppl, V206, P1; HELDAL M, 1993, J INTERN MED, V234, P71, DOI 10.1111/j.1365-2796.1993.tb00707.x; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1322; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1543; IMMELMAN EJ, 1984, CLIN CHEST MED, V5, P537; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI, P1; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; LINDNER DJ, 1986, J VASC SURG, V4, P436, DOI 10.1067/mva.1986.avs0040436; MONREAL M, 1993, J INTERN MED, V233, P233, DOI 10.1111/j.1365-2796.1993.tb00981.x; ODONNELL TF, 1977, J SURG RES, V22, P483, DOI 10.1016/0022-4804(77)90030-0; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Salzman E. X., 1993, HEMOSTASIS THROMBOSI, P1275; Salzmann E, 1993, HEMOSTASIS THROMBOSI, P1346; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; STRANDNESS DE, 1983, JAMA-J AM MED ASSOC, V250, P1289, DOI 10.1001/jama.250.10.1289; WIDMER LK, 1985, VASA-J VASCULAR DIS, V14, P264	27	1602	1657	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1996	125	1					1	+		10.7326/0003-4819-125-1-199607010-00001	http://dx.doi.org/10.7326/0003-4819-125-1-199607010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT399	8644983				2022-12-01	WOS:A1996UT39900001
J	Leuther, KK; Bushnell, DA; Kornberg, RD				Leuther, KK; Bushnell, DA; Kornberg, RD			Two-dimensional crystallography of TFIIB- and IIE-RNA polymerase II complexes: Implications for start site selection and initiation complex formation	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; TATA-BINDING-PROTEIN; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; 2-DIMENSIONAL CRYSTALS; FUNCTIONAL DOMAINS; YEAST; DNA; RESOLUTION	Transcription factors IIB (TFIIB) and IIE (TFIIE) bound to RNA polymerase II have been revealed by electron crystallography in projection at 15.7 Angstrom resolution. The results lead to simple hypotheses for the roles of these factors in the initiation of transcription. TFIIB is suggested to define the distance from TATA box to transcription start site by bringing TATA DNA in contact with polymerase at that distance from the active center of the enzyme. TFIIE is suggested to participate in a key conformational switch occurring at the active center upon polymerase-DNA interaction.			Leuther, KK (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305, USA.				NIAID NIH HHS [AI21144] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; ASTURIAS FJ, 1995, J STRUCT BIOL, V114, P60, DOI 10.1006/jsbi.1995.1005; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BRISSON A, 1994, BIOL CELL, V80, P221, DOI 10.1016/0248-4900(94)90045-0; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)90823-O; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOMBERG RD, 1991, CURR OPIN STRUC BIOL, V1, P642; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; SVEJSTRUP JQ, 1996, J BIOL CHEM, V2, P643; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	69	87	86	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					773	779		10.1016/S0092-8674(00)81242-8	http://dx.doi.org/10.1016/S0092-8674(00)81242-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646784	Bronze			2022-12-01	WOS:A1996UP34400016
J	Fey, R; Pearson, N				Fey, R; Pearson, N			Statins and coronary heart disease	LANCET			English	Editorial Material									AVON HLTH, DIST HLTH AUTHOR, BRISTOL BS2 8EE, AVON, ENGLAND		Fey, R (corresponding author), AVON HLTH, AVON FAMILY HLTH SERV AUTHOR, 10 DIGHTON ST, BRISTOL BS2 8EE, AVON, ENGLAND.							ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; DEAN M, 1995, LANCET, V346, P1415, DOI 10.1016/S0140-6736(95)92414-0; FOULDS J, 1995, BRIT MED J, V311, P1152, DOI 10.1136/bmj.311.7013.1152; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; *OFF POP CENS SURV, 1995, SER PP2, V19; OLIVER MF, 1995, LANCET, V346, P1378, DOI 10.1016/S0140-6736(95)92399-3; *OPCS SOC SURV DIV, 1995, 1993 HLTH SURV ENGL; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDERSEN TR, 1995, NEW ENGL J MED, V333, P1350, DOI 10.1056/NEJM199511163332010; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHEPHERD J, 1995, AM J CARDIOL, V76, P485; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; 1996, ANN INTERN MED, V14, P515; 1995, BRIT NATL FORMUL SEP	17	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1389	1390		10.1016/S0140-6736(96)91019-3	http://dx.doi.org/10.1016/S0140-6736(96)91019-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637349				2022-12-01	WOS:A1996UL90400018
J	Verheugt, FWA				Verheugt, FWA			Primary angioplasty for acute myocardial infarction: Is the balloon half full or half empty?	LANCET			English	Editorial Material							IMMEDIATE ANGIOPLASTY				Verheugt, FWA (corresponding author), UNIV NIJMEGEN HOSP, DEPT CARDIOL, 6500 HB NIJMEGEN, NETHERLANDS.		Verheugt, F.W.A./H-8105-2014					AHMAD T, 1995, AM J CARDIOL, V76, P77, DOI 10.1016/S0002-9149(99)80807-8; Elizaga J., 1993, European Heart Journal, V14, P118; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grinfeld Liliana, 1996, Journal of the American College of Cardiology, V27, p222A; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; Ribichini Flavio, 1996, Journal of the American College of Cardiology, V27, p221A; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	9	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1996	347	9011					1276	1277		10.1016/S0140-6736(96)90933-2	http://dx.doi.org/10.1016/S0140-6736(96)90933-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622499	Green Submitted			2022-12-01	WOS:A1996UK75800004
J	Geiger, JH; Hahn, S; Lee, S; Sigler, PB				Geiger, JH; Hahn, S; Lee, S; Sigler, PB			Crystal structure of the yeast TFIIA/TBP/DNA complex	SCIENCE			English	Article							TRANSCRIPTION INITIATION SITES; SACCHAROMYCES-CEREVISIAE; FACTOR-IIA; TFIIA; SUBUNITS; ACTIVATION; CDNA; GENE	The crystal structure of the yeast TFIIA/TBP/TATA promoter complex was solved to 3 angstrom resolution by double-edge multiple wavelength anomalous diffraction from two different species of anomalous scattering elements in the same crystal. The large and small subunits of TFIIA associate intimately to form both domains of a two-domain folding pattern. TFIIA binds as a heterodimer to the side of the TBP/TATA complex opposite to the side that binds TFIIB and does not alter the TBP/DNA interaction. The six-stranded beta-sandwich domain interacts with the amino-terminal end of TBP through a stereospecific parallel beta-strand interface and with the backbone of the TATA box and the 5'-flanking B-DNA segment. The four-helix-bundle domain projects away from the TBP/TATA complex, thereby presenting a substantial surface for further protein-protein interactions.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center				Geiger, James/0000-0002-9443-4488				AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BRYANT GW, COMMUNICATION; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; GE H, 1994, J BIOL CHEM, V269, P17136; GuzikevichGuerstein G, 1996, NAT STRUCT BIOL, V3, P32, DOI 10.1038/nsb0196-32; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; LAGRANGE T, COMMUNICATION; LEE DK, 1992, MOL CELL BIOL, V12, P96; MA D, COMMUNICATION; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RANISH J, COMMUNICATION; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RANISH JA, UNPUB; RANISH JA, IN PRESS CURR OPIN G; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313	46	233	236	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					830	836		10.1126/science.272.5263.830	http://dx.doi.org/10.1126/science.272.5263.830			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629014				2022-12-01	WOS:A1996UK75700043
J	Voloshin, ON; Wang, LJ; CameriniOtero, RD				Voloshin, ON; Wang, LJ; CameriniOtero, RD			Homologous DNA pairing promoted by a 20-amino acid peptide derived from RecA	SCIENCE			English	Article							SINGLE-STRANDED FRAGMENTS; ESCHERICHIA-COLI; SUPERHELICAL DNA; BRANCH MIGRATION; UVSX PROTEIN; BACTERIOPHAGE-T4; RECOMBINATION; BINDING; YEAST	The molecular structure of the Escherichia coli RecA protein in the absence of DNA revealed two disordered or mobile loops that were proposed to be DNA binding sites. A short peptide spanning one of these loops was shown to carry out the key reaction mediated by the whole RecA protein: pairing (targeting) of a single-stranded DNA to its homologous site on a duplex DNA. In the course of the reaction the peptide bound to both substrate DNAs, unstacked the single-stranded DNA, and assumed a beta structure. These events probably recapitulate the underlying molecular pathway or mechanism used by homologous recombination proteins.	NIDDKD,GENET BIOMED BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS LD, 1988, BIOCHEMISTRY-US, V27, P6954, DOI 10.1021/bi00418a042; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KANSY JW, 1986, J BIOMOL STRUCT DYN, V3, P1079, DOI 10.1080/07391102.1986.10508487; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; KOLLER T, 1983, MECHANISMS DNA REPLI, P723; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI C, 1994, ANN REV BIOCH, V63, P991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P538; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MARABOEUF O, 1995, J BIOL CHEM, V270, P30927; Maxam A M, 1980, Methods Enzymol, V65, P499; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; RAO BJ, 1995, TRENDS BIOCHEM SCI, V20, P109, DOI 10.1016/S0968-0004(00)88976-8; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VOLOSHIN ON, UNPUB; Wang L., UNPUB; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	42	75	88	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					868	872		10.1126/science.272.5263.868	http://dx.doi.org/10.1126/science.272.5263.868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629021				2022-12-01	WOS:A1996UK75700058
J	Mendall, MA; Patel, P; Ballam, L; Strachan, D; Northfield, TC				Mendall, MA; Patel, P; Ballam, L; Strachan, D; Northfield, TC			C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ACUTE PHASE; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; LIPIDS; SERUM; INFECTION; DISEASE	Objective-To test the hypothesis that minor chronic insults such as smoking, chronic bronchitis, and two persistent bacterial infections may be associated with increases in C reactive protein concentration within the normal range and that variations in the C reactive protein concentration in turn may be associated with levels of cardiovascular risk factors and chronic coronary heart disease. Design-Population based cross sectional study. Setting-General practices in Merton, Sutton, and Wandsworth. Subjects-A random sample of 388 men aged 50-69 years from general practice registers. 612 men were invited to attend and 413 attended, of whom 25 non-white men were excluded. The first 303 of the remaining 388 men had full risk factor profiles determined. Interventions-Measurements of serum C reactive protein concentrations by in house enzyme linked immunosorbent assay (ELISA); other determinations by standard methods. Coronary heart disease was sought by the Rose angina questionnaire and Minnesota coded electrocardiograms. Main outcome measures-Serum C reactive protein concentrations, cardiovascular risk factor levels, and the presence of coronary heart disease. Results-Increasing age, smoking, symptoms of chronic bronchitis, Helicobacter pylori and Chlamydia pneumoniae infections, and body mass index were all associated with raised concentrations of C reactive protein. C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. C Reactive protein concentration was negatively associated with high density lipoprotein cholesterol concentration. There was a weaker positive relation with low density lipoprotein cholesterol concentration and no relation with apolipoprotein A I value. C Reactive protein concentration was also strongly associated with coronary heart disease. Conclusion-The body's response to inflammation may play an important part in influencing the progression of atherosclerosis. The association of C reactive protein concentration with coronary heart disease needs testing in prospective studies.			Mendall, MA (corresponding author), ST GEORGES MED SCH,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND.							AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALVAREZ C, 1986, CLIN CHEM, V32, P142; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; CABANA VG, 1989, J LIPID RES, V30, P39; COOMBES EJ, 1980, J TRAUMA, V20, P971, DOI 10.1097/00005373-198011000-00012; DEBEER FC, 1982, J IMMUNOL METHODS, V50, P299, DOI 10.1016/0022-1759(82)90168-5; FAHIEWILSON M, 1987, CLIN CHIM ACTA, V167, P197, DOI 10.1016/0009-8981(87)90372-X; FEINGOLD KR, 1992, DIABETES, V41, P97, DOI 10.2337/diab.41.2.S97; GAULDIE J, 1989, ANN NY ACAD SCI, V557, P46; HELDENBERG D, 1980, ATHEROSCLEROSIS, V35, P433, DOI 10.1016/0021-9150(80)90184-7; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KAHN C, 1995, SCIENCE, V373, P384; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MENDALL MA, 1994, BRIT HEART J, V71, P437; NAITO H K, 1987, Comprehensive Therapy, V13, P43; PALOSUO T, 1986, ACTA MED SCAND, V220, P175; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	27	709	740	0	40	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1061	1065						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616412				2022-12-01	WOS:A1996UH81600023
J	Bamji, AN				Bamji, AN			Brain injury rehabilitation: Jaw jaw not war war	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					916	917						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611911				2022-12-01	WOS:A1996UE37100071
J	Darbar, D; Luck, J; Davidson, N; Pringle, T; Main, G; McNeill, G; Struthers, AD				Darbar, D; Luck, J; Davidson, N; Pringle, T; Main, G; McNeill, G; Struthers, AD			Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR ARRHYTHMIAS; RECOVERY	Objective-To determine whether QTc dispersion, which is easily obtained from a standard electrocardiogram, can predict those patients with peripheral vascular disease who will subsequently suffer a cardiac death, despite having no cardiac symptoms or signs. Design-Patients with peripheral vascular disease were followed up for five years after they had had coronary angiography, radionuclide ventriculography, and their QTc dispersion calculated from their 12 lead electrocardiogram. Subjects-49 such patients were then divided into three groups: survivors (34), cardiac death (12), and non-cardiac death (3). Main outcome measure-Survival. Results-The mean (SD; range) ejection fractions were similar in all three groups: survivors 45.9 (11.0; 27.0-52.0), cardiac death 44.0 (7.90; 28.5-59.0), and non-cardiac death 45.3 (4.55; 39.0-50.0). QTc dispersion was significantly prolonged in the cardiac death group compared with in the survivors (86.3 (23.9; 41.0-139) v 56.5 (25.4; 25.0-164); P=0.002). A QTc dispersion greater than or equal to 60 ms had a 92% sensitivity and 81% specificity in predicting cardiac death. QTc dispersion in patients with diffuse coronary artery disease was significantly (P<0.05) greater than in those with no disease or disease affecting one, two, or three vessels. Conclusions-There is a strong link between QTc dispersion and cardiac death in patients with peripheral vascular disease. QTc dispersion may therefore be a cheap and non-invasive way of assessing the risk of cardiac death in patients with peripheral vascular disease.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CARDIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee			Darbar, Dawood/C-9079-2015	Darbar, Dawood/0000-0002-4103-5977; Struthers, Allan/0000-0002-2926-2528				BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BELTRAMI CA, 1994, CIRCULATION, V89, P151, DOI 10.1161/01.CIR.89.1.151; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; DAVEY P, 1994, BRIT HEART J, V71, P268; HIGHAM P, 1994, BRIT HEART J, V71, P508; KAUTZNER J, 1994, PACE, V17, P928, DOI 10.1111/j.1540-8159.1994.tb01435.x; LEE HS, 1994, BR HEART J S5, V71, P98; MERX W, 1977, AM HEART J, V94, P603, DOI 10.1016/S0002-8703(77)80130-0; MORENO FL, 1994, CIRCULATION, V90, P94, DOI 10.1161/01.CIR.90.1.94; MURRAY A, 1994, BRIT HEART J, V71, P386; Potratz J., 1993, European Heart Journal, V14, P254; PYE M, 1994, BRIT HEART J, V71, P511; PYE MP, 1992, CARDIOVASC RES, V26, P740, DOI 10.1093/cvr/26.8.740; STOLETNIY LN, 1994, J AM COLL CARDIOL, pA178; WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUNUS A, 1994, J AM COLL CARDIOL, pA179	18	78	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					874	878						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611874				2022-12-01	WOS:A1996UE37100018
J	Heichman, KA; Roberts, JM				Heichman, KA; Roberts, JM			The yeast CDC16 and CDC27 genes restrict DNA replication to once per cell cycle	CELL			English	Article							POLE BODY DUPLICATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; BUDDING YEAST; ASPERGILLUS-NIDULANS; NUCLEAR DIVISION; LICENSING FACTOR; MITOSIS; ANAPHASE; MUTANTS	CDC16 and CDC27 were identified as genes in S. cerevisiae necessary to limit DNA replication to once per cell cycle. A screen for mutants that overreplicated their DNA uncovered new conditional alleles that cause accumulation of up to 8C DNA. DNA overreplication involves all chromosomes and does not require passage through mitosis or another START. It occurs within a single cell cycle and can cause arrest at the MEC1 checkpoint. Remarkably, CIb2-Cdc28 activity remains elevated in the overreplicating cells. These observations distinguish CDC16 and CDC27 from other mutants that accumulate extra DNA after completing an aberrent mitosis, or skipping mitosis altogether, and entering a second, inappropriate G1 and S phase. CDC16 and CDC27 may contribute to replication control by targeted proteolysis of an S phase initiator.			Heichman, KA (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.							ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; CREANOR J, 1990, J CELL SCI, V96, P435; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUBERMAN JA, 1995, NATURE, V375, P360, DOI 10.1038/375360a0; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KLYCE HR, 1973, EXP CELL RES, V82, P47, DOI 10.1016/0014-4827(73)90243-7; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; ODONNELL KL, 1991, J CELL SCI, V99, P711; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	53	78	80	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					39	48		10.1016/S0092-8674(00)81080-6	http://dx.doi.org/10.1016/S0092-8674(00)81080-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620535	Bronze			2022-12-01	WOS:A1996UE55900007
J	Konig, P; Giraldo, R; Chapman, L; Rhodes, D				Konig, P; Giraldo, R; Chapman, L; Rhodes, D			The crystal structure of the DNA-binding domain of yeast RAP1 in complex with telomeric DNA	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ANTENNAPEDIA HOMEODOMAIN; PROTEIN; SILENCER; LENGTH; TRANSCRIPTION; RESOLUTION; SEQUENCES; STABILITY; ERRORS	Telomeres, the nucleoprotein complexes at the ends of eukaryotic chromosomes, are essential for chromosome stability. In the yeast S. cerevisiae, telomeric DNA is bound in a sequence-specific manner by RAP1, a multifunctional protein also involved in transcriptional regulation. Here we report the crystal structure of the DNA-binding domain of RAP1 in complex with a telomeric DNA site at 2.25 Angstrom resolution. The protein contains two similar domains that bind DNA in a tandem orientation, recognizing a tandemly repeated DNA sequence. The domains are structurally related to the homeodomain and the proto-oncogene Myb, but show novel features in their DNA-binding mode. A structured linker between the domains and a long C-terminal tail contribute to the binding specificity. This structure provides insight into the recognition of the conserved telomeric DNA sequences by a protein.	CSIC,CTR INVEST BIOL,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Konig, P (corresponding author), MRC,MOLEC BIOL LAB,LONDON W1N 4AL,ENGLAND.		Giraldo, Rafael/P-3289-2014	Giraldo, Rafael/0000-0002-5358-7488				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; FREEMAN K, 1995, GENETICS, V141, P1253; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1995, NUCLEIC ACIDS MOL BI, V9, P308; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HENRY YAL, 1990, NUCLEIC ACIDS RES, V18, P2617, DOI 10.1093/nar/18.9.2617; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P110; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1995, CURR OPIN STRUC BIOL, V5, P311, DOI 10.1016/0959-440X(95)80092-1; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TSANG JSH, 1990, NUCLEIC ACIDS RES, V18, P7331, DOI 10.1093/nar/18.24.7331; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035; ZAKIAN AV, 1995, SCIENCE, V270, P1601	64	250	253	4	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					125	136		10.1016/S0092-8674(00)81088-0	http://dx.doi.org/10.1016/S0092-8674(00)81088-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620531	Bronze			2022-12-01	WOS:A1996UE55900015
J	Green, AR				Green, AR			Pathogenesis of polycythaemia vera	LANCET			English	Editorial Material							POLYCYTHEMIA-VERA; ERYTHROPOIETIN				Green, AR (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,MRC CTR,CAMBRIDGE,ENGLAND.			Green, Anthony/0000-0002-9795-0218				ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; Aldred M. A., 1995, American Journal of Human Genetics, V57, pA255; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1992, BLOOD, V80, P891; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; FISHER MJ, 1994, BLOOD, V84, P1982; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; KRALOVICS R, 1995, BLOOD, V86, P733; KRALOVICS R, 1995, BLOOD, V86, P270; NUNEZ C, 1994, BLOOD, V85, P635; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	15	20	20	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					844	845		10.1016/S0140-6736(96)91338-0	http://dx.doi.org/10.1016/S0140-6736(96)91338-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622384				2022-12-01	WOS:A1996UC45000002
J	Tarn, WY; Steitz, JA				Tarn, WY; Steitz, JA			A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro	CELL			English	Article							SMALL NUCLEAR-RNA; CROSS-LINKING; ACTIVE-SITE; U6 SNRNA; RIBONUCLEOPROTEIN; MUTATIONS; PROBES; U4/U6; YEAST; CAP	A minor class of introns with noncanonical splice (AT-AC) and branch site sequences exists in metazoan protein coding genes. We have established a HeLa cell in vitro system that accurately splices a pre-mRNA substrate containing such an intron from the human P120 gene. Splicing occurs via a lariat intermediate whose branch site A residue is predicted to bulge from a duplex formed with the low abundance U12 small nuclear ribonucleoprotein (snRNP), which we confirm by psoralen cross-linking. Native gel electrophoresis reveals that U11, U12, and U5 snRNPs assemble onto the P120 pre-mRNA to form splicing complexes. Inhibition of P120 splicing by 2'-O-methyl oligonucleotides complementary to U12 or U5 demonstrates that U12 and U5 snRNPs perform essential roles in the AT-AC spliceosome.			Tarn, WY (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW HAVEN, CT 06536 USA.		Tarn, Woan-Yuh/N-8464-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026154, R01GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHANFREAU G, 1994, NUCLEIC ACIDS RES, V22, P1981, DOI 10.1093/nar/22.11.1981; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CRISPINO JD, 1995, GENE DEV, V9, P2314, DOI 10.1101/gad.9.18.2314; GILLIAM AC, 1993, P NATL ACAD SCI USA, V90, P6781, DOI 10.1073/pnas.90.14.6781; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; HALL SL, 1986, IN PRESS SCIENCE; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LARSON RG, 1990, CANCER COMMUN, V2, P63, DOI 10.3727/095535490820874704; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; SCADDEN ADJ, 1995, EMBO J, V14, P3236; SONTHEIMER EJ, 1992, MOL CELL BIOL, V12, P734, DOI 10.1128/MCB.12.2.734; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TARN WY, 1995, RNA, V1, P644; TARN WY, 1994, P NATL ACAD SCI USA, V8, P2704; WASSARMAN DA, 1993, MOL BIOL REP, V17, P143, DOI 10.1007/BF00996222; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	41	185	188	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					801	811		10.1016/S0092-8674(00)81057-0	http://dx.doi.org/10.1016/S0092-8674(00)81057-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625417	hybrid			2022-12-01	WOS:A1996TZ99000017
J	Matsumoto, M; Mariathasan, S; Nahm, MH; Baranyay, F; Peschon, JJ; Chaplin, DD				Matsumoto, M; Mariathasan, S; Nahm, MH; Baranyay, F; Peschon, JJ; Chaplin, DD			Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; BETA; MONOCYTOGENES; ACTIVATION; RESOLUTION; RESPONSES; RESISTANT; INFECTION; SURFACE; COMPLEX	In mice deficient in either lymphotoxin-alpha (LT-alpha) or the type I tumor necrosis factor (TNF) receptor, but not the type II TNF receptor, germinal centers failed to develop in peripheral lymphoid organs. Germinal center formation was restored in LT-alpha-deficient mice by transplantation of normal bone marrow, indicating that the LT-alpha-expressing cells required to establish this lymphoid structure are derived from bone marrow.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)				Nahm, Moon/0000-0002-6922-1042; Chaplin, David/0000-0002-1354-3069				BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; HAKOSHIMA T, 1988, J MOL BIOL, V201, P455, DOI 10.1016/0022-2836(88)90153-2; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KRAAL G, 1986, IMMUNOLOGY, V58, P665; MARIATHASAN S, 1995, J INFLAMM, V45, P72; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PESCHON JJ, UNPUB; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAMESH N, 1994, IMMUNOL REV, V138, P87, DOI 10.1111/j.1600-065X.1994.tb00848.x; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUDDLE NH, 1992, CURR OPIN IMMUNOL, V4, P327, DOI 10.1016/0952-7915(92)90084-R; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; STEFFEN M, 1988, J IMMUNOL, V140, P2621; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	33	332	348	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1289	1291		10.1126/science.271.5253.1289	http://dx.doi.org/10.1126/science.271.5253.1289			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638112				2022-12-01	WOS:A1996TX69500039
J	Cluzel, P; Lebrun, A; Heller, C; Lavery, R; Viovy, JL; Chatenay, D; Caron, F				Cluzel, P; Lebrun, A; Heller, C; Lavery, R; Viovy, JL; Chatenay, D; Caron, F			DNA: An extensible molecule	SCIENCE			English	Article							RECA PROTEIN; SINGLE	The force-displacement response of a single duplex DNA molecule was measured. The force saturates at a plateau around 70 piconewtons, which ends when the DNA has been stretched about 1.7 times its contour length. This behavior reveals a highly cooperative transition to a state here termed S-DNA. Addition of an intercalator suppresses this transition. Molecular modeling of the process also yields a force plateau and suggests a structure for the extended form. These results may shed light on biological processes involving DNA extension and open the route for mechanical studies on individual molecules in a previously unexplored range.	ECOLE NORMALE SUPER,CNRS,URA 1302,GENET MOLEC LAB,F-75230 PARIS,FRANCE; INST CURIE,CNRS,URA 448,F-75005 PARIS,FRANCE; INST CURIE,CNRS,URA 1379,F-75005 PARIS,FRANCE; INST BIOL PHYSICOCHIM,CNRS,URA 77,LAB BIOCHIM THEOR,F-75005 PARIS,FRANCE; INST PHYS,LUDFC,F-67084 STRASBOURG,FRANCE; MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society			Lavery, Richard/G-1422-2011	Lavery, Richard/0000-0001-9901-6640; Heller, Christoph/0000-0002-9434-8192; Viovy, Jean-Louis/0000-0002-8223-4040				BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; Cox R. G., 1970, Journal of Fluid Mechanics, V44, P791, DOI 10.1017/S002211207000215X; CRICK FHC, 1954, PROC R SOC LON SER-A, V223, P80, DOI 10.1098/rspa.1954.0101; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRASER MJ, 1951, NATURE, V167, P760; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HILL TL, 1959, J CHEM PHYS, V30, P383, DOI 10.1063/1.1729961; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LAVERY R, 1995, COMPUT PHYS COMMUN, V91, P135, DOI 10.1016/0010-4655(95)00046-I; LAVERY R, 1994, ADV COMP BIOL, V1, P69; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Smith Steven B., 1995, Biophysical Journal, V68, pA250; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Sundaralingam M., 1988, STRUCTURE EXPRESSION, P191; VIOVY JL, 1994, CR ACAD SCI III-VIE, V317, P795; WILKINS MHF, 1951, NATURE, V167, P759, DOI 10.1038/167759a0; WILKINS MHF, 1953, NATURE, V171, P738, DOI 10.1038/171738a0; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	23	860	892	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					792	794		10.1126/science.271.5250.792	http://dx.doi.org/10.1126/science.271.5250.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628993				2022-12-01	WOS:A1996TU69400041
J	Hansson, LE; Nyren, O; Hsing, AW; Bergstrom, R; Josefsson, S; Chow, WH; Fraumeni, JF; Adami, HO				Hansson, LE; Nyren, O; Hsing, AW; Bergstrom, R; Josefsson, S; Chow, WH; Fraumeni, JF; Adami, HO			The risk of stomach cancer in patients with gastric or duodenal ulcer disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HELICOBACTER-PYLORI; PEPTIC-ULCER; ASCORBIC-ACID; ASPIRIN USE; CARCINOMA; ALCOHOL; DRUGS	Background Helicobacter pylori infection, now considered to be a cause of gastric cancer, is also strongly associated with gastric and duodenal ulcer disease. The discovery of these relations has brought the long-controversial connection between peptic ulcers and gastric cancer into focus. Methods We estimated the risk of stomach cancer in a large cohort of hospitalized patients with gastric or duodenal ulcers, as recorded in the Swedish Inpatient Register between 1965 and 1983. Altogether, 57,936 patients were followed through 1989, for an average of 9.1 years. The standardized incidence ratio - the ratio of the observed number of cancers to the number expected on the basis of the incidence in the Swedish population at large - was used as a measure of relative risk. Results After peaking in the first 3 years of followup, the standardized incidence ratio for gastric cancer among 29,287 patients with gastric ulcers leveled off at 1.8 (95 percent confidence interval, 1.6 to 2.0) and remained significantly increased throughout followup, which was as long as 24 years for some patients. Prepyloric ulcer, diagnosed in 8646 patients, was not associated with a significant excess risk (standardized incidence ratio, 1.2; 95 percent confidence interval, 0.8 to 1.6). In the cohort of patients with duodenal ulcers (24,456 patients), the incidence of gastric cancer was significantly lower than expected. After the second year of follow-up, the standardized incidence ratio was only 0.6 (95 percent confidence interval, 0.4 to 0.7) and remained stable thereafter. Conclusions Gastric ulcer disease and gastric cancer have etiologic factors in common. A likely cause of both is atrophic gastritis induced by H. pylori. By contrast, there appear to be factors associated with duodenal ulcer disease that protect against gastric cancer. (C) 1996, Massachusetts Medical Society.	UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT STAT,S-75185 UPPSALA,SWEDEN; MORA HOSP,DEPT SURG,MORA,SWEDEN; NCI,DIV CANC EPIDEMIOL & GENET,BETHESDA,MD 20892; INT EPIDEMIOL INST,ROCKVILLE,MD; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health					PHS HHS [85636-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMI HO, 1987, SCAND J GASTROENTERO, V22, P889, DOI 10.3109/00365528708991931; AGREUS L, 1995, SCAND J GASTROENTERO, V30, P752, DOI 10.3109/00365529509096323; BAILAR JC, 1964, BIOMETRICS, V20, P639; BARTSCH H, 1988, MUTAT RES, V202, P307, DOI 10.1016/0027-5107(88)90194-7; CAHILL RJ, 1993, ACTA GASTROENTER S61, V56; CAMELS S, 1991, IARC SCI PUBL, V105, P187; CRUVEILHIER J, 1835, ANATOMIE PATHOLOGIQU; DEKKER W, 1977, GASTROENTEROLOGY, V73, P710; DOOLEY CP, 1984, ANN INTERN MED, V101, P538, DOI 10.7326/0003-4819-101-4-538; DUTERTRE Y, 1993, ACTA GASTROENTEROL S, V56, P61; EIDT S, 1994, DIGESTION, V55, P13, DOI 10.1159/000201116; ELLIS DJ, 1979, BRIT J SURG, V66, P117, DOI 10.1002/bjs.1800660211; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HANSSON LE, 1994, INT J CANCER, V57, P26, DOI 10.1002/ijc.2910570106; HIROHATA T, 1968, J NATL CANCER I, V41, P895; HOLE DJ, 1987, SCAND J GASTROENTERO, V22, P17, DOI 10.3109/00365528708991850; HSING AW, 1993, CANCER, V71, P745, DOI 10.1002/1097-0142(19930201)71:3<745::AID-CNCR2820710316>3.0.CO;2-1; IHRE B. J. E., 1964, GASTROENTEROLOGIA, V102, P78; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JACKSON JH, 1989, J CLIN INVEST, V84, P1644, DOI 10.1172/JCI114342; KATO I, 1992, AM J EPIDEMIOL, V135, P521, DOI 10.1093/oxfordjournals.aje.a116319; Kawashima T, 1991, Nihon Shokakibyo Gakkai Zasshi, V88, P1161; KEKKI M, 1990, GASTROEN CLIN BIOL, V14, P217; KRAUSE U, 1963, ACTA CHIR SCAND    S, V310, P1; KUIPERS EJ, 1995, LANCET, V345, P1525, DOI 10.1016/S0140-6736(95)91084-0; *KUNGL MED, 1965, INT STAT CLASS DIS I; LANAS A, 1992, GASTROENTEROLOGY, V103, P862, DOI 10.1016/0016-5085(92)90018-T; LECHAGO J, 1993, GASTROENTEROLOGY, V104, P1554, DOI 10.1016/0016-5085(93)90370-R; LEE S, 1990, SCAND J GASTROENTERO, V25, P1223, DOI 10.3109/00365529008998557; LEWIS JH, 1982, AM J GASTROENTEROL, V77, P368; LUNDEGARDH G, 1988, NEW ENGL J MED, V319, P195, DOI 10.1056/NEJM198807283190402; LUNDEGARDH G, 1994, GUT, V35, P946, DOI 10.1136/gut.35.7.946; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MOLLER H, 1992, GUT, V33, P1166, DOI 10.1136/gut.33.9.1166; MUNOZ N, 1994, CANCER EPIDEM BIOMAR, V3, P445; NAGAYO T, 1986, HISTOGENESIS PRECURS, P115; *NAT BOARD HLTH WE, 1973, INT STAT CLASS DIS I; NORFLEET RG, 1989, J CLIN GASTROENTEROL, V11, P382, DOI 10.1097/00004836-198908000-00006; NYREN O, 1995, JNCI-J NATL CANCER I, V87, P28, DOI 10.1093/jnci/87.1.28; ROOD JC, 1994, NUTR CANCER, V22, P65, DOI 10.1080/01635589409514332; SCHRAGER J, 1967, GUT, V8, P497, DOI 10.1136/gut.8.5.497; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; SIPPONEN P, 1992, EUR J GASTROEN HEPAT, V4, pS25; SOBALA GM, 1989, GASTROENTEROLOGY, V97, P357, DOI 10.1016/0016-5085(89)90071-1; SOMERVILLE K, 1986, LANCET, V1, P462; SPIRO HM, 1993, CLIN GASTROENTEROLOG; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THUN MJ, 1993, CANCER RES, V53, P1322; TSUGANE S, 1993, CANCER CAUSE CONTROL, V4, P297, DOI 10.1007/BF00051331; WESTLUND K, 1963, MORTALITY PEPTIC ULC; WONG J, 1980, J SURG RES, V29, P446, DOI 10.1016/0022-4804(80)90058-X; World Health Organization, 1994, IARC MON EV CARC RIS, P177; Yamagata S, 1979, World J Surg, V3, P671	53	493	513	2	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					242	249		10.1056/NEJM199607253350404	http://dx.doi.org/10.1056/NEJM199607253350404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657240	Bronze			2022-12-01	WOS:A1996UZ53200004
J	Mansergh, G; Haddix, AC; Steketee, RW; Nieburg, PI; Hu, DJ; Simonds, RJ; Rogers, M				Mansergh, G; Haddix, AC; Steketee, RW; Nieburg, PI; Hu, DJ; Simonds, RJ; Rogers, M			Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS	Objective.-To evaluate the cost-effectiveness of a short-course zidovudine program to prevent perinatal transmission of human immunodeficiency virus (HIV) type 1 in sub-Saharan African country settings. Design and Setting.-Several clinical trials of short-course zidovudine during pregnancy for prevention of perinatal transmission of HIV are under way in developing countries in sub-Saharan Africa. A decision model was used to examine the cost-effectiveness of zidovudine programs in a hypothetical 1-year birth cohort in a sub-Saharan African setting from the perspective of the health care system and of society. A completed short course of zidovudine was assumed to reduce perinatal HIV transmission from 25% to 16.5%, approximately one half of the effect of the longer-course zidovudine. Estimates of program costs, lifetime HIV-related health care costs, and lost productivity costs were derived from the published literature and from preliminary data available from sites of planned clinical trials. Sensitivity analyses were conducted on all relevant parameters. Main Outcome Measures.-Medical costs, lost productivity costs, program costs, cost savings, and incremental cost-effectiveness, expressed as cost per infant HIV infection prevented. Results.-The model estimated that a national zidovudine program in a setting with 12.5% HIV seroprevalence would reduce perinatal HIV incidence by 12% (4.9 infections per 1000 births), The cost to the health care system would be $3748 per infant HIV infection prevented. When productivity losses were included in the model, the cost decreases to $1115 per infant HIV infection prevented. The cost to implement a national zidovudine program including the cost of counseling, testing, and drugs, would be $2 million per 100 000 births or $20 per pregnant woman. In the base case, decreases in the cost of counseling and testing and increases in maternal HIV prevalence, zidovudine efficacy, and medical and lost productivity costs improved cost-effectiveness of the zidovudine program. Conclusions.-Assuming demonstrable efficacy of short-course zidovudine prevention of perinatal HIV, a national perinatal HIV prevention program with zidovudine in most sub-Saharan African country settings would reduce the incidence of infant HIV infection and, in some settings, provide societal savings; however, substantial initial investment in such programs will be required. Where health care resources are limited, as in these regions, allocation of resources to a perinatal zidovudine program will need to be considered in the context of resources required for other pressing medical care needs.	CTR DIS CONTROL & PREVENT,OFF DIRECTOR,NATL CTR HIV AIDS STD & TB PREVENT,NCHSTP,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mansergh, G (corresponding author), CTR DIS CONTROL & PREVENT,EPIDEMIOL BRANCH,DIV HIV AIDS PREVENT,NCHSTP,MSE-45,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; [Anonymous], 1992, Wkly Epidemiol Rec, V67, P145; CAMERON C, 1992, 8 INT C AIDS AMST; COHEN J, 1995, SCIENCE, V269, P624, DOI 10.1126/science.7624786; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; EKPINI E, 1994, 10TH INT C AIDS YOK; Gillespie S., 1989, Land Use Policy, V6, P301, DOI 10.1016/0264-8377(89)90022-7; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P335; HANSON K, 1992, HEALTH POLICY PLANN, V7, P315, DOI 10.1093/heapol/7.4.315; HEYMANN SJ, 1990, AM J PUBLIC HEALTH, V80, P1305, DOI 10.2105/AJPH.80.11.1305; HU DJ, 1992, AIDS, V6, P1505, DOI 10.1097/00002030-199212000-00014; *INT PROGR CTR POP, 1995, 20 INT PROGR CTR POP; *INT PROGR CTR POP, 1994, 15 US BUR CENS INT P; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; NORSE D, 1991, 7 INT C AIDS FLOR; OVER M, 1989, HEALTH POLICY, V11, P169, DOI 10.1016/0168-8510(89)90034-1; OVER M, 1988, GLOBAL IMPACT AIDS, P123; PARROTT RH, 1991, J ACQ IMMUN DEF SYND, V4, P122; SATO PA, 1994, B WORLD HEALTH ORGAN, V72, P129; SCITOVSKY AA, 1988, AIDS, V2, pS71, DOI 10.1097/00002030-198800001-00011; *UNICEF, 1995, STAT WORLDS CHILDR 1; VIRAVAIDYA M, 1993, EC IMPLICATIONS AIDS, P7; *WORLD BANK, 1994, 1994 WORLD BANK WORL; *WORLD BANK, 1992, TANZ AIDS ASS PLANN; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	29	63	63	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					139	145		10.1001/jama.276.2.139	http://dx.doi.org/10.1001/jama.276.2.139			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV485	8656506				2022-12-01	WOS:A1996UV48500029
J	Mallonee, S; Istre, GR; Rosenberg, M; ReddishDouglas, M; Jordan, F; Silverstein, P; Tunell, W				Mallonee, S; Istre, GR; Rosenberg, M; ReddishDouglas, M; Jordan, F; Silverstein, P; Tunell, W			Surveillance and prevention of residential-fire injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION	Background The majority of severe and fatal burn injuries result from residential fires. We studied the effectiveness of a smoke-alarm-giveaway program in the prevention of burn injuries in an area with a high rate of such injuries. Methods We collected data on burn injuries in Oklahoma City from September 1987 through April 1990. The target area for the intervention was an area of 24 square miles (62 km(2)) with the highest rate of injuries related to residential fires in the city. We distributed smoke alarms door to door in the target area and then surveyed alarm use and function in a sample of the homes that had received an alarm. We also calculated the rates of fire injury per 100,000 population and per 100 fires for both the target area and the rest of the city before and after the smoke-alarm giveaway. Results Before the intervention the rate of burn injuries per 100,000 population was 4.2 times higher in the target area than in the rest of Oklahoma City. An initial survey indicated that 11,881 of the 34,945 homes in the target area (34 percent) did not have smoke alarms. A total of 10,100 smoke alarms were distributed to 9291 homes; 45 percent were functioning four years later. The annualized fire-injury rates declined by 80 percent in the target area during the four years after the intervention (from 15.3 to 3.1 per 100,000 population), as compared with a small increase in the rest of the city (from 3.6 to 3.9 per 100,000 population). There was also a 74 percent de dine in the target area in the injury rate per 100 fires (from 5.0 to 1.3; rate ratio, 0.3; 95 percent confidence interval, 0.1 to 0.6), as compared with a small in crease in the rest of the city. Conclusions A targeted intervention involving a smoke-alarm-giveaway program can reduce the incidence of injuries from residential fires. (C)1996, Massachusetts Medical Society.	OKLAHOMA DEPT HLTH,EPIDEMIOL SERV,OKLAHOMA CITY,OK 73117; CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; OFF CHIEF MED EXAMINER,OKLAHOMA CITY,OK; BAPTIST MED CTR OKLAHOMA,OKLAHOMA CITY,OK; CHILDRENS HOSP OKLAHOMA,OKLAHOMA CITY,OK	Centers for Disease Control & Prevention - USA	Mallonee, S (corresponding author), OKLAHOMA DEPT HLTH,INJURY PREVENT SERV 0307,1000 NE 10TH,OKLAHOMA CITY,OK 73117, USA.				PHS HHS [R49/CCR603696] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1982, EPIDEMIOLOGIC RES; [Anonymous], COST INJURY US; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BALLARD JE, 1992, PUBLIC HEALTH REP, V107, P402; BARILLO DJ, 1986, AM SURGEON, V52, P641; BIRKY MM, 1979, FIRE MATER, V3, P211, DOI 10.1002/fam.810030406; Dean A. G., 1990, EPI INFO VERSION 5 W; HALL JR, 1983, FIRE SERV TODAY, V50, P18; HEMENWAY D, 1990, Q J ECON, V105, P1063, DOI 10.2307/2937886; ISTRE GR, 1992, PUBLIC HEALTH SURVEILLANCE, P42; JAMES KE, 1973, BIOMETRICS, V29, P121, DOI 10.2307/2529681; JERNIGAN W, 1987, FIRE J, V81, P57; Karter M J Jr, 1994, NFPA J, V88, P57; LEVINE MS, 1977, AM J PUBLIC HEALTH, V67, P1077, DOI 10.2105/AJPH.67.11.1077; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; *NAT FIR PROT AG, 1990, 901 NFPA FIR FACTS; PATETTA MJ, 1990, AM J PUBLIC HEALTH, V80, P1116, DOI 10.2105/AJPH.80.9.1116; ROSSOMANDO C, 1995, COMMUNITY BASED FIRE; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; Thacker SB, 1996, FIELD EPIDEMIOLOGY, P16; *US FIR ADM, 1990, FIR US 1983 1987; *US FIR ADM FED EM, 1980, EV RES SMOK DET PERF; 1987, JAMA-J AM MED ASSOC, V257, P1618; 1985, MMWR-MORBID MORTAL W, V34, P623; 1987, MMWR-MORBID MORTAL W, V36, P644	27	132	135	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					27	31		10.1056/NEJM199607043350106	http://dx.doi.org/10.1056/NEJM199607043350106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU479	8637539				2022-12-01	WOS:A1996UU47900006
J	Zablackis, E; York, WS; Pauly, M; Hantus, S; Reiter, WD; Chapple, CCS; Albersheim, P; Darvill, A				Zablackis, E; York, WS; Pauly, M; Hantus, S; Reiter, WD; Chapple, CCS; Albersheim, P; Darvill, A			Substitution of L-fucose by L-galactose in cell walls of Arabidopsis mur1	SCIENCE			English	Article							XYLOGLUCAN-OLIGOSACCHARIDES; STRUCTURAL-ANALYSIS; SEED XYLOGLUCAN; GROWTH; PLANTS	An Arabidopsis thaliana mutant (mur1) has less than 2 percent of the normal amounts of L-fucose in the primary cell walls of aerial portions of the plant. The survival of mur1 plants challenged the hypothesis that fucose is a required component of biologically active oligosaccharides derived from cell wall xyloglucan. However, the replacement of L-fucose (that is, 6-deoxy-L-galactose) by L-galactose does not detectably alter the biological activity of the oligosaccharides derived from xyloglucan. Thus, essential structural and conformational features of xyloglucan and xyloglucan-derived oligosaccharides are retained when L-galactose replaces L-fucose.	UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602; UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Connecticut; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Chapple, Clint CS/Q-5456-2017; Pauly, Markus/B-5895-2008	Chapple, Clint CS/0000-0002-5195-562X; Pauly, Markus/0000-0002-3116-2198				AUGUR C, 1992, PLANT PHYSIOL, V99, P180, DOI 10.1104/pp.99.1.180; BAUER WD, 1973, PLANT PHYSIOL, V51, P174, DOI 10.1104/pp.51.1.174; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; DARVILL A, 1992, GLYCOBIOLOGY, V2, P181, DOI 10.1093/glycob/2.3.181; DARVILL A, 1980, BIOCH PLANTS, V1; Feingold D. S., 1982, ENCY PLANT PHYSL A, V13A, P3; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; FRY SC, 1993, PLANT PHYSIOL, V103, P1, DOI 10.1104/pp.103.1.1; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; HALLGREN C, 1995, J CARBOHYD CHEM, V14, P453, DOI 10.1080/07328309508005350; HAYASHI T, 1984, PLANT PHYSIOL, V75, P596, DOI 10.1104/pp.75.3.596; LORENCES EP, 1990, PHYSIOL PLANTARUM, V80, P109; MCDOUGALL GJ, 1989, J EXP BOT, V40, P233, DOI 10.1093/jxb/40.2.233; MCDOUGALL GJ, 1991, J PLANT PHYSIOL, V137, P332, DOI 10.1016/S0176-1617(11)80141-0; Pauly M, 1996, CARBOHYD RES, V282, P1, DOI 10.1016/0008-6215(95)00362-2; REITER WD, 1993, SCIENCE, V261, P1032, DOI 10.1126/science.261.5124.1032; ROBERTS RM, 1973, PHYTOCHEMISTRY, V12, P2679, DOI 10.1016/0031-9422(73)85079-4; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; WATANABE T, 1980, AGR BIOL CHEM TOKYO, V44, P791, DOI 10.1080/00021369.1980.10864032; YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295; YORK WS, 1993, CARBOHYD RES, V248, P285, DOI 10.1016/0008-6215(93)84135-S; YORK WS, 1995, CARBOHYD RES, V267, P79, DOI 10.1016/0008-6215(94)00287-P; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; ZABLACKIS E, 1995, PLANT PHYSIOL, V107, P1129, DOI 10.1104/pp.107.4.1129	26	117	119	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1808	1810		10.1126/science.272.5269.1808	http://dx.doi.org/10.1126/science.272.5269.1808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650583				2022-12-01	WOS:A1996UT11000049
J	Chemello, L; Cavalletto, L; Casarin, C; Bonetti, P; Bernardinello, E; Pontisso, P; Donada, C; Belussi, F; Martinelli, S; Alberti, A				Chemello, L; Cavalletto, L; Casarin, C; Bonetti, P; Bernardinello, E; Pontisso, P; Donada, C; Belussi, F; Martinelli, S; Alberti, A			Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; THERAPY; ALFA; RNA	Objective: To define long-term outcome in patients with chronic hepatitis C who remain viremic after sustained biochemical response to interferon-alpha therapy. Design: Prospective evaluation of an outpatient cohort. Setting: University hospital. Patients: 107 patients with chronic hepatitis C who maintained normal aminotransferase levels as long as 12 months after interferon-alpha therapy. Patients were followed prospectively for an additional 6 to 36 months. Measurements: Aminotransferase levels were monitored at 3-month intervals. Serum hepatitis C virus (HCV) RNA was tested by polymerase chain reaction before therapy, at the end of therapy, and 12 months after therapy. The HCV genotype was defined by spot hybridization using serum specimens obtained before treatment, Results: Hepatitis C virus RNA was detected in 27 (25%) patients with sustained biochemical response; 80 (75%) patients were negative for HCV RNA. Patients positive for HCV RNA were older (P < 0.001), had received a smaller interferon-a dose (P = 0.02), and were more frequently infected with HCV genotype 2 (P < 0.01). Liver histologic findings were active in 57% of patients positive for HCV RNA, despite normal alanine aminotransferase levels, compared with only 12% of patients who were negative for HCV RNA (P = 0.01). The estimated probability of hepatitis relapse by 4 years after therapy was 53% in viremic patients and 0% in patients negative for HCV RNA (P < 0.001). Conclusion: Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-alpha therapy to determine whether the response is complete and permanent.	UNIV PADUA, MED CLIN 2, I-35100 PADUA, ITALY; OSPED CIVILE, DIV MED 3, I-33170 PORDENONE, ITALY; OSPED LE GRAZIE, DIV MALATTIE INFETT, I-30124 VENICE, ITALY; OSPED CIVILE CITTADELLA, DIV MED, I-35013 CITTADELLA, PD, ITALY	University of Padua; ULSS 6 Euganea; Ospedale di Cittadella			chemello, liliana/AAU-9414-2020; PONTISSO, PATRIZIA/K-3574-2018	PONTISSO, PATRIZIA/0000-0003-2077-9202; ALBERTI, ALFREDO/0000-0001-9926-2382				Casarin C., 1994, Journal of Hepatology, V21, pS62; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1002/hep.1840220303; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KASAHARA A, 1995, HEPATOLOGY, V21, P291, DOI 10.1016/0270-9139(95)90083-7; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; TISMINETZKY SG, 1994, INT HEPATOL COMMUN, V2, P105, DOI 10.1016/0928-4346(94)90020-5	12	107	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1058	1060		10.7326/0003-4819-124-12-199606150-00005	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633819				2022-12-01	WOS:A1996UQ65800005
J	Kauffman, CA				Kauffman, CA			Quandary about treatment of aspergillomas persists	LANCET			English	Editorial Material							PULMONARY ASPERGILLOMA				Kauffman, CA (corresponding author), VET AFFAIRS MED CTR,INFECT DIS SECT,ANN ARBOR,MI 48105, USA.							DIOT P, 1995, EUR RESPIR J, V8, P1263, DOI 10.1183/09031936.95.08081263; ISRAEL HL, 1982, CHEST, V82, P430, DOI 10.1378/chest.82.4.430; JEWKES J, 1983, THORAX, V38, P572, DOI 10.1136/thx.38.8.572; MASSARD G, 1992, ANN THORAC SURG, V54, P1159, DOI 10.1016/0003-4975(92)90086-J; Rumbak M, 1996, THORAX, V51, P253, DOI 10.1136/thx.51.3.253; YAMADA H, 1993, CHEST, V103, P1421, DOI 10.1378/chest.103.5.1421	6	57	58	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1640	1640		10.1016/S0140-6736(96)91481-6	http://dx.doi.org/10.1016/S0140-6736(96)91481-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642952				2022-12-01	WOS:A1996UQ70100004
J	Marks, MB; McKendry, RJR				Marks, MB; McKendry, RJR			Orthoses for rheumatoid feet: Does it matter what's underfoot?	LANCET			English	Editorial Material									UNIV OTTAWA,RHEUMAT DIS UNIT,FAC MED,OTTAWA,ON,CANADA	University of Ottawa	Marks, MB (corresponding author), UNIV OTTAWA,PHYS MED & REHABIL UNIT,FAC MED,OTTAWA,ON,CANADA.							Budiman-Mak E, 1995, J Clin Rheumatol, V1, P313, DOI 10.1097/00124743-199512000-00001; BUDIMANMAK E, 1991, J CLIN EPIDEMIOL, V44, P561, DOI 10.1016/0895-4356(91)90220-4; Conrad KJ, 1996, J CLIN EPIDEMIOL, V49, P1, DOI 10.1016/0895-4356(96)00534-3; CRACCHIOLO A, 1988, FOOT BOOK, P239; CRAXFORD AD, 1982, CLIN ORTHOP RELAT R, P121; LANG LMG, 1987, BAILLIERE CLIN RHEUM, V1, P215, DOI 10.1016/S0950-3579(87)80001-8; MERRITT JL, 1987, J RHEUMATOL, V14, P62; Philps JW, 1990, FUNCTIONAL FOOT ORTH; SMIDT L, 1987, BAILLIERE CLIN RHEUM, V1, P275, DOI 10.1016/S0950-3579(87)80004-3; TINLEY P, 1987, BAILLIERE CLIN RHEUM, V1, P383, DOI 10.1016/S0950-3579(87)80009-2	10	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1639	1639		10.1016/S0140-6736(96)91480-4	http://dx.doi.org/10.1016/S0140-6736(96)91480-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642951				2022-12-01	WOS:A1996UQ70100003
J	Alam, SM; Travers, PJ; Wung, JL; Nasholds, W; Redpath, S; Jameson, SC; Gascoigne, NRJ				Alam, SM; Travers, PJ; Wung, JL; Nasholds, W; Redpath, S; Jameson, SC; Gascoigne, NRJ			T-cell-receptor affinity and thymocyte positive selection	NATURE			English	Article							MOLECULE	DEVELOPMENT Of thymocytes involves two distinct outcomes resulting from superficially similar events, Recognition by thymocytes of major histocompatibility complex (MHC) proteins plus peptide leads to their rescue from apoptosis (positive selection), and recognition of antigenic peptide induces cell death (negative selection)(1), Antigen analogues(1-3), and sometimes low concentrations of antigenic peptide(4,5), induce positive selection; such analogues are often antagonists of mature T-cell clones(1-3,6) Various models seek to explain how recognition of different peptide/MHC complexes leads to such different outcomes(1,7-10): quantitative models relate response to the affinity, avidity or kinetics of T cell-antigen receptor (TCR) binding, whereas qualitative models require conformational or spatial changes in the TCR or associated molecules to modulate signal transduction(7,9). We have used surface plasmon resonance(11) to measure the kinetics of TCR interactions with positively and negatively selecting ligands to distinguish between these models, and find that affinity correlates to the outcome of selection. A 'window' of affinity resulting in positive selection extends over a 1-log range starting threefold below the affinity for negative selection.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV LONDON BIRKBECK COLL, DEPT CRYSTALLOG, LONDON WC1E 7HX, ENGLAND; UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	Scripps Research Institute; University of London; Birkbeck University London; University of Minnesota System; University of Minnesota Twin Cities			Alam, S. Munir/AAC-6711-2019; Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146				AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; ALRAMADI BK, 1995, J IMMUNOL, V155, P662; Arden Bernhard, 1995, Immunogenetics, V42, P501; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; JANEWAY CA, 1995, IMMUNOL TODAY, V16, P223, DOI 10.1016/0167-5699(95)80163-4; KAPPLER J, 1994, P NATL ACAD SCI USA, V91, P8462, DOI 10.1073/pnas.91.18.8462; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KELLY JM, 1993, EUR J IMMUNOL, V23, P3318, DOI 10.1002/eji.1830231239; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; SCORER CA, 1994, BIO-TECHNOL, V12, P181, DOI 10.1038/nbt0294-181; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	29	519	524	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					616	620		10.1038/381616a0	http://dx.doi.org/10.1038/381616a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637599				2022-12-01	WOS:A1996UQ65700054
J	Cui, XQ; Wise, RP; Schnable, PS				Cui, XQ; Wise, RP; Schnable, PS			The rf2 nuclear restorer gene of male-sterile T-cytoplasm maize	SCIENCE			English	Article							ZEA-MAYS L; PROTEIN; PLANTS; MITOCHONDRIA; MICROSPOROGENESIS; DEHYDROGENASE; LOCALIZATION; DISEASE; ENCODES; T-URF13	The T cytoplasm of maize serves as a model for the nuclear restoration of cytoplasmic male sterility. The rf2 gene, one of two nuclear genes required for fertility restoration in male-sterile T-cytoplasm (cmsT) maize, was cloned. The protein predicted by the rf2 sequence is a putative aldehyde dehydrogenase, which suggests several mechanisms that might explain Rf2-mediated fertility restoration in cmsT maize. Aldehyde dehydrogenase may be involved in the detoxification of acetaldehyde produced by ethanolic fermentation during pollen development, may play a role in energy metabolism or may interact with URF13, the mitochondrial protein associated with male sterility in cmsT maize.	IOWA STATE UNIV SCI & TECHNOL, DEPT AGRON, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT ZOOL & GENET, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT PLANT PATHOL, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, USDA ARS, AMES, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University; Iowa State University; United States Department of Agriculture (USDA)				Wise, Roger/0000-0001-7786-1528; Schnable, Patrick/0000-0001-9169-5204; Cui, Xiangqin/0000-0003-0621-9313				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMBROZIAK W, 1993, ADV EXP MED BIOL, V328, P5; ASKER H, 1985, PHYTOCHEMISTRY, V24, P689, DOI 10.1016/S0031-9422(00)84877-3; BARKAN A, COMMUNICATION; BUCHER M, 1994, EMBO J, V13, P2755, DOI 10.1002/j.1460-2075.1994.tb06569.x; BUCHER M, 1995, PLANT MOL BIOL, V28, P739, DOI 10.1007/BF00021197; COMSTOCK JC, 1973, PHYTOPATHOLOGY, V63, P1357, DOI 10.1094/Phyto-63-1357; DEAN C, 1985, EMBO J, V4, P3055, DOI 10.1002/j.1460-2075.1985.tb04045.x; DELONG A, 1993, CELL, V74, P757, DOI 10.1016/0092-8674(93)90522-R; DEWEY RE, 1987, P NATL ACAD SCI USA, V84, P5374, DOI 10.1073/pnas.84.15.5374; DEWEY RE, 1986, CELL, V44, P439, DOI 10.1016/0092-8674(86)90465-4; DUVICK DONALD N., 1965, ADVANCE GENET, V13, P1, DOI 10.1016/S0065-2660(08)60046-2; FLAVELL R, 1974, PLANT SCI LETT, V3, P259, DOI 10.1016/0304-4211(74)90096-0; FORDE BG, 1980, P NATL ACAD SCI-BIOL, V77, P418, DOI 10.1073/pnas.77.1.418; HACK E, 1991, PLANT PHYSIOL, V95, P861, DOI 10.1104/pp.95.3.861; HANSON MR, 1985, INT REV CYTOL, V94, P213, DOI 10.1016/S0074-7696(08)60398-8; HOOKER A L, 1970, Plant Disease Reporter, V54, P708; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KENNELL JC, 1987, MOL GEN GENET, V210, P399, DOI 10.1007/BF00327189; KENNELL JC, 1989, MOL GEN GENET, V216, P16, DOI 10.1007/BF00332225; KORTH KL, 1991, P NATL ACAD SCI USA, V88, P10865, DOI 10.1073/pnas.88.23.10865; LASER KD, 1972, BOT REV, V38, P425, DOI 10.1007/BF02860010; LAUGHNAN JR, 1983, ANNU REV GENET, V17, P27, DOI 10.1146/annurev.ge.17.120183.000331; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINGS CS, 1993, PLANT CELL, V5, P1285, DOI 10.2307/3869781; MACKENZIE S, 1994, PLANT PHYSIOL, V105, P775, DOI 10.1104/pp.105.3.775; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PRING DR, 1989, ANNU REV PHYTOPATHOL, V27, P483; PRING DR, 1988, PHILOS T ROY SOC B, V319, P187, DOI 10.1098/rstb.1988.0042; SCHNABLE PS, 1994, GENETICS, V136, P1171; TASAYCO ML, 1990, ARCH BIOCHEM BIOPHYS, V278, P444, DOI 10.1016/0003-9861(90)90283-5; ULLSTRUP AJ, 1972, ANNU REV PHYTOPATHOL, V10, P37, DOI 10.1146/annurev.py.10.090172.000345; VILLEMUR R, 1992, J MOL BIOL, V227, P81, DOI 10.1016/0022-2836(92)90683-B; WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X; WARMKE HE, 1977, J HERED, V68, P213, DOI 10.1093/oxfordjournals.jhered.a108817; WISE RP, 1994, THEOR APPL GENET, V88, P785, DOI 10.1007/BF01253987; WISE RP, 1987, PLANT MOL BIOL, V9, P121, DOI 10.1007/BF00015644; WISE RP, IN PRESS GENETICS; YODER OC, 1973, PHYTOPATHOLOGY, V63, P1361, DOI 10.1094/Phyto-63-1361	39	301	381	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1334	1336		10.1126/science.272.5266.1334	http://dx.doi.org/10.1126/science.272.5266.1334			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650543				2022-12-01	WOS:A1996UN47200045
J	Taggart, AKP; Pugh, BF				Taggart, AKP; Pugh, BF			Dimerization of TFIID when not bound to DNA	SCIENCE			English	Article							BINDING-PROTEIN; TRANSCRIPTION	For unknown reasons, the eukaryotic transcription factor TFIID inefficiently recognizes promoters. Human TFIID was found to form highly specific homodimers that must dissociate before DNA binding. TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID. Chemical cross-linking experiments in HeLa cells revealed the presence of TBP dimers in vivo. These findings suggest that dimerization through TBP is the physiological state of TFIID when not bound to DNA. Thus, the inefficiency of TFIID binding to a promoter may be partly attributable to the competitive effect of dimerization.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1994, CURRENT PROTOCOLS MO; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1995, IN VITRO TRANSCRIPTI, V37, P359; TAGGART AK, 1994, NUCLEIC ACIDS RES, V22, P1179; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P55; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	16	56	56	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1331	1333		10.1126/science.272.5266.1331	http://dx.doi.org/10.1126/science.272.5266.1331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650542				2022-12-01	WOS:A1996UN47200044
J	Asch, DA				Asch, DA			The role of critical care nurses in euthanasia and assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTARY EUTHANASIA; ATTITUDES	Background. Euthanasia and assisted suicide have received considerable attention recently in medical literature, public discussion, and proposed state legislation. Almost all the discussion in this area has focused on the role of physicians. However, nurses - especially critical care nurses - may be in a special position to understand the wishes of patients and to act on this understanding. Methods. I mailed a survey to 1600 critical care nurses in the United States, asking them to describe anonymously any requests from patients, family members or others acting for patients (surrogates), or physicians to perform euthanasia or assisted suicide, as well as their own practices. Results. Of the 1139 nurses who responded (71 percent), 852 said they practiced exclusively in intensive care units for adults in the United States. Of these 852 nurses, 141 (17 percent) reported that they had received requests from patients or family members to perform euthanasia or assist in suicide; 129 (16 percent of those for whom data were available) reported that they had engaged in such practices; and an additional 35 (4 percent) reported that they had hastened a patient's death by only pretending to provide life-sustaining treatment ordered by a physician. Some nurses reported engaging in these practices without the request or advance knowledge of physicians or others. The method of euthanasia most commonly described was the administration of a high dose of an opiate to a terminally ill patient. Conclusions. As public debate continues about euthanasia and assisted suicide, some critical care nurses in the United States are engaging in such practices. (C) 1995, Massachusetts Medical Society.	VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,CTR BIOETH,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania				Asch, David/0000-0002-7970-286X				*AM NURS ASS, 1994, POS STAT ACT EUTH; ANDERSON JG, 1993, SOC SCI MED, V37, P105, DOI 10.1016/0277-9536(93)90323-V; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ASCH DA, 1995, CRIT CARE MED, V151, P288; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BLACKSHER EA, 1995, HASTINGS CENT REP, V25, P47; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; KUHSE H, 1993, INT J NURS STUD, V30, P311, DOI 10.1016/0020-7489(93)90103-2; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; Kuhse H, 1992, Aust Nurses J, V21, P21; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Stevens C A, 1994, Med Law, V13, P541; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; Young A, 1993, Oncol Nurs Forum, V20, P445; 1988, JAMA-J AM MED ASSOC, V259, P272; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	174	178	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1374	1379		10.1056/NEJM199605233342106	http://dx.doi.org/10.1056/NEJM199605233342106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL251	8614424				2022-12-01	WOS:A1996UL25100006
J	Miller, G; Rigsby, MO; Heston, L; Grogan, E; Sun, R; Metroka, C; Levy, JA; Gao, SJ; Chang, Y; Moore, P				Miller, G; Rigsby, MO; Heston, L; Grogan, E; Sun, R; Metroka, C; Levy, JA; Gao, SJ; Chang, Y; Moore, P			Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; CYTOMEGALO-VIRUS; CELLS; EXPRESSION; DNA; ACTIVATION; SEQUENCES; PROTEINS; AIDS; GENE	Background. The recent identification in patients with Kaposi's sarcoma of DNA sequences with homology to gammaherpesviruses has led to the hypothesis that a newly identified virus, Kaposi's sarcoma-associated herpeslike virus (KSHV), has a role in the pathogenesis of Kaposi's sarcoma. We developed serologic markers for KSHV infection. Methods. KSHV antigens were prepared from a cell line (BC-1) that contains the genomes of both KSHV and the Epstein-Barr virus (EBV). We used immunoblot and immunofluorescence assays to examine serum samples from 102 patients with human immunodeficiency virus type 1 (HIV-1) infection for antibodies to KSHV-associated proteins and to distinguish these antibodies from antibodies to EBV antigens. A positive serologic response was defined by the recognition of an antigenic polypeptide, p40, in n-butyrate-treated BC-1 cells and by the absence of p40 recognition in untreated BC-1 cells or EBV-infected, KSHV-negative cells. The detection by the immunofluorescence assay of 10 to 20 times more antigen-positive cells in n-butyrate-treated BC-1 cells than in untreated cells was considered a positive response. Results. Antibodies to the p40 antigen expressed by chemically treated BC-1 cells were identified in 32 of 48 HIV-1-infected patients with Kaposi's sarcoma (67 percent), as compared with only 7 of 54 HIV-1-infected patients without Kaposi's sarcoma (13 percent). These results were confirmed by an immunofluorescence assay. The positive predictive value of the serologic tests for Kaposi's sarcoma was 82 percent, and the negative predictive value 75 percent. Conclusions. The presence of antibodies to a KSHV antigenic peptide correlates with the presence of Kaposi's sarcoma in a high-risk population and provides further evidence of an etiologic role for KSHV.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, NEW YORK, NY USA	Yale University; Yale University; Yale University; Yale University; Mount Sinai St. Luke's; Mount Sinai West; University of California System; University of California San Francisco; Columbia University; Columbia University	Miller, G (corresponding author), YALE UNIV, SCH MED, DEPT PEDIAT, 333 CEDAR ST, RM 420 LSOG, NEW HAVEN, CT 06520 USA.		Moore, Patrick/GVR-8294-2022; Gao, Shou-Jiang/B-8641-2012; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL CANCER INSTITUTE [R01CA070036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022959] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70036] Funding Source: Medline; NIAID NIH HHS [AI 22959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AMBINDER RF, 1987, J INFECT DIS, V156, P193, DOI 10.1093/infdis/156.1.193; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1991, CANCER SURV, V10, P5; BERAL V, 1992, CANCER SURV, V12, pA225; BOSHOFF C, 1995, LANCET, V345, P1043; BURNS LJ, 1988, BLOOD, V72, P1536; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GALLANT JE, 1994, ARCH INTERN MED, V154, P566, DOI 10.1001/archinte.154.5.566; GIRALDO G, 1980, INT J CANCER, V26, P23, DOI 10.1002/ijc.2910260105; GORDON JA, 1972, CENT AFR J MED, V19, P1; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; JAHAN N, 1989, AIDS RES HUM RETROV, V5, P225, DOI 10.1089/aid.1989.5.225; Kaposi M., 1872, ARCH DERMATOL SYPH-G, V4, P265, DOI 10.1007/BF01830024; KNOWLES DM, 1989, BLOOD, V73, P792; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOETHE F, 1963, ACTA PATHOL MIC SC, V161, P1; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RABSON M, 1983, P NATL ACAD SCI-BIOL, V80, P2762, DOI 10.1073/pnas.80.9.2762; SAFAI B, 1980, CLIN BULL, V10, P62; SCHALLING M, 1995, NAT MED, V1, P705; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGRUNSVEN WMJ, 1993, J VIROL, V67, P3908, DOI 10.1128/JVI.67.7.3908-3916.1993; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; ZURHAUSEN H, 1978, NATURE, V272, P373; 1981, MMWR-MORBID MORTAL W, V30, P305	39	222	234	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1292	1297		10.1056/NEJM199605163342003	http://dx.doi.org/10.1056/NEJM199605163342003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609946				2022-12-01	WOS:A1996UK88000003
J	Pestotnik, SL; Classen, DC; Evans, RS; Burke, JP				Pestotnik, SL; Classen, DC; Evans, RS; Burke, JP			Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes	ANNALS OF INTERNAL MEDICINE			English	Article						practice guidelines; antibiotics; outcome and process assessment (health care); decision making, computer-assisted; cost-benefit analysis	EDUCATIONAL ORDER FORM; ANTIMICROBIAL AGENTS; PRESCRIBING PATTERNS; SURVEILLANCE; INFECTIONS; QUALITY; SYSTEM; REMINDERS; MISUSE; CARE	Objective: To determine the clinical and financial outcomes of antibiotic practice guidelines implemented through computer-assisted decision support. Design: Descriptive epidemiologic study and financial analysis. Setting: 520-bed community teaching hospital in Salt Lake City, Utah. Patients: All 162 196 patients discharged from LDS Hospital between 1 January 1988 and 31 December 1994. Intervention: An antibiotic management program that used local clinician-derived consensus guidelines embedded in computer-assisted decision support programs. Prescribing guidelines were developed for inpatient prophylactic, empiric, and therapeutic uses of antibiotics. Measurements: Measures of antibiotic use included timing of preoperative antibiotic administration and duration of postoperative antibiotic use. Clinical outcomes included rates of adverse drug events, patterns of antimicrobial resistance, mortality, and length of hospital stay. Financial and use outcomes were expressed as yearly expenditures for antibiotics and defined daily doses per 100 occupied bed-days. Results: During the 7-year study period, 63 759 hospitalized patients (39.3%) received antibiotics. The proportion of the hospitalized patients who received antibiotics increased each year, from 31.8% in 1988 to 53.1% in 1994. Use of broad-spectrum antibiotics increased from 24% of all antibiotic use in 1988 to 47% in 1994. The annual Medicare case-mix index increased from 1.7481 in 1988 to 2.0520 in 1993. Total acquisition costs of antibiotics (adjusted for inflation) decreased from 24.8% ($987 547) of the pharmacy drug expenditure budget in 1988 to 12.9% ($612 500) in 1994. Antibiotic costs per treated patient (adjusted for inflation) decreased from $122.66 per patient in 1988 to $51.90 per patient in 1994. Analysis using a standardized method (defined daily doses) to compare antibiotic use showed that antibiotic use decreased by 22.8% overall. Measures of antibiotic use and clinical outcomes improved during the study period. The percentage of patients having surgery who received appropriately timed preoperative antibiotics increased from 40% in 1988 to 99.1% in 1994. The average number of antibiotic doses administered for surgical prophylaxis was reduced from 19 doses in the base year to 5.3 doses in 1994. Antibiotic-associated adverse drug events decreased by 30%. During the study, antimicrobial resistance patterns were stable, and length of stay remained the same. Mortality rates decreased from 3.65% in 1988 to 2.65% in 1994 (P < 0.001). Conclusions: Computer-assisted decision support programs that use local clinician-derived practice guidelines can improve antibiotic use, reduce associated costs, and stabilize the emergence of antibiotic-resistant pathogens.	LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, SALT LAKE CITY, UT 84143 USA				Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BERMAN JR, 1992, AM J HOSP PHARM, V49, P1701, DOI 10.1093/ajhp/49.7.1701; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BURKE JP, 1991, J HOSP INFECT, V18, P424, DOI 10.1016/0195-6701(91)90052-A; BURKE JP, 1995, CURR OPIN INFECT DIS, V8, P269, DOI 10.1097/00001432-199508000-00009; BURKE JP, 1992, ASSESSING QUALITY HL, P509; CLASSEN D, 1993, THESIS U UTAH SALT L; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; COL NF, 1987, REV INFECT DIS, V9, pS232; DUNAGAN WC, 1991, REV INFECT DIS, V13, P405; DUNAGAN WC, 1993, DIAGN MICR INFEC DIS, V16, P265, DOI 10.1016/0732-8893(93)90120-V; EAST TD, 1991, INT J CLIN MONIT COM, V8, P263, DOI 10.1007/BF01739127; ECHOLS RM, 1984, J INFECT DIS, V150, P803, DOI 10.1093/infdis/150.6.803; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; EVANS RS, 1993, M D COMPUT, V10, P17; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1990, DICP ANN PHARMAC, V24, P351, DOI 10.1177/106002809002400401; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GROSSKOPF S, 1993, MED CARE, V31, P525, DOI 10.1097/00005650-199306000-00006; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; HUTH TS, 1991, INFECT CONT HOSP EP, V12, P525; James B C, 1993, Front Health Serv Manage, V10, P3; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KUNIN CM, 1990, REV INFECT DIS, V12, P12; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LEE KR, 1994, INFECT CONT HOSP EP, V15, P710, DOI 10.2307/30148337; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; McDonald CJ, 1996, ANN INTERN MED, V124, P170, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00018; MCGOWAN JE, 1994, INFECT CONT HOSP EP, V15, P478; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P993; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P989; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P983; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; PESTOTNIK SL, 1993, THESIS U UTAH SALT L; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; PRYOR TA, 1990, INT J CLIN MONIT COM, V7, P137, DOI 10.1007/BF02915578; RILEY DK, 1994, 4 ANN M SOC HOSP EP; RYAN BA, 1993, AM J HOSP PHARM, V50, pS3, DOI 10.1093/ajhp/50.8_Suppl_4.S3; SANTELL JP, 1995, AM J HEALTH-SYST PH, V52, P151, DOI 10.1093/ajhp/52.2.151; SHULKIN DJ, 1993, AM J HOSP PHARM, V50, pS8, DOI 10.1093/ajhp/50.8_Suppl_4.S8; SLOAN FA, 1993, MED CARE, V31, P851, DOI 10.1097/00005650-199310000-00001; SOUMERAI SB, 1993, MED CARE, V31, P552, DOI 10.1097/00005650-199306000-00009; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; Volpp K G, 1994, JAMA, V271, P1370, DOI 10.1001/jama.271.17.1370; WALKER RD, 1994, WESTERN J MED, V161, P39; Wilson C N, 1994, Hosp Pharm, V29, P961; WILSON CN, 1994, HOSP PHARM, V29, P961; WILSON CN, 1994, HOSP PHARM, V29, P964	65	457	462	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					884	+		10.7326/0003-4819-124-10-199605150-00004	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610917				2022-12-01	WOS:A1996UJ80100004
J	Collignon, J; Varlet, I; Robertson, EJ				Collignon, J; Varlet, I; Robertson, EJ			Relationship between asymmetric nodal expression and the direction of embryonic turning	NATURE			English	Article							MOUSE EMBRYO; AUTORADIOGRAPHIC ANALYSIS; GASTRULATION; MUTATION; ECTODERM; POTENCY; FATE	GROWTH factors related to TGF-beta provide important signals for patterning the vertebrate body plan(1-3), One such family member, nodal, is required for formation of the primitive streak during mouse gastrulation(4-6), Here we have used a nodal-lacZ reporter allele to demonstrate asymmetric nodal expression in the mouse node, a structure thought to be the functional equivalent of the frog and chick 'organizer'(7), and in lateral plate mesoderm cells, We have also identified two additional genes acting with nodal in a pathway determining the left-right body axis. Thus we observe in inv mutant embryos(8) that the sidedness of nodal expression correlates with the direction of heart looping and embryonic turning, In contrast, HNF3-beta(+/-) nodal(lacZ/+) double-heterozygous embryos display LacZ staining on both left and right sides, and frequently exhibit defects in body situs, Taken together, these experiments, along with similar findings in chick(9), demonstrate that elements of the genetic pathway that establish the left-right body axis are conserved in vertebrates.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			collignon, jerome/K-8148-2017	Collignon, Jerome/0000-0002-1212-4006				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Conlon Frank, 1995, Seminars in Developmental Biology, V6, P249, DOI 10.1016/S1044-5781(06)80050-2; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Hogan B., 2014, MANIPULATING MOUSE E; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MARTI E, 1995, DEVELOPMENT, V121, P2537; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NEITO MA, 1992, DEVELOPMENT, V116, P227; PARAMESWARAN M, 1995, DEV GENET, V17, P16, DOI 10.1002/dvg.1020170104; POIRIER F, 1993, DEVELOPMENT, V119, P1229; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SMITH JL, 1994, DEV DYNAM, V201, P279, DOI 10.1002/aja.1002010310; TAM PPL, 1987, DEVELOPMENT, V99, P109; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	478	496	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					155	158		10.1038/381155a0	http://dx.doi.org/10.1038/381155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610012				2022-12-01	WOS:A1996UK13900049
J	Lucas, A; Morley, R; Fewtrell, MS				Lucas, A; Morley, R; Fewtrell, MS			Low triiodothyronine concentration in preterm infants and subsequent intelligence quotient (IQ) at 8 year follow up	BRITISH MEDICAL JOURNAL			English	Article											Lucas, A (corresponding author), MRC,DUNN NUTR UNIT,INFANT & CHILD NUTR GRP,CAMBRIDGE CB4 1XJ,ENGLAND.							BAKER BA, 1988, ARCH DIS CHILD, V63, P1198, DOI 10.1136/adc.63.10.1198; BRASEL JA, 1975, PERINATAL THYROID PH, P59; LUCAS A, 1994, ARCH DIS CHILD, V71, P288, DOI 10.1136/adc.71.4.288; LUCAS A, 1990, ARCH DIS CHILD, V65, P977, DOI 10.1136/adc.65.9.977; LUCAS A, 1988, ARCH DIS CHILD, V63, P1202	5	90	90	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1132	1133						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620130				2022-12-01	WOS:A1996UK06900023
J	Pell, J; Gruer, L; Christie, P; Goldberg, D				Pell, J; Gruer, L; Christie, P; Goldberg, D			Management of HIV infected health care workers: Lessons from three cases	BRITISH MEDICAL JOURNAL			English	Article								Three cases in which doctors in Glasgow were diagnosed as having HIV infection were all handled differently in relation to telling patients and the media. In the first patients were not told because the doctor had been doing administrative work and there was thought to be no risk to patients; although the media did report the case, it accepted the assurances given. In the second case, where a doctor had done many jobs in different specialities and places, the media identified the doctor before most patients had been informed: most calls to the helpline subsequently set up by the health authority were fi om patients who had not been treated bg this doctor. This episode, however, allowed the incident team to be prepared for the next case, enabling the helpline to be established swiftly. In this case the doctor voluntarily identified himself, and this served to allay public fears and reduce the number of inappropriate calls to the helpline.	RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW J20 9NB,LANARK,SCOTLAND		Pell, J (corresponding author), GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G1 1ET,LANARK,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				BEIL DM, 1991, 7 INT C AIDS FLOR I; CHRISTIE P, 1994, HIV INFECTED HEALTHC; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Heptonstall J, 1995, OCCUPATIONAL TRANSMI; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PELL J, 1995, LANCET, V346, P1425, DOI 10.1016/S0140-6736(95)92439-6; PELL JP, 1994, HIV INFECTED HLTH CA; STARK C, 1994, BRIT MED J, V309, P44, DOI 10.1136/bmj.309.6946.44; *UK DEP HLTH, 1993, AIDS HIV INF HLTH CA; 1990, MMWR-MORBID MORTAL W, V39, P489	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1150	1152						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620136	Green Published			2022-12-01	WOS:A1996UK06900031
J	Chin, YE; Kitagawa, M; Su, WCS; You, ZH; Iwamoto, Y; Fu, XY				Chin, YE; Kitagawa, M; Su, WCS; You, ZH; Iwamoto, Y; Fu, XY			Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1	SCIENCE			English	Article							GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; INTERFERON-ALPHA; TRANSCRIPTION FACTOR; C-FOS; STIMULATED TRANSCRIPTION; ACTIVATION; ISGF3; PHOSPHORYLATION; EGF	Signal transducers and activators of transcription (STAT) proteins can be conditionally activated in response to epidermal growth factor (EGF) and interferon (IFN)-gamma. STAT activation was correlated with cell growth inhibition in response to EGF and IFN-gamma. Activated STAT proteins' specifically recognized the conserved STAT-responsive elements in the promoter of the gene encoding the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/CIP1) and regulated the induction of p21 messenger RNA. IFN-gamma did not inhibit the growth of U3A cells, which are deficient in STAT1, but did inhibit the growth of U3A cells into which STAT1 alpha was reintroduced. Thus, STAT1 protein is essential for cell growth suppression in response to IFN-gamma. The STAT signaling pathway appears to negatively regulate the cell cycle by inducing CDK inhibitors in response to cytokines.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520	Yale University			Kitagawa, Motoo/W-8468-2019; You, Zhu-Hong/AAI-6862-2020	Kitagawa, Motoo/0000-0003-1036-840X; Su, Wu-Chou/0000-0003-2953-4105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34522] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FU XY, 1995, INDUCIBLE GENE EXPRE, V2, P99; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KITAGAWA M, UNPUB; KWOK TT, 1994, CANCER RES, V54, P2834; LAMER AC, 1993, SCIENCE, V261, P1730; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOU Z, UNPUB; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; [No title captured]	44	712	740	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					719	722		10.1126/science.272.5262.719	http://dx.doi.org/10.1126/science.272.5262.719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614832				2022-12-01	WOS:A1996UJ05100050
J	LaSalle, JM; Lalande, M				LaSalle, JM; Lalande, M			Homologous association of oppositely imprinted chromosomal domains	SCIENCE			English	Article							INSITU HYBRIDIZATION; NUCLEI; TRANSVECTION; REPLICATION; DROSOPHILA	Human chromosome 15q11-q13 encompasses the Prader-Willi syndrome (PWS) and the Angelman syndrome (AS) loci, which are subject to parental imprinting, a process that marks the parental origin of certain chromosomal subregions. A temporal and spatial association between maternal and paternal chromosomes 15 was observed in human T lymphocytes by three-dimensional fluorescence in situ hybridization. This association occurred specifically at the imprinted 15q11-q13 regions only during the late S phase of the cell-cycle. Cells from PWS and AS patients were deficient in association, which suggests that normal imprinting involves mutual recognition and preferential association of maternal and paternal chromosomes 15.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,GENET DIV,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			LaSalle, Janine M./A-4643-2008	LaSalle, Janine M./0000-0002-3480-2031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030628] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS30628] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOTTANI A, 1994, AM J MED GENET, V51, P35, DOI 10.1002/ajmg.1320510109; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CROUSE HV, 1960, GENETICS, V45, P1429; EMMERICH P, 1989, EXP CELL RES, V181, P126, DOI 10.1016/0014-4827(89)90188-2; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LALANDE M, 1994, NAT GENET, V8, P5, DOI 10.1038/ng0994-5; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LASALLE JM, UNPUB; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LESKO SA, 1995, EXP CELL RES, V219, P499, DOI 10.1006/excr.1995.1258; LEWIS JP, 1993, HUM GENET, V92, P577, DOI 10.1007/BF00420942; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PIRROTTA V, 1990, BIOESSAYS, V12, P409, DOI 10.1002/bies.950120903; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Robinson W. P., 1993, European Journal of Human Genetics, V1, P280; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TSAI JY, 1991, GENETICS, V129, P1159; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	32	209	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					725	728		10.1126/science.272.5262.725	http://dx.doi.org/10.1126/science.272.5262.725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614834				2022-12-01	WOS:A1996UJ05100052
J	Rudel, T; Schmid, A; Benz, R; Kolb, HA; Lang, F; Meyer, TF				Rudel, T; Schmid, A; Benz, R; Kolb, HA; Lang, F; Meyer, TF			Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: Parallels between pathogen accommodation and mitochondrial endosymbiosis	CELL			English	Article							OUTER-MEMBRANE PROTEINS; DEPENDENT ANION CHANNEL; HUMAN EPITHELIAL-CELLS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; LIPID BILAYERS; GONOCOCCAL-INFECTION; SELECTIVE CHANNELS; RECEPTOR PROTEIN; BACTERIAL PORIN	PorB of the pathogenic Neisseria species belongs to the large family of pore-forming proteins (porins) produced by gram-negative bacteria. PorB is exceptional in that it is capable of translocating vectorially into membranes of infected target cells and functions in the infection process. Here we report on an unexpected similarity between Neisserial PorB and mitochondrial porins. Both porin classes interact with purine nucleoside triphosphates, which down-regulate pore size and cause a shift in voltage dependence and ion selectivity. Patch-clamp analyses indicate that PorB channel activity is tightly regulated in intact epithelial cells. In light of recent findings on the pivotal role of PorB in virulence and the prevention of phagosome lysosome fusion, these data provide important mechanistic clues on the intracellular pathogen accommodation reminiscent of mitochondrial endosymbiosis.	MAX PLANCK INST BIOL, INFEKT BIOL ABT, D-72076 TUBINGEN, GERMANY; MAX PLANCK INST INFEKT BIOL, MOLEK BIOL ABT, D-10117 BERLIN, GERMANY; UNIV WURZBURG, THEODOR BOVERI INST BIOZENTRUM, LEHRSTUHL BIOTECHNOL, D-97074 WURZBURG, GERMANY; UNIV TUBINGEN, INST PHYSIOL 1, D-72076 TUBINGEN, GERMANY	Max Planck Society; Max Planck Society; University of Wurzburg; Eberhard Karls University of Tubingen			Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679; Benz, Roland/0000-0002-9510-9265				BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BENZ R, 1992, BIOL CHEM H-S, V373, P295, DOI 10.1515/bchm3.1992.373.1.295; Benz R., 1994, BACTERIAL CELL WALL, P397; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Blake M.S., 1985, PATHOGENESIS BACTERI, P51; BLAKE MS, 1987, BACTERIAL OUTER MEMB, P377; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; FISCHER K, 1994, J BIOL CHEM, V269, P25754; FLORKE H, 1994, BIOL CHEM H-S, V375, P513, DOI 10.1515/bchm3.1994.375.8.513; GRAY PTA, 1984, PROC R SOC SER B-BIO, V221, P395, DOI 10.1098/rspb.1984.0041; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HAINES KA, 1988, J BIOL CHEM, V263, P945; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANCOCK REW, 1982, J BACTERIOL, V150, P730, DOI 10.1128/JB.150.2.730-738.1982; HANCOCK REW, 1992, J BACTERIOL, V174, P471, DOI 10.1128/jb.174.2.471-476.1992; HITCHCOCK PJ, 1989, CLIN MICROBIOL REV, V2, pS64, DOI 10.1128/CMR.2.Suppl.S64-S65.1989; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; JALONEN T, 1989, ACTA PHYSIOL SCAND, V136, P611, DOI 10.1111/j.1748-1716.1989.tb08709.x; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KOLB HA, 1991, REV PHYSIOL BIOCH P, V118, P1; KOLB HA, 1987, BIOCHIM BIOPHYS ACTA, V899, P239, DOI 10.1016/0005-2736(87)90405-6; KOLB HA, 1985, PFLUG ARCH EUR J PHY, V403, P262, DOI 10.1007/BF00583597; KONIG U, 1991, BIOL CHEM H-S, V372, P565, DOI 10.1515/bchm3.1991.372.2.565; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3818, DOI 10.1073/pnas.75.8.3818; KRIEGERBRAUER HJ, 1980, ARCH MICROBIOL, V124, P233, DOI 10.1007/BF00427732; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MAIER C, 1988, J BIOL CHEM, V263, P2493; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; MARRERO H, 1991, EUR J NEUROSCI, V3, P813, DOI 10.1111/j.1460-9568.1991.tb01677.x; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MCGEE ZA, 1981, J INFECT DIS, V143, P413, DOI 10.1093/infdis/143.3.413; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NELSON DJ, 1984, J MEMBRANE BIOL, V80, P81, DOI 10.1007/BF01868692; NEWHALL WJ, 1980, INFECT IMMUN, V28, P785; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SANDSTROM EG, 1984, SEX TRANSM DIS, V11, P77, DOI 10.1097/00007435-198404000-00005; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SCHWARZE W, 1984, PFLUG ARCH EUR J PHY, V402, P281, DOI 10.1007/BF00585511; SHAFER WM, 1989, ANNU REV MICROBIOL, V43, P121; SIEHNEL RJ, 1988, MOL MICROBIOL, V2, P347, DOI 10.1111/j.1365-2958.1988.tb00038.x; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TOKUNAGA H, 1981, J BIOL CHEM, V256, P8024; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1988, BIOCHIM BIOPHYS ACTA, V938, P493, DOI 10.1016/0005-2736(88)90148-4; TROLL H, 1992, J BIOL CHEM, V267, P21072; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; VIRJI M, 1992, MOL MICROBIOL, V6, P2785, DOI 10.1111/j.1365-2958.1992.tb01458.x; WARD MJ, 1992, FEMS MICROBIOL LETT, V94, P283, DOI 10.1111/j.1574-6968.1992.tb05332.x; WEEL JFL, 1991, RES MICROBIOL, V142, P985, DOI 10.1016/0923-2508(91)90009-Y; WEEL JFL, 1991, J EXP MED, V174, P705, DOI 10.1084/jem.174.3.705; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WHITIN JC, 1980, J BIOL CHEM, V255, P1874; ZIZI M, 1994, J BIOL CHEM, V269, P1614	81	95	99	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					391	402		10.1016/S0092-8674(00)81117-4	http://dx.doi.org/10.1016/S0092-8674(00)81117-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616894	Bronze, Green Published			2022-12-01	WOS:A1996UK14000012
J	Naylor, CD; Sermer, M; Chen, EL; Sykora, K				Naylor, CD; Sermer, M; Chen, EL; Sykora, K			Cesarean delivery in relation to birth weight and gestational glucose tolerance - Pathophysiology or practice style?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; SHOULDER DYSTOCIA; SCREENING-TESTS; PREGNANCY; COMPLICATIONS; CRITERIA; SECTION; REPRESENT; ONTARIO	Objectives.-To examine the relationship between birth weight and mode of delivery among women with untreated borderline gestational diabetes mellitus (GDM), treated overt GDM, and normoglycemia. Design.-Prospective cohort study. Setting.-Three Toronto, Ontario, teaching hospitals. Patients.-A total of 3778 volunteers aged 24 years or older. Interventions.-Subjects underwent a 3-hour, 100-g oral glucose tolerance test at 28 weeks' gestation, regardless of screening test results. Usual care was provided to 143 women who met the National Diabetes Data Group criteria for GDM, Physicians were blinded to glucose test results for all others, including 115 untreated women with borderline GDM by the broader criteria of Carpenter and Coustan. Main Outcome Measures.-Crude and adjusted rates of cesarean delivery and neonatal macrosomia (birth weight >4000 g). Results.-Compared with normoglycemic controls, the untreated borderline GDM group had increased rates of macrosomia (28.7% vs 13.7%, P<.001) and cesarean delivery (29.6% vs 20.2%, P=.02). Cesarean delivery in this subgroup was associated with macrosomia (45.5% vs 23.5%, P=.03). Usual care of known GDM normalized birth weights, but the cesarean delivery rate was about 33% whether macrosomia was present or absent. A clearly increased risk of cesarean delivery among treated patients compared with normoglycemic controls persisted after adjustment for multiple maternal risk factors (adjusted odds ratio, 2.1; 95% confidence interval, 1.3 to 3.6). Conclusions.-Infant macrosomia was a mediating factor in high cesarean delivery rates for women with untreated borderline GDM, While detection and treatment of GDM normalized birth weights, rates of cesarean delivery remained inexplicably high. Recognition of GDM may lead to a lower threshold for surgical delivery that mitigates the potential benefits of treatment.	UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,SUNNYBROOK UNIT,TORONTO,ON M5S 1A1,CANADA; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto								ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; ANDERSON GM, 1989, CAN MED ASSOC J, V141, P1049; BUCHANAN TA, 1994, DIABETES CARE, V17, P275, DOI 10.2337/diacare.17.4.275; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CATALANO PM, 1986, AM J OBSTET GYNECOL, V155, P1255, DOI 10.1016/0002-9378(86)90155-9; Freinkel N, 1985, Diabetes, V34 Suppl 2, P1; GABBE SG, 1986, NEW ENGL J MED, V315, P1025, DOI 10.1056/NEJM198610163151609; GOLDMAN M, 1991, DIABETES, V40, P79, DOI 10.2337/diab.40.2.S79; HARRIS MI, 1988, DIABETES CARE, V11, P402, DOI 10.2337/diacare.11.5.402; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HUNTER DS, 1991, EFFECTIVE CARE PREGN, P403; JACOBSON JD, 1989, AM J OBSTET GYNECOL, V161, P981, DOI 10.1016/0002-9378(89)90767-9; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LANGER O, 1991, AM J OBSTET GYNECOL, V165, P831, DOI 10.1016/0002-9378(91)90424-P; LANGER O, 1994, AM J OBSTET GYNECOL, V170, P1036, DOI 10.1016/S0002-9378(94)70097-4; LEIKIN EL, 1987, OBSTET GYNECOL, V69, P570; LINDSAY MK, 1989, OBSTET GYNECOL, V73, P103; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LUCAS MJ, 1993, OBSTET GYNECOL, V82, P260; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Metzger B E, 1985, Diabetes, V34 Suppl 2, P111; MODANLOU HD, 1982, OBSTET GYNECOL, V60, P417; NAYLOR CD, 1989, DIABETES CARE, V12, P565, DOI 10.2337/diacare.12.8.565; O'Sullivan JB, 1979, CARBOHYD METABOL, P425; OSULLIVAN JB, 1964, DIABETES, V13, P278; SACKS DA, 1989, AM J OBSTET GYNECOL, V161, P638, DOI 10.1016/0002-9378(89)90369-4; SAS Institute Inc, 1990, SAS STAT US GUID VER, P1; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607, DOI 10.1016/0002-9378(94)90072-8; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; WALKINSHAW SA, 1993, PREGNANCY CHILDBIRTH; 1985, DIABETES S2, V34, P123; 1979, DIABETES, V28, P1039	34	262	269	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1165	1170		10.1001/jama.275.15.1165	http://dx.doi.org/10.1001/jama.275.15.1165			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609683				2022-12-01	WOS:A1996UE62500027
J	Jansen, RP; Dowzer, C; Michaelis, C; Galova, M; Nasmyth, K				Jansen, RP; Dowzer, C; Michaelis, C; Galova, M; Nasmyth, K			Mother cell-specific HO expression in budding yeast depends on the unconventional myosin myo4p and other cytoplasmic proteins	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLE REGULATION; TRANSCRIPTION; GENE; ASYMMETRY; DIVISION	Certain cell types give rise to progeny that adopt different patterns of gene expression in the absence of any differences in their environment. Cells of budding yeast give birth to mother and daughter cells that differ in that only mother cells express the HO endonuclease gene and thereby switch mating types. We describe the identification of five genes, called SHE1-SHE5, that encode cytoplasmic proteins required for mother-specific HO expression. She1p, which is identical to the minimyosin Myo4p, and She3p are not, however, mother-specific proteins. On the contrary, they accumulate in growing buds. She proteins might be required for the transport of factors that promote HO repression from the mother cell into its bud. In an accompanying paper, we show that SHE genes are needed for the accumulation in daughter nuclei of Ash1p, a repressor of HO.			Jansen, RP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				BECAM AM, 1994, YEAST, V10, P1; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAARER BK, 1994, J CELL SCI, V107, P1055; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927	36	260	262	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					687	697		10.1016/S0092-8674(00)81047-8	http://dx.doi.org/10.1016/S0092-8674(00)81047-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625407	Bronze			2022-12-01	WOS:A1996TZ99000007
J	Wiertz, EJHJ; Jones, TR; Sun, L; Bogyo, M; Geuze, HJ; Ploegh, HL				Wiertz, EJHJ; Jones, TR; Sun, L; Bogyo, M; Geuze, HJ; Ploegh, HL			The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol	CELL			English	Article							COMPLEX CLASS-I; TRANSLOCATION; EXPRESSION; STABILITY; ANTIGENS; SEC61P	Human cytomegalovirus (HCMV) down-regulates expression of MHC class I products by selective proteolysis. A single HCMV gene, US11, which encodes an endoplasmic reticulum (ER) resident type-I transmembrane glycoprotein, is sufficient to cause this effect. In US11(+) cells, MHC class I molecules are core-glycosylated and therefore inserted into the ER. They are degraded with a half-time of less than 1 min. A full-length breakdown intermediate that has lost the single N-linked glycan in an N-glycanase-catalyzed reaction transiently accumulates in cells exposed to the protease inhibitors LLnL, Cbz-LLL, and lactacystin, identifying the proteasome as a key protease. Subcellular fractionation experiments show this intermediate to be cytosolic. Thus, US11 dislocates newly synthesized class I molecules from the ER to the cytosol, where they are acted upon by an N-glycanase and the proteasome.	WYETH AYERST RES, DEPT BIOL MOLEC, INFECT DIS SECT, PEARL RIVER, NY 10965 USA; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Pfizer; Utrecht University	Wiertz, EJHJ (corresponding author), MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA.			Bogyo, Matthew/0000-0003-3753-4412	NCI NIH HHS [5-P30-CA14501] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; JONES TR, 1991, J VIROL, V65, P3742; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KIM YJ, 1994, CELL, V78, P845; LARDY HENRY A., 1965, P245; LIOU W, 1994, IMPROVED FINE STRUCT, P1; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; NEEFJES JJ, 1993, EUR J IMMUNOL, V23, P840, DOI 10.1002/eji.1830230411; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	43	898	919	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					769	779		10.1016/S0092-8674(00)81054-5	http://dx.doi.org/10.1016/S0092-8674(00)81054-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625414	Bronze			2022-12-01	WOS:A1996TZ99000014
J	Willett, WC; Stampfer, MJ; Manson, JE; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH				Willett, WC; Stampfer, MJ; Manson, JE; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH			Coffee consumption and coronary heart disease in women - A ten-year follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; DEATH; QUESTIONNAIRE; MEN	Objective.-To assess the relationship between coffee consumption and risk of coronary heart disease (CHD) among women. Design.-Prospective cohort study with coffee consumption measured in 1980, 1984, and 1986, and follow-up through 1990. Setting.-Female registered nurses in the United States. Participants.-A total of 85 747 US women 34 to 59 years of age in 1980 and without history of CHD, stroke, or cancer. Main Outcome Measure.-Ten-year incidence of CHD (defined as nonfatal myocardial infarction or fatal CHD). Results.-During 10 years of follow-up we documented 712 cases of CHD. After adjustment for age, smoking, and other CHD risk factors, we found no evidence for any positive association between coffee consumption and risk of subsequent CHD. For women drinking six or more cups of caffeine-containing coffee per day in 1980, the relative risk was 0.95 (95% confidence interval, 0.73 to 1.26) compared with women who did not consume this beverage. Similarly, there was no association when the first 4 years of follow-up were excluded, when nonfatal and fatal CHD end points were examined separately, or when we updated coffee consumption in 1984 or 1986 and examined only CHD during the next 2-year interval. Further, there was no association with caffeine intake from all sources combined or with decaffeinated coffee consumption. Conclusions.-These data indicate that coffee as consumed by US women is not an important cause of CHD.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Willett, WC (corresponding author), CHANNING LABS,818 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594, HL 24074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; Hennekens C., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1976, NEW ENGL J MED, V294, P633, DOI 10.1056/NEJM197603182941203; KALANDIDI A, 1993, INT J EPIDEMIOL, V21, P174; KAWACHI I, 1994, BRIT HEART J, V72, P269; Klag Michael J., 1994, Annals of Epidemiology, V4, P425, DOI 10.1016/1047-2797(94)90001-9; KLATSKY AL, 1990, AM J EPIDEMIOL, V132, P479, DOI 10.1093/oxfordjournals.aje.a115684; MANN JI, 1975, LANCET, V2, P1215; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MYERS MG, 1992, ARCH INTERN MED, V152, P1767, DOI 10.1001/archinte.152.9.1767; Rose GA., 1982, WHO MONOGRAPH SERIES, V58; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q	18	79	84	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					458	462		10.1001/jama.275.6.458	http://dx.doi.org/10.1001/jama.275.6.458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627967				2022-12-01	WOS:A1996TU63800034
J	Bounameaux, H; Hicklin, L; Desmarais, S				Bounameaux, H; Hicklin, L; Desmarais, S			Seasonal variation in deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Bounameaux, H (corresponding author), UNIV HOSP GENEVA, DEPT INTERNAL MED, DIV ANGIOL & HAEMOSTASIS, CH-1211 GENEVA 4, SWITZERLAND.							COOKE EA, 1995, BRIT MED J, V310, P129, DOI 10.1136/bmj.310.6972.129b; GALLERANI M, 1992, EUR HEART J, V13, P661, DOI 10.1093/oxfordjournals.eurheartj.a060232; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; WROBLEWSKI BM, 1992, CLIN ORTHOP RELAT R, P222	5	55	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	1996	312	7026					284	285						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611784				2022-12-01	WOS:A1996TU50700022
J	Semenza, JC; Rubin, CH; Falter, KH; Selanikio, JD; Flanders, WD; Howe, HL; Wilhelm, JL				Semenza, JC; Rubin, CH; Falter, KH; Selanikio, JD; Flanders, WD; Howe, HL; Wilhelm, JL			Heat-related deaths during the July 1995 heat wave in Chicago	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APPARENT TEMPERATURE; ST-LOUIS; SULTRINESS; MORTALITY	Background During a record-setting heat wave in Chicago in July 1995, there were at least 700 excess deaths, most of which were classified as heat-related. We sought to determine who was at greatest risk for heat-related death. Methods We conducted a case-control study in Chicago to identify risk factors associated with heat-related death and death from cardiovascular causes from July 14 through July 17, 1995. Beginning on July 21, we interviewed 339 relatives, neighbors, or friends of those who died and 339 controls matched to the case subjects according to neighborhood and age. Results The risk of heat-related death was increased for people with known medical problems who were confined to bed (odds ratio as compared with those who were not confined to bed, 5.5) or who were unable to care for themselves (odds ratio, 4.1). Also at increased risk were those who did not leave home each day (odds ratio, 6.7), who lived alone (odds ratio, 2.3), or who lived on the top floor of a building (odds ratio, 4.7). Having social contacts such as group activities or friends in the area was protective. In a multivariate analysis, the strongest risk factors for heat-related death were being confined to bed (odds ratio, 8.2) and living alone (odds ratio, 2.3); the risk of death was reduced for people with working air conditioners (odds ratio, 0.3) and those with access to transportation (odds ratio, 0.3). Deaths classified as due to cardiovascular causes had risk factors similar to those for heat-related death. Conclusions In this study of the 1995 Chicago heat wave, those at greatest risk of dying from the heat were people with medical illnesses who were socially isolated and did not have access to air conditioning. In future heat emergencies, interventions directed to such persons should reduce deaths related to the heat. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,ATLANTA,GA 30341; ILLINOIS DEPT PUBL HLTH,SPRINGFIELD,IL 62761; DEPT PUBL HLTH,CHICAGO,IL	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Chicago Department of Public Health								AGRESTI A, 1990, CATEGORICAL DATA ANA, P56; ALDERSON MR, 1967, BRIT J PREV SOC MED, V21, P22; [Anonymous], 1982, EPIDEMIOLOGIC RES; APPLEGATE WB, 1981, J AM GERIATR SOC, V29, P337, DOI 10.1111/j.1532-5415.1981.tb01238.x; BAROR O, 1969, J APPL PHYSIOL, V26, P403, DOI 10.1152/jappl.1969.26.4.403; BEADENKOPF WG, 1963, J CHRON DIS, V16, P249, DOI 10.1016/0021-9681(63)90030-4; Bridger C A, 1968, Int J Biometeorol, V12, P51, DOI 10.1007/BF01552978; CLARKE JF, 1972, ENVIRON RES, V5, P93, DOI 10.1016/0013-9351(72)90023-0; ELLIS FP, 1980, Q J MED, V49, P1; ELLIS FP, 1972, ENVIRON RES, V5, P1, DOI 10.1016/0013-9351(72)90019-9; GOVER MARY, 1938, PUBL HEALTH REPTS, V53, P1122, DOI 10.2307/4582590; GWYNNE JF, 1974, NEW ZEAL MED J, V80, P336; HAYMES EM, 1975, J APPL PHYSIOL, V39, P457, DOI 10.1152/jappl.1975.39.3.457; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; KILBOURNE EM, 1982, JAMA-J AM MED ASSOC, V247, P3332, DOI 10.1001/jama.247.24.3332; KILBOURNE EM, 1986, MAXCY ROSENAU PUBLIC, P703; KOLLIAS J, 1964, J PHARMACOL EXP THER, V145, P373; MARTINEZ BF, 1989, JAMA-J AM MED ASSOC, V262, P2246, DOI 10.1001/jama.262.16.2246; *NAT CTR HLTH STAT, 1992, MORT PUBL US COMP DA; *NAT OC ATM ADM, 1995, 1995 NAT OC ATM ADM; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; SAS Institute, 1992, SAS STAT SOFTW CHANG; SCHUMAN SH, 1972, ENVIRON RES, V5, P59, DOI 10.1016/0013-9351(72)90020-5; SCHUMAN SH, 1964, JAMA-J AM MED ASSOC, V189, P733; STEADMAN RG, 1979, J APPL METEOROL, V18, P861, DOI 10.1175/1520-0450(1979)018<0861:TAOSPI>2.0.CO;2; STEADMAN RG, 1984, J CLIM APPL METEOROL, V23, P1674, DOI 10.1175/1520-0450(1984)023<1674:AUSOAT>2.0.CO;2; STEADMAN RG, 1979, J APPL METEOROL, V18, P874, DOI 10.1175/1520-0450(1979)018<0874:TAOSPI>2.0.CO;2; YAGLOU C. P., 1927, JOUR IND HYG, V9, P297; 1981, MMWR-MORBID MORTAL W, V30, P277; 1995, MMWR-MORBID MORTAL W, V44, P577	31	850	892	4	114	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1996	335	2					84	90		10.1056/NEJM199607113350203	http://dx.doi.org/10.1056/NEJM199607113350203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW353	8649494	Bronze			2022-12-01	WOS:A1996UW35300003
J	Lerman, C; Narod, S; Schulman, K; Hughes, C; GomezCaminero, A; Bonney, G; Gold, K; Trock, B; Main, D; Lynch, J; Fulmore, C; Snyder, C; Lemon, SJ; Conway, T; Tonin, P; Lenoir, G; Lynch, H				Lerman, C; Narod, S; Schulman, K; Hughes, C; GomezCaminero, A; Bonney, G; Gold, K; Trock, B; Main, D; Lynch, J; Fulmore, C; Snyder, C; Lemon, SJ; Conway, T; Tonin, P; Lenoir, G; Lynch, H			BRCA1 testing in families with hereditary breast-ovarian cancer - A prospective study of patient decision making and outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUNTINGTONS-DISEASE; SUSCEPTIBILITY; RISK; MODELS	Objectives.-To identify predictors of utilization of breast-ovarian cancer susceptibility (BRCA1 gene) testing and to evaluate outcomes of participation in a testing program. Design.-Prospective cohort study with baseline interview assessment of predictor variables (eg, sociodemographic factors, knowledge about hereditary cancer and genetic testing, perceptions of testing benefits, limitations, and risks). BRCA1 test results were offered after an education and counseling session in a research setting. Outcome variables (including depression, functional health status, and prophylactic surgery plans [follow-up only]) were assessed at baseline and 1-month follow-up interviews. Participants.-Adult male and female members (n=279) of families with BRCA1-linked hereditary breast-ovarian cancer (HBOC). Results.-Of subjects who completed a baseline interview (n=192), 60% requested BRCA1 test results (43% of all study subjects requested results). Requests for results were more frequent for persons with health insurance (odds ratio [OR], 3.74; 95% confidence interval [CI], 2.06-6.80); more first-degree relatives affected with breast cancer (OR, 1.59; 95% CI, 1.16-2.16); more knowledge about BRCA1 testing (OR, 1.85; 95% CI, 1.36-2.50); and indicating that test benefits are important (OR, 1.45; 95% CI, 1.13-1.86). At follow-up, noncarriers of BRCA1 mutations showed statistically significant reductions in depressive symptoms and functional impairment compared with carriers and nontested individuals. individuals identified as mutation carriers did not exhibit increases in depression and functional impairment. Among unaffected women with no prior prophylactic surgery, 17% of carriers (2/12) intended to have mastectomies and 33% (4/12) to have oophorectomies. Conclusions.-Only a subset of HBOC family members are likely to request BRCA1 testing when available. Rates of test use may be higher in persons of a higher socioeconomic status and those with more relatives affected with breast cancer. For some high-risk individuals who receive test results in a research setting that includes counseling, there may be psychological benefits. More research is needed to assess the generalizability of these results and evaluate the long-term consequences of BRCA1 testing.	WOMENS COLL HOSP,DEPT MED,TORONTO,ON M5S 1B2,CANADA; FOX CHASE CANC CTR,DIV POPULAT SCI,PHILADELPHIA,PA 19111; CREIGHTON UNIV,MED CTR,DEPT PREVENT MED & PUBL HLTH,OMAHA,NE 68178; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 2T5,CANADA; INT AGCY RES CANC,UNIT MECHANISMS CARCINOGENESIS,F-69372 LYON,FRANCE	University of Toronto; University Toronto Affiliates; Womens College Hospital; Fox Chase Cancer Center; Creighton University; McGill University; World Health Organization; International Agency for Research on Cancer (IARC)	Lerman, C (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT MED,LOMBARDI CANC CTR,DIV CANC PREVENT & CONTROL,WASHINGTON,DC 20007, USA.		Narod, Steven A/AAA-6112-2022; Lerman, Caryn/AHC-5180-2022	Gomez-Caminero, Andres/0000-0002-8728-3124	NCI NIH HHS [CA01604] Funding Source: Medline; NIMH NIH HHS [MH54435] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA001604] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajzen I., 1980, UNDERSTANDING ATTITU; BEKKER H, 1993, BRIT MED J, V306, P14; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BONNEY GE, 1986, BIOMETRICS, V42, P611, DOI 10.2307/2531211; BONNEY GE, 1992, HUM HERED, V42, P28, DOI 10.1159/000154044; CHALIKI H, 1995, AM J PUBLIC HEALTH, V85, P1133, DOI 10.2105/AJPH.85.8_Pt_1.1133; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; CRAUFURD D, 1989, LANCET, V2, P603; EASTON DF, 1993, AM J HUM GENET, V52, P678; ENGEL JF, 1995, CONSUMER BEHAVIOR; EVERSKIEBOOMS G, 1989, CLIN GENET, V35, P29; FEUNTEUN J, 1993, AM J HUM GENET, V52, P736; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; LERMAN C, 1995, AM J MED GENET, V57, P385, DOI 10.1002/ajmg.1320570304; LYNCH HT, 1994, CANCER, V74, P1184, DOI 10.1002/1097-0142(19940801)74:3+<1184::AID-CNCR2820741530>3.0.CO;2-4; LYNCH HT, 1992, CANCER, V69, P1404, DOI 10.1002/1097-0142(19920315)69:6<1404::AID-CNCR2820690616>3.0.CO;2-R; LYNCH HT, 1993, ARCH INTERN MED, V153, P1979; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NELSON N, 1995, J NATL CANCER I, V88, P70; *OFF TECHN ASS, 1992, OTABPBA98 PUBL; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SEROVA O, 1996, AM J HUM GENET, V58, P51; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P205; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P194; STRUEWING JP, 1995, CANCER EPIDEM BIOMAR, V4, P169; STRUEWING JP, 1995, NAT GENET, V11, P196; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; *US DEP HLTH HUM S, 1993, NIH PUBL; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1994, JAMA-J AM MED ASSOC, V271, P785; 1994, AM J HUM GENET, V55, pR2	43	637	638	1	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1885	1892		10.1001/jama.275.24.1885	http://dx.doi.org/10.1001/jama.275.24.1885			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR975	8648868				2022-12-01	WOS:A1996UR97500033
J	Morrison, HI; Schaubel, D; Desmeules, M; Wigle, DT				Morrison, HI; Schaubel, D; Desmeules, M; Wigle, DT			Serum folate and risk of fatal coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAROTID ARTERIAL-DISEASE; CANADA SURVEY COHORT; FOLLOW-UP; DEFICIENCY; MORTALITY; ADULTS	Objective.-To assess the relationship between serum folate level and the risk of fatal coronary heart disease (CHD) among men and women. Design.-Retrospective cohort study with serum folate levels measured from September 1970 to December 1972, with follow-up through 1985. Setting.-Participants in the Nutrition Canada Survey. Participants.-A total of 5056 Canadian men and women aged 35 to 79 years with no history of self-reported CHD. Main Outcome Measure.-Fifteen-year CHD mortality. Results.-A total of 165 CHD deaths were observed. We found a statistically significant association between serum folate level and risk of fatal CHD, with rate ratios for individuals in the lowest serum folate level category (<6.8 nmol/L [3 ng/mL]) compared with the highest category (>13.6 nmol/L [6 ng/mL]) of 1.69 (95% confidence interval, 1.10-2.61). Conclusions.-These data indicate that low serum folate levels are associated with an increased risk of fatal CHD.			Morrison, HI (corresponding author), DEPT HLTH & WELF,CANC BUR,LAB CTR DIS CONTROL BLDG,TUNNEYS PASTURE,OTTAWA,ON K1A 0L2,CANADA.							ARONOW WS, 1992, NEW YORK STATE J MED, V92, P424; ARONOW WS, 1992, CORONARY ARTERY DIS, V3, P249, DOI 10.1097/00019501-199203000-00012; BAYLIS EM, 1971, LANCET, V1, P62; BLOCK G, 1993, J NATL CANCER I, V85, P846, DOI 10.1093/jnci/85.11.846; BUTTERWORTH CE, 1992, JAMA-J AM MED ASSOC, V267, P528, DOI 10.1001/jama.267.4.528; CHANARIN I, 1994, CLIN INVEST MED, V17, P253; *DEP NAT HLTH WELF, 1978, H58361973 DEP NAT HL; *DEP NAT HLTH WELF, 1973, H58361973 DEP NAT HL; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; GABY SK, 1991, VITAMIN INTAKE HLTH; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; JOHANSEN H, 1987, CAN MED ASSOC J, V136, P823; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; Kannel WB, 1983, PREVENTION CORONARY, P1; MARTIN M, 1986, LANCET, V2, P923; MOJONNIER L, 1968, J AM DIET ASSOC, V52, P288; *NAT CTR HLTH STAT, 1967, INT CLASS DIS AD US; *NAT RES COUNC, 1989, REC DIET ALL; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; ROMANO PS, 1995, AM J PUBLIC HEALTH, V85, P667, DOI 10.2105/AJPH.85.5.667; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SAUBERLICH HE, 1987, AM J CLIN NUTR, V46, P1016, DOI 10.1093/ajcn/46.6.1016; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SEMENCIW RM, 1988, INT J EPIDEMIOL, V17, P317, DOI 10.1093/ije/17.2.317; SHANNON HS, 1989, CAN J PUBLIC HEALTH, V80, P54; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; [No title captured]; 1991, LANCET, V338, P131	32	263	271	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1893	1896		10.1001/jama.275.24.1893	http://dx.doi.org/10.1001/jama.275.24.1893			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR975	8648869				2022-12-01	WOS:A1996UR97500034
J	Calder, SJ; Anderson, GH; Gregg, PJ				Calder, SJ; Anderson, GH; Gregg, PJ			Certification of cause of death in patients dying soon after proximal femoral fracture	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY		UNIV LEICESTER,GLENFIELD GEN HOSP,DEPT ORTHOPAED SURG,LEICESTER LE3 9QP,LEICS,ENGLAND; LEICESTER ROYAL INFIRM,DEPT ORTHOPAED SURG,LEICESTER LE1 5WW,LEICS,ENGLAND	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		PARKER MJ, 1991, PUBLIC HEALTH, V105, P443, DOI 10.1016/S0033-3506(05)80614-6; WOOD DJ, 1992, J BONE JOINT SURG BR, V74, P199, DOI 10.1302/0301-620X.74B2.1544951; 1992, RIGHTS RESPONSIBILIT, P79	3	19	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1515	1515		10.1136/bmj.312.7045.1515	http://dx.doi.org/10.1136/bmj.312.7045.1515			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UR823	8646144	Green Published			2022-12-01	WOS:A1996UR82300022
J	Spicer, DB; Rhee, J; Cheung, WL; Lassar, AB				Spicer, DB; Rhee, J; Cheung, WL; Lassar, AB			Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein twist	SCIENCE			English	Article							MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; REGULATORY ELEMENTS; DROSOPHILA-TWIST; BINDING-FACTOR; HLH PROTEINS; CELLS; EXPRESSION; MYF-5; INACTIVATION	The myogenic basic helix-loop-helix (bHLH) and MEF2 transcription factors are expressed in the myotome of developing somites and cooperatively activate skeletal muscle gene expression. The bHLH protein Twist is expressed throughout the epithelial somite and is subsequently excluded from the myotome. Ectopically expressed mouse Twist (Mtwist) was shown to inhibit myogenesis by blocking DNA binding by MyoD, by titrating E proteins, and by inhibiting trans-activation by MEF2. For inhibition of MEF2, Mtwist required heterodimerization with E proteins and an intact basic domain and carboxyl-terminus. Thus, Mtwist inhibits both families of myogenic regulators and may regulate myotome formation temporally or spatially.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Rhee, James/V-9973-2019		NIAMS NIH HHS [5-F32-AR08214-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BATE M, 1991, DEVELOPMENT, V113, P79; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IP YT, 1992, GENE DEV, V6, P1516; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JANES J, 1988, MOL CELL BIOL, V8, P62; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LILY B, 1994, P NATL ACAD SCI USA, V91, P5662; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAIDU PS, 1995, MOL CELL BIOL, V15, P3703; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SIMPSON P, 1983, GENETICS, V105, P605; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SPICER DB, UNPUB; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TAYLOR MV, 1995, CURR BIOL, V5, P740, DOI 10.1016/S0960-9822(95)00149-7; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG W, 1995, GENE DEV, V9, P1386	62	268	272	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1476	1480		10.1126/science.272.5267.1476	http://dx.doi.org/10.1126/science.272.5267.1476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633239				2022-12-01	WOS:A1996UP89900046
J	Tang, XJ; Halleck, MS; Schlegel, RA; Williamson, P				Tang, XJ; Halleck, MS; Schlegel, RA; Williamson, P			A subfamily of P-type ATPases with aminophospholipid transporting activity	SCIENCE			English	Article							TRANSBILAYER MOVEMENT; SENSITIVE ATPASE; PLASMA-MEMBRANE; PHOSPHATIDYLSERINE; PROTEIN; PURIFICATION; RECOGNITION; MACROPHAGES; ASYMMETRY; SURFACE	The appearance of phosphatidylserine on the surface of animal cells triggers phagocytosis and blood coagulation. Normally, phosphatidylserine is confined to the inner leaflet of the plasma membrane by an aminophospholipid translocase, which has now been cloned and sequenced. The bovine enzyme is a member of a previously unrecognized subfamily of P-type adenosine triphosphatases (ATPases) that may have diverged from the primordial enzyme before the separation of the known families of ion-translocating ATPases. Studies in Saccharomyces cerevisiae suggest that aminophospholipid translocation is a general function of members of this family.	AMHERST COLL,DEPT BIOL,AMHERST,MA 01002; PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Amherst College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BOGDANOV A, 1993, BIOCHEM SOC T, V21, P271, DOI 10.1042/bst0210271; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAGAN MJ, 1994, J MOL EVOL, V38, P57; HICKS BW, 1992, J NEUROCHEM, V58, P1211, DOI 10.1111/j.1471-4159.1992.tb11331.x; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KRISHNA S, 1994, EXP PARASITOL, V78, P113, DOI 10.1006/expr.1994.1011; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PRADHAN D, 1994, MOL MEMBR BIOL, V11, P181, DOI 10.3109/09687689409162237; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; SCHLEGEL RA, IN PRESS P 6 INT C L; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; TROTTEIN F, 1995, EUR J BIOCHEM, V227, P214, DOI 10.1111/j.1432-1033.1995.tb20379.x; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; XIE XS, 1989, J BIOL CHEM, V264, P1710; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2; ZACHOWSKI A, 1990, J NEUROCHEM, V55, P1352, DOI 10.1111/j.1471-4159.1990.tb03146.x	30	405	412	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1495	1497		10.1126/science.272.5267.1495	http://dx.doi.org/10.1126/science.272.5267.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633245				2022-12-01	WOS:A1996UP89900052
J	Schorle, H; Meier, P; Buchert, M; Jaenisch, R; Mitchell, PJ				Schorle, H; Meier, P; Buchert, M; Jaenisch, R; Mitchell, PJ			Transcription factor AP-2 essential for cranial closure and craniofacial development	NATURE			English	Article							NEURAL CREST; VERTEBRATES; DISRUPTION; BINDING; ORIGIN; CELLS; TUBE	DURING closure of the neural tube in the mouse, transcription factor AP-2 (refs 1-4) is expressed in ectoderm and in neural-crest cells migrating from the cranial neural folds(5). Cranial neural crest cells provide patterning information for craniofacial morphogenesis, generate most of the skull bones, and, together with placodal ectoderm, form the cranial ganglia(6-8). To study the role of AP-2 during embryogenesis, we undertook a targeted mutagenesis of the AP-2 gene in the mouse. Here we report that AP-2(-/-) mice died perinatally with cranio-abdominoschisis and severe dismorphogenesis of the face, skull, sensory organs and cranial ganglia. Failure of cranial closure between 9 and 9.5 days postcoitum coincided with increased apoptosis in the midbrain, anterior hindbrain and proximal mesenchyme of the first branchial arch, but did not involve loss of expression of twist or Pax-3, two other regulatory genes known to be required for cranial closure.	MIT, DEPT BIOL, CAMBRIDGE, MA 02138 USA; UNIV ZURICH, INST MOLEC BIOL, CH-8057 ZURICH, SWITZERLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); University of Zurich; Massachusetts Institute of Technology (MIT); Whitehead Institute			Schorle, Hubert/M-5001-2016; Schorle, Hubert/S-1713-2019; Buchert, Michael/Z-1777-2019	Schorle, Hubert/0000-0001-8272-0076; Buchert, Michael/0000-0003-2672-0148; Meier, Pascal/0000-0003-2760-6523				CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; COULY GF, 1993, DEVELOPMENT, V117, P409; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; EMFORS P, 1995, NATURE, V368, P147; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON R, 1985, J EMBRYOL EXP MORPH, V89, P229; Hogan B., 2014, MANIPULATING MOUSE E; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kaufman M.H., 1992, ATLAS MOUSE DEV; Le Douarin N.M., 1982, NEURAL CREST; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; Richman J, 1996, CURR BIOL, V6, P364, DOI 10.1016/S0960-9822(02)00496-7; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; WILKINSON DG, 1992, IN SITU HYDRIDIZATIO; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAMADA G, 1995, DEVELOPMENT, V121, P2917	30	492	501	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 16	1996	381	6579					235	238		10.1038/381235a0	http://dx.doi.org/10.1038/381235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622765				2022-12-01	WOS:A1996UL24900054
J	Heynen, AJ; Abraham, WC; Bear, MF				Heynen, AJ; Abraham, WC; Bear, MF			Bidirectional modification of CA1 synapses in the adult hippocampus in vivo	NATURE			English	Article							LONG-TERM POTENTIATION; AREA CA1; DEPRESSION	MEMORIES are believed to be stored by synaptic modifications. One type of activity-dependent synaptic modification, long-term potentiation (LTP), has received considerable attention as a possible memory mechanism, particularly in hippocampus(1). However, use-dependent decreases in synaptic strength can store information as well. A form of homosynaptic long-term depression (LTD) has been described and widely studied in the CA1 region of the developing hippocampus in vitro(2-4). However, the relevance of this model of LTD to memory has been questioned because of failures to replicate it in the adult brain in vitro(5) and, more recently, in vivo(6). Here we re-examine this important issue and find that homosynaptic LTD can in fact be elicited in the adult hippocampus in vivo, that it has all the properties described in immature CA1 in vitro, and that LTD and LTP are reversible modifications of the same Schaffer collateral synapses. Thus homosynaptic LTD is not peculiar to brain slices, nor is it only of developmental significance. Rather, our data suggest that the mechanisms of LTP and LTD may be equal partners in the mnemonic operations of hippocampal neural networks.	BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912; BROWN UNIV,HOWARD HUGHES MED INST,PROVIDENCE,RI 02912; UNIV OTAGO,DEPT PSYCHOL,DUNEDIN,NEW ZEALAND; UNIV OTAGO,NEUROSCI RES CTR,DUNEDIN,NEW ZEALAND	Brown University; Brown University; Howard Hughes Medical Institute; University of Otago; University of Otago				Bear, Mark/0000-0002-9903-2541				ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREESE CR, 1989, J NEUROSCI, V9, P1097; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; KERR DS, 1995, P NATL ACAD SCI USA, V92, P11637, DOI 10.1073/pnas.92.25.11637; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; THIELS E, 1994, J NEUROPHYSIOL, V71, P3009; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	12	149	152	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					163	166		10.1038/381163a0	http://dx.doi.org/10.1038/381163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610015				2022-12-01	WOS:A1996UK13900052
J	Bentham, G				Bentham, G			Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; TIME TRENDS; EXPOSURE; EPIDEMIOLOGY; CANCER; RISK	Objectives-To examine whether the incidence of non-Hodgkin's lymphoma in different areas of England and Wales is associated with levels of solar ultraviolet radiation. Design-Geographically based study examining the association between incidence of non-Hodgkin's lymphoma and estimated levels of solar ultraviolet radiation, controlling for social class and employment in agriculture. Setting-59 counties in England and Wales. Subjects-All registered cases of non-Hodgkin's lymphoma during the period 1968-85. Main outcome measure-Age and sex adjusted odds ratio for non-Hodgkin's lymphoma in each county. Results-Incidence of non-Hodgkin's lymphoma was significantly associated with solar ultraviolet radiation levels (P<0.001), even after social class and employment in agriculture were controlled for (P=0.004). In a comparison of counties in the highest and lowest quarters of solar ultraviolet radiation, the relative risk of non-Hodgkin's lymphoma was 1.27 (95% confidence interval 1.24 to 1.29), rising to 1.34 (1.32 to 1.37) after adjustment for social class and employment in agriculture. Conclusions-The incidence of non-Hodgkin's lymphoma in different areas of England and Wales is positively associated with levels of solar ultraviolet radiation. These results are consistent with the hypothesis that exposure to solar ultraviolet radiation increases the risk of non-Hodgkin's lymphoma.			Bentham, G (corresponding author), UNIV E ANGLIA,SCH ENVIRONM SCI,CTR SOCIAL & ECON RES GLOBAL ENVIRONM,NORWICH NR4 7TJ,NORFOLK,ENGLAND.							ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ADAMI J, 1995, BMJ-BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750b; BARROW EM, 1993, 1961 90 BASELINE CLI; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; DEVESA SS, 1992, CANCER RES, V52, pS5432; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOETTSCH W, 1993, THYMUS, V21, P93; GREINER TC, 1994, DIAGN ONCOL, V4, P26; Hartge P., 1992, CANC RES S, V52, p5466s; HOLFORD TR, 1992, CANCER RES, V52, pS5443; KINLEN L, 1992, CANCER RES, V52, pS5474; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; LEVINE AM, 1992, CANCER RES, V52, pS5482; MADRONICH S, 1995, AMBIO, V24, P143; MCKINNEY PA, 1991, LEUKEMIA LYMPHOMA, V4, P123, DOI 10.3109/10428199109068055; MO T, 1974, PHOTOCHEM PHOTOBIOL, V20, P483, DOI 10.1111/j.1751-1097.1974.tb06607.x; MUELLER NE, 1992, CANCER RES, V52, pS5479; NEWTON R, 1995, BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750a; *OFF POP CENS SURV, 1975, CENS 1971 ENGL WAL E; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PEARCE N, 1992, CANCER RES, V52, pS5496; SASIENI P, 1995, BRIT MED J, V311, P749, DOI 10.1136/bmj.311.7007.749a; SCHERR PA, 1992, CANCER RES, V52, pS5503; SWERDLOW A, 1993, ATLAS CANC INCIDENCE; VICKERS M, 1995, BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750; WEISENBURGER DD, 1994, ANN ONCOL, V5, pS19, DOI 10.1093/annonc/5.suppl_1.S19; WHO World Health Organization, 1994, ENV HLTH CRIT, V160; ZAHM SH, 1992, CANCER RES, V52, pS5485; 1990, ARCH INTERN MED, V150, P2473	34	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1128	1131						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620128				2022-12-01	WOS:A1996UK06900021
J	Borel, AC; Simon, SM				Borel, AC; Simon, SM			Biogenesis of polytopic membrane proteins: Membrane segments assemble within translocation channels prior to membrane integration	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN; SECRETORY PROTEINS; TRANSMEMBRANE GLYCOPROTEIN; MULTIDRUG RESISTANCE; TRANSLATION PRODUCTS; ESCHERICHIA-COLI; SIGNAL SEQUENCE; INSERTION	The initial steps in the biogenesis of membrane proteins parallel that of secretory proteins. The translocation of membrane proteins, however, must be interrupted prior to the complete traversal of the membrane. This is followed by their folding and integrating into the lipid bilayer. We have previously shown that as each latent transmembrane segment (TMS) in a polytopic membrane protein emerges from the ribosome, it sequentially translocates across the membrane. Here we demonstrate that these translocated TMSs can be extracted from the membrane with urea. This suggests that nascent TMSs do not integrate into the bilayer as they achieve a transmembrane topography. The integration is delayed until after the protein is synthesized and released from the ribosome. Prior to insertion into the bilayer, these TMSs appear to be stabilized by salt-sensitive electrostatic bonds within an aqueous-accessible compartment.	ROCKEFELLER UNIV,LAB CELLULAR BIOPHYS,NEW YORK,NY 10021	Rockefeller University				Simon, Sanford/0000-0002-8615-4224				ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1967, J MOL BIOL, V26, P293, DOI 10.1016/0022-2836(67)90298-7; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KAWAHARA K, 1965, BIOCHEMISTRY-US, V4, P1203, DOI 10.1021/bi00883a001; LINGAPPA VR, 1978, J BIOL CHEM, V253, P8667; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1981, P NATL ACAD SCI-BIOL, V78, P5127, DOI 10.1073/pnas.78.8.5127; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; REDMAN CM, 1966, J BIOL CHEM, V241, P1150; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	53	115	115	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					379	389		10.1016/S0092-8674(00)81116-2	http://dx.doi.org/10.1016/S0092-8674(00)81116-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616893	Bronze			2022-12-01	WOS:A1996UK14000011
J	Normand, SLT; Glickman, ME; Sharma, RGVRK; McNeil, BJ				Normand, SLT; Glickman, ME; Sharma, RGVRK; McNeil, BJ			Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients - Results from the Cooperative Cardiovascular Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES; DISEASE; RISK; CARE	Objective.-To develop a prediction model of death within 30 days of hospital admission for Medicare patients with acute myocardial infarction that would permit use of risk-adjusted mortality rates as hospital quality measures. Design.-Retrospective cohort study using data created from medical charts and administrative flies. Setting.-All acute care hospitals in Alabama, Connecticut, Iowa, or Wisconsin. Patients.-A cohort of 14 581 patients with acute myocardial infarction covered by Medicare in 1993. Results.-The unadjusted 30-day mortality rate was 21%, ranging from 18% in Connecticut to 23% in Alabama. The 4 largest contributors to variability in mortality rates were mean arterial pressure, age, respiratory rate, and serum urea nitrogen level. The area under the receiver operator characteristic curve was 0.79 in a developmental sample of 10 936 patients and 0.78 in a validation sample of 3645 patients. Based on admission variables, we were able to explain 27% of the variability in 30-day mortality rates. During the index admission, aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and thrombolytic agents were used in 72%, 39%, 32%, and 15% of patients, respectively. Explained variation increased by 6 percentage points to 33% when drug therapies and revascularization procedures performed during the index admission were added to the model predictors, Conclusions.-Short-term mortality remains high for elderly patients with acute myocardial infarction, and a large percentage of variation remains unexplained after controlling for admission severity. Part of the unexplained variability can be explained by the location of the admitting hospital; some of the remaining unexplained variation may reflect differences in quality of care or unmeasured differences in disease severity. Researchers should develop quality indicators based on process measures for acute myocardial infarction and should incorporate these measures into mortality models to determine whether quality accounts for variation in 30-day mortality rates beyond that explained by clinical status at admission.	HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; DEPT VET AFFAIRS MED CTR,DIV CARDIOL,BROCKTON,MA; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Brigham & Women's Hospital	Normand, SLT (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,PARCEL B,1ST FLOOR,25 SHATTUCK ST,BOSTON,MA 02115, USA.			Glickman, Mark/0000-0003-3993-2801	AHRQ HHS [R01-HS06341, R01-HS08071] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BERGER CJ, 1992, JAMA-J AM MED ASSOC, V268, P1545, DOI 10.1001/jama.268.12.1545; Codman EA, 1916, SURG GYNECOL OBSTET, V22, P119; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; CRAWFORD SL, 1995, J CLIN EPIDEMIOL, V48, P209, DOI 10.1016/0895-4356(94)00124-9; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FIRSHEIN J, 1993, F GRAYS MED HLTH, V47, P3; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KRAKAUER H, 1993, INQUIRY-J HEALTH CAR, V30, P115; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LITTLE RJ, 1987, STAT ANAL MISSING DA, P9; LITTLE RJA, 1985, BIOMETRIKA, V72, P497, DOI 10.2307/2336722; NAGELKERKE NJ, 1991, BIOMETRIKA, V3, P691; NORMAND SLT, 1995, J CLIN EPIDEMIOL, V48, P229, DOI 10.1016/0895-4356(94)00126-B; Paik, 2003, STAT METHODS RATES P, P598; PARSONNET V, 1989, CIRCULATION, V79, P3; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; *SAS I INC, 1990, SAS STAT US GUID VER, P2; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEP HLTH HUM S, 1992, MED HOSP INF 1992; VLADECK BC, 1988, HEALTH AFFAIR, V7, P122, DOI 10.1377/hlthaff.7.1.122	24	116	120	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1322	1328		10.1001/jama.275.17.1322	http://dx.doi.org/10.1001/jama.275.17.1322			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614117				2022-12-01	WOS:A1996UG61200028
J	Remarque, EJ; Cools, HJM; Boere, TJ; vanderKlis, RJ; Masurel, N; Ligthart, GJ				Remarque, EJ; Cools, HJM; Boere, TJ; vanderKlis, RJ; Masurel, N; Ligthart, GJ			Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV,DEPT GEN PRACTICE,SECT DUTCH NURSING HOME MED,2301 RC LEIDEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT VIROL,WHO NATL INFLUENZA CTR NETHERLANDS,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	Remarque, EJ (corresponding author), UNIV LEIDEN HOSP,DEPT PATHOL,SECT GERONTOL,BLDG 1 P3-Q,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Remarque, Edmond J/B-2217-2010; Remarque, Ed/AAE-8643-2020					BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; REMARQUE EJ, 1993, VACCINE, V11, P649, DOI 10.1016/0264-410X(93)90311-K	5	32	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1015	1015						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616350				2022-12-01	WOS:A1996UG61000028
J	Mal, A; Poon, RYC; Howe, PH; Toyoshima, H; Hunter, T; Harter, ML				Mal, A; Poon, RYC; Howe, PH; Toyoshima, H; Hunter, T; Harter, ML			Inactivation of p27(Kip1) by the viral E1A oncoprotein in TGF beta-treated cells	NATURE			English	Article							GROWTH ARREST; INHIBITION; KINASE; PHOSPHORYLATION; PROTEINS; P34CDC2; CYCLE	THE adenovirus oncoprotein E1A and the simian virus SV40 large T antigen can both reverse the strong growth-inhibitory effect of transforming growth factor(TGF)-beta on mink lung epithelial cells(1,2): exposure of TGF-beta causes these cells to arrest late in the G1 phase of the cell cycle (ref. 3). This arrest correlates with an increase in expression of the protein p15(Ink4B) (ref. 4), inactivation of the cyclin E/A-cdk2 complex by the inhibitory protein p27(Kip1) (refs 5-7), and with the accumulation of unphosphorylated retinoblastoma protein(8). The rescue by E1A of cells from TGF-beta arrest is partly independent of its binding to retinoblastoma protein(1). Here we show that E1A directly affects the cyclin-dependent kinase inhibitor p27(Kip1) in TGF-beta-treated cells by binding to it and blocking its inhibitory effect, thereby restoring the activity of the cyclin-cdk2 kinase complex. In this way, E1A can overcome the effect of TGF-beta and modulate the cell cycle. To our knowledge, E1A provides the first example of a viral oncoprotein that can disable a cellular protein whose function is to inhibit the activity of cyclin-dependent kinases.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Salk Institute				Poon, Randy/0000-0001-5571-6231				ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; BANERJEE AC, 1994, ONCOGENE, V9, P1733; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; REYNISDOTTIR I, 1995, J GENES DEV, V9, P1831; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7	26	136	139	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					262	265		10.1038/380262a0	http://dx.doi.org/10.1038/380262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637577				2022-12-01	WOS:A1996UB11700056
J	Michels, KB; Willett, WC; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE				Michels, KB; Willett, WC; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE			Prospective assessment of breastfeeding and breast cancer incidence among 89887 women	LANCET			English	Article							RISK-FACTORS; LACTATION; POPULATION; AGE; ASSOCIATION; PREGNANCY; DURATION; 1ST	Background The relation between breastfeeding and breast-cancer risk has been examined in many studies; some have reported no association, and others a reduced risk, particularly among premenopausal women. In the only prospective cohort study, no association was found. We have assessed prospectively the association between breastfeeding and incidence of breast cancer among 89 887 women in the US Nurses' Health Study. Methods In 1986, participants were asked about the number of months they breastfed for all their children combined. Parous women with no history of cancer were included in this analysis. During 6 years of follow-up (513 015 person-years), 1459 invasive breast cancer cases were diagnosed. Findings Relative to women who had never breastfed, no significant overall association was found-after adjusting for established risk factors for breast cancer-between a history of having breastfed and subsequent development of breast cancer (relative risk [RR] 0.93, 95% CI 0.83-1.03). No inverse trend was observed with duration of breastfeeding; women who breastfed for 2 years or longer had a RR of 1.11 (0.90-1.38). Among women who had given birth only once, women who had breastfed their child experienced a lower incidence of breast cancer (RR 0.68, 0.46-1.00). Among premenopausal women, who tended to be near menopause due to the age structure of the cohort, the RR of breast cancer for those who had lactated was 1.16 (0.89-1.50). Premenopausal women who had lactated for 1 year or more had a RR of 1.10 (0.78-1.57). Interpretation These data suggest that there is no important overall association between breast-feeding and the occurrence of breast cancer.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Michels, KB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; BRIGNONE G, 1987, INT J EPIDEMIOL, V16, P356, DOI 10.1093/ije/16.3.356; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; CHILVERS CED, 1993, BRIT MED J, V307, P17, DOI 10.1136/bmj.307.6895.17; DEWAILLY E, 1994, J NATL CANCER I, V86, P803, DOI 10.1093/jnci/86.10.803-a; Haring M H, 1992, Ned Tijdschr Geneeskd, V136, P743; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HENDERSHOT GE, 1984, PEDIATRICS, V74, P591; HENDERSON BE, 1985, CANCER, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9; ING R, 1977, LANCET, V2, P124; Jensen A.A., 1991, CHEM CONTAMINANTS HU; KALACHE A, 1980, BRIT MED J, V280, P223, DOI 10.1136/bmj.280.6209.223-a; KELSEY JL, 1994, NEW ENGL J MED, V330, P136, DOI 10.1056/NEJM199401133300210; KURINIJ N, 1989, AM J PUBLIC HEALTH, V79, P1247, DOI 10.2105/AJPH.79.9.1247; KVALE G, 1988, J EPIDEMIOL COMMUN H, V42, P30, DOI 10.1136/jech.42.1.30; LAING AE, 1993, J NATL MED ASSOC, V85, P931; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P157, DOI 10.1007/BF01830262; LANECLAYPON JE, 1926, 32 HM STAT OFF REP; LAWRENCE RA, 1994, BREASTFEEDING GUIDE; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LONDON SJ, 1994, NEW ENGL J MED, V330, P1682, DOI 10.1056/NEJM199406093302311; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MACMAHON B, 1982, JNCI-J NATL CANCER I, V69, P1035; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V42, P185; MACMAHON B, 1993, JNCI-J NATL CANCER I, V71, P3183; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Romieu I., 1994, American Journal of Epidemiology, V139, pS68; ROSEROBIXBY L, 1987, INT J CANCER, V40, P747, DOI 10.1002/ijc.2910400606; Rosner B., 2011, FUNDAMENTALS BIOSTAT, P352; RUSSO J, 1980, AM J PATHOL, V100, P497; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Segi M, 1957, GANN               S, V48, P1; SIMOPOULOS AP, 1984, PEDIATRICS, V74, P603; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; TAO SC, 1988, INT J CANCER, V42, P495, DOI 10.1002/ijc.2910420404; THOMAS DB, 1993, INT J EPIDEMIOL, V22, P619, DOI 10.1093/ije/22.4.619; Wainwright J. M., 1931, AM J CANCER, V15, P2610; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YOO KY, 1992, AM J EPIDEMIOL, V135, P726, DOI 10.1093/oxfordjournals.aje.a116359	42	75	78	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 17	1996	347	8999					431	436		10.1016/S0140-6736(96)90010-0	http://dx.doi.org/10.1016/S0140-6736(96)90010-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618484				2022-12-01	WOS:A1996TV72200010
J	Giros, B; Jaber, M; Jones, SR; Wightman, RM; Caron, MG				Giros, B; Jaber, M; Jones, SR; Wightman, RM; Caron, MG			Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter	NATURE			English	Article							NUCLEUS-ACCUMBENS; MESSENGER-RNA; RECEPTOR GENE; RAT STRIATUM; NEURONS; MECHANISMS; EXPRESSION; NEUROTRANSMISSION; INHIBITOR; RELEASE	Disruption of the mouse dopamine transporter gene results in spontaneous hyperlocomotion despite major adaptive changes, such as decreases in neurotransmitter and receptor levels. In homozygote mice, dopamine persists at least 100 times longer in the extracellular space, explaining the biochemical basis of the hyperdopaminergic phenotype and demonstrating the critical role of the transporter in regulating neurotransmission. The dopamine transporter is an obligatory target of cocaine and amphetamine, as these psychostimulants have no effect on locomotor activity or dopamine release and uptake in mice lacking the transporter.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; UNIV N CAROLINA, CURRICULUM NEUROBIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27514 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Jones, Sara R/K-4816-2014; Giros, Bruno/ABD-5790-2021; Jansen, Heiko T./A-5770-2008	Jones, Sara R/0000-0002-3424-7576; Giros, Bruno/0000-0001-5876-9822; Jansen, Heiko T./0000-0003-0178-396X; Jaber, Mohamed/0000-0003-2536-1913				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BALK JH, 1995, NATURE, V377, P424; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BAUMANN MH, 1993, BRAIN RES, V608, P175, DOI 10.1016/0006-8993(93)90792-L; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Byck R, 1977, NIDA Res Monogr, VSeries 13, P97; CERRUTI C, 1993, MOL BRAIN RES, V18, P181, DOI 10.1016/0169-328X(93)90187-T; CHIODO LA, 1992, NEUROCHEM INT, V20, pS81; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; CROW TJ, 1980, BRIT J PSYCHIAT, V137, P383, DOI 10.1192/S0007125000071919; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; FULLER RW, 1991, MED RES REV, V11, P17, DOI 10.1002/med.2610110103; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GRAHAM JH, 1995, J PHARMACOL EXP THER, V274, P707; HITRI A, 1994, CLIN NEUROPHARMACOL, V17, P1, DOI 10.1097/00002826-199402000-00001; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JABER M, 1995, NEUROSCIENCE, V65, P1041, DOI 10.1016/0306-4522(94)00537-F; JACOCKS HM, 1992, J PHARMACOL EXP THER, V262, P356; JONES SR, 1995, J NEUROCHEM, V64, P2581; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KENNEDY RT, 1992, J NEUROCHEM, V59, P449, DOI 10.1111/j.1471-4159.1992.tb09391.x; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEMOINE C, 1990, P NATL ACAD SCI USA, V87, P230, DOI 10.1073/pnas.87.1.230; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; MEISTER B, 1993, NEUROENDOCRINOLOGY, V58, P388, DOI 10.1159/000126568; PARKER EM, 1986, J PHARMACOL EXP THER, V237, P179; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RAITERI M, 1979, J PHARMACOL EXP THER, V208, P195; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SULZER D, 1995, J NEUROSCI, V15, P4102; TISON F, 1994, NEUROSCI LETT, V166, P48, DOI 10.1016/0304-3940(94)90837-0; WALL SC, 1995, MOL PHARMACOL, V47, P544; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; Wise R A, 1985, Psychiatr Med, V3, P445; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIMMERBERG B, 1992, PHYSIOL BEHAV, V52, P379, DOI 10.1016/0031-9384(92)90287-C	48	1946	1986	1	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					606	612		10.1038/379606a0	http://dx.doi.org/10.1038/379606a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628395				2022-12-01	WOS:A1996TV68800042
J	Tiku, PE; Gracey, AY; Macartney, AI; Beynon, RJ; Cossins, AR				Tiku, PE; Gracey, AY; Macartney, AI; Beynon, RJ; Cossins, AR			Cold-induced expression of Delta(9)-desaturase in carp by transcriptional and posttranslational mechanisms	SCIENCE			English	Article							STEARYL-COA DESATURASE; LIVER; MEMBRANES	Poikilothermic animals respond to chronic cold by increasing phosphoglyceride unsaturation to restore the fluidity of cold-rigidified membranes. Despite the importance of this compensatory response,the enzymes involved have not-been clearly identified, and the mechanisms that control their activity are unknown. In carp liver, cold induces an 8- to 10-fold increase in specific activity of the microsomal stearoyl coenzyme A desaturase. Cold-induced up-regulation of gene transcription resulted in a 10-fold increase in desaturase transcript amounts after 48 to 60 hours. However, this increase was preceded by the activation of latent desaturase, probably by a posttranslational mechanism. These two mechanisms may act sequentially to match desaturase expression to the demands imposed by a progressive decrease in temperature.	UNIV LIVERPOOL,DEPT ENVIRONM & EVOLUTIONARY BIOL,ENVIRONM PHYSIOL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV MANCHESTER,INST SCI & TECHNOL,DEPT BIOCHEM & APPL MOLEC BIOL,MANCHESTER M60 1QD,LANCS,ENGLAND	University of Liverpool; University of Manchester			Beynon, Robert J/K-1408-2014; Gracey, Andrew Y/A-3060-2008	Beynon, Robert J/0000-0003-0857-495X; Cossins, Andrew/0000-0002-0813-5212				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSSINS AR, 1982, BIOCHIM BIOPHYS ACTA, V687, P303, DOI 10.1016/0005-2736(82)90559-4; Cossins AR, 1994, TEMPERATURE ADAPTATI; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; HAZEL JR, 1995, ANNU REV PHYSIOL, V57, P19, DOI 10.1146/annurev.ph.57.030195.000315; LEIFKOWITH JB, 1990, BIOCHIM BIOPHYS ACTA, V1044, P13; Liu Z J, 1990, DNA Seq, V1, P125, DOI 10.3109/10425179009016040; Macartney A., 1994, TEMPERATURE ADAPTATI, P129; MACARTNEY AI, UNPUB; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHUNKE M, 1983, BIOCHIM BIOPHYS ACTA, V734, P70, DOI 10.1016/0005-2736(83)90076-7; STRITTMATTER P, 1988, J BIOL CHEM, V263, P2532; TAKAMURA H, 1986, LIPIDS, V21, P356, DOI 10.1007/BF02535701; WODTKE E, 1991, BIOCHIM BIOPHYS ACTA, V1064, P343, DOI 10.1016/0005-2736(91)90321-X	15	228	244	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					815	818		10.1126/science.271.5250.815	http://dx.doi.org/10.1126/science.271.5250.815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629000				2022-12-01	WOS:A1996TU69400049
J	Wong, GT; Gannon, KS; Margolskee, RF				Wong, GT; Gannon, KS; Margolskee, RF			Transduction of bitter and sweet taste by gustducin	NATURE			English	Article							RECEPTOR-CELLS; MICE; DISRUPTION; EXPRESSION; RESPONSES	SFVERAL lines of evidence suggest that both sweet and bitter tastes are transduced via receptors coupled to heterotrimeric guanine-nucleotide-binding proteins (G proteins) (reviewed in refs 1, 2). Gustducin is a taste receptor cell (TRC)-specific G protein that is closely related to the transducins(3). Gustducin and rod transducin, which is also expressed in TRCs (ref. 4), have been proposed to couple bitter-responsive receptors to TRC-specific phosphodiesterases to regulate intracellular cyclic nucleotides(2-5). Here we investigate gustducin's role in taste transduction by generating and characterizing mice deficient in the gustducin alpha-subunit (alpha gustducin). As predicted, the mutant mice showed reduced behavioural and electrophysiological responses to bitter compounds, whereas they were indistinguishable from wild-type controls in their responses to salty and sour stimuli. Unexpectedly, mutant mice also exhibited reduced behavioural and electrophysiological responses to sweet compounds. Our results suggest that gustducin is a principal mediator of both bitter and sweet signal transduction.	CUNY MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Alshali, Rasha A/K-8051-2012	Margolskee, Robert/0000-0002-9572-2887				AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AVENET P, 1987, J MEMBRANE BIOL, V97, P223, DOI 10.1007/BF01869225; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; GANNON KS, 1995, PHYSIOL BEHAV, V57, P231, DOI 10.1016/0031-9384(94)00279-E; HARDER DB, 1989, CHEM SENSES, V14, P547, DOI 10.1093/chemse/14.4.547; KINNAMON SC, 1992, ANNU REV PHYSIOL, V54, P715, DOI 10.1146/annurev.physiol.54.1.715; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KWEE L, 1995, DEVELOPMENT, V121, P489; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Margolskee Robert F., 1993, Current Opinion in Neurobiology, V3, P526, DOI 10.1016/0959-4388(93)90051-Y; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MISTRETTA CM, 1991, SMELL TASTE HLTH DIS, P35; NAIM M, 1991, COMP BIOCHEM PHYS B, V100, P455, DOI 10.1016/0305-0491(91)90203-P; NAIM M, 1994, BIOCHEM J, V297, P451, DOI 10.1042/bj2970451; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NINOMIYA Y, 1984, BRAIN RES, V302, P305, DOI 10.1016/0006-8993(84)90244-0; NINOMIYA Y, 1989, COMP BIOCHEM PHYS A, V92, P371; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spielman AI, 1996, AM J PHYSIOL-CELL PH, V270, pC926, DOI 10.1152/ajpcell.1996.270.3.C926; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; SZABO P, 1994, DEVELOPMENT, V120, P1651; TINTI JM, 1991, ACS SYM SER, V450, P88; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; ZYLSTRA MLE, 1989, NATURE, V342, P435	30	524	567	5	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 27	1996	381	6585					796	800		10.1038/381796a0	http://dx.doi.org/10.1038/381796a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657284				2022-12-01	WOS:A1996UU35600063
J	Kibota, TT; Lynch, M				Kibota, TT; Lynch, M			Estimate of the genomic mutation rate deleterious to overall fitness in E-coli	NATURE			English	Article							POPULATIONS; EVOLUTION	MUTATIONS are a double-edged sword: they are the ultimate source of genetic variation upon which evolution depends, yet most mutations affecting fitness (viability and reproductive success) appear to be harmful(1). Deleterious mutations of small effect can escape natural selection, and should accumulate in small populations(2-4). Reduced fitness from deleterious-mutation accumulation may be important in the evolution of sex(5-7), mate choice(8,9), and diploid life-cycles(10), and in the extinction of small populations(11,12). Few empirical data exist, however. Minimum estimates of the genomic deleterious-mutation rate for viability in Drosophila melanogaster are surprisingly high(1,13,14), leading to the conjecture that the rate for total fitness could exceed 1.0 mutation per individual per generation(5,6). Here we use Escherichia coli to provide an estimate of the genomic deleterious-mutation rate for total fitness in a microbe. We estimate that the per-microbe rate of deleterious mutations is in excess of 0.0002.	UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon	Kibota, TT (corresponding author), CLARK COLL,DEPT BIOL,1800 E MCLOUGHLIN BLVD,VANCOUVER,WA 98663, USA.							BATEMAN AJ, 1959, INT J RADIAT BIOL, P170; Carlton BC, 1981, MANUAL METHODS GENER, P222; Cavalier-Smith T., 1985, P69; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; CHARLESWORTH D, 1993, GENET RES, V61, P39, DOI 10.1017/S0016672300031086; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; HALGH J, 1978, THEOR POPUL BIOL, V14, P251; HARTL DL, 1994, GENETICS, V138, P227; Herdman M., 1985, EVOLUTION GENOME SIZ, P37; JENKINS CD, 1995, EVOLUTION, V49, P512, DOI [10.1111/j.1558-5646.1995.tb02283.x, 10.2307/2410275]; KEIGHTLEY PD, 1994, GENETICS, V138, P1315; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.1111/j.1558-5646.1994.tb02188.x, 10.2307/2410240]; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LENSKI RE, 1991, AM NAT, V138, P315; LINDSLEY DL, 1980, GENETICS BIOL DROSOP, P226; LYNCH M, 1993, J HERED, V84, P339, DOI 10.1093/oxfordjournals.jhered.a111354; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; Lynch Michael, 1994, P86; [No title captured]; [No title captured]	24	252	255	1	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					694	696		10.1038/381694a0	http://dx.doi.org/10.1038/381694a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649513				2022-12-01	WOS:A1996UR97900051
J	Offit, K; Gilewski, T; McGuire, P; Schluger, A; Hampel, H; Brown, K; Swensen, J; Neuhausen, S; Skolnick, M; Norton, L; Goldgar, D				Offit, K; Gilewski, T; McGuire, P; Schluger, A; Hampel, H; Brown, K; Swensen, J; Neuhausen, S; Skolnick, M; Norton, L; Goldgar, D			Germline BRCA1 185delAG mutations in Jewish women with breast cancer	LANCET			English	Article							POLYMERASE CHAIN-REACTION; ENZYMATIC AMPLIFICATION	Background We aimed to find out the proportion of breast cancers in Ashkenazi Jewish women attributable to the frameshift mutation at position 185 involving the deletion of adenine and guanine (185delAG) in the breast cancer gene BRCA1. Methods We studied 107 Ashkenazi Jewish women with breast cancer seen at medical oncology acid genetic counselling clinics in New York over a three and a half year period beginning in 1992. 80 of the women were diagnosed before age 42 years; the other 27 were diagnosed between 42 and 50 years and had a positive family history, Genomic DNA testing by PCR amplification was done to identify any 185delAG mutations of the BRCA1 gene. Findings Of the 80 women diagnosed before the age of 42 years, 16 (20%, 95% CI 11 . 2-28 . 8) were heterozygous for the mutation, All 16 women had at least one first-degree or second-degree relative with breast or ovarian cancer, Of 27 probands diagnosed with breast cancer between the ages of 42 and 50 years who had at least one first-degree relative affected with breast or ovarian cancer, 8 (30%, 95% CI 12-47) had 185delAG mutations, Interpretation These data suggest that screening for the 185delAG mutation may be useful in genetic counselling of these women where options for detection and prevention of possible cancers can be discussed.	MEM SLOAN KETTERING CANC CTR,DEPT MED,BREAST ONCOL SERV,NEW YORK,NY 10021; UNIV UTAH,SCH MED,DEPT MED INFORMAT,GENET EPIDEMIOL GRP,SALT LAKE CITY,UT; MYRIAD GENET INC,SALT LAKE CITY,UT; INT AGCY RES CANC,UNIT GENET EPIDEMIOL,F-69372 LYON,FRANCE	Memorial Sloan Kettering Cancer Center; Utah System of Higher Education; University of Utah; Myriad Genetics, Inc; World Health Organization; International Agency for Research on Cancer (IARC)	Offit, K (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,CLIN GENET SERV,NEW YORK,NY 10021, USA.		Hampel, Heather/AAV-4041-2020	Hampel, Heather/0000-0001-7558-9794	NATIONAL CANCER INSTITUTE [P20CA058232, R01CA065673, R01CA055914] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 65673, P20 CA 58232, R01 CA 55914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; TONIN P, 1995, AM J HUM GENET, V57, P189; WEBER JL, 1989, AM J HUM GENET, V44, P388	10	117	121	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1643	1645		10.1016/S0140-6736(96)91484-1	http://dx.doi.org/10.1016/S0140-6736(96)91484-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642955				2022-12-01	WOS:A1996UQ70100007
J	deCharms, RC; Merzenich, MM				deCharms, RC; Merzenich, MM			Primary cortical representation of sounds by the coordination of action-potential timing	NATURE			English	Article							AUDITORY-CORTEX; STRIATE CORTEX; MACAQUE MONKEY; NEURONS; RESPONSES; CAT; SYNCHRONIZATION	CORTICAL population coding could in principle rely on either the mean rate of neuronal action potentials, or the relative timing of action potentials, or both, When a single sensory stimulus drives many neurons to fire at elevated rates, the spikes of these neurons become tightly synchronized(1,2), which could be involved in 'binding' together individual firing-rate feature representations into a unified object percept(3), Here we demonstrate that the relative timing of cortical action potentials can signal stimulus features themselves, a function even more basic than feature grouping, Populations of neurons in the primary auditory cortex can coordinate the relative timing of their action potentials such that spikes occur closer together in time during continuous stimuli. In this way cortical neurons can signal stimuli even when their firing rates do not change, Population coding based on relative spike timing can systematically signal stimulus features, it is topographically mapped, and it follows the stimulus time course even where mean firing rate does not.	UNIV CALIF SAN FRANCISCO, KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; BEMANDER O, 1994, NEURAL COMPUT, V6, P622; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; CREUTZFELDT O, 1980, EXP BRAIN RES, V39, P87; DICKSON JW, 1974, J NEUROPHYSIOL, V37, P1239, DOI 10.1152/jn.1974.37.6.1239; Efron B, 1982, JACKKNIFE BOOTSTRAP, P75, DOI [10.1137/1.9781611970319.ch10, DOI 10.1137/1.9781611970319.CH10]; EGGERMONT JJ, 1994, J NEUROPHYSIOL, V71, P246, DOI 10.1152/jn.1994.71.1.246; GABBOTT PLA, 1987, NEUROSCIENCE, V21, P833, DOI 10.1016/0306-4522(87)90040-6; GRANNAN ER, 1993, NEURAL COMPUT, V5, P550, DOI 10.1162/neco.1993.5.4.550; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LEHMANN EL, 1975, NONPARAMETRICS; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P374, DOI 10.1152/jn.1957.20.4.374; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MURTHY VN, 1994, NEURAL COMPUT, V6, P1111, DOI 10.1162/neco.1994.6.6.1111; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; PFINGST BE, 1981, J NEUROPHYSIOL, V45, P16, DOI 10.1152/jn.1981.45.1.16; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; TSO DY, 1986, J NEUROSCI, V6, P1160; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VONDERMALSBURG C, 1981, INTERNAL REPORT M PL	30	393	397	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					610	613		10.1038/381610a0	http://dx.doi.org/10.1038/381610a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637597				2022-12-01	WOS:A1996UQ65700052
J	Yuan, JM; Ross, RK; Wang, XL; Gao, YT; Henderson, BE; Yu, MC				Yuan, JM; Ross, RK; Wang, XL; Gao, YT; Henderson, BE; Yu, MC			Morbidity and mortality in relation to cigarette smoking in Shanghai, China - A prospective male cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MAJOR RISK-FACTORS; MIDDLE-AGED MEN; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; FOLLOW-UP; STROKE; CANCER; SMOKERS; WOMEN	Objective.-To evaluate prospectively the health risk of cigarette smoking in middle-aged men in Shanghai, China. Design.-Prospective cohort study with annual follow-up. Participants.-A total of 18244 male residents of Shanghai, China. enrolled in the study during January 1, 1986, through September 30, 1989, and actively followed via annual visits. Results.-By September 30, 1993, 852 deaths and 554 incident cancer cases were identified during the follow-up period, which averaged 5.4 years per subject. The overall incidence rate for cancer was 568 per 100 000 man-years, with the 3 leading sites being lung (146/100000), stomach (116/100000), and liver (81/100000). Forty-one percent of all deaths were from cancer. Stroke was the most frequent cause of death unrelated to cancer, with an age-adjusted rate 4.2 times higher than that of US white men (201/100000 vs 48/100000), followed by ischemic heart disease, with an age-adjusted rate one-fifth that of US white men (69/100000 vs 366/100000). Compared with lifelong nonsmokers, the relative risks in heavy smokers (20 or more cigarettes per day) after adjustment for alcohol consumption were 2.2 fdr any incident cancer, 9.4 for incident lung cancer, 6.7 for head and neck cancer, and 1.8 for liver cancer. In terms of mortality, heavy smokers were at a 60% greater risk of death relative to lifelong nonsmokers; there was a 2.3-fold excess risk of death gram cancer and 2-fold to 3-fold excess risk of death from heart disease. Conclusions.-Cigarette smoking is an important predictor of risk of cancer and mortality in men in Shanghai. Among the study subjects, 36% of all cases of cancer and 21% of all deaths could be attributed to cigarette smoking.	SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA	Shanghai Jiao Tong University	Yuan, JM (corresponding author), UNIV SO CALIF,NORRIS COMPREHENS CANC CTR,1441 EASTLAKE AVE,LOS ANGELES,CA 90033, USA.			Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [R01 CA043092-20, R01 CA43092, R35 CA53890, R01 CA043092] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043092, R35CA053890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BARON AE, 1993, CANCER EPIDEM BIOMAR, V2, P519; BRESLOW NE, 1987, INT AGENCY RES CANC, V82; CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; *CDC, 1989, 898411 CDC US DEP HL; CHEN DY, 1992, NEUROEPIDEMIOLOGY, V11, P15, DOI 10.1159/000110902; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P59; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; DENG J, 1985, CHIN J PREV MED, V5, P271; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Freund K M, 1993, Ann Epidemiol, V3, P417, DOI 10.1016/1047-2797(93)90070-K; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAMMOND EC, 1961, J NATL CANCER I, V27, P419; HAMMOND EC, 1980, PREV MED, V9, P169, DOI 10.1016/0091-7435(80)90071-7; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; Kodama K, 1993, Ann Epidemiol, V3, P524; LAM KC, 1982, CANCER RES, V42, P5246; LEUNG HM, 1981, BIOMETRICS, V37, P293, DOI 10.2307/2530418; MENOTTI A, 1990, PREV MED, V19, P270, DOI 10.1016/0091-7435(90)90027-H; *NAT CTR HLTH STAT, 1993, US DEP HLTH HUM SERV; NOVOTNY TE, 1988, PUBLIC HLTH REPORTS, V103, P552; PAGANINIHILL A, 1994, AM J PUBLIC HEALTH, V84, P992, DOI 10.2105/AJPH.84.6.992; PARKIN DM, 1992, INT AGENCY RES CANC, V120; PETO R, 1986, LANCET, V2, P1038; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGOT E, 1980, PUBLIC HLTH REP, V95, P218; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; ROSS RK, IN PRESS AM J EPIDEM; SEMENCIW RM, 1988, INT J EPIDEMIOL, V17, P317, DOI 10.1093/ije/17.2.317; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Thom T J, 1993, Ann Epidemiol, V3, P509; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YU JJ, 1990, JAMA-J AM MED ASSOC, V264, P1575, DOI 10.1001/jama.264.12.1575; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; 1993, MMWR-MORBID MORTAL W, V42, P645; 1987, CHIN MED J, V67, P229	39	147	155	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1646	1650						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637137				2022-12-01	WOS:A1996UN25200026
J	Tytler, D; Fan, XM; Burles, S				Tytler, D; Fan, XM; Burles, S			Cosmological baryon density derived from the deuterium abundance at redshift z=3.57	NATURE			English	Article								THE primordial ratio of deuterium to hydrogen nuclei (D/H), created as a result of the Big Bang, provides the most sensitive measure of the cosmological density of baryons(1-5). Measurements of the D/H ratio in the interstellar medium of our Galaxy place a strict lower limit on the primordial ratio(6), because processing of gas by stars reduces the abundance of deuterium relative to hydrogen. Absorption of radiation from distant quasars by intervening clouds of gas offers a means of probing D/H ratios at large redshifts, where the effects of stellar processing should be negligible. Measurements(7,8) on one absorption system have indicated an extremely high primordial abundance ratio of 24 x 10(-5). Here we report a measurement of the D/H ratio in another high-redshift absorption system, and obtain a value that is an order of magnitude lower than that reported previously(7,8). The measured ratio of 2.3 x 10(-5) is consistent with that in the interstellar medium (after allowing for Galactic chemical evolution(9,10)), and indicates that the absorption spectra on which the earlier estimates are based may have been subject to strong contamination. We calculate a baryon density that is 5% of the critical density required to close the Universe.	UNIV CALIF SAN DIEGO, CTR ASTROPHYS & SPACE SCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Tytler, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHYS, C0111, LA JOLLA, CA 92093 USA.							Carswell RF, 1996, MON NOT R ASTRON SOC, V278, P506, DOI 10.1093/mnras/278.2.506; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1; CHARBONNEL C, 1995, ASTROPHYS J, V453, pL41; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; DONAHUE M, 1991, ASTROPHYS J, V383, P511, DOI 10.1086/170809; EDMUNDS MG, 1994, MON NOT R ASTRON SOC, V270, pL37; GAIL HP, 1974, ASTRON ASTROPHYS, V32, P65; GALLI D, 1995, ASTROPHYS J, V443, P536, DOI 10.1086/175546; GEISS J, 1994, ORIGIN EVOLUTION ELE, V89; HU EM, 1995, ASTRON J, V110, P1526, DOI 10.1086/117625; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; KRAUSS LM, 1995, PHYS LETT B, V347, P347, DOI 10.1016/0370-2693(95)00082-V; Levshakov SA, 1996, MON NOT R ASTRON SOC, V278, P497, DOI 10.1093/mnras/278.2.497; LINSKY JL, 1995, ASTROPHYS J, V451, P335, DOI 10.1086/176223; MATHEWS WG, 1987, ASTROPHYS J, V323, P456, DOI 10.1086/165843; MCCULLOUGH PR, 1992, ASTROPHYS J, V390, P213, DOI 10.1086/171271; MORTON DC, 1991, ASTROPHYS J SUPPL S, V77, P119, DOI 10.1086/191601; PAGEL BEJ, 1992, MON NOT R ASTRON SOC, V255, P325, DOI 10.1093/mnras/255.2.325; PAGEL BEJ, 1994, ESO EIPC WORKSH LIGH, P155; PERSIC M, 1992, MON NOT R ASTRON SOC, V258, pP14, DOI 10.1093/mnras/258.1.14P; PETITJEAN P, 1990, ASTRON ASTROPHYS, V231, P309; PRATT M, 1996, WORKSHOP DARK MATTER; Ryan SG, 1996, ASTROPHYS J, V458, P543, DOI 10.1086/176838; SARKAR S, UNPUB REP PROG PHYS; SASSELOV D, 1995, ASTROPHYS J, V444, pL5; SMITH MS, 1993, ASTROPHYS J SUPPL S, V85, P219, DOI 10.1086/191763; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; STEIGMAN G, 1992, ASTROPHYS J, V401, P150, DOI 10.1086/172048; STEIGMAN G, 1995, ASTROPHYS J, V453, P173, DOI 10.1086/176378; THUAN TX, 1996, INTERPLAY MASSIVE ST; VAUCLAIR S, 1995, ASTRON ASTROPHYS, V295, P715; VOGT S, 1994, P SOC PHOTO-OPT INS, V2198, P362, DOI 10.1117/12.176725; WALKER TP, 1991, ASTROPHYS J, V376, P51, DOI 10.1086/170255; WAMPLER EJ, UNPUB	34	287	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					207	209		10.1038/381207a0	http://dx.doi.org/10.1038/381207a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622761	Green Submitted			2022-12-01	WOS:A1996UL24900044
J	Levy, EM; Viscoli, CM; Horwitz, RI				Levy, EM; Viscoli, CM; Horwitz, RI			The effect of acute renal failure on mortality - A cohort analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNIT; RISK-FACTORS; APACHE-II; PREDICTION; SURVIVAL; INSUFFICIENCY; HEMODIALYSIS; PROGNOSIS; VARIABLES; PATTERNS	Objective.-To determine if the high mortality in acute renal failure is explained by underlying illnesses (comorbidity). Design.-Cohort analytic study. Setting.-An 826-bed general hospital providing primary, secondary, and tertiary care. Patients.-From 16248 inpatients undergoing radiocontrast procedures between 1987 and 1989, we identified 183 index subjects who developed contrast media-associated renal failure (defined as an increase in serum creatinine level of at least 25%, to at least 177 mu mol/L [2 mg/dL], within 2 days of receiving contrast material) and 174 paired subjects, matched for age and baseline serum creatinine level, who underwent similar contrast procedures without developing renal failure. Main Outcome Measure.-Death during hospitalization. Results.-The mortality rate in subjects without renal failure was 7%, compared with 34% in the corresponding index subjects with renal failure (odds ratio, 6.5; P<.001). After adjusting for differences in comorbidity, renal failure was associated with an odds ratio of dying of 5.5. Subjects who died after developing renal failure had complicated clinical courses characterized by sepsis, bleeding, delirium, and respiratory failure; most of these complications developed after the onset of renal failure. Deaths from renal causes were rare. Conclusions.-The high mortality rate in acute renal failure is not explained by the underlying conditions alone, Renal failure appears to increase the risk of developing severe nonrenal complications that lead to death and should not be regarded as a treatable complication of serious illness.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University	Levy, EM (corresponding author), BRIGHAM & WOMENS HOSP,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABREO K, 1986, ARCH INTERN MED, V146, P1338, DOI 10.1001/archinte.146.7.1338; ANDERSON RJ, 1977, NEW ENGL J MED, V296, P1134, DOI 10.1056/NEJM197705192962002; BOULTONJONES M, 1994, LANCET, V344, P559, DOI 10.1016/S0140-6736(94)91958-5; BULLOCK ML, 1985, AM J KIDNEY DIS, V5, P97, DOI 10.1016/S0272-6386(85)80003-2; CAMERON JS, 1986, Q J MED, V59, P337; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CIOFFI WG, 1984, ANN SURG, V200, P205, DOI 10.1097/00000658-198408000-00015; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; DOUMA CE, 1994, J AM SOC NEPHROL, V5, P391; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; FLEISS JL, 1981, STATISTICAL METHODS, P143; FROST L, 1993, SCAND J UROL NEPHROL, V27, P453, DOI 10.3109/00365599309182277; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GROENEVELD ABJ, 1991, NEPHRON, V59, P602, DOI 10.1159/000186651; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Halstenberg W., 1993, Journal of the American Society of Nephrology, V4, P317; HOSMER DW, 1989, APPL LOGISTIC REGRES, V1, P10; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVY EM, 1994, J AM SOC NEPHROL, V4, P319; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; MAHER ER, 1989, Q J MED, V72, P857; MCMURRAY SD, 1978, ARCH INTERN MED, V138, P950, DOI 10.1001/archinte.138.6.950; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; RASMUSSEN HH, 1985, ARCH INTERN MED, V145, P2015, DOI 10.1001/archinte.145.11.2015; RASMUSSEN HH, 1982, AM J MED, V73, P211, DOI 10.1016/0002-9343(82)90181-4; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; ROUTH GS, 1980, POSTGRAD MED J, V56, P244, DOI 10.1136/pgmj.56.654.244; SCHAEFER JH, 1991, INTENS CARE MED, V17, P19, DOI 10.1007/BF01708404; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; WERB R, 1979, RESUSCITATION, V7, P95, DOI 10.1016/0300-9572(79)90003-0; WHEELER DC, 1986, Q J MED, V61, P977; WILKINS RG, 1983, ANAESTHESIA, V38, P628, DOI 10.1111/j.1365-2044.1983.tb12153.x	35	1063	1126	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1489	1494		10.1001/jama.275.19.1489	http://dx.doi.org/10.1001/jama.275.19.1489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622223				2022-12-01	WOS:A1996UJ93700032
J	Phillips, MJ; Ackerley, CA; Superina, RA; Roberts, EA; Filler, RM; Levy, GA				Phillips, MJ; Ackerley, CA; Superina, RA; Roberts, EA; Filler, RM; Levy, GA			Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children	LANCET			English	Article								Background High hepatic copper concentrations have been reported in several liver disorders. We report six Native Canadian children with severe chronic cholestatic liver disease, who had excess hepatic copper and zinc. Methods The children, aged 22 months to 8 years, dame from northern Ontario, Canada. All were referred for possible liver transplantation because of end-stage liver disease. We examined explanted liver samples (or liver biopsy material in one case) by scanning transmission electronmicroscopic (STEM) X-ray elemental microanalysis and atomic absorption spectrophotometry. Samples from four controls (two with no liver pathology, one with biliary atresia, and one with Wilson's disease) were also analysed by atomic absorption spectrophotometry. Findings The explanted livers showed similar distinctive signs of advanced biliary cirrhosis, and on electronmicroscopy there were dense deposits in enlarged lyosomes and in cytoplasm. Hepatic copper concentrations were many times higher in the five patients with measurements (47.6-56.9 mu g/g dry weight) than in two samples of normal control liver tissue (2.3 and 2.9 mu g/g). Similarly, hepatic zinc concentrations were many times higher in the patients than in controls (104-128 vs 1.9-3.2 mu g/g dry weight). Interpretation The excess copper may be due to chronic cholestasis but the excess zinc is unexplained. Since three of the patients are related (shared grandparents), a genetic disorder of metal metabolism is possible, but we cannot exclude environmental factors.	HOSP SICK CHILDREN,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT SURG,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO,ON M5G 1X8,CANADA; TORONTO HOSP,DEPT MED,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PAEDIAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto								ADAMS PC, 1994, HEPATOLOGY, V19, P101, DOI 10.1016/0270-9139(94)90059-0; HORSLEN SP, 1994, GUT, V35, P1497, DOI 10.1136/gut.35.10.1497; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; VONMUHLENDAHL KE, 1994, LANCET, V344, P1515; WEBER AM, 1981, GASTROENTEROLOGY, V81, P653	6	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					866	868		10.1016/S0140-6736(96)91347-1	http://dx.doi.org/10.1016/S0140-6736(96)91347-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622393				2022-12-01	WOS:A1996UC45000011
J	Raffle, AE				Raffle, AE			Trust me, I'm a scientist: Will urologists set a lead for geneticists to follow?	LANCET			English	Editorial Material											Raffle, AE (corresponding author), AVON HLTH AUTHOR,KING SQ HOUSE,KING SQ,BRISTOL BS2 8EE,AVON,ENGLAND.							Harper PS, 1995, LANCET, V346, P1645, DOI 10.1016/S0140-6736(95)92835-9; KNOX EG, 1982, CANC UTERINE CERVIX; KNOX G, 1991, PUBLIC HEALTH, V105, P55, DOI 10.1016/S0033-3506(05)80317-8; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MILLER AB, 1986, IARC SCI PUBLICATION, V76; MURPHY SB, 1991, LANCET, V337, P344, DOI 10.1016/0140-6736(91)90957-Q; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, LANCET, V341, P100; STROUD E, 1990, BLOOD CHOLESTEROL TE; Wilson JM, 1968, PUBLIC HLTH PAPERS W, V34; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1995, NATURE, V337, P273	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					883	884		10.1016/S0140-6736(96)91353-7	http://dx.doi.org/10.1016/S0140-6736(96)91353-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622399				2022-12-01	WOS:A1996UC45000017
J	FungLeung, WP; Surh, CD; Liljedahl, M; Pang, J; Leturcq, D; Peterson, PA; Webb, SR; Karlsson, L				FungLeung, WP; Surh, CD; Liljedahl, M; Pang, J; Leturcq, D; Peterson, PA; Webb, SR; Karlsson, L			Antigen presentation and T cell development in H2-M-deficient mice	SCIENCE			English	Article							INVARIANT CHAIN; I-A; PEPTIDE; MOLECULES; LACKING; REGION	HLA-DM (DM) facilitates peptide loading of major histocompatibility complex class II molecules in human cell lines. Mice lacking functional H2-M, the mouse equivalent of DM, have normal amounts of class II molecules at the cell surface, but most of these are associated with invariant chain-derived CLIP peptides. These mice contain large numbers of CD4(+) T cells, which is indicative of positive selection in the thymus. Their CD4(+) cells were unresponsive to self H2-M-deficient antigen-presenting cells (APCs) but were hyperreactive to wild-type APCs. H2-M-deficient APCs failed to elicit proliferative responses from wild-type T cells.	SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute			Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045; Fung-Leung, Wai-Ping/0000-0001-7013-8855				BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROOKS AG, 1994, J IMMUNOL, V153, P5382; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DORNMAIR K, 1989, COLD SH Q B, V54, P409; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FUNGLEUNG WP, 1994, J EXP MED, V180, P959, DOI 10.1084/jem.180.3.959; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; HASENKRUG KJ, 1987, IMMUNOGENETICS, V25, P136, DOI 10.1007/BF00364282; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KARLSSON L, UNPUB; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; SURH CD, 1993, J EXP MED, V177, P379, DOI 10.1084/jem.177.2.379; SURH CD, UNPUB; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEBB SR, 1990, SCIENCE, V248, P1643	29	241	243	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1278	1281		10.1126/science.271.5253.1278	http://dx.doi.org/10.1126/science.271.5253.1278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638109				2022-12-01	WOS:A1996TX69500036
J	Coupland, RM				Coupland, RM			The effect of weapons on health	LANCET			English	Editorial Material							RED-CROSS				Coupland, RM (corresponding author), RED CROSS,INT COMM,DIV MED,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; BECK LD, 1993, BLINDING WEAPONS; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; GILLOW JT, 1995, J ROY SOC MED, V88, pP347; 1994, LANCET, V344, P1649	7	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					450	451		10.1016/S0140-6736(96)90017-3	http://dx.doi.org/10.1016/S0140-6736(96)90017-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618490				2022-12-01	WOS:A1996TV72200016
J	Pei, X; Moss, F				Pei, X; Moss, F			Characterization of low-dimensional dynamics in the crayfish caudal photoreceptor	NATURE			English	Article							STRANGE SETS; TIME-SERIES; CHAOS; ORBITS; SYSTEM	ATTEMPTS to detect and characterize chaos in biological systems are of considerable interest, especially in medical science, where successful demonstrations may lead to new diagnostic tools and therapies(1). Unfortunately, conventional methods for identifying chaos often yield equivocal results when applied to biological data(2-8), which are usually heavily contaminated with noise. For such applications, a new technique(1) based on the detection of unstable periodic orbits holds promise, Infinite sets of unstable periodic orbits underlie chaos in dissipative systems(4,9); accordingly, the new method searches a time series only for rare events(8) characteristic of these unstable orbits(10), rather than analysing the structure of the series as a whole. Here we demonstrate the efficacy of the method when applied to the dynamics of the crayfish caudal photoreceptor (subject to stimuli representative of the animal's natural habitat). Our findings confirm the existence of low-dimensional dynamics in the system, and strongly suggest the existence of deterministic chaos. More importantly, these results demonstrate the power of methods based on the detection of unstable periodic orbits for identifying low-dimensional dynamics-and, in particular, chaos-in biological systems.			Pei, X (corresponding author), UNIV MISSOURI, DEPT PHYS & ASTRON, LAB NEURODYNAM, ST LOUIS, MO 63121 USA.							Abraham NB, 1993, INT J BIFURCAT CHAOS, V3, P485, DOI 10.1142/S0218127493000398; ARTUSO R, 1990, NONLINEARITY, V3, P325, DOI 10.1088/0951-7715/3/2/005; ARTUSO R, 1990, NONLINEARITY, V3, P361, DOI 10.1088/0951-7715/3/2/006; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P48; CHANG T, 1994, BIOPHYS J, V67, P671, DOI 10.1016/S0006-3495(94)80526-0; CHRISTINI DJ, 1995, PHYS REV LETT, V75, P2782, DOI 10.1103/PhysRevLett.75.2782; CVITANOVIC P, 1988, PHYS REV LETT, V61, P2729, DOI 10.1103/PhysRevLett.61.2729; CVITANOVIC P, 1991, PHYSICA D, V51, P138, DOI 10.1016/0167-2789(91)90227-Z; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; GRASSBERGER P, 1983, PHYSICA D, V9, P189, DOI 10.1016/0167-2789(83)90298-1; HAYASHI H, 1992, J THEOR BIOL, V156, P269, DOI 10.1016/S0022-5193(05)80676-9; HERMANN HT, 1968, J GEN PHYSIOL, V51, P534, DOI 10.1085/jgp.51.4.534; HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953; KAPLAN DT, 1994, PHYSICA D, V73, P38, DOI 10.1016/0167-2789(94)90224-0; KENNEDY DONALD, 1963, JOUR GEN PHYSIOL, V46, P551, DOI 10.1085/jgp.46.3.551; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1979, ANN NY ACAD SCI, V316, P517; Moon F.C., 1987, CHAOTIC VIBRATIONS; PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0; PIERSON D, 1995, PHYS REV LETT, V75, P2124, DOI 10.1103/PhysRevLett.75.2124; ROLLINS RW, 1993, PHYS REV E, V47, pR780, DOI 10.1103/PhysRevE.47.R780; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; RUELLE D, 1971, COMMUN MATH PHYS, V20, P167, DOI 10.1007/BF01646553; RUELLE D, 1990, P ROY SOC LOND A MAT, V427, P241, DOI 10.1098/rspa.1990.0010; RUELLE D, 1994, PHYS TODAY, V47, P24, DOI 10.1063/1.881395; RUELLE D, 1980, RECHERCHE, V11, P132; RUELLE D, 1987, 8TH INT C MATH PHYS, P273; SCHIFF SJ, 1994, NATURE, V370, P615, DOI 10.1038/370615a0; Scott DA, 1995, BIOPHYS J, V69, P1748, DOI 10.1016/S0006-3495(95)80044-5; SHINBROT T, 1993, NATURE, V363, P411, DOI 10.1038/363411a0; STROGATZ SH, 1994, NONLINEAR DYNAMICS C, pCH12; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; WILKENS LA, 1994, J EXP BIOL, V189, P263; WILKENS LA, 1988, COMP BIOCHEM PHYS C, V91, P61, DOI 10.1016/0742-8413(88)90169-7; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9	37	104	106	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					618	621		10.1038/379618a0	http://dx.doi.org/10.1038/379618a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628396				2022-12-01	WOS:A1996TV68800045
J	Paterson, CR; Ogston, SA; Henry, RM				Paterson, CR; Ogston, SA; Henry, RM			Life expectancy in osteogenesis imperfecta	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV STRATHCLYDE,DEPT MANAGEMENT SCI,GLASGOW G1 1XH,LANARK,SCOTLAND	University of Dundee; University of Strathclyde	Paterson, CR (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND.							BAKER RJ, 1978, GLIM SYSTEM; MATTEI JP, 1994, CLIN RHEUMATOL, V13, P447; PATERSON CR, 1987, ACTA PAEDIATR SCAND, V76, P548, DOI 10.1111/j.1651-2227.1987.tb10519.x; SILLENCE D, 1981, CLIN ORTHOPAEDICS, V159, P11; 1983, MORTALITY STATISTICS	5	44	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					351	351						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611834				2022-12-01	WOS:A1996TV69800026
J	Eberhart, CG; Maines, JZ; Wasserman, SA				Eberhart, CG; Maines, JZ; Wasserman, SA			Meiotic cell cycle requirement for a fly homologue of human Deleted in Azoospermia	NATURE			English	Article							CDC25 HOMOLOG; DROSOPHILA; SPERMATOGENESIS; TWINE; GENE	INFERTILITY resulting from a severe defect in sperm production affects 2% of men worldwide(1,2). Of these men with azoospermia, the absence of sperm in semen, one in eight carry de novo deletions for a specific region of the Y chromosome(3-5). A candidate gene for the Y-chromosome azoospermia factor (AZF) has been identified and named Deleted in Azoospermia (DAZ)(5). Here we describe the cloning and characterization of the Drosophila gene boule, which is a homologue of DAZ. The two genes encode closely related proteins that contain a predicted RNA-binding motif, and both loci are expressed exclusively in the testis. Loss of bottle function results in azoospermia; meiotic divisions are blocked, although limited spermatid differentiation occurs. Histological examination of boule testes with cell-cycle markers indicates that the primary defect is at the meiotic G2/M transition. These results support the hypothesis that DAZ is the human AZF, and indicate that Boule and DAZ have an essential meiotic function in fly and human spermatogenesis.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; CASTRILLON DH, 1993, GENETICS, V135, P489; CENCI G, 1994, J CELL SCI, V107, P3521; COMHAIRE FH, 1987, INT J ANDROL S, V7, P3; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; COURTOT C, 1992, DEVELOPMENT, V116, P405; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; FULLER M, 1993, DEV DROSOPHILA, P61; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; HEGER RW, 1914, GERM CELL CYCLE ANIM; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; KARSCHMIZRACHI I, 1993, NUCLEIC ACIDS RES, V21, P2229, DOI 10.1093/nar/21.9.2229; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lindsley D.L., 1980, Genetics and Biology of Drosophila, V2d, P225; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; SILBER SJ, 1995, HUM REPROD, V10, P1031, DOI 10.1093/oxfordjournals.humrep.a136085; SODERSTROM KO, 1980, ARCH PATHOL LAB MED, V104, P476; STEM C, 1941, J EXP ZOOL, V87, P113; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	30	337	361	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					783	785		10.1038/381783a0	http://dx.doi.org/10.1038/381783a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657280				2022-12-01	WOS:A1996UU35600059
J	Bloor, K; Freemantle, N				Bloor, K; Freemantle, N			Lessons from international experience in controlling pharmaceutical expenditure .2. Influencing doctors	BRITISH MEDICAL JOURNAL			English	Article							COSTS	This is the second of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies influencing doctors' prescribing of drugs-particularly the use of budgetary restrictions, information and feedback, and guidelines-and evaluates the impact of these policies. Studies evaluating incentive systems are Limited, but evidence suggests that providing information on its own will not lead to substantial changes in practice and that more active strategies should be evaluated.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	Bloor, K (corresponding author), UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Freemantle, Nick/0000-0001-5807-5740; Bloor, Karen/0000-0003-4852-9854				*AG HLTH CAR POL R, 1992, CLIN PRACT GUID, V3; *AG HLTH CAR POL R, 1994, CLIN PRACT GUID, V8; [Anonymous], 1994, EFF HLTH CAR B; Bloor K, 1993, PURCHASING PROVIDING; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BROWN SS, 1995, BRIT MED J, V311, P1543; Cook T.D., 1979, QUASIEXPERIMENTATION; MALING TJB, 1994, PHARMACOECONOMICS, V6, P5, DOI 10.2165/00019053-199406010-00002; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; Maynard A, 1996, NEW ENGL J MED, V334, P604, DOI 10.1056/NEJM199602293340918; *MIN WELF HLTH CUL, 1994, V8E MIN WELF HLTH CU; PELC A, 1994, PHARMACOECONOMICS, V6, P28, DOI 10.2165/00019053-199400061-00009; SCHULENBURG JM, 1994, HEALTH ECON, V3, P301; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; SOUMERAI SB, 1989, MILBANK Q, V67, P296; Stryer D. B., 1995, JGIM, V10, P114; *U LEEDS, 1993, EFF HLTH CAR B, V5; 1994, SCRIP           1129, P3; 1995, SCRIP           0314, P3; 1995, SCRIP           0310, P3; 1995, SCRIP           0530, P16	22	77	78	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1525	1527		10.1136/bmj.312.7045.1525	http://dx.doi.org/10.1136/bmj.312.7045.1525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646148	Green Published			2022-12-01	WOS:A1996UR82300026
J	Martyn, CN; Gale, CR; Sayer, AA; Fall, C				Martyn, CN; Gale, CR; Sayer, AA; Fall, C			Growth in utero and cognitive function in adult life: Follow up study of people born between 1920 and 1943	BRITISH MEDICAL JOURNAL			English	Article							WEIGHT; BIRTH; CIRCUMFERENCE; INFANTS; DISEASE; BRAIN; FETAL; DEATH; HEAD	Objectives-To examine the relation between fetal growth and cognitive function in adult life. Design-A follow up study of men and women whose birth weights and other measurements of body size had been recorded at birth. Setting-Hertfordshire, Preston, and Sheffield. Subjects-1576 men and women born in Hertfordshire, Sheffield, or Preston between 1920 and 1943. Main outcome measures-Intelligence quotient as measured by the AH4 test and amount of decline in cognitive function with age as estimated by the difference between score on the Mill Hill vocabulary test and score on the AH4 test. Results-Score on the intelligence test was higher in people who had a large biparietal head diameter at birth, but it was not related to any other measure of body size or proportions. No association was found between decline in cognitive function and any measure of size or proportions at birth. Conclusion-Impaired fetal growth was not associated with poorer cognitive performance in adult life. Adaptations made by the fetus in response to conditions that retard its growth seem to be largely successful in maintaining brain development.			Martyn, CN (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Sayer, Avan Aihie/A-4359-2012; Gale, Catharine R/B-1653-2012	Aihie Sayer, Avan/0000-0003-1283-6457; Gale, Catharine/0000-0002-3361-8638; Fall, Caroline/0000-0003-4402-5552	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], [No title captured]; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BERK LE, 1991, CHILD DEV; CAMPBELL S, 1977, BRIT J OBSTET GYNAEC, V84, P165, DOI 10.1111/j.1471-0528.1977.tb12550.x; COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9; CRAVIOTO J, 1975, PERCEPTUAL LEARNING, V2, P3; DAVIES PA, 1975, BRIT MED BULL, V31, P85, DOI 10.1093/oxfordjournals.bmb.a071248; FANCOURT R, 1976, BMJ-BRIT MED J, V1, P1435, DOI 10.1136/bmj.1.6023.1435; FOULDS GA, 1948, J MENT SCI, V94, P133, DOI 10.1192/bjp.94.394.133; GORMAN KS, 1992, INFANT BEHAV DEV, V15, P279, DOI 10.1016/0163-6383(92)80001-B; HOLLAND CA, 1991, REV CLIN GERONTOLOGY, V1, P81, DOI DOI 10.1017/S0959259800002598; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; KLINE J, 1976, CONCEPTION BIRTH EPI; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; MORGANE PJ, 1992, VULNERABLE BRAIN ENV, V1, P3; NELSON KB, 1970, DEV MED CHILD NEUROL, V12, P487; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Osofsky H J, 1975, Obstet Gynecol Surv, V30, P227, DOI 10.1097/00006254-197504000-00001; RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055; RABBITT P, 1990, APPL COGNITIVE PSYCH, V4, P225, DOI 10.1002/acp.2350040402; RABBITT P, 1993, Z GERONTOL, V26, P176; SCHERJON SA, 1993, THESIS U AMSTERDAM A; SMART JL, 1977, GENETICS ENV INTELLI, P215; STEIN Z, 1975, PEDIATR RES, V9, P70, DOI 10.1203/00006450-197509020-00003; Stein Z., 1975, FAMINE HUM DEV DUTCH; VILLAR J, 1984, PEDIATRICS, V74, P783; WARSHAW JB, 1985, PEDIATRICS, V6, P998; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; Winick M., 1972, Lipids, malnutrition and the developing brain. A Ciba Foundation Symposium jointly with the Nestle Foundation in memory of Sir Norman Wright., P199	32	73	78	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1996	312	7043					1393	1396						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP434	8646096				2022-12-01	WOS:A1996UP43400023
J	Cash, S; Zucker, RS; Poo, MM				Cash, S; Zucker, RS; Poo, MM			Spread of synaptic depression mediated by presynaptic cytoplasmic signaling	SCIENCE			English	Article							LONG-TERM POTENTIATION; NEURONS; INVITRO; CULTURE; CELLS; INDUCTION; TRANSPORT; SYNAPSES; CURRENTS; RELEASE	Postsynaptic activity may modulate presynaptic functions by transsynaptic retrograde signals, At developing neuromuscular synapses in Xenopus nerve-muscle cultures, a brief increase in the cytosolic calcium ion (Ca2+) concentration in postsynaptic myocytes induced persistent depression of presynaptic transmitter secretion, This depression spread to distant synapses formed by the same neuron, Clearance of extracellular fluid did not prevent the spread of depression, and depression could not be induced by increasing the Ca2+ concentration in a nearby myocyte not in contact with the presynaptic neuron, Thus, the spread of depression is mediated by signaling in the presynaptic cytoplasm, rather than by a retrograde factor in the extracellular space.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; UNIV CALIF BERKELEY,DIV NEUROBIOL,BERKELEY,CA 94720	Columbia University; University of California System; University of California Berkeley			Zucker, Robert S/J-9995-2012	Zucker, Robert S/0000-0003-1068-2343	NINDS NIH HHS [NS15114] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015114] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM WC, 1983, NATURE, V305, P717, DOI 10.1038/305717a0; ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BOURNE HR, 1993, NEURON S, V10, P65; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CASH S, IN PRESS NEURON; CHOW I, 1984, J PHYSIOL-LONDON, V346, P181, DOI 10.1113/jphysiol.1984.sp015015; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; EVERS J, 1989, J NEUROSCI, V9, P1523; GOODMAN CS, 1993, NEURON S, V10, P77; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRSCH JC, 1992, SYNAPSE, V12, P82, DOI 10.1002/syn.890120110; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LANDO L, 1994, J NEUROPHYSIOL, V72, P825, DOI 10.1152/jn.1994.72.2.825; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MARTY A, 1995, CURR OPIN NEUROBIOL, V5, P335, DOI 10.1016/0959-4388(95)80046-8; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; NICOLL RA, 1995, NATURE, V377, P155; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; POPOV S, 1992, J NEUROSCI, V12, P77; PURVES D, 1985, PRINCIPLES NEURAL DE; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Tabti N., 1991, CULTURING NERVE CELL, P137; VINCENT P, 1993, NEURON, V11, P885, DOI 10.1016/0896-6273(93)90118-B; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L	34	37	38	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					998	1001		10.1126/science.272.5264.998	http://dx.doi.org/10.1126/science.272.5264.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638143				2022-12-01	WOS:A1996UL61900041
J	Geli, MI; Riezman, H				Geli, MI; Riezman, H			Role of type I myosins in receptor-mediated endocytosis in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; ACTIN; CELLS	Type I myosins are thought to drive actin-dependent membrane motility, but the direct demonstration in vivo of their involvement in specific cellular processes has been difficult. Deletion of the genes MYO3 and MYO5, which encode the yeast type I myosins, almost abolished growth. A double-deleted mutant complemented with a MYO5 temperature-sensitive allele (myo5-1) showed a strong defect in the internalization step of receptor-mediated endocytosis, whereas the secretory pathway remained apparently unaffected. Thus, myosin I activity is required for a budding event in endocytosis but not for several other aspects of membrane traffic.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel			Geli, Maria Isabel/L-3246-2014	Geli, Maria Isabel/0000-0002-3452-6700; Riezman, Howard/0000-0003-4680-9422				BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DULIC V, 1991, METHOD ENZYMOL, V194, P697; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HICKE L, UNPUB; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; 1988, GENE, V74, P527	28	219	225	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					533	535		10.1126/science.272.5261.533	http://dx.doi.org/10.1126/science.272.5261.533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614799				2022-12-01	WOS:A1996UG82600039
J	Dixon, MS; Jones, DA; Keddie, JS; Thomas, CM; Harrison, K; Jones, JDG				Dixon, MS; Jones, DA; Keddie, JS; Thomas, CM; Harrison, K; Jones, JDG			The tomato Cf-2 disease resistance locus comprises two functional genes encoding leucine-rich repeat proteins	CELL			English	Article							CLADOSPORIUM-FULVUM; CLONING; KINASE	In plants, resistance to pathogens is frequently determined by dominant resistance genes, whose products are proposed to recognize pathogen-encoded avirulence gene (Avr) products. The tomato resistance locus Cf-2 was isolated by positional cloning and found to contain two almost identical genes, each conferring resistance to isolates of tomato leaf mould (C. fulvum) expressing the corresponding Avr2 gene. The two Cf-2 genes encode protein products that differ from each other by only three amino acids and contain 38 leucine-rich repeat (LRR) motifs. Of the LRRs, 20 show extremely conserved alternating repeats. The C-terminus of Cf-2 carries regions of pronounced homology to the protein encoded by the unlinked Cf-9 gene. We suggest that this conserved region interacts with other proteins involved in activating plant defense mechanisms.	JOHN INNES CTR,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Jones, David A/C-9507-2009; Jones, Jonathan DG/J-5129-2012	Jones, David A/0000-0001-8809-5822; Jones, Jonathan DG/0000-0002-4953-261X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHFIELD T, 1994, MOL PLANT MICROBE IN, V7, P645, DOI 10.1094/MPMI-7-0645; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; CARROLL BJ, 1995, GENETICS, V139, P407; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON MS, 1995, MOL PLANT MICROBE IN, V8, P200, DOI 10.1094/MPMI-8-0200; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; Flor H. H., 1946, JOUR AGRIC RES, V73, P335; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, MOL PLANT MICROBE IN, V7, P58, DOI 10.1094/MPMI-7-0058; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JONES JDG, 1994, CURR BIOL, V4, P749, DOI 10.1016/S0960-9822(00)00168-8; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MAY MJ, 1996, IN PRESS PLANT PHYSL; MINDRINOS M, 1994, CELL, V78, P1069; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; OLIVER RP, 1993, MOL PLANT MICROBE IN, V6, P521, DOI 10.1094/MPMI-6-521; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Sambrook J., 1989, MOL CLONING LAB MANU; SCONFIEDL S, 1992, PLANT CELL, V4, P573; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Stevens MA, 1988, THE TOMATO CROP, P35; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; VERAESTRELLA R, 1992, PLANT PHYSIOL, V99, P1208, DOI 10.1104/pp.99.3.1208; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1994, PLANT MOL BIOL, V26, P1599, DOI 10.1007/BF00016492; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	44	448	504	1	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					451	459		10.1016/S0092-8674(00)81290-8	http://dx.doi.org/10.1016/S0092-8674(00)81290-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608599	Bronze			2022-12-01	WOS:A1996TV70800014
J	Hellman, S; Weichselbaum, RR				Hellman, S; Weichselbaum, RR			Radiation oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Hellman, S (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HANKS GE, 1995, CANCER, V75, P1972, DOI 10.1002/1097-0142(19950401)75:7+<1972::AID-CNCR2820751636>3.0.CO;2-P; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; SANDLER HM, 1995, INT J RADIAT ONCOL, V33, P797, DOI 10.1016/0360-3016(95)00219-7; Zelefsky M J, 1995, Cancer J Sci Am, V1, P142	7	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1852	1853		10.1001/jama.275.23.1852	http://dx.doi.org/10.1001/jama.275.23.1852			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642748				2022-12-01	WOS:A1996UQ15200047
J	Radestad, I; Steineck, G; Nordin, C; Sjogren, B				Radestad, I; Steineck, G; Nordin, C; Sjogren, B			Psychological complications after stillbirth - Influence of memories and immediate management: Population based study	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL DEATH; FOLLOW-UP; GRIEF; FAMILIES	Objective-To identify factors that may predict long term psychological complications among women who have had a stillborn child, Design-Nationwide population based study using epidemiological methods, Subjects-380 subjects and 379 controls who had had a stillborn or non-deformed live child in Sweden in 1991. Results-Information was provided by 636 (84%) women, The ratio (95% confidence interval) of proportions of women with symptoms related to anxiety above the 90th centile for women who had had a stillborn child compared with those who had not was 2.1 (1.2 to 3.9), An interval of 25 hours or more from the diagnosis of death in utero to the start of delivery gave a ratio of 4.8 (1.5 to 15.9). The ratio was 2.3 (1.1 to 5.3) for not seeing the child as long as the mother had wished and 3.1 (1.6 to 6.0) for no possession of a token of remembrance, Conclusion-It is advisable to induce the delivery as soon as feasible after the diagnosis of death in utero, A calm environment for the woman to spend as much time as she wants with her stillborn child is beneficial, and tokens of remembrance should be collected.	KAROLINSKA INST,CTR CARING SCI N,STOCKHOLM,SWEDEN; KAROLINSKA INST,RADIUMHEMMET,CANC EPIDEMIOL UNIT,STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT WOMENS & CHILDRENS HLTH,STOCKHOLM,SWEDEN; LINKOPING UNIV HOSP,DEPT PSYCHIAT,S-58185 LINKOPING,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University			Steineck, Gunnar/W-1515-2019	Steineck, Gunnar/0000-0002-0787-3969				Beckey R D, 1985, J Obstet Gynecol Neonatal Nurs, V14, P194, DOI 10.1111/j.1552-6909.1985.tb02227.x; BOURNE P, 1983, BRIT MED J, V286, P144; Bourne S, 1968, J R Coll Gen Pract, V16, P103; COHEN L, 1978, AM J ORTHOPSYCHIAT, V48, P727, DOI 10.1111/j.1939-0025.1978.tb02577.x; Cullberg J, 1966, Lakartidningen, V63, P3980; GILES PFH, 1970, AUST NZ J OBSTET GYN, V10, P207, DOI 10.1111/j.1479-828X.1970.tb00431.x; KELLNER KR, 1981, DEATH EDUC, V5, P29, DOI 10.1080/07481188108252075; Kennel JH, 1978, CONTEMP OBSTET GYNEC, V12, P53; KENNELL JH, 1970, NEW ENGL J MED, V283, P344, DOI 10.1056/NEJM197008132830706; KIRKLEYBEST E, 1982, AM J ORTHOPSYCHIAT, V52, P420, DOI 10.1111/j.1939-0025.1982.tb01428.x; KOWALSKI K, 1980, Clinical Obstetrics and Gynecology, V23, P1113, DOI 10.1097/00003081-198012000-00015; LAROCHE C, 1984, CAN J PSYCHIAT, V29, P14, DOI 10.1177/070674378402900104; LEON IG, 1992, CLIN PEDIATR, V31, P366, DOI 10.1177/000992289203100611; LEWIS E, 1976, LANCET, V2, P619; Long J, 1992, Midwives Chron, V105, P51; NICOL MT, 1986, MED J AUSTRALIA, V144, P287, DOI 10.5694/j.1326-5377.1986.tb128375.x; RADLOFF LS, 1994, APPL PSYCH MEAS, V1, P385; ROWE J, 1978, PEDIATRICS, V62, P166; *SAS I, 1993, P243 SAS; SPECK WT, 1980, PEDIATR REV, V2, P59; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; TOEDTER LJ, 1988, AM J ORTHOPSYCHIAT, V58, P435, DOI 10.1111/j.1939-0025.1988.tb01604.x; TUDEHOPE DI, 1986, MED J AUSTRALIA, V144, P290, DOI 10.5694/j.1326-5377.1986.tb128376.x; Welch I D, 1991, Neonatal Netw, V9, P53; ZEANAH CH, 1989, J AM ACAD CHILD PSY, V28, P467, DOI 10.1097/00004583-198907000-00001	25	136	138	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1505	1508		10.1136/bmj.312.7045.1505	http://dx.doi.org/10.1136/bmj.312.7045.1505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UR823	8646141	Green Published			2022-12-01	WOS:A1996UR82300019
J	Erkman, L; McEvilly, RJ; Luo, L; Ryan, AK; Hooshmand, F; OConnell, SM; Keithley, EM; Rapaport, DH; Ryan, AF; Rosenfeld, MG				Erkman, L; McEvilly, RJ; Luo, L; Ryan, AK; Hooshmand, F; OConnell, SM; Keithley, EM; Rapaport, DH; Ryan, AF; Rosenfeld, MG			Role of transcription factors Brn-3.1 and Brn-3.2 in auditory and visual system development	NATURE			English	Article							CELL LINEAGE; CAT RETINA; C-ELEGANS; GENE; MOUSE; DIFFERENTIATION; HOMEODOMAIN; EXPRESSION; DISTINCT; IDENTITY	THE neurally expressed genes Brn-3.1 and Brn-3.2 (refs 1-6) are mammalian orthologues of the Caenorhabditis elegans unc-86 gene(7) that constitute, with Brn-3.0 (refs 1-3,8,9), the class IV POU-domain transcription factors(10), Brn-3.1 and Brn-3.2 provide a means of exploring the potentially distinct biological functions of expanded gene families in neural development, The highly related members of the Brn-3 family have similar DNA-binding preferences(1,2) and overlapping expression patterns in the sensory nervous system, midbrain and hindbrain(1-6,8,9), suggesting functional redundancy, Here we report that Brn-3.1 and Brn-3.2 critically modulate the terminal differentiation of distinct sensorineural cells in which they exhibit selective spatial and temporal expression patterns, Deletion of the Brn-3.2 gene causes the loss of most retinal ganglion cells, defining distinct ganglion cell populations, Mutation of Brn-3.1 results in complete deafness, owing to a failure of hair cells to appear in the inner ear, with subsequent loss of cochlear and vestibular ganglia.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG, DIV ANAT, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, VET ADM MED CTR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG OTOLARYNGOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego					BLRD VA [I01 BX001205] Funding Source: Medline; Veterans Affairs [I01BX001205] Funding Source: NIH RePORTER	BLRD VA; Veterans Affairs(US Department of Veterans Affairs)		COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; CRENSHAW EB, 1991, J NEUROSCI, V11, P1524; DRAGER UC, 1981, INVEST OPHTH VIS SCI, V20, P285; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1995, NEURON, V14, P1153, DOI 10.1016/0896-6273(95)90263-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUO L, 1993, HEARING RES, V69, P182; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RAPAPORT DH, 1991, J COMP NEUROL, V312, P341, DOI 10.1002/cne.903120303; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Sidman R.L., 1961, STRUCTURE EYE; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Stone J., 1981, WHOLEMOUNT HDB; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; WASSLE H, 1987, J COMP NEUROL, V265, P391, DOI 10.1002/cne.902650308; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WONG ROL, 1987, J COMP NEUROL, V255, P159, DOI 10.1002/cne.902550202; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; XIANG MQ, 1995, J NEUROSCI, V15, P4762; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	30	419	435	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					603	606		10.1038/381603a0	http://dx.doi.org/10.1038/381603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637595				2022-12-01	WOS:A1996UQ65700050
J	Frydman, J; Hartl, FU				Frydman, J; Hartl, FU			Principles of chaperone-assisted protein folding: Differences between in vitro and in vivo mechanisms	SCIENCE			English	Article							T-COMPLEX POLYPEPTIDE-1; MOLECULAR CHAPERONES; MESSENGER-RNA; IN-VIVO; ACTIN; DEGRADATION	Molecular chaperones in the eukaryotic cytosol were shown to interact differently with chemically denatured proteins and their newly translated counterparts. During refolding from denaturant, actin partitioned freely between 70-kilodalton heat shock protein, the bulk cytosol, and the chaperonin TCP1-ring complex. In contrast, during cell-free translation, the chaperones were recruited to the elongating polypeptide and protected it from exposure to the bulk cytosol during folding. Posttranslational cycling between chaperone-bound and free states was observed with subunits of oligomeric proteins and with aberrant polypeptides; this cycling allowed the subunits to assemble and the aberrant polypeptides to be degraded. Thus, folding, oligomerization, and degradation are linked hierarchically to ensure the correct fate of newly synthesized polypeptides.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS J, 1994, CURR OPIN STRUC BIOL, V4, P117; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Freedman Robert B., 1992, P455; FREEMAN BC, 1996, EMBO J, V12, P2969; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SOLOMON JM, 1991, NEW BIOL, V3, P1106; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	43	210	224	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1497	1502		10.1126/science.272.5267.1497	http://dx.doi.org/10.1126/science.272.5267.1497			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633246				2022-12-01	WOS:A1996UP89900053
J	Gilmore, AP; Burridge, K				Gilmore, AP; Burridge, K			Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate	NATURE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; PURIFICATION; PROTEINS	VINCULIN, a prominent cytoskeletal protein at cell-substrate adhesions (focal adhesions) and cell-cell adhesions (adherens junctions)(1), interacts with other cytoskeletal proteins, including talin and actin(2,3). An intramolecular interaction between the head and tail domains of vinculin masks the binding sites for both proteins(4,5). The exposure of cryptic binding sites may be important for promoting focal adhesion assembly. Several agents that induce the formation of focal adhesions act through the GTP-binding protein Rho(6-9), which elevates phosphatidylinositol-4,5-bisphosphate (PtdInsP(2)) levels by activating phosphatidylinositol-4-phosphate-5-OH kinase (PtdIns-5-OH kinase)(10). PtdInsP(2) regulates several actin-binding proteins, including profilin(11), gelsolin(12) and alpha-actinin(13), and interacts with vinculin(14,15). Here we report that PtdInsP(2) dissociates vinculin's head-tail interaction, unmasking its talin- and actin-binding sites. Microinjection of antibodies against PtdInsP(2) inhibit assembly of stress fibres and focal adhesions.			Gilmore, AP (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.							BARRY ST, 1994, J CELL SCI, V107, P2033; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHRZANOWSKAWODN.M, 1994, J CELL SCI, V107, P3543; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; WOOD CK, 1994, J CELL SCI, V107, P709	30	442	450	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					531	535		10.1038/381531a0	http://dx.doi.org/10.1038/381531a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632828				2022-12-01	WOS:A1996UP43500063
J	deCelis, JF; Barrio, R; Kafatos, FC				deCelis, JF; Barrio, R; Kafatos, FC			A gene complex acting downstream of dpp in Drosophila wing morphogenesis	NATURE			English	Article							EXPRESSION; DISK	LOCALIZED expression of the transforming growth factor-beta (TGF-beta) homologue decapentaplegic (dpp) is crucial for Drosophila wing development(1-4). Here we show that spalt and spalt-related (sal and salr), two closely related genes that encode transcription factors, are expressed in response to dpp in a central territory of the wing imaginal disc, where they are required for the patterning of the wing. They are among the first identified elements that act downstream of dpp in wing development. The phenotypic consequences of misexpression of sal and salr suggest that an important outcome of dpp activity is the subdivision of the wing disc into territories smaller than lineage compartments, through the regulation of transcription-factor-encoding genes such as sal and salr.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 4TH,ENGLAND; INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,CRETE,GREECE	European Molecular Biology Laboratory (EMBL); University of Cambridge			Barrio, Rosa/F-8712-2011; de+Celis, Jose/AAE-8142-2019	Barrio, Rosa/0000-0002-9663-0669; de Celis, Jose F./0000-0003-4808-9844				BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; Reuter D, 1996, CHROMOSOMA, V104, P445, DOI 10.1007/BF00352268; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SWEENEY ST, 1985, NEURON, V14, P342; TABATA T, 1995, DEVELOPMENT, V121, P3359	21	197	199	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					421	424		10.1038/381421a0	http://dx.doi.org/10.1038/381421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632798				2022-12-01	WOS:A1996UN47900051
J	Erickson, JC; Clegg, KE; Palmiter, RD				Erickson, JC; Clegg, KE; Palmiter, RD			Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y	NATURE			English	Article							RAT HIPPOCAMPAL SLICE; PRESYNAPTIC INHIBITION; FOOD-DEPRIVATION; FEEDING-BEHAVIOR; RECEPTOR; NEURONS; MECHANISM; INVITRO; BRAIN	NEUROPEPTIDE Y (NPY), a 36-amino-acid transmitter distributed throughout the nervous system(1,2), is thought to function as a central stimulator of feeding behaviour(1-4). NPY has also been implicated in the modulation of mood(5), cerebrocortical excitability(6), hypothalamic-pituitary signalling(7), cardiovascular physiology(1,8) and sympathetic function(9,10). However, the biological significance of NPY has been difficult to establish owing to a lack of pharmacological antagonists, We report here that mice deficient for NPY have normal food intake and body weight, and become hyperphagic following food deprivation. Mutant mice decrease their food intake and lose weight, initially to a greater extent than controls, when treated with recombinant leptin. Occasional, mild seizures occur in NPY-deficient mice and mutants are more susceptible to seizures induced by a GABA (gamma-aminobutyric acid) antagonist, These results indicate that NPY is not essential for certain feeding responses or leptin actions but is an important modulator of excitability in the central nervous system.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								BECK B, 1990, BRAIN RES, V528, P245, DOI 10.1016/0006-8993(90)91664-3; BLEAKMAN D, 1992, BRIT J PHARMACOL, V107, P334, DOI 10.1111/j.1476-5381.1992.tb12747.x; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; COLMERS WF, 1987, J PHYSIOL-LONDON, V383, P285; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; COLMERS WF, 1994, TRENDS NEUROSCI, V17, P373, DOI 10.1016/0166-2236(94)90046-9; COLMERS WF, 1988, J NEUROSCI, V8, P3827; COLMERS WF, 1993, BIOL NEUROPEPTIDE Y; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; HAAS HL, 1987, J COMP NEUROL, V257, P208, DOI 10.1002/cne.902570207; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; KLAPSTEIN GJ, 1993, HIPPOCAMPUS, V3, P103, DOI 10.1002/hipo.450030111; LEIBOWITZ SF, 1991, BRAIN RES BULL, V27, P333, DOI 10.1016/0361-9230(91)90121-Y; MCDERMOTT BJ, 1993, CARDIOVASC RES, V27, P893, DOI 10.1093/cvr/27.6.893; MCDONALD JK, 1993, BIOL NEUROPEPTIDE Y, P457; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; ORLOFF MJ, 1949, P SOC EXP BIOL MED, V70, P254; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SCHWARTZ MW, IN PRESS DIABETES; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STJARNE L, 1986, NEUROSCIENCE, V18, P151, DOI 10.1016/0306-4522(86)90184-3; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	894	911	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					415	418		10.1038/381415a0	http://dx.doi.org/10.1038/381415a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632796				2022-12-01	WOS:A1996UN47900049
J	Chou, MM; Blenis, J				Chou, MM; Blenis, J			The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1	CELL			English	Article							DISTINCT MECHANISMS; RAF-1 KINASE; RAPAMYCIN; DOMAIN; RAS; FIBROBLASTS; INHIBITION; ONCOGENE; LYMPHOMA; MEMBRANE	The 70 kDa ribosomal S6 kinase (pp70(S6k)) plays an important role in the progression of cells through G1 phase of the cell cycle. However, little is known of the signaling molecules that mediate its activation. We demonstrate that Rho family G proteins regulate pp70(S6k) activity in vivo. Activated alleles of Cdc42 and Rac1, but not RhoA, stimulate pp70(S6k) activity in multiple cell types. Activation requires an intact effector domain and isoprenylation of Cdc42 and Rac1. Coexpression of Dbl, an exchange factor for Cdc42, also activates pp70(S6k). Growth factor-induced activation of pp70(S6k) is abrogated by dominant negative alleles of Cdc42 and Rad. In addition, Cdc42 and Rad form a GTP-dependent complex with the catalytically inactive form of pp70(S6k) in vitro and in vivo, suggesting a mechanism by which these G proteins activate pp70(S6k).	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SELF AJ, 1993, ONCOGENE, V8, P655; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	61	261	263	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					573	583		10.1016/S0092-8674(00)81257-X	http://dx.doi.org/10.1016/S0092-8674(00)81257-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653792	Bronze			2022-12-01	WOS:A1996UM41500014
J	Hedges, SB; Parker, PH; Sibley, CG; Kumar, S				Hedges, SB; Parker, PH; Sibley, CG; Kumar, S			Continental breakup and the ordinal diversification of birds and mammals	NATURE			English	Article							EVOLUTION; PHYLOGENY	THE classical hypothesis for the diversification of birds and mammals proposes that most of the orders diverged rapidly in adaptive radiations after the Cretaceous/Tertiary (K/T) extinction event 65 million years ago (1-3). Evidence is provided by the near-absence of fossils representing modern orders before the K/T boundary(4,5). However, fossil-based estimates of divergence time are known to be conservative because of sampling biases(6), and some molecular/time estimates point to earlier divergences among orders(7-10). In an attempt to resolve this controversy, we have estimated times of divergence among avian and mammalian orders with a comprehensive set of genes that exhibit a constant rate of substitution. Here we report molecular estimates of divergence times that average about 50-90% earlier than those predicted by the classical hypothesis, and show that the timing of these divergences coincides with the Mesozoic fragmentation of emergent land areas. This suggests that continental breakup may have been an important mechanism in the ordinal diversification of birds and mammals.	PENN STATE UNIV,INST MOLEC EVOLUT GENET,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), PENN STATE UNIV,DEPT BIOL,208 MUELLER LAB,UNIVERSITY PK,PA 16802, USA.		Kumar, Sudhir/F-1411-2011	Kumar, Sudhir/0000-0002-9918-8212				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; HAY JM, 1995, MOL BIOL EVOL, V12, P928; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P9861, DOI 10.1073/pnas.91.21.9861; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JANKE A, 1994, GENETICS, V137, P243; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OTA T, 1994, J MOL EVOL, V38, P642; Padian K., 1985, P41; PRAGER EM, 1974, J MOL EVOL, V3, P243, DOI 10.1007/BF01796041; RAMIREZ V, 1993, J MOL EVOL, V37, P296, DOI 10.1007/BF00175506; Russell Dale E., 1995, Historical Biology, V10, P3; SMITHSON TR, 1989, NATURE, V342, P676, DOI 10.1038/342676a0; TAJIMA F, 1993, GENETICS, V135, P599; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	20	378	385	2	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					226	229		10.1038/381226a0	http://dx.doi.org/10.1038/381226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622763				2022-12-01	WOS:A1996UL24900051
J	Lange, P; Ulrik, CS; Vestbo, J				Lange, P; Ulrik, CS; Vestbo, J			Mortality in adults with self-reported asthma	LANCET			English	Article							AIR-FLOW OBSTRUCTION; GENERAL-POPULATION; FOLLOW-UP; BRONCHIAL-ASTHMA; SAMPLE; QUESTIONNAIRES; PROGNOSIS; SYMPTOMS; DISEASE	Background On the question of whether asthma shortens survival the published work gives no clear answer. We have prospectively analysed overall and cause-specific mortality in persons with self-reported asthma. Methods A sample of 13 540 individuals (6104 men) 20 years of age or older, randomly selected from the general population of the city of Copenhagen, was followed for 17 years. Findings Survival in participants with self-reported asthma was significantly poorer than in non-asthmatics, the excess mortality being limited to pulmonary mortality. After statistical adjustment for age, length of school education, and smoking, women with asthma had a 1.7 higher risk of dying than women without asthma (95% confidence interval 1.3-2.2). Although the relative risk (RR) of dying with asthma was sightly lower in men (RR=1.5, 95% CI 1.2-1.9) the difference between sexes was not significant. The results were similar within smoking groups and the highest risk of death associated with asthma was seen among never-smokers (RR=2.1, 95% CI 1.6-2.3). Inclusion of one-second forced expiratory volume, in % predicted, in the mortality analyses showed that the increased risk of death associated with asthma was mediated mainly through reduced lung function. Interpretation We conclude that, in the general population, self-reported asthma is associated with a slight excess of mortality, mainly from respiratory diseases.	BISPEBJERG HOSP,DEPT PULM MED,DK-2400 COPENHAGEN,DENMARK; KOMMUNE HOSP COPENHAGEN,COPENHAGEN CTR PROSPECT POPULAT STUDIES,COPENHAGEN,DENMARK; KOMMUNE HOSP COPENHAGEN,INST PREVENT MED,COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital	Lange, P (corresponding author), RIGSHOSP,COPENHAGEN CITY HEART STUDY,EPIDEMIOL RES UNIT,DEPT 7121,DK-2200 COPENHAGEN N,DENMARK.		Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362				ALDERSON M, 1977, BRIT J DIS CHEST, V71, P198, DOI 10.1016/0007-0971(77)90110-3; ALDERSON M, 1974, LANCET, V2, P1475; ALMIND M, 1992, DAN MED BULL, V39, P561; [Anonymous], 1984, Acta Med Scand Suppl, V682, P1; BEATY TH, 1985, J CHRON DIS, V38, P703, DOI 10.1016/0021-9681(85)90024-4; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BUIST AS, 1994, NEW ENGL J MED, V331, P1584, DOI 10.1056/NEJM199412083312309; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; COX DR, 1972, J R STAT SOC B, V34, P187; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; KOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LANGE P, 1990, THORAX, V45, P579, DOI 10.1136/thx.45.8.579; MARKOWE HLJ, 1987, BRIT MED J, V295, P949, DOI 10.1136/bmj.295.6604.949; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; OPENSHAW PJM, 1989, RESP MED, V83, P25, DOI 10.1016/S0954-6111(89)80056-3; ROBINETTE CD, 1978, J CHRON DIS, V31, P619, DOI 10.1016/0021-9681(78)90022-X; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Toren K., 1994, European Respiratory Journal, V7, p253S; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; VESTBO J, 1988, AM REV RESPIR DIS, V137, P1114, DOI 10.1164/ajrccm/137.5.1114; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WU AH, 1995, AM J EPIDEMIOL, V141, P1023, DOI 10.1093/oxfordjournals.aje.a117366	30	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1285	1289		10.1016/S0140-6736(96)90937-X	http://dx.doi.org/10.1016/S0140-6736(96)90937-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622503				2022-12-01	WOS:A1996UK75800008
J	Young, RE; Smith, MA; Sobeck, CK				Young, RE; Smith, MA; Sobeck, CK			Galileo probe: In situ observations of Jupiter's atmosphere	SCIENCE			English	Article							VOYAGER-2; WINDS; BELT	The Galileo probe performed the first in situ measurements of the atmosphere of Jupiter on 7 December 1995, The probe returned data until it reached a depth corresponding to an atmospheric pressure of similar to 24 bars. This report presents a brief overview of the origins and purpose of the mission. Science objectives, entry parameters and mission events, and results are described. The remaining reports address in more detail the individual experiments summarized here.			Young, RE (corresponding author), NASA,AMES RES CTR,MOFFETT FIELD,CA 94035, USA.							Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; Atreya S. K., 1985, Recent Advances in Planetary Meteorology. Seymour Hess Memorial Symposium at the 1983 IUGG General Assembly, P17; Beebe RF, 1996, SCIENCE, V272, P841, DOI 10.1126/science.272.5263.841; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CONRATH B, 1987, J GEOPHYS RES, V92, P15006; DEPATER I, 1986, ICARUS, V68, P344, DOI 10.1016/0019-1035(86)90027-8; Fischer HM, 1996, SCIENCE, V272, P856, DOI 10.1126/science.272.5263.856; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; Lanzerotti LJ, 1996, SCIENCE, V272, P858, DOI 10.1126/science.272.5263.858; LIMAYE SS, 1982, J ATMOS SCI, V39, P1413, DOI 10.1175/1520-0469(1982)039<1413:JWFVPI>2.0.CO;2; LIMAYE SS, 1991, J GEOPHYS RES-PLANET, V96, P18941, DOI 10.1029/91JA01701; NEFF J, 1990, GLLMDT90195 JPL IOM; NEFF J, 1996, GLLNAV965 JPL IOM; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RUSSELL CT, 1992, SPACE SCI REV, V60; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH BA, 1986, SCIENCE, V233, P43, DOI 10.1126/science.233.4759.43; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; [No title captured]	25	47	47	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					837	838		10.1126/science.272.5263.837	http://dx.doi.org/10.1126/science.272.5263.837			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629015				2022-12-01	WOS:A1996UK75700044
J	Schrader, H; Obelieniene, D; Bovim, G; Surkiene, D; Mickeviciene, D; Miseviciene, I; Sand, T				Schrader, H; Obelieniene, D; Bovim, G; Surkiene, D; Mickeviciene, D; Miseviciene, I; Sand, T			Natural evolution of late whiplash syndrome outside the medicolegal context	LANCET			English	Article							SOFT-TISSUE INJURIES; CERVICAL-SPINE; NECK	Background In Lithuania, few car drivers and passengers are covered by insurance and there is little awareness among the general public about the potentially disabling consequences of a whiplash injury. We took this opportunity to study the natural course of head and neck symptoms after rear-end car collisions. Methods In a retrospective questionnaire-based cohort study, 202 individuals (157 men; 45 women) were identified from the records of the traffic police department in Kaunas, Lithuania. These individuals were interviewed 1-3 years after experiencing a rear-end car collision. Neck pain, headache, subjective cognitive dysfunction, psychological disorders, and low back pain in this group were compared with the same complaints in a sex-matched and age-matched control group of uninjured individuals selected randomly from the population register of the same geographic area. Findings Neck pain was reported by 71 (35% [95% CI 29-42]) accident victims and 67 (33% [27-40]) controls. Headache was reported by 107 (53% [46-60]) accident victims and 100 (50% [42-57]) controls. Chronic neck pain and chronic headache (more than 7 days per month) were also reported in similar proportions (17 [8 . 4%; 5-13] vs 14 [6 . 9%; 4-12] and 19 [9 . 4%; 6-15] vs 12 [5 . 9%; 3-10]) by the two groups, Of those who reported chronic neck pain or daily headache after the accident, substantial proportions had had similar symptoms before the accident (7/17 for chronic neck pain; 10/12 for daily headache). There was no significant difference found. No one in the study group had disabling or persistent symptoms as a result of the car accident. There was no relation between the impact severity and degree of pain. A family history of neck pain was the most important risk factor for current neck symptoms in logistic regression analyses. Interpretation Our results suggest that chronic symptoms were not usually caused by the car accident. Expectation of disability, a family history, and attribution of pre-existing symptoms to the trauma may be more important for the evolution of the late whiplash syndrome.	KAUNAS MED ACAD,DEPT NEUROL,KAUNAS,LITHUANIA; KAUNAS MED ACAD,DEPT PREVENT MED,KAUNAS,LITHUANIA	Lithuanian University of Health Sciences; Lithuanian University of Health Sciences	Schrader, H (corresponding author), UNIV TRONDHEIM HOSP,DEPT NEUROL,N-7006 TRONDHEIM,NORWAY.			Obelieniene, Diana/0000-0002-7356-7150; Schrader, Harald/0000-0001-9975-1960				AWERBUCH MS, 1992, MED J AUSTRALIA, V156, P193; Balla J, 1987, Clin Exp Neurol, V23, P179; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; BORCHGREVINK GE, 1995, ACTA RADIOL, V36, P425; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; CARETTE S, 1994, NEW ENGL J MED, V330, P1083, DOI 10.1056/NEJM199404143301512; CROWE H, 1928, ANN M W ORTH ASS SAN; DAVIS SJ, 1991, RADIOLOGY, V180, P245, DOI 10.1148/radiology.180.1.2052703; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; ELLERTSEN AB, 1978, ACTA NEUROL SCAND  S, V67, P269; GOBEL H, 1994, CEPHALALGIA, V14, P97, DOI 10.1046/j.1468-2982.1994.1402097.x; GOTTEN N, 1956, JAMA-J AM MED ASSOC, V162, P856; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; HOHL M, 1974, J BONE JOINT SURG AM, VA 56, P1675, DOI 10.2106/00004623-197456080-00018; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MAKELA M, 1991, AM J EPIDEMIOL, V134, P1356; MARSHALL PD, 1995, INJURY, V20, P17; Michler Ralf-Peter, 1993, Tidsskrift for den Norske Laegeforening, V113, P1104; MILES KA, 1988, SKELETAL RADIOL, V17, P493, DOI 10.1007/BF00364043; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; WATKINSON A, 1991, INJURY, V22, P307, DOI 10.1016/0020-1383(91)90012-4; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	29	277	281	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1207	1211		10.1016/S0140-6736(96)90733-3	http://dx.doi.org/10.1016/S0140-6736(96)90733-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622449				2022-12-01	WOS:A1996UJ59700008
J	Savilahti, H; Mizuuchi, K				Savilahti, H; Mizuuchi, K			Mu transpositional recombination: Donor DNA cleavage and strand transfer in trans by the Mu transposase	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYNUCLEOTIDYL TRANSFER; INTEGRASE PROTEIN; INVITRO PROCEEDS; BACTERIOPHAGE-MU; SITE; MECHANISM; DOMAINS; IDENTIFICATION; COMPLEX	Central to the Mu transpositional recombination are the two chemical steps; donor DNA cleavage and strand transfer. These reactions occur within the Mu transpososome that contains two Mu DNA end segments bound to a tetramer of MuA, the transposase. To investigate which MuA-monomer catalyzes which chemical reaction, we made transpososomes containing wild-type and active site mutant MuA. By preloading the MuA variants onto Mu end DNA fragments of different length prior to transpososome assembly, we could track the catalysis by MuA bound to each Mu end segment. The donor DNA end that underwent the chemical reaction was identified. Both the donor DNA cleavage and strand transfer were catalyzed in trans by the MuA monomers bound to the partner Mu end. This arrangement explains why the transpososome assembly is a prerequisite for the chemical steps.	NIDDKD, MOLEC BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Savilahti, Harri/0000-0002-6246-2572				ARCISZEWSKA LK, 1991, NUCLEIC ACIDS RES, V19, P5021, DOI 10.1093/nar/19.18.5021; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; Berg D. E., 1989, MOBILE DNA; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JOHNSON R, 1996, DNA PROTEIN STRUCTUR, P141; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; MIZUCHI M, 1996, CELL, V83, P375; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VANGENT DC, 1996, IN PRESS SCIENCE; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOU AH, 1991, J BIOL CHEM, V266, P20478	59	81	89	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					271	280		10.1016/S0092-8674(00)81103-4	http://dx.doi.org/10.1016/S0092-8674(00)81103-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612279	Bronze			2022-12-01	WOS:A1996UG25500015
J	Smith, JJ; Travis, SM; Greenberg, EP; Welsh, MJ				Smith, JJ; Travis, SM; Greenberg, EP; Welsh, MJ			Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid	CELL			English	Article							ELECTROLYTE TRANSPORT; LUNG-DISEASE; CELLS; EXPRESSION; CULTURES; SITE	Despite an increased understanding of the cellular and molecular biology of the CFTR Cl- channel, it is not known how defective Cl- transport across airway epithelia causes chronic bacterial infections in cystic fibrosis (CF) airways. Here, we show that common CF pathogens were killed when added to the apical surface of normal airway epithelia. In contrast, these bacteria multiplied on CF epithelia. We found that bactericidal activity was present in airway surface fluid of both normal and CF epithelia. However, because bacterial killing required a low NaCl concentration and because CF surface fluid has a high NaCl concentration, CF epithelia failed to kill bacteria. This defect was corrected by reducing the NaCl concentration on CF epithelia. These data explain how the loss of CFTR Cl- channels may lead to lung disease and suggest new approaches to therapy.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Smith, JJ (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.			Greenberg, Everett/0000-0001-9474-8041; Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL42385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BOUCHER RC, 1983, LUNG, V161, P1, DOI 10.1007/BF02713837; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DAVIS PB, 1993, CYSTIC FIBROSIS, P193; DEKOSTER JA, 1995, AM IND HYG ASSOC J, V56, P573, DOI 10.1202/0002-8894(1995)056<0573:BCINCA>2.0.CO;2; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FICK RB, 1981, J CLIN INVEST, V68, P899, DOI 10.1172/JCI110345; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; GOLDSTEIN IM, 1994, TXB RESPIRATORY MED, P402; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Konstan M.W., 1993, CYSTIC FIBROSIS, V64, P219; LARIVEE P, 1994, AIRWAY SECRETION PHY, P469; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Pilewski J M, 1995, Curr Opin Pulm Med, V1, P435, DOI 10.1097/00063198-199511000-00002; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SANCHIS J, 1973, NEW ENGL J MED, V288, P651, DOI 10.1056/NEJM197303292881304; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; Taussig LM, 1984, CYSTIC FIBROSIS, P338; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; Wine JJ, 1995, CURR BIOL, V5, P1357, DOI 10.1016/S0960-9822(95)00269-7; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; YEATES DB, 1976, ARCH DIS CHILD, V51, P28, DOI 10.1136/adc.51.1.28; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585	42	790	817	3	69	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					229	236		10.1016/S0092-8674(00)81099-5	http://dx.doi.org/10.1016/S0092-8674(00)81099-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612275	Bronze			2022-12-01	WOS:A1996UG25500011
J	Lichtenstein, P; Olausson, PO; Kallen, AJB				Lichtenstein, P; Olausson, PO; Kallen, AJB			Twin births to mothers who are twins: A registry based study	BRITISH MEDICAL JOURNAL			English	Article							GENE	Objectives-To estimate the risk of having twin infants for mothers who are twins; to investigate the genetic influence on twinning. Design-Retrospective study of multiple births in two nationwide registries. Setting-Sweden. Subjects-Multiple births among 31586 deliveries between 1973 and 1991 to women who were twins. Main outcome measures-Numbers of monozygotic and dizygotic twin births expected and estimated. Results-Women who are dizygotic twins have a moderately increased risk of having twins (relative risk 1.30, 95% confidence interval 1.14 to 1.49) which seems to be completely the result of dizygotic twinning. When a mother is a monozygotic twin, her risk of having twins of the same sex is significantly increased (1.47; 1.10 to 1.97). This is the result of an excess of monozygotic twins (39 pairs estimated, 18 expected). Conclusion-Women who are twins have an increased risk of giving birth to twins. Genetic components of monozygotic and dizygotic twinning seem to be independent.	NATL BOARD HLTH & WELF,CTR EPIDEMIOL,S-10630 STOCKHOLM,SWEDEN; LUND UNIV,TORNBALD INST,S-22362 LUND,SWEDEN	National Board of Health & Welfare; Lund University	Lichtenstein, P (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,BOX 210,S-17177 STOCKHOLM,SWEDEN.			lichtenstein, paul/0000-0003-3037-5287				Bulmer MG, 1970, BIOL TWINNING MAN; CARMELLI D, 1978, TWIN RES, V3, P81; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; CEDERLOF R, 1978, TWIN RES, V3, P189; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; CRUMPACKER DW, 1979, ACTA GENET MED GEMEL, V28, P173, DOI 10.1017/S0001566000009041; DAVIS GH, 1991, BIOL REPROD, V44, P620, DOI 10.1095/biolreprod44.4.620; Derom R, 1995, MULTIPLE PREGNANCY E, P145; JAMES WH, 1992, ACTA GENET MED GEMEL, V41, P33, DOI 10.1017/S0001566000002488; Medlund P, 1976, Acta Med Scand Suppl, V600, P1; MILLHAM S, 1964, LANCET, V2, P566; MONTGOMERY GW, 1993, NAT GENET, V4, P410, DOI 10.1038/ng0893-410; NYLANDER PP, 1970, ACTA GENET MED GEMEL, V19, P36, DOI 10.1017/S1120962300024951; PARAZZINI F, 1993, ACTA OBSTET GYN SCAN, V72, P177, DOI 10.3109/00016349309013368; PARISI P, 1983, NATURE, V304, P626, DOI 10.1038/304626a0; PHILIPPE P, 1985, AM J MED GENET, V20, P97, DOI 10.1002/ajmg.1320200112; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; WEINBERG W, 1902, PFLUGERS ARCH GES PH, V88, P346; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P322; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P470; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P609; WYSHAK G, 1965, AM J PUBLIC HEALTH N, V55, P1586, DOI 10.2105/AJPH.55.10.1586	22	30	30	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					879	881						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611875				2022-12-01	WOS:A1996UE37100020
J	Serrano, M; Lee, HW; Chin, L; CordonCardo, C; Beach, D; DePinho, RA				Serrano, M; Lee, HW; Chin, L; CordonCardo, C; Beach, D; DePinho, RA			Role of the INK4a locus in tumor suppression and cell mortality	CELL			English	Article							ONCOGENES; MICE; CYCLINS; RAS; TRANSFORMATION; EXPRESSION; REQUIRES; KINASES	The cell cycle inhibitor p16(INK4a) is inactivated in many human tumors and in families with hereditary melanoma and pancreatic cancer. Tumor-associated alterations in the INK4a locus may also affect the overlapping gene encoding p19(ARF) and the adjacent gene encoding p15(INK4b), both negative regulators of cell proliferation. We report the phenotype of mice carrying a targeted deletion of the INK4a locus that eliminates both p-16(INK4a) and p19(ARF). The mice are viable but develop spontaneous tumors at an early age and are highly sensitive to carcinogenic treatments. INK4a-deficient primary fibroblasts proliferate rapidly and have a high colony-formation efficiency. in contrast with normal cells, the introduction of activated Ha-ras into INK4a-deficient fibroblasts can result in neoplastic transformation. These findings directly demonstrate that the INK4a locus functions to suppress neoplastic growth.	ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	Serrano, M (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA09173] Funding Source: Medline; NEI NIH HHS [EY09300] Funding Source: Medline; NICHD NIH HHS [HD28317] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BATES S, 1994, ONCOGENE, V9, P71; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Conzen SD, 1995, ONCOGENE, V11, P2295; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DEGRUIJL FR, 1991, CANCER RES, V51, P979; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DURO D, 1995, ONCOGENE, V11, P21; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAMA T, 1995, BLOOD, V86, P841; Holland EA, 1995, ONCOGENE, V11, P2289; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; KRIPKE ML, 1994, CANCER RES, V54, P6102; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MAO L, 1995, CANCER RES, V55, P2995; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PALMIERI S, 1989, CURR TOP MICROBIOL, V148, P43; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Silver W. K., 1979, COAT COLORS MICE MOD; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ueki K, 1996, CANCER RES, V56, P150; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIDA S, 1995, CANCER RES, V55, P2756; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	76	1353	1402	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					27	37		10.1016/S0092-8674(00)81079-X	http://dx.doi.org/10.1016/S0092-8674(00)81079-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620534	Bronze			2022-12-01	WOS:A1996UE55900006
J	Ferster, D; Chung, S; Wheat, H				Ferster, D; Chung, S; Wheat, H			Orientation selectivity of thalamic input to simple cells of cat visual cortex	NATURE			English	Article							RESPONSE PROPERTIES; RECEPTIVE-FIELDS; STRIATE CORTEX; AREA 17; NEURONS; PROJECTIONS; INHIBITION	MORE than 30 years after Hubel and Wiesel(1) first described orientation selectivity in the mammalian visual cortex, the mechanism that gives rise to this property is still controversial. Hubel and Wiesel(1) proposed a simple model for the origin of orientation tuning, in which the circularly symmetrical receptive fields of neurons in the lateral geniculate nucleus that excite a cortical simple cell are arranged in rows. Since this model was proposed, several experiments(2-6) and neuronal simulations(7,8) have suggested that the connectivity between the lateral geniculate nucleus and the cortex is not well organized in an orientation-specific fashion, and that orientation tuning arises instead from extensive interactions within the cortex. To test these models we have recorded visually evoked synaptic potentials in simple cells while cooling the cortex(9), which largely inactivates the cortical network, but leaves geniculate synaptic input functional. We report that the orientation tuning of these potentials is almost unaffected by cooling the cortex, in agreement with Hubel and Wiesel's original proposal(1).			Ferster, D (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CREUTZFELDT OD, 1974, EXP BRAIN RES, V21, P251; CROOK JM, 1991, NEUROSCIENCE, V40, P1, DOI 10.1016/0306-4522(91)90169-O; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; FERSTER D, 1986, J NEUROSCI, V6, P1284; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; FERSTER D, 1992, J NEUROSCI, V12, P1262; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1975, J COMP NEUROL, V163, P81, DOI 10.1002/cne.901630106; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; KISVARDAY ZF, 1994, EUR J NEUROSCI, V6, P1619, DOI 10.1111/j.1460-9568.1994.tb00553.x; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; MAEX R, 1994, THESIS KATHOLIEKE U; MILLER KD, 1994, J NEUROSCI, V14, P409; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SAUL AB, 1990, J NEUROPHYSIOL, V64, P206, DOI 10.1152/jn.1990.64.1.206; SCHWARK HD, 1986, J NEUROPHYSIOL, V56, P1074, DOI 10.1152/jn.1986.56.4.1074; SHATZ CJ, 1977, J COMP NEUROL, V173, P497, DOI 10.1002/cne.901730307; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SOMERS DC, 1995, J NEUROSCI, V15, P5448; SUAREZ H, 1995, J NEUROSCI, V15, P6700; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303	30	412	416	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					249	252		10.1038/380249a0	http://dx.doi.org/10.1038/380249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637573				2022-12-01	WOS:A1996UB11700052
J	Sil, A; Herskowitz, I				Sil, A; Herskowitz, I			Identification of an asymmetrically localized determinant, Ash1p, required for lineage-specific transcription of the yeast HO gene	CELL			English	Article							CELL-CYCLE REGULATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; LIFE-CYCLE; EXPRESSION; DNA; SW15; INTERCONVERSION; ENCODES; START	S. cerevisiae cells exhibit asymmetric determination of cell fate. Cell division yields a mother cell, which is competent to transcribe the HO gene and switch mating type, and a daughter cell, which is not. We have isolated a mutant in which daughters transcribe HO and switch mating type. This mutation defines the ASH1 gene (asymmetric synthesis of HO). Deletion and overexpression of ASH1 cause reciprocal cell fate transformations: in ash1 Delta strains, daughters switch mating type as efficiently as mothers. Conversely, overexpression of ASH1 inhibits switching in mother cells. Ash1p has a zinc finger motif related to those of GATA transcriptional regulators. Ash1p is localized to the daughter nucleus in cells that have undergone nuclear division. Thus, Ash1p is a cell fate determinant that is asymmetrically localized to the daughter nucleus where it inhibits HO transcription.			Sil, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, P949; HICKS JB, 1976, GENETICS, V83, P245; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRUGER WD, 1991, THESIS U CALFORNIA S; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; ORKIN SH, 1992, BLOOD, V80, P575; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; ROSE MD, 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091	49	216	219	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					711	722		10.1016/S0092-8674(00)81049-1	http://dx.doi.org/10.1016/S0092-8674(00)81049-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625409	Bronze			2022-12-01	WOS:A1996TZ99000009
J	Dragic, T; Litwin, V; Allaway, GP; Martin, SR; Huang, YX; Nagashima, KA; Cayanan, C; Maddon, PJ; Koup, RA; Moore, JP; Paxton, WA				Dragic, T; Litwin, V; Allaway, GP; Martin, SR; Huang, YX; Nagashima, KA; Cayanan, C; Maddon, PJ; Koup, RA; Moore, JP; Paxton, WA			HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS; FUNCTIONAL EXPRESSION; CD4-MEDIATED FUSION	The beta-chemokines MIP-1 alpha, MIP-1 beta and RANTES inhibit infection of CD4(+) T cells by primary, non-syncytium-inducing (NSI) HIV-1 strains at the virus entry stage, and also block env-mediated cell-cell membrane fusion. CD4(+) T cells from some HIV-1-exposed uninfected individuals cannot fuse with NSI HIV-1 strains and secrete high levels of beta-chemokines. Expression of the beta-chemokine receptor CC-CKR-5 in CD4(+), non-permissive human and non-human cells renders them susceptible to infection by NSI strains, and allows env-mediated membrane fusion. CC-CKR-5 is a second receptor for NSI primary viruses.	ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; PROGEN PHARMACEUT INC,TARRYTOWN,NY 10591	Rockefeller University			paxton, william/R-9747-2019	Paxton, William/0000-0001-5200-0801; Paxton, William/0000-0002-2654-5186				ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; COOCHI F, 1995, SCIENCE, V270, P1811; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LITWIN V, IN PRESS J VIROL; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1995, AIDS, V9 Suppl A, pS117; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Puri A, 1996, VIROLOGY, V219, P262, DOI 10.1006/viro.1996.0244; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53	29	2781	2925	1	162	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					667	673		10.1038/381667a0	http://dx.doi.org/10.1038/381667a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649512	Bronze			2022-12-01	WOS:A1996UR97900042
J	Hickok, G; Bellugi, U; Klima, ES				Hickok, G; Bellugi, U; Klima, ES			The neurobiology of sign language and its implications for the neural basis of language	NATURE			English	Article								THE left cerebral hemisphere is dominant for language, and many aspects of language use are more impaired by damage to the left than the right hemisphere, The basis for this asymmetry, however, is a matter of debate; the left hemisphere may be specialized for processing linguistic information(1-3) or for some more general function on which language depends, such as the processing of rapidly changing temporal information(4) or execution of complex motor patterns(5). To investigate these possibilities, we examined the linguistic abilities of 23 sign-language users with unilateral brain lesions. Despite the fact that sign language relies on visuospatial rather than rapid temporal information, the same left-hemispheric dominance emerged. Correlation analyses of the production of sign language versus non-linguistic hand gestures suggest that these processes are largely independent, Our findings support the view that the left-hemisphere dominance for language is not reducible solely to more general sensory or motor processes.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92186	University of California System; University of California San Diego	Hickok, G (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BELIUGI U, 1989, TRENDS NEUROSCI, V10, P380; CHIARELLO C, 1982, BRAIN, V105, P29, DOI 10.1093/brain/105.1.29; Corina D., 1993, PHONOLOGY, V10, P165, DOI [10.1017/S0952675700000038, DOI 10.1017/S0952675700000038]; Corina David P., 1993, PHONETICS PHONOLOGY, P63; CORINA DP, 1992, SCIENCE, V255, P1258, DOI 10.1126/science.1546327; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; GOODGLASS H, 1976, ASSESSMENT APHASIA R; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; Kimura D., 1993, NEUROMOTOR MECH HUMA; Klima E., 1979, SIGNS LANGUAGE; Liddell Scott K, 1980, AM SIGN LANGUAGE SYN; Lillo-Martin D., 1990, THEORETICAL ISSUES S, P191, DOI DOI 10.1007/978-94-011-3468-2; Lillo-Martin Diane., 1991, UNIVERSAL GRAMMAR AM; Osterrieth P. A., 1944, ARCHIVESPSYCHOLOGIE, V30, P206; PERLMUTTER DM, 1992, LINGUIST INQ, V23, P407; POIZNER H, 1993, ANN NY ACAD SCI, V682, P192, DOI 10.1111/j.1749-6632.1993.tb22969.x; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; [No title captured]	19	114	116	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					699	702		10.1038/381699a0	http://dx.doi.org/10.1038/381699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649515				2022-12-01	WOS:A1996UR97900053
J	Roberts, I				Roberts, I			Safely to school?	LANCET			English	Editorial Material											Roberts, I (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND.							CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; *DEP TRANSP, 1995, TRANSP STAT REP; Department of Health, 1996, STRAT STAT PHYS ACT; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; Preston B., 1992, CUTTING PEDESTRIAN C; ROBERTS I, 1995, EPIDEMIOLOGY, V6, P169, DOI 10.1097/00001648-199503000-00014; WOODROFFE C, 1993, CHILDREN TEENAGERS H	7	19	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1642	1642		10.1016/S0140-6736(96)91483-X	http://dx.doi.org/10.1016/S0140-6736(96)91483-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642954				2022-12-01	WOS:A1996UQ70100006
J	Yamatsuji, T; Matsui, T; Okamoto, T; Komatsuzaki, K; Takeda, S; Fukumoto, H; Iwatsubo, T; Suzuki, N; AsamiOdaka, A; Ireland, S; Kinane, TB; Giambarella, U; Nishimoto, I				Yamatsuji, T; Matsui, T; Okamoto, T; Komatsuzaki, K; Takeda, S; Fukumoto, H; Iwatsubo, T; Suzuki, N; AsamiOdaka, A; Ireland, S; Kinane, TB; Giambarella, U; Nishimoto, I			G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; MISSENSE MUTATION; ALPHA-SUBUNIT; GENE; CELLS; APOPTOSIS; INDUCTION; DEATH	Missense mutations in the 595-amino acid form of the amyloid precursor protein (APP(695)) cosegregate with disease phenotype in families with dominantly inherited Alzheimer's disease. These mutations convert valine at position 642 to isoleucine, phenylalanine, or glycine. Expression of these mutant proteins, but not of normal APP(695), was shown to induce nucleosomal DNA fragmentation in neuronal cells. Induction of DNA fragmentation required the cytoplasmic domain of the mutants and appeared to be mediated by heterotrimeric guanosine triphosphate-binding proteins (G proteins).	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CARDIVASC RES CTR,DEPT MED,CHARLESTOWN,MA 02129; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT NEUROPATHOL & NEUROSCI,BUNKYO KU,TOKYO 113,JAPAN; TAKEDA CHEM IND LTD,TSUKUBA,IBARAKI 30042,JAPAN; ONCOR INC,GAITHERSBURG,MD 20877; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT PEDIAT,RENAL UNIT,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; University of Tokyo; Takeda Chemical Industries; Harvard University; Massachusetts General Hospital								ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JOFFE I, 1993, CALCIFIED TISSUE INT, V53, P45, DOI 10.1007/BF01352014; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEE VMY, 1986, J NEUROSCI, V6, P514; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; YAMATSUJI T, UNPUB; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	40	218	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1349	1352		10.1126/science.272.5266.1349	http://dx.doi.org/10.1126/science.272.5266.1349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650548				2022-12-01	WOS:A1996UN47200050
J	Graff, JM; Bansal, A; Melton, DA				Graff, JM; Bansal, A; Melton, DA			Xenopus Mad proteins transduce distinct subsets of signals for the TGF beta superfamily	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM-INDUCING ACTIVITY; VENTRALIZING FACTOR; AXIAL MESODERM; EARLY RESPONSE; INDUCTION; EMBRYOS; RNA; EXPRESSION; EMBRYOGENESIS	Xenopus cDNAs homologous to the Drosophila Mad gene and C. elegans CEM genes have been cloned and functionally analyzed by microinjection into frog embryos. The results show that these genes (Xmad) encode intracellular proteins that act downstream of TGF beta superfamily ligands. Most interesting is the fact that different Xmad proteins produce distinct biological responses. Xmad1 produces ventral mesoderm, apparently transducing a signal for BMP2 and BMP4, whereas Xmad2 induces dorsal mesoderm like Vg1, activin, and nodal. These results suggest that an individual Xmad protein waits poised in the cytoplasm for instruction from a distinct subset of TGF beta ligands and then conveys specific information to the nucleus.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NEWFELD SJ, 1996, IN PRESS DEVELOPMENT; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RAFTERY LA, 1995, GENETICS, V139, P241; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SAVAGE C, 1996, P NATL ACAD SCI USA, V93, P7790; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	56	396	409	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					479	487		10.1016/S0092-8674(00)81249-0	http://dx.doi.org/10.1016/S0092-8674(00)81249-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653784	Bronze			2022-12-01	WOS:A1996UM41500006
J	Tsang, SH; Gouras, P; Yamashita, CK; Kjeldbye, H; Fisher, J; Farber, DB; Goff, SP				Tsang, SH; Gouras, P; Yamashita, CK; Kjeldbye, H; Fisher, J; Farber, DB; Goff, SP			Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; DOMINANT RETINITIS-PIGMENTOSA; BETA-SUBUNIT; OUTER SEGMENTS; RHODOPSIN MUTATIONS; PHOTORECEPTOR CELLS; NONSENSE MUTATION; MOUSE RETINA; G-PROTEIN; RDS GENE	The retinal cyclic guanosine 3',5'-monophosphate (cGMP) phosphodiesterase (PDE) is a key regulator of phototransduction in the vertebrate visual system, PDE consists of a catalytic core of alpha and beta subunits associated with two inhibitory gamma subunits. A gene-targeting approach was used to disrupt the mouse PDE gamma gene, This mutation resulted in a rapid retinal degeneration resembling human retinitis pigmentosa. In homozygous mutant mice, reduced rather than increased PDE activity was apparent; the PDE alpha beta dimer was formed but lacked hydrolytic activity, Thus, the inhibitory gamma subunit appears to be necessary for integrity of the photoreceptors and expression of PDE activity in vivo.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OPHTHALMOL,EDWARD HARKNESS EYE INST,NEW YORK,NY 10032; UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90095	Columbia University; Howard Hughes Medical Institute; Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Farber, Debora/0000-0002-3207-697X	NEI NIH HHS [R01 EY008285, K08 EY000408, K08 EY000408-01, EY08285] Funding Source: Medline; NIGMS NIH HHS [T32 GM 073667-14] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008285, K08EY000408] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYES M, 1995, HUM MUTAT, V5, P228, DOI 10.1002/humu.1380050307; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; DANCIGER M, 1995, GENOMICS, V3, P1; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; FARBER DB, 1976, J CYCLIC NUCL PROT, V2, P139; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GOURAS P, 1994, INVEST OPHTH VIS SCI, V35, P3145; HANH LB, 1994, INVEST OPHTH VIS SCI, V35, P1077; HUANG SH, 1995, INVEST OPHTH VIS SCI, V36, pS825; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KROLL S, 1989, J BIOL CHEM, V264, P4490; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MCINNES RR, 1992, NAT GENET, V1, P155, DOI 10.1038/ng0692-155; MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249; MIKI N, 1975, J BIOL CHEM, V250, P6320; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; RAY K, 1994, INVEST OPHTH VIS SCI, V35, P4291; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; TSANG S, UNPUB; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	49	148	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1026	1029		10.1126/science.272.5264.1026	http://dx.doi.org/10.1126/science.272.5264.1026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638127	Green Accepted			2022-12-01	WOS:A1996UL61900050
J	Wiznia, AA; Crane, M; Lambert, G; Sansary, J; Harris, A; Solomon, L				Wiznia, AA; Crane, M; Lambert, G; Sansary, J; Harris, A; Solomon, L			Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective:-To evaluate whether zidovudine treatment was accepted and used by pregnant women subsequent to the release of the results of a multicenter, randomized, placebo-controlled trial (AIDS Clinical Trial Group [ACTG] Protocol 076) that showed that zidovudine significantly reduced maternal-infant human immunodeficiency virus (HIV) type 1 transmission. Design.-Prospective study. Setting:-A community hospital with an integrated, multidisciplinary HIV-dedicated program located in an impoverished, HIV-endemic urban setting. Participants.-All HIV-infected pregnant women identified after the release of the ACTG 076 results who were offered zidovudine therapy to reduce maternal-infant transmission. Results.-Only 49 of the 125 HIV-infected pregnant women delivering at our site during this study period were identified prenatally. Perinatal zidovudine therapy was chosen by 37 (75%) of 49 women. Women refusing zidovudine were more likely to report injection drug use as their HIV risk factor and to continue to use drugs during their pregnancy. Of women choosing zidovudine and delivering, 24 of 36 received all components of their elected therapy. The intrapartum dose was missed by 12 women, 4 of whom also missed their prescribed prenatal oral therapy. Lack of adherence to chosen therapy was associated with continued cocaine use during pregnancy. Conclusions.-Zidovudine therapy to interrupt vertical transmission of HIV was not widely used by these HIV-infected pregnant women. Further studies evaluating factors affecting the acceptance and use of recently published public health recommendations are needed.	BRONX LEBANON HOSP CTR,DEPT OBSTET GYNECOL,BRONX,NY 10457; ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT OBSTET GYNECOL,BRONX,NY 10467	BronxCare Health System; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Wiznia, AA (corresponding author), BRONX LEBANON HOSP CTR,DIV PEDIAT INFECT DIS,1650 SELWYN AVE,APT 2C,BRONX,NY 10457, USA.				NIAID NIH HHS [AI32914-03] Funding Source: Medline; PHS HHS [U64/CCU206826-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032914] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYER R, 1994, NEW ENGL J MED, V331, P1223, DOI 10.1056/NEJM199411033311811; BURKETT G, 1994, AM J OBSTET GYNECOL, V171, P372, DOI 10.1016/S0002-9378(94)70037-0; CDCP, 1994, EP INF VERS 6 WORD P; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PLESSINGER MA, 1993, CLIN OBSTET GYNECOL, V36, P267, DOI 10.1097/00003081-199306000-00008; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; ROGERS MF, 1994, NEW ENGL J MED, V331, P1223; *STAT NY DEP HLTH, 1994, CLIN GUID US ZID THE; *US DEP HHS, 1995, EX SUMM ACTG 152 RAN; *US DEP HHS, 1995, EX SUMM ACTG 175 RAN; WEHBEH H, 1995, AM J OBSTET GYNECOL, V172, P1014; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	17	55	55	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1504	1506		10.1001/jama.275.19.1504	http://dx.doi.org/10.1001/jama.275.19.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622226				2022-12-01	WOS:A1996UJ93700035
J	Reidenberg, MM				Reidenberg, MM			Barriers to controlling pain in patients with cancer	LANCET			English	Editorial Material							MANAGEMENT				Reidenberg, MM (corresponding author), CORNELL UNIV,COLL MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.							BRANDT EN, 1984, JAMA-J AM MED ASSOC, V251, P1191; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Drayer RA, 1996, J INVEST MED, V44, pA311; HILL CS, 1993, SEMIN ONCOL, V20, P1; Lee LE, 1941, J AMER MED ASSOC, V116, P216, DOI 10.1001/jama.1941.02820030038009; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *WHO EXP COMM, 1990, TECHN REP SERIES WHO, V804; World Health Organization, 1986, CANC PAIN REL; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; 1983, ANN INTERN MED, V99, P870; 1996, BRIT MED J, V312, P823	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1278	1278		10.1016/S0140-6736(96)90935-6	http://dx.doi.org/10.1016/S0140-6736(96)90935-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622501	hybrid			2022-12-01	WOS:A1996UK75800006
J	Groettrup, M; Soza, A; Eggers, M; Kuehn, L; Dick, TP; Schild, H; Rammensee, HG; Koszinowski, UH; Kloetzel, PM				Groettrup, M; Soza, A; Eggers, M; Kuehn, L; Dick, TP; Schild, H; Rammensee, HG; Koszinowski, UH; Kloetzel, PM			A role for the proteasome regulator PA28 alpha in antigen presentation	NATURE			English	Article							MURINE CYTOMEGALO-VIRUS; PEPTIDES	CYTOTOXIC T cells recognize viral proteins as peptide fragments which are produced in the cytosol and transported on major histocompatibility complex (MHC) class I proteins to the cell surface(1). Viral peptides that meet the stringent binding characteristics of class I proteins are generated by the 20S proteasome(2,3), The interferon (IFN)-gamma-inducible activator of the 20S proteasome, PA28 (refs 4-6), strongly influences the proteasomal cleavage pattern in vitro(7), This led us to investigate whether changes in cellular levels of PA28 affect the efficiency of viral antigen processing, A mouse fibroblast line expressing the murine cytomegalovirus pp89 protein was transfected with either the human or murine gene encoding the PA28 alpha subunit, which is sufficient to activate the peptide-hydrolysing activity of the 20S proteasome in vitro. Here we report that enhanced expression of PA28 alpha at a level similar to that obtained after IFN-gamma induction resulted in a marked enhancement of recognition by pp89-specific cytotoxic T cells; the presentation of influenza nucleoprotein was also significantly improved, These results demonstrate a fundamental in vivo function for PA28 alpha in antigen processing.	HUMBOLDT UNIV BERLIN,FAC MED CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY; GERMAN CANC RES CTR,D-69009 HEIDELBERG,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)				Eggers, Maren/0000-0001-8485-9485; Soza, Andrea/0000-0003-3783-5231				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DELVAL M, 1989, CELL, V58, P305, DOI 10.1016/0092-8674(89)90845-3; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; KEIL GM, 1985, J VIROL, V54, P422, DOI 10.1128/JVI.54.2.422-428.1985; KOSZINOWSKI UH, 1986, J VIROL, V58, P59, DOI 10.1128/JVI.58.1.59-66.1986; MOTT JD, 1994, J BIOL CHEM, V269, P31466; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SEELIG A, 1993, ENZYME PROTEIN, V47, P330, DOI 10.1159/000468691; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O	21	302	319	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					166	168		10.1038/381166a0	http://dx.doi.org/10.1038/381166a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610016				2022-12-01	WOS:A1996UK13900053
J	MacKie, RM; Hole, DJ				MacKie, RM; Hole, DJ			Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective-To study incidence of and survival from cutaneous malignant melanoma in relation to socioeconomic status. Design-Application of Carstairs deprivation score to all malignant melanoma patients diagnosed in a geographically defined area over a 15 year period. Setting-West of Scotland (area population 2 716 900). Subjects-3142 patients first diagnosed with malignant melanoma in the period 1979-93. Interventions-Surgical excision of primary malignant melanoma with additional treatment as appropriate and follow up until December 1994. Main outcome measures-Malignant melanoma incidence, primary tumour thickness and five year survival by socioeconomic status Results-From 1979 to 1993, the age standardised incidence rate for cutaneous malignant melanoma was 9.1/100 000 for the most affluent men and 2.4/100 000 for the least affluent men and 16.1/100 000 and 5.0/100 000 respectively for most and least affluent women (P<0.001 for trend in both). The incidence increased steadily over time in both sexes in all socioeconomic groups. Good prognosis tumours (<1.5 mm thick) were most common in the most affluent men and women, and over the study period the proportion of such tumours increased most in the intermediate affluence group (both sexes) and in the least affluent women. Five year disease free survival from melanoma for the sexes combined was 81% for most affluent, 77% for intermediate, and 73% for least affluent groups. Even after adjustment for known prognostic factors of tumour thickness, ulceration, age, and body site of primary melanoma, the more affluent the group, the better the survival. Conclusion-Although the incidence of cutaneous malignant melanoma is higher among more affluent people, the prognosis is better in this group than for less affluent individuals. Early diagnosis campaigns should be targeted particularly to less affluent men and primary prevention campaigns should emphasise the greater risk in more affluent women.	RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GREATER GLASGOW HLTH BOARD,GLASGOW,LANARK,SCOTLAND	University of Glasgow	MacKie, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,LANARK,SCOTLAND.							BRESLOW A, 1975, ANN SURG, V182, P572, DOI 10.1097/00000658-197511000-00007; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; Carstairs V., 1991, DEPRIVATION HLTH SCO; COX DR, 1972, J R STAT SOC B, V34, P187; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; LEE JAH, 1980, BRIT J CANCER, V41, P757, DOI 10.1038/bjc.1980.138; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; NELEMANS PJ, 1993, ENVIRON HEALTH PERSP, V101, P252, DOI 10.2307/3431552; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317	9	74	78	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1125	1128						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620127				2022-12-01	WOS:A1996UK06900020
J	Hensch, TK; Stryker, MP				Hensch, TK; Stryker, MP			Ocular dominance plasticity under metabotropic glutamate receptor blockade	SCIENCE			English	Article							CATS VISUAL-CORTEX; KITTEN STRIATE CORTEX; LONG-TERM DEPRESSION; MONOCULAR DEPRIVATION; HIPPOCAMPAL-NEURONS; ANTAGONISM; INDUCTION; NEOCORTEX; ARBORS	Occluding vision through one eye during a critical period in early life nearly abolishes responses to that eye in visual cortex. This phenomenon is mimicked by long-term depression of synaptic transmission in vitro, which may require metabotropic glutamate receptors (mGluRs) and is age-dependent. Peaks in mGluR expression and glutamate stimulated phosphoinositide turnover during visual cortical development have been proposed as biochemical bases for the critical period. Pharmacological blockade of mGluRs specifically prevented synapse weakening in mouse visual cortical slices but did not alter kitten ocular dominance plasticity in vivo. Thus, a heightened mGluR response does not account for the critical period in development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,CTR INTEGRATED NEUROSCI,WM KECK FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Hensch, Takao/L-4182-2019	Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [R01 EY002874, EY02874] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002874, R01EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ANTONINI A, 1993, J NEUROSCI, V13, P3549; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ANTONINI A, IN PRESS J COMP NEUR; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; BASKYS A, 1992, TRENDS NEUROSCI, V15, P92, DOI 10.1016/0166-2236(92)90018-4; BIRSE EF, 1993, NEUROSCIENCE, V52, P481, DOI 10.1016/0306-4522(93)90400-A; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P489, DOI 10.1113/jphysiol.1982.sp014244; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; BRABETI, 1995, NEUROPHARMACOLOGY, V34, P895; CAHUSAC PMB, 1994, EUR J NEUROSCI, V6, P1505, DOI 10.1111/j.1460-9568.1994.tb01012.x; CATANIA MV, 1994, NEUROSCIENCE, V61, P481, DOI 10.1016/0306-4522(94)90428-6; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DRAGER UC, 1978, J NEUROPHYSIOL, V41, P28, DOI 10.1152/jn.1978.41.1.28; DUDEK SM, 1989, SCIENCE, V246, P673, DOI 10.1126/science.2573152; DUDEK SM, 1993, J NEUROSCI, V13, P2910; DUDEK SM, 1994, SOC NEUR ABSTR, V20; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; GEREAU RW, 1995, J NEUROPHYSIOL, V74, P122, DOI 10.1152/jn.1995.74.1.122; GORDON JA, IN PRESS J NEUROSCI; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HARUTA H, 1994, NEUROREPORT, V5, P1829, DOI 10.1097/00001756-199409080-00036; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HENSCH TK, 1995, SOC NEUR ABSTR, V21; HSIA AY, 1995, NEUROPHARMACOLOGY, V34, P1567, DOI 10.1016/0028-3908(95)00115-M; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; JIA WWG, 1995, DEV BRAIN RES, V85, P109, DOI 10.1016/0165-3806(94)00181-X; JOLY C, 1995, J NEUROSCI, V15, P3970; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LINGENHOHL K, 1993, NEUROSCI RES, V18, P229, DOI 10.1016/0168-0102(93)90058-X; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; OMARA SM, 1995, NEUROPHARMACOLOGY, V34, P983, DOI 10.1016/0028-3908(95)00062-B; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; REID SNM, 1995, SOC NEUR ABSTR, V21; REITER HO, 1986, EXP BRAIN RES, V65, P182; RICHTER-LEVIN G, 1994, NEUROPHARMACOLOGY, V33, P853, DOI 10.1016/0028-3908(94)90181-3; RIEDEL G, 1995, J NEUROSCI, V15, P87; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; SAUGSTAD JA, 1995, EUR J PHARM-MOLEC PH, V289, P395, DOI 10.1016/0922-4106(95)90120-5; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; THOMSEN C, 1994, EUR J PHARM-MOLEC PH, V267, P77, DOI 10.1016/0922-4106(94)90227-5; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; YANG XD, 1994, J NEUROPHYSIOL, V71, P1586, DOI 10.1152/jn.1994.71.4.1586; YI PL, 1995, NEUROSCI LETT, V185, P207, DOI 10.1016/0304-3940(95)11264-W	66	50	51	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					554	557		10.1126/science.272.5261.554	http://dx.doi.org/10.1126/science.272.5261.554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614806				2022-12-01	WOS:A1996UG82600046
J	Kleyn, PW; Fan, W; Kovats, SG; Lee, JJ; Pulido, JC; Wu, Y; Berkemeier, LR; Misumi, DJ; Holmgren, L; Charlat, O; Woolf, EA; Tayber, O; Brody, T; Shu, P; Hawkins, F; Kennedy, B; Baldini, L; Ebeling, C; Alperin, GD; Deeds, J; Lakey, ND; Culpepper, J; Chen, H; GlucksmannKuis, MA; Carlson, GA; Duyk, GM; Moore, KJ				Kleyn, PW; Fan, W; Kovats, SG; Lee, JJ; Pulido, JC; Wu, Y; Berkemeier, LR; Misumi, DJ; Holmgren, L; Charlat, O; Woolf, EA; Tayber, O; Brody, T; Shu, P; Hawkins, F; Kennedy, B; Baldini, L; Ebeling, C; Alperin, GD; Deeds, J; Lakey, ND; Culpepper, J; Chen, H; GlucksmannKuis, MA; Carlson, GA; Duyk, GM; Moore, KJ			Identification and characterization of the mouse obesity gene tubby: A member of a novel gene family	CELL			English	Article							NEUROPEPTIDE-Y; FOOD-INTAKE; WEIGHT; MICE	The mutated gene responsible for the tubby obesity phenotype has been identified by positional cloning. A single base change within a splice donor site results in the incorrect retention of a single intron in the mature tub mRNA transcript. The consequence of this mutation is the substitution of the carboxy-terminal 44 amino acids with 24 intron-encoded amino acids. The normal transcript appears to be abundantly expressed in the hypothalamus, a region of the brain involved in body weight regulation. Variation in the relative abundance of alternative splice products is observed between inbred mouse strains and appears to correlate with an intron length polymorphism. This allele of tub is a candidate for a previously reported diet-induced obesity quantitative trait locus on mouse chromosome 7.	MCLAUGHLIN RES INST BIOMED SCI,GREAT FALLS,MT 59405	McLaughlin Research Institute for Biomedical Sciences, Inc.	Kleyn, PW (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEMORIAL DR,CAMBRIDGE,MA 02139, USA.							ALLISON DB, 1994, HEALTH PSYCHOL, V13, P362, DOI 10.1037/0278-6133.13.4.362; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1995, CELL, V81, P289; BAI FL, 1985, BRAIN RES, V331, P172, DOI 10.1016/0006-8993(85)90730-9; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAY GA, 1984, INT J OBES S8, V1, P119; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIE JM, 1994, GENOMICS, V23, P575, DOI 10.1006/geno.1994.1545; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; GOLD RM, 1977, PHYSIOL BEHAV, V18, P1111, DOI 10.1016/0031-9384(77)90019-1; GRUNDY SM, 1990, DM-DIS MON, V36, P641; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HEWITT JK, 1991, ACTA GENET MED GEMEL, V40, P133, DOI 10.1017/S0001566000002567; JONES JM, 1992, GENOMICS, V14, P197, DOI 10.1016/S0888-7543(05)80308-8; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; KNOLL JHM, 1993, AM J MED GENET, V46, P2, DOI 10.1002/ajmg.1320460103; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; MAYER J, 1955, AM J PHYSIOL, V182, P75, DOI 10.1152/ajplegacy.1955.182.1.75; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NISHINA PM, 1994, METABOLISM, V43, P554, DOI 10.1016/0026-0495(94)90195-3; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PRICE RA, 1987, AM J PSYCHIAT, V144, P1003; PRICE RA, 1990, INT J OBESITY, V14, P185; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SELDIN MF, 1994, J CLIN INVEST, V94, P269, DOI 10.1172/JCI117317; SHORPOSNER G, 1985, PHYSIOL BEHAV, V35, P883, DOI 10.1016/0031-9384(85)90255-0; STANLEY BG, 1985, LIFE SCI, V33, P2635; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VAMBUTAS V, 1994, BBA-GENE STRUCT EXPR, V1217, P203, DOI 10.1016/0167-4781(94)90036-1; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; XU Y, 1994, ISMB, V2, P376; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1994, HUM MOL GENET, V3, P621	44	272	290	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					281	290		10.1016/S0092-8674(00)81104-6	http://dx.doi.org/10.1016/S0092-8674(00)81104-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612280	Bronze			2022-12-01	WOS:A1996UG25500016
J	Lewis, MJ; Pelham, HRB				Lewis, MJ; Pelham, HRB			SNARE-mediated retrograde traffic from the Golgi complex to the endoplasmic reticulum	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; LUMINAL ER PROTEINS; SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SHUTTLE VECTORS; YEAST GENES; ENCODES; FUSION; RETRIEVAL	Operation of the secretory pathway in eukaryotic cells requires the selective docking and fusion of transport vesicles with the appropriate target organelle. This is mediated in part by integral membrane proteins termed v-SNAREs (on vesicles) and t-SNAREs (on the target membranes). We describe a novel yeast t-SNARE that resides on the endoplasmic reticulum and mediates retrograde traffic from the Golgi complex. Mutation of this protein prevents both the HDEL receptor and a membrane protein bearing a dibasic retrieval signal from recycling to the endoplasmic reticulum. Forward traffic is also blocked, but only indirectly. Comparison with other yeast mutants indicates that Sec21p (gamma-COP) and Sec20p (an endoplasmic reticulum membrane protein) are also involved primarily, if not exclusively, in retrograde transport.			Lewis, MJ (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECHERER KA, 1994, GUIDEBOOK SECRETORY, P253; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HILL J, 1991, NUCLEIC ACIDS RES, V19, P529; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319	52	178	179	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					205	215		10.1016/S0092-8674(00)81097-1	http://dx.doi.org/10.1016/S0092-8674(00)81097-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612273	Bronze			2022-12-01	WOS:A1996UG25500009
J	Herlitze, S; Garcia, DE; Mackie, K; Hille, B; Scheuer, T; Catterall, WA				Herlitze, S; Garcia, DE; Mackie, K; Hille, B; Scheuer, T; Catterall, WA			Modulation of Ca2+ channels by G-protein beta gamma subunits	NATURE			English	Article							CALCIUM CHANNELS; SYNAPTIC TRANSMISSION; SYMPATHETIC NEURONS; RECEPTORS; INHIBITION	CALCIUM ions entering cells through voltage-gated Ca2+ channels initiate rapid release of neurotransmitters and secretion of hormones. Ca2+ currents can be inhibited in many cell types by neurotransmitters acting through G proteins via a membrane-delimited pathway independently of soluble intracellular messengers(1-4). Inhibition is typically caused by a positive shift in the voltage dependence and a slowing of channel activation and is relieved by strong depolarization resulting in facilitation of Ca2+ currents(1,4-6). This pathway regulates the activity of N-type and P/Q-type Ca2+ channels(1,2,7), which are localized in presynaptic terminals(8,9) and participate in neurotransmitter release(10-13). Synaptic transmission is inhibited by neurotransmitters through this mechanism(1,4). G-protein alpha subunits confer specificity in receptor coupling(1-4,14-17), but it is not known whether the G alpha or G beta gamma subunits are responsible for modulation of Ca2+ channels. Here we report that G beta gamma subunits can modulate Ca2+ channels. Transfection of G beta gamma into cells expressing P/Q-type Ca2+ channels induces modulation like that caused by activation of G protein-coupled receptors, but G alpha subunits do not. Similarly, injection or expression of G beta gamma subunits in sympathetic ganglion neurons induces facilitation and occludes modulation of N-type channels by noradrenaline, but G alpha subunits do not. In both cases, the G gamma subunit is ineffective by itself, but overexpression of exogenous G beta subunits is sufficient to cause channel modulation.	UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195; NATL AUTONOMOUS UNIV MEXICO,FAC MED,DEPT PHYSIOL,MEXICO CITY 04510,DF,MEXICO	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidad Nacional Autonoma de Mexico	Herlitze, S (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Garcia, David/AAE-8176-2020; Mackie, Kenneth P/B-7358-2011; Mackie, Ken/E-3715-2013; Garcia, David/A-7626-2008	Mackie, Ken/0000-0001-8501-6199; 				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hescheler J, 1993, Curr Opin Neurobiol, V3, P360, DOI 10.1016/0959-4388(93)90129-M; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HIMING LD, 1988, SCIENCE, V239, P57; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	30	672	684	1	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					258	262		10.1038/380258a0	http://dx.doi.org/10.1038/380258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637576				2022-12-01	WOS:A1996UB11700055
J	Verkhovsky, MI; Morgan, JE; Puustinen, A; Wikstrom, M				Verkhovsky, MI; Morgan, JE; Puustinen, A; Wikstrom, M			Kinetic trapping of oxygen in cell respiration	NATURE			English	Article							CYTOCHROME-C-OXIDASE; LOW-SPIN HEME; ELECTRON-TRANSFER; ESCHERICHIA-COLI; FLOW-FLASH; SITE	CELL respiration in eukaryotes is catalysed by the mitochondri`al enzyme cytochrome c oxidase. In bacteria there are many variants of this enzyme, all of which have a binuclear haem iron-copper centre at which O-2 reduction occurs, and a low-spin haem, which serves as the immediate electron donor to this centre(1). It is essential that the components of the cell respiratory system have a high affinity for oxygen because of the low concentrations of dissolved O-2 in the tissues; however, the binding of O-2 to the respiratory haem-copper oxidases is very weak(2,3). This paradox has been attributed to kinetic trapping during fast reactions of O-2 bound within the enzyme's binuclear haem iron-copper centre(2). Our earlier work(3) indicated that electron transfer from the low-spin haem to the oxygen-bound binuclear centre may be necessary for such kinetic oxygen trapping. Here we show that a specific decrease of this haem-haem electron transfer rate in the respiratory haem-copper oxidase from Escherichia coli leads to a corresponding decrease in the enzyme's operational steady-state affinity for O-2. This demonstrates directly that fast electron transfer between the haem groups is a key process in achieving the high affinity for oxygen in cell respiration.	UNIV HELSINKI,BIOCENTRUM HELSINKI,SF-00014 HELSINKI,FINLAND	University of Helsinki	Verkhovsky, MI (corresponding author), UNIV HELSINKI,INST BIOMED SCI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,PB 8,SF-00014 HELSINKI,FINLAND.		Wikstrom, Marten KF/A-4403-2008	Puustinen, Anne/0000-0002-0262-9975; Wikstrom, Marten/0000-0002-7527-4415				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1965, J GEN PHYSIOL, V49, P163, DOI 10.1085/jgp.49.1.163; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MORGAN JE, 1993, BIOCHEMISTRY-US, V32, P11412; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; PETERSEN LC, 1974, BIOCHEM J, V142, P247, DOI 10.1042/bj1420247; PROVENCHER SW, 1983, PROGR SCI COMPUTING, V2, P304; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; SVENSSON M, 1993, BIOCHEMISTRY-US, V32, P5442, DOI 10.1021/bi00071a021; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042	14	90	90	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					268	270		10.1038/380268a0	http://dx.doi.org/10.1038/380268a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637579				2022-12-01	WOS:A1996UB11700058
J	Phull, PS; Halliday, D; Price, AB; Jacyna, MR				Phull, PS; Halliday, D; Price, AB; Jacyna, MR			Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication	BRITISH MEDICAL JOURNAL			English	Article											Phull, PS (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.							ATHERTON JC, 1994, GUT, V35, P723, DOI 10.1136/gut.35.6.723; LOGAN RPH, 1991, EUR J GASTROEN HEPAT, V3, P915; PHULL PS, 1995, POSTGRAD MED J, V71, P413, DOI 10.1136/pgmj.71.837.413; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					349	350						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611832	Green Published			2022-12-01	WOS:A1996TV69800024
J	Sharp, D				Sharp, D			Gun deaths in schools, in the USA	LANCET			English	Editorial Material																		Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; Burns R, 1996, JAMA-J AM MED ASSOC, V275, P1775; Kachur SP, 1996, JAMA-J AM MED ASSOC, V275, P1729, DOI 10.1001/jama.275.22.1729	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1712	1712		10.1016/S0140-6736(96)90805-3	http://dx.doi.org/10.1016/S0140-6736(96)90805-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656903				2022-12-01	WOS:A1996UT39600007
J	Sieratzki, JS; Woll, B				Sieratzki, JS; Woll, B			Why do mothers cradle babies on their left?	LANCET			English	Article							CARRYING NEWBORN-INFANTS; LEFT-SIDE PREFERENCE; HANDEDNESS; LATERALITY; PERCEPTION; HEARTBEAT; LANGUAGE; CHILD	Many explanations have been put forward for the observed preference of mothers to cradle babies on the left side. These include handedness, the importance of the maternal heartbeat, left breast sensitivity, socio-psychological factors, and advantages in monitoring the infant. We propose that protection and facilitation of affective communication Is at the core of cradling; and explore the relation between left-cradling and the role of the right hemisphere in early mother-infant interaction. Left-cradling not only directs maternal communication to the infant's right hemisphere but also facilitates affective feedback to the maternal right brain. The underlying neuro-linguistic mechanisms proposed in this article may be important in the early course of child language development and may also serve to illuminate our understanding of the evolution of human language.	CITY UNIV LONDON, DEPT CLIN COMMUN STUDIES, LONDON EC1V 0HB, ENGLAND	City University London	Sieratzki, JS (corresponding author), HAMMERSMITH HOSP, DEPT PAEDIAT & NEONATOL, LONDON, ENGLAND.		Woll, Bencie/C-2040-2008	Woll, Bencie/0000-0002-3300-4775				BERTONCINI J, 1989, BRAIN LANG, V37, P591, DOI 10.1016/0093-934X(89)90113-2; BOGREN LY, 1984, ACTA PSYCHIAT SCAND, V69, P13, DOI 10.1111/j.1600-0447.1984.tb04512.x; BOROD JC, 1990, BRAIN COGNITION, V13, P167, DOI 10.1016/0278-2626(90)90048-S; BRYDEN MP, 1991, CORTEX, V27, P229, DOI 10.1016/S0010-9452(13)80127-X; CODE C, 1984, EXPT CLIN PHONETICS, P166; Cruttenden A., 1994, INPUT INTERACTION LA, P135, DOI 10.1017/cbo9780511620690.008; DAVIDSON RJ, 1995, CURR OPIN NEUROBIOL, V5, P217, DOI 10.1016/0959-4388(95)80029-8; DECHATEAU P, 1987, ACTA PSYCHIAT SCAND, V75, P283; DECHATEAU P, 1976, DEV MED CHILD NEUROL, V18, P738; DIENSKE H, 1995, BEHAVIOUR, V132, P801, DOI 10.1163/156853995X00153; FERNALD A, 1989, J CHILD LANG, V16, P477, DOI 10.1017/S0305000900010679; FIFER WP, 1994, ACTA PAEDIATR, V83, P86, DOI 10.1111/j.1651-2227.1994.tb13270.x; FINGER S, 1975, CHILD DEV, V46, P267; GINSBURG HJ, 1979, CHILD DEV, V50, P280, DOI 10.2307/1129073; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; HUHEEY JE, 1977, BEHAV GENET, V7, P29; Kupfermann I., 1991, PRINCIPLES NEURAL SC, P823; LUCAS MD, 1993, J GENET PSYCHOL, V154, P347; MANNING JT, 1990, ANIM BEHAV, V39, P1224, DOI 10.1016/S0003-3472(05)80800-0; MANNING JT, 1994, J COMP PSYCHOL, V108, P262, DOI 10.1037/0735-7036.108.3.262; PALMQVIST H, 1975, CHILD DEV, V46, P292; ROSS ED, 1993, NEUROL CLIN, V11, P9, DOI 10.1016/S0733-8619(18)30168-3; SALING MM, 1984, CURR ANTHROPOL, V25, P333, DOI 10.1086/203140; SALK L, 1973, SCI AM, V228, P24, DOI 10.1038/scientificamerican0573-24; SHIPLEYBROWN F, 1988, BRAIN LANG, V33, P16, DOI 10.1016/0093-934X(88)90051-X; SOLMS KLK, 1988, PERCEPT MOTOR SKILL, V67, P55; THOMPSON AM, 1993, CORTEX, V29, P649, DOI 10.1016/S0010-9452(13)80288-2; TREHUB SE, 1993, ADV CHILD DEV BEHAV, V24, P1, DOI 10.1016/S0065-2407(08)60298-0; WEILAND JH, 1970, J GENET PSYCHOL, V117, P157; WEINSTEIN S, 1963, AM J PSYCHOL, V76, P475, DOI 10.2307/1419791; Woll B., 1989, SOCIAL COGNITIVE ASP, P129	31	67	69	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	1996	347	9017					1746	1748		10.1016/S0140-6736(96)90813-2	http://dx.doi.org/10.1016/S0140-6736(96)90813-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT396	8656911				2022-12-01	WOS:A1996UT39600015
J	Jackson, SR; Avery, NC; Tarlton, JF; Echford, SD; Abrams, P; Bailey, AJ				Jackson, SR; Avery, NC; Tarlton, JF; Echford, SD; Abrams, P; Bailey, AJ			Changes in metabolism of collagen in genitourinary	LANCET			English	Article								Background Genitourinary prolapse is a common problem, the pathophysiology of which is unknown. Methods We analysed vaginal-epithelial tissue from premenopausal women with genitourinary prolapse and compared them with controls. Findings We found that genitourinary prolapse is associated with a reduction in total collagen content and a decrease in collagen solubility. Both intermediate intermolecular cross-links acid advanced glycation crosslinks were increased in prolapse tissue. Collagen turnover, as indicated by matrix metalloproteinase activity, was up to four times higher in prolapse tissue. Collagen-type ratios, mature cross-link pyridinoline and total elastin content were similar in both prolapse and control tissues. Increased collagenolytic activity causes loss of collagen from prolapse tissue. Interpretation Based on these findings, we have identified a probable mechanism for genitourinary prolapse. Development of agents to inhibit collagenolytic activity may help in the treatment of this condition.	UNIV BRISTOL, COLLLAGEN RES GRP, BRISTOL, AVON, ENGLAND	University of Bristol	Jackson, SR (corresponding author), SOUTHMEAD GEN HOSP, BRISTOL UROL INST, BRISTOL BS10 5NB, AVON, ENGLAND.							AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BAILEY AJ, 1995, BIOCHEM J, V305, P385, DOI 10.1042/bj3050385; BAILEY AJ, 1994, J HAND SURG-BRIT EUR, V19B, P522, DOI 10.1016/0266-7681(94)90220-8; BANNISTER DW, 1970, ANALYST, V95, P596, DOI 10.1039/an9709500596; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; el-Kholi G Y, 1975, J Egypt Med Assoc, V58, P196; Keane D, 1992, NEUROUROL URODYNAM, V11, P308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT ND, 1982, BIOCHIM BIOPHYS ACTA, V702, P30, DOI 10.1016/0167-4838(82)90024-3; LIGHT ND, 1982, STRUCTURAL CONTRACTI; MAKINEN J, 1986, ARCH GYNECOL OBSTET, V239, P17, DOI 10.1007/BF02134283; MATRISIAN LM, 1994, CONTRIB NEPHROL, V107, P94; NAGASE H, 1994, CONTRIB NEPHROL, V107, P85; NORTON DP, 1990, MATER LETT, V9, P321, DOI 10.1016/0167-577X(90)90170-Q; SAYER TR, 1990, NEUROUROL URODYNAM, V9, P319; SELL DR, 1989, J BIOL CHEM, V264, P21597; SIMS TJ, 1992, J CHROMATOGR-BIOMED, V582, P49, DOI 10.1016/0378-4347(92)80301-6	17	273	286	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1658	1661		10.1016/S0140-6736(96)91489-0	http://dx.doi.org/10.1016/S0140-6736(96)91489-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642960				2022-12-01	WOS:A1996UQ70100012
J	DErchia, AM; Gissi, C; Pesole, G; Saccone, C; Arnason, U				DErchia, AM; Gissi, C; Pesole, G; Saccone, C; Arnason, U			The guinea-pig is not a rodent	NATURE			English	Article							MITOCHONDRIAL-DNA; NUCLEOTIDE-SEQUENCE; EVOLUTION; PHYLOGENY; MAMMALS; GENE; SEAL	IN 1991 Graur et al. raised the question of whether the guinea-pig, Cavia porcellus, is a rodent(1). They suggested that the guinea-pig and myomorph rodents diverged before the separation between myormorph rodents and a lineage leading to primates and artiodactyls. Several findings have since been reported, both for and against this phylogeny, thereby highlighting the issue of the validity of molecular analysis in mammalian phylogeny. Here we present findings based on the sequence of the complete mitochondrial genome of the guinea-pig, which strongly contradict rodent monophyly. The conclusions are based on the cumulative evidence provided by orthologically inherited genes and the use of three different analytic al methods, none of which joins the guinea-pig with myomorph rodents. In addition to the phylogenetic conclusions, we also draw attention to several factors that are important for the validity of phylogenetic analysis based on molecular data.	UNIV BARI, DIPARTMENTO BIOCHIM & BIOL MOLEC, I-70125 BARI, ITALY; LUND UNIV, DEPT EVOLUTIONARY MOL SYSTEMAT, S-22362 LUND, SWEDEN; UNIV BASILICATA, DIPARTIMENTO BIOL DBAF, I-30100 POTENZA, ITALY; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, I-70125 BARI, ITALY	Universita degli Studi di Bari Aldo Moro; Lund University; University of Basilicata; Consiglio Nazionale delle Ricerche (CNR)			Pesole, Graziano/K-5283-2019; Pesole, Graziano/C-1408-2009; Pesole, Graziano/E-9051-2014; D'Erchia, Anna maria/K-9001-2016	Pesole, Graziano/0000-0003-3663-0859; Pesole, Graziano/0000-0003-3663-0859; Gissi, Carmela/0000-0002-2269-079X; D'ERCHIA, Anna Maria/0000-0002-4627-0626				ARNASON U, 1993, J MOL EVOL, V37, P323; Arnason U, 1996, J MOL EVOL, V42, P145, DOI 10.1007/BF02198840; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ARNASON U, 1992, J MOL EVOL, V34, P493, DOI 10.1007/BF00160463; CAO Y, 1994, MOL BIOL EVOL, V11, P593; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Felsestein J., 1993, PHYLIP PHYLOGENY INF; FRYE MS, 1995, MOL BIOL EVOL, V12, P168, DOI 10.1093/oxfordjournals.molbev.a040186; GRAUR D, 1992, COMP BIOCHEM PHYS B, V101, P495, DOI 10.1016/0305-0491(92)90327-N; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Graur D, 1996, NATURE, V379, P333, DOI 10.1038/379333a0; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; GRAUR D, 1993, FEBS LETT, V325, P152, DOI 10.1016/0014-5793(93)81432-Y; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; HASEGAWA M, 1992, NATURE, V355, P595, DOI 10.1038/355595a0; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; Krettek A, 1995, J MOL EVOL, V41, P952; KUMA K, 1994, JPN J GENET, V69, P555, DOI 10.1266/jjg.69.555; LI WH, 1992, J HERED, V83, P174, DOI 10.1093/oxfordjournals.jhered.a111188; MA DP, 1993, J MOL EVOL, V36, P327; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P9698, DOI 10.1073/pnas.90.20.9698; NOGUCHI T, 1994, COMP BIOCHEM PHYS B, V107, P179, DOI 10.1016/0305-0491(94)90037-X; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; SACCONE C, 1990, METHOD ENZYMOL, V183, P570; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Swofford D., 1998, PAUP PHYLOGENETIC AN; WOLF B, 1993, BIOL CHEM H-S, V374, P641, DOI 10.1515/bchm3.1993.374.7-12.641; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	28	271	279	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					597	600		10.1038/381597a0	http://dx.doi.org/10.1038/381597a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637593				2022-12-01	WOS:A1996UQ65700048
J	Diem, SJ; Lantos, JD; Tulsky, JA				Diem, SJ; Lantos, JD; Tulsky, JA			Cardiopulmonary resuscitation on television - Miracles and misinformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; PARAMEDIC SERVICES; METROPOLITAN-AREA; SURVIVAL; OUTCOMES; YOUNGER; OLDER; AGE	Background. Responsible, shared decision making on the part of physicians and patients about the potential use of cardiopulmonary resuscitation (CPR) requires patients who are educated about the procedure's risks and benefits, Television is an important source of information about CPR for patients, We analyzed how three popular television programs depict CPR, Methods. We watched all the episodes of the television programs ER and Chicago Hope during the 1994-1995 viewing season and 50 consecutive episodes of Rescue 911 broadcast over a three-month period in 1995, We identified all occurrences of CPR in each episode and recorded the causes of cardiac arrest, the identifiable demographic characteristics of the patients, the underlying illnesses, and the outcomes. Results. There were 60 occurrences of CPR in the 97 television episodes - 31 on ER, 11 on Chicago Hope, and 18 on Rescue 911, In the majority of cases, cardiac arrest was caused by trauma; only 28 percent were due to primary cardiac causes, Sixty-five percent of the cardiac arrests occurred in children, teenagers, or young adults, Seventy-five percent of the patients survived the immediate arrest, and 67 percent appeared to have survived to hospital discharge. Conclusions. The survival rates in our study are significantly higher than the most optimistic survival rates in the medical literature, and the portrayal of CPR on television may lead the viewing public to have an unrealistic impression of CPR and its chances for success, Physicians discussing the use of CPR with patients and families should be aware of the images of CPR depicted on television and the misperceptions these images may foster. (C) 1996, Massachusetts Medical Society.	DUKE UNIV,MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC; DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DURHAM,NC; UNIV CHICAGO,MACLEAN CTR MED ETH,CHICAGO,IL	Duke University; Duke University; University of Chicago	Diem, SJ (corresponding author), VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,508 FULTON ST,DURHAM,NC 27705, USA.		Diem, Susan/B-6479-2013					ANNAS GJ, 1995, HASTINGS CENT REP, V25, P40, DOI 10.2307/3562794; APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, LANCET, V1, P812; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; KARETZKY M, 1995, ARCH INTERN MED, V155, P1277, DOI 10.1001/archinte.155.12.1277; LAVELLE JM, 1993, CRIT CARE MED, V21, P368, DOI 10.1097/00003246-199303000-00013; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; Turow Joseph, 1989, PLAYING DOCTOR TELEV; VERTESI L, 1983, CAN MED ASSOC J, V128, P809; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	315	323	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1578	1582		10.1056/NEJM199606133342406	http://dx.doi.org/10.1056/NEJM199606133342406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP663	8628340				2022-12-01	WOS:A1996UP66300006
J	Rhodes, CJ; Anderson, RM				Rhodes, CJ; Anderson, RM			Power laws governing epidemics in isolated populations	NATURE			English	Article							FOREST-FIRE MODEL; MEASLES DYNAMICS; TIME-SERIES; CHAOS; ERROR	TEMPORAL changes in the incidence of measles virus infection within large urban communities in the developed world have been the focus of much discussion in the context of the identification and analysis of nonlinear and chaotic patterns in biological time series(1-11). In contrast, the measles records for small isolated island populations are highly irregular, because of frequent fade-outs of infection(12-14), and traditional analysis(15) does not yield useful insight. Here we use measurements of the distribution of epidemic sizes and duration to show that regularities in the dynamics of such systems do become apparent. Specifically, these biological systems are characterized by well-defined power laws in a manner reminiscent of other nonlinear, spatially extended dynamical systems in the physical sciences(16-19). We further show that the observed power-law exponents are well described by a simple lattice-based model which reflects the social interaction between individual hosts.			Rhodes, CJ (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, S PARKS RD, OXFORD OX1 3PS, ENGLAND.			Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1990, PHYS LETT A, V147, P297, DOI 10.1016/0375-9601(90)90451-S; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; BLACK FL, 1966, J THEOR BIOL, V11, P207, DOI 10.1016/0022-5193(66)90161-5; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; CHEN K, 1991, PHYS REV A, V43, P625, DOI 10.1103/PhysRevA.43.625; CLAR S, 1994, PHYS REV E, V50, P1009, DOI 10.1103/PhysRevE.50.1009; Cliff Andrew, 1993, HIST GEOGRAPHY MAJOR; DROSSEL B, 1992, PHYS REV LETT, V69, P1629, DOI 10.1103/PhysRevLett.69.1629; FERGUSON N, IN PRESS PRINCETON M; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; Gutenberg B., 1956, ANN GEOPHIS, V9, P1, DOI DOI 10.4401/AG-5590; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1987, PROC R SOC LON SER-A, V413, P27, DOI 10.1016/0920-5632(87)90020-X; OLSEN LF, 1988, THEOR POPUL BIOL, V33, P344, DOI 10.1016/0040-5809(88)90019-6; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; SOMETTE A, 1989, EPL-EUROPHYS LETT, V9, P197; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; TIDD CW, 1993, P ROY SOC B-BIOL SCI, V254, P257, DOI 10.1098/rspb.1993.0155	24	132	140	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					600	602		10.1038/381600a0	http://dx.doi.org/10.1038/381600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637594				2022-12-01	WOS:A1996UQ65700049
J	Plas, DR; Johnson, R; Pingel, JT; Matthews, RJ; Dalton, M; Roy, G; Chan, AC; Thomas, ML				Plas, DR; Johnson, R; Pingel, JT; Matthews, RJ; Dalton, M; Roy, G; Chan, AC; Thomas, ML			Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling	SCIENCE			English	Article							PHOSPHATASE; SPECIFICITY	The threshold at which antigen triggers lymphocyte activation is set by the enzymes that regulate tyrosine phosphorylation. Upon T cell activation, the protein tyrosine phosphatase SHP-1 was found to bind to the protein tyrosine kinase ZAP-70. This interaction resulted in an increase in SHP-1 phosphatase activity and a decrease in ZAP-70 kinase activity. Expression of a dominant negative mutant of SHP-1 in T cells increased the sensitivity of the antigen receptor. Thus, SHP-1 functions as a negative regulator of the T cell antigen receptor and in setting the threshold of activation.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Roy, Garbiñe/AAG-2570-2021	Roy, Garbiñe/0000-0001-6124-7574				BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.tb20747.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; EVAVOLD BD, 1992, J IMMUNOL, V148, P3471; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLAS DR, UNPUB; ROY G, 1995, ADV PROTEIN PHOSPHAT, V9, P121; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	22	327	333	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1173	1176		10.1126/science.272.5265.1173	http://dx.doi.org/10.1126/science.272.5265.1173			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638162				2022-12-01	WOS:A1996UM88900051
J	[Anonymous]				[Anonymous]			Reductionists lay claim to the mind	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					97	97						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610018				2022-12-01	WOS:A1996UK13900001
J	Bigbee, WL; Jensen, RH; Veidebaum, T; Tekkel, M; Rahu, M; Stengrevics, A; Kesminiene, A; Kurtinaitis, J; Auvinen, A; Hakulinen, T; Servomaa, E; Rytomaa, T; Obrams, GI; Boice, JD				Bigbee, WL; Jensen, RH; Veidebaum, T; Tekkel, M; Rahu, M; Stengrevics, A; Kesminiene, A; Kurtinaitis, J; Auvinen, A; Hakulinen, T; Servomaa, E; Rytomaa, T; Obrams, GI; Boice, JD			Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries	BRITISH MEDICAL JOURNAL			English	Article									UNIV PITTSBURGH,INST CANC,MOL CARCINOGENESIS PROGRAM,PITTSBURGH,PA 15238; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; INST EXPT & CLIN MED,DEPT EPIDEMIOL & BIOSTAT,TALLINN,ESTONIA; LATVIA CANC REGISTRY,RIGA,LATVIA; LITHUANIAN CHERNOBYL MED CTR,VILNIUS,LITHUANIA; LITHUANIAN CANC REGISTRY,MITHUANIAN ONCOL CTR,VILNIUS,LITHUANIA; FINNISH CTR RADIAT & NUCL SAFETY,HELSINKI,FINLAND; FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND; NCI,EXTRAMURAL PROGRAMS BRANCH,BETHESDA,MD 20892; NCI,RADIAT EPIDEMIOL BRANCH,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; National Cancer Institute - Lithuania; Radiation & Nuclear Safety Authority (STUK); Finnish Cancer Registry; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bigbee, WL (corresponding author), UNIV PITTSBURGH,CTR ENVIRONM & OCCUPAT HLTH & TOXICOL,GRAD SCH PUBL HLTH,PITTSBURGH,PA 15238, USA.		Auvinen, Anssi/AAL-2111-2020; Auvinen, Anssi/AAD-9311-2020; Rahu, Mati/A-9981-2008	Auvinen, Anssi/0000-0003-1125-4818; 	NCI NIH HHS [N01-CP-50520] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		JENSEN RH, 1995, RADIAT RES, V141, P129, DOI 10.2307/3579040; JENSEN RH, IN PRESS CYTOMETRY; LANGLOIS RG, 1993, RADIAT RES, V136, P111, DOI 10.2307/3578647; STRAUME T, 1991, HEALTH PHYS, V60, P71, DOI 10.1097/00004032-199101000-00011; *UN SCI COMM EFF A, 1988, SOURC EFF RISK ION R	5	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1078	1079						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616416				2022-12-01	WOS:A1996UH81600027
J	Danziger, R				Danziger, R			An epidemic like any other? Rights and responsibilities in HIV prevention	BRITISH MEDICAL JOURNAL			English	Article								Throughout the 1980s and into the 1990s, HIV prevention has been closely associated with the protection of individual human rights. Traditional public health measures such as compulsory testing and isolation have largely been rejected as ineffective in public health terms and inappropriate in the context of human rights protection. HIV prevention has been based instead chiefly on elective measures -information, education, counselling, and voluntary testing. In the past five years there have been important clinical, epidemiological, and social developments in the AIDS epidemic. These changes, combined with a growing recognition of possible weaknesses inherent in a strictly voluntarist approach to HIV prevention, may herald a new approach to AIDS control which places more weight on social responsibility in the context of HIV prevention.			Danziger, R (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							Bayer Ronald, 1992, ADIS IND DEMOCRACIES, P1; BERRIDGE V, 1992, AIDS MAKING CHRONIC, P299; CHRYSTIE IL, 1995, BRIT MED J, V311, P928, DOI 10.1136/bmj.311.7010.928; CLARKE A, 1994, SOC SCI MED, V39, P591, DOI 10.1016/0277-9536(94)90102-3; DILLNER L, 1995, BRIT MED J, V311, P827, DOI 10.1136/bmj.311.7009.827; ETZIONI A, 1993, TIME MAGAZINE    DEC, V13, P60; JOSEPH SC, 1992, DRAGON GATES ONCE FU, P82; MINKOFF H, 1995, JAMA-J AM MED ASSOC, V274, P1165, DOI 10.1001/jama.274.14.1165; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; SCHEPERHUGHES N, 1994, SOC SCI MED, V39, P991, DOI 10.1016/0277-9536(94)90210-0; SIGNORILE M, 1995, GUARDIAN        0301; *UN COMM HUM RIGHT, 1993, DISCR HIV INF PEOPL; VEEKEN H, 1995, BRIT MED J, V311, P935; WILFERT CM, 1994, CLIN INFECT DIS, V19, P664, DOI 10.1093/clinids/19.4.664	14	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1083	1084						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616419				2022-12-01	WOS:A1996UH81600031
J	Coggon, D; Winter, P; Martyn, C; Inskip, H				Coggon, D; Winter, P; Martyn, C; Inskip, H			Contrasting epidemiology of aortic aneurysm and peripheral vascular disease in England and Wales	BRITISH MEDICAL JOURNAL			English	Article											Coggon, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				BEGNTSSON H, 1992, EUR J SURG, V158, P19; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; MARMOT M, 1992, CORONARY HEART DIS E, P3; REED D, 1992, CIRCULATION, V85, P205, DOI 10.1161/01.CIR.85.1.205; VANLAARHOVEN CJHM, 1993, EUR J VASCULAR SURG, V7, P386, DOI 10.1016/S0950-821X(05)80254-3	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					948	948						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616309				2022-12-01	WOS:A1996UF65900021
J	SelaHerman, S; Scharschmidt, BF				SelaHerman, S; Scharschmidt, BF			Choledochal cyst, a disease for all ages	LANCET			English	Editorial Material									UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SelaHerman, S (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA.							Chaudhary A, 1996, BRIT J SURG, V83, P186, DOI 10.1046/j.1365-2168.1996.02042.x; IWAI N, 1992, ANN SURG, V215, P27, DOI 10.1097/00000658-199201000-00003; LIPSETT PA, 1994, ANN SURG, V220, P644, DOI 10.1097/00000658-199411000-00007; STAIN SC, 1995, ANN SURG, V222, P128, DOI 10.1097/00000658-199508000-00004; Stringer MD, 1995, ARCH DIS CHILD, V73, P528, DOI 10.1136/adc.73.6.528	5	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					779	779		10.1016/S0140-6736(96)90864-8	http://dx.doi.org/10.1016/S0140-6736(96)90864-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622330				2022-12-01	WOS:A1996UB15300005
J	Oliet, SHR; Malenka, RC; Nicoll, RA				Oliet, SHR; Malenka, RC; Nicoll, RA			Bidirectional control of quantal size by synaptic activity in the hippocampus	SCIENCE			English	Article							LONG-TERM POTENTIATION; TRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTION; NEURONS; CA1; STRONTIUM; CURRENTS; SLICES; CA2+	Analysis of strontium-induced asynchronous release of quanta from stimulated synapses revealed that long-term potentiation and long-term depression in the CA1 region of the mammalian hippocampus are associated with an increase and a decrease, respectively, in quantal size. At a single set of synapses, the increase in quantal size seen with long-term potentiation was completely reversed by depotentiating stimuli. Long-term potentiation and depression are also associated with an increase and decrease, respectively, in the frequency of quantal events, consistent with an all-or-none regulation (up or down) of clusters of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, a change in the release of transmitter, or both.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Oliet, SHR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143, USA.			Oliet, Stephane/0000-0003-0595-9029				ASZTELY F, 1991, BRAIN RES, V558, P153, DOI 10.1016/0006-8993(91)90734-D; BAIN AI, 1992, J PHYSIOL-LONDON, V450, P63, DOI 10.1113/jphysiol.1992.sp019116; BEKKERS JM, 1995, J NEUROPHYSIOL, V73, P1145, DOI 10.1152/jn.1995.73.3.1145; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DODGE FA, 1969, J PHYSIOL-LONDON, V200, P267, DOI 10.1113/jphysiol.1969.sp008692; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GROVER LM, 1995, SYNAPSE, V19, P121, DOI 10.1002/syn.890190208; HANSE E, 1994, J NEUROSCI, V14, P5028; HUBER KM, 1995, J NEUROPHYSIOL, V73, P270, DOI 10.1152/jn.1995.73.1.270; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Katz B., 1966, NERVE MUSCLE SYNAPSE; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MEIRI U, 1971, J PHYSIOL-LONDON, V215, P709, DOI 10.1113/jphysiol.1971.sp009493; MILEDI R, 1966, NATURE, V212, P1233, DOI 10.1038/2121233a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175	34	171	171	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1294	1297		10.1126/science.271.5253.1294	http://dx.doi.org/10.1126/science.271.5253.1294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638114				2022-12-01	WOS:A1996TX69500041
J	Maruyama, H; Raphael, JH; Djerassi, C				Maruyama, H; Raphael, JH; Djerassi, C			Why Japan ought to legalize the pill	NATURE			English	Editorial Material											Maruyama, H (corresponding author), STANFORD UNIV, ASIA PACIFIC RES CTR, STANFORD, CA 94305 USA.							ANDERSON A, 1985, NATURE, V317, P760, DOI 10.1038/317760c0; Coleman Samuel, 1983, FAMILY PLANNING JAPA; JITSUKAWA M, 1994, SCIENCE, V265, P1048, DOI 10.1126/science.8066442; MURAMATSU M, 1973, B I PUBL HLTH, V22, P228; MURAMATSU M, 1974, ABORTION RES INT EXP, P133; NATHAN R, 1995, NAT MED, V1, P1115, DOI 10.1038/nm1195-1115; RIPHAGEN FE, 1987, WIEN MED WOCHENSCHR, V137, P488; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; WEINSTEIN M, 1990, POP STUD-J DEMOG, V44, P447, DOI 10.1080/0032472031000144846; 1993, 1992 YUSEI HOGO TOKE, P20; 1994, SUMMARY 22ND NATIONA; 1992, SUMMARY 21ST NATIONA; 1995, NIKKEI UERUNESU, V12, P10; 1995, WORLD POPULATION DAT	14	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					579	580		10.1038/379579a0	http://dx.doi.org/10.1038/379579a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV688	8628389				2022-12-01	WOS:A1996TV68800021
J	Rawlings, DJ; Scharenberg, AM; Park, H; Wahl, MI; Lin, SQ; Kato, RM; Fluckiger, AC; Witte, ON; Kinet, JP				Rawlings, DJ; Scharenberg, AM; Park, H; Wahl, MI; Lin, SQ; Kato, RM; Fluckiger, AC; Witte, ON; Kinet, JP			Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; TYROSINE KINASE; B-CELLS; CHROMOSOME; PP60C-SRC; MUTATION; GENES; MICE	Bruton's tyrosine kinase (BTK) is pivotal in B cell activation and development through its participation in the signaling pathways of multiple hematopoietic receptors. The mechanisms controlling BTK activation were studied here by examination of the biochemical consequences of an interaction between BTK and SRC family kinases. This interaction of BTK with SRC kinases transphosphorylated BTK on tyrosine at residue 551, which led to BTK activation. BTK then autophosphorylated at a second site. The same two sites were phosphorylated upon B cell antigen receptor cross-linking. The activated BTK was predominantly membrane-associated, which suggests that BTK integrates distinct receptor signals resulting in SRC kinase activation and BTK membrane targeting.	BETH ISRAEL HOSP, LAB ALLERGY & IMMUNOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036834, K11AR001912] Funding Source: NIH RePORTER; NCI NIH HHS [CA09120-20] Funding Source: Medline; NIAMS NIH HHS [AR01912, AR36834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER MD, 1993, PROGR IMMUNOLOGY, P535; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EARL PL, 1987, CURRENT PROTOCOLS MO; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Park H., UNPUB; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCRIBNER CL, 1987, J IMMUNOL, V138, P3611; SHIMAOKA J, UNPUB; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	45	378	384	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	1996	271	5250					822	825		10.1126/science.271.5250.822	http://dx.doi.org/10.1126/science.271.5250.822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629002				2022-12-01	WOS:A1996TU69400051
J	Orwar, O; Jardemark, K; Jacobson, I; Moscho, A; Fishman, HA; Scheller, RH; Zare, RN				Orwar, O; Jardemark, K; Jacobson, I; Moscho, A; Fishman, HA; Scheller, RH; Zare, RN			Patch-clamp detection of neurotransmitters in capillary electrophoresis	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; METHYL-D-ASPARTATE; CEREBELLAR GRANULE CELLS; FRESHLY ISOLATED NEURONS; RAT OLFACTORY-BULB; SYNAPTIC TRANSMISSION; GROWTH CONES; CURRENTS; GLUTAMATE; CHANNELS	Gamma-aminobutyrate acid, L-glutamate, and N-methyl-D-aspartate were separated by capillary electrophoresis and detected by the use of whole-cell and outside-out patch-clamp techniques on freshly dissociated rat olfactory interneurons. These neuroactive compounds could be identified from their electrophoretic migration times, unitary channel conductances, and power spectra that yielded corner frequencies and mean single-channel conductances characteristic for each of the different agonist-receptor interactions. This technique has the sensitivity to observe the opening of a single ion channel for agonists separated by capillary electrophoresis.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; GOTHENBURG UNIV,DEPT ANAT & CELL BIOL,S-41390 GOTHENBURG,SWEDEN; STANFORD UNIV,HOWARD HUGHES INST,DEPT MOL & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University; University of Gothenburg; Howard Hughes Medical Institute; Stanford University			Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253	NIDA NIH HHS [DA 09873-01] Funding Source: Medline; NIMH NIH HHS [R01 MH112188, MH 45423-06] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045423, R01MH112188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; ANDINE P, 1991, J NEUROCHEM, V57, P230, DOI 10.1111/j.1471-4159.1991.tb02120.x; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BUCH RM, 1989, ANAL CHEM, V61, pA533, DOI 10.1021/ac00183a001; BUFLER J, 1992, J COMP PHYSIOL A, V170, P153; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; CULLCANDY S, 1995, CURR BIOL, V5, P841, DOI 10.1016/S0960-9822(95)00168-0; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DO KQ, 1986, J NEUROCHEM, V46, P779, DOI 10.1111/j.1471-4159.1986.tb13040.x; FISHMAN HA, 1995, P NATL ACAD SCI USA, V92, P7877, DOI 10.1073/pnas.92.17.7877; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HU YB, 1994, BRAIN RES, V659, P117, DOI 10.1016/0006-8993(94)90870-2; HUME RI, 1983, NATURE, V305, P632, DOI 10.1038/305632a0; JACOBSON I, 1991, NEUROSCI RES COMMUN, V8, P11; JACOBSON I, 1992, NEUROSCI RES COMMUN, V10, P177; Jahr C E, 1992, Curr Opin Neurobiol, V2, P270, DOI 10.1016/0959-4388(92)90114-Z; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KANEDA M, 1995, J PHYSIOL-LONDON, V485, P419, DOI 10.1113/jphysiol.1995.sp020739; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KILIC G, 1993, EUR J NEUROSCI, V5, P65, DOI 10.1111/j.1460-9568.1993.tb00206.x; KIMURA M, 1995, NEUROSCIENCE, V66, P609, DOI 10.1016/0306-4522(95)00023-C; LEAL WS, 1995, P NATL ACAD SCI USA, V92, P1033, DOI 10.1073/pnas.92.4.1033; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LI XY, 1993, NEUROSCI LETT, V155, P42, DOI 10.1016/0304-3940(93)90669-C; MA GH, 1995, MOL PHARMACOL, V47, P1035; MAEDA T, 1995, NEURON, V15, P253, DOI 10.1016/0896-6273(95)90031-4; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MELDRUM B, 1995, DIVERSITY INTERACTIN, V757, P492; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; OLNEY JW, 1975, J NEUROPATH EXP NEUR, V34, P167, DOI 10.1097/00005072-197503000-00005; ORWAR O, 1994, J NEUROCHEM, V63, P1371; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; RECHNITZ GA, 1978, SCIENCE, V199, P440, DOI 10.1126/science.619467; Sakmann B., 1995, SINGLE CHANNEL RECOR; SANDBERG M, 1986, J NEUROCHEM, V47, P178; SCHONROCK B, 1993, EUR J NEUROSCI, V5, P1042, DOI 10.1111/j.1460-9568.1993.tb00957.x; SHEAR JB, 1995, SCIENCE, V267, P74, DOI 10.1126/science.7809609; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Trombley P Q, 1993, Curr Opin Neurobiol, V3, P540, DOI 10.1016/0959-4388(93)90053-2; TROMBLEY PQ, 1994, J NEUROPHYSIOL, V71, P761, DOI 10.1152/jn.1994.71.2.761; TROMBLEY PQ, 1990, J NEUROPHYSIOL, V64, P598, DOI 10.1152/jn.1990.64.2.598; WALLINGFORD RA, 1987, ANAL CHEM, V59, P1762, DOI 10.1021/ac00141a005; WEISS JH, 1988, SCIENCE, V241, P973, DOI 10.1126/science.3136549; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZOLLINGER M, 1994, J NEUROCHEM, V63, P1133	51	39	42	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1779	1782		10.1126/science.272.5269.1779	http://dx.doi.org/10.1126/science.272.5269.1779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650575				2022-12-01	WOS:A1996UT11000040
J	Sabbert, D; Engelbrecht, S; Junge, W				Sabbert, D; Engelbrecht, S; Junge, W			Intersubunit rotation in active F-ATPase	NATURE			English	Article							GAMMA-SUBUNIT; SYNTHASE; MECHANISM; DELTA	THE enzyme ATP synthase, or F-ATPase, is present in the membranes of bacteria, chloroplasts and mitochondria, Its structure is bipartite, with a proton-conducting, integral membrane portion, F-0, and a peripheral portion, F-1. Solubilized F-1 is composed of five different subunits, (alpha beta)(3) gamma delta epsilon, and is active as an ATPase(1,2). The function of F-ATPase is to couple proton translocation through F-0 with ATP synthesis in F-1 (ref. 3), Several fines of evidence support the spontaneous formation of ATP on F-1 (refs 4, 5) and its endergonic release(6) at cooperative and rotating (or at feast alternating) sites(7). The release of ATP at the expense of protonmotive force might involve mechanical energy transduction from F-0 into F-1 by rotation of the smaller subunits (mainly gamma) within (alpha beta)(3), the catalytic hexagon of F-1 as suggested by electron microscopy(8), by X-ray crystal structure analysis(9) and by the use of cleavable crosslinkers(10). Here we record an intersubunit rotation in real time in the functional enzyme by applying polarized absorption relaxation after photobleaching to immobilized F-1 with eosin-labelled gamma, We observe the rotation of gamma relative to immobilized (alpha beta)(3) in a timespan of 100 ms, compatible with the rate of ATP hydrolysis by immobilized F-1. Its angular range, which is of at least 200 degrees, favours a triple-site mechanism of catalysis(7,11), with gamma acting as a crankshaft in (alpha beta)(3). The rotation of gamma is blocked when ATP is substituted with its non-hydrolysable analogue AMP-PNP.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,BIOPHYS ABT,D-49069 OSNABRUCK,GERMANY	University Osnabruck								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; ENGELBRECHT S, 1989, EUR J BIOCHEM, V179, P117, DOI 10.1111/j.1432-1033.1989.tb14528.x; ENGELBRECHT S, 1986, EUR J BIOCHEM, V160, P635, DOI 10.1111/j.1432-1033.1986.tb10085.x; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Jablonski A, 1935, Z PHYS, V96, P236, DOI 10.1007/BF01341525; JUNGE W, 1977, BIOCHIM BIOPHYS ACTA, V462, P73, DOI 10.1016/0005-2728(77)90190-6; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; PARKER CA, 1961, T FARADAY SOC, V57, P1894, DOI 10.1039/tf9615701894; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; WAGNER R, 1982, BIOCHEMISTRY-US, V21, P1890, DOI 10.1021/bi00537a029; WAHL P, 1975, CHEM PHYS, V7, P210, DOI 10.1016/0301-0104(75)87003-0; WALKER JE, 1994, BIOCHEMIST, V16, P31; WEBER J, 1994, J BIOL CHEM, V269, P20462	22	458	466	1	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					623	625		10.1038/381623a0	http://dx.doi.org/10.1038/381623a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637601				2022-12-01	WOS:A1996UQ65700056
J	Wokke, JHJ				Wokke, JHJ			Diseases that masquerade as motor neuron disease	LANCET			English	Editorial Material											Wokke, JHJ (corresponding author), UNIV UTRECHT HOSP,DEPT NEUROL,UTRECHT,NETHERLANDS.							BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BLEXRUD MD, 1993, ANN NEUROL, V34, P622, DOI 10.1002/ana.410340419; BRAAKMAN R, 1994, J NEUROL NEUROSUR PS, V57, P257, DOI 10.1136/jnnp.57.3.257; Davenport RJ, 1996, J NEUROL NEUROSUR PS, V60, P147, DOI 10.1136/jnnp.60.2.147; NIGHTINGALE SL, 1995, JAMA-J AM MED ASSOC, V274, P292; SWASH M, 1992, NEUROMUSCULAR DISORD, V2, P7, DOI 10.1016/0960-8966(92)90020-7; SWASH M, 1988, J NEUROL NEUROSUR PS, V51, P165, DOI 10.1136/jnnp.51.2.165; VANDENBERG LH, 1995, NEUROLOGY, V45, P987, DOI 10.1212/WNL.45.5.987; 1992, J NEUROL NEUROSUR PS, V55, P536	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1347	1348		10.1016/S0140-6736(96)91005-3	http://dx.doi.org/10.1016/S0140-6736(96)91005-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637336	Bronze			2022-12-01	WOS:A1996UL90400004
J	Rice, WR				Rice, WR			Sexually antagonistic male adaptation triggered by experimental arrest of female evolution	NATURE			English	Article								EACH sex is part of the environment of the other sex. This may lead to perpetual coevolution between the sexes, when adaptation by one sex reduces fitness of the other. Indirect evidence comes from experiments with Drosophila melanogaster indicating that seminal fluid reduces the competitive ability of sperm from other males, thereby increasing male fitness(1,2). It also reduces a female's propensity to remate and increases her egg-laying rate(3). In contrast to these benefits to males, seminal fluid has substantial toxic side effects in females, with increasing quantity leading to decreasing female survival(4,5). Here I show that when female D. melanogaster are experimentally prevented from coevolving with males, males rapidly adapt to the static female phenotype. This male adaptation leads to a reduction in female survivorship, which is mediated by an increased rate of remating and increased toxicity of seminal fluid.			Rice, WR (corresponding author), UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064, USA.							BARTON NH, 1995, GENETICS, V140, P821; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; CHARLESWORTH D, 1993, GENET RES, V61, P1289; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; CLARK AG, 1995, GENETICS, V139, P189; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; MANNING JT, 1984, ACTA BIOTHEOR, V33, P219, DOI 10.1007/BF00048429; Muller H., 1942, BIOL S, V6, P71; ORR HA, 1995, GENETICS, V139, P1805; Palopoli M.F., 1994, ANNU REV GENET, V27, P283, DOI 10.1146/annurev.ge.28.120194.001435; PECK JR, 1994, GENETICS, V137, P597; RICE WR, 1994, TRENDS ECOL EVOL, V9, P235, DOI 10.1016/0169-5347(94)90258-5; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Van Valen L., 1973, EVOL THEORY, V1, P1, DOI DOI 10.1038/344864A0	17	765	774	0	173	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					232	234		10.1038/381232a0	http://dx.doi.org/10.1038/381232a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622764				2022-12-01	WOS:A1996UL24900053
J	Surks, MI; DeFesi, CR				Surks, MI; DeFesi, CR			Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine - A paradox resolved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM PHENYTOIN; EPILEPTIC PATIENTS; ANTICONVULSANT DRUGS; EQUILIBRIUM DIALYSIS; FUNCTION TESTS; FREE-THYROXINE; DIPHENYLHYDANTOIN; TRIIODOTHYRONINE; BINDING; 5,5'-DIPHENYLHYDANTOIN	Objective.-To address the paradox that phenytoin- and carbamazepine-treated patients have decreased serum free thyroxine (T-4) and triiodothyronine (T-3) concentrations but appear clinically euthyroid and have normal serum thyroid-stimulating hormone (TSH) concentrations. Design.-In vitro studies comparing measurements of total and free T-4 and T-3 by ultrafiltration assay (undiluted serum) and a commercial free T-4 estimate kit in control serum samples or serum samples containing added therapeutic levels of phenytoin or carbamazepine. These measurements were made in serum samples diluted 1:5 with either identical serum or phosphate buffer, pH 7.4, and in serum samples from patients with seizure disorders who were treated with phenytoin or carbamazepine. Setting.-A 650-bed teaching hospital. Patients.-Selected patients (n=19) who were in good health except for seizure disorder, with stable anticonvulsant drug levels in the upper half of the therapeutic range, and were not taking any other drugs that could affect thyroid parameters. Main Outcome Measure.-Serum concentrations of free T-4 and free T-3 in patients taking phenytoin or carbamazepine vs normal controls. Results-Addition of phenytoin or carbamazepine to normal human serum in vitro resulted in a significant increase in free T-4 fraction and free T-4 (P<.001). In patients taking phenytoin or carbamazepine, serum total T-4 decreased significantly to 60% and 74%, respectively, of the control serum concentration (P<.001 for both phenytoin and carbamazepine); free T-4 fraction (by ultrafiltration assay) increased 65% and 44%, respectively (P<.001 for phenytoin, P<.01 for carbamazepine); and free T-4 remained unchanged. Free T-4 concentration measured by a commercial kit (1.5 serum dilution) was significantly lower than the control concentration in both phenytoin- and carbamazepine-treated patients. Serum free T-3 and serum TSH were also normal in phenytoin- and carbamazepine-treated patients. Conclusions.-Therapeutic levels of phenytoin and carbamazepine displace T-4 and T-3 from serum binding proteins. When added to serum, the drugs effect an increase in free hormone fractions and free T-4 and T-3. In drug-treated patients, increased free T-4 and free T-3 fractions offset the significant decrease in serum T-4 and T-3, resulting in normal free T-4 and free T-3 concentrations. Since currently available clinical tests will continue to show decreased free T-4 concentrations in patients taking phenytoin or carbamazepine, clinicians should rely on serum TSH measurements to confirm the euthyroid status of these patients.	ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Surks, MI (corresponding author), MONTEFIORE MED CTR, DEPT MED & PATHOL, DIV ENDOCRINOL & METAB, 111 E 210TH ST, BRONX, NY 10467 USA.							BENTSEN KD, 1983, ACTA NEUROL SCAND, V67, P235, DOI 10.1111/j.1600-0404.1983.tb04569.x; BLACKSHEAR JL, 1983, ANN INTERN MED, V99, P341, DOI 10.7326/0003-4819-99-3-341; CAVALIERI RR, 1979, METABOLISM, V28, P1161, DOI 10.1016/0026-0495(79)90156-2; CHIN W, 1968, J CLIN ENDOCR METAB, V28, P181, DOI 10.1210/jcem-28-2-181; CONNELL JMC, 1984, EUR J CLIN PHARMACOL, V26, P453, DOI 10.1007/BF00542140; EKINS R, 1990, ENDOCR REV, V11, P5, DOI 10.1210/edrv-11-1-5; FICHSEL H, 1978, EPILEPSIA, V19, P323, DOI 10.1111/j.1528-1157.1978.tb04498.x; FRANKLYN JA, 1985, J ENDOCRINOL, V104, P201, DOI 10.1677/joe.0.1040201; FRANKLYN JA, 1984, EUR J CLIN PHARMACOL, V26, P633, DOI 10.1007/BF00543499; HANSEN JM, 1974, J CLIN ENDOCR METAB, V39, P785, DOI 10.1210/jcem-39-4-785; HEGEDUS L, 1985, CLIN ENDOCRINOL, V23, P423, DOI 10.1111/j.1365-2265.1985.tb01100.x; HERMAN R, 1991, BIOL PSYCHIAT, V29, P779, DOI 10.1016/0006-3223(91)90197-T; HEYMA P, 1977, CLIN ENDOCRINOL, V6, P369, DOI 10.1111/j.1365-2265.1977.tb02023.x; ISOJARVI JIT, 1990, ARCH NEUROL-CHICAGO, V47, P670, DOI 10.1001/archneur.1990.00530060082023; ISOJARVI JIT, 1993, J NEUROL NEUROSUR PS, V56, P710, DOI 10.1136/jnnp.56.6.710; ISOJARVI JIT, 1989, ARCH NEUROL-CHICAGO, V46, P1175, DOI 10.1001/archneur.1989.00520470029021; LARSEN PR, 1970, J CLIN INVEST, V49, P1266, DOI 10.1172/JCI106339; LIEWENDAHL K, 1976, SCAND J CLIN LAB INV, V36, P141, DOI 10.3109/00365517609055240; LIEWENDAHL K, 1978, CLIN ENDOCRINOL, V8, P185, DOI 10.1111/j.1365-2265.1978.tb01493.x; LIEWENDAHL K, 1985, CLIN CHEM, V31, P1993; LIM CF, 1988, J CLIN ENDOCR METAB, V67, P682, DOI 10.1210/jcem-67-4-682; MANN DN, 1983, ENDOCRINOLOGY, V112, P1723, DOI 10.1210/endo-112-5-1723; OPPENHEIMER J, 1961, J CLIN ENDOCR METAB, V21, P252, DOI 10.1210/jcem-21-3-252; OPPENHEIMER JH, 1962, ENDOCRINOLOGY, V71, P496, DOI 10.1210/endo-71-3-496; ROOTWELT K, 1978, SCAND J CLIN LAB INV, V38, P731, DOI 10.3109/00365517809104880; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; Snedecor GW, 1967, STAT METHODS; STJERNHOLM MR, 1975, CLIN CHEM, V21, P1388; SURKS MI, 1988, J CLIN ENDOCR METAB, V67, P1031, DOI 10.1210/jcem-67-5-1031; YEO PPB, 1978, BRIT MED J, V1, P1581, DOI 10.1136/bmj.1.6127.1581	30	70	72	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1495	1498		10.1001/jama.275.19.1495	http://dx.doi.org/10.1001/jama.275.19.1495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622224				2022-12-01	WOS:A1996UJ93700033
J	Sromovsky, LA; Best, FA; Collard, AD; Fry, PM; Revercomb, HE; Freedman, RS; Orton, GS; Hayden, JL; Tomasko, MG; Lemmon, MT				Sromovsky, LA; Best, FA; Collard, AD; Fry, PM; Revercomb, HE; Freedman, RS; Orton, GS; Hayden, JL; Tomasko, MG; Lemmon, MT			Solar and thermal radiation in Jupiter's atmosphere: Initial results of the Galileo probe net flux radiometer	SCIENCE			English	Article								The Galileo probe net flux radiometer measured radiation within Jupiter's atmosphere over the 125-kilometer altitude range between pressures of 0.44 bar and 14 bars. Evidence for the expected ammonia cloud was seen in solar and thermal channels down to 0.5 to 0.6 bar. Between 0.6 and 10 bars large thermal fluxes imply very low gaseous opacities and provide no evidence for a deep water cloud. Near 8 bars the water vapor abundance appears to be about 10 percent of what would be expected for a solar abundance of oxygen. Below 8 bars, measurements suggest an increasing water abundance with depth or a deep cloud layer. Ammonia appears to follow a significantly subsaturated profile above 3 bars. Unexpectedly high absorption of sunlight was found at wavelengths greater than 600 nanometers.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; CALTECH,JET PROP LAB,PASADENA,CA 91109; LOCKHEED MARTIN ASTRONAUT,DENVER,CO 80201; UNIV ARIZONA,TUCSON,AZ 85721	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Lockheed Martin; University of Arizona	Sromovsky, LA (corresponding author), UNIV WISCONSIN,MADISON,WI 53706, USA.		Lemmon, Mark/X-2333-2019; Orton, Glenn/AAD-9862-2020; Lemmon, Mark T/E-9983-2010	Lemmon, Mark/0000-0002-4504-5136; Lemmon, Mark T/0000-0002-4504-5136				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; DEPATER I, 1993, J GEOPHYS RES-PLANET, V98, P5471, DOI 10.1029/92JE02810; GIVER LP, 1989, B AM ASTRON SOC, V21, P947; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; LANZEROTTI LJ, COMMUNICATION; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; RAGENT B, 1996, SCIENCE, V272, P855; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SROMOVSKY LA, 1992, SPACE SCI REV, V60, P233, DOI 10.1007/BF00216856; SROMOVSKY LA, 1994, P 4 INFR SENS CAL S; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837	14	34	34	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					851	854		10.1126/science.272.5263.851	http://dx.doi.org/10.1126/science.272.5263.851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629018				2022-12-01	WOS:A1996UK75700051
J	Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jockel, KH; Becher, R				Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jockel, KH; Becher, R			Prognostic implications of monosomy 3 in uveal melanoma	LANCET			English	Article							ENUCLEATION; CHROMOSOME-3	Background A high proportion of patients with uveal melanoma die of metastatic disease. In a subgroup of uveal melanomas there is the loss of one chromosome 3, To assess the prognostic implications of this genetic anomaly, we studied 54 patients for a median of 3 . 4 years. Methods 180 patients underwent primary enucleation for malignant uveal melanoma at the Ophthalmology Department of the Universitatskiinikum Essen between 1987 and 1993. Tumour material was available for chromosome analysis and DNA preparation from 69 of these patients (for logistic reasons unlikely, we believe, to introduce bias), 15 patients were excluded from our study: nine because the methods for assessment of monosomy 3 were unsuccessful; five because of insufficient information about their relapse status; one because histopathological data were incomplete. Of the 54 remaining patients, the tumours of 16 were assessed for copy number of chromosome 3 by karyotype analysis, of 30 by comparative genomic hybridisation, and of eight by both techniques. Clinical status was assessed by contact with family doctor or a clinical check up. Statistical analysis was by the log-rank test and Cox proportional-hazard regression. Findings The tumours of 30 patients had monosomy 3. 17 (57%) of these patients relapsed with metastatic disease, and the 3-year relapse-free survival rate was 50%. By contrast, of the 24 patients whose tumours had retained both chromosomes 3, none developed metastatic disease, In univariate analysis monosomy 3 was the most significant (p<0 . 0001) predictor of poor prognosis in uveal melanoma, followed by tumour location (p<0 . 0007) and tumour diameter (p<0 . 0021). Histopathological subtype, age, sex, extrascleral growth, and tumour thickness had no additional predictive value. Interpretation In uveal melanoma, monosomy 3 is a significant predictor of both relapse-free and overall survival.	UNIV KLINIKUM ESSEN,INNERE KLIN & POLIKLIN,D-45122 ESSEN,GERMANY; UNIV KLINIKUM ESSEN,INST MED INFORMAT BIOMETRIE & EPIDEMIOL,D-45122 ESSEN,GERMANY; UNIV KLINIKUM ESSEN,INST HUMAN GENET,D-45122 ESSEN,GERMANY; FREE UNIV BERLIN,AUGENKLIN & POLIKLIN,UNIV KLINIKUM BENJAMIN FRANKLIN,W-1000 BERLIN,GERMANY	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								ALBERT DM, 1992, SURV OPHTHALMOL, V36, P429, DOI 10.1016/S0039-6257(05)80024-4; COLEMAN K, 1993, BRIT J OPHTHALMOL, V77, P688, DOI 10.1136/bjo.77.11.688; DIENERWEST M, 1992, ARCH OPHTHALMOL-CHIC, V110, P245, DOI 10.1001/archopht.1992.01080140101036; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; FOLBERG R, 1993, OPHTHALMOLOGY, V100, P1389; GORDON KB, 1994, CANCER RES, V54, P4764; HORSMAN DE, 1993, CANCER, V71, P811, DOI 10.1002/1097-0142(19930201)71:3<811::AID-CNCR2820710325>3.0.CO;2-F; HORSTHEMKE B, 1992, GENE CHROMOSOME CANC, V4, P217, DOI 10.1002/gcc.2870040305; JENSEN OA, 1982, ACTA OPHTHALMOL, V60, P161; MCLEAN IW, 1982, HUM PATHOL, V13, P123; MCLEAN IW, 1995, OPHTHALMOLOGY, V102, P1060; PRESCHER G, 1992, LANCET, V339, P691, DOI 10.1016/0140-6736(92)90861-V; PRESCHER G, 1990, J NATL CANCER I, V82, P1765, DOI 10.1093/jnci/82.22.1765; RUMMELT V, 1995, OPHTHALMOLOGY, V102, P844, DOI 10.1016/S0161-6420(95)30947-5; SEDDON JM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1894; SHIELDS JA, 1993, CANCER, V72, P2067, DOI 10.1002/1097-0142(19931001)72:7<2067::AID-CNCR2820720702>3.0.CO;2-0; SISLEY K, 1990, GENE CHROMOSOME CANC, V2, P205, DOI 10.1002/gcc.2870020307; Soulen M C, 1994, Oncology (Williston Park), V8, P77; SPEICHER MR, 1994, CANCER RES, V54, P3817	19	538	547	1	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1222	1225						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622452				2022-12-01	WOS:A1996UJ59700011
J	Satsangi, J; Welsh, KI; Bunce, M; Julier, C; Farrant, JM; Bell, JI; Jewell, DP				Satsangi, J; Welsh, KI; Bunce, M; Julier, C; Farrant, JM; Bell, JI; Jewell, DP			Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease	LANCET			English	Article							PRIMARY SCLEROSING CHOLANGITIS; PRIMERS PCR-SSP; ULCERATIVE-COLITIS; CROHNS-DISEASE; HLA; LINKAGE	Background Despite strong evidence implicating immune dysfunction and genetic predisposition in the pathogenesis of the chronic inflammatory bower diseases Crohn's disease and ulcerative colitis, the importance of the genes of the major histocompatibility complex remains uncertain, We have investigated the contribution of HLA DRB1 and DQB genes by the strategies of non-parametric linkage analysis (affected sibling pair method) as well as association study. The relation between genotype and phenotype was examined in detail. Methods For linkage analysis 74 families in whom two or more siblings had inflammatory bowel disease were studied. A total of 83 affected sibling pairs were involved: in 42 pairs both siblings had Crohn's disease; in 29 both had ulcerative colitis; in 12 one sibling had Crohn's disease, the other ulcerative colitis. for the association study there were 175 patients with ulcerative colitis, 173 with Crohn's disease, and 472 controls. Details of sex, age of onset, disease extent, and family history were analysed. 24 patients with ulcerative colitis and 92 with Crohn's disease required surgery for refractory disease, HLA DRB1 and DQB1 gene-typing was performed by polymerase chain reaction with sequence-specific primers. Findings in ulcerative colitis, the sharing of alleles among affected sibling pairs provided evidence for linkage with DRB1 locus (p=0 . 017, chi(2)=5 . 32). Of 29 affected sibling pairs studied, only one pair shared no DRB1 DQB haplotypes. 15 shared two DRB DQB haplotypes. In contrast, no linkage was noted for Crohn's disease (42 sibling pairs; p=0 . 30, chi 2=0 . 16) or for inflammatory bowel disease overall (83 sibling pairs, p=0 . 16, chi(2)=2 . 28), In the association study the rare DRB1*103 (8 . 3% vs 3 . 2% in controls) and DRB1*12 (8 . 6% vs 2 . 1% in controls) alleles were associated with ulcerative colitis (p=0 . 0074, chi(2)=7 . 22, odds ratio OR=2 . 9 [95% CI 1 . 3-6-4] and p=0 . 0056, chi(2)=12 . 63, OR=4 . 33 [1 . 8-11 . 0] respectively). No association with alleles representing DR2 (p=0 . 55, chi(2)=0 . 34) was noted, No overall association was seen in Crohn's disease, In ulcerative colitis, the frequency of DRB1*0301 DQB*0201 (DR3 DQ2) was reduced in females (9 . 8% vs 26 . 3% in controls, p=0 . 037, chi(2)=8 . 39 OR=0 . 34 (0 . 15-0 . 71]), particularly in those with distal disease (2 . 3%, p=0 . 001 vs controls, chi(2)=11 . 35, OR=0 . 07 [0 . 00-0 . 39]). In both males and females, the DR3 DQ2 haplotype was predictive of extensive ulcerative colitis (32 . 9% vs 10 . 7% in distal disease, p<0 . 01, chi(2)=10 . 94, OR 4 . 09 [1 . 70-10 . 6]) but not of need for surgery (p=0 . 93, chi(2)=0 . 01), Interpretation These data provide strong evidence for genetic heterogeneity in inflammatory bower disease. Genes of the major histocompatibility complex are implicated as important inherited determinants of susceptibility to ulcerative colitis and may also influence the pattern of disease. In Crohn's disease, important susceptibility genes are likely to exist outside the HLA region.	OXFORD RADCLIFFE HOSP,GASTROENTEROL UNIT,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD,ENGLAND; WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics			JULIER, Cécile/M-9824-2017	JULIER, Cécile/0000-0002-1538-0240	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASAKURA H, 1982, GASTROENTEROLOGY, V82, P413; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BRIGGS DC, 1991, LANCET, V338, P661, DOI 10.1016/0140-6736(91)91235-M; BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R; BUNCE M, IN PRESS TISSUE ANTI; CHAPMAN RW, 1991, GUT, V32, P1433, DOI 10.1136/gut.32.12.1433; DUERR RH, 1995, GASTROENTEROLOGY, V108, P423, DOI 10.1016/0016-5085(95)90069-1; FARMER RG, 1985, GASTROENTEROLOGY, V88, P1818, DOI 10.1016/0016-5085(85)90006-X; FARRANT JM, 1992, HEPATOLOGY, V16, P390, DOI 10.1002/hep.1840160217; HASHIMOTO M, 1994, TISSUE ANTIGENS, V44, P166, DOI 10.1111/j.1399-0039.1994.tb02375.x; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; MCCONNELL RB, 1992, GENETIC BASIS COMMON, P326; MERRETT M, 1992, Gastroenterology, V102, pA935; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAOM IS, 1994, GUT, V35, pS30; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; REIJONEN H, 1994, TISSUE ANTIGENS, V43, P1, DOI 10.1111/j.1399-0039.1994.tb02289.x; RISCH N, 1987, AM J HUM GENET, V40, P1; ROITBERGTAMBUR A, 1994, TISSUE ANTIGENS, V43, P219, DOI 10.1111/j.1399-0039.1994.tb02328.x; ROTTER JI, 1984, CLIN GENET, V26, P529; SATSANGI J, 1994, GUT, V35, P696, DOI 10.1136/gut.35.5.696; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TOYODA H, 1993, GASTROENTEROLOGY, V104, P741, DOI 10.1016/0016-5085(93)91009-7; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WASSMUTH R, 1994, EUR J GASTROEN HEPAT, V6, P405; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	29	319	334	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1212	1217		10.1016/S0140-6736(96)90734-5	http://dx.doi.org/10.1016/S0140-6736(96)90734-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622450				2022-12-01	WOS:A1996UJ59700009
J	Svoboda, K; Tank, DW; Denk, W				Svoboda, K; Tank, DW; Denk, W			Direct measurement of coupling between dendritic spines and shafts	SCIENCE			English	Article							LONG-TERM POTENTIATION; SERIAL ELECTRON-MICROSCOPY; BIOPHYSICAL CHARACTERISTICS; FLUORESCENCE MICROSCOPY; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; PURKINJE-CELLS; CALCIUM; VARIABILITY; AMPLITUDE	Characterization of the diffusional and electrotonic coupling of spines to the dendritic shaft is crucial to understanding neuronal integration and synaptic plasticity. Two-photon photobleaching and photorelease of fluorescein dextran were used to generate concentration gradients between spines and shafts in rat CAI pyramidal neurons. Diffusional reequilibration was monitored with two-photon fluorescence imaging. The time course of reequilibration was exponential, with time constants in the range of 20 to 100 milliseconds, demonstrating chemical compartmentalization on such time scales. These values imply that electrical spine neck resistances are unlikely to exceed 150 megohms and more likely range from 4 to 50 megohms.	AT&T BELL LABS,LUCENT TECHNOL,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; Baudry M., 1994, LONG TERM POTENTIATI, V2; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Berg, 2018, RANDOM WALKS BIOL; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN TH, 1992, SINGLE NEURON COMPUT, P81; CAUCHETEUXSILBERZAN I, 1993, BIOPHYS J, V64, pA109; CHANG HT, 1952, COLD SPRING HARB SYM, V17, P189, DOI 10.1101/SQB.1952.017.01.019; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; DENK W, UNPUB; Denk Winfried, 1995, P445; FROMHERZ P, 1994, P NATL ACAD SCI USA, V91, P4604, DOI 10.1073/pnas.91.10.4604; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1992, J NEUROSCI, V12, P2685; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HOLMES WR, 1990, BRAIN RES, V519, P338, DOI 10.1016/0006-8993(90)90098-V; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; KOCH C, 1983, PROC R SOC SER B-BIO, V218, P455, DOI 10.1098/rspb.1983.0051; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LANNI F, 1985, J CELL BIOL, V100, P1091, DOI 10.1083/jcb.100.4.1091; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MAJOR G, 1994, J NEUROSCI, V14, P4613; MALENKA RC, 1994, LONG TERM POTENTIATI, V2, P121; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; PETROZZINO JJ, 1995, NEURON, V14, P1223, DOI 10.1016/0896-6273(95)90269-4; POPOV S, 1992, J NEUROSCI, V12, P77; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; Rall W., 1978, STUDIES NEUROPHYSIOL, P203; SEJNOWSKI TJ, 1992, SINGLE NEURON COMPUT, P117; SVOBODA K, UNPUB; Tank DW, 1995, J NEUROSCI, V15, P7940; WILSON CJ, 1984, J NEUROSCI, V4, P281; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	43	386	395	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					716	719		10.1126/science.272.5262.716	http://dx.doi.org/10.1126/science.272.5262.716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614831				2022-12-01	WOS:A1996UJ05100049
J	Emsley, P; Charles, IG; Fairweather, NF; Isaacs, NW				Emsley, P; Charles, IG; Fairweather, NF; Isaacs, NW			Structure of Bordetella pertussis virulence factor P.69 pertactin	NATURE			English	Article							PROTEIN; IDENTIFICATION; MOTIF	A NEW generation of whooping-cough vaccines contain P.69 pertactin, a surface-exposed domain of an outer membrane protein expressed by the virulent bacterium Bordetella pertussis(1-3). This protein is a virulence factor that mediates adhesion to target mammalian cells, a reaction that is in part mediated by an RGD sequence, The X-ray crystal structure of P.69 pertactin has been determined to 2.5 Angstrom. The protein fold consists of a 16-stranded parallel beta-helix with a V-shaped cross-section, and is the largest beta-helix known to date, Several between-strand weakly conserved amino-acid repeats form internal and external ladders, The structure appears as a helix from which several loops protrude, which contain sequence motifs associated with the biological activity of the protein. One particular (GGXXP)(5) sequence is located directly after the RGD motif, and may mediate interaction with epithelial cells. The carboxy-terminal region of P.69 pertactin incorporates a (PQP)(5) motif loop containing the major immunoprotective epitope.	UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; UCL, CRUCIFORM PROJECT, LONDON W1P 9LN, ENGLAND; GLAXO WELLCOME RES LABS, DEPT CELL BIOL, BECKENHAM BR3 385, KENT, ENGLAND	University of Glasgow; University of London; University College London; GlaxoSmithKline; Wellcome Research Laboratories					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BRUNGRE AT, 1988, X PLOR REFERENCE MAN; CHARLES I, 1994, MICROBIOL-SGM, V140, P3301, DOI 10.1099/13500872-140-12-3301; CHARLES IG, 1989, P NATL ACAD SCI USA, V86, P3554, DOI 10.1073/pnas.86.10.3554; CHARLES IG, 1991, EUR J IMMUNOL, V21, P1147, DOI 10.1002/eji.1830210509; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; EMSLEY P, 1994, J MOL BIOL, V235, P772, DOI 10.1006/jmbi.1994.1029; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HYNES RO, 1987, CELL, V48, P547; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; MAKOFF AJ, 1990, BIO-TECHNOL, V8, P1030, DOI 10.1038/nbt1190-1030; MONTARAZ JA, 1985, INFECT IMMUN, V47, P744, DOI 10.1128/IAI.47.3.744-751.1985; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; OTWINOWSKI Z, 1992, DATA COLLECTION PROC, P56; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; 1988, LANCET, V8592, P955	28	254	271	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					90	92		10.1038/381090a0	http://dx.doi.org/10.1038/381090a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609998				2022-12-01	WOS:A1996UJ05300064
J	Robertson, JM; Burtt, DS; Edmonds, KL; Molina, PL; Kiefe, CI; Ellner, JJ				Robertson, JM; Burtt, DS; Edmonds, KL; Molina, PL; Kiefe, CI; Ellner, JJ			Delayed tuberculin reactivity in persons of Indochinese origin: Implications for preventive therapy	ANNALS OF INTERNAL MEDICINE			English	Article						tuberculin test; tuberculosis; Vietnam; ethnic groups; lymphocyte transformation	SKIN-TEST; LYMPHOCYTE-RESPONSES; SUPPRESSION; REACTORS	Objectives: To 1) study a variant delayed reaction to tuberculin testing as a way to enhance screening for tuberculosis among high-risk persons and 2) correlate the delayed reaction with lymphocyte blastogenesis. Design: Cross-sectional study. Setting: 2 public health department clinics in North Carolina. Participants: 121 adults who had recently emigrated from Vietnam to North Carolina and who were ethnic Vietnamese and ethnic Dega, a minority population group from the central highlands region of Vietnam. Measurements: Medical history, physical examination, laboratory evaluation, and standard purified protein derivative (PPD) testing (Mantoux method). Skin test results were read at 72 hours and again at 6 days. Variant reactivity was defined as induration of less than 10 mm at 72 hours that, when reassessed at 6 days, had increased in size to 10 mm or greater. Persons with negative (n = 54) and variant (n = 32) PPD results also had booster testing at 10 to 12 weeks. Serum samples were obtained from 57 participants for lymphocyte blastogenesis studies. Results: 26% of participants had variant tuberculin reactivity. Variant reactivity was strongly associated with booster positivity: Sixty-five percent of persons with variant PPD results had booster positivity compared with 16% of persons with negative PPD results (P < 0.001). The lymphocyte blastogenesis response of persons with variant PPD results was between the response of persons with negative PPD results and that of persons with positive PPD results. Conclusions: Variant reactivity in this high-risk group was a predictor of booster positivity. Together with the blastogenic response pattern, this association strongly-suggests that variant reactivity has a high positive predictive value for tuberculous infection. Clinicians should incorporate these findings into their approach for choosing candidates for preventive therapy.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; UNIV N CAROLINA, SCH MED, DEPT RADIOL, CHAPEL HILL, NC 27599 USA; UNIV ALABAMA, DEPT MED, DIV PREVENT MED, BIRMINGHAM, AL 35205 USA	Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham	Robertson, JM (corresponding author), UNIV NEW MEXICO, DEPT MED, SCH MED, ACC 5TH FLOOR, 2211 LOMAS NE, ALBUQUERQUE, NM 87131 USA.			Ellner, Jerrold/0000-0001-6150-0082				*AM SOC HLTH SYST, 1995, AHFS DRUG INF, P1722; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BASS JB, 1993, TUBERCULOSIS COMPREH, P139; BURTT DS, 1992, EVALUATING ALTERNATI; ELLNER JJ, 1979, CELL IMMUNOL, V45, P213, DOI 10.1016/0008-8749(79)90379-4; HAVLIR DV, 1991, CHEST, V99, P1172, DOI 10.1378/chest.99.5.1172; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; KLEINHENZ ME, 1981, J CLIN INVEST, V68, P153, DOI 10.1172/JCI110231; KLEINHENZ ME, 1983, J LAB CLIN MED, V102, P751; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MCANULTY JM, 1995, ARCH INTERN MED, V155, P713, DOI 10.1001/archinte.155.7.713; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P109, DOI 10.1016/S0037-198X(05)80100-2; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; *STAT CORP, 1993, STAT VERS 3 1; *US BUR CENS, 1995, STAT ABSTR US, P11; *USD, 1990, EPI INFO VERS 5 0 WO; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; Wenzel M, 1991, Nurse Pract, V16, P25; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P961; 1993, MMWR-MORBID MORTAL W, V42, P628	26	12	13	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					779	+		10.7326/0003-4819-124-9-199605010-00001	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610946				2022-12-01	WOS:A1996UG25400001
J	Schilham, MW; Oosterwegel, MA; Moerer, P; Ya, J; deBoer, PAJ; vandeWetering, M; Verbeek, S; Lamers, WH; Kruisbeek, AM; Cumano, A; Clevers, H				Schilham, MW; Oosterwegel, MA; Moerer, P; Ya, J; deBoer, PAJ; vandeWetering, M; Verbeek, S; Lamers, WH; Kruisbeek, AM; Cumano, A; Clevers, H			Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4	NATURE			English	Article							SEX-DETERMINING REGION; CELL DEVELOPMENT; BONE-MARROW; GENE; PROTEIN; FAMILY	A STRIKING example of the relationship between regulation of transcription and phenotype is the central role of the Y-chromo somal gene Sry in mammalian sex determination(1,2). Sry is the founding member of a large family of so-called Sox genes(1,3). During murine embryogenesis, the transcriptional activator Sox-4 is expressed at several sites, hut in adult mice expression is restricted to immature B and T lymphocytes(4). Using targeted genedisruption, we have found that Sox-4(-/-) embryos succumb to circulatory failure at day E14. This was a result of impaired development of the endocardial ridges (a specific site of Sox-4 expression) into the semilunar valves and the outlet portion of the muscular ventricular septum. The observed range of septation defects is known as 'common arterial trunk' in man. We studied haemopoiesis in lethally irradiated mice reconstituted with Sox-4(-/-) fetal liver cells acid found that a specific block occurred in B-cell development at the pro-B cell stage. In line with this, the frequency and proliferative capacity of IL-7-responsive B cell progenitors in fetal liver were severely decreased in vitro.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,TRANSGEN MOUSE FACIL,3508 GA UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DIV IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT ANAT & EMBRYOL,1105 A2 AMSTERDAM,NETHERLANDS; INST PASTEUR,UNITE BIOL MOL GENE,F-75024 PARIS 15,FRANCE	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lamers, Wouter H./D-2965-2012; Schilham, Marco W./AAL-7223-2021	Schilham, Marco W./0000-0003-4391-6003; Cumano, Ana/0000-0002-4578-959X				ANGELINI P, 1974, EUR J CARDIOL, V2, P11; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P2009, DOI 10.1093/nar/21.8.2009; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VANMIEROP LHS, 1969, CIBA COLLECTION MEDI, V5, P112; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VONDEWETERING M, 1993, EMBO J, V12, P3847; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	30	373	380	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					711	714		10.1038/380711a0	http://dx.doi.org/10.1038/380711a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614465				2022-12-01	WOS:A1996UG82700051
J	Euling, S; Ambros, V				Euling, S; Ambros, V			Heterochronic genes control cell cycle progress and developmental competence of C-elegans vulva precursor cells	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ENCODES; EXPRESSION; LINEAGES; FATES; MUTANTS; LIN-14; LOCUS; IDENTIFICATION; PROLIFERATION	Heterochronic genes control the timing of vulval development in the C. elegans hermaphrodite. lin-14 or lin-28 loss-of-function mutations cause the vulval precursor cells (VPCs) to enter S phase and to divide one larval stage earlier than in the wild type. A precocious vulva is formed by essentially normal cell lineage patterns, governed by the same intercellular signals as in the wild type. Mutations that prevent the normal developmental down-regulation of lin-14 activity delay or block VPC division and prevent vulval differentiation. A genetic pathway that includes lin-4, lin-14, and lin-28 controls when VPCs complete G1 and also controls when VPCs acquire the competence to respond to the intercellular patterning signals and express vulval fates.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	Euling, S (corresponding author), DARTMOUTH COLL,DEPT BIOL SCI,HANOVER,NH 03755, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034028] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON D, 1987, DEV BIOL, V63, P165; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1981, CELL, V24, P56; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CLARK SG, 1994, GENETICS, V137, P987; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EULING S, 1993, THESIS HARVARD U CAM; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREYD G, 1991, THESIS MIT CAMBRIDGE; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HILL RJ, 1993, DEVELOPMENT S, V119, P9; HORVITZ HR, 1980, GENETICS, V96, P435; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; Kornberg A., 1992, DNA REPLICATION; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; LIU ZC, 1995, DEVELOPMENT, V121, P2471; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROUGVIE AE, 1995, DEVELOPMENT, V121, P2491; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; Sokal R., 1981, BIOMETRY; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TUCK S, 1995, GENE DEV, V9, P347; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WILKINSON HA, 1995, GENETICS, V141, P513; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	57	86	94	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					667	676		10.1016/S0092-8674(00)81045-4	http://dx.doi.org/10.1016/S0092-8674(00)81045-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625405	Bronze			2022-12-01	WOS:A1996TZ99000005
J	Leshner, AI				Leshner, AI			Molecular mechanisms of cocaine addiction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Leshner, AI (corresponding author), NIDA,ROCKVILLE,MD 20857, USA.							CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586	3	31	32	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1996	335	2					128	129		10.1056/NEJM199607113350211	http://dx.doi.org/10.1056/NEJM199607113350211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW353	8649475				2022-12-01	WOS:A1996UW35300011
J	Deyton, L				Deyton, L			Importance of surrogate markers in evaluation of antiviral therapy for HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL-TRIALS; END-POINTS; AIDS				Deyton, L (corresponding author), NIAID, DIV AIDS,HIV RES BRANCH,NIH,SOLAR BLDG ROOM 2C16, 6003 EXECUT BLVD MSC 7620, BETHESDA, MD 20892 USA.							CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAQUILA RT, 1995, P 2 NAT C HUM RETR R; DEGRUTTOLA V, 1994, J INFECT DIS, V169, P713, DOI 10.1093/infdis/169.4.713; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLEMING TR, 1994, STAT MED, V13, P955, DOI 10.1002/sim.4780130906; FLEMING TR, 1994, STAT MED, V13, P1423, DOI 10.1002/sim.4780131318; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GAZZARD B, 1996, P 3 C RETR OPP INF W; HAMMER SM, 1996, P 3 C RETR OPP INF W; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUGHES MD, 1995, J ACQ IMMUN DEF SYND, V10, pS1; *I MED, 1990, SURR ENDP EV EFF DRU; KAPPES JC, 1995, J ACQ IMMUN DEF SYND, V10, P139, DOI 10.1097/00042560-199510020-00005; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; REICHELDERFER PS, 1995, J ACQ IMMUN DEF SYND, V10, pS19; SARAVOLATZ L, 1996, P 3 C RETR OPP INF W; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; THOMPSON M, 1995, CPCRA036 HIV RNA PRO; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	28	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					159	160		10.1001/jama.276.2.159	http://dx.doi.org/10.1001/jama.276.2.159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656509				2022-12-01	WOS:A1996UV48500033
J	Schreiber, GB; Busch, MP; Kleinman, SH; Korelitz, JJ				Schreiber, GB; Busch, MP; Kleinman, SH; Korelitz, JJ			The risk of transfusion-transmitted viral infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B-HEPATITIS; STATES BLOOD-DONORS; NON-A-HEPATITIS; UNITED-STATES; LONG-TERM; RECIPIENTS; ANTIBODY; TRANSMISSION	Background. Accurate estimates of the risk of transfusion-transmitted infectious disease are essential for monitoring the safety of the blood supply and evaluating the potential effect of new screening tests. We estimated the risk of transmitting the human immunodeficiency virus (HIV), the human T-cell lymphotropic virus (HTLV), the hepatitis C virus (HCV), and the hepatitis B virus (HBV) from screened blood units donated during the window period following a recent, undetected infection. Methods. Using data on 586,507 persons who each donated blood more than once between 1991 and 1993 at five blood centers (for a total of 2,318,356 allogeneic blood donations), we calculated the incidence rates of seroconversion among those whose donations passed all the screening tests used. We adjusted these rates for the estimated duration of the infectious window period for each virus. We then estimated the further reductions in risk that would result from the use of new and more sensitive viral-antigen or nucleic acid screening tests. Results. Among donors whose units passed all screening tests, the risks of giving blood during an infectious window period were estimated as follows: for HIV, 1 in 493,000 (95 percent confidence interval, 202,000 to 2,778,000); for HTLV, 1 in 641,000 (256,000 to 2,000,000); for HCV, 1 in 103,000 (28,000 to 288,000); and for HBV, 1 in 63,000 (31,000 to 147,000). HBV and HCV accounted for 88 percent of the aggregate risk of 1 in 34,000. New screening tests that shorten the window periods for the four viruses should reduce the risks by 27 to 72 percent. Conclusions. The risk of transmitting HIV, HTLV, HCV, or HBV infection by the transfusion of screened blood is very small, and new screening tests will reduce the risk even further. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, BLOOD & PLATELET CTR, LOS ANGELES, CA USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles	Schreiber, GB (corresponding author), WESTAT CORP, 1650 RES BLVD, ROCKVILLE, MD 20850 USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077, N01HB097078] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97114, N01-HB-97077, N01-HB-97078] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Aubuchon J. P., 1995, Transfusion (Bethesda), V35, p43S; BUSCH MP, 1994, BLOOD, V83, P1143; BUSCH MP, 1993, TRANSFUSION, V33, P84, DOI 10.1046/j.1537-2995.1993.33193142316.x; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; HJELLE B, 1993, BLOOD, V81, P1641; HOOFNAGLE JH, 1978, VIRAL HEPATITIS, P219; HUGHES W, 1995, TRANSFUSION MED, V5, P225, DOI 10.1111/j.1365-3148.1995.tb00232.x; IWARSON S, 1995, CLIN INFECT DIS, V20, P1361, DOI 10.1093/clinids/20.5.1361; JAGODZINSKI L, 1994, TRANSFUSION, V34, pS37; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; KLEINMAN S, 1992, BLOOD SAFETY CURRENT, P169; KLEINMAN SH, 1994, J CLIN MICROBIOL, V32, P603, DOI 10.1128/JCM.32.3.603-607.1994; KLEINMAN SH, 1996, CLIN PRACTICE TRANSF, P809; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LELIE PN, 1992, J MED VIROL, V37, P203, DOI 10.1002/jmv.1890370310; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MIMMS LT, 1993, BRIT MED J, V307, P1095, DOI 10.1136/bmj.307.6912.1095; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; RENZULLO PO, 1995, J ACQ IMMUN DEF SYND, V10, P177, DOI 10.1097/00042560-199510020-00011; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; STRAUSS D, 1994, TRANSFUSION, V34, pS34; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; 1994, MMWR-MORBID MORTAL W, V42, P1	41	1367	1444	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1685	1690		10.1056/NEJM199606273342601	http://dx.doi.org/10.1056/NEJM199606273342601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637512				2022-12-01	WOS:A1996UT40000001
J	Hofmann, E; Wrench, PM; Sharples, FP; Hiller, RG; Welte, W; Diederichs, K				Hofmann, E; Wrench, PM; Sharples, FP; Hiller, RG; Welte, W; Diederichs, K			Structural basis of light harvesting by carotenoids: Peridinin-chlorophyll-protein from Amphidinium carterae	SCIENCE			English	Article							BACTERIOCHLOROPHYLL-A-PROTEIN; PROSTHECOCHLORIS-AESTUARII; MARINE DINOFLAGELLATE; LOCATION; COMPLEX	Peridinin-chlorophyll-protein, a water-soluble light-harvesting complex that has a blue-green absorbing carotenoid as its main pigment, is present in most photosynthetic dinoflagellates, Its high-resolution (2.0 angstrom) x-ray structure reveals a noncrystallographic trimer in which each polypeptide contains an unusual jellyroll fold of the alpha-helical amino- and carboxyl-terminal domains, These domains constitute a scaffold with pseudo-twofold symmetry surrounding a hydrophobic cavity filled by two lipid, eight peridinin, and two chlorophyll a molecules, The structural basis for efficient excitonic energy transfer from peridinin to chlorophyll is found in the clustering of peridinins around the chlorophylls at van der Waals distances.	UNIV KONSTANZ,FAK BIOL,D-78434 CONSTANCE,GERMANY; MACQUARIE UNIV,SCH BIOL SCI,N RYDE,NSW 2109,AUSTRALIA	University of Konstanz; Macquarie University			Hofmann, Eckhard/GPF-5024-2022	Hofmann, Eckhard/0000-0003-4874-372X				BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, XPLOR VERSION 3 1; CARBONERA D, 1995, SPECTROCHIM ACTA A, V51, P115, DOI 10.1016/0584-8539(94)00204-O; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; DIEDERICHS K, 1994, JT CCP4 ESF EACBM NE, V31, P23; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; Frank H. A., 1993, CAROTENOIDS PHOTOSYN; FUJIOSHI Y, 1994, NATURE, V367, P614; FUREY W, IN PRESS METHODS ENZ; GILLBRO T, 1993, PHOTOCHEM PHOTOBIOL, V57, P44, DOI 10.1111/j.1751-1097.1993.tb02253.x; HAXO FT, 1976, PLANT PHYSIOL, V57, P297, DOI 10.1104/pp.57.2.297; HILLER RG, 1995, FEBS LETT, V363, P175, DOI 10.1016/0014-5793(95)00297-M; HILLER RG, 1993, PHOTOCHEM PHOTOBIOL, V57, P125, DOI 10.1111/j.1751-1097.1993.tb02267.x; HILLER RG, 1995, PHOTOSYNTHESIS LIGHT, V1, P24; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; IGLESIASPRIETO R, 1991, P ROY SOC B-BIOL SCI, V246, P275, DOI 10.1098/rspb.1991.0155; IGLESIASPRIETO R, 1993, PHILOS T ROY SOC B, V340, P381, DOI 10.1098/rstb.1993.0080; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOKA P, 1977, BIOCHIM BIOPHYS ACTA, V495, P220, DOI 10.1016/0005-2795(77)90379-8; Koyama Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P243, DOI 10.1111/j.1751-1097.1996.tb03021.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MIMURO M, 1990, BIOCHIM BIOPHYS ACTA, V1016, P280, DOI 10.1016/0005-2728(90)90070-K; NORRIS BJ, 1994, PLANT MOL BIOL, V24, P673, DOI 10.1007/BF00023563; RAWLYER A, 1995, BIOCHIM BIOPHYS ACTA, V1233, P122; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SONG PS, 1976, BIOCHEMISTRY-US, V15, P4422, DOI 10.1021/bi00665a012; STECK K, 1990, FEBS LETT, V268, P48, DOI 10.1016/0014-5793(90)80969-P; Triplett Edward L., 1993, Molecular Marine Biology and Biotechnology, V2, P246; TRONRUD DE, 1986, J MOL BIOL, V188, P443, DOI 10.1016/0022-2836(86)90167-1; [No title captured]	38	369	389	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1788	1791		10.1126/science.272.5269.1788	http://dx.doi.org/10.1126/science.272.5269.1788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650577	Green Submitted			2022-12-01	WOS:A1996UT11000043
J	Jayaraman, T; Ondrias, K; Ondriasova, E; Marks, AR				Jayaraman, T; Ondrias, K; Ondriasova, E; Marks, AR			Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation	SCIENCE			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; PROTEIN-KINASE; BINDING-SITE; MUTANT MICE; CHANNELS; TRANSDUCTION; CEREBELLUM	Tyrosine kinases indirectly raise intracellular calcium concentration ([Ca2+](i)) by activating phospholipases that generate inositol 1,4,5-trisphosphate (IP3). IP3 activates the IP3 receptor (IP(3)R), an intracellular calcium release channel on the endoplasmic reticulum. T cell receptor stimulation triggered a physical association between the nonreceptor protein tyrosine kinase Fyn and the IP(3)R, which induced tyrosine phosphorylation of the IP(3)R. Fyn activated an IP3-gated calcium channel in vitro, and tyrosine phosphorylation of the IP(3)R during T cell activation was reduced in thymocytes from fyn(-/-) mice. Thus, activation of the IP(3)R by tyrosine phosphorylation may play a role in regulating [Ca2+](i).	CUNY MT SINAI SCH MED,DEPT MED,MOLEC CARDIOL LAB,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Ondrias, Karol/0000-0001-8329-3563; Ondriasova, Elena/0000-0002-2990-990X	PHS HHS [N529814] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; JAYARAMAN T, UNPUB; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKADE S, 1994, J BIOL CHEM, V269, P6735; ONDRIAS K, UNPUB; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; WATRAS J, 1991, J NEUROSCI, V11, P3239; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	27	190	197	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1492	1494		10.1126/science.272.5267.1492	http://dx.doi.org/10.1126/science.272.5267.1492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633244				2022-12-01	WOS:A1996UP89900051
J	Allison, MC; Mills, PR				Allison, MC; Mills, PR			Controversies in management: Screening asymptomatic people at high risk for hepatitis C - The case against	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTTRANSFUSION HEPATITIS		GARTNAVEL ROYAL HOSP, GLASGOW G12 0YN, LANARK, SCOTLAND	Gartnavel Royal Hospital	Allison, MC (corresponding author), ROYAL GWENT HOSP, NEWPORT NP9 2UB, GWENT, WALES.							ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; BOOTH JCL, 1995, GUT, V37, P449, DOI 10.1136/gut.37.4.449; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DUSHEIKO GM, 1994, ALIMENT PHARM THER, V8, P229; GORDON SC, 1993, HEPATOLOGY, V18, P1338, DOI 10.1002/hep.1840180609; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; MCMAHON RFT, 1994, HISTOPATHOLOGY, V24, P517; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SANGIOVANNI A, 1995, HEPATOLOGY, V22, P734; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHIELL A, 1994, MED J AUSTRALIA, V160, P268, DOI 10.5694/j.1326-5377.1994.tb125830.x; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5	16	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1996	312	7042					1349	1350		10.1136/bmj.312.7042.1349	http://dx.doi.org/10.1136/bmj.312.7042.1349			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646053	Green Published			2022-12-01	WOS:A1996UN47600028
J	Tsukihara, T; Aoyama, H; Yamashita, E; Tomizaki, T; Yamaguchi, H; ShinzawaItoh, K; Nakashima, R; Yaono, R; Yoshikawa, S				Tsukihara, T; Aoyama, H; Yamashita, E; Tomizaki, T; Yamaguchi, H; ShinzawaItoh, K; Nakashima, R; Yaono, R; Yoshikawa, S			The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 angstrom	SCIENCE			English	Article							CARBON-MONOXIDE BINDING; PARACOCCUS-DENITRIFICANS; SUBUNITS; RESOLUTION; CONFORMERS; PROTEINS; ENERGY	The crystal structure of bovine heart cytochrome c oxidase at 2.8 Angstrom resolution with an R Value of 19.9 percent reveals 13 subunits, each different from the other, five phosphatidyl ethanolamines, three phosphatidyl glycerols and two cholates, two hemes A, and three copper, one magnesium, and one zinc. Of 3606 amino acid residues in the dimer, 3560 have been converged to a reasonable structure by refinement, A hydrogen-bonded system, including a propionate of a heme A (heme a), part of peptide backbone, and an imidazole ligand of Cu-A, could provide an electron transfer pathway between Cu-A and heme a, Two possible proton pathways for pumping, each spanning from the matrix to the cytosolic surfaces, were identified, including hydrogen bonds, internal cavities likely to contain water molecules, and structures that could form hydrogen bonds with small possible conformational change of amino acid side chains. Possible channels for chemical protons to produce H2O, for removing the produced water, and for O-2, respectively, were identified.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGOHRI AKOH,HYOGO 67812,JAPAN	Osaka University; University of Hyogo			Yamashita, Eiki/V-6758-2019	Yamashita, Eiki/0000-0002-4278-0039; Aoyama, Hiroshi/0000-0001-7915-8975				ANDYMARK WH, 1994, NATURE, V367, P750; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BLOOMER AC, 1978, NATURE, V276, P362, DOI 10.1038/276362a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; GARAVITO R M, 1990, Methods (Orlando), V1, P57, DOI 10.1016/S1046-2023(05)80147-1; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL BC, 1994, J BIOL CHEM, V269, P2419; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, TRENDS BIOCHEM SCI, V8, P398, DOI 10.1016/0968-0004(83)90302-X; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V26, P599, DOI 10.1007/BF00831534; MULLER M, 1988, BIOCHEM BIOPH RES CO, V154, P1260, DOI 10.1016/0006-291X(88)90275-6; PALMER G, 1991, LONG RANGE ELECT TRA; Perutz M. F., 1990, MECH COOPERATIVITY; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; ROBINSON NC, 1982, BIOCHEMISTRY-US, V21, P184, DOI 10.1021/bi00530a031; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VASSILEV AO, 1995, P NATL ACAD SCI USA, V92, P8680, DOI 10.1073/pnas.92.19.8680; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Warburg O, 1929, BIOCHEM Z, V214, P64; WIKSTROM MKF, 1976, FEBS LETT, V65, P259, DOI 10.1016/0014-5793(76)80127-5; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHANG YZ, 1991, BIOCHEMISTRY-US, V30, P3674, DOI 10.1021/bi00229a012	33	1880	1916	4	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1136	1144		10.1126/science.272.5265.1136	http://dx.doi.org/10.1126/science.272.5265.1136			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638158				2022-12-01	WOS:A1996UM88900040
J	Wonderling, D; McDermott, C; Buxton, M; Kinmonth, AL; Pyke, S; Thompson, S; Wood, D				Wonderling, D; McDermott, C; Buxton, M; Kinmonth, AL; Pyke, S; Thompson, S; Wood, D			Costs and cost effectiveness of cardiovascular screening and intervention: The British family heart study	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure costs and cost effectiveness of the British family heart study cardiovascular screening and intervention programme. Design-Cost effectiveness analysis of randomised controlled trial. Clinical and resource use data taken from trial and unit cost data from external estimates. Setting-13 general practices across Britain. Subjects-4185 men aged 40-59 and their 2827 partners. Intervention-Nurse led programme using a family centred approach, with follow up according to degree of risk. Main outcome measures-Cost of the programme itself; overall short term cost to NHS; cost per 1% reduction in coronary risk at one year. Results-Estimated cost of putting the programme into practice for one year was pound 63 per person (95% confidence interval pound 60 to pound 65). The overall short term cost to the health service was pound 77 per man (pound 29 to pound 124) but only pound 13 per woman (-pound 48 to pound 74), owing to differences in utilisation of other health service resources. The cost per 1% reduction in risk was pound 5.08 per man (pound 5.92 including broader health service costs) and pound 5.78 per woman (pound 1.28 taking into account wider health service savings). Conclusions-The direct cost of the programme to a four partner practice of 7500 patients would be approximately pound 58 000. Annually, pound 8300 would currently be paid to a practice of this size working to the ma target on the health promotion bands, plus any additional reimbursement of practice staff salaries for which the practice qualified. The broader short term costs to the NHS may augment these costs for men but offset them considerably for women.	BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; UNIV SOUTHAMPTON,FAC MED,SOUTHALL SO16 5ST,MIDDX,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND; NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND	Brunel University; University of Southampton; University of London; London School of Hygiene & Tropical Medicine; Imperial College London				Wonderling, David/0000-0003-0315-6273				[Anonymous], 1995, COMP HLTH STAT; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; *CHAR I PUBL FIN A, 1994, HLTH DATABASE 994, V1; *DEP EMPL, 1994, 1994 DEP EMPL A; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; NETTEN A, 1994, UNIT COSTS COMMUNITY; *OFF POP CENS SURV, 1994, OPCS MON 1994; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; 1994, BRIT MED J, V308, P313; 1995, BRIT MED J, V310, P1099; 1994, BR J GEN PRACT, V44, P62	13	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1269	1273		10.1136/bmj.312.7041.1269	http://dx.doi.org/10.1136/bmj.312.7041.1269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634617	Green Published, Green Submitted			2022-12-01	WOS:A1996UM40400023
J	Kurten, RC; Cadena, DL; Gill, GN				Kurten, RC; Cadena, DL; Gill, GN			Enhanced degradation of EGF receptors by a sorting nexin, SNX1	SCIENCE			English	Article								The vectorial movement of proteins requires specific recognition by components of the vesicular trafficking machinery. A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code, SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation. Thus, SNX1 is likely to play a role in sorting EGFR to lysosomes.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008666] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIDDK NIH HHS [F32DK08666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; CADENA DL, 1994, J BIOL CHEM, V269, P260; EKENA K, 1995, MOL CELL BIOL, V15, P1671; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KURTEN RC, UNPUB; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	11	308	317	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1008	1010		10.1126/science.272.5264.1008	http://dx.doi.org/10.1126/science.272.5264.1008			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638121				2022-12-01	WOS:A1996UL61900044
J	Li, KJ; Kaufman, TC				Li, KJ; Kaufman, TC			The homeotic target gene centrosomin encodes an essential centrosomal component	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; DROSOPHILA EMBRYO; SEGMENTAL DETERMINATION; BITHORAX COMPLEX; GAMMA-TUBULIN; ULTRABITHORAX; RECOMBINASE; EXPRESSION; MUTATIONS; PROTEINS	The centrosomin (cnn) gene encodes a protein associated with mitotic centrosomes in Drosophila melanogaster and is a target of homeotic gene regulation. Here we report that CNN is an essential component of the centrosome. Loss of zygotic cnn expression disrupts the development of the second midgut constriction, the gastric caeca, and the nervous system. Embryos that lack maternal as well as zygotic cnn expression display defects in nuclear division, chromosome alignment, and microtubule organization, while adult flies that are mosaic for cnn(-) cells exhibit defects indicative of a block in cell proliferation. We propose that cnn provides an example of homeotic genes directly regulating the accumulation of essential cellular proteins to carry out segment-specific morphogenetic functions.	INDIANA UNIV, HOWARD HUGHES MED INST, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Howard Hughes Medical Institute; Indiana University System; Indiana University Bloomington								AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AHMAD FJ, 1994, NEURON, V12, P271, DOI 10.1016/0896-6273(94)90270-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; Ashburner M., 1989, DROSOPHILA LAB HDB; BAAS PW, 1992, J CELL BIOL, V119, P171, DOI 10.1083/jcb.119.1.171; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BOOKER R, 1989, DEVELOPMENT, V105, P621; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BRYANT PJ, 1971, DEV BIOL, V26, P606, DOI 10.1016/0012-1606(71)90146-1; BRYANT PJ, 1973, GENETICS, V75, P623; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Fuller M.T., 1993, SPERMATOGENESIS DEV; GHYSEN A, 1985, CELL, V40, P943, DOI 10.1016/0092-8674(85)90354-X; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ C, 1990, J CELL SCI, V96, P605; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Goodman Corey S., 1993, P1131; GOULD AP, 1992, DEVELOPMENT, V116, P1163; GRABA Y, 1995, DEVELOPMENT, V121, P209; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; HEUER JG, 1995, DEVELOPMENT, V121, P3861; HINZ U, 1992, DEVELOPMENT, V116, P543; JIJAKLI H, 1992, INT J DEV BIOL, V36, P93; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; MASTICK GS, 1995, GENETICS, V139, P349; OEGEMA K, 1995, J CELL BIOL, V131, P1261, DOI 10.1083/jcb.131.5.1261; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; REUTER R, 1990, DEVELOPMENT, V109, P289; RUSSELL MA, 1974, DEV BIOL, V40, P24, DOI 10.1016/0012-1606(74)90104-3; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SULLIVAN W, 1990, DEVELOPMENT, V110, P311; SUNKEL CE, 1988, J CELL SCI, V89, P25; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, 1994, DROSOPHILA MELANOGAS, P489; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; VERHEYEN E, 1994, DROSOPHILA MELANOGAS, P545; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WHITFIELD WGF, 1995, J CELL SCI, V108, P3377; XU T, 1993, DEVELOPMENT, V117, P1223; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	56	111	113	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1996	85	4					585	596		10.1016/S0092-8674(00)81258-1	http://dx.doi.org/10.1016/S0092-8674(00)81258-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653793	Bronze			2022-12-01	WOS:A1996UM41500015
J	Sheng, HZ; Zhadanov, AB; Mosinger, B; Fujii, T; Bertuzzi, S; Grinberg, A; Lee, EJ; Huang, SP; Mahon, KA; Westphal, H				Sheng, HZ; Zhadanov, AB; Mosinger, B; Fujii, T; Bertuzzi, S; Grinberg, A; Lee, EJ; Huang, SP; Mahon, KA; Westphal, H			Specification of pituitary cell lineages by the LIM homeobox gene Lhx3	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; EXPRESSION; ONTOGENESIS; MESENCHYME; LETHALITY; INVITRO	During pituitary organogenesis, the progressive differentiation of distinct pituitary-specific cell lineages from a common primordium involves a series of developmental decisions and inductive interactions. Targeted gene disruption in mice showed that Lhx3, a LIM homeobox gene expressed in the pituitary throughout development, is essential for differentiation and proliferation of pituitary cell lineages, In mice homozygous for the Lhx3 mutation, Rathke's pouch formed but failed to grow and differentiate; such mice lacked both the anterior and intermediate robes of the pituitary. The determination of all pituitary cell lineages, except the corticotrophs, was affected, suggesting that a distinct, Lhx3-independent ontogenetic pathway exists for the initial specification of this lineage.	NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHIN WW, 1981, P NATL ACAD SCI-BIOL, V78, P5329, DOI 10.1073/pnas.78.9.5329; DAIKOKU S, 1983, DEV BIOL, V97, P81, DOI 10.1016/0012-1606(83)90065-9; DIAKOKU S, 1982, DEV BIOL, V90, P198; ELKABES S, 1989, DEV BRAIN RES, V46, P85, DOI 10.1016/0165-3806(89)90145-4; ETKIN W, 1967, NEUROENDOCRINOLOGY, P261; FERRAND R, 1972, Archives de Biologie, V83, P297; Hermesz E, 1996, DEVELOPMENT, V122, P41; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAWAMURA K, 1995, CELL TISSUE RES, V279, P233, DOI 10.1007/s004410050278; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KIKUYAMA S, 1993, J EXP ZOOL, V266, P216, DOI 10.1002/jez.1402660307; KUSAKABE M, 1984, DEV GROWTH DIFFER, V26, P263; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINZER DIH, 1985, J BIOL CHEM, V260, P9574; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; OFFIELD MF, IN PRESS DEVELOPMENT; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHENG H, UNPUB; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WATANABE YG, 1982, CELL TISSUE RES, V227, P257, DOI 10.1007/BF00210884; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; ZHADANOV AB, 1995, GENOMICS, V27, P27, DOI 10.1006/geno.1995.1004; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	33	368	374	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1004	1007		10.1126/science.272.5264.1004	http://dx.doi.org/10.1126/science.272.5264.1004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638120				2022-12-01	WOS:A1996UL61900043
J	Malonek, D; Grinvald, A				Malonek, D; Grinvald, A			Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: Implications for functional brain mapping	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; HUMAN VISUAL-CORTEX; ISO-ORIENTATION DOMAINS; SENSORY STIMULATION; HIPPOCAMPAL SLICES; INTRINSIC SIGNALS; NEURAL ACTIVITY; STRIATE CORTEX; ARCHITECTURE; ORGANIZATION	Modern neuroimaging techniques use signals originating from microcirculation to map brain function. In this study, activity-dependent changes in oxyhemoglobin, deoxyhemoglobin, and light scattering were characterized by an imaging spectroscopy approach that offers high spatial, temporal, and spectral resolution. Sensory stimulation of cortical columns initiates tissue hypoxia and vascular responses that occur within the first 3 seconds and are highly localized to individual cortical columns. However, the later phase of the vascular response is less localized, spreading over distances of 3 to 5 millimeters.			Malonek, D (corresponding author), WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL.							BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; CHANCE B, 1962, SCIENCE, V137, P499, DOI 10.1126/science.137.3529.499; COHEN LB, 1973, PHYSIOL REV, V53, P373; COHEN LB, 1968, NATURE, V218, P438, DOI 10.1038/218438a0; DIRNAGL U, COMMUNICATION; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; GREENBERG J, 1979, Acta Neurologica Scandinavica Supplementum, V60, P12; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HEINRICH U, 1987, PFLUG ARCH EUR J PHY, V409, P152, DOI 10.1007/BF00584764; HENNIG T, 1994, MAGNET RESON MED, V31, P85, DOI 10.1002/mrm.1910310115; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; JOBSIS FF, 1977, J APPL PHYSIOL, V43, P858; KATO M, 1974, EXP NEUROL, V42, P65, DOI 10.1016/0014-4886(74)90006-5; KUSCHINSKY W, 1992, CEREBROVAS BRAIN MET, V4, P261; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LASSEN NA, 1961, EXPERIENTIA, V17, P42, DOI 10.1007/BF02157946; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MENON RS, 1994, P SOC MAGN RES, V1, P68; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OLESEN J, 1971, BRAIN, V94, P635, DOI 10.1093/brain/94.4.635; RAICHLE ME, 1994, SCI AM, V270, P58, DOI 10.1038/scientificamerican0494-58; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; RISBERG J, 1973, BRAIN, V96, P737, DOI 10.1093/brain/96.4.737; Roy C S, 1890, J Physiol, V11, P85; SALZBERG BM, 1983, NATURE, V306, P36, DOI 10.1038/306036a0; Silver I A, 1978, Ciba Found Symp, P49; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TASAKI I, 1968, P NATL ACAD SCI USA, V61, P883, DOI 10.1073/pnas.61.3.883; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; Turner R, 1994, P SOC MAGN RESON, V1, P430; WATANABE M, 1994, J CEREBR BLOOD F MET, V14, P75, DOI 10.1038/jcbfm.1994.12; WELIKY M, 1995, NEURON, V15, P541, DOI 10.1016/0896-6273(95)90143-4	44	849	858	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					551	554		10.1126/science.272.5261.551	http://dx.doi.org/10.1126/science.272.5261.551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614805				2022-12-01	WOS:A1996UG82600045
J	Lazarovits, AI; Poppema, S; Zhang, Z; Khandaker, M; LeFeuvre, CE; Singhal, SK; Garcia, BM; Ogasa, N; Jevnikar, AM; White, MJ; Singh, G; Stiller, CR; Zhong, RZ				Lazarovits, AI; Poppema, S; Zhang, Z; Khandaker, M; LeFeuvre, CE; Singhal, SK; Garcia, BM; Ogasa, N; Jevnikar, AM; White, MJ; Singh, G; Stiller, CR; Zhong, RZ			Prevention and reversal of renal allograft rejection by antibody against CD45RB	NATURE			English	Article								REJECTION continues to be the single largest impediment to successful organ transplantation(1). Antilymphocyte globulin, which contains antibodies that react with the leukocyte common antigen known as CD45 (refs 2-6), has proved to be one of the most effective agents for preventing rejection. We have shown earlier that a monoclonal antibody directed against the RB isoform of CD45 substantially inhibits the alloreactivity of human CD4(+) lymphocytes in vitro(7). Here we investigate whether CD45RB could be an appropriate target for preventing renal allograft rejection in mice. Mice treated with two injections of a monoclonal antibody (MB23G2) (ref. 8) raised against CD45RB protein all survived and had normal renal function. Furthermore, this antibody reversed acute rejection when therapy was delayed until day 4, and the mice survived for their natural lifespan. The immunosuppression achieved may find application in the prevention and treatment of transplant rejection in man.	UNIV WESTERN ONTARIO,FAC MED,DEPT MED,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT SURG,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT PATHOL,LONDON,ON N6A 5A5,CANADA; UNIV GRONINGEN,DEPT PATHOL,9713 EZ GRONINGEN,NETHERLANDS	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Groningen	Lazarovits, AI (corresponding author), JOHN P ROBARTS RES INST,LONDON HLTH SCI CTR,MULTIORGAN TRANSPLANT SERV,UNIV CAMPUS,LONDON,ON N6A 5A5,CANADA.		Jevnikar, Anthony M./G-3309-2011; Poppema, Sibrand/D-1204-2012					BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BONNEFOYBERARD N, 1991, TRANSPLANTATION, V51, P669, DOI 10.1097/00007890-199103000-00024; FABRE JW, 1977, TRANSPLANTATION, V23, P349, DOI 10.1097/00007890-197704000-00009; FABRE JW, 1980, TRANSPLANTATION, V30, P167, DOI 10.1097/00007890-198009000-00003; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; IBRAHIM S, 1995, TRANSPLANTATION, V59, P724, DOI 10.1097/00007890-199503150-00015; LAZAROVITS AI, 1992, TRANSPLANTATION, V54, P724, DOI 10.1097/00007890-199210000-00030; LAZAROVITS AI, 1994, J IMMUNOL, V153, P3956; LAZAROVITS AI, 1993, J IMMUNOL, V150, P5163; QUAN D, 1994, TRANSPLANTATION, V58, P808, DOI 10.1097/00007890-199410150-00011; REBELLATO LM, 1994, TRANSPLANTATION, V57, P685, DOI 10.1097/00007890-199403150-00010; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WARR GW, 1976, IMMUNOCHEMISTRY, V13, P753, DOI 10.1016/0019-2791(76)90196-8; ZHANG Z, 1995, MICROSURG, V16, P103, DOI 10.1002/micr.1920160212	15	135	149	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					717	720		10.1038/380717a0	http://dx.doi.org/10.1038/380717a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614467				2022-12-01	WOS:A1996UG82700053
J	Mira, M; Alperstein, G; Karr, M; Ranmuthugala, G; Causer, J; Niec, A; Lilburne, AM				Mira, M; Alperstein, G; Karr, M; Ranmuthugala, G; Causer, J; Niec, A; Lilburne, AM			Haem iron intake in 12-36 month old children depleted in iron: Case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEFICIENCY ANEMIA; INFANTS; RISK; MILK	Objective-To compare the intakes of haem and non-haem iron in iron depleted and iron replete children. Design-Case-control study. Setting-Early Childhood Centres and a long day care centre in Sydney, Australia. Subjects-Children aged 12-36 months depleted in iron and controls matched for age and sex. Mean outcome measures-Iron status by using plasma ferritin concentration. A three day weighed dietary intake record completed by the parents. Risk factors for iron deficiency assessed by questionnaire. Results-Fifty six iron depleted and 68 iron replete children participated. The average daily intake of haem iron was significantly lower in the iron depleted group (t=2.392, P=0.018); there was a tendency towards a lower average daily intake of non-haem iron (t=1 724, P=0.086) and vitamin C (t=1.921, P=0.057) for iron depleted children. Low intake of haem iron (<0 71 mg/day) was significantly associated with iron depletion with an odds ratio of 3.0 (P=0.005). The proportion of iron depleted children who were given whole cows' milk before 12 months of age was almost double that of iron replete children; multivariate analysis showed that both haem iron intake and age of introduction of cows' milk were independently associated with iron depletion. Conclusions-The results of this study show that, in young children in developed countries, a lower haem iron intake is a major risk factor for iron depletion; the introduction of whole cows' milk before 12 months is further confirmed as a risk factor. Parental education on nutrition should now focus on these two aspects of nutrition for infants and young children.	ROYAL PRINCE ALFRED HOSP, CENT SYDNEY AREA HLTH SERV, COMMUNITY HLTH SERV, CAMPERDOWN, NSW 2050, AUSTRALIA; AUSTRALIAN NATL UNIV, NATL CTR EPIDEMIOL & POPULAT HLTH, CANBERRA, ACT, AUSTRALIA	University of Sydney; Australian National University	Mira, M (corresponding author), CENT SYDNEY AREA HLTH SERV, DIV GEN PRACTICE, BALMAIN, NSW 2041, AUSTRALIA.		Ranmuthugala, Geetha/F-5938-2012; Ranmuthugala, Geetha/P-5041-2019	Ranmuthugala, Geetha/0000-0002-4893-5775; Ranmuthugala, Geetha/0000-0002-4893-5775				BJORNRASMUSSEN E, 1974, J CLIN INVEST, V53, P237; CALVO EB, 1992, PEDIATRICS, V90, P375; DALLMAN P, 1989, AM J CLIN NUTR, V50, P575; DALLMAN PR, 1980, AM J CLIN NUTR, V33, P86, DOI 10.1093/ajcn/33.1.86; Dean A. G., 1990, EPI INFO VERSION 5 W; FRIEL JK, 1990, CAN MED ASSOC J, V143, P733; GEBSKI V, 1992, STAT PACKAGE INTERAC; HALLBERG L, 1984, AM J CLIN NUTR, V39, P577, DOI 10.1093/ajcn/39.4.577; HERCBERG S, 1987, NUTR REP INT, V35, P307; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MACPHAIL AP, 1989, ACTA PAEDIATR SCAND, P114; MILLS AF, 1990, ARCH DIS CHILD, V65, P428, DOI 10.1136/adc.65.4.428; MONSEN ER, 1978, AM J CLIN NUTR, V31, P134, DOI 10.1093/ajcn/31.1.134; *NAT HLTH MED RES, 1991, NH MRC REC DIET INT; OSKI FA, 1983, PEDIATRICS, V71, P877; SIIMES MA, 1984, J PEDIATR-US, V104, P196, DOI 10.1016/S0022-3476(84)80991-9; TUNNESSEN WW, 1987, J PEDIATR-US, V111, P813, DOI 10.1016/S0022-3476(87)80193-2; VAZQUEZSEOANE P, 1985, NEW ENGL J MED, V313, P1239, DOI 10.1056/NEJM198511073131936; WALTER T, 1989, PEDIATRICS, V84, P7; *XYR, 1989, DIET 1 VERS 3 00; [No title captured]	21	33	33	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1996	312	7035					881	883						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611876	Green Published			2022-12-01	WOS:A1996UE37100021
J	Ikeda, SR				Ikeda, SR			Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits	NATURE			English	Article							RAT SYMPATHETIC NEURONS; CA2+ CHANNELS; BINDING; INHIBITION; MUTATIONS; CURRENTS	THE most commonly used signal transduction pathway for receptor-mediated N-type Ca2+-channel modulation involves activation of a heterotrimeric G protein to produce voltage-dependent inhibition(1). Although it is widely assumed that G alpha mediates this effect, experiments to address this hypothesis directly are lacking. Here I show that transient overexpression of G beta gamma in sympathetic neurons mimics and occludes the voltage-dependent Ca2+ channel modulation produced by noradrenaline (NA). Conversely, overexpression of G alpha produces minimal effects on basal Ca2+ channel behaviour but attenuates NA-mediated inhibition in a manner consistent with the buffering of G beta gamma. These observations indicate that it is G beta gamma, and not G alpha, that mediates voltage-dependent inhibition of N-type Ca2+ channels. The identification of G beta gamma as the mediator of this pathway has broad implications as G-protein-coupled receptors, many of which are implicated in disease or are targets of therapeutic agents, couple to N-type Ca2+ channels(2) and may modulate synaptic transmission by this mechanism(3,4).			Ikeda, SR (corresponding author), MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA.			Ikeda, Stephen/0000-0002-4088-9508				ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bourinet E., 1995, Society for Neuroscience Abstracts, V21, P515; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HELM R, 1995, NATURE, V373, P663; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MULLER S, 1995, BIOCHEM SOC T, V23, P141; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; ROCHE JP, 1995, FEBS LETT, V371, P43, DOI 10.1016/0014-5793(95)00860-C; SCHOFIELD GG, 1990, EUR J PHARMACOL, V180, P37, DOI 10.1016/0014-2999(90)90590-3; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	30	652	663	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1996	380	6571					255	258		10.1038/380255a0	http://dx.doi.org/10.1038/380255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637575				2022-12-01	WOS:A1996UB11700054
J	Fields, PE; Gajewski, TF; Fitch, FW				Fields, PE; Gajewski, TF; Fitch, FW			Blocked ras activation in anergic CD4(+) T cells	SCIENCE			English	Article							CLONAL ANERGY; ANTIGEN RECEPTOR; IL-2; STIMULATION; INVITRO; P21RAS	T cell anergy is a state of functional unresponsiveness characterized by the inability to produce interleukin-2 (IL-2) upon T cell receptor stimulation. The mitogen-activated protein kinases ERK-1 and ERK-2 and the guanosine triphosphate-binding protein p21(Ras) were found to remain unactivated upon stimulation of anergic murine T helper cell 1 clones. The inability to activate the Ras pathway did not result from a defect in association among Shc, Grb-2, and murine Son of Sevenless, nor from a defect in their tyrosine phosphorylation. This block in Ras activation may lead to defective transactivation at activator protein 1 sites in anergic cells and may enable T cells to shut down IL-2 production selectively during anergy.	UNIV CHICAGO,COMM IMMUNOL,BEN MAY INST,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60637	University of Chicago; University of Chicago			Fields, Patrick E/G-4878-2012	Fields, Patrick/0000-0002-6797-4139				BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIELDS PI, UNPUB; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QUILL H, 1992, J IMMUNOL, V149, P2887; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; STACK RM, 1994, J IMMUNOL, V152, P5723; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WOODROW M, 1993, J IMMUNOL, V150, P1	26	352	359	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1276	1278		10.1126/science.271.5253.1276	http://dx.doi.org/10.1126/science.271.5253.1276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638108				2022-12-01	WOS:A1996TX69500035
J	Gerasimenko, OV; Gerasimenko, JV; Belan, PV; Petersen, OH				Gerasimenko, OV; Gerasimenko, JV; Belan, PV; Petersen, OH			Inositol trisphosphate and cyclic ADP-ribose-mediated release of Ca2+ from single isolated pancreatic zymogen granules	CELL			English	Article							EXOCRINE PANCREAS; ACINAR-CELLS; SUBCELLULAR-DISTRIBUTION; ENDOPLASMIC-RETICULUM; PROTEIN-SYNTHESIS; CALCIUM; SECRETION; OSCILLATIONS; THAPSIGARGIN; INHIBITION	In pancreatic acinar cells low (physiological) agonist concentrations evoke cytosolic Ca2+ spikes specifically in the apical secretory pole that contains a high density of secretory (zymogen) granules (ZGs). Inositol 1,4,5-trisphosphate (IP3) is believed to release Ca2+ from the endoplasmic reticulum, but we have now tested whether the Ca2+-releasing messengers IP3 and cyclic ADP-ribose (cADPr) can liberate Ca2+ from ZGs. In experiments on single isolated ZGs, we show using confocal microscopy that IP3 and cADPr evoke a marked decrease in the free intragranular Ca2+ concentration. Using a novel high resolution method, we have measured changes in the Ca2+ concentration in the vicinity of an isolated ZG and show that IP3 and cADPr cause rapid Ca2+ release from the granule, explaining the agonist-evoked cytosolic Ca2+ rise in the secretory pole.	UNIV LIVERPOOL,PHYSIOL LAB,MRC SECRETORY CONTROL,RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Gerasimenko, Oleg/A-6622-2010; Petersen, Ole H/E-8708-2010; Gerasimenko, Julia/A-7688-2010; Belan, Pavel/AAV-3522-2021	Gerasimenko, Oleg/0000-0003-2573-8258; Belan, Pavel/0000-0001-5429-3716; Gerasimenko, Julia/0000-0002-2262-2543; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEMENTE F, 1975, J CELL BIOL, V65, P88, DOI 10.1083/jcb.65.1.88; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V415, P29, DOI 10.1007/BF00373138; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gorelick Frederick S., 1994, P1353; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASAI H, 1995, CIBA F SYMP, V188, P104; Kern Horst F., 1993, P9; MARTY A, 1991, J MEMBRANE BIOL, V124, P189, DOI 10.1007/BF01994353; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; NAKAGAKI I, 1984, PFLUG ARCH EUR J PHY, V401, P340, DOI 10.1007/BF00584333; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROGERS J, 1987, BIOCHIM BIOPHYS ACTA, V897, P217, DOI 10.1016/0005-2736(87)90418-4; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; WILCOX RA, 1994, J BIOL CHEM, V269, P26815; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	40	207	217	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					473	480		10.1016/S0092-8674(00)81292-1	http://dx.doi.org/10.1016/S0092-8674(00)81292-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608601	Bronze			2022-12-01	WOS:A1996TV70800016
J	GalchevaGargova, Z; Konstantinov, KN; Wu, IH; Klier, FG; Barrett, T; Davis, RJ				GalchevaGargova, Z; Konstantinov, KN; Wu, IH; Klier, FG; Barrett, T; Davis, RJ			Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor	SCIENCE			English	Article							SIGNAL TRANSDUCTION; TYROSINE KINASE; SH3 DOMAINS; A431 CELLS; MECHANISM; AFFINITY	ZPR1 is a zinc finger protein that binds to the cytoplasmic tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Deletion analysis demonstrated that this binding interaction is mediated by the zinc fingers of ZPR1 and subdomains X and XI of the EGFR tyrosine kinase. Treatment of mammalian cells with EGF caused decreased binding of ZPR1 to the EGFR and the accumulation of ZPR1 in the nucleus. The effect of EGF to regulate ZPR1 binding is dependent on tyrosine phosphorylation of the EGFR. ZPR1 therefore represents a prototype for a class of molecule that binds to the EGFR and is released from the receptor after activation.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Scripps Research Institute; Scripps Research Institute					NCI NIH HHS [R01-CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRITZLER MJ, 1994, MOL BIOL CELL, V5, P1043; GALCHEVA Z, UNPUB; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2836; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU HM, 1994, J BIOL CHEM, V269, P30069; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONSTANTINOV KN, UNPUB; KOTZIN BL, 1984, J IMMUNOL, V133, P2554; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROY LM, 1991, J CELL PHYSIOL, V146, P63, DOI 10.1002/jcp.1041460109; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU RY, 1994, J BIOL CHEM, V269, P25085	35	92	100	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1797	1802		10.1126/science.272.5269.1797	http://dx.doi.org/10.1126/science.272.5269.1797			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650580				2022-12-01	WOS:A1996UT11000046
J	Xu, DM; Nouraini, S; Field, D; Tang, SJ; Friesen, JD				Xu, DM; Nouraini, S; Field, D; Tang, SJ; Friesen, JD			An RNA-dependent ATPase associated with U2/U6 snRNAs in pre-mRNA splicing	NATURE			English	Article							SMALL NUCLEAR-RNA; YEAST; PROTEIN; SPLICEOSOME; MECHANISM; SUGGESTS; FIDELITY; PATHWAY; ROLES; U2	THE hydrolysis of ATP by a group of RNA dependent ATPases (DEAD/H proteins(1)) is required for spliceosome assembly, but not for the subsequent transesterification reactions(2). Little is known about the function of these ATPases in relation to the RNA conformational changes that occur in formation of active structures, in which U2/U6 small nuclear RNA (snRNA) interactions(3,4) are essential for splicing to take place, Using a synthetic lethal genetic screen, we have isolated four yeast splicing factors involved in U2/U6 snRNA interactions (D.X. et al., manuscript in preparation). The RNA-dependent ATPase activity associated with one such factor, the Slt22 protein, is stimulated preferentially by annealed U2/U6 snRNAs. Both mutant slt22-1 and U2 snRNA cause a reduction in stimulation, The slt22-1 mutation blocks splicing at or before the first step, resulting in the accumulation of an unusual complex which lacks U5 snRNA. Our results indicate that the U2/U6 snRNA interactions facilitated by Slt22 are also Involved in the interaction of U5 snRNA with tire spliceosome.	HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; Field DJ, 1996, GENE DEV, V10, P489, DOI 10.1101/gad.10.4.489; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; FULLERPACE FV, 1993, EMBO J, V12, P369; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAUBER J, IN PRESS EMBO J; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; Moore M., 1993, RNA WORLD, P303; Newman AJ, 1995, RNA, V1, P968; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TAM WY, 1993, P NATL ACAD SCI USA, V90, P10821; [No title captured]	25	70	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1996	381	6584					709	713		10.1038/381709a0	http://dx.doi.org/10.1038/381709a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649518				2022-12-01	WOS:A1996UR97900056
J	Ernst, M; Zametkin, AJ; Matochik, JA; Pascualvaca, D; Jons, PH; Hardy, K; Hankerson, JG; Doudet, DJ; Cohen, RM				Ernst, M; Zametkin, AJ; Matochik, JA; Pascualvaca, D; Jons, PH; Hardy, K; Hankerson, JG; Doudet, DJ; Cohen, RM			Presynaptic dopaminergic deficits in Lesch-Nyhan disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; F-18 DOPA; PARKINSONS-DISEASE; BRAIN; MODEL; BEHAVIOR; NEUROTRANSMITTERS; CARBIDOPA; MONKEYS	Background. Lesch-Nyhan disease is a rare, devastating, X-linked recessive disorder of purine synthesis. Patients present with hyperuricemia, choreoathetosis, dystonia, and aggressive and self-injurious behavior. Although the genetic and biochemical abnormalities have been identified, the causes of the neuropsychiatric syndrome remain unclear. Methods. We used positron-emission tomography to measure presynaptic accumulation of fluorodopa F 18 tracer in the dopaminergic regions of the brains of 12 patients with Lesch-Nyhan disease (age, 10 to 20 years) and 15 healthy controls (age, 12 to 23). The results were expressed as ratios of specific to nonspecific radioactive counts. A low ratio indicates decreased dopa decarboxylase activity and dopamine storage. Results. The fluorodopa F 18 ratio was significantly lower in the putamen (31 percent of control values), caudate nucleus (39 percent), frontal cortex (44 percent), and ventral tegmental complex (substantia nigra and ventral tegmentum; 57 percent) in the patients with Lesch-Nyhan disease than in the controls. Uptake of the tracer was abnormally low even in the youngest patients tested, and there was no overlap in the values between patients and controls. Conclusions. Patients with Lesch-Nyhan disease have abnormally few dopaminergic nerve terminals and cell bodies. The abnormality involves all dopaminergic pathways and is not restricted to the basal ganglia. These dopaminergic deficits are pervasive and appear to be developmental in origin, which suggests that they contribute to the characteristic neuropsychiatric manifestations of the disease. (C) 1996, Massachusetts Medical Society.	NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT ANESTHESIOL,BETHESDA,MD 20892; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of British Columbia	Ernst, M (corresponding author), NIMH,CEREBRAL METAB LAB,BLDG 36,CONVENT DR,MSC 4030,BETHESDA,MD 20892, USA.			Hardy, Kristina/0000-0002-5479-5043				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; ANDERSON LT, 1992, J AUTISM DEV DISORD, V22, P189, DOI 10.1007/BF01058150; ANDERSON LT, 1994, J AUTISM DEV DISORD, V24, P67, DOI 10.1007/BF02172213; BOYES BE, 1986, LIFE SCI, V39, P2243, DOI 10.1016/0024-3205(86)90403-0; BREESE GR, 1984, PHARMACOL BIOCHEM BE, V21, P459, DOI 10.1016/S0091-3057(84)80110-0; BROOKS DJ, 1990, ANN NEUROL, V28, P547, DOI 10.1002/ana.410280412; CASASBRUGE M, 1985, LANCET, V1, P991; DOUDET DJ, 1992, J NUCL MED, V33, P1383; DOUDET DJ, 1992, PSYCHIAT RES-NEUROIM, V45, P153, DOI 10.1016/0925-4927(92)90023-W; DUNNETT SB, 1989, BRAIN RES, V501, P401, DOI 10.1016/0006-8993(89)90659-8; FREEMAN TB, 1991, EXP NEUROL, V113, P344, DOI 10.1016/0014-4886(91)90025-8; GJEDDE A, 1986, SOC NEUROSCI, V12; GOLDSTEIN M, 1986, BRAIN RES, V367, P114, DOI 10.1016/0006-8993(86)91584-2; HARRIS J, 1991, SOC NEUROSCI, V17; HARRIS J, 1994, 41 ANN M AM AC CHILD, V10; HOLLINGSHEAD AB, 1958, SOCIAL CLASS MENTAL, P387; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JANKOVIC J, 1988, ANN NEUROL, V23, P466, DOI 10.1002/ana.410230507; JINNAH HA, 1994, J NEUROSCI, V14, P1164; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAKE CR, 1977, SCIENCE, V196, P905, DOI 10.1126/science.860124; LEENDERS KL, 1990, ARCH NEUROL-CHICAGO, V47, P1290, DOI 10.1001/archneur.1990.00530120034007; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; LLOYD KG, 1981, NEW ENGL J MED, V305, P1106, DOI 10.1056/NEJM198111053051902; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MCLELLAN CA, 1991, APPL RADIAT ISOTOPES, V42, P847; OLSON L, 1973, Z ANAT ENTWICKLUNGS, V139, P259, DOI 10.1007/BF00519968; Reich W., 1988, DIAGNOSTIC INTERVIEW; SAWLE GV, 1992, ANN NEUROL, V32, P609, DOI 10.1002/ana.410320503; SEMPLE WE, 1993, IMAGING DRUG ACTION, P297; SILANI V, 1994, EXP NEUROL, V128, P59, DOI 10.1006/exnr.1994.1113; SILVERSTEIN FS, 1985, NEUROLOGY, V35, P907, DOI 10.1212/WNL.35.6.907; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd; Thorndike R.L., 1986, STANFORD BINET INTEL; WATTS RWE, 1982, Q J MED, V201, P43; WECHSLER D, 1974, WISC 3 WECHSLER INTE; Wechsler D., 1981, WAIS R WECHSLER ADUL; WONG DF, 1992, SOC NEUROSCI, V18	39	134	138	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1568	1572		10.1056/NEJM199606133342403	http://dx.doi.org/10.1056/NEJM199606133342403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628337	Bronze			2022-12-01	WOS:A1996UP66300003
J	Ambros, IM; Zellner, A; Roald, B; Amann, G; Ladenstein, R; Printz, D; Gadner, H; Ambros, PF				Ambros, IM; Zellner, A; Roald, B; Amann, G; Ladenstein, R; Printz, D; Gadner, H; Ambros, PF			Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN NEURO-BLASTOMA; N-MYC AMPLIFICATION; ALPHA-SATELLITE DNA; GROWTH-FACTOR; INSITU HYBRIDIZATION; PARAFFIN SECTIONS; X-CHROMOSOME; FACTOR-BETA; SHORT ARM; SEQUENCE	Background. Neuroblastoma is a heterogeneous disease, with manifestations ranging from spontaneous regression to lethal spread. Sometimes the tumor spontaneously differentiates toward a benign ganglioneuroma (maturing neuroblastoma). The prognosis is frequently related to ploidy, deletions in the short arm of chromosome 1, and amplifications of the N-myc oncogene. Maturing neuroblastomas consist of both neuronal cells and Schwann cells. We investigated the genetic composition of both cell types in maturing neuroblastomas, to determine the relation between genetic abnormalities and maturation. Methods. We studied 20 maturing and mature neuroblastomas by in situ hybridization to count the chromosomes and evaluate possible deletions in the short arm of chromosome 1 in neuronal and Schwann cells. The DNA content of the cells was measured by flow cytometry. Results. Neuroblastic and ganglionic cells showed aberrations in the number of chromosomes. In situ hybridization and flow cytometry demonstrated near-triploidy in 18 of 19 tumors and pentaploidy in the remaining tumor. The Schwann cells in all 20 neuroblastomas contained normal numbers of chromosomes. In 18 tumors studied, there were no chromosome 1 deletions in either type of cell. Conclusions. The Schwann cells in maturing neuroblastomas differ genetically from the neuronal cells. The normal number of chromosomes in Schwann cells and the abnormal number in neuroblastic and ganglionic cells suggest that Schwann cells are a reactive population of normal cells that invade the neuroblastoma. Near-triploidy of neuroblastoma cells and intact chromosome 1 are presumably genetic prerequisites for spontaneous organoid maturation, because we found no diploidy or chromosome 1 deletions in the neuronal cells of spontaneously maturing neuroblastormas. (C) 1996, Massachusetts Medical Society.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN PATHOL,VIENNA,AUSTRIA; ULLEVAL UNIV HOSP,DEPT PATHOL,OSLO,NORWAY	Saint Anna Children's Hospital; University of Vienna; University of Oslo			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211				AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BRESSLER JP, 1985, BRAIN RES, V344, P249, DOI 10.1016/0006-8993(85)90802-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; DANGIO GJ, 1971, LANCET, V1, P1046; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DEVILEE P, 1988, Genomics, V3, P1, DOI 10.1016/0888-7543(88)90151-6; EVANS AE, 1980, CANCER, V45, P833, DOI 10.1002/1097-0142(19800301)45:5<833::AID-CNCR2820450502>3.0.CO;2-U; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GIANNAKUDIS J, 1987, CYTOGENET CELL GENET, V46, P619; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; HAAS D, 1988, CANCER, V62, P818, DOI 10.1002/1097-0142(19880815)62:4<818::AID-CNCR2820620430>3.0.CO;2-K; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HEIDEN T, 1991, CYTOMETRY, V12, P614, DOI 10.1002/cyto.990120705; HOPMAN AHN, 1991, MODERN PATHOL, V4, P503; JABS EW, 1984, P NATL ACAD SCI-BIOL, V81, P4884, DOI 10.1073/pnas.81.15.4884; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KANEKO Y, 1987, CANCER RES, V47, P311; KOGNER P, 1993, CANCER RES, V53, P2044; Kushner BH, 1996, J CLIN ONCOL, V14, P373, DOI 10.1200/JCO.1996.14.2.373; LEMKE GE, 1984, J NEUROSCI, V4, P75; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LIM R, 1990, DEV BIOL, V137, P444, DOI 10.1016/0012-1606(90)90269-O; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MATTHAY KK, 1989, J CLIN ONCOL, V7, P236, DOI 10.1200/JCO.1989.7.2.236; MITELMAN F, 1994, CATALOG CHROMOSOME A; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1986, EXP CELL BIOL, V54, P287; STOCK C, 1993, GENE CHROMOSOME CANC, V6, P1, DOI 10.1002/gcc.2870060103; STOCK C, 1994, GENE CHROMOSOME CANC, V11, P40, DOI 10.1002/gcc.2870110107; STREHL S, 1993, CYTOGENET CELL GENET, V63, P24, DOI 10.1159/000133494; TAYLOR SR, 1988, CANCER, V62, P749, DOI 10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W; TSOKOS M, 1987, AM J PATHOL, V128, P484; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0	53	177	179	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1505	1511		10.1056/NEJM199606063342304	http://dx.doi.org/10.1056/NEJM199606063342304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618605				2022-12-01	WOS:A1996UN79900004
J	Jiang, W; Babyak, M; Krantz, DS; Waugh, RA; Coleman, RE; Hanson, MM; Frid, DJ; McNulty, S; Morris, JJ; OConnor, CM; Blumenthal, JA				Jiang, W; Babyak, M; Krantz, DS; Waugh, RA; Coleman, RE; Hanson, MM; Frid, DJ; McNulty, S; Morris, JJ; OConnor, CM; Blumenthal, JA			Mental stress-induced myocardial ischemia and cardiac events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; STABLE ANGINA-PECTORIS; SEGMENT DEPRESSION; PROGNOSTIC VALUE; SILENT ISCHEMIA; HEART-DISEASE; DAILY LIFE; INFARCTION; EXERCISE; ANGIOGRAPHY	Objective.-To assess the clinical significance of mental stress-induced myocardial ischemia in patients with coronary artery disease (CAD). Design and Setting.-Cohort study in outpatients in a tertiary care teaching hospital assessed at baseline and followed up for up to 5 years. Subjects.-A total of 126 volunteer patients (112 men, 14 women; mean age, 59 years) with documented CAD and exercise-induced myocardial ischemia. Outcome Measures.-Patients underwent baseline mental stress and exercise testing using radionuclide ventriculography and 48-hour Holter monitoring. Patients were subsequently contacted by mailed questionnaires or telephone to document cardiac events, including death, nonfatal myocardial infarction, and cardiac revascularization procedures, Logistic regression and Cox proportional hazards models were used to examine the prognostic value of the ischemic measures after adjusting for such potential confounding factors as age, baseline left ventricular ejection fraction (LVEF), and history of myocardial infarction. Results.-Twenty-eight patients (22%) experienced at least 1 cardiac event, Baseline mental stress-induced ischemia was associated with significantly higher rates of subsequent cardiac events (odds ratio, 2.8; 95% confidence interval [CI], 1.0-7.7; P<.05), The LVEF change during mental stress was significantly related to event-free survival (risk ratio [RR], 2.4; 95% CI, 1.12-5.14; P=.02), controlling for age, history of prior myocardial infarction, and baseline LVEF. This relationship remained significant after controlling for electrocardiogram (ECG)-defined ischemia during exercise (RR, 2.2; 95% CI, 1.01-4.81; P<.05). The RR for EGG-defined ischemia during exercise testing was 1,9 (95% CI, 0.95-3.96; P=.07) and the RR for ambulatory ECG ischemia was 0.75 (95% CI, 0.35-1.64; P=.47). Conclusions.-The presence of mental stress-induced ischemia is associated with significantly higher rates of subsequent fatal and nonfatal cardiac events, independent of age, baseline LVEF, and previous myocardial infarction, and predicted events over and above exercise-induced ischemia, These data suggest that the relationship between psychological stress and adverse cardiac events may be mediated by the occurrence of myocardial ischemia.	DUKE UNIV,CTR LIVING,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PSYCHIAT & BEHAV SCI,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710; UNIFORMED SERV UNIV HLTH SCI,DEPT MED CLIN PSYCHOL,BETHESDA,MD 20814	Duke University; Duke University; Duke University; Duke University; Uniformed Services University of the Health Sciences - USA			Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049572, R01HL043028, R01HL047337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47337, HL 49572, HL 43028] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM RD, 1986, AM J CARDIOL, V58, P423, DOI 10.1016/0002-9149(86)90008-1; BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; BLUMENTHAL JA, 1987, APPL BEHAV MED HLTH, P3; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; CORBETT JR, 1981, CIRCULATION, V64, P535, DOI 10.1161/01.CIR.64.3.535; COX DR, 1972, J R STAT SOC B, V34, P187; DAKAK N, 1995, AM J CARDIOL, V76, P125, DOI 10.1016/S0002-9149(99)80043-5; DEANFIELD JE, 1984, LANCET, V2, P1001; DEANFIELD JE, 1983, LANCET, V2, P753; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; FRASURESMITH N, 1989, PSYCHOSOM MED, V51, P485, DOI 10.1097/00006842-198909000-00002; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; FULLER CM, 1981, ANN INTERN MED, V94, P734, DOI 10.7326/0003-4819-94-6-734; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; Gill JB, 1996, NEW ENGL J MED, V334, P65, DOI 10.1056/NEJM199601113340201; GOTTDIENER JS, 1994, J AM COLL CARDIOL, V24, P1645, DOI 10.1016/0735-1097(94)90169-4; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; IRONSON G, 1992, AM J CARDIOL, V70, P281, DOI 10.1016/0002-9149(92)90605-X; JAIN D, 1995, AM J CARDIOL, V76, P31, DOI 10.1016/S0002-9149(99)80796-6; JIANG W, 1995, AM J CARDIOL, V76, P350, DOI 10.1016/S0002-9149(99)80099-X; LEGAULT SE, 1995, AM J CARDIOL, V75, P1007, DOI 10.1016/S0002-9149(99)80713-9; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; MILLER TQ, 1994, J BEHAV MED, V17, P567, DOI 10.1007/BF01857598; NEWMAN GF, 1980, CIRCULATION, V62, P1204, DOI 10.1161/01.CIR.62.6.1204; PETERSON ED, 1995, CIRCULATION, V92, P272; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; STERN S, 1974, BRIT HEART J, V36, P481; TALIERCIO CP, 1988, MAYO CLIN PROC, V63, P573, DOI 10.1016/S0025-6196(12)64887-3; TAVAZZI L, 1990, ADV CARDIOL, V37, P53; Trauner Michael A., 1994, Annals of Behavioral Medicine, V16, P24; TZIVONI D, 1989, AM J CARDIOL, V63, P273, DOI 10.1016/0002-9149(89)90329-9; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; YEUNG AC, 1991, CIRCULATION, V83, P1598, DOI 10.1161/01.CIR.83.5.1598	38	252	260	3	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1651	1656		10.1001/jama.275.21.1651	http://dx.doi.org/10.1001/jama.275.21.1651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637138				2022-12-01	WOS:A1996UN25200027
J	Lecuit, T; Brook, WJ; Ng, M; Calleja, M; Sun, H; Cohen, SM				Lecuit, T; Brook, WJ; Ng, M; Calleja, M; Sun, H; Cohen, SM			Two distinct mechanisms for long-range patterning by decapentaplegic in the Drosophila wing	NATURE			English	Article							OPTOMOTOR-BLIND; GENE-EXPRESSION; MELANOGASTER; MORPHOGENESIS; THRESHOLDS; ACTIVIN; HOMOLOG	Secreted signalling molecules provide cells with positional information that organizes long-range pattern during the development of multicellular animals. Evidence is presented that localized expression of Decapentaplegic instructs cells about their position along the anterior-posterior axis of the Drosophila wing in two distinct ways. One mechanism is based on the local concentration of the secreted protein; the other is based on the ability of the cells to retain an instruction received at an earlier time when their progenitors were in close proximity to the signal. Both mechanisms are involved in axis formation.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV AUTONOMA MADRID, E-28029 MADRID, SPAIN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	European Molecular Biology Laboratory (EMBL); Autonomous University of Madrid; Academia Sinica - Taiwan			Cohen, Stephen M/G-9930-2011; Sun, Y. Henry/AAZ-7966-2021; Sun, Y. Henry/ABC-4614-2021	Cohen, Stephen M/0000-0003-2858-9163; Sun, Y. Henry/0000-0001-8279-5270				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DURINBORKOWSKI OA, 1995, DEV BIOL, V168, P689; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lawrence P. A., 1992, MAKING FLY GENETICS; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1990, GENETICS, V126, P91; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RAFTERY LA, 1995, GENETICS, V139, P241; SANICOLA M, 1995, GENETICS, V139, P745; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; WIERSDORFF V, IN PRESS DEVELOPMENT; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; ZECCA M, 1995, DEVELOPMENT, V121, P2265	44	559	565	4	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					387	393		10.1038/381387a0	http://dx.doi.org/10.1038/381387a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632795				2022-12-01	WOS:A1996UN47900041
J	[Anonymous]				[Anonymous]			How not to act on good advice	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					351	351						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632781				2022-12-01	WOS:A1996UN47900001
J	Matsumine, A; Ogai, A; Senda, T; Okumura, N; Satoh, K; Baeg, GH; Kawahara, T; Kobayashi, S; Okada, M; Toyoshima, K; Akiyama, T				Matsumine, A; Ogai, A; Senda, T; Okumura, N; Satoh, K; Baeg, GH; Kawahara, T; Kobayashi, S; Okada, M; Toyoshima, K; Akiyama, T			Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; IMMUNOELECTRON MICROSCOPY; SEPTATE JUNCTIONS; MEMBRANE-PROTEIN; GENE-PRODUCT; IDENTIFICATION; MUTATIONS; CHROMOSOME-5Q21; ASSOCIATION; CANCER	The adenomatous polyposis coli gene (APC) is mutated in familial adenomatous polyposis and in sporadic colorectal tumors, and its product binds to the adherens junction protein beta-catenin. Overexpression of APC blocks cell cycle progression, The APC-beta-catenin complex was shown to bind to DLG, the human homolog of the Drosophila discs large tumor suppressor protein, This interaction required the carboxyl-terminal region of APC and the DLG homology repeat region of DLG. APC colocalized with DLG at the lateral cytoplasm in rat colon epithelial cells and at the synapse in cultured hippocampal neurons. These results suggest that the APC-DLG complex may participate in regulation of both cell cycle progression and neuronal function.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT 1,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN; CTR ADULT DIS,OSAKA 537,JAPAN	Osaka University; Nagoya University; Osaka University			Baeg, Gyeong-Hun/A-2951-2008; Satoh, Kiyotoshi/M-3653-2017	Satoh, Kiyotoshi/0000-0001-6029-6534				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bartel PL, 1993, USING 2 HYBRID SYSTE, P153; BHAT RV, 1994, J NEUROSCI, V14, P3059; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MATSUMINE A, UNPUB; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SENDA T, UNPUB; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	36	399	410	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1020	1023		10.1126/science.272.5264.1020	http://dx.doi.org/10.1126/science.272.5264.1020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638125				2022-12-01	WOS:A1996UL61900048
J	Rubinfeld, B; Albert, I; Porfiri, E; Fiol, C; Munemitsu, S; Polakis, P				Rubinfeld, B; Albert, I; Porfiri, E; Fiol, C; Munemitsu, S; Polakis, P			Binding of GSK3 beta to the APC-beta-catenin complex and regulation of complex assembly	SCIENCE			English	Article							CYTOPLASMIC DOMAIN; GENE-PRODUCT; E-CADHERIN; MUTATIONS; IDENTIFICATION; PROTEIN; CHROMOSOME-5Q21; PHOSPHORYLATION; ASSOCIATION; ANTIBODIES	The adenomatous polyposis coli gene (APC) is mutated in most colon cancers. The APC protein binds lo the cellular adhesion molecule beta-catenin, which is a mammalian homolog of ARMADILLO, a component of the WINGLESS signaling pathway in Drosophila development. Here it is shown that when beta-catenin is present in excess, APC binds to another component of the WINGLESS pathway, glycogen synthase kinase 3 beta (GSK3 beta), a mammalian homolog of Drosophila ZESTE WHITE 3. APC was a good substrate for GSK3 beta in vitro, and the phosphorylation sites were mapped to the central region of APC. Binding of beta-catenin to this region was dependent on phosphorylation by GSK3 beta.	ONYX PHARMACEUT,RICHMOND,CA 94806; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Rubinfeld, Bonnee/0000-0001-9861-6775				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, UNPUB; MUNEMITSU S, 1995, P NATL ACAD SCI US, V92; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; WANG QM, 1994, ANAL BIOCHEM, V220, P397, DOI 10.1006/abio.1994.1356	30	1231	1277	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1023	1026		10.1126/science.272.5264.1023	http://dx.doi.org/10.1126/science.272.5264.1023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638126				2022-12-01	WOS:A1996UL61900049
J	Nkata, M				Nkata, M			Rupture of the uterus: A review of 32 cases in a general hospital in Zambia	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL MORTALITY				Nkata, M (corresponding author), MANSA GEN HOSP,POB 710156,MANSA,ZAMBIA.							CHIPHANGWI JD, 1992, E AFR MED J, V69, P675; FALEYIMU BL, 1990, TROP DOCT, V20, P188, DOI 10.1177/004947559002000425; SUNDARI TK, 1992, INT J HEALTH SERV, V22, P513, DOI 10.2190/91YH-A52T-AFBB-1LEA; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1204	1205						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634565				2022-12-01	WOS:A1996UL05800022
J	Rizzoli, R; Bonjour, JP				Rizzoli, R; Bonjour, JP			Pregnancy-associated osteoporosis	LANCET			English	Editorial Material							BONE MASS ACCUMULATION; LACTATION; DENSITY; WOMEN				Rizzoli, R (corresponding author), UNIV HOSP GENEVA,DIV CLIN PATHOPHYSIOL,WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,GENEVA,SWITZERLAND.							BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; COURTNEY AC, 1994, CALCIFIED TISSUE INT, V55, P55; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; DUNNE F, 1993, CLIN ENDOCRINOL, V39, P487, DOI 10.1111/j.1365-2265.1993.tb02398.x; GALLACHER SJ, 1994, EUR J ENDOCRINOL, V131, P369, DOI 10.1530/eje.0.1310369; KRITZSILVERSTEIN D, 1992, AM J EPIDEMIOL, V136, P1052, DOI 10.1093/oxfordjournals.aje.a116570; LAKHANPAL S, 1987, ANN INTERN MED, V106, P444, DOI 10.7326/0003-4819-106-3-444; MAILIS A, 1992, J RHEUMATOL, V19, P758; PECK WA, 1993, AM J MED, V94, P646; Smith R, 1995, QJM-MON J ASSOC PHYS, V88, P865; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060	12	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1274	1276		10.1016/S0140-6736(96)90932-0	http://dx.doi.org/10.1016/S0140-6736(96)90932-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622498				2022-12-01	WOS:A1996UK75800003
J	Meno, C; Saijoh, Y; Fujii, H; Ikeda, M; Yokoyama, T; Yokoyama, M; Toyoda, Y; Hamada, H				Meno, C; Saijoh, Y; Fujii, H; Ikeda, M; Yokoyama, T; Yokoyama, M; Toyoda, Y; Hamada, H			Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos	NATURE			English	Article							REVERSAL; GENE	EXAMPLES Of lateral asymmetry are often found in vertebrates, such as the heart being on the left side, but the molecular mechanism governing the establishment of this left-right (LR) handedness is unknown(1). A diffusible morphogen may determine L-R polarity(2), but a likely molecule has not so far been identified. Here we report on the gene lefty, a member of the transforming growth factor-beta family, which may encode a morphogen for L-R determination. Lefty protein contains the cysteine-knot motif(3) characteristic of this superfamily(4,5) and is secreted as a processed form of relative molecular mass 25K-32K. Surprisingly, lefty is expressed in the left half of gastrulating mouse embryos. This asymmetric expression is very transient and occurs just before the first sign of lateral asymmetry appears. In the mouse mutants iv and inv, which cause situs inversus, the sites of lefty expression are inverted, indicating that lefty is downstream of iv and inv. These results suggest that lefty may be involved in setting up L-R asymmetry in the organ systems of mammals.	TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; MBL CO LTD, INA LAB, INA, NAGANO 396, JAPAN; TOKYO WOMENS MED COLL, DEPT ANAT & DEV BIOL, SHINJUKU KU, TOKYO 162, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Tokyo Metropolitan Institute of Medical Science; Osaka University; Tokyo Women's Medical University; University of Tokyo			Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948; Saijoh, Yukio/0000-0002-7548-4789				BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1993, NATURE, V363, P303, DOI 10.1038/363303a0; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; HOGAN BLM, 1994, DEVELOPMENT, P53; Hummel K. P., 1959, Journal of Heredity, V50, P9; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SAIJOH Y, IN PRESS GENES CELLS; THEILER K, 1989, HOUSE MOUSE ATLAS EM, P40; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	18	366	378	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					151	155		10.1038/381151a0	http://dx.doi.org/10.1038/381151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610011				2022-12-01	WOS:A1996UK13900048
J	Kolde, G; Bachus, R; Ludolph, AC				Kolde, G; Bachus, R; Ludolph, AC			Skin involvement in amyotrophic lateral sclerosis	LANCET			English	Article								Background Patients with sporadic amyotrophic lateral sclerosis (ALS) show disorganised collagen and elastin of the dermis. We looked for inflammatory alterations to cutaneous blood vessels. Patients and findings Seven patients with sporadic ALS were investigated; five were confined to bed, but none had bedsores. Light and electron microscopy of skin showed an oedematous dermis with collagen fibrils of irregular diameter. Small blood vessels were characterised by duplicated basement membranes and deposition of beta-amyloid protein, the main component of the neuronal and non-neuronal amyloid deposits in Alzheimer's disease. These skin changes were seen in all degrees of disability, but none was found in age-matched and sex-matched controls. Interpretation The skin in ALS is characterised by a distinctive pattern of alterations of connective tissue and blood vessels. Examination of skin is an additional and easily accessible investigation which may help elucidate the pathogenesis of ALS.	HUMBOLDT UNIV BERLIN,DEPT NEUROL,D-10117 BERLIN,GERMANY	Humboldt University of Berlin	Kolde, G (corresponding author), HUMBOLDT UNIV BERLIN,DEPT DERMATOL,VIRCHOW CLIN,DEPT DERMATOL,D-13353 BERLIN,GERMANY.							CHARCOT JM, 1880, LECON MALADIES SYSTE, V2; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; DANIEL RK, 1981, ARCH PHYS MED REHAB, V62, P492; FURUKAWA T, 1976, LANCET, V1, P862; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KNIFFEN JC, 1969, NEUROLOGY, V19, P312; LUDOLPH AC, 1987, BRAIN, V110, P149, DOI 10.1093/brain/110.1.149; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; NORRIS FH, 1974, NEUROLOGY, V24, P721, DOI 10.1212/WNL.24.8.721; ONO S, 1994, J NEUROL NEUROSUR PS, V57, P94, DOI 10.1136/jnnp.57.1.94; ROY DN, 1990, TOXICANTS PLANT ORIG, P170; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6	12	48	48	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1226	1227		10.1016/S0140-6736(96)90737-0	http://dx.doi.org/10.1016/S0140-6736(96)90737-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622453				2022-12-01	WOS:A1996UJ59700012
J	Murphy, JJ				Murphy, JJ			Current practice and complications of temporary transvenous cardiac pacing	BRITISH MEDICAL JOURNAL			English	Article											Murphy, JJ (corresponding author), DARLINGTON MEM HOSP,DEPT MED,DARLINGTON DL3 6HX,DURHAM,ENGLAND.							ANDREWS R, 1992, BRIT HEART J, V68, P91; MURPHY JJ, 1995, BRIT J CLIN PRACT, V49, P126; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161	4	66	68	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1134	1134						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620131				2022-12-01	WOS:A1996UK06900025
J	Doyle, JJ; Hnatiuk, OW; Torrington, KG; Slade, AR; Howard, RS				Doyle, JJ; Hnatiuk, OW; Torrington, KG; Slade, AR; Howard, RS			Necessity of routine chest roentgenography after thoracentesis	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; THORACOCENTESIS	Objective: To determine the necessity of posteroanterior chest roentgenography for the identification of pneumothorax and other complications after thoracentesis. Design: Prospective cohort study. Setting: Tertiary care teaching hospital. Patients: 67 men and 43 women (mean age +/- SD, 62.4 +/- 13.2 years). Exclusion criteria included age younger than 18 years, concurrent pleural biopsy, ultrasound guidance, and use of mechanical ventilation. Measurements: 174 thoracenteses done between March 1991 and June 1993. Results: 2 hemothoraces (1.2%) occurred, and 8 patients had a total of 9 pneumothoraces (5.2%). The roentgenograms obtained immediately after the procedures identified 8 pneumothoraces; the other pneumothorax was seen incidentally on a delayed roentgenogram obtained 3 days later. Pneumothorax was suspected in 5 of the 8 cases, and tube thoracostomy was done in 4 of these 5 cases. Patients with unsuspected pneumothorax identified on the roentgenogram obtained immediately after the procedure did not receive treatment for their pneumothoraces. Univariate analysis showed that the variables that correlated significantly with pneumothorax were aspiration of air during the procedure (relative risk ratio, 12.3; 95% CI, 3.7 to 41.4), number of passes with the thoracentesis needle (relative risk ratio, 6.1; CI, 1.6 to 23.3), history of thoracic radiation therapy (relative risk ratio, 10.5; CI, 2.5 to 44.4), and operator suspicion of pneumothorax (relative risk ratio, 25.9; CI, 8.6 to 78.5). Conclusion: Among hospitalized patients with pleural effusions, we identified a subgroup of patients in whom the risk for pneumothorax is low enough (approximately 1%) with sufficiently minimal clinical consequences to justify the avoidance of about 60% of chest roentgenograms obtained after thoracentesis. These patients are clinically stable, have not previously received chest irradiation, had only one pass at thoracentesis attempted without the aspiration of any air, and give no other indication of pneumothorax.	WALTER REED ARMY MED CTR, PULM & CRIT CARE MED SERV, WASHINGTON, DC 20307 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA								BARTTER T, 1993, CHEST, V103, P1873, DOI 10.1378/chest.103.6.1873; BRANDSTETTER RD, 1994, HEART LUNG, V23, P67; COLLINS TR, 1987, CHEST, V91, P817, DOI 10.1378/chest.91.6.817; Gerardi D., 1994, Chest, V106, p83S; GROGAN DR, 1990, ARCH INTERN MED, V150, P873, DOI 10.1001/archinte.150.4.873; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; RAPTOPOULOS V, 1991, AM J ROENTGENOL, V156, P917, DOI 10.2214/ajr.156.5.2017951; ROTH BJ, 1991, ARCH INTERN MED, V151, P2095; SENEFF MG, 1986, CHEST, V90, P97, DOI 10.1378/chest.90.1.97; SOKOLOWSKI JW, 1989, AM REV RESPIR DIS, V140, P257, DOI 10.1164/ajrccm/140.1.257; SWINBURNE AJ, 1991, ARCH INTERN MED, V151, P2095, DOI 10.1001/archinte.1991.00400100147025; WALSHE ADP, 1992, THORAX, V47, P734, DOI 10.1136/thx.47.9.734	12	57	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					816	820		10.7326/0003-4819-124-9-199605010-00005	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610950				2022-12-01	WOS:A1996UG25400005
J	Peat, TS; Frank, EG; McDonald, JP; Levine, AS; Woodgate, R; Hendrickson, WA				Peat, TS; Frank, EG; McDonald, JP; Levine, AS; Woodgate, R; Hendrickson, WA			Structure of the UmuD' protein and its regulation in response to DNA damage	NATURE			English	Article							RECA-MEDIATED CLEAVAGE; MUTANT LEXA PROTEINS; ANOMALOUS DIFFRACTION; DEPENDENT CLEAVAGE; ESCHERICHIA-COLI; SOS MUTAGENESIS; AUTODIGESTION; POLYMERASE	FOR life to be sustained, mistakes in DNA repair must be tolerated when damage obscures the genetic information. In bacteria such as Escherichia coli, DNA damage elicits the well regulated 'SOS response' (reviewed in ref. 1). For the extreme case of damage that cannot be repaired by conventional enzymes, there are proteins that allow the replication of DNA through such lesions, but with a reduction in the fidelity of replication(2). Essential proteins in this mutagenic process are RecA, DNA polymerase III, UmuD, UmuD' and UmuC (umu: UV mutagenesis)(1-3). Regulation of this response involves a RecA-mediated self-cleavage of UmuD to produce UmuD'. To understand this system in more detail, we have determined the crystal structure of the E. coli UmuD' mutagenesis protein at 2.5 Angstrom resolution. Globular heads folded in an unusual beta-structure associate to form molecular dimers, and extended amino-terminal tails associate to produce crystallized filaments. The structure provides insight into the mechanism of the self-cleavage reaction that UmuD-like proteins undergo as part of the global SOS response(4-8).	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892	Columbia University; Columbia University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Peat, Thomas S/F-9817-2010	Peat, Thomas S/0000-0002-6488-0831; Woodgate, Roger/0000-0001-5581-4616				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; DEBAERDEMAEKER T, 1988, ACTA CRYSTALLOGR A, V44, P353, DOI 10.1107/S0108767388000017; EVANS R, 1990, VIA, V11, P134; FRIEDBERG EC, 1995, DNA REPAIR; GIMBLE FS, 1986, J MOL BIOL, V192, P39, DOI 10.1016/0022-2836(86)90462-6; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1993, J BACTERIOL, V175, P4939; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PEAT TS, IN PRESS PROTEINS; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; ROLAND KL, 1992, J MOL BIOL, V228, P395, DOI 10.1016/0022-2836(92)90829-9; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x	30	140	142	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					727	730		10.1038/380727a0	http://dx.doi.org/10.1038/380727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614470				2022-12-01	WOS:A1996UG82700056
J	Hegde, RS; Lingappa, VR				Hegde, RS; Lingappa, VR			Sequence-specific alteration of the ribosome-membrane junction exposes nascent secretory proteins to the cytosol	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; APOLIPOPROTEIN-B; ER MEMBRANE; TRANSLOCATION; POLYPEPTIDE; PROTEOLIPOSOMES; ENVIRONMENT; COMPLEX	Tight docking of the ribosome at the translocation channel ensures that nascent secretory proteins are shielded from the cytoplasm during transfer into the endoplasmic reticulum. Discrete pause transfer sequences mediate the transient stopping of translocation in certain proteins. Here we show that during a translocational pause, the junction between the ribosome and translocation channel is opened, exposing the nascent chain to the cytosol. While transient, this opening is sufficient to demonstrate macromolecular interactions between the translocating chain and molecules added to the cytosol, such as antibodies and site-specific proteases. Moreover, this opening is accompanied by alterations in the proteins that neighbor the nascent chain. These results demonstrate that specific sequences within a translocating nascent chain can elicit dramatic and reversible structural changes in the translocation machinery. Thus, the translocon is dynamic and can be regulated.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Hegde, RS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline; NIA NIH HHS [AG 02132] Funding Source: Medline; NIGMS NIH HHS [GM 07618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Sambrook J., 1989, MOL CLONING LAB MANU; SIEGEL V, 1995, CELL, V82, P167, DOI 10.1016/0092-8674(95)90301-1; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	30	66	66	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					217	228		10.1016/S0092-8674(00)81098-3	http://dx.doi.org/10.1016/S0092-8674(00)81098-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612274	Bronze			2022-12-01	WOS:A1996UG25500010
J	Gao, SJ; Kingsley, L; Hoover, DR; Spira, TJ; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Parry, P; Chang, Y; Moore, PS				Gao, SJ; Kingsley, L; Hoover, DR; Spira, TJ; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Parry, P; Chang, Y; Moore, PS			Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR VIRUS; AIDS; INFECTION; SYPHILIS; HIV; RESPONSES; PROTEINS; MEN	Background If Kaposi's sarcoma-associated herpesvirus (KSHV) is the cause of Kaposi's sarcoma, serologic evidence of infection should be present in patients before the disease develops. M Methods Using an immunoblot assay for two latent nuclear antigens of KSHV, we tested serum samples from homosexual male patients with the acquired immunodeficiency syndrome (AIDS) with and without Kaposi's sarcoma, HIV-infected men with hemophilia, HIV-seronegative blood donors, and HIV-seronegative patients with high titers of antibodies against Epstein-Barr virus (EBV). Serial serum samples obtained from patients with Kaposi's sarcoma before the diagnosis of the disease were tested for evidence of seroconversion. Results Of 40 patients with Kaposi's sarcoma, 32 (80 percent) were positive for antibodies against KSHV antigens by the immunoblot assay, as compared with only 7 of 40 homosexual men (18 percent) without Kaposi's sarcoma immediately before the onset of AIDS. Of 122 blood donors, 22 EBV-infected patients, and 20 HIV-infected men with hemophilia, none were seropositive. When studied by the immunoblot assay over a period of 13 to 103 months, 21 of the 40 patients with Kaposi's sarcoma (52 percent) seroconverted 6 to 75 months before the clinical appearance of Kaposi's sarcoma. The median duration of antibody seropositivity for KSHV-related latent nuclear antigens before the diagnosis of Kaposi's sarcoma was 33 months. Conclusions In most patients with Kaposi's sarcoma and AIDS, seroconversion to positivity for antibodies against KSHV-related nuclear antigens occurs before the clinical appearance of Kaposi's sarcoma. This supports the hypothesis that Kaposi's sarcoma results from infection with KSHV. (C) 1996, Massachusetts Medical Society.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10027; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15260; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,BALTIMORE,MD 21218; CTR DIS CONTROL & PREVENT,DIV AIDS SEXUALLY TRANSMITTED DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,TB LAB RES,NATL CTR INFECT DIS,ATLANTA,GA 30341; NORTHWESTERN UNIV,SCH MED,COMPREHENS AIDS CTR,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024	Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Northwestern University; University of California System; University of California Los Angeles	Gao, SJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,P&S 14-442,630 W 168TH ST,NEW YORK,NY 10032, USA.		Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022; Chang, Yuan/F-4146-2011; Gao, Shou-Jiang/B-8641-2012	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; Kingsley, Lawrence/0000-0002-7000-8556; Gao, Shou-Jiang/0000-0001-6194-1742	NIAID NIH HHS [U01-AI35040, U01-AI35039] Funding Source: Medline; PHS HHS [U64CCU210852-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035040, U01AI035039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams V, 1995, LANCET, V346, P1715, DOI 10.1016/S0140-6736(95)92887-1; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BOSHOFF C, 1995, LANCET, V345, P1043; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P186; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; GUPTA P, IN PRESS AIDS; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HICKS CB, 1987, ANN INTERN MED, V107, P946, DOI 10.7326/0003-4819-107-6-946_4; JOHNSON PDR, 1991, AIDS, V5, P419, DOI 10.1097/00002030-199104000-00010; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; Liebowitz David, 1993, P107; LIN JC, 1995, LANCET, V346, P1602; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; MILLER G, 1974, J INFECT DIS, V130, P187, DOI 10.1093/infdis/130.2.187; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PAGANO JS, 1995, ANTIVIRAL CHEMOTHERA, P155; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; RAHMAN MA, 1989, J INFECT DIS, V159, P472, DOI 10.1093/infdis/159.3.472; RANGAN SRS, 1977, J NATL CANCER I, V59, P165, DOI 10.1093/jnci/59.1.165; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; ROIZMAN B, 1995, NEW ENGL J MED, V332, P1227, DOI 10.1056/NEJM199505043321810; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SEIGNEURIN JM, 1987, INT J CANCER, V40, P349, DOI 10.1002/ijc.2910400311; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; ZALKA A, 1991, ANN INTERN MED, V114, P521, DOI 10.7326/0003-4819-114-6-521_2; ZURHAUSEN H, 1978, NATURE, V272, P373	44	482	494	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					233	241		10.1056/NEJM199607253350403	http://dx.doi.org/10.1056/NEJM199607253350403			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657239				2022-12-01	WOS:A1996UZ53200003
J	Cuvillier, O; Pirianov, G; Kleuser, B; Vanek, PG; Coso, OA; Gutkind, JS; Spiegel, S				Cuvillier, O; Pirianov, G; Kleuser, B; Vanek, PG; Coso, OA; Gutkind, JS; Spiegel, S			Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate	NATURE			English	Article							PROLIFERATION	CERAMIDE is an important regulatory participant of programmed cell death (apoptosis) induced by tumour-necrosis factor (TNF)-alpha and Fas ligand, members of the TNF superfamily(1-6). Conversely, sphingosine and sphingosine-1-phosphate, which are metabolites of ceramide, induce mitogenesis(7) and have been implicated as second messengers in cellular proliferation induced by platelet-derived growth factor and serum(8,9). Here we report that sphingosine-1-phosphate prevents the appearance of the key features of apoptosis, namely intranucleosomal DNA fragmentation and morphological changes, which result from increased concentrations of ceramide. Furthermore, inhibition of ceramide-mediated apoptosis by activation of protein kinase C results from stimulation of sphingosine kinase and the concomitant increase in intracellular sphingosine-l-phosphate. Finally sphingosine-1-phosphate not only stimulates the extracellular signal-regulated kinase (ERK) pathway(10), it counteracts the ceramide-induced activation of stress-activated protein kinase (SAPK/JNK). Thus, the balance between the intracellular levels of ceramide and sphingosine-1-phosphate and their regulatory effects on different family members of mitogen-activated protein kinases determines the fate of the cell.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; TREVIGEN INC,GAITHERSBURG,MD 20877; NIDR,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			CUVILLIER, Olivier/B-2567-2009; CUVILLIER, Olivier/S-1631-2019; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Gutkind, J. Silvio/0000-0002-5150-4482; Kleuser, Burkhard/0000-0002-1888-9595				BOMFELDT KE, 1995, J CELL BIOL, V130, P193; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUKE RC, 1992, CURRENT PROTOCOLS IM; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GULBINS E, 1995, IMMUNITY, V2, P1; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, CANCER RES, V54, P1707; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YATOMI T, 1995, ANAL BIOCHEM, V230, P315; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	30	1280	1330	2	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					800	803		10.1038/381800a0	http://dx.doi.org/10.1038/381800a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657285				2022-12-01	WOS:A1996UU35600064
J	Russell, RM				Russell, RM			Nutrition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Russell, RM (corresponding author), TUFTS UNIV,JEAN MAYER USDA HUMAN NUTR RES CTR AGING,BOSTON,MA 02111, USA.							BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; *DIET GUID ADV COM, 1996, REP DIET GUID ADV CO, P1; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; IRIBARREN C, 1995, NEW ENGL J MED, V333, P686, DOI 10.1056/NEJM199509143331102; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MORGANTI CM, 1995, MED SCI SPORT EXER, V27, P906; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461	16	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1828	1829		10.1001/jama.275.23.1828	http://dx.doi.org/10.1001/jama.275.23.1828			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642733				2022-12-01	WOS:A1996UQ15200032
J	Lohse, PA; Szostak, JW				Lohse, PA; Szostak, JW			Ribozyme-catalysed amino-acid transfer reactions	NATURE			English	Article							RNA	THE 'RNA world' hypothesis proposes an early stage in the evolution of life in which both genomic and catalytic functions were fulfilled by RNA(1). The evolution of RNA-catalysed protein synthesis would have been a necessary step in the transition from such an RNA world to modern protein-dominated biology, For this to have been possible, RNA must be capable of catalysing amide-bond formation using acylated carrier RNA substrates as amino-acid donors. We have used in vitro selection and evolution to isolate ribozymes with acyl transferase activity from a pool of random RNA sequences. One of these acyl transferases with a 5'-amino group transfers an amino acid to itself in a reaction that we propose to be analogous to peptidyl transfer on the ribosome.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHUNAG NM, 1971, BIOCHIM BIOPHYS ACTA, V228, P536, DOI 10.1016/0005-2787(71)90059-1; FAHNESTOCK S, 1970, BIOCHEMISTRY-US, V9, P2477, DOI 10.1021/bi00814a013; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; SYNETOS D, 1987, BIOCHIM BIOPHYS ACTA, V923, P275, DOI 10.1016/0304-4165(87)90014-6; ULANOVSKY L, 1990, NATURE, V343, P190, DOI 10.1038/343190a0; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	10	175	211	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					442	444		10.1038/381442a0	http://dx.doi.org/10.1038/381442a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632803				2022-12-01	WOS:A1996UN47900056
J	Shibuya, H; Yamaguchi, K; Shirakabe, K; Tonegawa, A; Gotoh, Y; Ueno, N; Irie, K; Nishida, E; Matsumoto, K				Shibuya, H; Yamaguchi, K; Shirakabe, K; Tonegawa, A; Gotoh, Y; Ueno, N; Irie, K; Nishida, E; Matsumoto, K			TAB1: An activator of the TAK1 MAPKKK in TGF-beta signal transduction	SCIENCE			English	Article							GENE	Transforming growth factor-beta (TGF-B) regulates many aspects of cellular function. A member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family, TAK1, was previously identified as a mediator in the signaling pathway of TGF-beta superfamily members. The yeast two-hybrid system has now revealed two human proteins, termed TAB1 and TAB2 (for TAK1 binding protein), that interact with TAK1. TAB1 and TAK1 were co-immunoprecipitated from mammalian cells. Overproduction of TAB1 enhanced activity of the plasminogen activator inhibitor 1 gene promoter, which is regulated by TGF-beta, and increased the kinase activity of TAK1. TAB1 may function as an activator of the TAK1 MAPKKK in TGF-beta signal transduction.	NAGOYA UNIV, FAC SCI, DEPT MOLEC BIOL, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; RES DEV CORP JAPAN, PRECURSORY RES EMBRYON SCI & TECHNOL, HIKARI, KYOTO 61902, JAPAN; HOKKAIDO UNIV, FAC PHARMACEUT SCI, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO UNIV, INST VIRUS RES, DEPT GENET & MOL BIOL, SAKYO KU, KYOTO 60601, JAPAN	Nagoya University; Japan Science & Technology Agency (JST); Hokkaido University; Kyoto University				Ueno, Naoto/0000-0002-8375-2317				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JOHNSON AD, 1994, GENE, V147, P223, DOI 10.1016/0378-1119(94)90070-1; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAGUCHI K, UNPUB	24	509	538	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1996	272	5265					1179	1182		10.1126/science.272.5265.1179	http://dx.doi.org/10.1126/science.272.5265.1179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638164				2022-12-01	WOS:A1996UM88900053
J	Annas, GJ; Caplan, A; Elias, S				Annas, GJ; Caplan, A; Elias, S			The politics of human-embryo research - Avoiding ethical gridlock	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118; UNIV PENN,CTR BIOETH,PHILADELPHIA,PA 19104; BAYLOR COLL MED,HOUSTON,TX 77030	Boston University; University of Pennsylvania; Pennsylvania Medicine; Baylor College of Medicine	Annas, GJ (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; CAMPBELL CS, 1995, HASTINGS CENT REP, V25, P44, DOI 10.2307/3562495; CARSON SA, 1995, CONTEMP OBSTET GYNEC, V40, P71; CHARO A, 1995, STANFORD LAW POLICY, V6, P2; COREA G, 1985, MOTHER MACHINE, P178; COWLEY G, 1995, NEWSWEEK        0612, P66; HEALY BP, 1995, J WOMENS HLTH, V4, P609; MORGAN D, 1995, WASH POST       1103, pA1; National Institute of Health, 1994, REP HUM EMBR RES PAN; NIEBUHR G, 1996, NY TIMES        0417, pA19; Purdum Todd S, 1996, N Y Times Web, pB10; ROBERTSON JA, 1995, HASTINGS CENT REP, V25, P37, DOI 10.2307/3562492; Schwartz John, 1994, WASH POST       0803	13	47	47	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1329	1332		10.1056/NEJM199605163342012	http://dx.doi.org/10.1056/NEJM199605163342012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UK880	8609955	Green Published			2022-12-01	WOS:A1996UK88000012
J	Williams, PT				Williams, PT			High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; DISTANCE RUNNERS; ALCOHOL INTAKE; UNITED-STATES; FOLLOW-UP; WOMEN; EXERCISE; PREMENOPAUSAL; SUBFRACTIONS	Background. Official guidelines from the Centers for Disease Control and Prevention assert that the majority of health benefits from physical activity are obtained by walking 2 miles (3.2 km) briskly most days of the week (the energy equivalent of running 8 to 12 km per week). The objective of our study was to examine the dose-response relation in women between risk factors for coronary heart disease, particularly the concentration of high-density lipoprotein (HDL) cholesterol, and vigorous exercise at levels that exceed the official guidelines. Methods. The number of kilometers run per week reported by 1837 female recreational runners in a national cross-sectional survey was compared with medical data provided by the women's physicians. Results. In these cross-sectional data, plasma HDL cholesterol concentrations were higher by an average (+/-SE) of 0.133+/-0.020 mg per deciliter (0.003+/-0.0005 mmol per liter) for every additional kilometer run per week, an amount nearly identical with that previously reported for men (0.136+/-0.006 mg per deciliter [0.004+/-0.0002 mmol per liter] per kilometer per week). Among women who ran less than 48 km per week, mean plasma HDL concentrations were significantly higher with each 16-km increment in distance. Women who ran more than 64 km per week had significantly higher mean concentrations of HDL cholesterol than did women who ran less than 48 km per week. They were also significantly more likely to have HDL cholesterol concentrations greater than 100, 90, or 80 mg per deciliter (2.6, 2.3, or 2.1 mmol per liter) than were women running less than 64 km per week. HDL cholesterol concentrations increased significantly in relation to the number of kilometers run per week in premenopausal women who were not using oral contraceptives and in postmenopausal women, whether they were receiving estrogen-replacement therapy or not. Conclusions. Substantial increases in HDL cholesterol concentrations were found in women who exercised at levels exceeding current guidelines; higher HDL cholesterol concentrations could provide added health benefits to these women.			Williams, PT (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BLDG 934,BERKELEY,CA 94720, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL045652, R01HL045652, R03HL055640] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45652, HL-55640] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, GUID EX TEST PRESCR; BLUMENTHAL JA, 1991, ARTERIOSCLER THROMB, V11, P912, DOI 10.1161/01.ATV.11.4.912; BROWNELL KD, 1982, CIRCULATION, V65, P477, DOI 10.1161/01.CIR.65.3.477; BRUNNER D, 1987, AM J CARDIOL, V59, P1271, DOI 10.1016/0002-9149(87)90903-9; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5; FULLER WA, 1987, MEASUREMENT ERROR MO, P4; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; HARTING GH, 1984, EXP AGING RES, V10, P13, DOI 10.1080/03610738408258535; HARTUNG GH, 1986, AM J CARDIOL, V58, P148, DOI 10.1016/0002-9149(86)90259-6; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; KAISERAUER S, 1989, MED SCI SPORT EXER, V21, P120; KRUMMEL D, 1993, P SOC EXP BIOL MED, V204, P123; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LaRosa J C, 1992, Womens Health Issues, V2, P102, DOI 10.1016/S1049-3867(05)80278-6; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LINDHEIM SR, 1994, OBSTET GYNECOL, V83, P167; LOKEY EA, 1989, INT J SPORTS MED, V10, P424, DOI 10.1055/s-2007-1024937; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Miller RG., 1986, ANOVA BASICS APPL ST; MOORE CE, 1983, METABOLISM, V32, P189, DOI 10.1016/0026-0495(83)90228-7; MORGAN DW, 1986, PHYSICIAN SPORTSMED, V14, P166, DOI 10.1080/00913847.1986.11709017; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PODL TR, 1994, METABOLISM, V43, P808, DOI 10.1016/0026-0495(94)90258-5; RAINVILLE S, 1984, INT J SPORTS MED, V5, P137, DOI 10.1055/s-2008-1025895; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SEIDELL JC, 1990, INT J EPIDEMIOL, V19, P303, DOI 10.1093/ije/19.2.303; STAMFORD BA, 1984, METABOLISM, V33, P585, DOI 10.1016/0026-0495(84)90053-2; SUTER E, 1992, J SPORT MED PHYS FIT, V32, P400; UPTON SJ, 1984, MED SCI SPORT EXER, V16, P67; WILLIAMS PT, 1982, JAMA-J AM MED ASSOC, V247, P2674, DOI 10.1001/jama.247.19.2674; WILLIAMS PT, 1992, ARTERIOSCLER THROMB, V12, P332, DOI 10.1161/01.ATV.12.3.332; WILLIAMS PT, 1993, ATHEROSCLEROSIS, V98, P251, DOI 10.1016/0021-9150(93)90134-G; WILLIAMS PT, 1994, METABOLISM, V43, P917, DOI 10.1016/0026-0495(94)90277-1; WILLIAMS PT, 1995, JAMA-J AM MED ASSOC, V274, P533, DOI 10.1001/jama.1995.03530070031016; WILLIAMS PT, 1994, CIRCULATION, V90, P471; Wood P D, 1977, Ann N Y Acad Sci, V301, P748, DOI 10.1111/j.1749-6632.1977.tb38244.x; 1995, MMWR-MORBID MORTAL W, V44, P105; 1995, MMWR-MORBID MORTAL W, V44, P113	41	129	131	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1298	1303		10.1056/NEJM199605163342004	http://dx.doi.org/10.1056/NEJM199605163342004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609947				2022-12-01	WOS:A1996UK88000004
J	Ames, R				Ames, R			Angioplasty for renal artery stenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ATHEROSCLEROTIC RENOVASCULAR DISEASE; PULMONARY-EDEMA; HYPERTENSION; INSUFFICIENCY; CAPTOPRIL; FAILURE				Ames, R (corresponding author), ST LUKES ROOSEVELT HOSP, DEPT MED, NEW YORK, NY 10025 USA.							DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DIAMOND JR, 1993, AM J KIDNEY DIS, V21, P328, DOI 10.1016/S0272-6386(12)80756-6; GRIM CE, 1981, ANN INTERN MED, V95, P439, DOI 10.7326/0003-4819-95-4-439; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; MAILLOUX LU, 1988, AM J MED, V84, P855, DOI 10.1016/0002-9343(88)90063-0; MISSOURIS CG, 1993, LANCET, V341, P1521, DOI 10.1016/0140-6736(93)90645-W; MIYAMORI I, 1988, AM J HYPERTENS, V1, P359, DOI 10.1093/ajh/1.4.359; *NIH NAT I DIAB DI, 1991, US REN DAT SYST 1991, P13; PEDERSEN TR, 1994, LANCET, V344, P1383; PICKERING TG, 1987, CIRCULATION, V76, P274; Pickering Thomas G., 1995, P2039; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; RIBSTEIN J, 1988, AM J HYPERTENS, V1, P239, DOI 10.1093/ajh/1.3.239; RIMMER JM, 1993, ANN INTERN MED, V118, P712, DOI 10.7326/0003-4819-118-9-199305010-00010; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; TOLLEFSON DFJ, 1991, J VASC SURG, V14, P327; TOTO RD, 1991, ANN INTERN MED, V115, P513, DOI 10.7326/0003-4819-115-7-513	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1476	1476		10.1001/jama.275.19.1476	http://dx.doi.org/10.1001/jama.275.19.1476			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622210				2022-12-01	WOS:A1996UJ93700016
J	Davis, GL				Davis, GL			Hepatitis C virus infection among health care workers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK-FACTORS; PERSONNEL				Davis, GL (corresponding author), UNIV FLORIDA,COLL MED,SECT HEPATOBILIARY DIS,GAINESVILLE,FL 32611, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; COOPER BW, 1992, INFECT CONT HOSP EP, V13, P82, DOI 10.1086/646477; DAVIS GL, 1994, GASTROENTEROL CLIN N, V23, P603; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; HOFMANN H, 1990, INFECTION, V18, P286, DOI 10.1007/BF01647006; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; MANIAN FA, 1992, ANN INTERN MED, V116, P345; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; SCHIFF ER, 1992, HEPATOLOGY, V16, P1300	11	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1474	1474		10.1001/jama.275.19.1474	http://dx.doi.org/10.1001/jama.275.19.1474			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622209				2022-12-01	WOS:A1996UJ93700015
J	Lifson, AR				Lifson, AR			Mosquitoes, models, and dengue	LANCET			English	Editorial Material											Lifson, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; GUBLER DJ, 1994, AM J TROP MED HYG, V50, P50, DOI 10.4269/ajtmh.1994.50.50; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; Horton R, 1996, LANCET, V347, P134, DOI 10.1016/S0140-6736(96)90333-5; LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; LLOYD LS, 1994, AM J TROP MED HYG, V50, P401, DOI 10.4269/ajtmh.1994.50.401; Organizacion Mundial de la Salud (OMS), 1995, DENGUE DENGUE HEMORR, V548; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; 1994, WKLY EPIDEMIOL REV, V69, P177	12	51	56	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1201	1202		10.1016/S0140-6736(96)90730-8	http://dx.doi.org/10.1016/S0140-6736(96)90730-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622446				2022-12-01	WOS:A1996UJ59700005
J	GeisterferLowrance, AAT; Christe, M; Conner, DA; Ingwall, JS; Schoen, FJ; Seidman, CE; Seidman, JG				GeisterferLowrance, AAT; Christe, M; Conner, DA; Ingwall, JS; Schoen, FJ; Seidman, CE; Seidman, JG			A mouse model of familial hypertrophic cardiomyopathy	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; MYOSIN HEAVY-CHAIN	A mouse model of familial hypertrophic cardiomyopathy (FHC) was generated by the introduction of an Arg(403)-->Gln mutation into the alpha cardiac myosin heavy chain (Mwc) gene. Homozygous alpha MHC(403/403) mice died 7 days after birth, and sedentary heterozygous alpha MHC(403/+) mice survived for 1 year. Cardiac histopathology and dysfunction in the alpha MHC(403/+) mice resembled human FHC. Cardiac dysfunction preceded histopathologic changes, and myocyte disarray, hypertrophy, and fibrosis increased with age. Young male alpha MHC(403/+) mice showed more evidence of disease than did their female counterparts. Preliminary results suggested that exercise capacity may have been compromised in the alpha MHC(403/+) mice. This mouse model may help to define the natural history of FHC.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute								CHRISTE M, UNPUB; CHRISTE ME, 1994, AM J PHYSIOL-HEART C, V267, pH2050, DOI 10.1152/ajpheart.1994.267.5.H2050; GEISTERFERLOWRA.AA, UNPUB; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; Seidman CE, 1995, MOL CARDIOVASCULAR M, P193; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEIS JH, 1994, CURRENT PROTOCOLS MO, pCH5; WYNNE J, 1992, HEART DISEASE TXB CA, P1394; ZHANG W, 1996, J EXP MED, V183, P1	18	410	423	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					731	734		10.1126/science.272.5262.731	http://dx.doi.org/10.1126/science.272.5262.731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614836				2022-12-01	WOS:A1996UJ05100054
J	Shah, NM; Groves, AK; Anderson, DJ				Shah, NM; Groves, AK; Anderson, DJ			Alternative neural crest cell fates are instructively promoted by TGF beta superfamily members	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; ACHAETE-SCUTE HOMOLOG-1; SMOOTH-MUSCLE CELL; CLONAL ANALYSIS; GROWTH-FACTORS; NEURONAL DIFFERENTIATION; NERVOUS-SYSTEM; MOUSE EMBRYO; LINEAGE; COMMITMENT	How growth factors influence the fate of multipotent progenitor cells is not well understood. Most hematopoietic growth factors act selectively as survival factors, rather than instructively as lineage determination signals. In the neural crest, neuregulin instructively promotes gliogenesis, but how alternative fates are determined is unclear. We demonstrate that bone morphogenic protein 2 (BMP2) induces the basic-helix-loop-helix protein MASH1 and neurogenesis in neural crest stem cells. In vivo, MASH1(+) cells are located near sites of BMPS mRNA expression. Some smooth muscle differentiation is also observed in BMP2. A related factor, transforming growth factor beta 1 (TGF beta 1), exclusively promotes smooth muscle differentiation. Like neuregulin, BMP2 and TGF beta 1 act instructively rather than selectively. The neural crest and hematopoietic systems may therefore utilize growth factors in different ways to generate cellular diversity.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute				Groves, Andrew/0000-0002-0784-7998	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BRONNERFRASER M, 1993, CURR OPIN GENET DEV, V3, P641, DOI 10.1016/0959-437X(93)90101-T; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVIS CB, 1994, CURR OPIN IMMUNOL, V6, P266, DOI 10.1016/0952-7915(94)90100-7; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DICKSON MC, 1993, DEVELOPMENT, V117, P625; DUPIN E, 1995, DEV BIOL, V168, P529, DOI 10.1006/dbio.1995.1100; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Horstadius S., 1950, NEURAL CREST; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; ITO K, 1993, DEV BIOL, V156, P191, DOI 10.1006/dbio.1993.1069; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KIRBY ML, 1987, PEDIATR RES, V21, P219, DOI 10.1203/00006450-198703000-00001; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KRANTZ SB, 1991, BLOOD, V77, P419; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MILLAN FA, 1991, DEVELOPMENT, V111, P131; NAKAMURA H, 1982, J EMBRYOL EXP MORPH, V70, P1; OGAWA M, 1993, BLOOD, V81, P2844; OWENS GK, 1995, PHYSIOL REV, V75, P487; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Sieber-Blum M., 1990, Comments on Developmental Neurobiology, V1, P225; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; SIMPSON P, 1995, NEURON, V15, P739, DOI 10.1016/0896-6273(95)90163-9; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STERN CD, 1991, DEVELOPMENT, V113, P207; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	74	675	707	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					331	343		10.1016/S0092-8674(00)81112-5	http://dx.doi.org/10.1016/S0092-8674(00)81112-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616889	Bronze			2022-12-01	WOS:A1996UK14000007
J	Maldonado, E; Shiekhattar, R; Sheldon, M; Cho, H; Drapkin, R; Rickert, P; Lees, E; Anderson, CW; Linn, S; Reinberg, D				Maldonado, E; Shiekhattar, R; Sheldon, M; Cho, H; Drapkin, R; Rickert, P; Lees, E; Anderson, CW; Linn, S; Reinberg, D			A human RNA polymerase II complex associated with SRB and DNA-repair proteins	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; GENE	WE report here the isolation of a human RNA polymerase II complex containing a subset of the basal transcription factors and the human homologues of the yeast SRB (for suppressors of RNA polymerase B) proteins(1-3). The complex contains transcriptional coactivators and increases the activation of transcription, In addition, some components of the RNA polymerase II complex participate in DNA repair.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; STANFORD UNIV,DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CHEM,PALO ALTO,CA 94304; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; UNIV CALIF BERKELEY,DEPT BIOCHEM,BERKELEY,CA 94720	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Berkeley			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERARD M, 1991, J BIOL CHEM, V266, P20940; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HWANG PI, 1995, FASEB J, V9, pA1398; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LESSMILLER SP, 1995, SCIENCE, V267, P1183; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OSSIPOW, 1995, CELL, V83, P137; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THOMPSON GM, 1995, P NATL ACAD SCI USA, V92, P4587; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0	31	306	314	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					86	89		10.1038/381086a0	http://dx.doi.org/10.1038/381086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609996				2022-12-01	WOS:A1996UJ05300063
J	Simske, JS; Kaech, SM; Harp, SA; Kim, SK				Simske, JS; Kaech, SM; Harp, SA; Kim, SK			LET-23 receptor localization by the cell junction protein LIN-7 during C-elegans vulval induction	CELL			English	Article							TUMOR SUPPRESSOR GENE; NEMATODE CAENORHABDITIS-ELEGANS; SEPTATE JUNCTIONS; MEMBRANE-PROTEIN; GUANYLATE KINASE; TYROSINE KINASE; DROSOPHILA; EXPRESSION; ENCODES; DISKS	In C. elegans, the anchor cell signal induces Pn.p cells to form the vulva by activating a conserved receptor tyrosine kinase pathway. lin-2 and lin-7 mutants exhibit a vulvaless phenotype similar to the phenotype observed when this signaling pathway is defective. We have found that LIN-7 is a cell junction-associated protein that binds to the LET-23 receptor tyrosine kinase. LET-23 is also localized to the cell junctions, and both LIN-2 and LIN-7 are required for this localization. LET-23 overexpression rescues the lin-2 or lin-7 vulvaless phenotype, suggesting that increased receptor density can compensate for mislocalization. These results suggest that proper localization of LET-23 receptor to the Pn.p cell junctions is required for signaling activity.			Simske, JS (corresponding author), STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043977] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM043977-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FEHON R, 1994, DEVELOPMENT, V103, P545; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FERGUSON EL, 1985, GENETICS, V110, P17; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1980, GENETICS, V96, P435; Hoskins R, 1996, DEVELOPMENT, V122, P97; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOGA M, 1995, DEVELOPMENT, V121, P2655; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wood WB, 1988, NEMATODE CAENORHABDI; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V	46	227	240	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					195	204		10.1016/S0092-8674(00)81096-X	http://dx.doi.org/10.1016/S0092-8674(00)81096-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612272	Bronze			2022-12-01	WOS:A1996UG25500008
J	Rimm, EB; Ascherio, A; Giovannucci, E; Spiegelman, D; Stampfer, MJ; Willett, WC				Rimm, EB; Ascherio, A; Giovannucci, E; Spiegelman, D; Stampfer, MJ; Willett, WC			Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOTAL DIETARY FIBER; FOOD FREQUENCY QUESTIONNAIRE; BLOOD-LIPIDS; PRODUCTS; FAT; MORTALITY; REPRODUCIBILITY; CHOLESTEROL; VALIDITY; CANCER	Objective.-To examine prospectively the relationship between dietary fiber and risk of coronary heart disease. Design.-Cohort study. Setting.-In 1986, a total of 43 757 US male health professionals 40 to 75 years of age and free from diagnosed cardiovascular disease and diabetes completed a detailed 131-item dietary questionnaire used to measure usual intake of total dietary fiber and specific food sources of fiber. Main Outcome Measure.-Fatal and nonfatal myocardial infarction (MI). Results.-During 6 years of follow-up, we documented 734 cases of MI (229 were fatal coronary heart disease). The age-adjusted relative risk (RR) for total MI was 0.59 (95% confidence interval [CI], 0.46 to 0.76) among men in the highest quintile of total dietary fiber intake (median, 28.9 g/d) compared with men in the lowest quartile (median, 12.4 g/d). The inverse association was strongest for fatal coronary disease (RR, 0.45; 95% CI, 0.28 to 0.72). After controlling for smoking, physical activity and other known nondietary cardiovascular risk factors, dietary saturated fat, vitamin E, total energy intake, and alcohol intake, the RRs were only modestly attenuated. A 10-g increase in total dietary fiber corresponded to an RR for total MI of 0.81 (95% CI, 0.70 to 0.93). Within the three main food contributors to total fiber intake (vegetable, fruit, and cereal), cereal fiber was most strongly associated with a reduced risk of total MI (RR, 0.71; 95% CI, 0.55 to 0.91 for each 10-g increase in cereal fiber per day). Conclusions.-Our results suggest an inverse association between fiber intake and MI. These results support current national dietary guidelines to increase dietary fiber intake and suggest that fiber, independent of fat intake, is an important dietary component for the prevention of coronary disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Rimm, EB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; ASCHERIO A, 1995, AM J EPIDEMIOL, V141, pS65; BURR ML, 1989, LANCET, V2, P757; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; HALLFRISCH J, 1995, AM J CLIN NUTR, V61, P379, DOI 10.1093/ajcn/61.2.379; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HOLLAND GWA, 1991, MCCANCE WIDDOWSONS C; HUMBLE CG, 1993, AM J PREV MED, V9, P197, DOI 10.1016/S0749-3797(18)30715-3; HUNNINGHAKE DB, 1994, AM J CLIN NUTR, V59, P1050, DOI 10.1093/ajcn/59.5.1050; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KROMHOUT D, 1982, LANCET, V2, P518; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARCKMANN P, 1990, ATHEROSCLEROSIS, V80, P227, DOI 10.1016/0021-9150(90)90030-M; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; PAUL AA, 1978, MCCANCE WIDDOWSONS C, P37; PROSKY L, 1985, J ASSOC OFF ANA CHEM, V68, P677; PROSKY L, 1984, J ASSOC OFF ANA CHEM, V67, P1044; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; RABEN A, 1994, AM J CLIN NUTR, V59, P1386, DOI 10.1093/ajcn/59.6.1386; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; Rose GA., 1982, WHO MONOGRAPH SERIES, V58; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROTHMANN K, 1986, MODERN EPIDEMIOLOGY; SMITH U, 1994, AM J CLIN NUTR, V59, p686S, DOI 10.1093/ajcn/59.3.686S; SUNDELL IB, 1993, HAEMOSTASIS, V23, P45; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; Trowell HC, 1981, W DIS THEIR EMERGENC; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316; Vollendorf Nicholas W., 1993, Journal of Food Composition and Analysis, V6, P203, DOI 10.1006/jfca.1993.1023; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; 1990, NIH903046 US DEP HLT; 1989, RECOMMENDED DIETARY; 1992, USDA HOME GARDEN B, V252	46	623	661	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					447	451		10.1001/jama.275.6.447	http://dx.doi.org/10.1001/jama.275.6.447			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627965				2022-12-01	WOS:A1996TU63800032
J	James, M				James, M			Isotretinoin for severe acne	LANCET			English	Article																			0	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1749	1750		10.1016/S0140-6736(96)90814-4	http://dx.doi.org/10.1016/S0140-6736(96)90814-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656912				2022-12-01	WOS:A1996UT39600016
J	Deng, HK; Liu, R; Ellmeier, W; Choe, S; Unutmaz, D; Burkhart, M; DiMarzio, P; Marmon, S; Sutton, RE; Hill, CM; Davis, CB; Peiper, SC; Schall, TJ; Littman, DR; Landau, NR				Deng, HK; Liu, R; Ellmeier, W; Choe, S; Unutmaz, D; Burkhart, M; DiMarzio, P; Marmon, S; Sutton, RE; Hill, CM; Davis, CB; Peiper, SC; Schall, TJ; Littman, DR; Landau, NR			Identification of a major co-receptor for primary isolates of HIV-1	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; MONONUCLEAR PHAGOCYTES; AIDS VIRUS; INFECTION; TROPISM; DOMAIN; PHENOTYPE; SYSTEM; BRAIN	Entry of HIV-1 into target cells requires cell-surface CD4 and additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T-cell lines was recently identified and named fusin. However, fusin does not promote entry of macrophage-tropic viruses, which are believed to be the key pathogenic strains in vivo. The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1 alpha and MIP-1 beta.	NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10016; ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV LOUISVILLE,SCH MED,JAMES GRAHAM BROWN CANC CTR,LOUISVILLE,KY 40207; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	New York University; Howard Hughes Medical Institute; New York University; Rockefeller University; Stanford University; University of Louisville; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Ellmeier, Wilfried/0000-0001-8192-8481				ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; COMELISSEN M, 1995, J VIROL, V69, P1810; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P936; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GAO JL, 1994, J BIOL CHEM, V269, P28539; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LIU ZQ, 1990, J VIROL, V64, P6148, DOI 10.1128/JVI.64.12.6148-6153.1990; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1990, J VIROL, V64, P5720; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; VEENSTRA J, 1995, CLIN INFECT DIS, V21, P556, DOI 10.1093/clinids/21.3.556; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	44	3115	3303	3	241	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					661	666		10.1038/381661a0	http://dx.doi.org/10.1038/381661a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649511				2022-12-01	WOS:A1996UR97900041
J	Olshausen, BA; Field, DJ				Olshausen, BA; Field, DJ			Emergence of simple-cell receptive field properties by learning a sparse code for natural images	NATURE			English	Article							CORTEX	THE receptive fields of simple cells in mammalian primary visual cortex can be characterized as being spatially localized, oriented(1-4) and bandpass (selective to structure at different spatial scales), comparable to the basis functions of wavelet transforms(5,6), One approach to understanding such response properties of visual neurons has been to consider their relationship to the statistical structure of natural images in terms of efficient coding(7-12), Along these lines, a number of studies have attempted to train unsupervised learning algorithms on natural images in the hope of developing receptive fields with similar properties(13-18), but none has succeeded in producing a full set that spans the image space and contains all three of the above properties. Here we investigate the proposal(8,12) that a coding strategy that maximizes sparseness is sufficient to account for these properties, We show that a learning algorithm that attempts to find sparse linear codes for natural scenes will develop a complete family of localized, oriented, bandpass receptive fields, similar to those found in the primary visual cortex, The resulting sparse image code provides a more efficient representation for later stages of processing because it possesses a higher degree of statistical independence among its outputs.	CORNELL UNIV,DEPT PSYCHOL,ITHACA,NY 14853; UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616	Cornell University; University of California System; University of California Davis			Field, David j/B-9211-2008					Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; BARROW HG, 1994, IEEE 1 INT C NEUR NE, V4, P115; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; DAUGMAN JG, 1989, IEEE T BIO-MED ENG, V36, P107, DOI 10.1109/10.16456; DAUGMAN JG, 1990, COMPUTATIONAL NEUROS, P403; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Field DJ, 1993, WAVELETS FRACTALS FO, P151; FOLDIAK P, 1990, BIOL CYBERN, V64, P165, DOI 10.1007/BF02331346; FYFE C, 1995, NETWORK-COMP NEURAL, V6, P333, DOI 10.1088/0954-898X/6/3/002; HANCOCK PJB, 1992, NETWORK-COMP NEURAL, V3, P61, DOI 10.1088/0954-898X/3/1/008; Harpur GF, 1996, NETWORK-COMP NEURAL, V7, P277, DOI 10.1088/0954-898X/7/2/007; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; INTRATOR N, 1992, NEURAL COMPUT, V4, P98, DOI 10.1162/neco.1992.4.1.98; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; LAW CC, 1994, P NATL ACAD SCI USA, V91, P7797, DOI 10.1073/pnas.91.16.7797; LINSKER R, 1988, COMPUTER         MAR, P105; LU ZL, 1996, 9615 U CAL IRV I MAT; Olshausen BA, 1996, NETWORK-COMP NEURAL, V7, P333, DOI 10.1088/0954-898X/7/2/014; PARKER AJ, 1988, J OPT SOC AM A, V5, P598, DOI 10.1364/JOSAA.5.000598; RUDERMAN DL, 1994, NETWORK-COMP NEURAL, V5, P517, DOI 10.1088/0954-898X/5/4/006; Sanger T. D., 1989, ADV NEURAL INFORMATI, V1, P11; SAUND E, 1995, NEURAL COMPUT, V7, P51, DOI 10.1162/neco.1995.7.1.51; Schmidhuber J, 1996, NEURAL COMPUT, V8, P773, DOI 10.1162/neco.1996.8.4.773; SRINIVASAN MV, 1982, PROC R SOC SER B-BIO, V216, P427, DOI 10.1098/rspb.1982.0085; VANHATEREN JH, 1992, NATURE, V360, P68, DOI 10.1038/360068a0; Zemel R, 1993, THESIS U TORONTO	30	3385	3606	21	300	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					607	609		10.1038/381607a0	http://dx.doi.org/10.1038/381607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637596				2022-12-01	WOS:A1996UQ65700051
J	Dobner, T; Horikoshi, N; Rubenwolf, S; Shenk, T				Dobner, T; Horikoshi, N; Rubenwolf, S; Shenk, T			Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor	SCIENCE			English	Article							LATE GENE-EXPRESSION; WILD-TYPE; DNA-BINDING; EARLY REGION-4; TRANSFORMED-CELLS; PROTEIN; SEQUENCE; ANTIGEN; DOMAIN; TRANSACTIVATION	The adenovirus E4orf6 protein is shown here to interact with the cellular tumor suppressor protein p53 and to block p53-mediated transcriptional activation. The adenovirus protein inhibited the ability of p53 to bind to human TAF(II)31, a component of transcription factor IID (TFIID). Earlier work demonstrated that the interaction of p53 with TAF(II)31 involves a sequence near the NH2-terminus of p53, whereas the E4orf6-p53 interaction occurs within amino acids 318 to 360 of p53. Thus, the E4orf6 protein interacts at a site on p53 distinct from the domain that binds to TAF(II)31 but nevertheless inhibits the p53-TAF(II)31 interaction.	PRINCETON UNIV, DEPT MOLEC BIOL, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA; UNIV REGENSBURG, INST MED MIKROBIOL & HYG, D-93042 REGENSBURG, GERMANY	Howard Hughes Medical Institute; Princeton University; University of Regensburg			Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178				BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KAO CC, 1990, VIROLOGY, V52, P456; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	39	256	263	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1470	1473		10.1126/science.272.5267.1470	http://dx.doi.org/10.1126/science.272.5267.1470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633237				2022-12-01	WOS:A1996UP89900044
J	Thorpe, S; Fize, D; Marlot, C				Thorpe, S; Fize, D; Marlot, C			Speed of processing in the human visual system	NATURE			English	Article							EVENT-RELATED POTENTIALS; FACES; PICTURES; RECOGNITION; TIME	How long does it take for the human visual system to process a complex natural image? Subjectively, recognition of familiar objects and scenes appears to be virtually instantaneous, but measuring this processing time experimentally has proved difficult. Behavioural measures such as reaction times can be used(1), but these include not only visual processing but also the time required for response execution. However, event-related potentials (ERPs) can sometimes reveal signs of neural processing well before the motor output(2). Here we use a go/no-go categorization task in which subjects have to decide whether a previously unseen photograph, flashed on for just 20 ms, contains an animal. ERP analysis revealed a frontal negativity specific to no-go trials that develops roughly 150 ms after stimulus onset. We conclude that the visual processing needed to perform this highly demanding task can be achieved in under 150 ms.			Thorpe, S (corresponding author), CTR RECH CERVEAU & COGNIT,UMR 5549,F-31062 TOULOUSE,FRANCE.		THORPE, Simon J/A-5661-2008; Fize, Denis/F-4525-2011	THORPE, Simon J/0000-0003-4997-3367; 				ALLISON T, 1994, CEREB CORTEX, V4, P544, DOI 10.1093/cercor/4.5.544; ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BARRETT SE, 1988, NEUROPSYCHOLOGIA, V26, P105, DOI 10.1016/0028-3932(88)90034-6; BARRETT SE, 1989, NEUROPSYCHOLOGIA, V27, P913, DOI 10.1016/0028-3932(89)90067-5; BARRETT SE, 1990, BRAIN COGNITION, V14, P201, DOI 10.1016/0278-2626(90)90029-N; BARRETT SE, 1990, BRAIN LANG, V38, P424, DOI 10.1016/0093-934X(90)90125-Z; BOBES MA, 1994, BRAIN COGNITION, V26, P1, DOI 10.1006/brcg.1994.1039; BULTHOFF HH, 1995, CEREB CORTEX, V5, P247, DOI 10.1093/cercor/5.3.247; CELEBRINI S, 1993, VISUAL NEUROSCI, V10, P811, DOI 10.1017/S0952523800006052; GEMBA DH, 1989, NEUROSCI LETT, V101, P263, DOI 10.1016/0304-3940(89)90543-0; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; HOLCOMB PJ, 1994, BRAIN COGNITION, V24, P259, DOI 10.1006/brcg.1994.1014; HUMMEL JE, 1992, PSYCHOL REV, V99, P480, DOI 10.1037/0033-295X.99.3.480; INTRAUB H, 1981, J EXP PSYCHOL HUMAN, V7, P604, DOI 10.1037/0096-1523.7.3.604; JEFFREYS DA, 1992, EXP BRAIN RES, V91, P340; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; ORAM MW, 1992, J NEUROPHYSIOL, V68, P70, DOI 10.1152/jn.1992.68.1.70; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; PRATARELLI ME, 1994, BRAIN COGNITION, V24, P137, DOI 10.1006/brcg.1994.1008; ROLLS ET, 1994, P ROY SOC B-BIOL SCI, V257, P9, DOI 10.1098/rspb.1994.0087; RUDELL AP, 1992, ELECTROEN CLIN NEURO, V83, P77, DOI 10.1016/0013-4694(92)90135-5; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; RUGG MD, 1995, J COGNITIVE NEUROSCI, V7, P209, DOI 10.1162/jocn.1995.7.2.209; SASAKI K, 1993, NEUROSCI RES, V18, P249, DOI 10.1016/0168-0102(93)90062-U; SEECK M, 1992, EXP BRAIN RES, V92, P338; THORPE SJ, 1989, CONNECTIONISM IN PERSPECTIVE, P63; VETTER T, 1995, CEREB CORTEX, V5, P261, DOI 10.1093/cercor/5.3.261	28	2355	2428	12	305	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					520	522		10.1038/381520a0	http://dx.doi.org/10.1038/381520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UP435	8632824				2022-12-01	WOS:A1996UP43500059
J	MacGregor, GA; Sever, PS				MacGregor, GA; Sever, PS			Salt - Overwhelming evidence but still no action: Can a consensus be reached with the food industry?	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; ETIOLOGY; KIDNEY; TRIAL		UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,LONDON W2 7PG,ENGLAND	Imperial College London	MacGregor, GA (corresponding author), ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							ANTONIOS TFT, IN PRESS LANCET; Cardiovascular Review Group Great Britain-Department of Health, 1994, NUTR ASP CARD DIS; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; DEWARDENER HE, 1990, CLIN SCI, V79, P193, DOI 10.1042/cs0790193; DEWARDENER HE, 1990, CLIN SCI, V79, P289, DOI 10.1042/cs0790289; FORTE JG, 1989, J HUM HYPERTENS, V3, P179; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; *ROWL CO, 1991, LIF FACTS SALT; SEVER PS, 1989, J HYPERTENS, V7, pS9, DOI 10.1097/00004872-198902001-00004; SINGER DRJ, 1995, HYPERTENSION, V25, P1042, DOI 10.1161/01.HYP.25.5.1042; UZODIKE VO, 1993, THESIS U LONDON LOND	14	64	68	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1287	1289		10.1136/bmj.312.7041.1287	http://dx.doi.org/10.1136/bmj.312.7041.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634621	Green Published			2022-12-01	WOS:A1996UM40400029
J	Field, SJ; Tsai, FY; Kuo, F; Zubiaga, AM; Kaelin, WG; Livingston, DM; Orkin, SH; Greenberg, ME				Field, SJ; Tsai, FY; Kuo, F; Zubiaga, AM; Kaelin, WG; Livingston, DM; Orkin, SH; Greenberg, ME			E2F-1 functions in mice to promote apoptosis and suppress proliferation	CELL			English	Article							TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; HUMAN MYC PROMOTER; RETINOBLASTOMA PROTEIN; CYCLIN-A; CELL-CYCLE; THYMIDINE KINASE; TRANS-ACTIVATION; S-PHASE; COMPLEX	Members of the E2F transcription factor family (E2F-1-E2F-5) are believed to be critical positive regulators of cell cycle progression in eukaryotes although the in vivo functions of the individual E2Fs have not been elucidated. Mice were generated that lack E2F-1 and, surprisingly, these mice develop and reproduce normally. However, E2F-1(-/-) mice exhibit a defect in T lymphocyte development leading to an excess of mature T cells due to a maturation stage-specific defect in thymocyte apoptosis. As E2F-1(-/-) mice age they exhibit a second phenotype marked by aberrant cell proliferation. These findings suggest that while certain members of the E2F family may positively regulate cell cycle progression, E2F-1 functions to regulate apoptosis and to suppress cell proliferation.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute			zubiaga, ana/S-3457-2019	zubiaga, ana/0000-0002-2132-9708; Field, Seth/0000-0002-8893-4806	NIDDK NIH HHS [DK49216] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK049216, P50DK049216] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KISIELOW P, 1991, ADV EXP MED BIOL, V292, P31; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OWEN JJT, 1988, IMMUNOLOGY, V63, P639; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P104; SALA A, 1994, CANCER RES, V54, P1402; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHI YF, 1991, J IMMUNOL, V146, P3340; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yang Xiao-He, 1995, Gene Expression, V4, P195	64	696	709	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					549	561		10.1016/S0092-8674(00)81255-6	http://dx.doi.org/10.1016/S0092-8674(00)81255-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653790	Bronze			2022-12-01	WOS:A1996UM41500012
J	Glass, DJ; Bowen, DC; Stitt, TN; Radziejewski, C; Bruno, J; Ryan, TE; Gies, DR; Shah, S; Mattsson, K; Burden, SJ; DiStefano, PS; Valenzuela, DM; DeChiara, TM; Yancopoulos, GD				Glass, DJ; Bowen, DC; Stitt, TN; Radziejewski, C; Bruno, J; Ryan, TE; Gies, DR; Shah, S; Mattsson, K; Burden, SJ; DiStefano, PS; Valenzuela, DM; DeChiara, TM; Yancopoulos, GD			Agrin acts via a MuSK receptor complex	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CULTURED MUSCLE-CELLS; ACETYLCHOLINE-RECEPTORS; NGF; PHOSPHORYLATION; AGGREGATION; COMPONENTS; PROTEINS; NEURONS; SURFACE	Formation of the neuromuscular junction depends upon reciprocal inductive interactions between the developing nerve and muscle, resulting in the precise juxtaposition of a differentiated nerve terminal with a highly specialized patch on the muscle membrane, termed the motor endplate. Agrin is a nerve-derived factor that can induce molecular reorganizations at the motor endplate, but the mechanism of action of agrin remains poorly understood. MuSK is a receptor tyrosine kinase localized to the motor endplate, seemingly well positioned to receive a key nerve-derived signal. Mice lacking either agrin or MUSK have recently been generated and exhibit similarly profound defects in their neuromuscular junctions. Here we demonstrate that agrin acts via a receptor complex that includes MuSK as well as a myotube-specific accessory component.	NYU,MED CTR,SKIRBALL INST,MOL NEUROBIOL PROGRAM,NEW YORK,NY 10016	New York University	Glass, DJ (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Glass, David/AAI-3910-2021	Burden, Steven/0000-0002-3550-6891	NINDS NIH HHS [R01 NS036193, R01 NS036193-01A1S1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036193] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BARBACID M, 1993, ONCOGENE, V8, P2033; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BURDEN SJ, 1995, DEV BIOL, V6, P59; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; PENG HB, 1991, NEURON, V6, P237; QU Z, 1994, J NEUROSCI, V14, P6834; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661	47	548	572	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					513	523		10.1016/S0092-8674(00)81252-0	http://dx.doi.org/10.1016/S0092-8674(00)81252-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653787	hybrid			2022-12-01	WOS:A1996UM41500009
J	Ebert, M; Grossmann, T; Heil, W; Otten, WE; Surkau, R; Leduc, M; Bachert, P; Knopp, MV; Schad, LR; Thelen, M				Ebert, M; Grossmann, T; Heil, W; Otten, WE; Surkau, R; Leduc, M; Bachert, P; Knopp, MV; Schad, LR; Thelen, M			Nuclear magnetic resonance imaging with hyperpolarised helium-3	LANCET			English	Article								Background Magnetic resonance imaging (MRI) relies on magnetisation of hydrogen nuclei (protons) of water molecules in tissue as source of the signal. This technique has been valuable for studying tissues that contain significant amounts of water, but biological settings with low proton content, notably the lungs, are difficult to image. We report use of spin-polarised helium-3 for lung MRI. Methods A volunteer inhaled hyperpolarised He-3 to fill the lungs, which were imaged with a conventional MRI detector assembly. The nuclear spin polarisation of helium, and other noble gases, can be greatly enhanced by laser optical pumping and is about 10(5) times larger than the polarisation of water protons, This enormous gain in polarisation easily overcomes the loss in signal due to the lower density of the gas. Findings The in-vivo experiment was done in a whole-body MRI scanner. The He-3 image showed clear demarcation of the lung against diaphragm, heart, chest wall, and blood vessels (which gave no signal). The signal intensity within the air spaces was greatest in lung regions that are preferentially ventilated in the supine position; less well ventilated areas, such as the apices, showed a weaker signal. Interpretation MRI with hyperpolarised He-3 gas could be an alternative to established nuclear medicine methods, The ability to image air spaces offers the possibility of investigating physiological and pathophysiological processes in pulmonary ventilation and differences in its regional distribution.	UNIV MAINZ,INST PHYS,D-55099 MAINZ,GERMANY; UNIV MAINZ,KLIN POLIKLIN RADIOL,D-55099 MAINZ,GERMANY; ECOLE NORMALE SUPER,F-75231 PARIS,FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM,FORSCH SCHWERPUNKT RADIOL DIAGNOST & THERAPIE,HEIDELBERG,GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Helmholtz Association; German Cancer Research Center (DKFZ)								ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; AMINOFF CG, 1989, REV PHYS APPL, V24, P827, DOI 10.1051/rphysap:01989002408082700; BECKER J, 1994, NUCL INSTRUM METH A, V346, P45, DOI 10.1016/0168-9002(94)90687-4; ECKERT G, 1992, NUCL INSTRUM METH A, V320, P53, DOI 10.1016/0168-9002(92)90769-Z; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HEIL W, 1995, PHYS LETT A, V201, P337, DOI 10.1016/0375-9601(95)00243-V; HEIL W, IN PRESS J NEUTRON R; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; SAAM B, 1995, PHYS REV A, V52, P862, DOI 10.1103/PhysRevA.52.862; WEST JB, 1971, LANCET, V1, P839; WEST JB, 1972, J APPL PHYSIOL, V32, P332, DOI 10.1152/jappl.1972.32.3.332	11	168	175	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1297	1299		10.1016/S0140-6736(96)90940-X	http://dx.doi.org/10.1016/S0140-6736(96)90940-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622506				2022-12-01	WOS:A1996UK75800011
J	Wolinsky, SM; Korber, BTM; Neumann, AU; Daniels, M; Kunstman, KJ; Whetsell, AJ; Furtado, MR; Cao, YZ; Ho, DD; Safrit, JT; Koup, RA				Wolinsky, SM; Korber, BTM; Neumann, AU; Daniels, M; Kunstman, KJ; Whetsell, AJ; Furtado, MR; Cao, YZ; Ho, DD; Safrit, JT; Koup, RA			Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; PRIMARY HIV-1 INFECTION; BIOLOGICAL PHENOTYPE; SYNDROME AIDS; CLONAL POOLS; POPULATIONS; TRANSMISSION; PROGRESSION; SEQUENCES; DIVERSITY	The rate of progression to disease varies considerably among individuals infected with human immunodeficiency virus-type 1 (HIV-1). Analyses of semiannual blood samples obtained from six infected men showed that a rapid rate of CD4 T cell loss was associated with relative evolutionary stasis of the HIV-1 quasispecies virus population. More moderate rates of CD4 T cell loss correlated with genetic evolution within three of four subjects. Consistent with selection by the immune constraints of these subjects, amino acid changes were apparent within the appropriate epitopes of human leukocyte antigen class I-restricted cytotoxic T lymphocytes. Thus, the evolutionary dynamics exhibited by the HIV-1 quasispecies virus populations under natural selection are compatible with adaptive evolution.	LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA; AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; ROCKEFELLER UNIV, NEW YORK, NY 10016 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Rockefeller University	Wolinsky, SM (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Wolinsky, Steven/B-2893-2012	Korber, Bette/0000-0002-2026-5757; Wolinsky, Steven/0000-0002-9625-6697; Furtado, Manohar/0000-0001-6016-1357	NIAID NIH HHS [AI32535, AI35522, AI45218] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035522, R37AI035522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1995, J VIROL, V69, P1001, DOI 10.1128/JVI.69.2.1001-1012.1995; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASJO B, 1986, LANCET, V2, P660; AUTRAN B, 1996, 10 C CEUT GARD, P118; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BUCHBINDER S, 1994, AIDS, V8, P393; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELATORRE JC, 1990, J VIROL, V64, P664, DOI 10.1128/JVI.64.2.664-671.1990; DELWART E, UNPUB; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; EIGEN M, 1987, COLD SPRING HARB SYM, V52, P307, DOI 10.1101/SQB.1987.052.01.036; Eigen M., 1988, RNA GENETICS, V3, P211; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Felsenstein J, 1993, PHYLIP PHYLOGENY INT; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; Ganeshan S., UNPUB; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GRASSBERGER P, 1983, PHYS LETT A, V97, P227, DOI 10.1016/0375-9601(83)90753-3; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HENIKOFF S, 1991, NEW BIOL, V3, P1148; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; IVERSEN AKN, 1995, J VIROL, V69, P5743, DOI 10.1128/JVI.69.9.5743-5753.1995; JOHNSON RP, 1993, J VIROL, V67, P438, DOI 10.1128/JVI.67.1.438-445.1993; KELT I, 1994, J INFECT DIS, V169, P1236; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KORBER B, UNPUB; KORBER BTM, 1995, NATURE, V378, P242, DOI 10.1038/378242a0; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, UNPUB; KUIKEN CL, 1992, J VIROL, V66, P4622, DOI 10.1128/JVI.66.7.4622-4627.1992; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LANDE R, 1985, P NATL ACAD SCI USA, V82, P7641, DOI 10.1073/pnas.82.22.7641; LEARMONT J, 1993, LANCET, V341, P113; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; MULLINS J, 1994, 9 C CENT GENT GARD, P77; MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496, DOI 10.1097/00042560-199504120-00010; Myers G, 1994, HUMAN RETROVIRUSES A; NEWMAN CM, 1985, NATURE, V315, P400, DOI 10.1038/315400a0; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; NOWAK MA, 1995, NATURE, V375, P534; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; Renyi A., 1970, PROBABILITY THEORY; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SAAG MS, 1991, J EXP MED, V172, P1055; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; SCHRAGER LK, 1994, AIDS, V8, P895; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; STEINHAUER DA, 1989, J VIROL, V63, P2063, DOI 10.1128/JVI.63.5.2063-2071.1989; STEINHAUER DA, 1989, J VIROL, V63, P2072, DOI 10.1128/JVI.63.5.2072-2080.1989; SWOFFEND D, 1988, THESIS U ILLINOIS UR; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; WAINHOBSON S, 1995, NATURE, V373, P102, DOI 10.1038/373102a0; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY S, UNPUB; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; WOLINSKY SM, 1994, 9 C CENT GENT GARD, P95; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; WRIGHT S, 1977, EVOLUTION GENETICS P, V1; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	94	495	512	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					537	542		10.1126/science.272.5261.537	http://dx.doi.org/10.1126/science.272.5261.537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614801				2022-12-01	WOS:A1996UG82600041
J	Presti, JC				Presti, JC			Estrogen therapy for prostate carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CANCER				Presti, JC (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT UROL,SAN FRANCISCO,CA 94143, USA.							BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; HENRIKSSON P, 1986, BRIT MED J, V293, P413, DOI 10.1136/bmj.293.6544.413; JOHANSSON JE, 1991, J UROLOGY, V145, P519, DOI 10.1016/S0022-5347(17)38385-4; 1984, NEW ENGL J MED, V311, P1281	4	5	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1153	1153		10.1001/jama.275.15.1153	http://dx.doi.org/10.1001/jama.275.15.1153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609673				2022-12-01	WOS:A1996UE62500010
J	Deckert, T; Yokoyama, H; Mathiesen, E; Ronn, B; Jensen, T; FeldtRasmussen, B; BorchJohnsen, K; Jensen, JS				Deckert, T; Yokoyama, H; Mathiesen, E; Ronn, B; Jensen, T; FeldtRasmussen, B; BorchJohnsen, K; Jensen, JS			Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article							INCIPIENT NEPHROPATHY; DENSITY-LIPOPROTEIN; BLOOD-PRESSURE; RISK-FACTORS; MICROALBUMINURIA; MORTALITY; MELLITUS; HYPERTENSION; PREVALENCE; NIDDM	Objective-To examine whether slightly elevated urinary albumin excretion precedes development of atherosclerotic vascular disease in patients with insulin dependent diabetes independently of conventional atherogenic risk factors and of diabetic nephropathy. Design-Cohort study with 11 year follow up. Setting-Diabetes centre in Denmark. Subjects-259 patients aged 19-51 with insulin dependent diabetes of 6-34 years' duration and without atherosclerotic vascular disease or diabetic nephropathy at baseline. Main outcome measures-Baseline variables: urinary albumin excretion, blood pressure, smoking habits, and serum concentrations of total cholesterol, high density lipoprotein cholesterol, sialic acid, and von Willebrand factor. End point: atherosclerotic vascular disease assessed by death certificates, mailed questionnaires, and hospital records. Results-Thirty patients developed atherosclerotic vascular disease during follow up of 2457 person years. Elevated urinary albumin excretion was significantly predictive of atherosclerotic vascular disease (hazard ratio 1.06 (95% confidence interval 1.02 to 1.18) per 5 mg increase in 24 hour urinary albumin excretion, P=0.002). Predictive effect was independent of age; sex; blood pressure; smoking; serum concentrations of total cholesterol, high density lipoprotein cholesterol, sialic acid, and von Willebrand factor; level of haemoglobin A(1c); insulin dose; duration of diabetes; and diabetic nephropathy (hazard ratio 1.04 (1.01 to 1.08) per 5 mg increase in 24 hour urinary albumin excretion, P=0.03). Conclusion-Slightly elevated urinary albumin excretion independently predicted atherosclerotic vascular disease in patients with insulin dependent diabetes.	STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK	Steno Diabetes Center				Feldt-Rasmussen, Bo/0000-0002-8267-3027; Mathiesen, elisabeth/0000-0003-3279-0863				BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BRIT MED J, V294, P1561; CASTELLO M, 1979, NATURE, V281, P677; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CROOK MA, 1994, DIABETES CARE, V17, P305, DOI 10.2337/diacare.17.4.305; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DECKERT T, 1991, CARDIOVASCULAR RISK, V1, P154; Feldt-Rasmussen B, 1984, DIABETIC NEPHROPATHY, V3, P101; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1987, DIABETOLOGIA, V30, P610; INGERSLEV J, 1987, SCAND J CLIN LAB INV, V47, P143; Jarrett R J, 1984, Diabet Med, V1, P17; JARRETT RJ, 1989, DIABETES METAB REV, V5, P547, DOI 10.1002/dmr.5610050702; JENSEN G, 1983, ACTA MED SCAND S682, V214, P1; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1989, BRIT MED J, V298, P27, DOI 10.1136/bmj.298.6665.27-a; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, SCAND J CLIN LAB INV, V49, P589, DOI 10.3109/00365518909089140; JENSEN T, 1989, LANCET, V1, P461; JENSEN T, 1989, NEW ENGL J MED, V321, P1572, DOI 10.1056/NEJM198912073212304; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; NORGAARD K, 1990, DIABETOLOGIA, V33, P407, DOI 10.1007/BF00404089; OREKHOV AN, 1991, ATHEROSCLEROSIS, V86, P153, DOI 10.1016/0021-9150(91)90211-K; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P546; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHMITZ A, 1988, DIABETIC MED, V5, P1126; SCHNITZER JE, 1992, AM J PHYSIOL, V32, pH48; SCHROLL M, 1982, DAN MED BULL, V29, P213; SIMPSON H, 1993, BRIT J BIOMED SCI, V50, P164; SVENDSEN PA, 1980, DIABETOLOGIA, V19, P130, DOI 10.1007/BF00421859; TELMER S, 1984, ACTA MED SCAND, V215, P63; Torffvit Ole, 1993, Journal of Diabetes and its Complications, V7, P49, DOI 10.1016/1056-8727(93)90024-S; WISEMAN M, 1984, DIABETOLOGIA, V26, P401; YOKOYAMA H, 1995, J INTERN MED, V237, P519, DOI 10.1111/j.1365-2796.1995.tb00878.x; YUDKIN JS, 1988, LANCET, V2, P530	46	155	158	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					871	874						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611873				2022-12-01	WOS:A1996UE37100017
J	vanGent, DC; Ramsden, DA; Gellert, M				vanGent, DC; Ramsden, DA; Gellert, M			The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination	CELL			English	Article							MOUSE THYMOCYTES; SIGNALS; DNA	V(D)J recombination requires a pair of signal sequences with spacer lengths of 12 and 23 base pairs. Cleavage by the RAG1 and RAG2 proteins was previously shown to demand only a single signal sequence. Here, we establish conditions where 12- and 23-spacer signal sequences are both necessary for cleavage. Coupled cutting at both sites requires only the RAG1 and RAG2 proteins, but depends on the metal ion. In Mn2+, a single signal sequence supports efficient double strand cleavage, but cutting in Mg2+ requires two signal sequences and is best with the canonical 12/23 pair. Thus, the RAG proteins determine both aspects of the specificity of V(D)J recombination, the recognition of a single signal sequence and the correct 12/23 coupling in a pair of signals.			vanGent, DC (corresponding author), NIDDKD,MOLEC BIOL LAB,NIH,BETHESDA,MD 20892, USA.			Ramsden, Dale/0000-0003-1575-4748				BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RAMSDEN DA, 1996, IN PRESS EMBO J; Roberts R, 1993, NUCLEASES, P35; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	18	238	239	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					107	113		10.1016/S0092-8674(00)81086-7	http://dx.doi.org/10.1016/S0092-8674(00)81086-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620529	Bronze			2022-12-01	WOS:A1996UE55900013
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy with autologous bone marrow stem-cell rescue in lung cancer	LANCET			English	Editorial Material							THERAPY; CARCINOMA; SUPPORT		NARGIS DUTT MEM CANC HOSP,BARSHI,INDIA; CORNELL UNIV,MED CTR,NEW YORK HOSP,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), TATA MEM HOSP,DEPT MED ONCOL,BARSHI,INDIA.							BRUGGER W, 1995, SEMIN ONCOL, V22, P3; CANON JL, 1988, EUR J CANCER CLIN ON, V24, P147, DOI 10.1016/0277-5379(88)90245-3; ELIAS A, 1995, HIGH DOSE CANC THERA, P824; ELIAS AD, 1993, CHEST, V103, pS433, DOI 10.1378/chest.103.4.433S; LEONARD RCF, 1990, CANCER RES, V50, P6545; MARANGOLO M, 1989, BONE MARROW TRANSPL, V4, P405; SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278; SPITZER G, 1986, J CLIN ONCOL, V4, P4, DOI 10.1200/JCO.1986.4.1.4; STAHEL RA, 1985, J CLIN ONCOL, V3, P455, DOI 10.1200/JCO.1985.3.4.455; WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890	10	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					847	848		10.1016/S0140-6736(96)91341-0	http://dx.doi.org/10.1016/S0140-6736(96)91341-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622387				2022-12-01	WOS:A1996UC45000005
J	Spiller, RC				Spiller, RC			Cholesterol, fibre, and bile acids	LANCET			English	Editorial Material							DIETARY FIBER; LIPIDS; SERUM; MEN				Spiller, RC (corresponding author), UNIV HOSP,QUEENS MED CTR,DEPT THERAPEUT,NOTTINGHAM,ENGLAND.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500				DAVIDSON MH, 1991, JAMA-J AM MED ASSOC, V265, P1833, DOI 10.1001/jama.265.14.1833; EVERSON GT, 1992, J LIPID RES, V33, P1183; GELISSEN IC, 1995, BRIT J NUTR, V74, P221, DOI 10.1079/BJN19950125; JENKINS DJA, 1975, LANCET, V1, P1116, DOI 10.1016/S0140-6736(75)92503-9; KESANIEMI YA, 1990, AM J CLIN NUTR, V51, P1007, DOI 10.1093/ajcn/51.6.1007; MIETTINEN TA, 1987, AM J CLIN NUTR, V45, P1237, DOI 10.1093/ajcn/45.5.1237; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; TOPPING DL, 1991, NUTR REV, V49, P195, DOI 10.1111/j.1753-4887.1991.tb03021.x; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316	9	12	12	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					415	416		10.1016/S0140-6736(96)90005-7	http://dx.doi.org/10.1016/S0140-6736(96)90005-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618479				2022-12-01	WOS:A1996TV72200005
J	Meydan, N; Grunberger, T; Dadi, H; Shahar, M; Arpaia, E; Lapidot, Z; Leeder, JS; Freedman, M; Cohen, A; Gazit, A; Levitzki, A; Roifman, CM				Meydan, N; Grunberger, T; Dadi, H; Shahar, M; Arpaia, E; Lapidot, Z; Leeder, JS; Freedman, M; Cohen, A; Gazit, A; Levitzki, A; Roifman, CM			Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor	NATURE			English	Article							PROTEIN-TYROSINE KINASES; DEFICIENT SCID MICE; SRC FAMILY; LEUKEMIA; LYMPHOCYTES; CELLS; PHOSPHORYLATION; INTERLEUKIN-7; EXPRESSION; ACTIVATION	ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage(1,3). Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation(4-6). Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias(7,8), attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth(9,10). Here we show that leukaemic cells from patients in relapse have constitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis.	HOSP SICK CHILDREN, DIV ALLERGY IMMUNOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV HAEMATOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV PHARMACOL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Weizmann Institute of Science; Hebrew University of Jerusalem			Leeder, James Steven/ABD-5438-2021	Leeder, James Steven/0000-0001-6688-0504				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKE TR, 1993, J MED CHEM, V36, P425, DOI 10.1021/jm00056a001; COHEN A, 1991, BLOOD, V78, P94; CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020; DADI HK, 1993, BIOCHEM BIOPH RES CO, V192, P459, DOI 10.1006/bbrc.1993.1437; ESTROV Z, 1991, EXP HEMATOL, V19, P221; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GRIMALDI JC, 1989, BLOOD, V73, P2081; HARPUR AG, 1992, ONCOGENE, V7, P1347; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAMELREID S, 1992, LEUKEMIA, V6, P8; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; NADLER LM, 1983, J IMMUNOL, V131, P244; OSAMU M, 1994, BLOOD, V84, P1501; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	30	841	932	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					645	648		10.1038/379645a0	http://dx.doi.org/10.1038/379645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628398				2022-12-01	WOS:A1996TV68800054
J	Oliver, SG				Oliver, SG			From DNA sequence to biological function	NATURE			English	Article							HUMAN GENOME PROJECT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; YEAST; GENE; PROTEINS; GROWTH; SYSTEM; CELL	Genome sequencing is leading to the discovery of new genes at a rate 50-100 times greater than that achieved by classical genetics, but the biological function of almost half of these genes is completely unknown. In order fully to exploit genome sequence data, a systematic approach to the discovery of gene function is required. Possible strategies are discussed here in the context of functional analysis in the yeast Saccharomyces cerevisiae, a model eukaryote whose genome sequence will soon be completed.			Oliver, SG (corresponding author), UMIST, DEPT BIOCHEM & APPL MOLEC BIOL, POB 88, MANCHESTER M60 1QD, LANCS, ENGLAND.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLATTNER FR, 1993, JOHN INN S, P43; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADWICK DJ, 1992, CIBA F S, V171; CHATER KF, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P277; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DANG VD, 1994, YEAST, V10, P1273, DOI 10.1002/yea.320101004; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEVINE KM, 1995, TRENDS BIOTECHNOL, V13, P210, DOI 10.1016/S0167-7799(00)88948-9; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DULBECCO R, 1993, GENE, V135, P259, DOI 10.1016/0378-1119(93)90074-D; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; Hammond J. R. M., 1993, YEASTS, P7; HAVUKKALA I, 1995, J BIOTECHNOL, V41, P139, DOI 10.1016/0168-1656(95)00038-R; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; JIA Y, 1993, THESIS U P M CURIE P; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KABACK DB, 1979, NUCLEIC ACIDS RES, V6, P2499, DOI 10.1093/nar/6.7.2499; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KREUDTZFELDT C, 1991, BIOTECH HDB, V4, P5; LALO D, 1993, CR HEBD ACAD SCI, V316, P137; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; MORTIMER RK, 1986, GENETICS, V113, P35; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLIVER SG, 1993, JOHN INN S, P233; Olson M., 1991, MOL CELLULAR BIOL YE, P1; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; OUZOUNIS C, 1993, FEBS LETT, V322, P159, DOI 10.1016/0014-5793(93)81559-I; QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; RIEGER K, IN PRESS YEAST; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMIDT R, 1993, BIOESSAYS, V15, P63, DOI 10.1002/bies.950150110; SCHWARTZ K, 1994, NAT GENET, V8, P110, DOI 10.1038/ng1094-110; SHORT N, 1995, NATURE, V377, P1; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA S, 1993, NUCLEIC ACIDS RES, V21, P1149, DOI 10.1093/nar/21.5.1149; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATERSTON B, 1995, NATURE, V376, P111, DOI 10.1038/376111d0; Weinstock Keith G., 1994, Current Opinion in Biotechnology, V5, P599, DOI 10.1016/0958-1669(94)90081-7; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504; ZHENG L, 1958, P NATL ACAD SCI USA, V90, P2754	61	244	248	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					597	600		10.1038/379597a0	http://dx.doi.org/10.1038/379597a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628394				2022-12-01	WOS:A1996TV68800040
J	Hilgetag, CC; ONeill, MA; Young, MP				Hilgetag, CC; ONeill, MA; Young, MP			Indeterminate organization of the visual system	SCIENCE			English	Editorial Material							CORTICAL CONNECTIONS; AREAS				Hilgetag, CC (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PSYCHOL,NEURAL SYST GRP,RIDLEY BLDG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.		Hilgetag, Claus C/L-7282-2013; Hilgetag, Claus C/AAH-1760-2020	Hilgetag, Claus C/0000-0003-2129-8910; Hilgetag, Claus C/0000-0003-2129-8910				BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; COOGAN TA, 1993, J NEUROSCI, V13, P3749; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; MANUNSELL JHR, 1983, ANN REV NEUROSCI, V10, P363; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; Van Laarhoven P.J., 1987, MATH ITS APPL	7	123	125	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					776	777		10.1126/science.271.5250.776	http://dx.doi.org/10.1126/science.271.5250.776			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628990				2022-12-01	WOS:A1996TU69400035
J	Rowen, L; Koop, BF; Hood, L				Rowen, L; Koop, BF; Hood, L			The complete 685-kilobase DNA sequence of the human beta T cell receptor locus	SCIENCE			English	Article							VARIABLE REGION GENES; V-BETA; ANTIGEN RECEPTOR; ALPHA-CHAIN; ORGANIZATION; DIVERSITY; REPERTOIRE; POLYMORPHISM; FAMILIES; IDENTIFICATION	The human beta T cell receptor (TCR) locus, comprising a complex family of genes, has been sequenced, The locus contains two types of coding elements-TCR elements (65 variable gene segments and two clusters of diversity, joining, and constant segments) and eight trypsinogen genes-that constitute 4.6 percent of the DNA. Genome-wide interspersed repeats and locus-specific repeats span 30 and 47 percent, respectively, of the 685-kilobase sequence. A comparison of the germline variable elements with their approximately 300 complementary DNA counterparts reveals marked differential patterns of variable gene expression, the importance of exonuclease activity in generating TCR diversity, and the predominant tendency for only functional variable elements to be present in complementary DNA libraries.	UNIV VICTORIA, DEPT BIOL, CTR ENVIRONM HLTH, VICTORIA, BC V8W 2Y2, CANADA	University of Victoria	Rowen, L (corresponding author), UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA.		Koop, Ben F./A-8151-2008	Koop, Ben F./0000-0003-0045-5200				Adams M. D., 1994, AUTOMATED DNA SEQUEN; ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON SJ, 1989, MOL CELL BIOL, V9, P4835, DOI 10.1128/MCB.9.11.4835; Arden Bernhard, 1995, Immunogenetics, V42, P455; BOLLUM FJ, 1986, ADV CANCER RES, V47, P37, DOI 10.1016/S0065-230X(08)60197-9; CHARMLEY P, 1993, J EXP MED, V177, P135, DOI 10.1084/jem.177.1.135; CHARMLEY P, 1990, TISSUE ANTIGENS, V35, P157, DOI 10.1111/j.1399-0039.1990.tb01773.x; CHARMLEY P, 1995, GENOMICS, V29, P760, DOI 10.1006/geno.1995.9940; CONCANNON P, 1986, COLD SPRING HARB SYM, V51, P785, DOI 10.1101/SQB.1986.051.01.091; CONCANNON P, 1986, P NATL ACAD SCI USA, V83, P6598, DOI 10.1073/pnas.83.17.6598; CONCANNON P, 1992, MANUAL CLIN LABORATO, P885; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEININGER PL, 1993, EVOL BIOL, V27, P157; DOHERTY PJ, 1991, MOL IMMUNOL, V28, P607, DOI 10.1016/0161-5890(91)90129-8; EMI M, 1986, GENE, V41, P305; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUNKHOUSER SW, 1992, ARTHRITIS RHEUM, V35, P465, DOI 10.1002/art.1780350417; Green Paul, COMMUNICATION; HALL MA, 1995, HUM IMMUNOL, V43, P207, DOI 10.1016/0198-8859(95)00013-T; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HOOD L, 1975, ANNU REV GENET, V9, P305, DOI 10.1146/annurev.ge.09.120175.001513; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JORES R, 1993, J IMMUNOL, V151, P6110; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; LEVITT MH, COMMUNICATION; LI YX, 1991, J EXP MED, V174, P1537, DOI 10.1084/jem.174.6.1537; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; MAK TW, 1984, IMMUNOL REV, V81, P221, DOI 10.1111/j.1600-065X.1984.tb01112.x; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; POSNETT DN, 1994, J EXP MED, V179, P1707, DOI 10.1084/jem.179.5.1707; ROACH J, COMMUNICATION; ROBINSON MA, 1985, HUM IMMUNOL, V14, P195, DOI 10.1016/0198-8859(85)90228-9; ROBINSON MA, 1993, P NATL ACAD SCI USA, V90, P2433, DOI 10.1073/pnas.90.6.2433; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; ROWEN L, UNPUB; ROYER HD, 1987, P NATL ACAD SCI USA, V84, P232, DOI 10.1073/pnas.84.1.232; SEBOUN E, 1989, J EXP MED, V170, P1263, DOI 10.1084/jem.170.4.1263; SIU G, 1986, J EXP MED, V164, P1600, DOI 10.1084/jem.164.5.1600; SLIGHTOM JL, 1994, GENOMICS, V20, P149, DOI 10.1006/geno.1994.1149; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; SMIT AFA, COMMUNICATION; TANI T, 1990, NUCLEIC ACIDS RES, V18, P1631, DOI 10.1093/nar/18.6.1631; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; VERLINDE CLM, COMMUNICATION; Wang K., COMMUNICATION; WEI S, 1994, IMMUNOGENETICS, V40, P27, DOI 10.1007/BF00163961; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; ZHAO TM, 1994, J EXP MED, V180, P1405, DOI 10.1084/jem.180.4.1405	59	360	423	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1996	272	5269					1755	1762		10.1126/science.272.5269.1755	http://dx.doi.org/10.1126/science.272.5269.1755			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650574				2022-12-01	WOS:A1996UT11000034
J	Bichot, NP; Schall, JD; Thompson, KG				Bichot, NP; Schall, JD; Thompson, KG			Visual feature selectivity In frontal eye fields induced by experience in mature macaques	NATURE			English	Article							STRIATE CORTEX; SACCADES; MONKEY; ENHANCEMENT; ATTENTION; RESPONSES; NEURONS; SEARCH	WHEN examining a complex image, the eye movements of expert observers differ from those of novices; experts have learned to ignore features that are visually salient but are not relevant to the interpretation of the image(1-3). We have studied the neural basis of this form of perceptual-motor learning using monkeys that have learned to search for a visual target among distracters, Monkeys trained to search only for, say, a red stimulus among green distracters will ignore green stimuli even if they subsequently appear as targets in a complementary search array, that is, among red distracters, We recorded from neurons in the frontal eye field (FEF), a cortical area that responds to visual stimuli and controls purposive eye movements(4-6). Normally, FEF neurons do not exhibit feature selectivity, but their activity evolves to signal the target for an incipient eye movement(7). In monkeys trained exclusively on targets of one colour, however, FEF neurons show selectivity for stimuli of that colour, Because this selective response occurs so soon after presentation of the stimulus array, and is independent of location within the visual field, we propose that it reflects a form of experience-dependent plasticity that mediates the learning of arbitrary stimulus-response associations.	VANDERBILT UNIV, DEPT PSYCHOL, VANDERBILT VIS RES CTR, NASHVILLE, TN 37240 USA	Vanderbilt University								BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; BRUCE CJ, 1990, NEUROSCI IN, P261; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; FISHER D, 1981, EYE MOVEMENTS COGNIT; GOLDBERG ME, 1981, J NEUROPHYSIOL, V46, P773, DOI 10.1152/jn.1981.46.4.773; GOLDBERG ME, 1989, NEUROBIOLOGY SACCADI, V3, P283; GRONER R, 1985, EYE MOVEMENTS HUMAN; HANES DP, 1995, EXP BRAIN RES, V103, P85; LAMME VAF, 1995, J NEUROSCI, V15, P1605; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MOHLER CW, 1973, BRAIN RES, V61, P385, DOI 10.1016/0006-8993(73)90543-X; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; NOWAK LG, 1995, VISUAL NEUROSCI, V12, P371, DOI 10.1017/S095252380000804X; OREGAN JK, 1987, EYE MOVEMENTS PHYSL; SCHALL JD, 1995, J NEUROSCI, V15, P6905; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P559, DOI 10.1152/jn.1991.66.2.559; SCHALL JD, 1995, J NEUROSCI, V15, P4464; SCHALL JD, 1991, NEURAL BASIS VISUAL, P388; Thompson K. G., 1995, Society for Neuroscience Abstracts, V21, P1270; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P766, DOI 10.1152/jn.1976.39.4.766	24	177	179	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					697	699		10.1038/381697a0	http://dx.doi.org/10.1038/381697a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649514				2022-12-01	WOS:A1996UR97900052
J	Figurov, A; PozzoMiller, LD; Olafsson, P; Wang, T; Lu, B				Figurov, A; PozzoMiller, LD; Olafsson, P; Wang, T; Lu, B			Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus	NATURE			English	Article							LONG-TERM POTENTIATION; POSTNATAL RAT-BRAIN; MESSENGER-RNA; AREA CA1; BDNF; NT-3; ENHANCEMENT; EXPRESSION; PLASTICITY; INDUCTION	NEUROTROPHINS promote neuronal survival and differentiation, but the fact that their expression is modified by neuronal activity, suggests a role in regulating synapse development and plasticity(1-3). In developing hippocampus, the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB(4-7) increases in parallel with the ability to undergo long-term potentiation (LTP)(8-10). Here me report a mechanism by which BDNF modulates hippocampal LTP. Exogenous BDNF promoted the induction of LTP by tetanic stimulation in young (postnatal day 12-13) hippocampal slices, which in the absence of BDNF show only short-term potentiation (STP), This effect was due to an enhanced ability of hippocampal synapses to respond to tetanic stimulation, rather than to a direct modulation of the LTP-triggering mechanism. A TrkB-IgG fusion protein, which scavenges endogenous BDNF11, reduced the synaptic responses to tetanus as well as the magnitude of LTP in adult hippocampus.	NICHHD,DEV NEUROBIOL LAB,NIH,BETHESDA,MD 20892; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Lu, Bai/A-4018-2012	Pozzo-Miller, Lucas/0000-0001-6085-5527; Lu, Bai/0000-0001-5418-9759				ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CASTREN E, 1993, NEUROREPORT, V4, P895, DOI 10.1097/00001756-199307000-00014; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DUGICHDJORDJEVIC MM, 1993, NEUROREPORT, V4, P1091; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; FRIEDMAN WJ, 1991, EUR J NEUROSCI, V3, P688, DOI 10.1111/j.1460-9568.1991.tb00854.x; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HUANG YY, 1993, J NEUROSCI, V13, P568; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ISACKSON PJ, 1995, CURR OPIN NEUROBIOL, V5, P350, DOI 10.1016/0959-4388(95)80048-4; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412, DOI 10.1152/jn.1993.70.4.1412; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; PATTERSON S, 1992, NEURON, V9, P1981; PETROZZINO JJ, 1994, HIPPOCAMPUS, V4, P546, DOI 10.1002/hipo.450040504; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG T, 1995, J NEUROSCI, V15, P4796; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	922	945	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					706	709		10.1038/381706a0	http://dx.doi.org/10.1038/381706a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649517				2022-12-01	WOS:A1996UR97900055
J	Treiman, A				Treiman, A			To see a world in 80 kilograms of rock	SCIENCE			English	Editorial Material							SNC				Treiman, A (corresponding author), LUNAR & PLANETARY INST,HOUSTON,TX 77058, USA.							Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; EUGSTER O, 1996, LUNAR PLANET SCI, V27, P345; Gladman BJ, 1996, SCIENCE, V271, P1387, DOI 10.1126/science.271.5254.1387; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; HARVEY RP, 1996, LUNAR PLANET SCI, V27, P497; HARVEY RP, 1995, LUNAR PLANET SCI, V26, P555; JAGOUTZ E, 1996, LUNAR PLANET SCI, V27, P597; JAGOUTZ E, 1994, METEORITICS, V29, P479; KRING DA, 1996, LUNAR PLANET SCI, V27, P705; *LUN PLAN I, LUN PLAN I CONTR, V888; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MITTLEFEHLDT DW, 1996, LUNAR PLANET SCI, V27, P1099; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; ROMANEK CS, 1994, NATURE, V372, P665; SWINDLE TD, 1995, LUNAR PLANET SCI, V26, P1385; TREIMAN AH, 1993, METEORITICS, V28, P86, DOI 10.1111/j.1945-5100.1993.tb00251.x; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TREIMAN AH, 1995, J GEOPHYS RES-PLANET, V100, P5329, DOI 10.1029/94JE02184; [No title captured]; [No title captured]	22	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1447	1448		10.1126/science.272.5267.1447	http://dx.doi.org/10.1126/science.272.5267.1447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633232				2022-12-01	WOS:A1996UP89900034
J	Garrity, PA; Rao, Y; Salecker, I; McGlade, J; Pawson, T; Zipursky, SL				Garrity, PA; Rao, Y; Salecker, I; McGlade, J; Pawson, T; Zipursky, SL			Drosophila photoreceptor axon guidance and targeting requires the dreadlocks SH2/SH3 adapter protein	CELL			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; 1ST OPTIC GANGLION; TYROSINE PHOSPHORYLATION; INSERTIONAL MUTAGENESIS; GENETIC MOSAICS; NERVOUS-SYSTEM; COMPOUND EYE; MELANOGASTER; SH2; DOMAIN	Mutations in the Drosophila gene dreadlocks (dock) disrupt photoreceptor cell (R cell) axon guidance and targeting. Genetic mosaic analysis and cell-type-specific expression of dock transgenes demonstrate dock is required in R cells for proper innervation. Dock protein contains one SH2 and three SH3 domains, implicating it in tyrosine kinase signaling, and is highly related to the human proto-oncogene Nck. Dock expression is detected in R cell growth cones in the target region. We propose Dock transmits signals in the growth cone in response to guidance and targeting cues. These findings provide an important step for dissection of signaling pathways regulating growth cone motility.	UNIV CALIF LOS ANGELES, SCH MED, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Garrity, PA (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Pawson, Tony J/E-4578-2013; Salecker, Iris/V-1228-2018	Zipursky, Stephen/0000-0001-5630-7181; Salecker, Iris/0000-0003-3775-7763; Garrity, Paul/0000-0002-8274-6564				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBRUNER M, 1989, DROSOPHILA LAB MANUA; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1987, DEVELOPMENT, V101, P123; HAY BA, 1994, DEVELOPMENT, V120, P2121; HU QJ, 1995, MOL CELL BIOL, V15, P1169; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; KANKEL DR, 1976, DEV BIOL, V48, P1, DOI 10.1016/0012-1606(76)90041-5; KARPEN GH, 1992, GENETICS, V132, P737; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETOURNEAU PC, 1991, NERVE GROWTH CONE; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARDON G, 1994, DEVELOPMENT, V120, P3473; MARTIN KA, 1995, NEURON, V14, P229, DOI 10.1016/0896-6273(95)90281-3; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MELNERTZHAGEN IA, 1993, DEV DROSOPHILA MELAN, P1363; MISMER D, 1987, GENETICS, V116, P565; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; SALECKER I, 1995, J COMP NEUROL, V352, P33, DOI 10.1002/cne.903520104; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TOROK T, 1993, GENETICS, V135, P71; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WINBERG ML, 1992, DEVELOPMENT, V115, P903; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; XU T, 1993, DEVELOPMENT, V117, P1223; YAO KM, 1994, J NEUROCHEM, V63, P41	59	229	231	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					639	650		10.1016/S0092-8674(00)81231-3	http://dx.doi.org/10.1016/S0092-8674(00)81231-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646773	Bronze			2022-12-01	WOS:A1996UP34400005
J	Mumma, MJ; DiSanti, MA; DelloRusso, N; Fomenkova, M; MageeSauer, K; Kaminski, CD; Xie, DX				Mumma, MJ; DiSanti, MA; DelloRusso, N; Fomenkova, M; MageeSauer, K; Kaminski, CD; Xie, DX			Detection of abundant ethane and methane, along with carbon monoxide and water, in comet C/1996 B2 Hyakutake: Evidence for interstellar origin	SCIENCE			English	Article							MONOCARBOXYLIC ACIDS; HALLEYS-COMET; AUSTIN 1989C1; P-HALLEY; P/HALLEY; FORMALDEHYDE; EMISSION; IDENTIFICATION; EXCITATION; METEORITE	The saturated hydrocarbons ethane (C2H6) and methane (CH4) along with carbon monoxide (GO) and water (H2O) were detected in comet C/1996 B2 Hyakutake with the use of high-resolution infrared spectroscopy at the NASA Infrared Telescope Facility on Mauna Kea, Hawaii. The inferred production rates of molecular gases from the icy, cometary nucleus (in molecules per second) are 6.4 x 10(26) for C2H6, 1.2 x 10(27) for CH4, 9.8 x 10(27) for CO, and 1.7 x 10(29) for H2O. An abundance of C2H6 comparable to that of CH4 implies that ices in C/1996 B2 Hyakutake did not originate in a thermochemically equilibrated region of the solar nebula. The abundances are consistent with a kinetically controlled production process, but production of C2H6 by gas-phase ion molecule reactions in the natal cloud core is energetically forbidden. The high C2H6/CH4 ratio is consistent with production of C2H6 in icy grain mantles in the natal cloud, either by photolysis of CH4-rich ice or by hydrogen-addition reactions to acetylene condensed from the gas phase.	CATHOLIC UNIV AMER,DEPT PHYS,WASHINGTON,DC 20064; NASA,GODDARD SPACE FLIGHT CTR,WASHINGTON,DC 20064; UNIV CALIF SAN DIEGO,CTR ASTROPHYS & SPACE SCI,LA JOLLA,CA 92093; ROWAN COLL,DEPT CHEM & PHYS,GLASSBORO,NJ 08028; NASA,INFRARED TELESCOPE FACIL,HILO,HI 96720	Catholic University of America; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California San Diego; Rowan University; National Aeronautics & Space Administration (NASA)	Mumma, MJ (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771, USA.		Russo, Neil Dello/G-2727-2015; mumma, michael j/I-2764-2013; Magee-Sauer, Karen/K-6061-2015	Russo, Neil Dello/0000-0002-8379-7304; mumma, michael j/0000-0003-4627-750X; Magee-Sauer, Karen/0000-0002-4979-9875				ALLAMANDOLA LJ, 1988, ICARUS, V76, P225, DOI 10.1016/0019-1035(88)90070-X; ALLEN M, 1987, ASTRON ASTROPHYS, V187, P502; BOCKELEEMORVAN D, 1987, ASTRON ASTROPHYS, V187, P425; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1991, NATURE, V350, P318, DOI 10.1038/350318a0; BOICE DC, 1990, GEOPHYS RES LETT, V17, P1813, DOI 10.1029/GL017i011p01813; BROOKE TY, 1991, ASTROPHYS J, V372, pL113, DOI 10.1086/186036; CHAMLEY SB, 1995, ASTROPHYS J, V448, P232; Charlesby A., 1960, ATOMIC RAD POLYM; CHIN G, 1984, ASTROPHYS J, V285, P858, DOI 10.1086/162565; COMBES M, 1988, ICARUS, V76, P404, DOI 10.1016/0019-1035(88)90013-9; Cronin J.R., 1988, METEORITES EARLY SOL, P819; CROVISIER J, 1983, ASTRON ASTROPHYS, V126, P170; DAYHOFF MO, 1964, SCIENCE, V164, P1461; DELLORUSSO N, UNPUB; DISANTI MA, 1992, ICARUS, V96, P151, DOI 10.1016/0019-1035(92)90068-I; DISANTI MA, 1996, 6374 IAU; DRAPATZ S, 1987, ASTRON ASTROPHYS, V187, P497; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; ECK RV, 1966, SCIENCE, V153, P628, DOI 10.1126/science.153.3736.628; Fegley B.J., 1989, FORMATION EVOLUTION, P171; FELDMAN PD, 1996, 6370 IAU; FESTOU M, 1996, 6355 IAU; GERAKINES PA, IN PRESS ASTRON ASTR; GOLDMAN A, 1989, J QUANT SPECTROSC RA, V41, P17, DOI 10.1016/0022-4073(89)90016-2; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P311; HERBST E, 1983, ASTROPHYS J, V269, P329, DOI 10.1086/161046; Herzberg G., 1945, MOL SPECTRA MOL STRU; Herzberg G., 1966, MOL SPECTRA MOL STRU, V3; HIRAOKA K, 1994, CHEM PHYS LETT, V229, P408, DOI 10.1016/0009-2614(94)01066-8; HOBAN S, 1991, ICARUS, V93, P122, DOI 10.1016/0019-1035(91)90168-S; KAWARA K, 1988, ASTRON ASTROPHYS, V207, P174; LACY JH, 1991, ASTROPHYS J, V376, P556, DOI 10.1086/170304; LAMMERZAHL P, 1987, ASTRON ASTROPHYS, V187, P169; LARSON HP, 1989, ASTROPHYS J, V338, P1106, DOI 10.1086/167260; LAWLESS JG, 1979, NATURE, V282, P396, DOI 10.1038/282396a0; LII JH, 1992, J COMPUT CHEM, V13, P1138, DOI 10.1002/jcc.540130914; LIVINGSTON W, 1991, 91001 NSO; MATTHEWS HE, 1996, 6353 IAU; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; MOORE MH, 1992, ASTROPHYS J, V401, P353, DOI 10.1086/172065; MUMMA MJ, 1986, SCIENCE, V232, P1523, DOI 10.1126/science.232.4757.1523; MUMMA MJ, 1989, ASTROPHYS J, V344, P940, DOI 10.1086/167862; MUMMA MJ, 1995, B AM ASTRON SOC, V27, P1144; MUMMA MJ, 1996, 6366 IAU; MUMMA MJ, 1993, PROTOSTARS PLANETS, V3, P1177; Prinn R.G.P., 1989, ORIGIN EVOLUTION PLA, P78; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SCHLEICHER D, 1996, 6372 IAU; SCHLOERB FP, 1986, ASTROPHYS J, V310, pL55, DOI 10.1086/184781; SCHUTTE WA, 1991, ASTRON ASTROPHYS, V244, P190; SENAY M, 1996, 6335 IAU; SNYDER LE, 1989, ASTRON J, V97, P246, DOI 10.1086/114976; Stief LJ, 1965, J CHEM PHYS, V43, P2490, DOI 10.1063/1.1697148; STUDIER MH, 1965, SCIENCE, V149, P1455, DOI 10.1126/science.149.3691.1455; Tielens A.G.G.M., 1987, INTERSTELLAR PROCESS, P397; TOKUNAGA AT, 1996, 6378 IAU; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WEAVER HA, 1984, ASTROPHYS J, V276, P782, DOI 10.1086/161664; WEAVER HA, 1984, ASTROPHYS J, V285, P872, DOI 10.1086/162567; WEAVER HA, 1996, 6374 IAU; WEGMANN R, 1987, ASTRON ASTROPHYS, V187, P339; WOMACK M, 6345 IAU; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	64	271	272	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1310	1314		10.1126/science.272.5266.1310	http://dx.doi.org/10.1126/science.272.5266.1310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650540				2022-12-01	WOS:A1996UN47200037
J	Perry, RJ; Moore, CA; Morgan, BDG; Plummer, DL				Perry, RJ; Moore, CA; Morgan, BDG; Plummer, DL			Determining the approximate area of a burn: An inconsistency investigated and re-evaluated	BRITISH MEDICAL JOURNAL			English	Article									UCL HOSP, DEPT PLAST SURG, LONDON WC1E 6BT, ENGLAND; UCL, DEPT MED PHYS & BIOENGN, LONDON WC1E 6BT, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Perry, RJ (corresponding author), UCL, SCH MED, CIN SCI OFF, ADM, LONDON WC1E 6BT, ENGLAND.							Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; ELLIS H, 1993, LECT NOTES GEN SURG, P12; GEHAN EA, 1970, CANCER CHEMOTH REP 1, V54, P225; Plummer D., 1992, RIV NEURORADIOL, V5, P489; Proctor HJ., 1993, ADV TRAUMA LIFE SUPP	5	29	30	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1338	1338		10.1136/bmj.312.7042.1338	http://dx.doi.org/10.1136/bmj.312.7042.1338			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646048	Green Published			2022-12-01	WOS:A1996UN47600023
J	Cavallini, MC; Roman, MJ; Blank, SG; Pini, R; Pickering, TG; Devereux, RB				Cavallini, MC; Roman, MJ; Blank, SG; Pini, R; Pickering, TG; Devereux, RB			Association of the auscultatory gap with vascular disease in hypertensive patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; vascular diseases; blood pressure; auscultation; atherosclerosis	CAROTID-ARTERY ATHEROSCLEROSIS; BLOOD-PRESSURE; MEDIAL THICKNESS; ULTRASOUND; STIFFNESS; PULSE; POPULATIONS; VALIDATION; PREVALENCE; URBAN	Objective: To assess the relation of the auscultatory gap during blood pressure measurement to cardiovascular structure and function. Design: Cross-sectional study. Setting: A hypertension center in a university hospital. Patients: 168 persons with hypertension who were otherwise healthy and were not receiving medication. Measurements: Wideband external pulse recordings and ultrasonographic examination of the left ventricle and extracranial carotid arteries. Vascular stiffness was evaluated using simultaneous carotid pressure waveforms obtained by applanation tonometry of the contralateral carotid artery. Results: Classic auscultatory gaps were present in 21% of patients and were associated with older age (mean age +/- SD, 64 +/- 11 years for patients with gaps and 55 +/- 13 years for patients without gaps; P < 0.001), female sex (67% of patients with gaps and 44% of patients without gaps were female; P < 0.05), and increased arterial stiffness (arterial stiffness index, 8.5 +/- 4.6 in patients with gaps and 5.8 +/- 3.2 in patients without gaps; P < 0.005). The prevalence of atherosclerotic plaques was increased more than twofold among patients with gaps compared with patients without gaps (50% compared with 22%; P < 0.002). Patients with and without auscultatory gaps had similar blood pressures, left ventricular structure and function, serum cholesterol levels, and smoking history. Logistic regression analysis indicated that only female sex (P < 0.02), arterial stiffness (P < 0.002), and atherosclerotic plaque (P < 0.02) were independently associated with the presence of an auscultatory gap. Conclusions: This study provides strong evidence that auscultatory gaps are related to carotid atherosclerosis and to increased arterial stiffness in hypertensive patients, independent of age. Although these observations need to be confirmed prospectively, they suggest that auscultatory gaps may have prognostic relevance.	CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV CARDIOL, NEW YORK, NY 10021 USA; UNIV FLORENCE, IST GERONTOL & GERIATR, I-50141 FLORENCE, ITALY; CORNELL UNIV, MED CTR, NEW YORK HOSP, HYPERTENS CTR, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; University of Florence; Cornell University; NewYork-Presbyterian Hospital				Pini, Riccardo/0000-0002-7940-7908	NHLBI NIH HHS [P01 HL047540, HL 18323, HL 47540] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323, P01HL047540] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOLIO AP, 1985, CIRCULATION, V71, P202, DOI 10.1161/01.CIR.71.2.202; AVOLIO AP, 1983, CIRCULATION, V68, P50, DOI 10.1161/01.CIR.68.1.50; BLANK SG, 1991, HYPERTENSION, V17, P225, DOI 10.1161/01.HYP.17.2.225; BLANK SG, 1988, CIRCULATION, V77, P1297, DOI 10.1161/01.CIR.77.6.1297; Cook JE, 1917, J AMER MED ASSOC, V68, P1088; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DEVEREUX RB, 1993, CIRCULATION, V88, P1444, DOI 10.1161/01.CIR.88.4.1444; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; FLORAS JS, 1988, HYPERTENSION, V11, P273, DOI 10.1161/01.HYP.11.3.273; Hamilton WF, 1939, AM J PHYSIOL, V125, P48, DOI 10.1152/ajplegacy.1938.125.1.48; HANDA N, 1990, STROKE, V21, P1567, DOI 10.1161/01.STR.21.11.1567; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; KAWASAKI T, 1987, CARDIOVASC RES, V21, P678, DOI 10.1093/cvr/21.9.678; KELLY R, 1992, J AM COLL CARDIOL, V20, P952, DOI 10.1016/0735-1097(92)90198-V; Kelly R, 1989, J VASC MED BIOL, V3, P142; Kelly R, 1989, J VASC MED BIOL, V1, P241; KOCHAR MS, 1992, POSTGRAD MED, V91, P393; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P221; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P319; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P113; LONDON G, 1992, HYPERTENSION, V20, P10, DOI 10.1161/01.HYP.20.1.10; Mudd SG, 1928, ARCH INTERN MED, V41, P249, DOI 10.1001/archinte.1928.00130140111008; OROURKE M, 1990, HYPERTENSION, V15, P339, DOI 10.1161/01.HYP.15.4.339; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; PETERSON LH, 1960, CIRC RES, V8, P622, DOI 10.1161/01.RES.8.3.622; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; Ragan C, 1941, B JOHNS HOPKINS HOSP, V69, P504; RODBARD S, 1957, CIRCULATION, V15, P850, DOI 10.1161/01.CIR.15.6.850; ROMAN MJ, 1992, J HYPERTENS, V10, pS115; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; ROMAN MJ, 1992, CIRCULATION, V86, P1909, DOI 10.1161/01.CIR.86.6.1909; SABA PS, 1993, J AM COLL CARDIOL, V22, P1873, DOI 10.1016/0735-1097(93)90772-S; SAFAR ME, 1989, J HYPERTENS, V7, P769, DOI 10.1097/00004872-198910000-00001; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHNABEL TG, 1952, CIRCULATION, V5, P257, DOI 10.1161/01.CIR.5.2.257; SESSLER GM, 1966, J ACOUST SOC AM, V40, P1433, DOI 10.1121/1.1910245; TAVEL ME, 1969, CIRCULATION, V39, P465, DOI 10.1161/01.CIR.39.4.465; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; WEST JE, 1983, J ACOUST SOC AM, V74, P680, DOI 10.1121/1.389852	44	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					877	+		10.7326/0003-4819-124-10-199605150-00003	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610916				2022-12-01	WOS:A1996UJ80100003
J	Nellen, D; Burke, R; Struhl, G; Basler, K				Nellen, D; Burke, R; Struhl, G; Basler, K			Direct and long-range action of a DPP morphogen gradient	CELL			English	Article							DEVELOPING DROSOPHILA EYE; GENE-EXPRESSION; BETA FAMILY; PATTERN; PROTEIN; RECEPTOR; EMBRYO; CELLS; ACTS	During development of the Drosophila wing, the decapentaplegic (dpp) gene is expressed in a stripe of cells along the anteroposterior compartment boundary and gives rise to a secreted protein that exerts a long-range organizing influence on both compartments. Using clones of cells that express DPP, or in which DPP receptor activity has been constitutively activated or abolished, we show that DPP acts directly and at long range on responding cells, rather than by proxy through the short-range induction of other signaling molecules. Further, we show that two genes, optomotor-blind and spalt are transcriptionally activated at different distances from DPP-secreting cells and provide evidence that these genes respond to different threshold concentrations of DPP protein. We propose that DPP acts as a gradient morphogen during wing development.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	Nellen, D (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Burke, Richard/0000-0003-0086-0767; Basler, Konrad/0000-0003-3534-1529				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; Boveri T, 1903, VERHANDLUNGEN PHYSIK, V35, P67; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; INGHAM PW, 1994, CURR BIOL, V4, P374; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KOHNLEIN RP, 1994, EMBO J, V13, P168; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1972, J CELL SCI, V11, P815; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Morgan T.H., 1897, ROUX ARCH DEV BIOL, V5, P570; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Spemann H., 1938, EMBRYONIC DEV INDUCT; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STUMPF HF, 1966, NATURE, V212, P430, DOI 10.1038/212430a0; SUN YH, 1995, GENETICS, V141, P1075; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINCENT JP, 1994, TRENDS GENET, V10, P383, DOI 10.1016/0168-9525(94)90040-X; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOLPERT L, 1989, DEVELOPMENT S, P3; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	62	795	804	4	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					357	368		10.1016/S0092-8674(00)81114-9	http://dx.doi.org/10.1016/S0092-8674(00)81114-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616891	hybrid, Green Accepted			2022-12-01	WOS:A1996UK14000009
J	Echtenacher, B; Mannel, DN; Hultner, L				Echtenacher, B; Mannel, DN; Hultner, L			Critical protective role of mast cells in a model of acute septic peritonitis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CONNECTIVE-TISSUE-TYPE; FACTOR-ALPHA; TNF-ALPHA; GRANULOCYTE INFILTRATION; DEFICIENT W/WV; MICE; MOUSE; CACHECTIN; RECRUITMENT	MAST cells play a detrimental role in IgE dependent allergic reactions, In contrast, a protective function for mast cells has been proposed on the basis of some worm infection models. No reports exist on the in vivo significance of these cells in bacterial infections(1,2). Here we use congenitally mast-cell-deficient W/W-v mice and normal +/+ littermates(3,4) to analyse the role of mast cells in a model of acute septic peritonitis (caecum ligation and puncture (CLP)), Following CLP, W/W-v mice showed a significantly increased mortality compared to +/+ mice, The selective reconstitution of W/W-v mice with cultured +/+ mast cells substantially protected them from the lethal effects of CLP, whereas an anti-tumour-necrosis-factor (TNF) antibody injected immediately after CLP completely suppressed this protection, Our results reveal a previously unrecognized protective role of mast cells and mast-cell-derived TNF in acute bacterial peritonitis.	GSF MUNICH,INST EXPT HAMATOL,D-81377 MUNICH,GERMANY; UNIV REGENSBURG,INST PATHOL TUMORIMMUNOL,D-93042 REGENSBURG,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Regensburg								ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; ANSEL JC, 1993, J IMMUNOL, V150, P4478; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Echtenacher B, 1993, HOST DEFENSE DYSFUNC, P755; EGGER D, 1995, J IMMUNOL, V154, P1830; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HOLZHEIMER RG, 1991, INFECTION, V19, P447, DOI 10.1007/BF01726463; HULTNER L, 1989, J IMMUNOL, V142, P3440; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; MATSUDA H, 1989, J IMMUNOL, V142, P927; MCCLEAN KL, 1994, CLIN INFECT DIS, V19, P100, DOI 10.1093/clinids/19.1.100; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKANO T, 1987, J IMMUNOL, V138, P544; OTANI I, 1982, J IMMUNOL, V129, P2109; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; SCHWARTZ LB, 1994, CURR OPIN IMMUNOL, V6, P91, DOI 10.1016/0952-7915(94)90039-6; SHER A, 1979, LAB INVEST, V41, P490; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VRANIAN G, 1981, J IMMUNOL, V126, P2302; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1994, ADV EXP MED BIOL, V347, P39; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	30	754	782	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					75	77		10.1038/381075a0	http://dx.doi.org/10.1038/381075a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609992				2022-12-01	WOS:A1996UJ05300059
J	Aldaz, H; Schuster, E; Baker, TA				Aldaz, H; Schuster, E; Baker, TA			The interwoven architecture of the Mu transposase couples DNA synapsis to catalysis	CELL			English	Article							BACTERIOPHAGE-MU; TRANSPOSITIONAL ENHANCER; INVITRO TRANSPOSITION; STRAND TRANSFER; B-PROTEIN; A-PROTEIN; MINI-MU; SITE; RECOMBINATION; ENDS	Mu transposition occurs exclusively using a pair of recombination sites found at the ends of the phage genome. To address the mechanistic basis of this specificity, we have determined both where the individual subunits of the tetrameric transposase bind on the DNA and where they catalyze DNA joining. We demonstrate that subunits do not catalyze recombination at the site adjacent to where they are bound, but rather on the opposite end of the phage genome. Furthermore, subunits bound to two different sites contribute to catalysis of one reaction step. This interwoven subunit arrangement suggests a molecular explanation for the precision with which recombination occurs using a pair of DNA signals and provides an example of the way in which the architecture of a protein-DNA complex can define the reaction products.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Aldaz, H (corresponding author), MIT,DEPT BIOL,68-523,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Schuster, Eugene/0000-0001-5076-2810	NIGMS NIH HHS [GM499224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1991, J BIOL CHEM, V266, P6159; ALLISON RG, 1992, J BIOL CHEM, V267, P19963; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; Berg D. E., 1989, MOBILE DNA; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; GROENEN MAM, 1986, EMBO J, V5, P3687, DOI 10.1002/j.1460-2075.1986.tb04700.x; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, NUCLEIC ACIDS RES, V23, P3937, DOI 10.1093/nar/23.19.3937; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG SH, 1994, J BIOL CHEM, V269, P12789; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZOU A, 1991, J BIOL CHEM, V266, P20476; ZOU AH, 1991, EMBO J, V10, P1585	66	79	82	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					257	269		10.1016/S0092-8674(00)81102-2	http://dx.doi.org/10.1016/S0092-8674(00)81102-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612278	Bronze			2022-12-01	WOS:A1996UG25500014
J	Musco, G; Stier, G; Joseph, C; Morelli, MAC; Nilges, M; Gibson, TJ; Pastore, A				Musco, G; Stier, G; Joseph, C; Morelli, MAC; Nilges, M; Gibson, TJ; Pastore, A			Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome	CELL			English	Article							FMR-1 GENE; PROTEIN; RECOGNITION; SEQUENCE	The KH module is a sequence motif found in a number of proteins that are known to be in close association with RNA. Experimental evidence suggests a direct involvement of KH in RNA binding. The human FMR1 protein, which has two KH domains, is associated with fragile X syndrome, the most common inherited cause of mental retardation. Here we present the three-dimensional solution structure of the KH module. The domain consists of a stable beta alpha alpha beta beta alpha fold. On the basis of our results, we suggest a potential surface for RNA binding centered on the loop between the first two helices. Substitution of a well-conserved hydrophobic residue located on the second helix destroys the KH fold; a mutation of this position in FMR1 leads to an aggravated fragile X phenotype.	UNIV BASILICATA, I-85100 POTENZA, ITALY	University of Basilicata	Musco, G (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Musco, Giovanna/Q-2756-2019; Nilges, Michael/E-4803-2011; musco, giovanna/I-7122-2012	Nilges, Michael/0000-0002-1451-8092; musco, giovanna/0000-0002-0469-2994; Gibson, Toby James/0000-0003-0657-5166; Castiglione Morelli, Maria Antonietta/0000-0003-3967-3117				BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EBERSOLE TA, 1995, IN PRESS NATURE GENE; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GUENTERT P, 1991, Journal of Molecular Biology, V217, P517; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KHARRAT A, 1995, EMBO J, V14, P3563; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; LUYEBEEL KA, 1995, NAT GENET, V10, P483; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Mandel JL, 1992, CURR OPIN GENET DEV, V2, P422, DOI 10.1016/S0959-437X(05)80153-4; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; NUSSBAUM RL, 1995, METABOLIC BASIS INHE, P795; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; REGNIER P, 1987, J BIOL CHEM, V262, P63; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x	43	255	260	1	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 19	1996	85	2					237	245		10.1016/S0092-8674(00)81100-9	http://dx.doi.org/10.1016/S0092-8674(00)81100-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612276	Bronze			2022-12-01	WOS:A1996UG25500012
J	Kim, R; Rotnitzky, A; Sparrow, D; Weiss, ST; Wager, C; Hu, H				Kim, R; Rotnitzky, A; Sparrow, D; Weiss, ST; Wager, C; Hu, H			Longitudinal study of low-level lead exposure and impairment of renal function The normative aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; SERUM CREATININE; SMELTER WORKERS; HYPERTENSION; NEPHROPATHY; POPULATION; PARAMETERS; EXCRETION; FAILURE; PLASMA	Objective.-To determine whether low-level lead exposure is associated with impaired renal function. Design.-Retrospective cohort study. Setting and Participants.-Subjects were 459 men randomly selected from the participants of the Normative Aging Study who were originally recruited from healthy veterans in the greater Boston area in 1961 and were periodically examined at the Department of Veterans Affairs Outpatient Clinic every 3 to 5 years. We reconstructed blood lead concentrations for the period between 1979 and 1994 using samples of either archived red blood cells or fresh whole blood. Main Outcome Measures.-Serum creatinine concentration. Results.-After adjustment for age, body mass index, smoking, alcohol consumption, educational level, and hypertension, blood lead concentration was positively and significantly associated with concurrent concentration of serum creatinine (P=.005). A 10-fold increase in blood lead level predicted an increase of 7 mu mol/L (0.08 mg/dL) in serum creatinine concentration, which is roughly equivalent to the increase predicted by 20 years of aging. The association was also significant among subjects whose blood lead concentrations had never exceeded 0.48 mu mol/L (10 mu g/dL) throughout the study period. The age-related increase in serum creatinine level was earlier and faster in the group with the highest-quartile levels of long-term lead exposure than in the group with the lowest-quartile levels. Conclusions.-Low-level exposure to lead may impair renal function in middle-aged and older men. Longitudinal data suggest an acceleration of age-related impairment of renal function in association with long-term low-level lead exposure.	HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; DEPT VET AFFAIRS, OUTPATIENT CLIN, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kim, R (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES005947, R01ES005257] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42ES05947, ES05257] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BEHRINGER D, 1986, NEPHRON, V42, P323, DOI 10.1159/000183696; BELL B, 1972, AGING HUM DEVELOP, V3, P5, DOI 10.2190/GGVP-XLB5-PC3N-EF0G; BENNETT WM, 1985, KIDNEY INT, V28, P212, DOI 10.1038/ki.1985.143; BERNARD A, 1989, TOXICOL LETT, V46, P293, DOI 10.1016/0378-4274(89)90137-9; BROCHNERMORTENSEN J, 1977, SCAND J UROL NEPHROL, V11, P263, DOI 10.3109/00365597709179963; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; CAMPBELL BC, 1981, TOXICOL LETT, V9, P121, DOI 10.1016/0378-4274(81)90027-8; *CDC, 1985, PUBL CDC; *CDC, 1991, PREV LEAD POIS YOUNG; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COLLEONI N, 1986, NEPHRON, V44, P32, DOI 10.1159/000183908; CRAMER K, 1974, BRIT J IND MED, V31, P113; DESILVA PE, 1981, BRIT J IND MED, V38, P209; DOSSANTOS AC, 1994, AM J IND MED, V26, P635; ERJJUKA J, 1992, BR J IND MED, V49, P631; FOWLER BA, 1991, ENVIRON HEALTH PERSP, V91, P77, DOI 10.2307/3430986; FRIEDMAN SA, 1972, ANN INTERN MED, V76, P41, DOI 10.7326/0003-4819-76-1-41; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; Goyer R A, 1971, Curr Top Pathol, V55, P147; GOYER RA, 1970, ARCH ENVIRON HEALTH, V20, P705, DOI 10.1080/00039896.1970.10665647; GOYER RA, 1985, DIETARY ENV LEAD HUM; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HENDERSON D. A., 1958, MED JOUR AUSTRALIA I, V45, P377; Jaffe M., 1986, J PHYS CHEM-US, V10, P391, DOI DOI 10.1515/BCHM1.1886.10.5.391; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LILIS R, 1968, BRIT J IND MED, V25, P196; LILIS R, 1979, J ENVIRON PATHOL TOX, V2, P1447; LIN JL, 1994, J RHEUMATOL, V21, P705; MANTON WI, 1984, BRIT J IND MED, V41, P313; MEYER BR, 1984, AM J MED, V76, P989, DOI 10.1016/0002-9343(84)90847-7; MULDOON SB, 1994, AM J EPIDEMIOL, V139, P599, DOI 10.1093/oxfordjournals.aje.a117049; *OCC SAF HLTH ADM, 1978, 29CFR19101025 OCC SA; PAYTON M, 1994, AM J EPIDEMIOL, V140, P821, DOI 10.1093/oxfordjournals.aje.a117330; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROELS H, 1994, OCCUP ENVIRON MED, V51, P505, DOI 10.1136/oem.51.8.505; ROSE CL, 1976, GERONTOLOGIST, V16, P508, DOI 10.1093/geront/16.6.508; ROWE JW, 1979, J GERONTOL, V81, P155; SAUDIE E, 1984, J CHRON DIS, V37, P617; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH DR, 1992, ENVIRON RES, V57, P190, DOI 10.1016/S0013-9351(05)80079-9; SPARROW D, 1986, AM J CARDIOL, V57, P218, DOI 10.1016/0002-9149(86)90894-5; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; *TECHN, 1983, SG40011988 TECHN; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; VERSCHOOR M, 1987, AM J IND MED, V12, P341, DOI 10.1002/ajim.4700120402; VICTERY W, 1982, J LAB CLIN MED, V99, P354; WEDEEN RP, 1986, AM J KIDNEY DIS, V8, P380, DOI 10.1016/S0272-6386(86)80113-5; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7; WEISS ST, 1986, AM J EPIDEMIOL, V123, P800, DOI 10.1093/oxfordjournals.aje.a114309; *WHO, 1980, WHO, V647	56	155	159	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1177	1181		10.1001/jama.275.15.1177	http://dx.doi.org/10.1001/jama.275.15.1177			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609685				2022-12-01	WOS:A1996UE62500029
J	Armstrong, D; Reyburn, H; Jones, R				Armstrong, D; Reyburn, H; Jones, R			A study of general practitioners' reasons for changing their prescribing behaviour	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To explore general practitioners' reasons for recent changes in their prescribing behaviour. Design - Qualitative analysis of semistructured interviews. Setting - General practice in south east London. Subjects - A heterogeneous sample of 18 general practitioners. Results - Interviewees were able to identify between two and five specific changes that had occurred in their prescribing in the preceding six months. The most frequently mentioned changes related to fluoxetine, angiotensin converting enzyme inhibitors, and the antibiotic treatment of Helicobacter pylori. Three models of change were identified: an accumulation model, in which the volume and authority of evidence were important; a challenge model, in which behaviour change followed a dramatic or conflictual clinical event; and a continuity model, in which change took place against a background of willingness to change, modulated by other factors such as cost pressures and the comprehensible therapeutic action of a drug. Behaviour change was reinforced and sustained by experiences with individual patients. Conclusions - Multiple factors are involved in general practitioners) decisions to change their prescribing habits. Three models of change can be identified which have important implications for the design and evaluation of interventions aimed at behaviour change.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London			Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				[Anonymous], 1995, LANCET, V346, P785; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; SMITH R, 1995, BRIT MED J, V311, P961; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244	7	120	122	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					949	952						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616310				2022-12-01	WOS:A1996UF65900022
J	Sozzi, G; Veronese, ML; Negrini, M; Baffa, R; Cotticelli, MG; Inoue, H; Tornielli, S; Pilotti, S; DeGregorio, L; Pastorino, U; Pierotti, MA; Ohta, M; Huebner, K; Croce, CM				Sozzi, G; Veronese, ML; Negrini, M; Baffa, R; Cotticelli, MG; Inoue, H; Tornielli, S; Pilotti, S; DeGregorio, L; Pastorino, U; Pierotti, MA; Ohta, M; Huebner, K; Croce, CM			The FHIT gene at 3p14.2 is abnormal in lung cancer	CELL			English	Article							CHROMOSOMAL REGION 3P21; SMALL-CELL CARCINOMA; SHORT ARM; HOMOZYGOUS DELETION; P53 GENE; ADENOCARCINOMA; MUTATIONS; HETEROZYGOSITY; EXPRESSION; FREQUENT	To determine the role of the FHIT gene, which encompasses the fragile site at 3p14.2, we analyzed 59 tumors of the small cell and non-small cell type by reverse transcription of FHIT mRNA, followed by PCR amplification and sequencing of products. Allelic losses affecting the gene were evaluated by microsatellite polymorphism analysis and genomic alterations by hybridization using cDNA and genomic probes. Small cell lung tumors (80%) and non-small cell lung cancers (40%) showed abnormalities in RNA transcripts of FHIT, and 76% of the tumors exhibited loss of FHIT alleles. Abnormal lung tumor transcripts lack two or more exons of the FHIT gene. Small cell lung cancer tumors and cell lines were analyzed by Southern blotting and showed rearranged BamHI fragments. These data suggest a critical role of the FHIT gene in lung carcinogenesis.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	Sozzi, G (corresponding author), JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107, USA.		sozzi, gabriella/G-8259-2011; Negrini, Massimo/J-2377-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Pastorino, Ugo/C-2712-2017; Young, Richard A/F-6495-2012	sozzi, gabriella/0000-0001-9360-6914; Negrini, Massimo/0000-0002-0007-1920; Pierotti, Marco Alessandro/0000-0002-7431-8332; Pastorino, Ugo/0000-0001-9974-7902; Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA021124, R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860, P01CA21124, CA56336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; BARSKY SH, 1994, MODERN PATHOL, V7, P633; BAXI MD, 1994, BIOCHEMISTRY-US, V33, P14601, DOI 10.1021/bi00252a028; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHIBA I, 1990, ONCOGENE, V5, P1603; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; DRUCK T, 1995, CANCER RES, V55, P5348; EBINA M, 1994, CANCER RES, V54, P2496; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HORIO Y, 1993, CANCER RES, V53, P1; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; *INT UN CANC, 1987, TNM CLASS MAL TUM; Kastury K, 1996, CANCER RES, V56, P978; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KIM SY, 1993, AM J PATHOL, V142, P307; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOK K, 1994, CANCER RES, V54, P4183; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURATA M, 1992, JPN J HUM GENET, V37, P205, DOI 10.1007/BF01900714; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SOZZI G, 1991, CANCER RES, V51, P400; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; WEINMANNDORSCH C, 1984, EUR J BIOCHEM, V138, P179, DOI 10.1111/j.1432-1033.1984.tb07897.x; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; World Health Organization, 1981, HIST TYP LUNG TUM; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOYAMA S, 1992, CANCER RES, V52, P873	40	538	573	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					17	26		10.1016/S0092-8674(00)81078-8	http://dx.doi.org/10.1016/S0092-8674(00)81078-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620533	Bronze			2022-12-01	WOS:A1996UE55900005
J	Bradley, C; Blenkinsopp, A				Bradley, C; Blenkinsopp, A			Over the counter drugs - The future for self medication	BRITISH MEDICAL JOURNAL			English	Article								The increasing trend towards deregulation of more medicines to over the counter status has implications for the primary health care team as well as for consumers and patients. Better information for patients could improve the safety of over the counter medicines, but better systems need to be devised for reporting adverse reactions. ''Collaborative care'' could bring financial benefits. Doctors, nurses, and pharmacists need to discuss how they will respond to self medication practices, and ways of rewarding pharmacists for advising patients need to be found. Improved communication between doctors and pharmacists and the involvement of nurses could bring health care professionals into a new and more constructive interaction with each other and with the patient-or the changes required could split the professions as they each try to keep control of medicines.	UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Bradley, C (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				Blenkinsopp A, 1996, BRIT MED J, V312, P629; BRADLEY C, 1995, PRESCRIBER      0305, P75; DRIFE JO, 1993, BRIT MED J, V307, P695, DOI 10.1136/bmj.307.6906.695; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; *MED CONTR AG, 1992, CHANG LEG CLASS PRES; 1995, PHARM J, V254, P433; 1993, LANCET, V342, P565; 1992, OFFICIAL J EUROPEA L, P113	9	65	67	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					835	837						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608296				2022-12-01	WOS:A1996UD37800032
J	Taylor, FC; Ramsay, ME; Renton, A; Cohen, H				Taylor, FC; Ramsay, ME; Renton, A; Cohen, H			Methods for managing the increased workload in anticoagulant clinic	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,SCH MED,DEPT PUBL HLTH,HLTH CARE DEV UNIT,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT HAEMATOL,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London	Taylor, FC (corresponding author), ROYAL COLL PHYSICIANS,RES UNIT,LONDON NW1 4LE,ENGLAND.							DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; LOWE GDO, 1992, BRIT MED J, V305, P1445, DOI 10.1136/bmj.305.6867.1445; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; Taylor F., 1994, British Journal of Haematology, V86, P68; VANDENBESSELAAR AMHP, 1990, THROMB HAEMOSTASIS, V63, P316	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611786				2022-12-01	WOS:A1996TU50700024
